Document:

EX-10.12

 Exhibit 10.12 

EXECUTION VERSION 
  

 
 TERM LOAN AGREEMENT 

dated as of 

September 23, 2015 

between 
 GENOMEDX
BIOSCIENCES INC. 
 as Borrower, 

The SUBSIDIARY GUARANTORS from Time to Time Party Hereto, 

CRG PARTNERS III L.P., CRG PARTNERS III – PARALLEL FUND “A” L.P. and 

CRG PARTNERS III (CAYMAN) L.P. 

as Lenders, and 
 CRG
PARTNERS III L.P. as Agent on behalf of the Lenders 
 Up to U.S. $25,000,000 

 
  

 

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
			
	 SECTION 1
	  	 DEFINITIONS  . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	1	 
			
	 1.01
	  	 Certain Defined Terms  . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	1	 
			
	 1.02
	  	 Accounting Terms and Principles  . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	21	 
			
	 1.03
	  	 Interpretation  . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	22	 
			
	 1.04
	  	 Changes to GAAP  . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	22	 
			
	 SECTION 2
	  	 THE COMMITMENT  . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	23	 
			
	 2.01
	  	 Commitments  . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	23	 
			
	 2.02
	  	 Borrowing Procedures  . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	23	 
			
	 2.03
	  	 Fees  . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	23	 
			
	 2.04
	  	 Notes  . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	23	 
			
	 2.05
	  	 Use of Proceeds  . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	23	 
			
	 2.06
	  	 Defaulting Lenders  . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	23	 
			
	 2.07
	  	 Substitution of Lenders  . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	24	 
			
	 2.08
	  	 Non-Disturbance Agreements  . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	25	 
			
	 SECTION 3
	  	 PAYMENTS OF PRINCIPAL AND INTEREST  . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	25	 
			
	 3.01
	  	 Repayment  . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	25	 
			
	 3.02
	  	 Interest  . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	26	 
			
	 3.03
	  	 Prepayments  . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	27	 
			
	 SECTION 4
	  	 PAYMENTS, ETC  . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	29	 
			
	 4.01
	  	 Payments  . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	29	 
			
	 4.02
	  	 Computations  . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	30	 
			
	 4.03
	  	 Notices  . . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	30	 
			
	 4.04
	  	 Set-Off  . . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	30	 
			
	 SECTION 5
	  	 YIELD PROTECTION, ETC  . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	30	 
			
	 5.01
	  	 Additional Costs  . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	30	 
			
	 5.02
	  	 Illegality  . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	31	 
			
	 5.03
	  	 Taxes  . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	32	 
			
	 SECTION 6
	  	 CONDITIONS PRECEDENT  . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	35	 
			
	 6.01
	  	 Conditions to the First Borrowing  . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	35	 
			
	 6.02
	  	 Conditions to Second Borrowing  . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	37	 
			
	 6.03
	  	 Conditions to Third Borrowing  . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	38	 
			
	 6.04
	  	 Conditions to Each Borrowing  . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	38	 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	  	 	  	Page	 
			
	 SECTION 7
	  	 REPRESENTATIONS AND WARRANTIES  . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	39	 
			
	 7.01
	  	 Power and Authority  . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	39	 
			
	 7.02
	  	 Authorization; Enforceability  . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	39	 
			
	 7.03
	  	 Governmental and Other Approvals; No Conflicts  . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	39	 
			
	 7.04
	  	 Financial Statements; Material Adverse Change  . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	40	 
			
	 7.05
	  	 Properties  . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	40	 
			
	 7.06
	  	 No Actions or Proceedings  . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	43	 
			
	 7.07
	  	 Compliance with Laws and Agreements  . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	44	 
			
	 7.08
	  	 Taxes  . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	44	 
			
	 7.09
	  	 Full Disclosure  . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	44	 
			
	 7.10
	  	 Regulation  . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	44	 
			
	 7.11
	  	 Solvency  . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	44	 
			
	 7.12
	  	 Subsidiaries  . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	44	 
			
	 7.13
	  	 Indebtedness and Liens  . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	45	 
			
	 7.14
	  	 Material Agreements  . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	45	 
			
	 7.15
	  	 Restrictive Agreements  . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	45	 
			
	 7.16
	  	 Real Property  . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	45	 
			
	 7.17
	  	 Pension Matters  . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	46	 
			
	 7.18
	  	 Collateral; Security Interest  . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	46	 
			
	 7.19
	  	 Regulatory Approvals  . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	46	 
			
	 7.20
	  	 Update of Schedules  . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	46	 
			
	 7.21
	  	 Canadian Pension or Benefit Plans  . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	47	 
			
	 SECTION 8
	  	 AFFIRMATIVE COVENANTS  . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	47	 
			
	 8.01
	  	 Financial Statements and Other Information  . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	47	 
			
	 8.02
	  	 Notices of Material Events  . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	49	 
			
	 8.03
	  	 Existence; Conduct of Business  . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	51	 
			
	 8.04
	  	 Payment of Obligations  . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	51	 
			
	 8.05
	  	 Insurance  . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	51	 
			
	 8.06
	  	 Books and Records; Inspection Rights  . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	52	 
			
	 8.07
	  	 Compliance with Laws and Other Obligations  . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	52	 
			
	 8.08
	  	 Maintenance of Properties, Etc  . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	52	 
			
	 8.09
	  	 Licenses  . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	53	 

  
 -ii- 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	  	 	  	Page	 
			
	 8.10
	  	 Action under Environmental Laws  . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	53	 
			
	 8.11
	  	 Use of Proceeds  . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	53	 
			
	 8.12
	  	 Certain Obligations Respecting Subsidiaries; Further
Assurances  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	53	 
			
	 8.13
	  	 Termination of Non-Permitted Liens  . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	55	 
			
	 8.14
	  	 Intellectual Property  . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	55	 
			
	 8.15
	  	 Board Observer Seat  . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	55	 
			
	 8.16
	  	 Post-Closing Items  . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	55	 
			
	 SECTION 9
	  	 NEGATIVE COVENANTS  . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	56	 
			
	 9.01
	  	 Indebtedness  . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	56	 
			
	 9.02
	  	 Liens  . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	58	 
			
	 9.03
	  	 Fundamental Changes and Acquisitions  . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	59	 
			
	 9.04
	  	 Lines of Business  . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	60	 
			
	 9.05
	  	 Investments  . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	60	 
			
	 9.06
	  	 Restricted Payments  . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	61	 
			
	 9.07
	  	 Payments of Indebtedness  . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	62	 
			
	 9.08
	  	 Change in Fiscal Year  . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	62	 
			
	 9.09
	  	 Sales of Assets, Etc  . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	62	 
			
	 9.10
	  	 Transactions with Affiliates  . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	63	 
			
	 9.11
	  	 Restrictive Agreements  . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	64	 
			
	 9.12
	  	 Termination of Material Agreements  . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	64	 
			
	 9.13
	  	 Operating Leases  . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	64	 
			
	 9.14
	  	 Sales and Leasebacks  . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	64	 
			
	 9.15
	  	 Hazardous Material  . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	65	 
			
	 9.16
	  	 Accounting Changes  . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	65	 
			
	 9.17
	  	 Compliance with ERISA  . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	65	 
			
	 9.18
	  	 Canadian Benefit Plans  . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	65	 
			
	 9.19
	  	 HSBC Bank Canada  . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	65	 
			
	 9.20
	  	 Preferred Share Issuances  . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	65	 
			
	 SECTION 10
	  	 FINANCIAL COVENANTS  . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	65	 
			
	 10.01
	  	 Minimum Liquidity  . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	65	 
			
	 10.02
	  	 Minimum Revenue  . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	66	 
			
	 10.03
	  	 Cure Right  . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	66	 

  
 -iii- 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	  	 	  	Page	 
			
	 SECTION 11
	  	 EVENTS OF DEFAULT  . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	67	 
			
	 11.01
	  	 Events of Default  . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	67	 
			
	 11.02
	  	 Remedies  . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	70	 
			
	 SECTION 12
	  	 MISCELLANEOUS  . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	71	 
			
	 12.01
	  	 No Waiver  . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	71	 
			
	 12.02
	  	 Notices  . . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	71	 
			
	 12.03
	  	 Expenses, Indemnification, Etc  . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	71	 
			
	 12.04
	  	 Amendments, Etc  . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	72	 
			
	 12.05
	  	 Successors and Assigns  . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	73	 
			
	 12.06
	  	 Survival  . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	75	 
			
	 12.07
	  	 Captions  . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	76	 
			
	 12.08
	  	 Counterparts  . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	76	 
			
	 12.09
	  	 Governing Law  . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	76	 
			
	 12.10
	  	 Jurisdiction, Service of Process and Venue  . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	76	 
			
	 12.11
	  	 Waiver of Jury Trial  . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	76	 
			
	 12.12
	  	 Waiver of Immunity  . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	77	 
			
	 12.13
	  	 Entire Agreement  . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	77	 
			
	 12.14
	  	 Severability  . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	77	 
			
	 12.15
	  	 No Fiduciary Relationship  . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	77	 
			
	 12.16
	  	 Confidentiality  . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	77	 
			
	 12.17
	  	 USA PATRIOT Act  . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	77	 
			
	 12.18
	  	 Maximum Rate of Interest  . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	78	 
			
	 12.19
	  	 Certain Waivers  . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	78	 
			
	 12.20
	  	 Releases of Guarantees and Liens  . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	79	 
			
	 12.21
	  	 Judgment Currency  . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	80	 
			
	 SECTION 13
	  	 GUARANTEE  . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	80	 
			
	 13.01
	  	 The Guarantee  . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	80	 
			
	 13.02
	  	 Obligations Unconditional  . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	80	 
			
	 13.03
	  	 Reinstatement  . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	81	 
			
	 13.04
	  	 Subrogation  . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	81	 
			
	 13.05
	  	 Remedies  . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	81	 
			
	 13.06
	  	 Instrument for the Payment of Money  . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	82	 

  
 -iv- 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	  	 	  	Page	 
			
	 13.07
	  	 Continuing Guarantee  . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	82	 
			
	 13.08
	  	 Rights of Contribution  . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	82	 
			
	 13.09
	  	 General Limitation on Guarantee Obligations  . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	83	 
			
	 SECTION 14
	  	 THE AGENT  . . . . . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	83	 
			
	 14.01
	  	 Appointment and Authority  . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	83	 
			
	 14.02
	  	 Rights as a Lender  . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	83	 
			
	 14.03
	  	 Exculpatory Provisions  . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	83	 
			
	 14.04
	  	 Reliance by Agent  . . . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	84	 
			
	 14.05
	  	 Delegation of Duties  . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	85	 
			
	 14.06
	  	 Resignation of Agent  . . . . . . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	85	 
			
	 14.07
	  	 Non-Reliance on Agent and Other Lenders  . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	86	 
			
	 14.08
	  	 Agent May File Proofs of Claim  . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	86	 
			
	 14.09
	  	 Collateral and Guaranty Matters  . . . . . . . . . . . . . . .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	  	 	87	 

 SCHEDULES AND EXHIBITS 
  

					
	 Schedule 1
	 	 -
	  	 Commitments

	 Schedule 7.05(b)
	 	 -
	  	 Certain Intellectual Property

	 Schedule 7.05(c)
	 	 -
	  	 Material Intellectual Property

	 Schedule 7.06
	 	 -
	  	 Certain Litigation

	 Schedule 7.08
	 	 -
	  	 Taxes

	 Schedule 7.12
	 	 -
	  	 Information Regarding Subsidiaries

	 Schedule 7.13(a)
	 	 -
	  	 Existing Indebtedness of Borrower and its Subsidiaries

	 Schedule 7.13(b)
	 	 -
	  	 Liens Granted by the Obligors

	 Schedule 7.14
	 	 -
	  	 Material Agreements of Obligors

	 Schedule 7.15
	 	 -
	  	 Restrictive Agreements

	 Schedule 7.16
	 	 -
	  	 Real Property Owned or Leased by Borrower or any Subsidiary

	 Schedule 7.17
	 	 -
	  	 Pension Matters

	 Schedule 7.18
	 	 -
	  	 Filings Required in Connection with Security Documents

	 Schedule 9.05
	 	 -
	  	 Existing Investments

	 Schedule 9.10
	 	 -
	  	 Transactions with Affiliates

	 Schedule 9.14
	 	 -
	  	 Permitted Sales and Leasebacks

			
	 Exhibit A
	 	 -
	  	 Form of Guarantee Assumption Agreement

	 Exhibit B
	 	 -
	  	 Form of Notice of Borrowing

	 Exhibit C-1
	 	 -
	  	 Form of Term Loan Note

	 Exhibit C-2
	 	 -
	  	 Form of PIK Loan Note

	 Exhibit D
	 	 -
	  	 Form of U.S. Tax Compliance Certificate

	 Exhibit E
	 	 -
	  	 Form of Compliance Certificate

	 Exhibit F
	 	 -
	  	 Opinion Request

  
 -v- 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	 	 	  	 	  	Page
				
	 Exhibit G
	 	 -
	  	 Form of Landlord Consent
	  	
	 Exhibit H
	 	 -
	  	 Form of Subordination Agreement
	  	
	 Exhibit I
	 	 -
	  	 Form of Intercreditor Agreement
	  	

  
 -vi- 

 TERM LOAN AGREEMENT (this
“Agreement”), dated as of September 23, 2015 (the “Closing Date”), among GENOMEDX BIOSCIENCES INC., a company incorporated in British Columbia, Canada (“Borrower”), the
SUBSIDIARY GUARANTORS from time to time party hereto, the Lenders from time to time party hereto and CRG PARTNERS III L.P. as administrative and collateral agent for the Lenders hereunder (in such capacity, the
“Agent”). 
 WITNESSETH: 

Borrower has requested the Lenders to make term loans to Borrower, and the Lenders are prepared to make such loans on and
subject to the terms and conditions hereof. Accordingly, the parties agree as follows: 
 SECTION 1 

DEFINITIONS 
 1.01
Certain Defined Terms. As used herein, the following terms have the following respective meanings: 

“Accounting Change Notice” has the meaning set forth in Section
1.04(a). 
 “Act” has the meaning set forth in
Section 12.17. 
 “Acquisition” means any
transaction, or any series of related transactions, by which any Person directly or indirectly, by means of a take-over bid, tender offer, amalgamation, merger, purchase of assets, or similar transaction having the same effect as any of the
foregoing, (a) acquires any business or all or substantially all of the assets of any Person engaged in any business, (b) acquires control of securities of a Person engaged in a business representing more than 50% of the ordinary voting
power for the election of directors or other governing body if the business affairs of such Person are managed by a board of directors or other governing body, or (c) acquires control of more than 50% of the ownership interest in any Person
engaged in any business that is not managed by a board of directors or other governing body. 

“Affected Lender” has the meaning set forth in Section
2.07(a). 
 “Affiliate” means, with respect to a
specified Person, another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified. 

“Agent” has the meaning set forth in the introduction hereto. 

“Agreed Currency” has the meaning set forth in Section
12.21. 
 “Agreement” has the meaning set forth in the
introduction hereto. 
 “Asset Sale” is defined in
Section 9.09. 
 “Asset Sale Net
Proceeds” means the aggregate amount of the cash proceeds received from any Asset Sale plus, with respect to any non-cash proceeds (other than future rights to  

  
 1 

 
receive cash) of an Asset Sale, the fair market value of such non cash proceeds as reasonably determined by the Majority Lenders in accordance with GAAP, in each case, net of any bona fide costs
incurred and taxes paid in connection with such Asset Sale. 
 “Assignment and
Assumption” means an assignment and assumption entered into by a Lender and an assignee of such Lender. 

“Bankruptcy Code” means Title II of the United States Code entitled
“Bankruptcy.” 
 “Benefit Plan” means any employee benefit
plan as defined in Section 3(3) of ERISA (whether governed by the laws of the United States or otherwise) to which any Obligor or Subsidiary thereof incurs or otherwise has any obligation or liability, contingent or otherwise.

 “Borrower” has the meaning set forth in the introduction hereto.

 “Borrower Lease” means (i) the Lease dated as of September 25,
2014 by and between GenomeDx Biosciences Corp. as lessee and Torrey Pines Science Center Limited Partnership, a Delaware limited partnership as lessor for the premises located at 10355 Science Center Drive, Suite 240, San Diego, CA 92121,
(ii) the Lease Agreement dated as of September 16, 2014 by and between the Borrower as lessee and 3959 Investments Ltd., as Lessor for the premises located at 1038 Homer Street, Vancouver, BC V6B 2W9, and (iii) each other lease
agreement relating to real estate leased by the Borrower and its Subsidiaries as set forth on Schedule 7.16. 

“Borrower Party” has the meaning set forth in Section 12.03(b). 

“Borrowing” means a borrowing consisting of Loans made on the same day by the Lenders
according to their respective Commitments (including without limitation a borrowing of a PIK Loan). 

“Borrowing Date” means the date of a Borrowing. 

“Borrowing Notice Date” means, (i) in the case of the first Borrowing, a date that
is at least twelve Business Days (or such shorter period as shall be acceptable to Lenders) prior to the Borrowing Date of such Borrowing and, (ii) in the case of a subsequent Borrowing, a date that is at least twenty Business Days (or such
shorter period as shall be acceptable to Lenders) prior to the Borrowing Date of such Borrowing. 

“Business Day” means a day (other than a Saturday or Sunday) on which commercial banks
are not authorized or required to close in New York City or Vancouver. 
 “Canadian
Benefit Plans” means all plans, arrangements, agreements, programs, policies, practices or undertakings, whether oral or written, formal or informal, funded or unfunded, insured or uninsured, registered or unregistered, to which an
Obligor or any of its Subsidiaries is a party or bound or in which their employees participate or under which an Obligor or any of its Subsidiaries has, or will have, any liability or contingent liability, or pursuant to which payments are made, or
benefits are provided to, or an entitlement to payments or benefits may arise with respect to, any of their employees or former employees, their directors or officers, individuals working on contract with an Obligor or any of its Subsidiaries or
other  

  
 2 

 
individuals providing services to an Obligor or any of its Subsidiaries of a kind normally provided by employees (or any spouses, dependents, survivors or beneficiaries of any such persons). 

“Canadian Pension Plans” means all Canadian Benefit Plans which are required to be
registered under Canadian provincial or federal pension benefits standards legislation. 

“Canadian Security Agreement” means the Canadian Security Agreement, dated as of the
date hereof, among the Borrower, the Canadian Subsidiaries from time to time party thereto, the Lenders and the Agent, granting a security interest in such Obligor’s personal Property in favor of the Agent for its own benefit and for the
ratable benefit of the Lenders. 
 “Canadian Subsidiary” means any
Subsidiary that is a corporation, limited liability company, partnership or similar business entity incorporated, formed or organized under the laws of Canada, or any province or territory of Canada. 

“Capital Lease Obligations” means, as to any Person, the obligations of such Person to
pay rent or other amounts under a lease of (or other agreement conveying the right to use) real and/or personal Property which obligations are required to be classified and accounted for as a capital lease on a balance sheet of such Person under
GAAP and, for purposes of this Agreement, the amount of such obligations shall be the capitalized amount thereof, determined in accordance with GAAP. 

“Change of Control” means (a) the acquisition of ownership, directly or indirectly, beneficially
or of record, by any Person or group of Persons acting jointly or otherwise in concert of capital stock representing more than 50% (or after a Qualified IPO, 25%) of the aggregate ordinary voting power represented by the issued and outstanding
capital stock of Borrower, (b) during any period of twelve (12) consecutive calendar months, the occupation of a majority of the seats (other than vacant seats) on the board of directors of Borrower by Persons who were neither
(i) nominated by the board of directors of Borrower, nor (ii) appointed by directors so nominated, or (c) the acquisition of direct or indirect Control of Borrower by any Person or group of Persons acting jointly or otherwise in
concert; in each case whether as a result of a tender or exchange offer, open market purchases, privately negotiated purchases or otherwise; provided however, that the occurrence of a Qualified IPO shall not be deemed a Change of Control
event. 
 “Claims” includes claims, demands, complaints, grievances, actions,
applications, suits, causes of action, orders, charges, indictments, prosecutions, informations (brought by a public prosecutor without grand jury indictment) or other similar processes, assessments or reassessments. 

“Closing Date” has the meaning set forth in the introduction hereto. 

“Closing Expense Cap” has the meaning set forth in the Fee Letter. 

“Code” means the Internal Revenue Code of 1986, as amended from time to time, and the
rules and regulations promulgated thereunder from time to time. 

  
 3 

 “Collateral” means any Property in
which a Lien is purported to be granted under any of the Security Documents (or all such Property, as the context may require). 

“Commitment” means, with respect to each Lender, the obligation of such Lender to make
Loans to Borrower in accordance with the terms and conditions of this Agreement, which commitment is in the amount set forth opposite such Lender’s name on Schedule 1 under the caption “Commitment”,
as such Schedule may be amended from time to time. The aggregate Commitments on the date hereof equal $25,000,000. For purposes of clarification, the amount of any PIK Loans shall not reduce the amount of the available Commitment. 

“Commitment Period” means the period from and including the first date on which all of
the conditions precedent set forth in Section 6.01 have been satisfied (or waived by the Lenders) and through and including September 27, 2016. 

“Commodity Account” is defined in the Security Agreement or the Canadian Security
Agreement, as applicable. 
 “Compliance Certificate” has the meaning
given to such term in Section 8.01(d). 

“Contracts” means contracts, licenses, leases, agreements, obligations, promises,
undertakings, understandings, arrangements, documents, commitments, entitlements or engagements under which a Person has, or will have, any liability or contingent liability (in each case, whether written or oral, express or implied).

 “Control” means, in respect of a particular Person, the possession,
directly or indirectly, of the power to direct or cause the direction of the management or policies of such Person, whether through the ability to exercise voting power, by contract or otherwise. “Controlling” and “Controlled”
have meanings correlative thereto. 
 “Controlled Foreign Corporation”
means a “controlled foreign corporation” as defined in the Code. 

“Copyright” is defined in the Security Agreement or the Canadian Security Agreement, as
applicable. 
 “Cure Amount” has the meaning set forth in
Section 10.03(a). 
 “Cure Right” has
the meaning set forth in Section 10.03(a). 

“Default” means any Event of Default and any event that, upon the giving of notice, the
lapse of time or both, would constitute an Event of Default. 
 “Defaulting Lender”
means, subject to Section 2.06, any Lender that (a) has failed to perform any of its funding obligations hereunder, including in respect of its Loans, within three (3) Business Days of the date required to be funded by it
hereunder, (b) has notified Borrower or any Lender that it does not intend to comply with its funding obligations or has made a public statement to that effect with respect to its funding obligations hereunder or under other agreements in which
it commits to extend credit, or (c) has, or has a direct or indirect parent 

  
 4 

 
company that has, (i) become the subject of an Insolvency Proceeding, (ii) had a receiver, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person
charged with reorganization or liquidation of its business or a custodian appointed for it, or (iii) taken any action in furtherance of, or indicated its consent to, approval of or acquiescence in any such proceeding or appointment; provided
that a Lender shall not be a Defaulting Lender solely by virtue of the ownership or acquisition of any equity interest in that Lender or any direct or indirect parent company thereof by a Governmental Authority. 

“Deposit Account” is defined in the Security Agreement or the Canadian Security
Agreement, as applicable. 
 “Dollars” and “$”
means lawful money of the United States of America. 
 “Domestic
Subsidiary” means any Subsidiary that is a corporation, limited liability company, partnership or similar business entity incorporated, formed or organized under the laws of the United States, any State of the United States or the
District of Columbia. 
 “Eligible Transferee” means and includes a
commercial bank, an insurance company, a finance company, a financial institution, any investment fund that invests in loans or any other “accredited investor” (as defined in Regulation D of the Securities Act) that is principally in the
business of managing investments or holding assets for investment purposes; provided that so long as no Event of Default has occurred and is continuing, “Eligible Transferee” shall not include any Person that (a) produces, markets or
sells, or develops a program to market or sell, a product in direct competition with the Borrower or (b) is a vulture or distressed debt fund as determined by the transferring Lender in its reasonable discretion. 

“Environmental Law” means any federal, state, provincial, territorial or local
governmental law, rule, regulation, order, writ, judgment, injunction or decree relating to pollution or protection of the environment or the treatment, storage, disposal, release, threatened release or handling of hazardous materials, and all local
laws and regulations related to environmental matters and any specific agreements entered into with any competent authorities which include commitments related to environmental matters. 

“Equity Cure Right” has the meaning set forth in Section
10.03(a). 
 “Equity Interest” shall mean, with
respect to any Person, any and all shares, interests, participations or other equivalents, including membership interests (however designated, whether voting or nonvoting), of equity of such Person, including, if such Person is a partnership,
partnership interests (whether general or limited) and any other interest or participation that confers on a Person the right to receive a share of the profits and losses of, or distributions of property of, such partnership, but excluding debt
securities convertible or exchangeable into such equity. 
 “Equivalent
Amount” means, with respect to an amount denominated in one currency, the amount in another currency that could be purchased by the amount in the first currency determined by reference to the Exchange Rate at the time of
determination. 
 “ERISA” means the United States Employee Retirement
Income Security Act of 1974, as  

  
 5 

 
amended. 
 “ERISA Affiliate”
means, collectively, any Obligor, Subsidiary thereof, and any Person under common control, or treated as a single employer, with any Obligor or Subsidiary thereof, within the meaning of Section 414(b), (c), (m) or (o) of the
Code. 
 “ERISA Event” means (i) a reportable event as defined in
Section 4043 of ERISA with respect to a Title IV Plan, excluding, however, such events as to which the PBGC by regulation has waived the requirement of Section 4043(a) of ERISA that it be notified within 30 days of the occurrence of such
event; (ii) the applicability of the requirements of Section 4043(b) of ERISA with respect to a contributing sponsor, as defined in Section 4001(a)(13) of ERISA, to any Title IV Plan where an event described in paragraph (9), (10),
(11), (12) or (13) of Section 4043(c) of ERISA is reasonably expected to occur with respect to such plan within the following 30 days; (iii) a withdrawal by any Obligor or any ERISA Affiliate thereof from a Title IV Plan or the
termination of any Title IV Plan resulting in liability under Sections 4063 or 4064 of ERISA; (iv) the withdrawal of any Obligor or any ERISA Affiliate thereof in a complete or partial withdrawal (within the meaning of Section 4203 and
4205 of ERISA) from any Multiemployer Plan if there is any potential liability therefore, or the receipt by any Obligor or any ERISA Affiliate thereof of notice from any Multiemployer Plan that it is in reorganization or insolvency pursuant to
Section 4241 or 4245 of ERISA; (v) the filing of a notice of intent to terminate, the treatment of a plan amendment as a termination under Section 4041 or 4041A of ERISA, or the commencement of proceedings by the PBGC to terminate a
Title IV Plan or Multiemployer Plan; (vi) the imposition of liability on any Obligor or any ERISA Affiliate thereof pursuant to Sections 4062(e) or 4069 of ERISA or by reason of the application of Section 4212(c) of ERISA; (vii) the
failure by any Obligor or any ERISA Affiliate thereof to make any required contribution to a Plan, or the failure to meet the minimum funding standard of Section 412 of the Code with respect to any Title IV Plan (whether or not waived in
accordance with Section 412(c) of the Code) or the failure to make by its due date a required installment under Section 430 of the Code with respect to any Title IV Plan or the failure to make any required contribution to a Multiemployer
Plan; (viii) the determination that any Title IV Plan is considered an at-risk plan or a plan in endangered to critical status within the meaning of Sections 430, 431 and 432 of the Code or Sections 303, 304 and 305 of ERISA; (ix) an event
or condition which might reasonably be expected to constitute grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Title IV Plan or Multiemployer Plan; (x) the imposition of any
liability under Title I or Title IV of ERISA, other than PBGC premiums due but not delinquent under Section 4007 of ERISA, upon any Obligor or any ERISA Affiliate thereof; (xi) an application for a funding waiver under Section 303 of
ERISA or an extension of any amortization period pursuant to Section 412 of the Code with respect to any Title IV Plan; (xii) the occurrence of a non-exempt prohibited transaction under Sections 406 or 407 of ERISA for which any Obligor or
any Subsidiary thereof may be directly or indirectly liable; (xiii) a violation of the applicable requirements of Section 404 or 405 of ERISA or the exclusive benefit rule under Section 401(a) of the Code by any fiduciary or
disqualified person for which any Obligor or any ERISA Affiliate thereof may be directly or indirectly liable; (xiv) the occurrence of an act or omission which would give rise to the imposition on any Obligor or any ERISA Affiliate thereof of
fines, penalties, taxes or related charges under Chapter 43 of the Code or under Sections 409, 502(c), (i) or (1) or 4071 of ERISA; (xv) the assertion of a material claim (other than routine claims for benefits) against any Plan or
the assets thereof, or against any  

  
 6 

 
Obligor or any Subsidiary thereof in connection with any such plan; (xvi) receipt from the IRS of notice of the failure of any Qualified Plan to qualify under Section 401(a) of the
Code, or the failure of any trust forming part of any Qualified Plan to fail to qualify for exemption from taxation under Section 501(a) of the Code; (xvii) the imposition of any lien (or the fulfillment of the conditions for the
imposition of any lien) on any of the rights, properties or assets of any Obligor or any ERISA Affiliate thereof, in either case pursuant to Title I or IV, including Section 302(f) or 303(k) of ERISA or to Section 401(a)(29) or 430(k) of
the Code; or (xviii) the establishment or amendment by any Obligor or any Subsidiary thereof of any “welfare plan”, as such term is defined in Section 3(1) of ERISA, that provides post-employment welfare benefits in a manner that
would increase the liability of any Obligor other than those benefits required under the Consolidated Omnibus Budget Reconciliation Act. 

“ERISA Funding Rules” means the rules regarding minimum required contributions
(including any installment payment thereof) to Title IV Plans, as set forth in Sections 412, 430, 431, 432 and 436 of the Code and Sections 302, 303, 304 and 305 of ERISA. 

“Event of Default” has the meaning set forth in Section
11.01. 
 “Exchange Rate” means the rate at which any
currency (the “Pre-Exchange Currency”) may be exchanged into another currency (the “Post-Exchange Currency”), as set forth on such date on the relevant Reuters screen at or about 11:00 a.m. (Central
time) on such date. In the event that such rate does not appear on the Reuters screen, the “Exchange Rate” with respect to exchanging such Pre-Exchange Currency into such Post-Exchange Currency shall be determined by reference to such
other publicly available service for displaying exchange rates as may be agreed upon by Borrower and the Majority Lenders or, in the absence of such agreement, such Exchange Rate shall instead be determined by the Majority Lenders by any reasonable
method as they deem applicable to determine such rate, and such determination shall be conclusive absent manifest error. 

“Excluded Accounts” shall have such meaning as set forth in the Security Agreement or
the Canadian Security Agreement, as applicable. 
 “Excluded Taxes” means any of the
following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient: (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes and branch profits Taxes, in
each case as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax, (b) Other Connection Taxes,
(c) U.S. federal withholding Taxes that are imposed on amounts payable to a Lender to the extent that the obligation to withhold amounts existed on the date that (i) such Lender became a “Lender” under this Agreement or
(ii) such Lender changes its lending office, except in each case to the extent such Lender is a direct or indirect assignee of any other Lender that was entitled, at the time the assignment of such other Lender became effective, to receive
additional amounts under Section 5.03 or such Lender was entitled to receive additional amounts under Section 5.03 immediately before it changed its lending office, (d) any Taxes imposed in connection with FATCA, and
(e) Taxes attributable to such Recipient’s failure to comply with Section 5.03(e). 

  
 7 

 “FATCA” means Sections 1471 through
1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations promulgated thereunder or official
interpretations thereof and any agreements entered into pursuant to Section 1471(b)(1) of the Code. 

“Fee Letter” means that fee letter agreement dated as of the date hereof between
Borrower and the Lenders party thereto. 
 “First-Tier Foreign
Subsidiary” means a Foreign Subsidiary that is a direct Subsidiary of Borrower, Borrower’s Domestic Subsidiaries and Borrower’s Canadian Subsidiaries. 

“Foreign Lender” means a Lender that is not a U.S. Person. 

“Foreign Subsidiary” means a Subsidiary of Borrower that is not a Domestic Subsidiary or
a Canadian Subsidiary. 
 “Funding Indemnity Letter” means the letter
agreement between the Borrower and the Lenders to be entered into not later than twelve Business Days prior to the Borrowing Date of the first Borrowing pursuant to which the Borrower agrees to indemnify the Lenders for costs relating to capital
calls made by the Lenders to fund the Loans on the first Borrowing Date. 
 “GAAP”
means generally accepted accounting principles in the United States of America, as in effect from time to time, set forth in the opinions, statements and pronouncements of the Financial Accounting Standards Board and in such other statements by such
other entity as may be in general use by significant segments of the accounting profession that are applicable to the circumstances as of the date of determination. Subject to Section 1.02, all references to “GAAP” shall be to
GAAP applied consistently with the principles used in the preparation of the financial statements described in Section 7.04(a). 

“GenomeDx Corp.” means GenomeDx Biosciences Corp., a Delaware corporation, a
wholly-owned Subsidiary of Borrower. 
 “Governmental Approval” means
any consent, authorization, approval, order, license, franchise, permit, certificate, accreditation, registration, filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority. 

“Governmental Authority” means any nation, government, branch of power (whether
executive, legislative or judicial), state, province, territory or municipality or other political subdivision thereof and any entity exercising executive, legislative, judicial, monetary, regulatory or administrative functions of or pertaining to
government, including without limitation regulatory authorities, governmental departments, agencies, commissions, bureaus, officials, ministers, courts, bodies, boards, tribunals and dispute settlement panels, and other law-, rule- or
regulation-making organizations or entities of any State, province, territory, county, city or other political subdivision of the United States or Canada. 

“Guarantee” of or by any Person (the “guarantor”) means any
obligation, contingent or otherwise, of the guarantor guaranteeing or having the economic effect of guaranteeing any  

  
 8 

 
Indebtedness or other obligation of any other Person (the “primary obligor”) in any manner, whether directly or indirectly, and including any obligation of the
guarantor, direct or indirect, (a) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation or to purchase (or to advance or supply funds for the purchase of) any security for the
payment thereof, (b) to purchase or lease property, securities or services for the purpose of assuring the owner of such Indebtedness or other obligation of the payment thereof, (c) to maintain working capital, equity capital or any other
financial statement condition or liquidity of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation or (d) as an account party in respect of any letter of credit or letter of guaranty issued to
support such Indebtedness or obligation; provided, that the term Guarantee shall not include endorsements for collection or deposit in the ordinary course of business. 

“Guarantee Assumption Agreement” means a Guarantee Assumption Agreement substantially in
the form of Exhibit A by an entity that, pursuant to Section 8.12(a), is required to become a “Subsidiary Guarantor” hereunder in favor of the Lenders.

 “Guaranteed Obligations” has the meaning set forth in
Section 13.01. 
 “Hazardous
Material” means any substance, element, chemical, compound, product, solid, gas, liquid, waste, by-product, pollutant, contaminant or material which is hazardous or toxic, and includes, without limitation, (a) asbestos,
polychlorinated biphenyls and petroleum (including crude oil or any fraction thereof) and (b) any material classified or regulated as “hazardous” or “toxic” or words of like import pursuant to an Environmental Law.

 “Hedging Agreement” means any interest rate exchange agreement, foreign
currency exchange agreement, commodity price protection agreement or other interest or currency exchange rate or commodity price hedging arrangement. 

“HSBC Accounts” means the HSBC Operating Account and the HSBC Cash Management
Account. 
 “HSBC Cash Management Account” means the account numbered
030-159326-002 maintained by Borrower with HSBC Bank Canada. 
 “HSBC Operating
Account” means the account numbered 030-159326-001 maintained by Borrower with HSBC Bank Canada. 

“Indebtedness” of any Person means, without duplication, (a) all obligations of
such Person for borrowed money or obligations of such Person with respect to deposits or advances of any kind by third parties, (b) all obligations of such Person evidenced by bonds, debentures, notes or similar instruments, (c) all
obligations of such Person upon which interest charges are customarily paid, (d) all obligations of such Person under conditional sale or other title retention agreements relating to property acquired by such Person, (e) all obligations of
such Person in respect of the deferred purchase price of property or services (excluding current accounts payable incurred in the ordinary course of business), (f) all Indebtedness of others secured by (or for which the holder of such
Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on property owned or acquired by such Person, whether or not the Indebtedness secured thereby has been assumed, (g) all Guarantees by such Person of 

  
 9 

 
Indebtedness of others, (h) all Capital Lease Obligations of such Person, (i) all obligations, contingent or otherwise, of such Person as an account party in respect of letters of
credit and letters of guaranty, (j) obligations under any Hedging Agreement currency swaps, forwards, futures or derivatives transactions, and (k) all obligations, contingent or otherwise, of such Person in respect of bankers’
acceptances. The Indebtedness of any Person shall include the Indebtedness of any other entity (including any partnership in which such Person is a general partner) to the extent such Person is liable therefor as a result of such Person’s
ownership interest in or other relationship with such entity, except to the extent the terms of such Indebtedness provide that such Person is not liable therefor. 

“Indemnified Party” has the meaning set forth in Section
12.03(b). 
 “Indemnified Taxes” means (a) Taxes,
other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any Obligation and (b) to the extent not otherwise described in clause (a), Other Taxes. 

“Insolvency Proceeding” means (i) any case, action or proceeding before any court
or other Governmental Authority relating to bankruptcy, reorganization, insolvency, liquidation, receivership, dissolution, winding-up or relief of debtors, including any proceeding under applicable Canadian federal or provincial corporate law
seeking an arrangement or compromise of some or all of the debts of a Person or a stay of proceedings to enforce some or all claims of creditors against a Person, or (ii) any general assignment for the benefit of creditors, composition,
marshaling of assets for creditors, or other, similar arrangement in respect of any Person’s creditors generally or any substantial portion of such Person’s creditors, in each case undertaken under U.S. Federal, state, provincial,
territorial or foreign law, including the Bankruptcy Code.  
 “Intellectual Property”
means all Patents, Trademarks, Copyrights, and Technical Information, whether registered or not, domestic and foreign. Intellectual Property shall include all: 

(a) applications or registrations relating to such Intellectual Property; 

(b) rights and privileges arising under applicable Laws with respect to such Intellectual Property; 

(c) rights to sue for past, present or future infringements of such Intellectual Property; and 

(d) rights of the same or similar effect or nature in any jurisdiction corresponding to such Intellectual Property throughout
the world. 
 “Interest-Only Period” means the period from and including the first
Borrowing Date and through and including the sixteenth (16th) Payment Date following the first Borrowing Date. 

“Interest Period” means, with respect to each Borrowing, (i) initially, the period
commencing on and including the Borrowing Date thereof and ending on and excluding the next Payment Date, and, (ii) thereafter, each period beginning on and including the last day of the 

  
 10 

 
immediately preceding Interest Period and ending on and excluding the next succeeding Payment Date; provided that the term “Interest Period” shall include any period selected
by the Majority Lenders from time to time in accordance with the definition of “ Post-Default Rate”. 

“Invention” means any novel, inventive and useful art, apparatus, method, process,
machine (including article or device), manufacture or composition of matter, or any novel, inventive and useful improvement in any art, method, process, machine (including article or device), manufacture or composition of matter.  

“Investment” means, for any Person: (a) the acquisition (whether for cash,
property, services or securities or otherwise) of capital stock, bonds, notes, debentures, partnership or other ownership interests or other securities of any other Person or any agreement to make any such acquisition (including any “short
sale” or any sale of any securities at a time when such securities are not owned by the Person entering into such sale); (b) the making of any deposit with, or advance, loan or other extension of credit to, any other Person (including the
purchase of property from another Person subject to an understanding or agreement, contingent or otherwise, to resell such property to such Person), but excluding any such advance, loan or extension of credit having a term not exceeding 90 days
arising in connection with the sale of inventory or supplies by such Person in the ordinary course of business; (c) the entering into of any Guarantee of, or other contingent obligation with respect to, Indebtedness or other liability of any
other Person and (without duplication) any amount committed to be advanced, lent or extended to such Person; or (d) the entering into of any Hedging Agreement. 

“IRS” means the U.S. Internal Revenue Service or any successor agency, and to the extent
relevant, the U.S. Department of the Treasury. 
 “Judgment Currency”
has the meaning set forth in Section 12.21. 

“Knowledge” means the actual knowledge of any Responsible Officer of any Person or, so
long as he or she is employed by Borrower or its Subsidiaries, the actual knowledge of Timothy Triche, Doug Dolginow, or Elai Davicioni, so long as such Person is an officer of Borrower. 

“Landlord Consent” means a Landlord Consent substantially in the form of
Exhibit G or such other form as may be acceptable to the Agent. 

“Laws” means, collectively, all international, foreign, federal, state, provincial,
territorial, municipal and local statutes, treaties, rules, guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority
charged with the enforcement, interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case
whether or not having the force of law. 
 “Lenders” means CRG Partners III L.P., CRG
Partners III–Parallel Fund “A” L.P. and CRG Partners III (Cayman) L.P., together with their successors and each assignee of a Lender pursuant to Section 12.05(b) and “Lender” means any one of them. 

  
 11 

 “Lien” means any mortgage, lien,
pledge, charge or other security interest, or any lease, title retention agreement, mortgage, restriction, easement, right-of-way, option or adverse claim (of ownership or possession) or other encumbrance of any kind or character whatsoever or any
preferential arrangement that has the practical effect of creating a security interest. 

“Liquidity” means the balance of unencumbered cash (other than by the Liens in
connection with the Obligations) and Permitted Cash Equivalent Investments (which for greater certainty shall not include any undrawn credit lines), in each case, to the extent held in an account over which the Lenders have a first priority
perfected security interest. 
 “Loan” means (i) each loan
advanced by a Lender pursuant to Section 2.01 and (ii) each PIK Loan deemed to have been advanced by a Lender pursuant to Section 3.02(d). For purposes of clarification, any calculation of the aggregate outstanding
principal amount of Loans on any date of determination shall include both the aggregate principal amount of loans advanced pursuant to Section 2.01 and not yet repaid, and all PIK Loans deemed to have been advanced and not yet repaid, on
or prior to such date of determination. 
 “Loan Documents” means,
collectively, this Agreement, the Funding Indemnity Letter, the Fee Letter, the Notes, the Security Documents, any subordination agreement or any intercreditor agreement entered into by Lenders with any other creditors of Obligors, and any other
present or future document, instrument, agreement or certificate executed by Obligors for the benefit of Lenders in connection with this Agreement or any of the other Loan Documents, all as amended, restated, supplemented or otherwise
modified. 
 “Loss” means judgments, debts, liabilities, expenses,
costs, damages or losses, contingent or otherwise, whether liquidated or unliquidated, matured or unmatured, disputed or undisputed, contractual, legal or equitable, including loss of value, professional fees, including fees and disbursements of
legal counsel on a full indemnity basis, and all costs incurred in investigating or pursuing any Claim or any proceeding relating to any Claim. 

“Majority Lenders” means, at any time, Lenders having at such time in excess of 50% of the aggregate
Commitments (or, if such Commitments are terminated, the outstanding principal amount of the Loans) then in effect, ignoring, in such calculation, the Commitments of and outstanding Loans owing to any Defaulting Lender. 

“Margin Stock” means “margin stock” within the meaning of Regulations U and
X. 
 “Material Adverse Change” and “Material Adverse
Effect” mean a material adverse change in or effect on (i) the business, financial condition, operations, performance, or Property of Borrower and its Subsidiaries taken as a whole, (ii) the ability of any Obligor to perform
its obligations under the Loan Documents, or (iii) the legality, validity, binding effect or enforceability of the Loan Documents or the rights and remedies of the Lenders under any of the Loan Documents. For the avoidance of doubt, the
following events, in and of themselves, shall not constitute a Material Adverse Change or a Material Adverse Effect: (a) termination of any of Borrower’s or its Subsidiaries’ leases, so long as Borrower has an alternative or
replacement Clinical Laboratory Improvement Amendments (CLIA) facility, (b) a “going concern” or like qualification or “emphasis of matter” paragraph in an auditor’s opinion, (c) a claimed or notice 

  
 12 

 
of breach or termination of a Permitted Commercialization Arrangement, (d) inspection results from any regulatory authority with jurisdiction over the Product, (e) a non-coverage
determination by any third party payor providing reimbursement for procedures involving the Product, (f) the mere filing of any claim for damages or injunctive relief, whether or not relating to the Intellectual Property of Borrower or any
Subsidiary, and (g) the failure of a patent application listed on Schedule 7.05(b) to issue in any jurisdiction in which it is filed; it being understood, however, that the consequences of any such event might give rise to a Material
Adverse Change or a Material Adverse Effect. 
 “Material Agreements”
means (A) the agreements which are listed in Schedule 7.14 (as updated by Borrower from time to time in accordance with Section 7.20 to list all such agreements that meet the description set forth
in clause (B) of this definition) and (B) all other agreements held by the Obligors from time to time, the absence or termination of any of which would reasonably be expected to result in a Material Adverse Effect; provided, however,
that “Material Agreements” exclude all: (i) licenses implied by the sale of a product; (ii) paid-up licenses for commonly available software programs under which an Obligor is the licensee and (iii) customer agreements
and commercial agreements entered into in the ordinary course of business in connection with the sale and use of Borrower’s products. “Material Agreement” means any one such agreement. 

“Material Indebtedness” means, at any time, any Indebtedness of any Obligor, the
outstanding principal amount of which, individually or in the aggregate, exceeds $500,000 (or the Equivalent Amount in other currencies). 

“Material Intellectual Property” means, the Obligor Intellectual Property described in
Schedule 7.05(c) and any other Obligor Intellectual Property after the date hereof the loss of which, in each case, could reasonably be expected to have a Material Adverse Effect. 

“Maturity Date” means the earlier to occur of (i) the Stated Maturity Date, and
(ii) the date on which the Loans are accelerated pursuant to Section 11.02. 

“Maximum Rate” has the meaning set forth in Section 12.18. 

“Minimum Required Revenue” has the meaning set forth in Section in
10.02. 
 “Multiemployer Plan” means any multiemployer plan, as
defined in Section 400l(a)(3) of ERISA, to which any ERISA Affiliate incurs or otherwise has any obligation or liability, contingent or otherwise. 

“Non-Consenting Lender” has the meaning set forth in Section
2.07(a). 
 “Non-Disclosure Agreement” has the meaning
set forth in Section 12.16. 

“Note” means a promissory note executed and delivered by Borrower to the Lenders
in accordance with Section 2.04 or 3.02(d). 
 “Notice of
Borrowing” has the meaning set forth in Section 2.02. 

  
 13 

 “Notice of Default Interest” has the
meaning set forth in Section 3.02(b). 

“Obligations” means, with respect to any Obligor, all amounts, obligations, liabilities,
covenants and duties of every type and description owing by such Obligor to any Lender, any other indemnitee hereunder or any participant, arising out of, under, or in connection with, any Loan Document, whether direct or indirect (regardless of
whether acquired by assignment), absolute or contingent, due or to become due, whether liquidated or not, now existing or hereafter arising and however acquired, and whether or not evidenced by any instrument or for the payment of money, including,
without duplication, (i) if such Obligor is Borrower, all Loans, (ii) all interest, whether or not accruing after the filing of any petition in bankruptcy or after the commencement of any insolvency, reorganization or similar proceeding,
and whether or not a claim for post-filing or post-petition interest is allowed in any such proceeding, and (iii) all other fees, expenses (including fees, charges and disbursements of counsel), interest, commissions, charges, costs,
disbursements, indemnities and reimbursement of amounts paid and other sums chargeable to such Obligor under any Loan Document. 

“Obligor Intellectual Property” means Intellectual Property owned by or licensed to any
of the Obligors. 
 “Obligors” means, collectively, Borrower and the
Subsidiary Guarantors and their respective successors and permitted assigns. 

“Original Lenders” means CRG Partners III L.P., CRG Partners III–Parallel Fund
“A” L.P. and CRG Partners III (Cayman) L.P. 
 “Other Connection
Taxes” means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed,
delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in
any Loan or Loan Document). 
 “Other Taxes” means all present or
future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security
interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section 5.03(g)). 

“Participant” has the meaning set forth in Section 12.05(e). 

“Participant Register” has the meaning set forth in Section
12.05(e). 
 “Patents” is defined in the Security
Agreement or the Canadian Security Agreement, as applicable. 
 “Payment
Date” means each March 31, June 30, September 30, December 31 and the Maturity Date, commencing on the first such date to occur following the first Borrowing Date; 

  
 14 

 
provided that, if any such date shall occur on a day that is not a Business Day, the applicable Payment Date shall be the next preceding Business Day. 

“PBGC” means the United States Pension Benefit Guaranty Corporation referred to and
defined in ERISA and any successor entity performing similar functions. 
 “Permitted
Acquisition” means any acquisition by Borrower or any of its wholly-owned Subsidiaries, whether by purchase, merger, amalgamation or otherwise, of all or substantially all of the assets of, all of the Equity Interests of, or a business
line or unit or a division of, any Person; provided that: 

(a) immediately prior to, and after giving effect thereto, no Default or Event of Default shall have occurred
and be continuing or would result therefrom; 
 (b) all transactions in connection therewith shall be
consummated, in all material respects, in accordance with all applicable Laws and in conformity with all applicable Governmental Approvals; 

(c) in the case of the acquisition of all of the Equity Interests of such Person, all of the Equity
Interests (except for any such securities in the nature of directors’ qualifying shares required pursuant to applicable Law) acquired, or otherwise issued by such Person or any newly formed Subsidiary of Borrower in connection with such
acquisition, shall be owned 100% by an Obligor or any other Subsidiary, and Borrower shall have taken, or caused to be taken, as of the date such Person becomes a Subsidiary of Borrower, each of the actions set forth in Section 8.12, if
applicable; 
 (d) Borrower and its Subsidiaries shall be in compliance with the financial
covenants set forth in Section 10.01 and Section 10.02 on a pro forma basis after giving effect to such acquisition;  

(e) such Person (in the case of an acquisition of Equity Interests) or assets (in the case of an acquisition of
assets or a division) (i) shall be engaged or used, as the case may be, in the same or similar business or lines of business, or businesses ancillary thereto, in which Borrower and/or its Subsidiaries are engaged or (ii) shall have a
similar customer base as Borrower and/or its Subsidiaries, or shall be in a business related to cancer diagnostics; and 

(f) such Person has not at any time in the past or present established or been associated with any Canadian
Pension Plans or any Canadian Benefit Plans. 
 “Permitted Cash Equivalent
Investments” means any investments permitted by Borrower’s board approved investment policy as in effect as of the date of this Agreement, which policy may not be amended with the consent of the Majority Lenders. 

“Permitted Commercialization Arrangement” means such commercialization, research and
development, co-marketing and other collaborative arrangements, including joint ventures, in each case where (A) such arrangements provide for licenses to Patents, Trademarks, Copyrights or other Intellectual Property rights and assets of
Borrower with Persons with a  

  
 15 

 
primary line of business in the development, commercialization or manufacture of medical or diagnostic products or devices; provided that (i) such licenses must be bona fide
arms’-length transfers of the right to use such Intellectual Property that do not have the economic substance of a sale, (ii) the terms of such licenses, on their face, do not provide for a sale or assignment of any Intellectual Property,
and (iii) Borrower retains legal ownership of such Intellectual Property, and (B) all upfront payments, royalties, milestone payments or other proceeds arising from such licensing agreements that are payable to Borrower or any of its
Subsidiary Guarantors are paid only to Deposit Accounts that are governed by control agreements in favor of the Lenders. 

“Permitted Commercialization Arrangement Vehicle” means an entity, which may be a joint
venture enterprise, engaged in the business of a Permitted Commercialization Arrangement and in which Borrower or its Subsidiaries have substantial representation in the governing body of such entity. 

“Permitted Cure Debt” means Indebtedness incurred in connection with the exercise of the
Subordinated Debt Cure Right and (i) that is governed by documentation containing representations, warranties, covenants and events of default no more burdensome or restrictive than those contained in the Loan Documents unless such terms are
also offered to Lenders hereunder, (ii) that has a maturity date later than the Maturity Date, (iii) in respect of which no cash payments of principal or interest are required prior to the Maturity Date, and (iv) in respect of which
the holders have agreed in favor of Borrower and Lenders (A) that prior to the date on which the Commitments have expired or been terminated and all Obligations have been paid in full indefeasibly in cash, such holders will not exercise any
remedies available to them in respect of such Indebtedness, (B) that such Indebtedness is unsecured, and (C) to terms of subordination substantially in the form attached hereto as Exhibit H or otherwise
satisfactory to the Majority Lenders. 
 “Permitted Indebtedness” means
any Indebtedness permitted under Section 9.01. 

“Permitted Liens” means any Liens permitted under Section
9.02. 
 “Permitted Priority Debt” means Indebtedness
of Borrower, in an amount not to exceed at any time 80% of the face amount at such time of Borrower’s non delinquent accounts receivable; provided that (a) such Indebtedness, if secured, is secured solely
by Borrower’s accounts receivable, inventory and cash proceeds thereof held in a segregated account but is otherwise unsecured, and (b) the holders or lenders thereof have executed and delivered to Lenders an intercreditor agreement in
substantially the form of Exhibit I and with such changes (if any) as shall be mutually satisfactory to the Majority Lenders and the provider of such Indebtedness. 

“Permitted Priority Liens” means (i) Liens permitted under
Section 9.02(c), (d), (e), (f), (g), and (j), and (ii) Liens permitted under Section 9.02(b) provided that such Liens are also of the type described in Section 9.02(c), (d), (e), (f), (g), and (j). 

“Permitted Refinancing” means, with respect to any Indebtedness, any extensions,
renewals and replacements of such Indebtedness; provided that such extension, renewal or replacement (i) shall not increase the outstanding principal amount of such Indebtedness, (ii) 

  
 16 

 
contains terms relating to outstanding principal amount, amortization, maturity, collateral (if any) and subordination (if any), and other material terms taken as a whole no less favorable in any
material respect to Borrower and its Subsidiaries or the Lenders than the terms of any agreement or instrument governing such existing Indebtedness, (iii) shall have an applicable interest rate which does not exceed the rate of interest of the
Indebtedness being replaced, and (iv) shall not contain any new requirement to grant any lien or security or to give any guarantee that was not an existing requirement of such Indebtedness. 

“Permitted Subordinated Debt“means Indebtedness incurred (i) that is governed by
documentation containing representations, warranties, covenants and events of default no more burdensome or restrictive than those contained in the Loan Documents unless such terms are also offered to Lenders hereunder, (ii) that has a maturity
date later than the Maturity Date, (iii) in respect of which no cash payments of principal or interest are required prior to the Maturity Date, (iv) in respect of which the holders have agreed in favor of Borrower and Lenders (A) that
prior to the date on which the Commitments have expired or been terminated and all Obligations have been paid in full indefeasibly in cash, such holders will not exercise any remedies available to them in respect of such Indebtedness, (B) that
such Indebtedness is unsecured, and (C) to terms of subordination substantially in the form attached hereto as Exhibit H or otherwise satisfactory to the Majority Lenders, and (v) that must be converted
without the discretion of the holders into Equity Interests of Borrower at the next equity fundraising round of Borrower or earlier. 

“Person” means any individual, corporation, company, voluntary association, partnership,
limited liability company, joint venture, trust, unincorporated organization or Governmental Authority or other entity of whatever nature. 

“PIK Loan” has the meaning set forth in Section 3.02(d). 

“PIK Period” means the period beginning on the first Borrowing Date through and
including the earlier to occur of (i) the sixteenth (16th) Payment Date after the first Borrowing Date and (ii) the date on which any Default shall have occurred (provided
that if such Default shall have been cured or waived, the PIK Period shall resume until the earlier to occur of the next Default and the sixteenth (16th) Payment Date after the first
Borrowing Date). 
 “Plan” means any employee pension benefit plan (other than
a Multiemployer Plan) subject to the provisions of Title IV of ERISA or Section 412 of the Code or Section 302 of ERISA, and in respect of which Borrower or any ERISA Affiliate is (or, if such plan were terminated, would under
Section 4069 of ERISA be deemed to be) an “employer” as defined in Section 3(5) of ERISA. 

“Post-Default Rate” has the meaning set forth in
Section 3.02(b).  

“PPSA” shall mean the Personal Property Security Act (British Columbia),
the Civil Code of Québec or any other applicable Canadian federal, provincial or territorial statute pertaining to the granting, perfecting, priority or ranking of security interests, liens, hypothecs on personal property, and any successor
statues, together with any regulations thereunder, in each case as in effect from time to time. References to sections of the PPSA shall be construed to also  

  
 17 

 
refer to any successor sections. 

“Prepayment Premium” has the meaning set forth in Section
3.03(a). 
 “Product” means the Decipher prostate
cancer classifier test, and each of its successors. 
 “Property” of any
Person means any property or assets, or interest therein, of such Person. 

“Proportionate Share” means, with respect to any Lender, the percentage obtained by
dividing (a) the sum of the Commitment (or, if the Commitments are terminated, the outstanding principal amount of the Loans) of such Lender then in effect by (b) the sum of the Commitments (or, if the Commitments are terminated, the
outstanding principal amount of the Loans) of all Lenders then in effect. 
 “Publicly Reporting
Company”means an issuer generally subject to the public reporting requirements of the Securities and Exchange Act of 1934. 

“Qualified IPO” means (a) an underwritten initial public offering of the Equity
Interests of Borrower or any direct or indirect parent on a recognized public securities exchange or (b) a reverse-triangular merger, amalgamation or other similar transaction or series of related transactions with a company whose shares are
publically traded, in which such company is the surviving entity after such merger, amalgamation, transaction or series of related transactions. 

“Qualified Plan” means an employee benefit plan (as defined in Section 3(3) of
ERISA) other than a Multiemployer Plan (i) that is or was at any time maintained or sponsored by any Obligor or any ERISA Affiliate thereof or to which any Obligor or any ERISA Affiliate thereof has ever made, or was ever obligated to make,
contributions, and (ii) that is intended to be tax qualified under Section 401(a) of the Code. 

“Real Property Security Documents” means the Landlord Consent and any mortgage or deed
of trust or any other real property security document executed or required hereunder to be executed by any Obligor and granting a security interest in real Property owned or leased (as tenant) by any Obligor in favor of the Lenders.

 “Recipient” means any Lender or any other recipient of any payment to be
made by or on account of any Obligation. 
 “Redemption Date” has the
meaning set forth in Section 3.03(a). 

“Redemption Price” has the meaning set forth in Section
3.03(a). 
 “Register” has the meaning set
forth in Section 12.05(d). 
 “Regulation T” means Regulation T of the
Board of Governors of the Federal Reserve System, as amended. 
 “Regulation
U” means Regulation U of the Board of Governors of the Federal Reserve  

  
 18 

 
System, as amended. 
 “Regulation
X” means Regulation X of the Board of Governors of the Federal Reserve System, as amended. 

“Regulatory Approvals” means any registrations, licenses, authorizations, permits or
approvals issued by any Governmental Authority and applications or submissions related to any of the foregoing. 

“Related Party” means, with respect to any Person, such Person’s Affiliates and the
partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of such Person and of such Person’s Affiliates. 

“Removal Effective Date” has the meaning set forth in Section
14.06(b). 
 “Requirement of Law” means, as to any
Person, any statute, law, treaty, rule or regulation or determination, order, injunction or judgment of an arbitrator or a court or other Governmental Authority, in each case applicable to or binding upon such Person or any of its Properties or
revenues. 
 “Resignation Effective Date” has the meaning set forth in
Section 14.06(a). 
 “Responsible
Officer” of any Person means each of the president, chief executive officer, chief financial officer, chief medical officer and chief scientific officer of such Person. 

“Restricted Payment” means any dividend or other distribution (whether in cash,
securities or other property) with respect to any Equity Interest of Borrower or any of its Subsidiaries, or any payment (whether in cash, securities or other property), including any sinking fund or similar deposit, on account of the purchase,
redemption, retirement, acquisition, cancellation or termination of any such shares of capital stock of Borrower or any of its Subsidiaries or any option, warrant or other right to acquire any such shares of capital stock of Borrower or any of its
Subsidiaries.  
 “Restrictive Agreement” has the meaning set forth in
Section 7.15. 
 “Revenue” of a
Person means all revenue, properly recognized under GAAP, consistently applied, less all rebates, discounts and other price allowances, and earned in the ordinary course of business activities of the entity (excluding all one-time or extraordinary
items). For the avoidance of doubt, product sales shall not be deemed to be “one-time” revenue items. 

“Security Agreement” means the Security Agreement, dated as of the date hereof, among
GenomeDx Biosciences Corp., the Domestic Subsidiaries from time to time party thereto, the Lenders and the Agent, granting a security interest in such Obligors’ personal Property in favor of the Agent for its own benefit and for the ratable
benefit of the Lenders. 
 “Security Documents” means, collectively, the
Canadian Security Agreement, the Security Agreement, each Short-Form IP Security Agreement, each Real Property Security Document, and each other security document, control agreement or financing statement required 

  
 19 

 
or recommended to perfect Liens in favor of the Lenders. 

“Securities Account” has the meaning set forth in the Security Agreement or the Canadian
Security Agreement, as applicable. 
 “Short-Form IP Security
Agreements” means short-form copyright, patent or trademark (as the case may be) security agreements entered into by one or more Obligors in favor of the Lenders, each in form and substance satisfactory to the Majority Lenders (and as
amended, modified or replaced from time to time). 
 “Solvent”
means, with respect to any Person at any time, that (a) the present fair saleable value of the Property of such Person is greater than the total amount of liabilities (including contingent liabilities) of such Person, (b) the present fair
saleable value of the Property of such Person is not less than the amount that will be required to pay the probable liability of such Person on its debts as they become absolute and matured, (c) such Person has not incurred and does not intend
to, and does not believe that it will, incur debts or liabilities beyond such Person’s ability to pay as such debts and liabilities mature, (d) is not “insolvent” within the meaning of the Bankruptcy Code and
((e)) is not an “insolvent person” within the meaning of the Bankruptcy and Insolvency Act (Canada). 

“Specified Financial Covenants” has the meaning set forth in Section
10.03(a). 
 “Specified Proceeds” has the meaning set
forth in Section 9.09. 
 “Stated Maturity
Date” means the twenty-fourth (24th) Payment Date following the first Borrowing Date. 

“Subordinated Debt Cure Right” has the meaning set forth in Section
10.03(a). 
 “Subordinated Debt Cure Right” has the
meaning set forth in Section 10.03(a). 

“Subsidiary” means, with respect to any Person (the “parent”) at
any date, any corporation, limited liability company, partnership, association or other entity the accounts of which would be consolidated with those of the parent in the parent’s consolidated financial statements if such financial statements
were prepared in accordance with GAAP as of such date, as well as any other corporation, limited liability company, partnership, association or other entity (a) of which securities or other ownership interests representing more than 50% of the
equity or more than 50% of the ordinary voting power or, in the case of a partnership, more than 50% of the general partnership interests are, as of such date, owned, controlled or held, or (b) that is, as of such date, otherwise Controlled, by
the parent or one or more subsidiaries of the parent or by the parent and one or more subsidiaries of the parent. 

“Subsidiary Guarantors” means each of the Subsidiaries of Borrower identified
under the caption “SUBSIDIARY GUARANTORS” on the signature pages hereto and each Subsidiary of Borrower that becomes, or is required to become, a “Subsidiary Guarantor” after the date hereof pursuant to Section 8.12(a) or
(b). 
 “Substitute Lender” has the meaning set forth in
Section 2.07(a). 

  
 20 

 “SVB Debt” means all obligations under
the SVB Term Loan Agreement and all related loan documentation. 
 “SVB Term Loan
Agreement” means that certain Loan and Security Agreement, dated as of August 21, 2014, as amended, by and among Borrower, the lenders from time to time party thereto and Silicon Valley Bank, as administrative agent for itself and
the lenders. 
 “Taxes” means all present or future taxes, levies,
imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto. 

“Technical Information” means all trade secrets and other proprietary or confidential
information, which may include information of a scientific, technical, or business nature in any form or medium, standards and specifications, conceptions, ideas, innovations, discoveries, Invention disclosures, all documented research,
developmental, demonstration or engineering work, data, plans, specifications, reports, summaries, experimental data, manuals, models, samples, know-how, technical information, systems, methodologies, computer programs or information technology.
 
 “Title IV Plan” means an employee benefit plan (as defined in
Section 3(3) of ERISA) other than a Multiemployer Plan (i) that is or was at any time maintained or sponsored by any Obligor or any ERISA Affiliate thereof or to which any Obligor or any ERISA Affiliate thereof has ever made, or was
obligated to make, contributions, and (ii) that is or was subject to Section 412 of the Code, Section 302 of ERISA or Title IV of ERISA. 

“Trademarks” is defined in the Security Agreement or the Canadian Security Agreement, as
applicable. 
 “Transactions” means the execution, delivery and
performance by each Obligor of this Agreement and the other Loan Documents to which such Obligor is intended to be a party and the Borrowings (and the use of the proceeds of the Loans). 

“U.S. Person” means a “United States Person” within the meaning of
Section 7701(a)(30) of the Code. 
 “U.S. Tax Compliance
Certificate” has the meaning set forth in Section 5.03(e)(ii)(B)(3). 

“Withdrawal Liability” means, at any time, any liability incurred (whether or not
assessed) by any ERISA Affiliate and not yet satisfied or paid in full at such time with respect to any Multiemployer Plan pursuant to Section 4201 of ERISA. 

1.02 Accounting Terms and Principles. All accounting determinations required to be made pursuant hereto shall, unless expressly
otherwise provided herein, be made in accordance with GAAP. All components of financial calculations made to determine compliance with this Agreement, including Section 10, shall be adjusted to include or exclude, as the case may be,
without duplication, such components of such calculations attributable to any Acquisition consummated after the first day of the applicable period of determination and prior to the end of  

  
 21 

 
such period, as determined in good faith by Borrower based on assumptions expressed therein and that were reasonable based on the information available to Borrower at the time of preparation of
the Compliance Certificate setting forth such calculations. 
 1.03 Interpretation. For all purposes of this Agreement, except as
otherwise expressly provided herein or unless the context otherwise requires, (a) the terms defined in this Agreement include the plural as well as the singular and vice versa; (b) words importing gender include all genders; (c) any
reference to a Section, Annex, Schedule or Exhibit refers to a Section of, or Annex, Schedule or Exhibit to, this Agreement; (d) any reference to “this Agreement” refers to this Agreement, including all Annexes, Schedules and Exhibits
hereto, and the words herein, hereof, hereto and hereunder and words of similar import refer to this Agreement and its Annexes, Schedules and Exhibits as a whole and not to any particular Section, Annex, Schedule, Exhibit or any other subdivision;
(e) references to days, months and years refer to calendar days, months and years, respectively; (f) all references herein to “include” or “including” shall be deemed to be followed by the words “without
limitation”; (g) the word “from” when used in connection with a period of time means “from and including” and the word “until” means “to but not including”; and (h) accounting terms not
specifically defined herein shall be construed in accordance with GAAP (except for the term “property” , which shall be interpreted as broadly as possible, including, in any case, cash, securities, other assets, rights under contractual
obligations and permits and any right or interest in any property, except where otherwise noted). Unless otherwise expressly provided herein, references to organizational documents, agreements (including the Loan Documents) and other contractual
instruments shall be deemed to include all permitted subsequent amendments, restatements, extensions, supplements and other modifications thereto. 

1.04 Changes to GAAP. If, after the date hereof, any change occurs in GAAP or in the application thereof and such change would cause
any amount required to be determined for the purposes of the covenants to be maintained or calculated pursuant to Section 8, 9 or 10 to be materially different than the amount that would be determined prior to such change,
then: 
 (a) Borrower will provide a detailed notice of such change (an “Accounting Change
Notice”) to the Lenders concurrently with the delivery of the next Compliance Certificate; 
 (b) either
Borrower or the Majority Lenders may indicate within 90 days following the date of the Accounting Change Notice that they wish to revise the method of calculating such financial covenants or amend any such amount, in which case the parties will in
good faith attempt to agree upon a revised method for calculating the financial covenants; 
 (c) until Borrower and the
Majority Lenders have reached agreement on such revisions, (i) such financial covenants or amounts will be determined without giving effect to such change and (ii) all financial statements, Compliance Certificates and similar documents
provided hereunder shall be provided together with a reconciliation between the calculations and amounts set forth therein before and after giving effect to such change in GAAP; 

(d) if no party elects to revise the method of calculating the financial covenants or amounts, then the financial covenants or
amounts will not be revised and will be determined in accordance with GAAP without giving effect to such change; and 

  
 22 

 (e) any Event of Default arising as a result of such change which is cured
by operation of this Section 1.04 shall be deemed to be of no effect ab initio. 
 SECTION 2 

THE COMMITMENT 
 2.01
Commitments. Each Lender agrees severally, on and subject to the terms and conditions of this Agreement (including Section 6), to make up to three term loans (provided that PIK Loans shall be deemed not to constitute “term
loans” for purposes of this Section 2.01 nor reduce a Lender’s Commitment) to Borrower, each on a Business Day during the Commitment Period, including an initial term loan on the Closing Date, in Dollars in an aggregate
principal amount for such Lender not to exceed such Lender’s Commitment; provided, however, that at no time shall any Lender be obligated to make a Loan in excess of such Lender’s Proportionate
Share of the amount by which the then effective Commitments exceeds the aggregate principal amount of Loans outstanding at such time. Amounts of Loans repaid may not be reborrowed. 

2.02 Borrowing Procedures. Subject to the terms and conditions of this Agreement (including Section 6), each Borrowing
(other than a Borrowing of PIK Loans) shall be made on written notice in the form of Exhibit B given by Borrower to the Lenders not later than 11:00 a.m. (Central time) on the Borrowing Notice Date (a “Notice of
Borrowing”). 
 2.03 Fees. The Borrower shall pay to the Lenders such fees as described in the Fee
Letter. 
 2.04 Notes. If requested by any Lender, the Loans of such Lender shall be evidenced by one or more promissory notes
(each a “Note”). Borrower shall prepare, execute and deliver to the Lenders such promissory note(s) payable to the Lenders (or, if requested by the Lenders, to the Lenders and their registered assigns) and in
the form attached hereto as Exhibit C-1. Thereafter, the Loans and interest thereon shall at all times (including after assignment pursuant to Section 12.05) be represented by one or more promissory notes in such form payable to
the payee named therein (or, if such promissory note is a registered note, to such payee and its registered assigns). 
 2.05 Use
of Proceeds. Borrower shall use the proceeds of the Loans for general working capital purposes and corporate purposes and to pay fees, costs and expenses incurred in connection with the Transactions and to repay in full the SVB Debt. 

2.06 Defaulting Lenders.  

(a) Adjustments. Notwithstanding anything to the contrary contained in this Agreement, if any Lender becomes a
Defaulting Lender, then, until such time as that Lender is no longer a Defaulting Lender, to the extent permitted by applicable law: 

(i) Waivers and Amendments. Such Defaulting Lender’s right to approve or disapprove any amendment, waiver
or consent with respect to this Agreement shall be restricted as set forth in Section 12.04. 
 (ii)
Reallocation of Payments. Any payment of principal, interest, fees or other amounts received by the Lenders for the account of such Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to Section 11 or
otherwise), shall be applied at  

  
 23 

 
such time or times as follows: first, as Borrower may request (so long as no Default exists), to the funding of any Loan in respect of which such Defaulting Lender has failed to fund its
portion thereof as required by this Agreement; second, if so determined by the Majority Lenders and Borrower, to be held in a non-interest bearing deposit account and released in order to satisfy obligations of such Defaulting Lender to fund Loans
under this Agreement; third, to the payment of any amounts owing to the Lenders as a result of any judgment of a court of competent jurisdiction obtained by any Lender against such Defaulting Lender as a result of such Defaulting Lender’s
breach of its obligations under this Agreement; fourth, so long as no Default exists, to the payment of any amounts owing to Borrower as a result of any judgment of a court of competent jurisdiction obtained by Borrower against such Defaulting
Lender as a result of such Defaulting Lender’s breach of its obligations under this Agreement; and fifth, to such Defaulting Lender or as otherwise directed by a court of competent jurisdiction; provided that if (A) such payment is a
payment of the principal amount of any Loans in respect of which such Defaulting Lender has not fully funded its appropriate share and (B) such Loans were made at a time when the conditions set forth in Section 6 were satisfied or
waived, such payment shall be applied solely to pay the Loans of all non-Defaulting Lenders on a pro rata basis prior to being applied to the payment of any Loans of such Defaulting Lender. Any payments, prepayments or other
amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender pursuant to this Section 2.06(a)(ii) shall be deemed paid to and redirected by such Defaulting Lender, and each Lender
irrevocably consents hereto.  
 (b) Defaulting Lender Cure. If Borrower and the Majority Lenders agree
in writing in their sole discretion that a Defaulting Lender should no longer be deemed to be a Defaulting Lender, that Lender will, to the extent applicable, purchase that portion of outstanding Loans of the other Lenders or take such other actions
as necessary to cause the Loans to be held on a pro rata basis by the Lenders in accordance with their Proportionate Share, whereupon that Lender will cease to be a Defaulting Lender; provided that no adjustments will be made
retroactively with respect to fees accrued or payments made by or on behalf of Borrower while that Lender was a Defaulting Lender; and provided, further, that except to the extent otherwise expressly agreed by the affected parties, no change
hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any party hereunder arising from that Lender’s having been a Defaulting Lender. 

2.07 Substitution of Lenders. 

(a) Substitution Right. If any Lender (an “Affected Lender”), (i) becomes a Defaulting
Lender or (ii) does not consent to any amendment, waiver or consent to any Loan Document for which the consent of the Majority Lenders is obtained but that requires the consent of other Lenders (a “Non-Consenting
Lender”), then (x) Borrower may elect to pay in full such Affected Lender with respect to all Obligations due to such Affected Lender (which for the avoidance of doubt, shall not include any Prepayment Premium due) or
(y) either Borrower or the Majority Lenders shall identify any willing Lender or Affiliate of any Lender or Eligible Transferee (in each case, a “Substitute Lender”) to substitute for such Affected Lender; provided
that any substitution of a Non-Consenting Lender shall occur only with the consent of Majority Lenders. 

  
 24 

 (b) Procedure. To substitute such Affected Lender or pay in
full all Obligations owed to such Affected Lender, Borrower shall deliver a notice to such Affected Lender. The effectiveness of such payment or substitution shall be subject to the delivery by Borrower (or, as may be applicable in the case of a
substitution, by the Substitute Lender) of (i) payment for the account of such Affected Lender, of, to the extent accrued through, and outstanding on, the effective date for such payment or substitution, all Obligations owing to such Affected
Lender (which for the avoidance of doubt, shall not include any Prepayment Premium) and (ii) in the case of a substitution, an Assignment and Assumption executed by the Substitute Lender, which shall thereunder, among other things, agree to be
bound by the terms of the Loan Documents; provided, however, that if the Affected Lender does not execute such Assignment and Assumption within ten (10) Business Days of delivery of the notice required hereunder, such Affected Lender shall be
deemed to have executed such Assignment and Assumption. 
 (c) Effectiveness. Upon satisfaction of the
conditions set forth in Section 2.07(a) and (b), the Agent shall record such substitution or payment in the Register, whereupon (i) in the case of any payment in full of an Affected Lender, such Affected Lender’s
Commitments shall be terminated and (ii) in the case of any substitution of an Affected Lender, (A) such Affected Lender shall sell and be relieved of, and the Substitute Lender shall purchase and assume, all rights and claims of such
Affected Lender under the Loan Documents, except that the Affected Lender shall retain such rights under the Loan Documents that expressly provide that they survive the repayment of the Obligations and the termination of the Commitments,
(B) such Affected Lender shall no longer constitute a “Lender” hereunder and such Substitute Lender shall become a “Lender” hereunder and (C) such Affected Lender shall execute and deliver an Assignment and Assumption
to evidence such substitution; provided, however, that the failure of any Affected Lender to execute any such Assignment and Assumption shall not render such sale and purchase (or the corresponding
assignment) invalid. 
 2.08 Non-Disturbance Agreements. Lenders agree not to unreasonably withhold consent in entering into a
mutually acceptable non-disturbance agreement in connection with any exclusive license of Intellectual Property otherwise permitted under this Agreement. 

SECTION 3 
 PAYMENTS OF
PRINCIPAL AND INTEREST 
 3.01 Repayment.  

(a) Repayment. During the Interest-Only Period, no payments of principal of the Loans shall be due. Borrower
agrees to repay to the Lenders the outstanding principal amount of the Loans, on each Payment Date occurring after the Interest-Only Period, in equal installments. The amounts of such installments shall be calculated by dividing (i) the sum of
the aggregate principal amount of the Loans outstanding on the first day following the end of the Interest-Only Period, by (b) the number of Payment Dates remaining prior to and including the Stated Maturity Date. 

(b) Application. Any optional or mandatory prepayment of the Loans shall be applied to the installments thereof
under Section 3.01(a) in the inverse order of maturity. To the  

  
 25 

 
extent not previously paid, the principal amount of the Loans, together with all other outstanding Obligations, shall be due and payable on the Maturity Date. 

3.02 Interest.  

(a) Interest Generally. Subject to Section 3.02(d), Borrower agrees to pay to the Lenders interest
on the unpaid principal amount of the Loans and the amount of all other outstanding Obligations, in the case of the Loans, for the period from the applicable Borrowing Date, and in the case of any other Obligation, from the date such other
Obligation is due and payable, in each case, until paid in full, at a rate per annum equal to 13.00%. 

(b) Default Interest. Notwithstanding the foregoing, if an Event of Default
has occurred and is continuing, as of the earlier of (i) the date on which the Lenders deliver to Borrower a written notice pursuant to this Section 3.02(b) (such notice, a “Notice of Default
Interest”) that the Loans shall bear interest at the Post-Default Rate because an Event of Default has occurred and is continuing, and (ii) if Borrower shall have failed to deliver notice pursuant to
Section 8.02(a) of such Event of Default, the date on which such Event of Default occurred, and during the continuance of any such Event of Default, the interest payable pursuant to
Section 3.02(a) shall increase by 4.00% per annum (such aggregate increased rate, the “Post-Default Rate”). Notwithstanding any other provision
herein (including Section 3.02(d)), if interest is required to be paid at the Post-Default Rate, it shall be paid entirely in cash. If any other Obligation is not paid when due under the applicable Loan
Document, the amount thereof shall accrue interest at a rate equal to 4.00% per annum (without duplication of interest payable at the Post-Default Rate). 

(c) Interest Payment Dates. Subject to Section 3.02(d), accrued interest on the Loans shall be
payable in arrears on each Payment Date with respect to the most recently completed Interest Period in cash, and upon the payment or prepayment of the Loans (on the principal amount being so paid or prepaid); provided that
interest payable at the Post-Default Rate shall be payable from time to time on demand. 
 (d) Paid In-Kind
Interest. Notwithstanding Section 3.01(a), at any time during the PIK Period, Borrower may elect to pay the interest on the outstanding principal amount of the Loans payable pursuant to Section 3.01 as follows:
(i) only 9.00% of the 13.00% per annum interest in cash and (ii) 4.00% of the 13.00% per annum interest as compounded interest, added to the aggregate principal amount of the Loans (the amount of any such compounded
interest being a “PIK Loan”). At the request of the Lenders, each PIK Loan may be evidenced by a Note in the form of Exhibit C-2. The principal amount of each PIK Loan shall accrue interest in accordance with the
provisions of this Agreement applicable to the Loans. 
 (e) Interest Act (Canada). For the purposes of this
Agreement, whenever interest is calculated on the basis of a period which is less than the actual number of days in a calendar year, each rate of interest determined pursuant to such calculation is, for the purposes of the Interest Act
(Canada), equivalent to such rate multiplied by the actual number of days in the calendar year in which such rate is to be ascertained and divided by the number of days used as the basis of such calculation. 

  
 26 

 3.03 Prepayments.  

(a) Optional Prepayments. Borrower shall have the right to optionally prepay in whole or in part the outstanding
principal amount of the Loans on any Payment Date (a “Redemption Date”) for an amount equal to the aggregate principal amount of the Loans being prepaid plus the Prepayment Premium plus any accrued but unpaid interest and any
fees then due and owing (such aggregate amount, the “Redemption Price”). The applicable “Prepayment Premium” shall be an amount calculated pursuant to Section 3.03(a)(i). 

(i) If the Redemption Date occurs: 

(A) on or prior to the fourth (4th) Payment Date, the Prepayment
Premium shall be an amount equal to 5.00% of the aggregate outstanding principal amount of the Loans being prepaid on such Redemption Date; 

(B) after the fourth (4th) Payment Date, and on or prior to the
eighth (8th) Payment Date, the Prepayment Premium shall be an amount equal to 4.00% of the aggregate outstanding principal amount of the Loans being prepaid on such Redemption Date; 

(C) after the eighth (8th) Payment Date, and on or prior to the
twelfth (12th) Payment Date, the Prepayment Premium shall be an amount equal to 3.00% of the aggregate outstanding principal amount of the Loans being prepaid on such Redemption Date; 

(D) after the twelfth (12th) Payment Date, and on or prior to the
sixteenth (16th) Payment Date, the Prepayment Premium shall be an amount equal to 2.00% of the aggregate outstanding principal amount of the Loans being prepaid on such Redemption Date; 

(E) after the sixteenth (16th) Payment Date, and on or prior to the
twentieth (20th) Payment Date, the Prepayment Premium shall be an amount equal to 1.00% of the aggregate outstanding principal amount of the Loans being prepaid on such Redemption Date; 

(F) after the twentieth (20th) Payment Date, the Prepayment Premium
shall be an amount equal to 0.00% of the aggregate outstanding principal amount of the Loans being prepaid on such Redemption Date. 

(ii) To determine the aggregate outstanding principal amount of the Loans, and how many Payment Dates have occurred, as
of any Redemption Date for purposes of Section 3.03(a): 
 (A) if, as of such Redemption Date, the Borrower
shall have made only one Borrowing, the number of Payment Dates shall be deemed to be the number of Payment Dates that shall have occurred following the first Borrowing Date; 

(B) if, as of such Redemption Date, the Borrower shall have made more than one Borrowing, then the Redemption Price shall
equal the sum of multiple Redemption Prices calculated with respect to the Loans of each Borrowing, each of which 

  
 27 

 
Redemption Prices shall be calculated based on solely the aggregate outstanding principal amount of the Loans borrowed in such Borrowing (and PIK Loans subsequently borrowed in respect of
interest payments thereon), as though the applicable number of Payment Dates equals the number of Payment Dates that shall have occurred following the applicable Borrowing Date. In the case of any partial prepayment, the amount of such prepayment
shall be allocated to Loans made in the various Borrowings (and PIK Loans in respect thereof) in the order in which such Borrowings were made; 

(iii) No partial prepayment shall be made under this Section 3.03(a) in connection with any event described
in Section 3.03(b). 
 (b) Mandatory Prepayments. 

(i) Asset Sales. In the event of any contemplated Asset Sale or series of Asset Sales (other than any Asset Sale
permitted under Section 9.09 (except Section 9.09(k)) or a transaction constituting a Change of Control) yielding Asset Sale Net Proceeds in excess of $1,000,000, Borrower shall provide 30 days’ prior written notice of
such Asset Sale to the Lenders, in which notice Borrower may inform the Lenders that Borrower intends to reinvest such Asset Sale Net Proceeds into Borrower’s business. Such reinvestment is permitted hereunder so long as the Asset Sale does not
consist of the sale of Borrower’s business, and no Default or Event of Default has occurred or is continuing or will result from such Asset Sale. 

If Borrower does not notify the Lenders of its intention to reinvest the Asset Sale Net Proceeds in such notice, and within
such notice period Majority Lenders advise Borrower that a prepayment is required pursuant to this Section 3.03(b)(i), Borrower shall: (x) if the assets sold represent substantially all of the assets or revenues of Borrower, or represent
any specific line of business which either on its own or together with other lines of business sold over the term of this Agreement account for revenue generated by such lines of business exceeding 20% of the revenue of Borrower based on the current
year’s board of directors’ approved budget, prepay the aggregate outstanding principal amount of the Loans in an amount equal to the Redemption Price applicable on the date of such Asset Sale in accordance with Section 3.03(a), and
(y) in the case of all other Asset Sales not described in the foregoing clause (x), prepay the Loans in an amount equal to the entire amount of the Asset Sale Net Proceeds of such Asset Sale, plus any accrued but unpaid interest and any
fees then due and owing, credited in the following order: 
 (A) first, in reduction of Borrower’s obligation to pay
any unpaid interest and any fees then due and owing; 
 (B) second, in reduction of Borrower’s obligation to
pay any Claims or Losses referred to in Section 12.03 then due and owing; 
 (C) third, in reduction of
Borrower’s obligation to pay any amounts due and owing on account of the unpaid principal amount of the Loans; 
 (D)
fourth, in reduction of any other Obligation then due and owing; and 

  
 28 

 (E) fifth, to Borrower or such other Persons as may lawfully be entitled to
or directed by Borrower to receive the remainder. 
 If, however, in such notice of an impending Asset Sale, the
Borrower notifies the Lenders that it intends to reinvest the Asset Sale Net Proceeds in the Borrower’s business, it shall, deliver to the Agent a Certificate of a Responsible Officer setting forth (x) that portion of such Asset Sale Net
Proceeds that the Borrower intends to reinvest in equipment or other productive assets of the general type used in the business of the Obligors within 120 days of such date of receipt of proceeds and (y) the proposed use of such portion of the
Net Asset Sale Proceeds and such other information with respect to such reinvestment as the Agent or the Lenders may reasonably request, and the Borrower shall, or shall cause one or more of its Subsidiaries to, promptly and diligently apply such
Asset Sale Net Proceeds to reinvest in productive assets of the general type used in the business of the Obligors within 180 days of such date of receipt of proceeds. If any portion of such Asset Sale Net Proceeds has not been so reinvested as
provided above 120 days after receipt of such proceeds, the Borrower shall prepay the Loans in an amount equal to the unused amount of the Asset Sale Net Proceeds of such Asset Sale, plus any accrued but unpaid interest and any fees then due and
owing, credited in the order set forth in Sections 3.03(b)(i)(A)-(E) above. 
 (ii) Change of
Control. In the event of a Change of Control, Borrower shall immediately provide notice of such Change of Control to the Lenders and, if within 10 days of receipt of such notice Majority Lenders notify Borrower in writing that a prepayment is
required pursuant to this Section 3.03(b)(ii), Borrower shall prepay the aggregate outstanding principal amount of the Loans in an amount equal to the Redemption Price applicable on the date of such Change of Control in accordance with
Section 3.03(a). 
 SECTION 4 

PAYMENTS, ETC. 
 4.01
Payments.  
 (a) Payments Generally. Each payment of principal, interest and other amounts to be
made by the Obligors under this Agreement or any other Loan Document shall be made in Dollars, in immediately available funds, without deduction, set off or counterclaim, to an account to be designated by the Majority Lenders by notice to Borrower,
not later than 4:00 p.m. (Central time) on the date on which such payment shall become due (each such payment made after such time on such due date to be deemed to have been made on the next succeeding Business Day). 

(b) Application of Payments. Each Obligor shall, at the time of making each payment under this Agreement or any
other Loan Document, specify to the Lenders the amounts payable by such Obligor hereunder to which such payment is to be applied (and in the event that Obligors fail to so specify, or if an Event of Default has occurred and is continuing, the
Lenders may apply such payment in the manner they determine to be appropriate). 
 (c) Non-Business
Days. If the due date of any payment under this Agreement (other than of principal of or interest on the Loans) would otherwise fall on a day that is not a Business  

  
 29 

 
Day, such date shall be extended to the next succeeding Business Day, and, in the case of any payment accruing interest, interest thereon shall be payable for the period of such extension. 

4.02 Computations. All computations of interest and fees hereunder shall be computed on the basis of a year of 360 days and actual days
elapsed during the period for which payable. 
 4.03 Notices. Each notice of optional prepayment shall be effective only if
received by the Lenders not later than 4:00 p.m. (Central time) on the date one Business Day prior to the date of prepayment. Each notice of optional prepayment shall specify the amount to be prepaid and the date of prepayment. 

4.04 Set-Off.  

(a) Set-Off Generally. Upon the occurrence and during the continuance of any Event of Default, the Lenders and
each of their Affiliates are hereby authorized at any time and from time to time, to the fullest extent permitted by law, to set off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held and other
indebtedness at any time owing by the Lenders or such Affiliates to or for the credit or the account of Borrower against any and all of the Obligations, whether or not the Lenders shall have made any demand and although such obligations may be
unmatured. The Lenders agree promptly to notify Borrower after any such set-off and application, provided that the failure to give such notice shall not affect the validity of such set-off and application. The rights of the Lenders and their
Affiliates under this Section 4.04 are in addition to other rights and remedies (including other rights of set-off) that the Lenders and their Affiliates may have. 

(b) Exercise of Rights Not Required. Nothing contained herein shall require the Lenders to exercise any such
right or shall affect the right of the Lenders to exercise, and retain the benefits of exercising, any such right with respect to any other indebtedness or obligation of Borrower. 

SECTION 5 
 YIELD
PROTECTION, ETC. 
 5.01 Additional Costs.  

(a) Change in Requirements of Law Generally. If, on or after the date hereof, the adoption of any Requirement of
Law, or any change in any Requirement of Law, or any change in the interpretation or administration thereof by any court or other Governmental Authority charged with the interpretation or administration thereof, or compliance by any of the Lenders
(or its lending office) with any request or directive (whether or not having the force of law) of any such Governmental Authority, shall impose, modify or deem applicable any reserve (including any such requirement imposed by the Board of Governors
of the Federal Reserve System), special deposit, contribution, insurance assessment or similar requirement, in each case that becomes effective after the date hereof, against assets of, deposits with or for the account of, or credit extended by, a
Lender (or its lending office) or shall impose on a Lender (or its lending office) any other condition affecting the Loans or the Commitment, and the result of any of the foregoing is to increase the cost to such Lender of making or maintaining the
Loans, or to reduce the amount of any sum received or receivable by such Lender under this Agreement or any other  

  
 30 

 
Loan Document, by an amount deemed by such Lender to be material (other than (i) Indemnified Taxes and (ii) Taxes described in clause (c) or (d) of the
definition of “Excluded Taxes”), then Borrower shall pay to such Lender on demand such additional amount or amounts as will compensate such Lender for such increased cost or reduction. 

(b) Change in Capital Requirements. If a Lender shall have determined that, on or after the date hereof, the
adoption of any Requirement of Law regarding capital adequacy, or any change therein, or any change in the interpretation or administration thereof by any Governmental Authority charged with the interpretation or administration thereof, or any
request or directive regarding capital adequacy (whether or not having the force of law) of any such Governmental Authority, in each case that becomes effective after the date hereof, has or would have the effect of reducing the rate of return on
capital of a Lender (or its parent) as a consequence of a Lender’s obligations hereunder or the Loans to a level below that which a Lender (or its parent) would have achieved but for such adoption, change, request or directive by an amount
reasonably deemed by it to be material, then Borrower shall pay to such Lender on demand such additional amount or amounts as will compensate such Lender (or its parent) for such reduction.  

(c) Notification by Lender. The Lenders will promptly notify Borrower of any event of which it has knowledge,
occurring after the date hereof, which will entitle a Lender to compensation pursuant to this Section 5.01. Before giving any such notice pursuant to this Section 5.01(c) such Lender shall designate a different lending office
if such designation (x) will, in the reasonable judgment of such Lender, avoid the need for, or reduce the amount of, such compensation and (y) will not, in the reasonable judgment of such Lender, be materially disadvantageous to such
Lender. A certificate of the Lender claiming compensation under this Section 5.01, setting forth the additional amount or amounts to be paid to it hereunder, shall be conclusive and binding on Borrower in the absence of manifest error.
 
 (d) Notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and
Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel
Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to constitute a change in Requirements of Law for all
purposes of this Section 5.01, regardless of the date enacted, adopted or issued. 
 5.02 Illegality.
Notwithstanding any other provision of this Agreement, in the event that on or after the date hereof the adoption of or any change in any Requirement of Law or in the interpretation or application thereof by any competent Governmental Authority
shall make it unlawful for a Lender or its lending office to make or maintain the Loans (and, in the opinion of such Lender, the designation of a different lending office would either not avoid such unlawfulness or would be disadvantageous to such
Lender), then such Lender shall promptly notify Borrower thereof following which (a) the Lender’s Commitment shall be suspended until such time as such Lender may again make and maintain the Loans hereunder and (b) if such Requirement
of Law shall so mandate, the Loans shall be prepaid by Borrower on or before such date as shall be mandated by such Requirement of Law in an amount equal to the Redemption Price applicable on the date of such prepayment in accordance with Section
3.03(a). 

  
 31 

 5.03 Taxes.  

(a) Payments Free of Taxes. Any and all payments by or on account of any Obligation shall be made without
deduction or withholding for any Taxes, except as required by applicable law. If any applicable law requires the deduction or withholding of any Tax from any such payment by an Obligor, then such Obligor shall be entitled to make such deduction or
withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable law and, if such Tax is an Indemnified Tax, then the sum payable by such Obligor shall be increased as
necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under Section 5.01 or 5.03) the applicable Recipient receives an amount equal to
the sum it would have received had no such deduction or withholding been made. 
 (b) Payment of Other
Taxes by Borrower. Borrower shall timely pay to the relevant Governmental Authority in accordance with applicable law, or at the option of each Lender, timely reimburse it for, Other Taxes. 

(c) Evidence of Payments. As soon as practicable after any payment of Taxes by Borrower to a Governmental
Authority, as a withholding Tax pursuant to this Section 5.03, Borrower shall deliver to each Lender the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return
reporting such payment or other evidence of such payment reasonably satisfactory to the applicable Lender. 

(d) Indemnification. Borrower shall reimburse and indemnify each Recipient, within 10 days after demand
therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under Section 5.01 or 5.03) payable or paid by such Recipient or required to be withheld
or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority; provided
that Borrower shall not be required to indemnify a Recipient pursuant to this Section 5.03(d) to the extent that such Recipient fails to notify Borrower of its intent to make a claim for indemnification under this Section within 180
days of the later of (i) the date on which the Indemnified Taxes are due to be paid by Recipient, or (ii) the date on which the relevant Governmental Authority asserts a claim for such Indemnified Taxes against Recipient. A certificate
as to the amount of such payment or liability delivered to Borrower by a Lender shall be conclusive absent manifest error. 

(e) Status of Lenders. 

(i) Any Lender that is entitled to an exemption from, or reduction of withholding Tax with respect to payments made under any
Loan Document shall timely deliver to Borrower such properly completed and executed documentation reasonably requested by Borrower as will permit such payments to be made without withholding or at a reduced rate of withholding; provided that, other
than in the case of U.S. Federal withholding Taxes, such Lender has received written notice from Borrower advising it of the availability of such exemption or reduction and containing all applicable documentation. In addition, any Lender

  
 32 

 
shall deliver such other documentation prescribed by applicable law as reasonably requested by Borrower as will enable Borrower to determine whether or not such Lender is subject to backup
withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in
Section 5.03(e)(ii)(A), (B), (C) or (D)) shall not be required if in the Lender’s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense
or would materially prejudice the legal or commercial position of such Lender. 
 (ii) Without limiting the
generality of the foregoing, in the event that Borrower is a U.S. Person: 
 (A) any Lender that is a U.S. Person shall
deliver to Borrower on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of Borrower), executed originals of IRS Form W-9 (or successor form) certifying that
such Lender is exempt from U.S. Federal backup withholding tax; 
 (B) any Foreign Lender shall, to the extent it is
legally entitled to do so, deliver to Borrower (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the
reasonable request of Borrower), whichever of the following is applicable: 
 (1) in the case of a Foreign Lender claiming
the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed originals of IRS Form W-8BEN (or successor form) establishing an exemption from, or reduction
of, U.S. Federal withholding Tax pursuant to the “interest” article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN (or successor form) establishing an exemption from,
or reduction of, U.S. Federal withholding Tax pursuant to the “business profits” or “other income” article of such tax treaty; 

(2) executed originals of IRS Form W-8ECI (or successor form); 

(3) in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under
Section 881(c) of the Code, (x) a certificate substantially in the form of Exhibit D to the effect that such Foreign Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the
Code, a “10 percent shareholder” of the applicable Borrower within the meaning of Section 881(c)(3)(B) of the Code, or a “controlled foreign corporation” described in Section 881(c)(3)(C) of the Code (a “U.S.
Tax Compliance Certificate”) and (y) executed originals of IRS Form W-8BEN (or successor form); or 

(4) to the extent a Foreign Lender is not the beneficial owner, executed originals of IRS Form W-8IMY (or successor form),
accompanied by IRS Form W-8ECI (or successor form), IRS Form W-8BEN (or successor form), a U.S. Tax Compliance 

  
 33 

 
Certificate, IRS Form W-9 (or successor form), and/or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and one or more
direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate on behalf of each such direct and indirect partner. 

(C) any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to Borrower (in such number of copies as
shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of Borrower), executed originals of any other form
prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. Federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit Borrower to determine
the withholding or deduction required to be made; and 
 (D) any Recipient shall deliver to Borrower any forms and
information necessary to establish that such Recipient is not subject to withholding tax under FATCA. 
 Each Recipient agrees that if any
form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall promptly update such form or certification or promptly notify Borrower in writing of its legal inability to do so. 

(f) Treatment of Certain Refunds. If any party determines, in its sole discretion exercised in good faith, that
it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section 5.03 (including by the payment of additional amounts pursuant to Section 5.01), it shall pay to the indemnifying party an
amount equal to such refund (but only to the extent of indemnity payments made under this Section 5.03 with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party
and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the written request of such indemnified party, shall repay to such indemnified party the amount
paid over pursuant to this paragraph (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority.
Notwithstanding anything to the contrary in this Section 5.03(f), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this Section 5.03(f) the payment of which would place
the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the indemnification payments or additional amounts giving rise to such refund had never been paid. This Section 5.03(f)
shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person. 

(g) Mitigation Obligations. If Borrower is required to pay any Indemnified Taxes or additional amounts to any
Lender or to any Governmental Authority for the account of any Lender pursuant to Section 5.01 or this Section 5.03, then such Lender shall (at the request of Borrower) use commercially reasonable efforts to designate a
different lending office for funding or booking its Loans hereunder or to assign and delegate its rights and obligations hereunder to  

  
 34 

 
another of its offices, branches or Affiliates if, in the sole reasonable judgment of such Lender, such designation or assignment and delegation would (i) eliminate or reduce amounts
payable pursuant to Section 5.01 or this Section 5.03, as the case may be, in the future, (ii) not subject such Lender to any unreimbursed cost or expense and (iii) not otherwise be disadvantageous to such Lender.
Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment and delegation. 

SECTION 6 
 CONDITIONS
PRECEDENT 
 6.01 Conditions to the First Borrowing. The obligation of each Lender to make a Loan as part of the first Borrowing
shall not become effective until the following conditions precedent shall have been reasonably satisfied or waived in writing by the Majority Lenders: 

(a) Borrowing Date. Such Borrowing shall be made on the date hereof. 

(b) Amount of First Borrowing. The amount of such Borrowing shall equal $15,000,000. 

(c) Terms of Material Agreements, Etc. Lenders shall be reasonably satisfied with the terms and conditions of
all of the Obligors’ Material Agreements. 
 (d) No Law Restraining Transactions. No applicable
law or regulation shall restrain, prevent or, in the reasonable judgment of the Lenders, impose materially adverse conditions upon the Transactions. 

(e) Payment of Fees. Lenders shall be satisfied with the arrangements to deduct the fees set forth in the Fee
Letter (including without limitation the financing fee required pursuant to the Fee Letter) from the proceeds advanced. 

(f) Lien Searches. Lenders shall be satisfied with Lien searches regarding Borrower and its Subsidiaries made
within two Business Days prior to such Borrowing. 
 (g) Documentary Deliveries. The Lenders shall have
received the following documents, each of which shall be in form and substance satisfactory to the Lenders: 

(i) Agreement. This Agreement duly executed and delivered by Borrower and each of the other parties hereto.

 (ii) Security Documents. 

(A) The Security Agreement, duly executed and delivered by GenomeDx Biosciences Corp. 

(B) The Canadian Security Agreement, duly executed and delivered by the Borrower. 

  
 35 

 (C) Each of the Short-Form IP Security Agreements, duly executed and
delivered by the applicable Obligor. 
 (D) Original share certificates or other documents or evidence of title with regard
to all Equity Interests owned by the Obligors (to the extent that such Equity Interests are certificated), together with share transfer documents, undated and executed in blank. 

(E) Subject to Section 8.16(c), duly executed control agreements in favor of the Lenders for all Deposit
Accounts, Securities Accounts and Commodity Accounts owned by the Obligors in the United States or in Canada. 
 (F)
Evidence of filing of UCC-1 or PPSA financing statements, as applicable, against each Obligor in its jurisdiction of formation or incorporation, the jurisdiction in which its chief executive office is located or the jurisdiction in which its assets
are located, as the case may be. 
 (G) Evidence of filing of each of the Short-Form IP Security Agreements in the United
States Patent and Trademark Office or the United States Copyright office, as applicable. 
 (H) Without limitation, all
other documents and instruments reasonably required to perfect the Lenders’ Lien on, and security interest in, the Collateral required to be delivered on or prior to such Borrowing Date shall have been duly executed and delivered and be in
proper form for filing, and shall create in favor of the Lenders, a perfected Lien on, and security interest in, the Collateral, subject to no Liens other than Permitted Liens. 

(iii) Notes. Any Notes requested in accordance with Section 2.04. 

(iv) Approvals. Copies of all material licenses, consents, authorizations and approvals of, and notices to and
filings and registrations with, any Governmental Authority (including all foreign exchange approvals), and of all third-party consents and approvals, necessary in connection with the making and performance by the Obligors of the Loan Documents and
the Transactions. 
 (v) Corporate Documents. Certified copies of the constitutive documents of each
Obligor (if publicly available in such Obligor’s jurisdiction of formation) and of resolutions of the Board of Directors (or shareholders, if applicable) of each Obligor authorizing the making and performance by it of the Loan Documents to
which it is a party. 
 (vi) Incumbency Certificate. A certificate of each Obligor as to the authority,
incumbency and specimen signatures of the persons who have executed the Loan Documents and any other documents in connection herewith on behalf of the Obligors. 

(vii) Good Standing Certificates. Subject to Section 8.16(e), a certificate from the appropriate
Governmental Authority, bearing a current date acceptable to the Agent, to the effect that each Obligor not an individual is in good standing and qualified to transact business in its jurisdiction of organization and in each other jurisdiction where
it transacts business. 

  
 36 

 (viii) Officer’s Certificate. A certificate, dated such
Borrowing Date and signed by the President, a Vice President or a financial officer of Borrower, confirming compliance with the conditions set forth in Section 6.04. 

(ix) Opinions of Counsel. A favorable opinion, dated such Borrowing Date, of counsel to each Obligor in form
acceptable to the Lenders and their counsel, responsive to the requests set forth in Exhibit F. 
 (x)
Insurance. Subject to Section 8.16(d), certificates of insurance evidencing the existence of all insurance required to be maintained by Borrower pursuant to Section 8.05(b) and the designation of the Lenders as lender
loss payees or additional insured, as the case may be, thereunder. 
 (xi) SVB Loan Agreement. A payoff
letter providing that (A) the SVB Term Loan Agreement shall be terminated and all loans and obligations thereunder repaid in full as of the Closing Date upon the funding of the Loans on such Borrowing Date, and (B) all Liens in favor of
the secured parties under the SVB Term Loan Agreement shall be released on such Borrowing Date or promptly thereafter with the filing of release documents, PPSA discharges and UCC termination statements. 

(xii) Funding Indemnity Letter. The Borrower shall have executed and delivered to the Lenders the Funding
Indemnity Letter no later than twelve (12) Business Days prior to the Borrowing Date of the first Borrowing hereunder. 

(xiii) Shareholder Consent. Evidence satisfactory to the Lenders that the shareholders of the Borrower holding
at least 35% of the Series B preferred stock of the Borrower have entered into a postponement agreement to postpone their rights to redeem the Series B preferred stock of Borrower until such time when all Obligations under this Agreement and the
other Loan Documents have been indefeasibly paid in full or such earlier time upon the written consent of the Lenders. 
 6.02
Conditions to Second Borrowing. The obligation of each Lender to make a Loan as part of a second Borrowing is subject to the following conditions precedent: 

(a) Borrowing Date. Such Borrowing shall occur on or prior to March 28, 2016, or if Borrower fails to meet
the minimum Revenue during the time period set forth in Section 6.02(c)(i), but meets the minimum Revenue during the time period set forth in Section 6.02(c)(ii), then on or prior to September 27, 2016. 

(b) Amount of Borrowing. The amount of such Borrowing shall be at Borrower’s option and shall be up to
$5,000,000. 
 (c) Borrowing Milestone. Borrower shall have achieved minimum Revenue of (i) at
least $4,000,000 during any consecutive three (3) month period, provided that Borrower shall have achieved such Borrowing milestone relating to minimum Revenue no later than December 31, 2015, or (ii) if Borrower
fails to meet the minimum Revenue during the time period set forth in Section 6.02(c)(i), at least $7,000,000 during any consecutive three (3) month period, provided that Borrower shall have achieved such
Borrowing milestone relating to minimum  

  
 37 

 
Revenue no later than June 30, 2016. For the avoidance of doubt, the conditions of this Section 6.02(c)(ii) and Section 6.03(c) may be satisfied with the same
three (3) month period. 
 (d) Notice of Milestone Achievement and Audit. Borrower shall have
delivered to the Lenders a notice certifying satisfaction of the conditions set forth in Section 6.02(c) no later than 60 calendar days thereafter, and the Lenders shall have been reasonably satisfied with the evidence of such
achievement and with the results of its audit of Borrower’s Revenue by examining Borrower’s books and records.  

(e) Notice of Borrowing. A Notice of Borrowing shall have been received no later than 60 calendar days after
satisfaction of the condition set forth in Section 6.02(c). 
 6.03 Conditions to Third Borrowing. The obligation of
each Lender to make a Loan as part of a third Borrowing is subject to the following conditions precedent: 

(a) Borrowing Date. Such Borrowing shall occur on or prior to September 27, 2016. 

(b) Amount of Borrowing. The amount of such Borrowing shall be at Borrower’s option and shall be up to
$5,000,000. 
 (c) Borrowing Milestone. Borrower shall have achieved minimum Revenue of at least
$7,000,000 during any consecutive three (3) month period, provided that Borrower shall have achieved such Borrowing milestone relating to minimum Revenue no later than June 30, 2016. For the avoidance of doubt, the
conditions of this Section 6.03(c) and Section 6.02(c)(ii) may be satisfied with the same three (3) month period. 

(d) Notice of Milestone Achievement and Audit. Borrower shall have delivered to the Lenders a notice certifying
satisfaction of the conditions set forth in Section 6.03(c) no later than 60 calendar days thereafter, and the Lenders shall have been reasonably satisfied with the evidence of such achievement and with the results of its audit of
Borrower’s Revenue by examining Borrower’s books and records.  
 (e) Notice of Borrowing. A
Notice of Borrowing shall have been received no later than 60 calendar days after satisfaction of the condition set forth in Section 6.03(c). 

(f) Second Borrowing. A second Borrowing has occurred pursuant to Section 6.02. 

6.04 Conditions to Each Borrowing. The obligation of each Lender to make a Loan as part of any Borrowing (including the first
Borrowing) is also subject to satisfaction of the following further conditions precedent on the applicable Borrowing Date: 

(a) Commitment Period. Except in the case of any PIK Loan, such Borrowing Date shall occur during the Commitment
Period. 
 (b) No Default; Representations and Warranties. Both immediately prior to the making of such
Loan and after giving effect thereto and to the intended use thereof: 
 (i) no Default shall have occurred and be
continuing; and 

  
 38 

 (ii) the representations and warranties made by Borrower in Section 7
shall be true on and as of the Borrowing Date, and immediately after giving effect to the application of the proceeds of the Borrowing, with the same force and effect as if made on and as of such date (except that the representation regarding
representations and warranties that refer to a specific earlier date shall be that they were true on such earlier date). 

(c) Notice of Borrowing. Except in the case of any PIK Loan, the Lenders shall have received a Notice of Borrowing as
and when required pursuant to Section 2.02. 
 Each Borrowing shall constitute a certification by Borrower to
the effect that the conditions set forth in this Section 6.04 have been fulfilled as of the applicable Borrowing Date. 

SECTION 7 

REPRESENTATIONS AND WARRANTIES 

Borrower represents and warrants to the Lenders that: 

7.01 Power and Authority. Each of Borrower and its Subsidiaries (a) is a duly organized and validly existing under the laws of its
jurisdiction of organization, (b) has all requisite corporate or other power, and has all material governmental licenses, authorizations, consents and approvals necessary to own its assets and carry on its business as now being or as proposed
to be conducted except to the extent that failure to have the same would not reasonably be expected to have a Material Adverse Effect, (c) is qualified to do business and is in good standing in all jurisdictions in which the nature of the
business conducted by it makes such qualification necessary and where failure so to qualify would (either individually or in the aggregate) have a Material Adverse Effect, and (d) has full power, authority and legal right to make and perform
each of the Loan Documents to which it is a party and, in the case of Borrower, to borrow the Loans hereunder. 
 7.02 Authorization;
Enforceability. The Transactions are within each Obligor’s corporate powers and have been duly authorized by all necessary corporate and, if required, by all necessary shareholder action. This Agreement has been duly executed and delivered
by each Obligor and constitutes, and each of the other Loan Documents to which it is a party when executed and delivered by such Obligor will constitute, a legal, valid and binding obligation of such Obligor, enforceable against each Obligor in
accordance with its terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability affecting the enforcement of creditors’ rights and (b) the
application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). 

7.03 Governmental and Other Approvals; No Conflicts. The Transactions (a) do not require any consent or approval of, registration
or filing with, or any other action by, any Governmental Authority or any third party, except for (i) such as have been obtained or made and are in full force and effect and (ii) filings and recordings in respect of the Liens created
pursuant to the Security Documents, (b) will not violate any applicable law or regulation or the charter, bylaws or other organizational documents of Borrower and its Subsidiaries or any order of any Governmental Authority, other than any such
violations that, either individually or in the 

  
 39 

 
aggregate, would not reasonably be expected to have a Material Adverse Effect, (c) will not violate or result in a default under any material indenture, agreement or other instrument binding
upon Borrower and its Subsidiaries or assets, or give rise to a right thereunder to require any payment to be made by any such Person, and (d) will not result in the creation or imposition of any Lien (other than Permitted Liens) on any asset
of Borrower and its Subsidiaries. 
 7.04 Financial Statements; Material Adverse Change. 

(a) Financial Statements. Borrower has heretofore furnished to the Lenders certain financial statements as
provided for in Section 8.01. Such financial statements present fairly, in all material respects, the financial position and results of operations and cash flows of Borrower and its Subsidiaries as of such dates and for such periods in
accordance with GAAP and consistent with Borrower’s past practice, subject to year-end audit adjustments and the absence of footnotes in the case of the previously-delivered statements of the type described in Section 8.01(b).
Neither Borrower nor any of its Subsidiaries has any material contingent liabilities or unusual forward or long-term commitments not disclosed in the aforementioned financial statements. 

(b) No Material Adverse Change. Since December 31, 2014, there has been no Material Adverse Change.

 7.05 Properties.  

(a) Property Generally. Each Obligor has good and marketable fee simple title to, or valid leasehold interests
in, all its real and personal Property material to its business, subject only to Permitted Liens and except as would not reasonably be expected to interfere with its ability to conduct its business as currently conducted or to utilize such
properties for their intended purposes. 
 (b) Intellectual Property. The Obligors represent and
warrant to the Lenders as of the date hereof as follows, and the Obligors acknowledge that the Lenders are relying on such representations and warranties in entering into this Agreement: 

(i) Schedule 7.05(b) (as amended from time to time by Borrower in accordance with Section 7.20)
contains: 
 (A) a complete and accurate list of all applied for or issued Patents, including the jurisdiction and
patent number; 
 (B) a complete and accurate list of all applied for or registered Trademarks, including the jurisdiction,
trademark application or registration number and the application or registration date; and 
 (C) a complete and accurate
list of all applied for or registered Copyrights; 
 (ii) Each Obligor is the sole or joint owner of all right, title and
interest in and , subject to any exclusive licenses granted thereunder, has the right to use the Obligor Intellectual 

  
 40 

 
Property purported to be owned by such Obligor, except as to expired Patents with no breaks in chain of title with good and marketable title, free and clear of any Liens or Claims of any kind
whatsoever other than Permitted Liens. Without limiting the foregoing, and except as set forth in Schedule 7.05(b) (as amended from time to time by Borrower in accordance with Section 7.20): 

(A) other than with respect to the Material Agreements, or as permitted by Section 9.09, the Obligors have
not transferred ownership of Material Intellectual Property, in whole or in part, to any other Person who is not an Obligor; 

(B) other than (i) the Material Agreements, (ii) customary restrictions in in-bound licenses of Intellectual
Property and non-disclosure agreements, or (iii) as would have been or is permitted by Section 9.09, there are no judgments, covenants not to sue, permits, grants, licenses, Liens (other than Permitted Liens), Claims, or other
agreements or arrangements relating to Borrower’s Material Intellectual Property, including any development, submission, services, research, license or support agreements, which bind, obligate or otherwise restrict the Obligors;  

(C) the use of any of the Obligor Intellectual Property, in the manner substantially similar to its use by Borrower in the
conduct of its business as of the date hereof, to Borrower’s Knowledge, does not breach, violate, infringe or interfere with or constitute a misappropriation of any valid rights arising under any Intellectual Property of any other Person; 

(D) there are no pending or, to Borrower’s Knowledge, threatened Claims against the Obligors asserted by any other
Person involving the Obligor Intellectual Property, including any Claims of adverse ownership, invalidity, infringement, misappropriation, violation or other opposition to such Intellectual Property; the Obligors have not received any written notice
from any Person that Borrower’s business, the use of the Obligor Intellectual Property, or the manufacture, use or sale of any product or the performance of any service by Borrower infringes, violates or constitutes a misappropriation of, or
may infringe, violate or constitute a misappropriation of, or otherwise interfere with, any other Intellectual Property of such Person; 

(E) the Obligors have no Knowledge that the Obligor Intellectual Property is being infringed, violated, misappropriated or
otherwise used by any other Person without the express authorization of the Obligors. Without limiting the foregoing, the Obligors have not put any other Person on notice of actual or potential infringement, violation or misappropriation of any of
the Obligor Intellectual Property; the Obligors have not initiated the enforcement of any Claim with respect to any of the Obligor Intellectual Property; 

(F) to Borrower’s Knowledge, all relevant current and former employees of Borrower and all independent contractors of
Borrower whose services reasonably might be expected to result in the creation of any Intellectual Property have executed written confidentiality and invention assignment Contracts with Borrower that irrevocably assign to Borrower or its designee
all of their rights to any Inventions relating to Borrower’s business; 

  
 41 

 (G) to the Knowledge of the Obligors, the Obligor Intellectual Property is
all the Intellectual Property necessary for the operation of Borrower’s business as it is currently conducted; 
 (H)
the Obligors have taken reasonable precautions to protect the secrecy, confidentiality and value of the trade secrets and confidential information in such Obligor’s Intellectual Property; 

(I) each Obligor has delivered to the Lenders accurate and complete copies of all Material Agreements relating to the Obligor
Intellectual Property; 
 (J) there are no pending or, to the Knowledge of any of the Obligors, threatened in writing
Claims against the Obligors asserted by any other Person relating to the Material Agreements, including any Claims of breach or default under such Material Agreements; 

(iii) With respect to the Material Intellectual Property consisting of Patents owned by an Obligor, except as set forth
in Schedule 7.05(b) (as amended from time to time by Borrower in accordance with Section 7.20), and without limiting the representations and warranties in Section 7.05(b)(ii): 

(A) each of the issued claims in such Patents, to Borrower’s Knowledge, is valid and enforceable; 

(B) the inventors identified in such Patents have executed written Contracts with Borrower (or other Obligor) or its
predecessor-in-interest that properly and irrevocably assigns to Borrower (or other Obligor) or predecessor-in-interest all of their rights to any of the Inventions claimed in such Patents to the extent permitted by applicable law; 

(C) none of such Patents, or the Inventions claimed in them, have been dedicated to the public except as a result of
intentional decisions made by the applicable Obligor; 
 (D) to Borrower’s Knowledge, all prior art material to such
Patents has been timely and adequately disclosed to or considered by the respective patent offices during prosecution of such Patents to the extent required by applicable law or regulation; 

(E) subsequent to the issuance of such Patents, neither Borrower nor any Subsidiary Guarantors or their predecessors in
interest, have filed any disclaimer of such Patents, other than terminal disclaimers to overcome double patenting rejections by the U.S. Patent and Trademark Office, or filed any other voluntary reduction in the scope of the Inventions claimed in
such Patents; 
 (F) Borrower has not received written notice that any claim of such Patent is subject to any competing
conception claims of allowable or allowed subject matter of any patent applications or patents of any third party and no such Patent has been the subject of any interference, re-examination, inter partes review, post-grant review, or opposition
proceedings, nor are the Obligors aware of any basis for any such interference, re-examination, inter partes review, post-grant review, or opposition proceedings; 

  
 42 

 (G) no such Patents, to Borrower’s Knowledge, have ever been finally
adjudicated to be invalid, unpatentable or unenforceable for any reason in any administrative, arbitration, judicial or other proceeding, and, with the exception of publicly available documents in the applicable Patent Office recorded with respect
to any Patents, the Obligors have not received any notice asserting that such Patents are invalid, unpatentable or unenforceable; if any of such Patents is terminally disclaimed to another patent or patent application, all patents and patent
applications subject to such terminal disclaimer are included in the Collateral; 
 (H) there is no fact or circumstance
known to the Obligors that would cause them to reasonably conclude that any of the issued patents in such Patents is invalid or unenforceable; 

(I) the Obligors have no Knowledge that they or any prior owner of such Patents or their respective agents or representatives
have engaged in any conduct, or omitted to perform any necessary act, the result of which would invalidate or render unpatentable or unenforceable any such Patents; and 

(J) all maintenance fees, annuities, and the like due or payable on the Patents have been timely paid or the failure to so
pay was the result of an intentional decision by the applicable Obligor or would not reasonably be expected to result in a Material Adverse Change. 

(iv) none of the foregoing representations and statements of fact contains any untrue statement of material fact or omits to
state any material fact necessary to make any such statement or representation not misleading to a prospective Lender seeking full information as to the Obligor Intellectual Property and the Borrower’s business. 

(c) Material Intellectual Property. Schedule 7.05(c) (as amended from time to time by Borrower in
accordance with Section 7.20) contains an accurate list of the Obligor Intellectual Property the loss of which, either individually or in the aggregate, reasonably would be expected to have a Material Adverse Effect, with an indication
as to whether the applicable Obligor owns or has an exclusive or non-exclusive license to such Obligor Intellectual Property.  

7.06 No Actions or Proceedings.  

(a) Litigation. There is no litigation, investigation or proceeding pending or, to Borrower’s Knowledge,
threatened in writing with respect to Borrower and its Subsidiaries by or before any Governmental Authority or arbitrator (i) that either individually or in the aggregate would reasonably be expected to have a Material Adverse Effect, except as
specified in Schedule 7.06 (as amended from time to time by Borrower in accordance with Section 7.20) or (ii) that involves this Agreement or the Transactions. 

(b) Environmental Matters. The operations and Property of Borrower and its Subsidiaries comply with all
applicable Environmental Laws, except to the extent the failure to so comply (either individually or in the aggregate) would not reasonably be expected to have a Material Adverse Effect. 

  
 43 

 (c) Labor Matters. There are no labor actions or disputes
involving the employees of Borrower that would reasonably be expected to have a Material Adverse Effect. 
 7.07 Compliance with
Laws and Agreements. Each of the Obligors is in compliance with all laws, regulations and orders of any Governmental Authority applicable to it or its property and all indentures, agreements and other instruments binding upon it or its property,
except where the failure to do so, individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Effect. No Default has occurred and is continuing. 

7.08 Taxes. Except as set forth on Schedule 7.08, each of the Obligors has timely filed or caused to be filed all material Tax
returns and reports required to have been filed and has paid or caused to be paid all material Taxes (assessed above $50,000) required to have been paid by it, except Taxes that are being contested in good faith by appropriate proceedings and for
which such Obligor has set aside on its books adequate reserves with respect thereto generally in accordance with GAAP and consistent with Borrower’s past practice.  

7.09 Full Disclosure. Borrower has disclosed to the Lenders all Material Agreements to which any Obligor is subject, and all other
matters to its Knowledge, that, individually or in the aggregate, would reasonably be expected to result in a Material Adverse Effect. None of the reports, financial statements, certificates or other information furnished by or on behalf of the
Obligors to the Lenders in connection with the negotiation of this Agreement and the other Loan Documents or delivered hereunder or thereunder (as modified or supplemented by other information so furnished) contains any material misstatement of
material fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that, with respect to projected financial
information, Borrower represents only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time. 

7.10 Regulation.  

(a) Investment Company Act. Neither Borrower nor any of its Subsidiaries is an “investment company” as
defined in, or subject to regulation under, the Investment Company Act of 1940. 
 (b) Margin Stock.
Neither Borrower nor any of its Subsidiaries is engaged principally, or as one of its important activities, in the business of extending credit for the purpose, whether immediate, incidental or ultimate, of buying or carrying Margin Stock, and no
part of the proceeds of the Loans will be used to buy or carry any Margin Stock in violation of Regulation T, U or X. 
 7.11
Solvency. Borrower is and, immediately after giving effect to the Borrowing and the use of proceeds thereof will be, Solvent. 

7.12 Subsidiaries. Set forth on Schedule 7.12 is a complete and correct list of all Subsidiaries as of the date hereof. Each
such Subsidiary is duly organized and validly existing under the jurisdiction of its organization shown in said Schedule 7.12, and the percentage ownership by Borrower of each such Subsidiary is as shown in said Schedule 7.12.

  
 44 

 7.13 Indebtedness and Liens. Set forth on Schedule 7.13(a) is a complete and
correct list of all Indebtedness of each Obligor outstanding as of the date hereof. Schedule 7.13(b) lists all Liens affirmatively granted by Borrower and other Obligors with respect to their respective Property and outstanding as of the date
hereof. 
 7.14 Material Agreements. Set forth on Schedule 7.14 (as amended from time to time by Borrower in accordance
with Section 7.20) is a complete and correct list of (i) each Material Agreement and (ii) each agreement creating or evidencing any Material Indebtedness. No Obligor is in material default under any such Material Agreement or
agreement creating or evidencing any Material Indebtedness. Except as otherwise disclosed on Schedule 7.14, all material vendor purchase agreements and supplier contracts of the Obligors are in full force and effect without material
modification from the form in which the same were disclosed to the Lenders, except for such modifications as would not reasonably be expected to be adverse to the interests of Lenders. 

7.15 Restrictive Agreements. None of the Obligors is subject to any indenture, agreement, instrument or other arrangement that
prohibits, restricts or imposes any condition upon (a) the ability of Borrower or any Subsidiary to create, incur or permit to exist any Lien upon any of its property or assets (other than (x) customary provisions in contracts (including
without limitation leases and in-bound licenses of Intellectual Property) restricting the assignment thereof, (y) restrictions or conditions imposed by any agreement governing secured Permitted
Indebtedness permitted under Section 9.01(h), to the extent that such restrictions or conditions apply only to the property or assets securing such Indebtedness), or (z) as such may apply to the interest of any Obligor in a
Permitted Commercialization Arrangement Vehicle), or (b) the ability of any Subsidiary to pay dividends or other distributions with respect to any shares of its capital stock or to make or repay loans or advances to Borrower or any other
Subsidiary or to Guarantee Indebtedness of Borrower or any other Subsidiary (each, a “Restrictive Agreement”), except (i) those listed on Schedule 7.15 or otherwise permitted under
Section 9.11, (ii) restrictions and conditions imposed by law or by this Agreement, (iii) customary restrictions and conditions contained in agreements relating to the sale of a Subsidiary or assets pending such sale, provided
such restrictions and conditions apply only to the Subsidiary or assets that are to be sold and such sale is permitted hereunder, (iv) any stockholder agreement, charter, by laws or other organizational documents of Borrower or any Subsidiary
as in effect on the date hereof, and (v) limitations associated with Permitted Liens. 
 7.16 Real Property.  

(a) Generally. Neither Borrower nor any of its Subsidiaries owns or leases (as tenant thereof) any real
property, except as described on Schedule 7.16 (as amended from time to time by Borrower in accordance with Section 7.20). 

(b) Borrower Lease. (i) Borrower has delivered a true, accurate and complete copy of each Borrower Lease to
Lenders.  
 (ii) Each Borrower Lease is in full force and effect and no default has occurred under any Borrower
Lease and, to the Knowledge of Borrower, there is no existing 

  
 45 

 
condition which, but for the passage of time or the giving of notice, would reasonably be expected to result in a default under the terms of any Borrower Lease. 

(iii) Either Borrower or a Subsidiary of Borrower is the tenant under each Borrower Lease and such tenant has not transferred,
sold, assigned, conveyed, disposed of, mortgaged, pledged, hypothecated, or encumbered any of its interest in, such Borrower Lease. 

7.17 Pension Matters. Schedule 7.17 sets forth, as of the date hereof, a complete and correct list of, and that separately
identifies, (a) all Title IV Plans, (b) all Multiemployer Plans and (c) all material Benefit Plans. Each Benefit Plan, and each trust thereunder, intended to qualify for tax exempt status under Section 401 or 501 of the Code or
other Requirements of Law so qualifies. Except for those that would not, in the aggregate, have a Material Adverse Effect, (x) each Benefit Plan is in compliance with applicable provisions of ERISA, the Code and other Requirements of Law,
(y) there are no existing or pending (or to the Knowledge of any Obligor or Subsidiary thereof, threatened) claims (other than routine claims for benefits in the normal course), sanctions, actions, lawsuits or other proceedings or investigation
involving any Benefit Plan to which any Obligor or Subsidiary thereof incurs or otherwise has or would have an obligation or any liability or Claim and (z) no ERISA Event is reasonably expected to occur. Borrower and each of its ERISA
Affiliates has met all applicable requirements under the ERISA Funding Rules with respect to each Title IV Plan, and no waiver of the minimum funding standards under the ERISA Funding Rules has been applied for or obtained. As of the most recent
valuation date for any Title IV Plan, the funding target attainment percentage (as defined in Section 430(d)(2) of the Code) is at least 60%, and neither Borrower nor any of its ERISA Affiliates knows of any facts or circumstances that would
reasonably be expected to cause the funding target attainment percentage to fall below 60% as of the most recent valuation date. As of the date hereof, no ERISA Event has occurred in connection with which obligations and liabilities (contingent or
otherwise) remain outstanding. No ERISA Affiliate would have any Withdrawal Liability as a result of a complete withdrawal from any Multiemployer Plan on the date this representation is made. 

7.18 Collateral; Security Interest. Each Security Document is effective to create in favor of the Lenders a legal, valid and
enforceable security interest in the Collateral subject thereto and each such security interest is perfected to the extent required by (and has the priority required by) the applicable Security Document. The Security Documents collectively, when
financing statements and other filings specified on Schedule 7.18 in appropriate form are filed in the offices specified on Schedule 7.18, are effective to create in favor of the Lenders a legal, valid and enforceable security interest
in the Collateral, which security interests are first-priority (subject only to Permitted Priority Liens). 
 7.19 Regulatory
Approvals. Borrower and its Subsidiaries hold, and will continue to hold, either directly or through licensees and agents, all Regulatory Approvals, licenses, permits and similar governmental authorizations of a Governmental Authority necessary
or required for Borrower and its Subsidiaries to conduct their operations and business in the manner currently conducted. 
 7.20
Update of Schedules. Each of Schedules 7.05(b) (in respect of the lists of Patents, Trademarks, and Copyrights under Section 7.05(b)(i)), 7.05(c), 7.06, 7.14 and 7.16 may be 

  
 46 

 
updated by Borrower from time to time (including concurrently with the delivery of each Compliance Certificate) in order to insure the continued accuracy of such Schedule as of any upcoming
date on which representations and warranties are made incorporating the information contained on such Schedule. Such update may be accomplished by Borrower providing to the Lenders, in writing (including by electronic means), a revised version of
such Schedule in accordance with the provisions of Section 12.02. Each such updated Schedule shall be effective immediately upon the receipt thereof by the Lenders. 

7.21 Canadian Pension or Benefit Plans. No Obligor has at any time in the past or present established or been associated with any
Canadian Pension Plans or any Canadian Benefit Plans. 
 SECTION 8 

AFFIRMATIVE COVENANTS 

Each Obligor covenants and agrees with the Lenders that, until the Commitments have expired or been terminated and all
Obligations (other than inchoate indemnity obligations) have been paid in full indefeasibly in cash: 
 8.01 Financial Statements and
Other Information. Borrower will furnish to the Lenders: 
 (a) (i) so long as Borrower is not a Publicly
Reporting Company, as soon as available and in any event within 45 days after the end of the first three fiscal quarters of each fiscal year (or 90 days, in the case of the fourth fiscal quarter), the consolidated balance sheets of the Obligors as
of the end of such quarter, and the related consolidated statements of income, shareholders’ equity and cash flows of Borrower and its Subsidiaries for such quarter and the portion of the fiscal year through the end of such quarter, prepared
generally in accordance with GAAP and Borrower’s past practice consistently applied, all in reasonable detail and setting forth in comparative form the figures for the corresponding period in the preceding fiscal year, together with a
certificate of a Responsible Officer of Borrower stating that such financial statements fairly present the financial condition of Borrower and its Subsidiaries as at such date and the results of operations of Borrower and its Subsidiaries for the
period ended on such date and have been prepared in accordance with GAAP and Borrower’s past practice consistently applied, subject to changes resulting from normal, year-end audit adjustments, adjustments in non-cash stock based compensation
and except for the absence of footnotes; 
 (ii) after Borrower becomes a Publicly Reporting Company, as soon as available
and in any event within 5 days following the date Borrower files the Quarterly Report on Form 10-Q with the SEC, the consolidated balance sheets of the Obligors as of the end of such quarter, and the related consolidated statements of income and
cash flows of Borrower and its Subsidiaries for such quarter and the portion of the fiscal year through the end of such quarter, prepared in accordance with GAAP and Borrower’s past practice consistently applied, all in reasonable detail and
setting forth in comparative form the figures for the corresponding period in the preceding fiscal year, together with a certificate of a Responsible Officer of Borrower stating that such financial statements fairly present the financial condition
of Borrower and its Subsidiaries as at such date and the results of operations of Borrower and its Subsidiaries for the period ended on such date and have been prepared in accordance with GAAP and past practice

  
 47 

 
consistently applied, subject to changes resulting from normal, year-end audit adjustments and except for the absence of footnotes; 

(b) (i) so long as Borrower is not a Publicly Reporting Company, as soon as available and in any event within 180 days after
the end of each fiscal year, the consolidated balance sheets of Borrower and its Subsidiaries as of the end of such fiscal year, and the related consolidated statements of income, shareholders’ equity and cash flows of Borrower and its
Subsidiaries for such fiscal year, prepared in accordance with GAAP consistently applied, all in reasonable detail and setting forth in comparative form the figures for the previous fiscal year, accompanied by a report containing the opinion thereon
of PriceWaterhouseCoopers or another firm of independent certified public accountants of recognized national standing acceptable to the Lenders, which report shall be prepared in accordance with generally accepted auditing standards (provided that
Lenders acknowledge that “going concern” or like qualification or “emphasis of matter” paragraph, in and of itself, will not render such opinion unacceptable to Lenders); 

(ii) after Borrower becomes a Publicly Reporting Company, as soon as available and in any event within 5 days following the
date Borrower files the Annual Report on Form 10-K with the SEC, the consolidated balance sheets of Borrower and its Subsidiaries as of the end of such fiscal year, and the related consolidated statements of income, shareholders’ equity and
cash flows of Borrower and its Subsidiaries for such fiscal year, prepared in accordance with GAAP and past practice consistently applied, all in reasonable detail and setting forth in comparative form the figures for the previous fiscal year,
accompanied by a report containing the opinion of an independent certified public accountant of recognized national standing reasonably acceptable to the Lenders which report shall be prepared in accordance with generally accepted auditing standards
(provided that Lenders acknowledge that a “going concern” or like qualification or “emphasis of matter” paragraph, in and of itself, will not render such opinion unacceptable to Lenders); 

(c) together with the financial statements required pursuant to Sections 8.01(a)
and (b), a compliance certificate of a Responsible Officer as of the end of the applicable accounting period (which delivery may, unless a Lender requests executed originals, be by electronic
communication including fax or email and shall be deemed to be an original authentic counterpart thereof for all purposes) in the form of Exhibit E (a “Compliance Certificate”) including
details of any issues that are material that are raised by auditors;  
 (d) promptly, and in any event within
five Business Days after receipt thereof by an Obligor thereof, copies of each notice or other correspondence received from any securities regulator or exchange to the authority of which Borrower may become subject from time to time concerning any
investigation or possible investigation or other inquiry by such agency regarding financial or other operational results of such Obligor; 

(e) as soon as available, a consolidated financial forecast for Borrower and its Subsidiaries for the following three fiscal
years, including forecasted consolidated balance sheets, consolidated statements of income, shareholders’ equity and cash flows of Borrower and its Subsidiaries, it being recognized by the Lenders that such forecasts as they relate to future

  
 48 

 
events are not to be viewed as fact and that factual results during the period or periods covered by such forecasts may differ from such forecasts; 

(f) promptly, and in any event within five Business Days after receipt thereof by an Obligor thereof, copies of each notice or
other correspondence received from any securities regulator or exchange to the authority of which Borrower may become subject from time to time concerning any investigation or possible investigation or other inquiry by such agency regarding
financial or other operational results of such Obligor; 
 (g) the information regarding insurance maintained by
Borrower and its Subsidiaries as required under Section 8.05;  
 (h) promptly following
Lenders’ written request at any time, proof of Borrower’s compliance with Sections 9.19, 9.20 and 10.01; and 

(i) within five (5) days of delivery, copies of all statements, reports and notices (including board kits) made
available to Borrower’s board of directors or holders of Borrower’s Equity Interests or holders of Permitted Cure Debt or Permitted Subordinated Debt, provided that any such material may be redacted by Borrower to exclude
information relating to the Lenders (including Borrower’s strategy regarding the Loans); and 
 (j) after
Borrower becomes a Publicly Reporting Company, within 5 days of filing, provide access (via posting and/or links on Borrower’s web site) to all reports on Form 10-K and Form 10-Q filed with the SEC, any Governmental Authority succeeding to any
or all of the functions of the SEC or with any national securities exchange; and within 5 days of filing, provide notice and access (via posting and/or links on Borrower’s web site) to all reports on Form 8-K filed with the SEC, and copies of
(or access to, via posting and/or links on Borrower’s web site) all other reports, proxy statements and other materials filed by Borrower with the SEC, any Governmental Authority succeeding to any of the functions of the SEC or with any
national securities exchange. 
 8.02 Notices of Material Events. Borrower will furnish to the Lenders written notice of the
following promptly after a Responsible Officer first learns of the existence of: 
 (a) the occurrence of any
Default; 
 (b) notice of the occurrence of any event with respect to its property or assets resulting in a Loss, to the
extent not covered by insurance, aggregating $500,000 (or the Equivalent Amount in other currencies) or more; 
 (c) (A) any
proposed acquisition of stock, assets or property by any Obligor that would reasonably be expected to result in environmental liability under Environmental Laws, and (B)(1) spillage, leakage, discharge, disposal, leaching, migration or release of
any Hazardous Material required to be reported to any Governmental Authority under applicable Environmental Laws, and (2) all actions, suits, claims, notices of violation, hearings, investigations or proceedings pending, or to Borrower’s
Knowledge, threatened against or affecting Borrower or any of its Subsidiaries or with respect to the ownership, use, maintenance and operation of their 

  
 49 

 
respective businesses, operations or properties, relating to Environmental Laws or Hazardous Material; 

(d) the assertion of any environmental matter by any Person against, or with respect to the activities of, Borrower or any of
its Subsidiaries and any alleged violation of or non-compliance with any Environmental Laws or any permits, licenses or authorizations which would reasonably be expected to involve damages in excess of $500,000 other than any environmental matter or
alleged violation that, if adversely determined, would not (either individually or in the aggregate) have a Material Adverse Effect; 

(e) the filing or commencement of any action, suit or proceeding by or before any arbitrator or Governmental Authority against
or directly affecting Borrower or any of its Affiliates that, if adversely determined, would reasonably be expected to result in a Material Adverse Effect; 

(f) (i) on or prior to any filing by any ERISA Affiliate of any notice of intent to terminate any Title IV Plan, a copy of
such notice and (ii) promptly, and in any event within ten days, after any Responsible Officer of any ERISA Affiliate knows or has reason to know that a request for a minimum funding waiver under Section 412 of the Code has been filed with
respect to any Title IV Plan or Multiemployer Plan, a notice (which may be made by telephone if promptly confirmed in writing) describing such waiver request and any action that any ERISA Affiliate proposes to take with respect thereto, together
with a copy of any notice filed with the PBGC or the IRS pertaining thereto; 
 (g) (i) the termination of any
Material Agreement; (ii) the receipt by Borrower or any of its Subsidiaries of a notice under any Material Agreement asserting default by Borrower or any of its Subsidiaries where such alleged default, if accurate, would permit such
counterparty to terminate such Material Agreement; (iii) the entering into of any new Material Agreement by an Obligor; or (iv) any material amendment to a Material Agreement, that is in any manner adverse to Lenders; provided that
notices required for this subsection (g) may be delivered with Borrower’s quarterly Compliance Certificate unless any of the foregoing events would reasonably be expected to have a Material Adverse Effect; 

(h) the reports and notices as required by the Security Documents; 

(i) concurrently with the delivery of each Compliance Certificate, notice of any material change in accounting policies or
financial reporting practices by the Obligors; 
 (j) promptly after the occurrence thereof, notice of any labor controversy
resulting in or threatening to result in any strike, work stoppage, boycott, shutdown or other material labor disruption against or involving an Obligor; 

(k) a licensing agreement or arrangement entered into by Borrower or any Subsidiary in connection with any infringement or
alleged infringement of the Intellectual Property of another Person; 
 (l) any other development that results in, or would
reasonably be expected to result in, a Material Adverse Effect; 

  
 50 

 (m) concurrently with the delivery of each Compliance Certificate, the
creation or other acquisition of any Intellectual Property by Borrower or any Subsidiary after the date hereof and during such prior fiscal year which is registered or becomes registered or the subject of an application for registration with the
U.S. Copyright Office or the U.S. Patent and Trademark Office, as applicable, or with any other equivalent foreign Governmental Authority; 

(n) any change to any Obligor’s ownership of Deposit Accounts, Securities Accounts and Commodity Accounts, by delivering
to Lenders an updated Annex 7 to the Security Agreement or the Canadian Security Agreement, as applicable, setting forth a complete and correct list of all such accounts as of the date of such change; or 

(o) such other information respecting the operations, properties, business or condition (financial or otherwise) of the
Obligors (including with respect to the Collateral) as the Majority Lenders may from time to time reasonably request in writing. 

Each notice delivered under this Section 8.02 shall be accompanied by a statement of a financial officer or other executive
officer of Borrower setting forth in reasonable detail the event or development requiring such notice and any action taken or proposed to be taken with respect thereto.  

8.03 Existence; Conduct of Business. Such Obligor will, and will cause each of its Subsidiaries to, do or cause to be done all things
necessary to preserve, renew and keep in full force and effect its legal existence and the rights, licenses, permits, privileges and franchises material to the conduct of its business; provided that the foregoing shall not
prohibit any merger, amalgamation, consolidation, liquidation or dissolution permitted under Section 9.03.  
 8.04
Payment of Obligations. Such Obligor will, and will cause each of its Subsidiaries to, pay and discharge its obligations, including (i) all Taxes, fees, assessments and governmental charges or levies imposed upon it or upon its properties
or assets prior to the date on which penalties attach thereto, and all lawful claims for labor, materials and supplies which, if unpaid, might become a Lien upon any properties or assets of Borrower or any Subsidiary, except to the extent such
Taxes, fees, assessments or governmental charges or levies, or such claims are being contested in good faith by appropriate proceedings and are adequately reserved against in accordance with GAAP; and (ii) all lawful claims which, if unpaid,
would by law become a Lien upon its property not constituting a Permitted Lien. 
 8.05 Insurance. Such Obligor will maintain,
and will cause each of its Subsidiaries to maintain, with financially sound and reputable insurance companies, insurance in such amounts and against such risks as are customarily maintained by companies engaged in the same or similar businesses
operating in the same or similar locations, it being understood and agreed that the insurance held by Borrower on the Closing Date is deemed to fulfill this requirement on the date hereof. Upon the written request of Majority Lenders, Borrower shall
furnish the Lenders from time to time with full information as to the insurance carried by it and, if so requested, copies of all such insurance policies. Borrower also shall furnish to the Lenders from time to time upon the written request of the
Majority Lenders a letter from Borrower’s insurance broker or other insurance specialist stating that all premiums then due on the policies relating to insurance on the Collateral have been paid, that such policies are in full force and effect.
 

  
 51 

 
Borrower shall use commercially reasonable efforts to ensure, that all insurance policies required under this Section 8.05 will not be terminated or cancelled nor shall any such
policy be materially changed in a manner adverse to Borrower without at least 30 days’ (10 days’ for nonpayment of premium) prior written notice to Borrower and the Lenders. Receipt of notice of termination or cancellation of any such
insurance policies or reduction of coverages or amounts thereunder shall entitle the Lenders to renew any such policies, cause the coverages and amounts thereof to be maintained at levels required pursuant to the first sentence of this
Section 8.05 or otherwise to obtain similar insurance in place of such policies, in each case at the expense of Borrower. 

8.06 Books and Records; Inspection Rights. Such Obligor will, and will cause each of its Subsidiaries to, keep proper books of record
and account in which full, true and correct entries are made of all dealings and transactions in relation to its business and activities. Such Obligor will, and will cause each of its Subsidiaries to, permit any representatives designated by the
Lenders, upon reasonable prior notice, to visit and inspect its properties, to examine and make extracts from its books and records, and to discuss its affairs, finances and condition with its officers and independent accountants, all at such
reasonable times (but not more often than once a year unless an Event of Default has occurred and is continuing).  
 8.07
Compliance with Laws and Other Obligations. Such Obligor will, and will cause each of its Subsidiaries to, (i) comply in all material respects with all laws, rules, regulations and orders of any Governmental Authority applicable to it or
its property (including Environmental Laws) and (ii) comply in all material respects with all terms of Indebtedness and all other Material Agreements, except where the failure to do so, individually or in the aggregate, would not reasonably be
expected to result in a Material Adverse Effect. 
 8.08 Maintenance of Properties, Etc.  

(a) Such Obligor shall, and shall cause each of its Subsidiaries to, maintain and preserve all of its properties necessary or
useful in the proper conduct of its business in good working order and condition in accordance with the general practice of other Persons of similar character and size, ordinary wear and tear and damage from casualty or condemnation excepted. 

(b) If Borrower or a Subsidiary of Borrower shall be in default under any Borrower Lease, Borrower shall permit the Lenders to
cause the default or defaults under such Borrower Lease to be remedied. 
 (c) If Borrower acquires or becomes the owner of
any piece of real property at any time with a fair market value in excess of $1,000,000, Borrower shall (i) enter into a mortgage securing the Obligations in favor of the Lenders, and (ii) in connection therewith, execute real property
security waivers reasonably requested by the Lenders in form reasonably satisfactory to the Lenders. 
 (d) Borrower shall
ensure that it maintains a Clinical Laboratory Improvement Amendments (CLIA) facility at all times that such facility is necessary to the conduct of Borrower’s business. 

  
 52 

 8.09 Licenses. Such Obligor shall, and shall cause each of its Subsidiaries to,
obtain and maintain all licenses, authorizations, consents, filings, exemptions, registrations and other Governmental Approvals necessary in connection with the execution, delivery and performance of the Loan Documents, the consummation of the
Transactions or the operation and conduct of its business and ownership of its properties, except where failure to do so would not reasonably be expected to have a Material Adverse Effect. 

8.10 Action under Environmental Laws. Such Obligor shall, and shall cause each of its Subsidiaries to, upon becoming aware of the
presence of any Hazardous Materials or the existence of any environmental liability under applicable Environmental Laws with respect to their respective businesses, operations or properties, take all actions, at their cost and expense, as shall be
necessary or advisable to investigate and clean up the condition of their respective businesses, operations or properties, including all required removal, containment and remedial actions, and restore their respective businesses, operations or
properties to a condition in compliance with applicable Environmental Laws. 
 8.11 Use of Proceeds. The proceeds of the Loans
will be used only as provided in Section 2.05. No part of the proceeds of the Loans will be used, whether directly or indirectly, for any purpose that entails a violation of any of the Regulations of the Board of Governors of the Federal
Reserve System, including Regulations T, U and X. 
 8.12 Certain Obligations Respecting Subsidiaries; Further Assurances.

 (a) Subsidiary Guarantors. Such Obligor will take such action, and will cause each of its Subsidiaries
to take such action, from time to time as shall be necessary to ensure that all Subsidiaries that are Domestic Subsidiaries or Canadian Subsidiaries, and such Foreign Subsidiaries as are required under Section 8.12(b), are
“Subsidiary Guarantors” hereunder. Without limiting the generality of the foregoing, in the event that Borrower or any of its Subsidiaries shall form or acquire any new Subsidiary that is a Domestic Subsidiary, Canadian Subsidiary or a
Foreign Subsidiary meeting the requirements of Section 8.12(b), such Obligor and its Subsidiaries will promptly and in any event within thirty (30) days (or such longer time as consented to by the Majority Lenders in writing) of the
formation or acquisition of such Subsidiary: 
 (i) cause such new Subsidiary to become a “Subsidiary
Guarantor” hereunder, and a “Grantor” under the Security Agreement or the Canadian Security Agreement, as applicable, pursuant to a Guarantee Assumption Agreement; 

(ii) take such action or cause such Subsidiary to take such action (including delivering such shares of stock together with
undated transfer powers executed in blank) as shall be necessary to create and perfect valid and enforceable first priority (subject to Permitted Priority Liens) Liens on substantially all of the personal property of such new Subsidiary as
collateral security for the obligations of such new Subsidiary hereunder; 
 (iii) to the extent that the parent of such
Subsidiary is not a party to the Security Agreement or the Canadian Security Agreement, or has not otherwise pledged Equity Interests in its Subsidiaries in accordance with the terms of the Security Agreement or the

  
 53 

 
Canadian Security Agreement and this Agreement, cause the parent of such Subsidiary to execute and deliver a pledge agreement in favor of the Lenders in respect of all outstanding issued shares
of such Subsidiary; and 
 (iv) deliver such proof of corporate action, incumbency of officers, opinions of counsel and
other documents as is consistent with those delivered by each Obligor pursuant to Section 6.01 or as the Majority Lenders shall have requested. 

(b) Foreign Subsidiaries. Subject to Section 8.12(c), in the event that, at any time, Foreign Subsidiaries
who are not Subsidiary Guarantors have, in the aggregate, (i) total revenues constituting 5% or more of the total revenues of Borrower and its Subsidiaries on a consolidated basis, or (ii) total assets constituting 5% or more of the total
assets of Borrower and its Subsidiaries on a consolidated basis, promptly (and, in any event, within 30 days after such time (or such longer time as consented to by the Majority Lenders in writing) Obligors shall cause one or more of such Foreign
Subsidiaries to become Subsidiary Guarantors in the manner set forth in Section 8.12(a), such that, after such Subsidiaries become Subsidiary Guarantors, the non-guarantor Foreign Subsidiaries in the aggregate shall cease to have
revenues or assets, as applicable, that meet the thresholds set forth in clauses (i) and (ii) above. In addition, any Foreign Subsidiary that owns a manufacturing facility that is material to the business of the Borrower, as
determined by the Lenders in their reasonable discretion, shall become a Subsidiary Guarantor in the manner set forth in Section 8.12(a); provided that in each case, no Foreign Subsidiary or Controlled Foreign Corporation shall be
required to become a Subsidiary Guarantor if doing so would result in material adverse tax consequences for Borrower and its Subsidiaries, taken as a whole. For the purposes of this section, the determination of whether a “material adverse tax
consequence” shall be deemed to result from such Foreign Subsidiary or Controlled Foreign Corporation becoming a Subsidiary Guarantor shall be made by the Majority Lenders in their sole reasonable discretion, following consultation with the
Borrower. 
 (ii) Subject to Section 8.12(c), each Obligor shall grant a perfected first priority security
interest and Lien in 100% of the voting stock of all First-Tier Foreign Subsidiaries in favor of the Lenders as Collateral for the Obligations. Without limiting the generality of the foregoing, in the event that any Obligor shall form or acquire any
new Subsidiary that is a First-Tier Foreign Subsidiary, such Obligor will promptly and in any event within thirty (30) days of the formation or acquisition of such Subsidiary (or such longer time as consented to by the Majority Lenders in
writing) grant a perfected first priority security interest and Lien in 100% of the voting stock of such Subsidiary in favor of the Lenders as Collateral for the Obligations; provided however, no Obligor shall be required to grant a perfected
first priority security interest and Lien in more than 65% of the voting stock of a First-Tier Foreign Subsidiary or a Controlled Foreign Corporation if doing so would result in material adverse tax consequences for Borrower and its Subsidiaries,
taken as a whole. For the purposes of this section, the determination of whether a “material adverse tax consequence” shall be deemed to result from such Obligor granting a perfected first priority security interest and Lien in more than
65% of the voting stock of a First-Tier Foreign Subsidiary or a Controlled Foreign Corporation shall be made by Majority Lenders in their sole reasonable discretion, following consultation with the Borrower. 

  
 54 

 (c) Further Assurances. Such Obligor will, and will cause each of its
Subsidiaries to, take such action from time to time as shall reasonably be requested in writing by the Majority Lenders to effectuate the purposes and objectives of this Agreement. 

Without limiting the generality of the foregoing, each Obligor will, and will cause each Person that is required to be a Subsidiary Guarantor
to, take such action from time to time (including executing and delivering such assignments, security agreements, control agreements and other instruments) as shall be reasonably requested by the Majority Lenders in writing to create, in favor of
the Lenders, perfected security interests and Liens in substantially all of the personal property of such Obligor as collateral security for the Obligations; provided that any such security interest or Lien shall be subject to the relevant
requirements of the Security Documents. 
 8.13 Termination of Non-Permitted Liens. In the event that Borrower or any of its
Subsidiaries shall become aware or be notified by the Lenders of the existence of any outstanding Lien against any Property of Borrower or any of its Subsidiaries, which Lien is not a Permitted Lien, Borrower shall use its best efforts to promptly
terminate or cause the termination of such Lien. 
 8.14 Intellectual Property. In the event that the Obligors acquire Obligor
Intellectual Property during the term of this Agreement, then the provisions of this Agreement shall automatically apply thereto and any such Obligor Intellectual Property shall automatically constitute part of the Collateral under the Security
Documents, without further action by any party, in each case from and after the date of such acquisition (except that any representations or warranties of any Obligor shall apply to any such Obligor Intellectual Property only from and after the
date, if any, subsequent to such acquisition that such representations and warranties are brought down or made anew as provided herein). 

8.15 Board Observer Seat. Borrower shall grant the Lenders the right to designate one observer to attend all meetings of the
Borrower’s board of directors. 
 8.16 Post-Closing Items. 

(a) Borrower shall use commercially reasonable efforts to cause the landlord of each leased property listed on Schedule
7.16 to execute and deliver to Lenders, not later than 60 days following the date hereof, a Landlord Consent. 
 (b)
Borrower shall use commercially reasonable efforts to execute and deliver to the Lenders, at the request of the Lenders, such duly executed Intellectual Property security agreements as the Lenders may require with respect to foreign Intellectual
Property, and take such other action as the Lenders may reasonably deem necessary or appropriate to duly record or otherwise perfect the security interest created thereunder in that portion of the Collateral consisting of Intellectual Property
located outside the United States. 
 (c) Not later than 30 days after the date hereof, Borrower shall execute and deliver
to the Lenders fully executed control agreements, in form and substance reasonably acceptable to the Majority Lenders, as may be required to perfect the security interest created under the Canadian Security Agreement, or as may otherwise be
reasonably requested by the Majority Lenders, in the HSBC Accounts. 

  
 55 

 (d) Not later than 30 days after the date hereof, Borrower shall deliver to
the Lenders insurance endorsements, each in form and substance satisfactory to the Majority Lenders, related to the property insurance policies of GenomeDx Corp. designating the Lenders as lender loss payees thereunder. 

(e) Not later than 15 days after the date hereof, Borrower shall deliver to the Lenders evidence in form and substance
reasonably acceptable to the Majority Lenders that GenomeDx Corp. is in good standing and qualified to transact business in the State of California. 

SECTION 9 
 NEGATIVE
COVENANTS 
 Each Obligor covenants and agrees with the Lenders that, until the Commitments have expired or been
terminated and all Obligations (other than inchoate indemnity obligations) have been paid in full indefeasibly in cash: 
 9.01
Indebtedness. Such Obligor will not, and will not permit any of its Subsidiaries to, create, incur, assume or permit to exist any Indebtedness, whether directly or indirectly, except: 

(a) the Obligations; 

(b) Indebtedness existing on the date hereof and set forth on Schedule 7.13(a) and Permitted Refinancings thereof; 

(c) Permitted Priority Debt; 

(d) accounts payable to trade creditors for goods and services and current operating liabilities (not the result of the
borrowing of money) incurred in the ordinary course of Borrower’s or such Subsidiary’s business in accordance with customary terms and paid within the specified time, unless contested in good faith by appropriate proceedings and reserved
for in accordance with GAAP; 
 (e) Indebtedness consisting of guarantees resulting from endorsement of negotiable
instruments for collection by any Obligor in the ordinary course of business; 
 (f) Indebtedness of any Obligor to the
extent the same is permitted as an Investment pursuant to Sections 9.05(e) and (f); 
 (g) Guarantees by
(i) any Obligor of Indebtedness of any other Obligor and (ii) any Subsidiary not a Subsidiary Guarantor of Indebtedness of any other Subsidiary not a Subsidiary Guarantor; 

(h) normal course of business equipment financing; provided that (i) if secured, the collateral therefor consists
solely of the assets being financed, the products and proceeds thereof and books and records related thereto, and (ii) the aggregate outstanding principal amount of such Indebtedness does not exceed $1,000,000 (or the Equivalent Amount in other
currencies) at any time; 

  
 56 

 (i) Unsecured Indebtedness in connection with corporate credit cards,
purchasing cards or bank card products in an aggregate principal amount at any time outstanding not to exceed $362,500 (or the Equivalent Amount in other currencies); 

(j) Indebtedness in respect of any agreement providing for treasury, depositary, or cash management services, including in
connection with any automated clearing house transfers of funds or any similar transactions, securities settlements, foreign exchange contracts, assumed settlement, netting services, overdraft protections and other cash management, intercompany cash
pooling and similar arrangements, in each case in the ordinary course of business; 
 (k) Indebtedness with respect to
letters of credit outstanding, provided that at any time in any given calendar year, the outstanding principal amount of such Indebtedness shall not exceed $50,000 at any time outstanding; 

(l) (i) Indebtedness incurred, assumed or otherwise acquired in connection with Permitted Acquisitions (which may be
Indebtedness existing prior to the Permitted Acquisition secured by the assets acquired as described in Section 9.02(k)(ii)), and (ii) and Permitted Refinancings thereof, so long as the principal amount of such Indebtedness, when
added to the aggregate consideration (cash or non-cash) paid by the Obligors for all Permitted Acquisitions, does not exceed $5,000,000; 

(m) Permitted Cure Debt; 

(n) Unsecured obligations under bona fide time-based licenses of Borrower or any Subsidiary in the ordinary course of
business; 
 (o) advance or deposits from customers or vendors received in the ordinary course of business and held with a
deposit bank insured by the Federal Deposit Insurance Corporation; 
 (p) Unsecured Indebtedness (other than for borrowed
money) that may be deemed to exist pursuant to any bona fide warranty or contractual service obligations or performance in the ordinary course of business; 

(q) Unsecured Indebtedness consisting of (i) the bona fide financing of insurance premiums or self-insurance obligations
(which must be commercially reasonable and consistent with insurance practices generally) or (ii) take-or-pay obligations contained in supply or similar agreements, in each case, in the ordinary course of business; 

(r) any indemnification, purchase price adjustment, earn-out or similar obligations incurred in connection with Investments
permitted by Section 9.03(e) (but subject to the same monetary limits as described in Section 9.03(e)); 

(s) other unsecured Indebtedness in an aggregate principal amount not to exceed $250,000 at any time outstanding; 

(t) Unsecured workers’ compensation claims, payment obligations in connection with health, disability or other types of
social security benefits, unemployment or other insurance 

  
 57 

 
obligations, reclamation and statutory obligations, in each case incurred in the ordinary course of Borrower’s or its Subsidiary’s business; 

(u) Permitted Subordinated Debt in an aggregate principal amount that does not exceed $20,000,000 at any time outstanding; and

 (v) Indebtedness approved in advance in writing by the Majority Lenders. 

9.02 Liens. Such Obligor will not, and will not permit any of its Subsidiaries to, create, incur, assume or permit to exist any Lien on
any property or asset now owned by it, or assign or sell any income or revenues (including accounts receivable) or rights in respect of any thereof, except: 

(a) Liens securing the Obligations; 

(b) any Lien on any property or asset of Borrower or any of its Subsidiaries existing on the date hereof and set forth in
Schedule 7.13(b); provided that (i) no such Lien shall extend to any other property or asset of Borrower or any of its Subsidiaries and (ii) any such Lien shall secure only those obligations which it secures on the date
hereof and extensions, renewals and replacements thereof that do not increase the outstanding principal amount thereof; 

(c) Liens described in the definition of “Permitted Priority Debt”; 

(d) Liens securing Indebtedness permitted under Section 9.01(h); provided that such Liens are restricted
solely to the collateral described in Section 9.01(h); 
 (e) Liens imposed by law which were incurred in the
ordinary course of business, including (but not limited to) carriers’, warehousemen’s and mechanics’ liens, liens relating to leasehold improvements and other similar liens arising in the ordinary course of business and which
(x) do not in the aggregate materially detract from the value of the Property subject thereto or materially impair the use thereof in the operations of the business of such Person or (y) are being contested in good faith by appropriate
proceedings, which proceedings have the effect of preventing the forfeiture or sale of the Property subject to such liens and for which adequate reserves have been made if required in accordance with GAAP; 

(f) Liens, pledges or deposits made in the ordinary course of business in connection with workers’ compensation,
unemployment insurance or other similar social security legislation; 
 (g) Liens securing taxes, assessments and other
governmental charges, the payment of which is not yet due or is being contested in good faith by appropriate proceedings promptly initiated and diligently conducted and for which such reserve or other appropriate provisions, if any, as shall be
required by GAAP shall have been made; 
 (h) servitudes, easements, rights of way, restrictions and other similar
encumbrances on real Property imposed by applicable Laws and encumbrances consisting of zoning or building restrictions, easements, licenses, restrictions on the use of property or minor imperfections in title thereto which, in the aggregate, are
not material, and which do not in any case materially detract 

  
 58 

 
from the value of the property subject thereto or interfere with the ordinary conduct of the business of any of the Obligors; 

(i) with respect to any real Property, (A) such defects or encroachments as might be revealed by an up-to-date survey of
such real Property; (B) the reservations, limitations, provisos and conditions expressed in the original grant, deed or patent of such property by the original owner of such real Property pursuant to applicable Laws; and (C) rights of
expropriation, access or user or any similar right conferred or reserved by or in applicable Laws, which, in the aggregate for (A), (B) and (C), are not material, and which do not in any case materially detract from the value of the property
subject thereto or interfere with the ordinary conduct of the business of any of the Obligors; and (D) leases or subleases granted in the ordinary course of business; 

(j) Bankers liens, rights of setoff and similar Liens incurred on deposits made in the ordinary course of business; 

(k) (i) Liens securing Indebtedness permitted in reliance on Section 9.01(l), provided that such Liens extend
solely to the assets acquired in such Permitted Acquisition; and (ii) Liens on property acquired in and existing at the time of a Permitted Acquisition, provided that such Liens do not attach to any other property of any other Obligor or
Subsidiary; and provided that such Liens are of the type otherwise permitted under this Section 9.02; 
 (l)
Non-exclusive licenses or sublicenses, leases or subleases of property (other than real Property or Intellectual Property) granted in the ordinary course of Borrower’s business, if the leases, subleases, licenses and sublicenses do not prohibit
an Obligor from granting Agent or any Lender a security interest in such property; 
 (m) Liens arising from judgments,
decrees or attachments in circumstances not constituting an Event of Default under Section 11.01(l); 
 (n)
Liens consisting of cash collateral arrangements made with respect to letters of credit permitted by Section 9.01(k) but not exceeding the amount of the Indebtedness permitted by Section 9.01(k); 

(o) Liens in connection with transfers permitted under Section 9.09; and 

(p) Liens the creation of which did not involve Borrower’s or its Subsidiaries’ consensual participation or
involvement encumbering assets not to exceed $50,000 in the aggregate. 
 provided that no Lien otherwise permitted under any of the
foregoing (other than Sections 9.02 (a), (k), (m) and (o)) shall apply to any Material Intellectual Property. 
 9.03
Fundamental Changes and Acquisitions. Such Obligor will not, and will not permit any of its Subsidiaries to, (i) enter into any transaction of merger, amalgamation or consolidation (ii) liquidate, wind up or dissolve itself (or suffer
any liquidation or dissolution), or (iii) make any Acquisition or otherwise acquire any business or substantially all the property from, or capital stock of, or be a party to any acquisition of, any Person, except: 

  
 59 

 (a) Investments permitted under Section 9.05(e) and 9.05(f);

 (b) the merger, amalgamation or consolidation of any Subsidiary Guarantor with or into Borrower or any other Subsidiary
Guarantor (provided that no Domestic Subsidiary shall merge, amalgate or consolidate with Borrower or a Canadian Subsidiary and no Canadian Subsidiary shall merge, amalgate or consolidate with a Domestic Subsidiary); 

(c) the sale, lease, transfer or other disposition by any Subsidiary Guarantor of any or all of its property (upon voluntary
liquidation or otherwise) to Borrower or any other Obligor, (provided that no Domestic Subsidiary shall sell, lease, transfer or otherwise dispose all or substantially of its property (upon voluntary liquidation or otherwise) to Borrower or a
Canadian Subsidiary and no Canadian Subsidiary shall sell, lease, transfer or otherwise dispose all or substantially of its property (upon voluntary liquidation or otherwise) to a Domestic Subsidiary); and 

(d) the sale, transfer or other disposition of the capital stock of any Subsidiary Guarantor to Borrower or any other Obligor;

 (e) Permitted Acquisitions in an amount not exceeding $5,000,000 in the aggregate (as measured by the sum of
(i) aggregate consideration (cash or non-cash) paid by Obligors for such acquisition, and (ii) the principal amount of any pre-existing Indebtedness of the acquired party assumed by Obligors under such acquisition), provided that any
non-cash consideration paid by Obligors for an acquisition of the capital stock of PFS Genomics Inc. not owned by the Borrower on the date hereof shall not be counted towards this $5,000,000 limit; and 

(f) the Obligors may enter into Permitted Commercialization Arrangements. 

9.04 Lines of Business. Such Obligor will not, and will not permit any of its Subsidiaries to, engage to any material extent in any
business other than the business engaged in on the date hereof by Borrower or any Subsidiary or a business reasonably related, incidental or complimentary thereto or reasonable extensions thereof and cancer diagnostics generally. 

9.05 Investments. Such Obligor will not, and will not permit any of its Subsidiaries to, make, directly or indirectly, or permit to
remain outstanding any Investments except: 
 (a) Investments outstanding on the date hereof and identified in Schedule
9.05; 
 (b) operating deposit accounts with banks; 

(c) extensions of credit in the nature of accounts receivable or notes receivable arising from the sales of goods or services
in the ordinary course of business; 
 (d) Permitted Cash Equivalent Investments; 

(e) Investments by Borrower or Subsidiary Guarantors in Subsidiary Guarantors; 

(f) Investments by Borrower or Subsidiary Guarantors in Foreign Subsidiaries consisting of (A) cash and equipment only in
an aggregate amount at any time outstanding (net 

  
 60 

 
of any intercompany loan repayments and returns of invested capital) not to exceed on the date any such Investment is made $500,000 or (B) the transfer of Intellectual Property,
(i) pursuant to a comprehensive plan that is approved by Borrower’s Board of Directors and designed to increase the tax efficiency of the Borrower and its Subsidiaries as a whole, and in all cases, (ii) subject to Majority
Lenders’ prior written consent (Lenders agree to consider in good faith through negotiation with the Borrower the advantages of such plan to the Borrower and its shareholders compared to any potential loss in collateral value, priority of
rights with respect to collateral or ability to enforce timely the Loan Documents for the Lenders and any related changes in creditworthiness of the Borrower and the Subsidiary Guarantors, in each case, associated with any such transfer of
Intellectual Property); 
 (g) Hedging Agreements entered into in the ordinary course of Borrower’s financial planning
solely to hedge currency risks (and not for speculative purposes) and in an aggregate net exposure amount for all such Hedging Agreements not in excess of $100,000 (or the Equivalent Amount in other currencies); 

(h) Investments consisting of security deposits with utilities, landlords and other like Persons made in the ordinary course
of business; 
 (i) employee loans, travel advances and guarantees in accordance with Borrower’s usual and customary
practices with respect thereto (if permitted by applicable law) which in the aggregate shall not exceed $200,000 outstanding at any time (or the Equivalent Amount in other currencies); 

(j) Investments received in connection with any Insolvency Proceedings in respect of any customers, suppliers or clients and
in settlement of delinquent obligations of, and other disputes with, customers, suppliers or clients; 
 (k) Investments as
part of a Permitted Commercialization Arrangement, provided that the value of the cash and tangible property components of such Investment shall not exceed $500,000 in the aggregate at any time outstanding for all such Permitted Commercialization
Arrangements taken together; 
 (l) Investments permitted under Section 9.03; and 

(m) Investments acquired as a result of a Permitted Acquisition to the extent that such Investments were not made in
contemplation of or in connection with such Permitted Acquisition and were in existence prior to the date of such Permitted Acquisition, subject to the other limits on Investments set forth in this Section 9.05 and the limit on Permitted
Acquisitions set forth in Section 9.03(e). 
 9.06 Restricted Payments. Such Obligor will not, and will not permit
any of its Subsidiaries to, declare or make, or agree to pay or make, directly or indirectly, any Restricted Payment, except: 

(a) Borrower may declare and pay dividends with respect to its capital stock payable solely in additional shares of its common
stock; 

  
 61 

 (b) Borrower may purchase, redeem, retire, or otherwise acquire shares of
its capital stock or other Equity Interests with the proceeds received from a substantially concurrent issue of new shares of its capital stock or other Equity Interests; 

(c) for payments pursuant to employee stock plans in an aggregate amount not to exceed the sum of $100,000; 

(d) a Restricted Payment of dividends by any Subsidiary Guarantor to any other Obligor; and 

(e) a Restricted Payment by any Subsidiary not a Subsidiary Guarantor to any Obligor or any other Subsidiary. 

9.07 Payments of Indebtedness. Such Obligor will not, and will not permit any of its Subsidiaries to, make any payments in respect of
any Indebtedness other than (i) payments of the Obligations, (ii) scheduled payments of other Indebtedness, and (iii) repayment of intercompany Indebtedness permitted in reliance upon Section 9.01(f). 

9.08 Change in Fiscal Year. Such Obligor will not, and will not permit any of its Subsidiaries to, change the last day of its fiscal
year from that in effect on the date hereof, except to change the fiscal year of a Subsidiary acquired in connection with an Acquisition to conform its fiscal year to that of Borrower. 

9.09 Sales of Assets, Etc. Unless the prepayment required under Section 3.03(b)(i) simultaneously is made, such Obligor
will not, and will not permit any of its Subsidiaries to, sell, lease, exclusively license (in terms of geography or field of use), transfer, or otherwise dispose of any of its Property (including accounts receivable and capital stock of
Subsidiaries) to any Person in one transaction or series of transactions (any thereof, an “Asset Sale”), except: 

(a) transfers of cash for equivalent value and inventory in the ordinary course of its business; 

(b) sales or leases of inventory in the ordinary course of its business on ordinary business terms; 

(c) development and other collaborative arrangements in the ordinary course of business, where such arrangements provide for
the licenses or disclosure of Patents, Trademarks, Copyrights or other Intellectual Property rights or other product or service marketing rights consistent with general market practices and the Borrower’s past practices; provided that such
arrangements are not a sale of the Property in substance; 
 (d) transfers of Property by any Obligor to any other Obligor
(subject to the limitations set forth in Section 9.03(b) and (c)); 
 (e) a sale, lease, exclusive license,
transfer or other disposition of any Property that is obsolete or worn out or no longer used or useful in connection with the business of Borrower or its Subsidiaries; 

  
 62 

 (f) dispositions consisting of the sale, transfer, assignment or other
disposition of unpaid and overdue accounts receivable in connection with the collection, compromise or settlement thereof in the ordinary course of business and not as part of a financing transaction; 

(g) dispositions of property to the extent that (i) such property is exchanged for credit against the purchase price of
similar replacement property or (ii) the proceeds (determined on an after-tax basis) of such disposition are applied to the purchase price of such replacement property within 180 days; 

(h) dispositions resulting from casualty events; 

(i) so long as no Event of Default has occurred and is continuing, non-exclusive licenses of Borrower’s Intellectual
Property to Foreign Subsidiaries that are terminable, at Majority Lenders’ request, upon the occurrence of an Event of Default unless such Foreign Subsidiaries become Subsidiary Guarantors hereunder; 

(j) licenses for the use of the Intellectual Property of Borrower or its Subsidiaries (but not to any of Borrower’s
Affiliates except for a Permitted Commercialization Arrangement Vehicle) that are approved by Borrower’s Board of Directors and which would not result in a legal transfer of title of the licensed property used either (i) for clinical
indications other than epilepsy (which may be exclusive or non-exclusive licenses), (ii) for clinical indications for epilepsy within the United States (which may be non-exclusive licenses only); or (iii) for clinical indications for
cancer diagnostics outside the United States to distributors only (which may be non-exclusive licenses, or licenses that are exclusive in scope or geography only); 

(k) any transaction permitted under Section 9.03 or 9.05. 

Notwithstanding the foregoing, unless a mandatory prepayment is required under Section 3.03(b)(i), in which case Borrower
shall pay any Specified Proceeds (defined below) directly to the Lenders, upon the occurrence of (A) a Material Adverse Change, (B) an Asset Sale of Intellectual Property or equipment generating gross proceeds in excess of $1,000,000 or
(C) an Asset Sale of a Subsidiary of Borrower, Borrower shall open a segregated deposit account with a deposit bank, in which a first priority security interest is granted in favor of the Lenders, which deposit account shall be subject to a
control agreement in favor of the Lenders, and Borrower shall thereafter deposit in such segregated account all proceeds from any Asset Sale described in clauses (B) and (C) hereof consisting of proceeds from Intellectual Property and
equipment (“Specified Proceeds”). For the avoidance of doubt, Asset Sale as used in this paragraph shall include the sale, license, lease or other transfer or disposition of any interest in Intellectual Property
and equipment. 
 9.10 Transactions with Affiliates. Such Obligor will not, and will not permit any of its Subsidiaries to, sell,
lease, license or otherwise transfer any assets to, or purchase, lease, license or otherwise acquire any assets from, or otherwise engage in any other transactions with, any of its Affiliates, except: 

(a) transactions between or among Obligors; 

(b) any transaction permitted under Section 9.01, 9.05, 9.06 or 9.09; 

  
 63 

 (c) customary compensation and indemnification of, and other employment
arrangements with, directors, officers and employees of Borrower or any Subsidiary in the ordinary course of business, 

(d) Borrower may issue Equity Interests to Affiliates in exchange for cash, provided that the terms thereof are
no less favorable (including the amount of cash received by Borrower) to Borrower than those that would be obtained in a comparable arm’s-length transaction with a Person not an Affiliate of Borrower; 

(e) transactions consented to by Majority Lenders, which consent shall not be unreasonably withheld, which increase the tax
efficiency of Borrower and its Subsidiaries as a whole that are undertaken between Borrower and its Subsidiaries in good faith based on advice of external legal counsel and that comply with arm’s length principles pursuant to Section 482
of the Code and regulations thereunder; and 
 (f) the transactions set forth on Schedule 9.10. 

9.11 Restrictive Agreements. Such Obligor will not, and will not permit any of its Subsidiaries to, directly or indirectly, enter into,
incur or permit to exist any Restrictive Agreement that contains terms and provisions that are inconsistent with those found in the Loan Documents such that a conflict would exist that would cause, or would reasonably be expected to cause, a
material breach of any Loan Document or such Restrictive Agreement. 
 9.12 Termination of Material Agreements. Such Obligor will
not, and will not permit any of its Subsidiaries to, terminate any Material Agreement (unless replaced with another agreement(s) that, viewed as a whole, is on the same or better terms for Borrower or such Subsidiary) without in each case the prior
written consent of the Lender (which consent shall not be unreasonably withheld or delayed). 
 9.13 Operating Leases. Borrower will
not, and will not permit any of its Subsidiaries to, make any expenditures in respect of operating leases, except for: 

(a) real estate operating leases; 

(b) operating leases between Borrower and any of its wholly-owned Subsidiaries or between any of Borrower’s wholly-owned
Subsidiaries; and 
 (c) operating leases that would not cause Borrower and its Subsidiaries, on a consolidated basis, to
make payments exceeding $400,000 (or the Equivalent Amount in other currencies) in any fiscal year. 
 9.14 Sales and Leasebacks.
Except as disclosed on Schedule 9.14 or as permitted by Section 9.01(h) or Section 9.13, such Obligor will not, and will not permit any of its Subsidiaries to, become liable, directly or indirectly, with respect to any
lease, whether an operating lease or a Capital Lease Obligation, of any property (whether real, personal, or mixed), whether now owned or hereafter acquired, (i) which Borrower or such Subsidiary has sold or transferred or is to sell or
transfer to any other Person and (ii) which Borrower or such Subsidiary intends to use for substantially the same purposes as property which has been or is to be sold or transferred. 

  
 64 

 9.15 Hazardous Material. Such Obligor will not, and will not permit any of its
Subsidiaries to, use, generate, manufacture, install, treat, release, store or dispose of any Hazardous Material, except in compliance with all applicable Environmental Laws or where the failure to comply would not reasonably be expected to result
in a Material Adverse Change. 
 9.16 Accounting Changes. Such Obligor will not, and will not permit any of its Subsidiaries to, make
any significant change in accounting treatment or reporting practices, except as required or permitted by GAAP. 
 9.17 Compliance with
ERISA. No ERISA Affiliate shall cause or suffer to exist (a) any event that would result in the imposition of a Lien with respect to any Title IV Plan or Multiemployer Plan or (b) any other ERISA Event that would, in the aggregate,
have a Material Adverse Effect. No Obligor or Subsidiary thereof shall cause or suffer to exist any event that would result in the imposition of a Lien with respect to any Benefit Plan that would have a Material Adverse Effect. 

9.18 Canadian Benefit Plans. No Obligor shall, nor shall it permit any of its Subsidiaries to, (a) establish or commence
contribution to or otherwise participate in any retirement or pension arrangement that provides defined benefits; (b) acquire an interest in any Person if such Person sponsors, administers, participates in, or has any liability in respect of,
any retirement or pension arrangement that provides defined benefits; or (c) establish a Canadian Pension Plan or Canadian Benefit Plan. 

9.19 HSBC Bank Canada. The Borrower shall not keep more than $17,500 in the aggregate in the HSBC Cash Management Account. 

9.20 Preferred Share Issuances. The Borrower shall not: 

(a) issue or repurchase any Class A Preferred Shares in the capital of the Borrower or Class B Preferred Shares in the
capital of the Borrower; 
 (b) create or issue any other class or series of shares to which there are attached terms and
provisions pursuant to which the holders of such shares can require that the Borrower redeem or otherwise repurchase such shares; 

(c) amend its notice of articles to the extent that such amendment would add to the terms and provisions of any class or
series of shares in the capital of the company a provision requiring the Borrower to redeem or otherwise repurchase any such class or series of shares. 

SECTION 10 
 FINANCIAL
COVENANTS 
 10.01 Minimum Liquidity. Borrower shall maintain at all times Liquidity in an amount which shall exceed the greater
of (i) $2,000,000 and (ii) to the extent Borrower has incurred Permitted Priority Debt, the minimum cash balance, if any, required of Borrower by Borrower’s Permitted Priority Debt creditors. 

  
 65 

 10.02 Minimum Revenue. Borrower and its Subsidiaries shall have annual Revenue (for
each respective calendar year, the “Minimum Required Revenue”): 
 (a) during the
twelve month period beginning on January 1, 2015, of at least $8,000,000; 
 (b) during the twelve month period
beginning on January 1, 2016, of at least $20,000,000; 
 (c) during the twelve month period beginning on
January 1, 2017, and during each twelve month period thereafter beginning on January 1 of each such period, of at least $30,000,000. 

10.03 Cure Right. 

(a) Notwithstanding anything to the contrary contained in Section 11, in the event that the Borrower fails to
comply with the covenants contained in Section 10.02(a) through (c) (such covenants for such applicable periods being the “Specified Financial Covenants”), Borrower shall have the right in the six
(6) months prior to (but only in respect of an Equity Cure Right) or within 90 (ninety) days after the end of the respective calendar year: 

(i) to issue additional shares of Equity Interests in exchange for cash (the “Equity Cure
Right”), or 
 (ii) to borrow Permitted Cure Debt (the “Subordinated
Debt Cure Right” and, collectively with the Equity Cure Right, the “Cure Right”), 
 in an amount equal
to (x) two (2) multiplied by (y) the then-applicable Minimum Required Revenue less Borrower’s annual Revenue (the “Cure Amount”). The cash therefrom immediately shall be contributed as equity or
subordinated debt (only as permitted pursuant to Section 9.01), as applicable, to Borrower, and upon the receipt by Borrower of the Cure Amount pursuant to the exercise of such Cure Right, such Cure Amount shall be deemed to constitute
Revenue of Borrower for purposes of the Specified Financial Covenants and the Specified Financial Covenants shall be recalculated for all purposes under the Loan Documents. If, after giving effect to the foregoing recalculation, Borrower shall then
be in compliance with the requirements of the Specified Financial Covenants, Borrower shall be deemed to have satisfied the requirements of the Specified Financial Covenants as of the relevant date of determination with the same effect as though
there had been no failure to comply therewith at such date, and the applicable breach of the Specified Financial Covenants that had occurred, the related Default and Event of Default, shall be deemed cured without any further action of Borrower or
Lenders for all purposes under the Loan Documents. 
 (b) Notwithstanding anything herein to the contrary the Cure Amount
received by Borrower from investors investing in or lending to Borrower pursuant to Section 10.03(a) shall be used to immediately prepay the Loans, without any Prepayment Premium, credited in the order set forth in Sections
3.03(b)(i)(A)-(E). 

  
 66 

 SECTION 11 

EVENTS OF DEFAULT 

11.01 Events of Default. Each of the following events shall constitute an “Event of Default”: 

(a) Borrower shall fail to pay any principal of any Loan when and as the same shall become due and payable, whether at the due
date thereof or at a date fixed for prepayment thereof or otherwise, and such failure shall continue unremedied for a period of one (1) Business Day; 

(b) any Obligor shall fail to pay any Obligation (other than an amount referred to in Section 11.01(a)) when and
as the same shall become due and payable, and such failure shall continue unremedied for a period of three (3) Business Days; 

(c) any representation or warranty made or deemed made by or on behalf of Borrower or any of its Subsidiaries in or in
connection with this Agreement or any other Loan Document or any amendment or modification hereof or thereof, or in any report, certificate, financial statement or other document furnished pursuant to or in connection with this Agreement or any
other Loan Document or any amendment or modification hereof or thereof, shall: (i) prove to have been incorrect when made or deemed made to the extent that such representation or warranty contains any materiality or Material Adverse Effect
qualifier; or (ii) prove to have been incorrect in any material respect when made or deemed made to the extent that such representation or warranty does not otherwise contain any materiality or Material Adverse Effect qualifier; 

(d) any Obligor shall fail to observe or perform any covenant, condition or agreement contained in Section 8.02,
8.03(a) (with respect to Borrower’s existence), 8.11, 8.12, 8.14, 8.16(a), (c), (d) or (e), 9 or 10; 

(e) any Obligor shall fail to observe or perform any covenant, condition or agreement contained in this Agreement (other than
those specified in Section 11.01(a), (b) or (d)) or any other Loan Document, and such failure shall continue unremedied for a period of 25 or more days after written notice thereof from the Lenders is received by a
Responsible Officer of Borrower; 
 (f) Borrower or any of its Subsidiaries shall fail to make any payment (whether of
principal or interest and regardless of amount) in respect of any Material Indebtedness, when and as the same shall become due and payable after giving effect to any applicable grace or cure period as originally provided by the terms of such
Indebtedness; 
 (g) any material breach of, or “event of default” or similar event by any Obligor under, any
Material Agreement shall occur, which would give the counterparty to such Material Agreement the right to terminate such Material Agreement pursuant to the terms thereof (after giving effect to any applicable grace or cure period and provided that
such material breach, “event of default” or similar event is not being contested in good faith with reasonable basis by such Obligor), to the extent that (i) the Obligor has received written notice of (A) termination of such
Material Agreement or (B) written notice of such material breach, “event of default”, or similar event and written notice of the counterparty’s intent to terminate such Material 

  
 67 

 
Agreement on the basis thereof and (ii) the counterparty to such Material Agreement has not waived such material breach, “event of default” or similar event; 

(h) (i) any material breach of, or “event of default” or similar event under, the documentation governing any
Material Indebtedness shall occur and such breach or “event of default” or similar event shall continue unremedied, uncured or unwaived after a period of five (5) Business Days after the expiration of any cure period thereunder, or
(ii), any event or condition occurs (A) that results in any Material Indebtedness becoming due prior to its scheduled maturity or (B) that enables or permits (with or without the giving of notice, the lapse of time or both) the holder or
holders of such Material Indebtedness or any trustee or agent on its or their behalf to cause such Material Indebtedness to become due, or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity;
provided that this Section 11.01(h) shall not apply to secured Indebtedness that becomes due as a result of the voluntary sale or transfer of the property or assets securing such Material Indebtedness. 

(i) any Obligor: 

(i) becomes insolvent, or generally does not or becomes unable to pay its debts or meet its liabilities as the same become
due, or admits in writing its inability to pay its debts generally, or declares any general moratorium on its indebtedness, or proposes a compromise or arrangement or deed of company arrangement between it and any class of its creditors; 

(ii) commits an act of bankruptcy or makes an assignment of its property for the general benefit of its creditors or makes a
proposal (or files a notice of its intention to do so); 
 (iii) institutes any proceeding seeking to adjudicate it an
insolvent, or seeking liquidation, dissolution, winding-up, reorganization, compromise, arrangement, adjustment, protection, moratorium, relief, stay of proceedings of creditors generally (or any class of creditors), or composition of it or its
debts or any other relief, under any federal, provincial or foreign Law now or hereafter in effect relating to bankruptcy, winding-up, insolvency, reorganization, receivership, plans of arrangement or relief or protection of debtors or at common law
or in equity, or files an answer admitting the material allegations of a petition filed against it in any such proceeding; 

(iv) applies for the appointment of, or the taking of possession by, a receiver, interim receiver, receiver/manager,
sequestrator, conservator, custodian, administrator, trustee, liquidator, voluntary administrator, receiver and manager or other similar official for it or any substantial part of its property; or 

(v) takes any action, corporate or otherwise, to approve, effect, consent to or authorize any of the actions described in this
Section 11.01(i) or (j), or otherwise acts in furtherance thereof or fails to act in a timely and appropriate manner in defense thereof; 

(j) any petition is filed, application made or other proceeding instituted against or in respect of Borrower or any
Subsidiary: 
 (i) seeking to adjudicate it as insolvent; 

  
 68 

 (ii) seeking a receiving order against it; 

(iii) seeking liquidation, dissolution, winding-up, reorganization, compromise, arrangement, adjustment, protection,
moratorium, relief, stay of proceedings of creditors generally (or any class of creditors), deed of company arrangement or composition of it or its debts or any other relief under any federal, provincial or foreign law now or hereafter in effect
relating to bankruptcy, winding-up, insolvency, reorganization, receivership, plans of arrangement or relief or protection of debtors or at common law or in equity; or 

(iv) seeking the entry of an order for relief or the appointment of, or the taking of possession by, a receiver, interim
receiver, receiver/manager, sequestrator, conservator, custodian, administrator, trustee, liquidator, voluntary administrator, receiver and manager or other similar official for it or any substantial part of its property, and such petition,
application or proceeding continues undismissed, or unstayed and in effect, for a period of forty-five (45) days after the institution thereof; provided that if an order, decree or judgment is granted or entered (whether or not entered
or subject to appeal) against Borrower or such Subsidiary thereunder in the interim, such grace period will cease to apply; provided further that if Borrower or such Subsidiary files an answer admitting the material allegations of a
petition filed against it in any such proceeding, such grace period will cease to apply; 
 (k) any other event occurs
which, under the laws of any applicable jurisdiction, has an effect equivalent to any of the events referred to in either of Section 11.01(i) or (j); 

(l) one or more judgments for the payment of money in an aggregate amount in excess of $250,000 (or the Equivalent Amount in
other currencies) shall be rendered against any Obligor or any combination thereof and the same shall remain undischarged for a period of 45 consecutive days during which execution shall not be effectively stayed, or any action shall be legally
taken by a judgment creditor to attach or levy upon any assets of any Obligor to enforce any such judgment; 
 (m) (i) an
ERISA Event shall have occurred that, in the opinion of the Lenders, when taken together with all other ERISA Events that have occurred, would reasonably be expected to result in liability of Borrower and its Subsidiaries in an aggregate amount
exceeding (i) $250,000 in any year or (ii) $750,000 for all periods until repayment of all Obligations; 
 (n) a
Material Adverse Change shall have occurred; 
 (o) (i) any Lien created by any of the Security Documents shall at any time
not constitute a valid and perfected Lien on the applicable Collateral intended to be covered thereby (to the extent perfection by filing, registration, recordation or possession is required herein or therein) in favor of the Lenders, free and clear
of all other Liens (other than Permitted Liens), (ii) except for expiration in accordance with its terms, any of the Security Documents or any Guarantee of any of the Obligations (including that contained in Section 13) shall for
whatever reason cease to be in full force and effect, or (iii) any of the Security Documents or any Guarantee of any of the Obligations (including that contained in Section 13), or the enforceability thereof, shall be repudiated or
contested by any Obligor; and 

  
 69 

 (p) any injunction, whether temporary or permanent, shall be rendered
against any Obligor that prevents the Obligors from selling or manufacturing in the United States for more than 45 consecutive calendar days (i) the Product or its commercially available successors, or (ii) any of their other material and
commercially available products where the injunction on the sale or manufacture of such other material product could reasonably be expected to cause a Material Adverse Effect. 

11.02 Remedies. (a) Upon the occurrence of any Event of Default, then, and in every such event (other than an Event of Default
described in Section 11.01(i), (j) or (k)), and at any time thereafter during the continuance of such event, Majority Lenders may, by notice to Borrower, take either or both of the following actions, at the same or
different times: (i) terminate the Commitments, and thereupon the Commitments shall terminate immediately, and (ii) declare the Loans then outstanding to be due and payable in whole (or in part, in which case any principal not so declared
to be due and payable may thereafter be declared to be due and payable), and thereupon the principal of the Loans so declared to be due and payable, together with accrued interest thereon and all fees and other Obligations, shall become due and
payable immediately (in the case of the Loans, at the Redemption Price therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor; 

(b) In case of an Event of Default described in Section 11.01(i), (j) or (k), the Commitment
shall automatically terminate and the principal of the Loans then outstanding, together with accrued interest thereon and all fees and other Obligations, shall automatically become due and payable immediately (in the case of the Loans, at the
Redemption Price therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor. 

(c) Prepayment Premium and Redemption Price. (i) For the avoidance of doubt, the Prepayment Premium (as a
component of the Redemption Price) shall be due and payable whenever so stated in this Agreement, or by any applicable operation of law, regardless of the circumstances causing any related acceleration or payment prior to the Stated Maturity Date,
including without limitation any Event of Default or other failure to comply with the terms of this Agreement, whether or not notice thereof has been given, or any acceleration by, through, or on account of any bankruptcy filing. 

(ii) For the avoidance of doubt, the Prepayment Premium (as a component of the Redemption Price) shall be due and payable at
any time the Loans become due and payable prior to the Stated Maturity Date for any reason, whether due to acceleration pursuant to the terms of this Agreement (in which case it shall be due immediately, upon the giving of notice to Borrower in
accordance with Section 11.02(a), or automatically, in accordance with Section 11.02(b)), by operation of law or otherwise (including, without limitation, where bankruptcy filings or the exercise of any bankruptcy right or
power, whether in any plan of reorganization or otherwise, results or would result in a payment, discharge, modification or other treatment of the Loans or Loan Documents that would otherwise evade, avoid, or otherwise disappoint the expectations of
Lenders in receiving the full benefit of their bargained-for Prepayment Premium or Redemption Price as provided herein). The Obligors and Lenders acknowledge and agree that any Prepayment Premium due and payable in accordance with this Agreement
shall not constitute unmatured interest, whether under section 502(b)(3) of the Bankruptcy Code or 

  
 70 

 
otherwise, but instead is reasonably calculated to ensure that the Lenders receive the benefit of their bargain under the terms of this Agreement. 

(iii) Each Obligor acknowledges and agrees that the Lenders shall be entitled to recover the full amount of the Redemption
Price in each and every circumstance such amount is due pursuant to or in connection with this Agreement, including without limitation in the case of any Obligor’s bankruptcy filing, so that the Lenders shall receive the benefit of their
bargain hereunder and otherwise receive full recovery as agreed under every possible circumstance, and Borrower hereby waives any defense to payment, whether such defense may be based in public policy, ambiguity, or otherwise. Each Obligor further
acknowledges and agrees, and waives any argument to the contrary, that payment of such amount does not constitute a penalty or an otherwise unenforceable or invalid obligation. Any damages that the Lenders may suffer or incur resulting from or
arising in connection with any breach by Borrower shall constitute secured obligations owing to the Lenders. 
 SECTION 12 

MISCELLANEOUS 
 12.01 No
Waiver. No failure on the part of the Lenders to exercise and no delay in exercising, and no course of dealing with respect to, any right, power or privilege under any Loan Document shall operate as a waiver thereof, nor shall any single or
partial exercise of any right, power or privilege under any Loan Document preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The remedies provided herein are cumulative and not exclusive of any
remedies provided by law. 
 12.02 Notices. All notices, requests, instructions, directions and other communications provided for
herein (including any modifications of, or waivers, requests or consents under, this Agreement) shall be given or made in writing (including by telecopy or electronic mail) delivered, if to Borrower, another Obligor or the Lenders, to its address
specified on the signature pages hereto or its Guarantee Assumption Agreement, as the case may be, or at such other address as shall be designated by such party in a notice to the other parties. Except as otherwise provided in this Agreement, all
such communications shall be deemed to have been duly given upon receipt of a legible copy thereof, in each case given or addressed as aforesaid. All such communications provided for herein by telecopy or electronic mail shall be confirmed in
writing promptly after the delivery of such communication (it being understood that non-receipt of written confirmation of such communication shall not invalidate such communication). Notwithstanding anything to the contrary in this Agreement, all
notices, documents, certificates and other deliverables to the Lenders by any Obligor may be made solely to the Agent and the Agent shall promptly deliver such notices, documents, certificates and other deliverables to the other Lenders hereunder.

 12.03 Expenses, Indemnification, Etc. 

(a) Expenses. Borrower agrees to pay or reimburse (i) the Lenders for all of their reasonable and documented out
of pocket costs and expenses (including the reasonable fees and expenses of Morrison & Foerster LLP and Osler, Hoskin & Harcourt LLP, each special counsel to the Lenders, and any sales, goods and services or other similar taxes
applicable thereto, and 

  
 71 

 
printing, reproduction, document delivery, communication and travel costs) in connection with (x) the negotiation, preparation, execution and delivery of this Agreement and the other Loan
Documents and the making of the Loans (exclusive of post-closing costs), (y) post-closing costs and (z) the negotiation or preparation of any modification, supplement or waiver of any of the terms of this Agreement or any of the other Loan
Documents (whether or not consummated) and (ii) the Lenders for all of their documented out of pocket costs and expenses (including the fees and expenses of legal counsel) in connection with any enforcement or collection proceedings resulting
from the occurrence of an Event of Default; provided, however, that Borrower shall not be required to pay or reimburse any amounts pursuant to Section 12.03(a)(i)(x) in excess of the Closing Expense Cap; provided further
that, so long as the first Borrowing is made, then such fees shall be credited from the fees paid by the Borrower pursuant to the Fee Letter; provided further that notwithstanding any provision under this Agreement or other Loan Document to the
contrary, Borrower and its Subsidiaries shall not be responsible for legal and filing costs, fees, expenses and other amounts in excess of $50,000 in respect of actions required under Section 8.12 for each foreign jurisdiction, or
$100,000 in the aggregate for all foreign jurisdictions. 
 (b) Indemnification. Borrower hereby indemnifies the
Lenders, their Affiliates, and their respective directors, officers, employees, attorneys, agents, advisors and controlling parties (each, an “Indemnified Party”) from and against, and agrees to hold them harmless against,
any and all Claims and Losses of any kind (including reasonable fees and disbursements of counsel), joint or several, that may be incurred by or asserted or awarded against any Indemnified Party, in each case arising out of or in connection with or
relating to any investigation, litigation or proceeding or the preparation of any defense with respect thereto arising out of or in connection with or relating to this Agreement or any of the other Loan Documents or the transactions contemplated
hereby or thereby or any use made or proposed to be made with the proceeds of the Loans, whether or not such investigation, litigation or proceeding is brought by Borrower, any of its shareholders or creditors, an Indemnified Party or any other
Person, or an Indemnified Party is otherwise a party thereto, and whether or not any of the conditions precedent set forth in Section 6 are satisfied or the other transactions contemplated by this Agreement are consummated, except to the
extent such Claim or Loss is found in a final, non-appealable judgment by a court of competent jurisdiction to have resulted from such Indemnified Party’s gross negligence or willful misconduct. No Obligor shall assert any claim against any
Indemnified Party, on any theory of liability, for consequential, indirect, special or punitive damages arising out of or otherwise relating to this Agreement or any of the other Loan Documents or any of the transactions contemplated hereby or
thereby or the actual or proposed use of the proceeds of the Loans. Borrower, its Subsidiaries and Affiliates and their respective directors, officers, employees, attorneys, agents, advisors and controlling parties are each sometimes referred to in
this Agreement as a “Borrower Party.” No Lender shall assert any claim against any Borrower Party, on any theory of liability, for consequential, indirect, special or punitive damages arising out of or otherwise relating to
this Agreement or any of the other Loan Documents or any of the transactions contemplated hereby or thereby or the actual or proposed use of the proceeds of the Loans. This Section shall not apply to Taxes governed by Section 5.03. 

12.04 Amendments, Etc. Except as otherwise expressly provided in this Agreement, any provision of this Agreement may be modified or
supplemented only by an instrument in writing signed by Borrower and the Lenders. Any consent, approval, (including without limitation any 

  
 72 

 
approval of or authorization for any amendment to any of the Loan Documents), instruction or other expression of the Lenders under any of the Loan Documents may be obtained by an instrument in
writing signed in one or more counterparts by the Agent and the Majority Lenders (or the Agent with the consent of the Majority Lenders); provided however, that the consent of all of the Lenders shall be required to: 

(a) amend, modify, discharge, terminate or waive any of the terms of this Agreement if such amendment, modification,
discharge, termination or waiver would increase the amount of the Loans, reduce the fees payable hereunder, reduce interest rates or other amounts payable with respect to the Loans, extend any date fixed for payment of principal, interest or other
amounts payable relating to the Loans or extend the repayment dates of the Loans; 
 (b) amend the provisions of Section
6; 
 (c) amend, modify, discharge, terminate or waive any Security Document if the effect is to release a material part
of the Collateral subject thereto otherwise than pursuant to the terms hereof or thereof; or 
 (d) amend this Section
12.04. 
 Notwithstanding anything to the contrary herein, a Defaulting Lender shall not have any right to approve or disapprove any
amendment, waiver or consent hereunder (and any amendment, waiver or consent which by its terms requires the consent of all Lenders or each affected Lender may be effected with the consent of the applicable Lenders other than Defaulting Lenders),
except that (x) the Commitment of any Defaulting Lender may not be increased or extended without the consent of such Lender and (y) any waiver, amendment or modification requiring the consent of all Lenders or each affected Lender that by
its terms affects any Defaulting Lender more adversely than other affected Lenders shall require the consent of such Defaulting Lender. 

12.05 Successors and Assigns. 

(a) General. The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and
their respective successors and assigns permitted hereby, except that Borrower may not assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of the Lenders. Any of the Lenders may assign or
otherwise transfer any of their rights or obligations hereunder to an assignee in accordance with the provisions of Section 12.05(b), (ii) by way of participation in accordance with the provisions of Section 12.05(e) or
(iii) by way of pledge or assignment of a security interest subject to the restrictions of Section 12.05(g). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties
hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in Section 12.05(d) and, to the extent expressly contemplated hereby, the Indemnified Parties) any legal or equitable right,
remedy or claim under or by reason of this Agreement. 
 (b) Assignments by Lenders. Any of the Lenders may at any
time assign to one or more Eligible Transferees (or, if an Event of Default has occurred and is continuing, to any Person) all or a portion of their rights and obligations under this Agreement (including all or a portion of the Commitment and the
Loans at the time owing to it); provided, however, that no 

  
 73 

 
such assignment shall be made to Borrower, an Affiliate of Borrower, or any employees or directors of Borrower at any time. Subject to the recording thereof by the Lenders pursuant to
Section 12.05(c), from and after the effective date specified in each Assignment and Assumption, the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption,
have the rights and obligations of the Lenders under this Agreement, and correspondingly the assigning Lender shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement
(and, in the case of an Assignment and Assumption covering all of a Lender’s rights and obligations under this Agreement, such Lender shall cease to be a party hereto) but shall continue to be entitled to the benefits of Section 5
and Section 12.03. Any assignment or transfer by a Lender of rights or obligations under this Agreement that does not comply with this Section 12.05(b) shall be treated for purposes of this Agreement as a sale by such Lender
of a participation in such rights and obligations in accordance with Section 12.05(e). 
 (c) Amendments to
Loan Documents. Each of the Lenders and the Obligors agrees to enter into such amendments to the Loan Documents, and such additional Security Documents and other instruments and agreements, in each case in form and substance reasonably
acceptable to the Lenders and the Obligors, as shall reasonably be necessary to implement and give effect to any assignment made under this Section 12.05. 

(d) Register. Each Lender, acting solely for this purpose as an agent of Borrower, shall maintain at one of its
offices (which shall be the office of the Agent) a register for the recordation of the name and address of any assignee of the Lenders and the Commitment and outstanding principal amount (and stated interest) of the Loans owing thereto (the
“Register”). The entries in the Register shall be conclusive, absent manifest error, and Borrower shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as the
“Lender” hereunder for all purposes of this Agreement, notwithstanding notice to the contrary. The Register shall be available for inspection by Borrower, at any reasonable time and from time to time upon reasonable prior notice.

 (e) Participations. Any of the Lenders may at any time, without the consent of, or notice to, Borrower,
sell participations to any Person (other than a natural person or Borrower or any of Borrower’s Affiliates or Subsidiaries) (each, a “Participant”) in all or a portion of such Lender’s rights and/or
obligations under this Agreement (including all or a portion of the Commitment and/or the Loans owing to it); provided that (i) such Lender’s obligations under this Agreement shall remain unchanged, (ii) such
Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) Borrower shall continue to deal solely and directly with the Lenders in connection therewith. 

Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole
right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; provided that such agreement or instrument may provide that such Lender will not, without the consent of the Participant,
agree to any amendment, modification or waiver that would (i) increase or extend the term of such Lender’s Commitment, (ii) extend the date fixed for the payment of principal of or interest on the Loans or any portion of any fee
hereunder payable to the Participant, (iii) reduce the amount of any such payment of principal, or (iv) reduce the rate at which interest is payable  

  
 74 

 
thereon to a level below the rate at which the Participant is entitled to receive such interest. Borrower agrees that each Participant shall be entitled to the benefits of
Section 5.03 (subject to the requirements and limitations therein, including the requirements under Section 5.03(e) (it being understood that the documentation required under Section 5.03(e) shall be delivered to
Borrower and the participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to Section 12.05(b) provided that such Participant (A) agrees to be subject to the provisions of
Section 5.03(g) as if it were an assignee under Section 12.05(b); and (B) shall not be entitled to receive any greater payment under Section 5.03, with respect to any participation, than its participating
Lender would have been entitled to receive. Each Lender that sells a participation agrees, at Borrower’s request and expense, to use reasonable efforts to cooperate with Borrower to effectuate the provisions of Section 5.03(g) with
respect to any Participant. To the extent permitted by law, each Participant also shall be entitled to the benefits of Section 4.04(a) as though it were the Lender. 

Each participation sold by a Lender shall be issued and maintained at all times in “registered form” as that term is
defined in Section 5f.103-1(c) of the United States Treasury Regulations. Each Lender that sells a participation shall, acting solely for this purpose as an agent of Borrower, maintain a register on which it enters the name and address of each
Participant and the principal amounts (and stated interest) of each Participant’s interest in the Loans or other obligations under the Loan Documents (the “Participant Register”); provided that no Lender shall have any
obligation to disclose all or any portion of the Participant Register (including the identity of any Participant or any information relating to a Participant’s interest in any commitments, loans, letters of credit or its other obligations under
any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury
Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this
Agreement notwithstanding any notice to the contrary. 
 (f) Limitations on Rights of Participants. A Participant
shall not be entitled to receive any greater payment under Section 5.01 or 5.03 than a Lender would have been entitled to receive with respect to the participation sold to such Participant, unless the sale of the participation to
such Participant is made with Borrower’s prior written consent. 
 (g) Certain Pledges. The Lenders may at any
time pledge or assign a security interest in all or any portion of its rights under this Agreement and any other Loan Document to secure obligations of the Lenders, including any pledge or assignment to secure obligations to a Federal Reserve Bank;
provided that no such pledge or assignment shall release the Lenders from any of their obligations hereunder or substitute any such pledgee or assignee for the Lenders as a party hereto. 

12.06 Survival. The obligations of Borrower under Sections 5.01, 5.02, 5.03, 12.03, 12.05,
12.09, 12.10, 12.11, 12.12, 12.13, 12.14 and Section 13 (solely to the extent guaranteeing any of the obligations under the foregoing Sections) shall survive the repayment of the Loans and the
termination of the Commitment and, in the case of the Lenders’ assignment of any interest in the Commitment or the Loans hereunder, shall survive, in the case of any event or circumstance that 

  
 75 

 
occurred prior to the effective date of such assignment, the making of such assignment, notwithstanding that the Lenders may cease to be “Lenders” hereunder. In addition, each
representation and warranty made, or deemed to be made by a notice of the Loans, herein or pursuant hereto shall survive the making of such representation and warranty. 

12.07 Captions. The table of contents and captions and section headings appearing herein are included solely for convenience of
reference and are not intended to affect the interpretation of any provision of this Agreement. 
 12.08 Counterparts. This Agreement
may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Agreement by signing any such counterpart. 

12.09 Governing Law. This Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in
accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that Section 5-1401 of the New York General
Obligations Law shall apply. 
 12.10 Jurisdiction, Service of Process and Venue. 

(a) Submission to Jurisdiction. Each Obligor agrees that any suit, action or proceeding with respect to this Agreement
or any other Loan Document to which it is a party or any judgment entered by any court in respect thereof may be brought initially in the federal or state courts in Houston, Texas or in the courts of its own corporate domicile and irrevocably
submits to the non-exclusive jurisdiction of each such court for the purpose of any such suit, action, proceeding or judgment. This Section 12.10(a) is for the benefit of the Lenders only and, as a result, no Lender shall be prevented
from taking proceedings in any other courts with jurisdiction. To the extent allowed by applicable Laws, the Lenders may take concurrent proceedings in any number of jurisdictions. 

(b) Alternative Process. Nothing herein shall in any way be deemed to limit the ability of the Lenders to serve any
such process or summonses in any other manner permitted by applicable law. 
 (c) Waiver of Venue, Etc. Each Obligor
irrevocably waives to the fullest extent permitted by law any objection that it may now or hereafter have to the laying of the venue of any suit, action or proceeding arising out of or relating to this Agreement or any other Loan Document and hereby
further irrevocably waives to the fullest extent permitted by law any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. A final judgment (in respect of which time for all appeals has
elapsed) in any such suit, action or proceeding shall be conclusive and may be enforced in any court to the jurisdiction of which such Obligor is or may be subject, by suit upon judgment. 

12.11 Waiver of Jury Trial. EACH OBLIGOR AND EACH LENDER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW,
ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER 

  
 76 

 
LOAN DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. 
 12.12 Waiver
of Immunity. To the extent that any Obligor may be or become entitled to claim for itself or its Property or revenues any immunity on the ground of sovereignty or the like from suit, court jurisdiction, attachment prior to judgment, attachment
in aid of execution of a judgment or execution of a judgment, and to the extent that in any such jurisdiction there may be attributed such an immunity (whether or not claimed), such Obligor hereby irrevocably agrees not to claim and hereby
irrevocably waives such immunity with respect to its obligations under this Agreement and the other Loan Documents. 
 12.13 Entire
Agreement. This Agreement and the other Loan Documents constitute the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede any and all previous agreements and understandings, oral or written,
relating to the subject matter hereof. EACH OBLIGOR ACKNOWLEDGES, REPRESENTS AND WARRANTS THAT IN DECIDING TO ENTER INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS OR IN TAKING OR NOT TAKING ANY ACTION HEREUNDER OR THEREUNDER, IT HAS NOT RELIED,
AND WILL NOT RELY, ON ANY STATEMENT, REPRESENTATION, WARRANTY, COVENANT, AGREEMENT OR UNDERSTANDING, WHETHER WRITTEN OR ORAL, OF OR WITH THE LENDERS OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS. 

12.14 Severability. If any provision hereof is found by a court to be invalid or unenforceable, to the fullest extent permitted by
applicable law the parties agree that such invalidity or unenforceability shall not impair the validity or enforceability of any other provision hereof. 

12.15 No Fiduciary Relationship. Borrower acknowledges that the Lenders have no fiduciary relationship with, or fiduciary duty to,
Borrower arising out of or in connection with this Agreement or the other Loan Documents, and the relationship between the Lenders and Borrower is solely that of creditor and debtor. This Agreement and the other Loan Documents do not create a joint
venture among the parties. 
 12.16 Confidentiality. The Lenders agree to maintain the confidentiality of the Confidential
Information (as defined in the Non-Disclosure Agreement (defined below)) in accordance with the terms of that certain non-disclosure agreement dated January 16, 2015 between Borrower and Capital Royalty L.P. (the “Non-Disclosure
Agreement”). Any new Lender that becomes party to this Agreement hereby agrees to be bound by the terms of the Non-Disclosure Agreement. The Original Lenders may announce the completion of this transaction to limited partners and
investors. The Original Lenders may reference this transaction in marketing materials in a manner to be mutually agreed upon by the Lenders and Borrower. 

12.17 USA PATRIOT Act. The Lenders hereby notify Borrower that pursuant to the requirements of the USA PATRIOT Act (Title III of Pub.
L. 107-56 (signed into law October 26, 2001)) (the “Act”), they are required to obtain, verify and record information that identifies Borrower, which information includes the name and address of Borrower and other
information that will allow such Lender to identify Borrower in accordance with the Act. 

  
 77 

 12.18 Maximum Rate of Interest.  

(a) Notwithstanding anything to the contrary contained in any Loan Document, the interest paid or agreed to be paid under the
Loan Documents shall not exceed the maximum rate of non-usurious interest permitted by applicable Law (in each case, the “Maximum Rate”). If the Lenders shall receive interest in an amount that exceeds the Maximum Rate, the
excess interest shall be applied to the principal of the Loans, and not to the payment of interest, or, if the excessive interest exceeds such unpaid principal, the amount exceeding the unpaid balance shall be refunded to the applicable Obligor. In
determining whether the interest contracted for, charged, or received by the Lenders exceeds the Maximum Rate, the Lenders may, to the extent permitted by applicable Law, (a) characterize any payment that is not principal as an expense, fee, or
premium rather than interest, (b) exclude voluntary prepayments and the effects thereof, (c) amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest throughout the contemplated term of the
Indebtedness and other obligations of any Obligor hereunder, or (d) allocate interest between portions of such Indebtedness and other obligations under the Loan Documents to the end that no such portion shall bear interest at a rate greater
than that permitted by applicable Law. 
 (b) If any provision of this Agreement would oblige the Borrower to make any
payment of interest or other amount payable to any Lender in an amount or calculated at a rate which would be prohibited by applicable law or would result in a receipt by that Lender of “interest” at a “criminal rate” (as such
terms are construed under the Criminal Code (Canada)), then, notwithstanding such provision, such amount or rate shall be deemed to have been adjusted with retroactive effect to the maximum amount or rate of interest, as the case may be, as would
not be so prohibited by law or so result in a receipt by that Lender of “interest” at a “criminal rate”, such adjustment to be effected, to the extent necessary (but only to the extent necessary), as follows: (i) first, by
reducing the amount or rate of interest; and (ii) thereafter, by reducing any fees, commissions, costs, expenses, premiums and other amounts required to be paid to the affected Lender which would constitute interest for purposes of section 347
of the Criminal Code (Canada). 
 12.19 Certain Waivers.  

(a) Real Property Security Waivers. 

(i) Each Obligor acknowledges that all or any portion of the Obligations may now or hereafter be secured by a Lien or Liens
upon real property evidenced by certain documents including, without limitation, deeds of trust and assignments of rents. Lenders may, pursuant to the terms of said real property security documents and applicable law, foreclose under all or any
portion of one or more of said Liens by means of judicial or nonjudicial sale or sales. Each Obligor agrees that Lenders may exercise whatever rights and remedies they may have with respect to said real property security, all without affecting the
liability of any Obligor under the Loan Documents, except to the extent Lenders realize payment by such action or proceeding. No election to proceed in one form of action or against any party, or on any obligation shall constitute a waiver of
Lenders’ rights to proceed in any other form of action or against any Obligor or any other Person, or diminish the liability of any Obligor, or affect the right of Lenders to proceed against any Obligor for any deficiency, except to the extent
Lenders 

  
 78 

 
realize payment by such action, notwithstanding the effect of such action upon any Obligor’s rights of subrogation, reimbursement or indemnity, if any, against Obligor or any other Person.

 (ii) To the extent permitted under applicable law, each Obligor hereby waives any rights and defenses that are or may
become available to such Obligor by reason of Sections 2787 to 2855, inclusive, of the California Civil Code. 
 (iii) To
the extent permitted under applicable law, each Obligor hereby waives all rights and defenses that such Obligor may have because the Obligations are or may be secured by real property. This means, among other things: 

(A) Lenders may collect from any Obligor without first foreclosing on any real or personal property collateral pledged by any
other Obligor; 
 (B) If Lenders foreclose on any real property collateral pledged by any Obligor: 

(1) The amount of the Loans may be reduced only by the price for which that collateral is sold at the foreclosure sale, even
if the collateral is worth more than the sale price; and 
 (2) Lenders may collect from each Obligor even if Lenders, by
foreclosing on the real property collateral, have destroyed any right that such Obligor may have to collect from any other Obligor. 

(3) To the extent permitted under applicable law, this is an unconditional and irrevocable waiver of any rights and defenses
each Obligor may have because the Obligations are or may be secured by real property. These rights and defenses include, but are not limited to, any rights or defenses based upon Section 580a, 580b, 580d or 726 of the California Code of Civil
Procedure. 
 (iv) To the extent permitted under applicable law, each Obligor waives all rights and defenses arising out of
an election of remedies by Lenders, even though that election of remedies, such as a nonjudicial foreclosure with respect to security for a guaranteed obligation, has destroyed such Obligor’s rights of subrogation and reimbursement against the
principal by the operation of Section 580d of the California Code of Civil Procedure or otherwise. 
 (b) Waiver of
Marshaling. WITHOUT LIMITING THE FOREGOING IN ANY WAY, EACH OBLIGOR HEREBY
IRREVOCABLY WAIVES AND RELEASES, TO THE EXTENT PERMITTED BY LAW, ANY
AND ALL RIGHTS IT MAY HAVE AT ANY TIME (WHETHER ARISING DIRECTLY
OR INDIRECTLY, BY OPERATION OF LAW, CONTRACT OR OTHERWISE) TO REQUIRE
THE MARSHALING OF ANY ASSETS OF ANY OBLIGOR, WHICH RIGHT OF
MARSHALING MIGHT OTHERWISE ARISE FROM ANY PAYMENTS MADE OR OBLIGATIONS PERFORMED.

 12.20 Releases of Guarantees and Liens. At such time as the Loans and the other Obligations (other than the inchoate
indemnity obligations) under the Loan Documents shall have been indefeasibly paid in full and the Commitments have been terminated, the Collateral shall be 

  
 79 

 
released from the Liens created by the Security Documents, and the Security Documents and all obligations (other than those expressly stated to survive such termination) of the Agent and each
Obligor under the Security Documents shall terminate, all without delivery of any instrument or performance of any act by any Person. 

12.21 Judgment Currency. If for the purpose of obtaining judgment in any court it is necessary to convert any amount owing or payable
to the Lenders under this Agreement from the currency in which it is due (the “Agreed Currency”) into a particular currency (the “Judgment Currency”), the rate of exchange applied in that conversion
shall be that at which such Lenders in accordance with their normal procedures, could purchase the Agreed Currency with the Judgment Currency at or about noon on the Business Day immediately preceding the date on which judgment is given. The
obligation of Borrower in respect of any amount owing or payable under this Agreement to the Lenders in the Agreed Currency shall, notwithstanding any judgment and payment in the Judgment Currency, be satisfied only to the extent that the Lenders in
accordance with its normal procedures, could purchase the Agreed Currency with the amount of the Judgment Currency so paid at or about noon on the next Business Day following that payment; and if the amount of the Agreed Currency which the Lenders
could so purchase is less than the amount originally due in the Agreed Currency, Borrower shall, as a separate obligation and notwithstanding the judgment or payment, indemnify the Lenders against any loss. 

SECTION 13 
 GUARANTEE

 13.01 The Guarantee. The Subsidiary Guarantors hereby jointly and severally guarantee to the Lenders and their successors and
assigns the prompt payment in full when due (whether at stated maturity, by acceleration or otherwise) of the principal of and interest on the Loans and all fees and other amounts from time to time owing to the Lenders by Borrower under this
Agreement or under any other Loan Document and by any other Obligor under any of the Loan Documents, in each case strictly in accordance with the terms thereof (such obligations being herein collectively called the “Guaranteed
Obligations”). The Subsidiary Guarantors hereby further jointly and severally agree that if Borrower shall fail to pay in full when due (whether at stated maturity, by acceleration or otherwise) any of the Guaranteed Obligations, the
Subsidiary Guarantors will promptly pay the same, without any demand or notice whatsoever, and that in the case of any extension of time of payment or renewal of any of the Guaranteed Obligations, the same will be promptly paid in full when due
(whether at extended maturity, by acceleration or otherwise) in accordance with the terms of such extension or renewal. 
 13.02
Obligations Unconditional. The obligations of the Subsidiary Guarantors under Section 13.01 are absolute and unconditional, joint and several, irrespective of the value, genuineness, validity, regularity or enforceability of the
obligations of Borrower under this Agreement or any other agreement or instrument referred to herein, or any substitution, release or exchange of any other guarantee of or security for any of the Guaranteed Obligations, and, to the fullest extent
permitted by applicable law, irrespective of any other circumstance whatsoever that might otherwise constitute a legal or equitable discharge or defense of a surety or guarantor, it being the intent of this Section 13.02 that the
obligations of the Subsidiary Guarantors hereunder shall be absolute and unconditional, joint and several, under any and all circumstances. Without limiting the generality of the foregoing, it is agreed that the occurrence of any one or more of the

  
 80 

 
following shall not alter or impair the liability of the Subsidiary Guarantors hereunder, which shall remain absolute and unconditional as described above: 

(a) at any time or from time to time, without notice to the Subsidiary Guarantors, the time for any performance of or
compliance with any of the Guaranteed Obligations shall be extended, or such performance or compliance shall be waived; 

(b) any of the acts mentioned in any of the provisions of this Agreement or any other agreement or instrument referred to
herein shall be done or omitted; 
 (c) the maturity of any of the Guaranteed Obligations shall be accelerated, or any of
the Guaranteed Obligations shall be modified, supplemented or amended in any respect, or any right under this Agreement or any other agreement or instrument referred to herein shall be waived or any other guarantee of any of the Guaranteed
Obligations or any security therefor shall be released or exchanged in whole or in part or otherwise dealt with; or 
 (d)
any lien or security interest granted to, or in favor of, the Lenders as security for any of the Guaranteed Obligations shall fail to be perfected. 

The Subsidiary Guarantors hereby expressly waive diligence, presentment, demand of payment, protest and all notices whatsoever, and any
requirement that the Lenders exhaust any right, power or remedy or proceed against Borrower under this Agreement or any other agreement or instrument referred to herein, or against any other Person under any other guarantee of, or security for, any
of the Guaranteed Obligations. 
 13.03 Reinstatement. The obligations of the Subsidiary Guarantors under this Section 13
shall be automatically reinstated if and to the extent that for any reason any payment by or on behalf of Borrower in respect of the Guaranteed Obligations is rescinded or must be otherwise restored by any holder of any of the Guaranteed
Obligations, whether as a result of any proceedings in bankruptcy or reorganization or otherwise, and the Subsidiary Guarantors jointly and severally agree that they will indemnify the Lenders on demand for all reasonable costs and expenses
(including fees of counsel) incurred by the Lenders in connection with such rescission or restoration, including any such costs and expenses incurred in defending against any claim alleging that such payment constituted a preference, fraudulent
transfer or similar payment under any bankruptcy, insolvency or similar law. 
 13.04 Subrogation. The Subsidiary Guarantors hereby
jointly and severally agree that until the payment and satisfaction in full of all Guaranteed Obligations and the expiration and termination of the Commitment of the Lenders under this Agreement they shall not exercise any right or remedy arising by
reason of any performance by them of their guarantee in Section 13.01, whether by subrogation or otherwise, against Borrower or any other guarantor of any of the Guaranteed Obligations or any security for any of the Guaranteed
Obligations. 
 13.05 Remedies. The Subsidiary Guarantors jointly and severally agree that, as between the Subsidiary Guarantors and
the Lenders, the obligations of Borrower under this Agreement and under the other Loan Documents may be declared to be forthwith due and payable as provided in Section 11 (and shall be deemed to have become automatically due and payable
in the circumstances provided in Section 11) for purposes of Section 13.01 notwithstanding any stay, 

  
 81 

 
injunction or other prohibition preventing such declaration (or such obligations from becoming automatically due and payable) as against Borrower and that, in the event of such declaration (or
such obligations being deemed to have become automatically due and payable), such obligations (whether or not due and payable by Borrower) shall forthwith become due and payable by the Subsidiary Guarantors for purposes of Section 13.01. 

13.06 Instrument for the Payment of Money. Each Subsidiary Guarantor hereby acknowledges that the guarantee in this
Section 13 constitutes an instrument for the payment of money, and consents and agrees that the Lenders, at their sole option, in the event of a dispute by such Subsidiary Guarantor in the payment of any moneys due hereunder, shall have
the right to proceed by motion for summary judgment in lieu of complaint pursuant to N.Y. Civ. Prac. L&R § 3213. 
 13.07
Continuing Guarantee. The guarantee in this Section 13 is a continuing guarantee, and shall apply to all Guaranteed Obligations whenever arising. 

13.08 Rights of Contribution. The Subsidiary Guarantors hereby agree, as between themselves, that if any Subsidiary Guarantor shall
become an Excess Funding Guarantor (as defined below) by reason of the payment by such Subsidiary Guarantor of any Guaranteed Obligations, each other Subsidiary Guarantor shall, on demand of such Excess Funding Guarantor (but subject to the next
sentence), pay to such Excess Funding Guarantor an amount equal to such Subsidiary Guarantor’s Pro rata Share (as defined below and determined, for this purpose, without reference to the properties, debts and liabilities of such Excess
Funding Guarantor) of the Excess Payment (as defined below) in respect of such Guaranteed Obligations. The payment obligation of a Subsidiary Guarantor to any Excess Funding Guarantor under this Section 13.08 shall be subordinate and
subject in right of payment to the prior payment in full of the obligations of such Subsidiary Guarantor under the other provisions of this Section 13 and such Excess Funding Guarantor shall not exercise any right or remedy with respect
to such excess until payment and satisfaction in full of all of such obligations. 
 For purposes of this Section 13.08,
(i) “Excess Funding Guarantor” means, in respect of any Guaranteed Obligations, a Subsidiary Guarantor that has paid an amount in excess of its Pro rata Share of such Guaranteed Obligations,
(ii) “Excess Payment” means, in respect of any Guaranteed Obligations, the amount paid by an Excess Funding Guarantor in excess of its Pro rata Share of such Guaranteed Obligations and (iii) “Pro
Rata Share” means, for any Subsidiary Guarantor, the ratio (expressed as a percentage) of (x) the amount by which the aggregate present fair saleable value of all properties of such Subsidiary Guarantor (excluding any shares of
stock of any other Subsidiary Guarantor) exceeds the amount of all the debts and liabilities of such Subsidiary Guarantor (including contingent, subordinated, unmatured and unliquidated liabilities, but excluding the obligations of such Subsidiary
Guarantor hereunder and any obligations of any other Subsidiary Guarantor that have been Guaranteed by such Subsidiary Guarantor) to (y) the amount by which the aggregate fair saleable value of all properties of all of the Subsidiary Guarantors
exceeds the amount of all the debts and liabilities (including contingent, subordinated, unmatured and unliquidated liabilities, but excluding the obligations of Borrower and the Subsidiary Guarantors hereunder and under the other Loan Documents) of
all of the Subsidiary Guarantors, determined (A) with respect to any Subsidiary Guarantor that is a party hereto on the first Borrowing Date, as of such Borrowing Date, and (B) with respect to any

  
 82 

 
other Subsidiary Guarantor, as of the date such Subsidiary Guarantor becomes a Subsidiary Guarantor hereunder. 

13.09 General Limitation on Guarantee Obligations. In any action or proceeding involving any provincial, territorial or state corporate
law, or any state, provincial, territorial or federal bankruptcy, insolvency, reorganization or other law affecting the rights of creditors generally, if the obligations of any Subsidiary Guarantor under Section 13.01 would otherwise,
taking into account the provisions of Section 13.08, be held or determined to be void, invalid or unenforceable, or subordinated to the claims of any other creditors, on account of the amount of its liability under
Section 13.01, then, notwithstanding any other provision hereof to the contrary, the amount of such liability shall, without any further action by such Subsidiary Guarantor, the Lenders or any other Person, be automatically limited and
reduced to the highest amount that is valid and enforceable and not subordinated to the claims of other creditors as determined in such action or proceeding. 

SECTION 14 
 THE AGENT

 14.01 Appointment and Authority. Each of the Lenders hereby irrevocably appoints CRG Partners III L.P. to act on its behalf as
the Agent hereunder and under the other Loan Documents and authorizes the Agent to take such actions on its behalf and to exercise such powers as are delegated to the Agent by the terms hereof or thereof, together with such actions and powers as are
reasonably incidental thereto. The provisions of this Section 14 are solely for the benefit of the Agent and the Lenders, and neither the Borrower nor any other party to the Loan Documents shall have rights as a third-party beneficiary of any
of such provisions. It is understood and agreed that the use of the term “agent” herein or in any other Loan Documents (or any other similar term) with reference to the Agent is not intended to connote any fiduciary or other implied (or
express) obligations arising under agency doctrine of any applicable law. Instead such term is used as a matter of market custom, and is intended to create or reflect only an administrative relationship between contracting parties. 

14.02 Rights as a Lender. The Person serving as the Agent hereunder shall have the same rights and powers in its capacity as a Lender
as any other Lender and may exercise the same as though it were not the Agent, and the term “Lender” or “Lenders” shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as
the Agent hereunder in its individual capacity. Such Person and its Affiliates may accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for, and generally engage in any kind of
business with, the Borrower or any Subsidiary or other Affiliate thereof as if such Person were not the Agent hereunder and without any duty to account therefor to the Lenders. 

14.03 Exculpatory Provisions. 

(a) The Agent shall not have any duties or obligations except those expressly set forth herein and in the other Loan
Documents, and its duties hereunder shall be administrative in nature. Without limiting the generality of the foregoing, the Agent: 

  
 83 

 (i) shall not be subject to any fiduciary or other implied duties,
regardless of whether a Default has occurred and is continuing; 
 (ii) shall not have any duty to take any discretionary
action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Agent is required to exercise as directed in writing by the Majority Lenders (or such other
number or percentage of the Lenders as shall be expressly provided for herein or in the other Loan Documents); provided that the Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the
Agent to liability or that is contrary to any Loan Document or applicable law, including for the avoidance of doubt any action that may be in violation of the automatic stay under the Bankruptcy Code or any similar debtor relief law or that may
effect a forfeiture, modification or termination of property of a Defaulting Lender in violation of the Bankruptcy Code or any similar debtor relief law; and 

(iii) shall not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and shall
not be liable for the failure to disclose, any information relating to the Borrower or any of its Affiliates that is communicated to or obtained by the Person serving as the Agent or any of its Affiliates in any capacity. 

(b) The Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the
Majority Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Agent shall believe in good faith shall be necessary, under the circumstances as provided in Sections 11.02 and 12.05(c)), or
(ii) in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and nonappealable judgment. The Agent shall be deemed not to have knowledge of any Default unless and until notice
describing such Default is given to the Agent in writing by the Borrower or a Lender. 
 (c) The Agent shall not be
responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other
document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any
Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document, or (v) the satisfaction of any condition set forth in Section 6
or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Agent. 
 14.04 Reliance by
Agent. The Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or
intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Agent also may rely upon any statement made to it orally or by telephone and believed by
it to have been made by the proper Person, and shall not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of a Loan that by its terms must be fulfilled to the satisfaction of a Lender, the

  
 84 

 
Agent may presume that such condition is satisfactory to such Lender unless the Agent shall have received notice to the contrary from such Lender prior to the making of such Loan. The Agent may
consult with legal counsel (who may be counsel for the Borrower), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel,
accountants or experts. 
 14.05 Delegation of Duties. The Agent may perform any and all of its duties and exercise its rights and
powers hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Agent. The Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their
respective Related Parties. The exculpatory provisions of this Article shall apply to any such sub-agent and to the Related Parties of the Agent and any such sub-agent, and shall apply to their respective activities in connection with the
syndication of the Facilities as well as activities as Agent. The Agent shall not be responsible for the negligence or misconduct of any sub-agents except to the extent that a court of competent jurisdiction determines in a final and nonappealable
judgment that the Agent acted with gross negligence or willful misconduct in the selection of such sub-agents. 
 14.06 Resignation of
Agent. 
 (a) The Agent may at any time give notice of its resignation to the Lenders and the Borrower. Upon receipt of
any such notice of resignation, the Majority Lenders shall have the right, in consultation with the Borrower, to appoint a successor. If no such successor shall have been so appointed by the Majority Lenders and shall have accepted such appointment
within 30 days after the retiring Agent gives notice of its resignation (or such earlier day as shall be agreed by the Majority Lenders) (the “Resignation Effective Date”), then the retiring Agent may (but shall not be
obligated to), on behalf of the Lenders, appoint a successor Agent meeting the qualifications set forth above. Whether or not a successor has been appointed, such resignation shall become effective in accordance with such notice on the Resignation
Effective Date. 
 (b) If the Person serving as Agent is a Defaulting Lender pursuant to clause (c) of the definition
thereof, the Majority Lenders may, to the extent permitted by applicable law, by notice in writing to the Borrower and such Person remove such Person as Agent and, in consultation with the Borrower, appoint a successor. If no such successor shall
have been so appointed by the Majority Lenders and shall have accepted such appointment within 30 days (or such earlier day as shall be agreed by the Majority Lenders) (the “Removal Effective Date”), then such removal shall
nonetheless become effective in accordance with such notice on the Removal Effective Date. 
 (c) With effect from the
Resignation Effective Date or the Removal Effective Date (as applicable) (1) the retiring or removed Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents (except that in the case of any
Collateral held by the Agent on behalf of the Lenders under any of the Loan Documents, the retiring or removed Agent shall continue to hold such Collateral until such time as a successor Agent is appointed) and (2) except for any indemnity
payments owed to the retiring or removed Agent, all payments, communications and determinations provided to be made by, to or through the Agent shall instead be made by or to each Lender directly, until such time, if any, as the Majority Lenders
appoint a successor Agent as provided for above. Upon the acceptance of a 

  
 85 

 
successor’s appointment as Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring or removed Agent (other
than any rights to indemnity payments owed to the retiring or removed Agent), and the retiring or removed Agent shall be discharged from all of its duties and obligations hereunder or under the other Loan Documents. The fees payable by the Borrower
to a successor Agent shall be the same as those payable to its predecessor unless otherwise agreed between the Borrower and such successor. After the retiring or removed Agent’s resignation or removal hereunder and under the other Loan
Documents, the provisions of this Section and Section 12.03 shall continue in effect for the benefit of such retiring or removed Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted
to be taken by any of them while the retiring or removed Agent was acting as Agent. 
 14.07 Non-Reliance on Agent and Other Lenders.
Each Lender acknowledges that it has, independently and without reliance upon the Agent or any other Lender or any of their Related Parties and based on such documents and information as it has deemed appropriate, made its own credit analysis and
decision to enter into this Agreement. Each Lender also acknowledges that it will, independently and without reliance upon the Agent or any other Lender or any of their Related Parties and based on such documents and information as it shall from
time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder. 

14.08 Agent May File Proofs of Claim. In case of the pendency of any Insolvency Proceeding or any other judicial proceeding relative to
any Obligor, the Agent (irrespective of whether the principal of any Loan shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Agent shall have made any demand on the Borrower) shall be
entitled and empowered (but not obligated), by intervention in such proceeding or otherwise: 
 (a) to file and prove a
claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans and all other Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of
the Lenders and the Agent (including any claim for the compensation, expenses, disbursements and advances of the Lenders and the Agent and their respective agents and counsel and all other amounts due the Lenders and the Agent under Sections
2.03 and 12.03) allowed in such judicial proceeding; and 
 (b) to collect and receive any monies or other
property payable or deliverable on any such claims and to distribute the same; 
 and any custodian, receiver, assignee, trustee,
liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender to make such payments to the Agent and, in the event that the Agent shall consent to the making of such payments directly to the
Lenders, to pay to the Agent any amount due for the compensation, expenses, disbursements and advances of the Agent and its agents and counsel, and any other amounts due the Agent under Sections 2.03 and 12.03. 

  
 86 

 Nothing contained herein shall be deemed to authorize the Agent to authorize or consent to
or accept or adopt on behalf of any Lender any plan of reorganization, arrangement, adjustment or composition affecting the Obligations or the rights of any Lender to authorize the Agent to vote in respect of the claim of any Lender in any such
proceeding. 
 14.09 Collateral and Guaranty Matters. 

(a) Without limiting the provisions of Section 14.09, the Lenders irrevocably authorize the Agent, at its option
and in its discretion: 
 (i) to release any Lien on any property granted to or held by the Agent under any Loan Document
(A) upon termination of all Commitments and payment in full of all Obligations (other than contingent indemnification obligations); (B) that is sold or otherwise disposed of or to be sold or otherwise disposed of as part of or in
connection with any sale or other disposition permitted under the Loan Documents; or (C) subject to Section 12.04, if approved, authorized or ratified in writing by the Majority Lenders (unless Section 12.04 requires
unanimous consent of all Lenders); 
 (ii) to subordinate any Lien on any property granted to or held by the Agent under any
Loan Document to the holder of any Lien on such property that is a Permitted Lien under Section 9.02(d); 

(iii) to release any Guarantor from its Guaranteed Obligations if such Person ceases to be a Subsidiary as a result of a
transaction permitted under the Loan Documents. 
 Upon request by the Agent at any time, the Majority Lenders will confirm
in writing the Agent’s authority to release or subordinate its interest in particular types or items of Collateral, or to release any Guarantor from its Guaranteed Obligations pursuant to this Section 14.09. 

(b) The Agent shall not be responsible for or have a duty to ascertain or inquire into any representation or warranty
regarding the existence, value or collectability of the Collateral, the existence, priority or perfection of the Agent’s Lien thereon, or any certificate prepared by any Obligor in connection therewith, nor shall the Agent be responsible or
liable to the Lenders for any failure to monitor or maintain any portion of the Collateral. 
 (c) The Agent is authorized
on behalf of all the Lenders, without the necessity of any notice to or further consent from the Lenders, from time to time to take any action with respect to any Collateral or the Security Documents which may be necessary to perfect and maintain
perfected the Liens on the Collateral granted pursuant to the Security Documents or protect and preserve the Agent’s ability to enforce the Liens or realize upon the Collateral. 

[Signature Pages Follow] 

  
 87 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed and delivered as of the day and year first above written. 
  

					
	 BORROWER:

	
	 GENOMEDX BIOSCIENCES INC.

		
	 By
	 	 /s/ Dave Matthews

		 	 Name:
	 	 Dave Matthews

		 	 Title:
	 	 Chief Financial Officer

	
	 Address for Notices:

	
	 1038 Homer Street

	 Vancouver BC

	 V7R 4V4

	 CANADA

		
	 Tel:
	 	
	 Fax:
	 	
	 Email:
	 	

  
 [Signature Page
1 to Term Loan Agreement] 

 
					
	 SUBSIDIARY GUARANTOR:

	
	 GENOMEDX BIOSCIENCES CORP.

		
	 By
	 	 /s/ Dave Matthews

		 	 Name:
	 	 Dave Matthews

		 	 Title:
	 	 Chief Financial Officer

	
	 Address for Notices:

	
	 1038 Homer Street

	 Vancouver BC

	 V7R 4V4

	 CANADA

		
	 Tel:
	 	
	 Fax:
	 	
	 Email:
	 	

  
 [Signature Page
2 to Term Loan Agreement] 

									
	 LENDERS:

	
	 CRG PARTNERS III L.P., in its

capacity as a Lender and as Agent

		 	 By CRG PARTNERS III GP L.P., its General Partner

		 		 	 By CRG PARTNERS III GP LLC, its General Partner

				
		 		 	 By
	 	 /s/ Nathan Hukill

		 		 		 	 Name:
	 	 Nathan Hukill

		 		 		 	 Title:
	 	 Authorized Signatory

	
	 CRG PARTNERS III–PARALLEL FUND “A” L.P.,

		 	 By CRG PARTNERS III – PARALLEL FUND “A” GP L.P., its General Partner

		 		 	 By CRG PARTNERS III – PARALLEL FUND “A” GP LLC, its General Partner

				
		 		 	 By
	 	 /s/ Nathan Hukill

		 		 		 	 Name:
	 	 Nathan Hukill

		 		 		 	 Title:
	 	 Authorized Signatory

	
	 CRG PARTNERS III (CAYMAN) L.P.,

		 	 By CRG PARTNERS III (CAYMAN) GP L.P., its General Partner

		 		 	 By CRG PARTNERS III (CAYMAN) GP LLC, its General Partner

				
		 		 	 By
	 	 /s/ Nathan Hukill

		 		 		 	 Name:
	 	 Nathan Hukill

		 		 		 	 Title:
	 	 Authorized Signatory

			
	
	 Address for Notices:

	
	 1000 Main Street, Suite 2500

	 Houston, TX 77002

	 Attn:
	 	 General Counsel

	 Tel.:
	 	
	 Fax:
	 	
	 Email:
	 	
		
		 	       Witnessed: /s/ Nicole Nesson

  
 [Signature Page
3 to Term Loan Agreement] 

 Schedule 1 

to Term Loan Agreement 

COMMITMENTS 
  

									
	 Lender
	  	Commitment	 	  	Proportionate Share	 
	 CRG Partners III L.P.
	  	$	6,967,500	 	  	 	27.87	% 
	 CRG Partners III–Parallel Fund “A” L.P.
	  	$	2,562,500	 	  	 	10.25	% 
	 CRG Partners III (Cayman) L.P.
	  	$	15,470,000	 	  	 	61.88	% 
		  	  
	  
	 	  	  
	  
	 
	 TOTAL
	  	$	25,000,000	 	  	 	100	% 
		  	  
	  
	 	  	  
	  
	 

 Schedule 7.05(b) 

to Term Loan Agreement 

CERTAIN INTELLECTUAL PROPERTY 
  

							
	 Title
	 	 Patent/Application

              
No.              
	 	 Filing Date
	 	 Country

   Code   

				
	 Compositions and Methods for Classifying Thyroid Nodule Disease
	 	9,074,258	 	11/28/2011	 	US
				
	 Compositions and Methods for Classifying Thyroid Nodule Disease
	 	14/727,801	 	6/1/2015	 	US
				
	 Compositions and Methods for Classifying Thyroid Nodule Disease
	 	2,754,049	 	8/30/2011	 	CA
				
	 Systems and Methods for Expression-Based Classification of Thyroid Tissue
	 	2,753,916	 	8/30/2011	 	CA
				
	 Systems and Methods for Expression-Based Classification of Thyroid Tissue
	 	13/258,429	 	4/29/2010	 	US
				
	 Thyroid Cancer Diagnostics
	 	14/020,183	 	9/6/2013	 	US
				
	 Thyroid Cancer Diagnostics
	 	2,885,202	 	9/6/2013	 	CA
				
	 Thyroid Cancer Diagnostics
	 	2898125	 	9/6/2013	 	EP
				
	 Systems and methods for expression-based discrimination of distinct clinical
disease states in prostate cancer
	 	12/994,408	 	5/28/2009	 	US
				
	 Systems and methods for expression-based discrimination of distinct clinical
disease states in prostate cancer
	 	2,725,978	 	5/28/2009	 	CA
				
	 Cancer Diagnostics Using Non-Coding Transcripts
	 	14/365,085	 	12/13/2012	 	US
				
	 Cancer Diagnostics Using Non-Coding Transcripts
	 	2,858,581	 	12/13/2012	 	CA
				
	 Cancer Diagnostics Using Non-Coding Transcripts
	 	2791359	 	12/13/2012	 	EP

  
 Schedule 7.05(b)

 Page 1 

							
	 Title
	 	 Patent/Application

              
No.              
	 	 Filing Date
	 	 Country

   Code   

				
	 Cancer Diagnostics Using Biomarkers
	 	13/968,838	 	8/16/2013	 	US
				
	 Cancer Diagnostics Using Biomarkers
	 	2,881,627	 	8/16/2013	 	CA
				
	 Cancer Diagnostics Using Biomarkers
	 	2885640	 	8/16/2013	 	EP
				
	 Cancer Biomarkers and Classifiers and Uses Thereof
	 	PCT/US2014/023693	 	3/11/2014	 	WO
				
	 Cancer biomarkers and classifiers and uses thereof
	 	PCT/CA2014/000787	 	11/4/2014	 	WO
				
	 Molecular Subtyping, Prognosis and Treatment of Prostate Cancer
	 	62/216,196	 	9/9/2015	 	US

  

													
	 Trademark
	 	 Country
	 	 Application Date
	 	
Application No.
	 	 	 Registration
Date
	 	 Registration

        No.     
   

	 DECIPHER
	 	 Canada
	 	18-May-2012	 	 	1,578,365	 	 		 	
	 DECIPHER
	 	 European Community
	 	8-Oct-2012	 	 	11245107	 	 	8-Mar-2013	 	11245107
	 DECIPHER
	 	 Israel
	 	26-Aug-2014	 	 	1227420	 	 		 	
	 DECIPHER
	 	 South Korea
	 	22-Jun-2015	 	 	1227420	 	 		 	
	 DECIPHER
	 	 United States of America
	 	11-Apr-2012	 	 	85/978,205	 	 		 	
	 DECIPHER
	 	 United States of America
	 	11-Apr-2012	 	 	85/595,288	 	 	29-Oct-2013	 	4426227
	 DECIPHER
	 	 United States of America
	 	11-Apr-2012	 	 	85/980,319	 	 	26-Nov-2013	 	4441544
	 DECIPHER GRID
	 	 United States of America
	 	12-May-2015	 	 	86/627,358	 	 		 	
	 GENOMEDX LOGO
	 	 European Community
	 	12-Sep-2013	 	 	1183819	 	 	14-Oct-2014	 	1183819
	 GENOMEDX LOGO
	 	 Israel
	 	26-Aug-2014	 	 	1183819	 	 		 	
	 GENOMEDX LOGO
	 	 United States of America
	 	13-Mar-2013	 	 	85/875,380	 	 		 	
	 GENOMEDX LOGO
	 	 United States of America
	 	13-Mar-2013	 	 	85/982,486	 	 	23-Sep-2014	 	4610916
	 GRID
	 	 United States of America
	 	12-May-2015	 	 	86/627,457	 	 		 	
	 INFORMATION FOR LIFE
	 	 European Community
	 	24-Jul-2014	 	 	1224895	 	 		 	
	 INFORMATION FOR LIFE
	 	 Israel
	 	24-Jul-2014	 	 	1224895	 	 		 	

  
 Schedule 7.05(b)

 Page 2 

													
	 Trademark
	 	 Country
	 	 Application Date
	 	
Application No.
	 	 	 Registration
Date
	 	 Registration

        No.     
   

	 INFORMATION FOR LIFE
	 	 United States of America
	 	27-Jan-2014	 	 	86/176,643	 	 	7-Oct-2014	 	4618847
	 UROSKETCH 3D
	 	 United States of America
	 	24-Apr-2013	 	 	85/913,957	 	 		 	
	 UROSKETCH 3D
	 	 United States of America
	 	24-Apr-2013	 	 	85/981,884	 	 	8-Jul-2014	 	4565463

  
 Schedule 7.05(b)

 Page 3 

 Schedule 7.05(c) 

to Term Loan Agreement 

MATERIAL INTELLECTUAL PROPERTY 
  

					
	 Title
	 	 Patent/Application
No.
	 	 Ownership

	 Cancer Diagnostics Using Biomarkers
	 	13/968,838	 	Co-owner
 Exclusive License

	 ncRNA and Uses Thereof
	 	13/299,000	 	Exclusive license

 Schedule 7.06 

to Term Loan Agreement 

CERTAIN LITIGATION 
 None.

 Schedule 7.08 

to Term Loan Agreement 

TAXES 
 None. 

 Schedule 7.12 

to Term Loan Agreement 

INFORMATION REGARDING SUBSIDIARIES 
  

									
	 Subsidiary
	  	Jurisdiction of
Organization	  	Direct Equity Holder	  	Percentage of
Subsidiary held
by Direct Equity
Holder	 
	 GenomeDx Biosciences Corp.
	  	 Delaware
	  	 GenomeDx Biosciences, Inc.    
	  	 	100	% 
	 PFS Genomics, Inc.
	  	 British Columbia,
Canada
	  	 GenomeDx Biosciences, Inc.
	  	 	10	% 

 Schedule 7.13(a) 

to Term Loan Agreement 

EXISTING INDEBTEDNESS OF BORROWER AND ITS SUBSIDIARIES 

HSBC Credit Card providing a line of credit of up to $17,500 in principal amount only (“HSBC Credit Card”) 

SVB Mastercard providing a line of credit of up to $120,000 in principal amount only (“SVB Mastercard”) 

 Schedule 7.13(b) 

to Term Loan Agreement 

LIENS GRANTED BY THE OBLIGORS 

Cash collateral as collateral support for obligations under the HSBC Credit Card up to $17,500 only. 

Cash collateral as collateral support for obligations under the SVB Credit Card up to $120,000 only. 

 Schedule 7.14 

to Term Loan Agreement 

MATERIAL AGREEMENTS OF OBLIGORS 
  

	 	 •
	 	 Lease dated September 15, 2014, between 3959 Investments Ltd. and GenomeDx Biosciences Inc. (1038 Homer
Street Lease) 

  

	 	 •
	 	 Lease dated September 25, 2014, between Torrey Pines Science Center Limited Partnership and GenomeDx
Biosciences Inc. (10355 Science Center Drive Street Lease) 

  

	 	 •
	 	 Patent and Know How License Agreement dated February 1, 2013, between Mayo Foundation for Medical
Education and Research and GenomeDx Biosciences Inc. 

  

	 	 •
	 	 License Agreement dated as of January 22, 2013 between Regents of the University of Michigan and GenomeDx
Biosciences Inc. 

  

	 	 •
	 	 Technology License Agreement dated as of September 24, 2013, between Veracyte Inc. and GenomeDx
Biosciences Inc. 

  

	 	 •
	 	 Canada US Inter-Company Services Agreement dated as of June 20, 2012, between GenomeDx Biosciences Inc.
and GenomeDx Biosciences Corp. 

  

	 	 •
	 	 Powered by Affymetrix Agreement dated as of March 6, 2014, between Affymetrix, Inc. and GenomeDx
Biosciences Inc. 

  

	 	 •
	 	 Supply and Service Provider Agreement dated as of July 1, 2013, between Nugen Technologies Inc. and
GenomeDx Biosciences Inc. 

  

	 	 •
	 	 PFS Genomics Inc. Class A Preferred Share Purchase Agreement dated as of April 24, 2015, by and
among PFS Genomics Inc., the Purchasers and the Existing Holders thereto 

  

	 	 •
	 	 PFS Genomics Inc. Purchase Option Agreement dated as of April 24, 2015, by and among PFS Genomics Inc.,
the Purchasers and the Existing Holders thereto 

  

	 	 •
	 	 PFS Genomics Inc. Purchasers Certificate dated as of April 24, 2015 executed by GenomeDx Biosciences Inc.

 Schedule 7.15 

to Term Loan Agreement 

RESTRICTIVE AGREEMENTS 

Technology License Agreement – Veracyte Inc., Sept 24 2013 

 Schedule 7.16 

to Term Loan Agreement 
 REAL
PROPERTY OWNED OR LEASED BY BORROWER OR ANY SUBSIDIARY 
 None. 

 Schedule 7.17 

to Term Loan Agreement 

PENSION MATTERS 
 None.

 Schedule 7.18 

to Term Loan Agreement 

FILINGS REQUIRED IN CONNECTION WITH SECURITY DOCUMENTS 
  

			
	 Filing
	  	 Filing Office

	 GenomeDx Biosciences, Inc.
	  	 PPSA – British Columbia

	 USPTO Filing – GenomeDx Biosciences, Inc.
	  	 USPTO

	 UCC Filing – GenomeDx Biosciences, Inc.
	  	 District of Columbia Recorder of Deeds

	 UCC Filing – GenomeDx Biosciences, Inc.
	  	 California Secretary of State

	 UCC Filing - GenomeDx Biosciences Corp.
	  	 Delaware Secretary of State

 Schedule 9.05 

to Term Loan Agreement 

EXISTING INVESTMENTS 
 10% equity
investment in PFS Genomics, Inc. 

 Schedule 9.10 

to Term Loan Agreement 

TRANSACTIONS WITH AFFILIATES 

10% equity investment in PFS Genomics, Inc. 

 Schedule 9.14 

to Term Loan Agreement 

PERMITTED SALES AND LEASEBACKS 

None. 

 Exhibit A 

to Term Loan Agreement 
 FORM
OF GUARANTEE ASSUMPTION AGREEMENT 
 GUARANTEE ASSUMPTION AGREEMENT dated as of [DATE] by [NAME OF ADDITIONAL
SUBSIDIARY GUARANTOR], a             [corporation][limited liability company] (the “Additional Subsidiary Guarantor”), in favor of CRG Partners III L.P., as Agent,
and CRG Partners III L.P., CRG Partners III–Parallel Fund “A” L.P. and CRG Partners III (Cayman) L.P., as Lenders (the “Lenders”) under that certain Term Loan Agreement, dated as of September 23, 2015 (as
amended, restated, supplemented or otherwise modified, renewed, refinanced or replaced, the “Loan Agreement”), among GenomeDx Biosciences Inc., a company incorporated in British Columbia, Canada
(“Borrower”), the lenders party thereto, the Agent and the Subsidiary Guarantors party thereto. 

Pursuant to Section 8.12(a) of the Loan Agreement, the Additional Subsidiary Guarantor hereby agrees to
become a “Subsidiary Guarantor” for all purposes of the Loan Agreement, and a “Grantor” for all purposes of the Security Agreement or the Canadian Security Agreement, as applicable. Without limiting the foregoing, the Additional
Subsidiary Guarantor hereby, jointly and severally with the other Subsidiary Guarantors, guarantees to the Lenders and its successors and assigns the prompt payment in full when due (whether at stated maturity, by acceleration or otherwise) of all
Guaranteed Obligations (as defined in Section 13.01 of the Loan Agreement) in the same manner and to the same extent as is provided in Section 13 of the Loan Agreement. In addition, as of the date hereof, the Additional
Subsidiary Guarantor hereby makes the representations and warranties set forth in Sections 7.01, 7.02, 7.03, 7.05(a), 7.06, 7.07, 7.08 and 7.18 of the Loan Agreement, and in
Section 2 of the Security Agreement or the Canadian Security Agreement, as applicable, with respect to itself and its obligations under this Agreement and the other Loan Documents, as if each reference in such Sections to the Loan
Documents included reference to this Agreement, such representations and warranties to be made as of the date hereof. 

The Additional Subsidiary Guarantor hereby instructs its counsel to deliver the opinions referred to in
Section 8.12(a) of the Loan Agreement to the Lenders. 
 IN WITNESS WHEREOF, the Additional Subsidiary
Guarantor has caused this Guarantee Assumption Agreement to be duly executed and delivered as of the day and year first above written. 
  

			
	 [ADDITIONAL SUBSIDIARY GUARANTOR]

		
	 By
	 	  

		 	 Name:

		 	 Title:

  
 Exhibit A-1 

 Exhibit B 

to Term Loan Agreement 
 FORM
OF NOTICE OF BORROWING 
  

			
	 Date:
	 	
[                    ]

		
	 To:
	 	 CRG Partners III L.P. and the other Lenders

1000 Main Street, Suite 2500

Houston, TX 77002
 Attn: General
Counsel

  

	 	 Re:
	 Borrowing under Term Loan Agreement 

Ladies and Gentlemen: 

The undersigned, GENOMEDX BIOSCIENCES INC., a [company incorporated in British Columbia, Canada]
(“Borrower”), refers to the Term Loan Agreement, [to be entered into on or about September 23, 2015]1/[dated as of September 23, 2015]2 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”), among Borrower, CRG Partners III L.P., as Agent, CRG
Partners III L.P., CRG Partners III–Parallel Fund “A” L.P., CRG Partners III (Cayman) L.P. and other parties from time to time party thereto as lenders (“Lenders”), and the subsidiary guarantors from time to
time party thereto. The terms defined in the Loan Agreement are herein used as therein defined. 
 Borrower hereby
gives you notice irrevocably, pursuant to Section 2.02 of the Loan Agreement, of the borrowing of the Loan specified herein: 

1. The proposed Borrowing Date is
[                    ]. 

2. The amount of the proposed Borrowing is
$[                    ]. 

3. The payment instructions with respect to the funds to be made available to Borrower are as follows: 

 

			
	 Bank name:
	  	
[                    ]

	 Bank Address:
	  	
[                    
]

			
	 Routing Number:
	  	
        [               
     ]

	 Account Number:
	  	
        [               
     ]

	 Swift Code:
	  	
        [               
     ]

 Borrower hereby certifies that the following statements are true on the date hereof, and will
be true on the date of the proposed borrowing of the Loan, before and after giving effect thereto and to the application of the proceeds therefrom: 

 

	 1 
	 Use this for First Borrowing. 

	 2 
	 Use this for each subsequent Borrowing. 

  
 Exhibit B-1 

 a) the representations and warranties made by Borrower in
Section 7 of the Loan Agreement shall be true on and as of the Borrowing Date and immediately after giving effect to the application of the proceeds of the Borrowing with the same force and effect as if made on and as of such date except
that the representation regarding representations and warranties that refer to a specific earlier date shall be that they were true on such earlier date;  

b) on and as of the Borrowing Date, there shall have occurred no Material Adverse Change since
[                    ]; and 

c) no Default exists or would result from such proposed borrowing. 

  
 Exhibit B-2 

 IN WITNESS WHEREOF, Borrower has caused this Notice of Borrowing to be duly
executed and delivered as of the day and year first above written. 
  

			
	 BORROWER:

	
	 GENOMEDX BIOSCIENCES INC.

		
	 By
	 	  

		 	 Name:

		 	 Title:

  
 Exhibit B-3 

 Exhibit C-1 

to Term Loan Agreement 
 FORM
OF TERM LOAN NOTE 
  

			
	 U.S. $[            ]
	  	[DATE]            

 FOR VALUE RECEIVED, the undersigned, GENOMEDX BIOSCIENCES INC., a [company
incorporated in British Columbia, Canada] (“Borrower”), hereby promises to pay to [CRG Partners III L.P./CRG Partners III–Parallel Fund “A” L.P. /CRG Partners III (Cayman) L.P.] or its assigns (the
“Lender”) at the Lender’s principal office in [                ], in immediately available funds, the aggregate principal sum set forth
above, or, if less, the aggregate unpaid principal amount of all Loans made by the Lender pursuant to Section 2.01 of the Term Loan Agreement, dated as of September 23, 2015 (as amended, restated,
supplemented or otherwise modified, renewed, refinanced or replaced, the “Loan Agreement”), among Borrower, the Lender, the other lenders party thereto and the Subsidiary Guarantors party thereto, on the date or dates
specified in the Loan Agreement, together with interest on the principal amount of such Loans from time to time outstanding thereunder at the rates, and payable in the manner and on the dates, specified in the Loan Agreement.  

This Note is a Note issued pursuant to the terms of Section 2.04 of the Loan Agreement, and this Note and
the holder hereof are entitled to all the benefits and security provided for thereby or referred to therein, to which Loan Agreement reference is hereby made for a statement thereof. All defined terms used in this Note, except terms otherwise
defined herein, shall have the same meaning as in the Loan Agreement.  
 THIS NOTE AND THE RIGHTS AND
OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF ANY OTHER
JURISDICTION; PROVIDED THAT SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW SHALL APPLY. 
 FOR
PURPOSES OF SECTIONS 1272, 1273 AND 1275 OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED, AND THE RULES AND REGULATIONS THEREUNDER, THIS NOTE IS BEING ISSUED WITH ORIGINAL ISSUE DISCOUNT; PLEASE CONTACT [NAME OF CFO OR TAX DIRECTOR OF ISSUER],
[TITLE], [ADDRESS], TELEPHONE: [TEL #] TO OBTAIN INFORMATION REGARDING THE ISSUE PRICE, THE AMOUNT OF ORIGINAL ISSUE DISCOUNT AND THE YIELD TO MATURITY. 

Borrower hereby waives demand, presentment, protest or notice of any kind hereunder, other than notices provided for in the
Loan Documents. The non-exercise by the holder hereof of any of its rights hereunder in any particular instance shall not constitute a waiver thereof in such particular or any subsequent instance. 

THIS NOTE MAY NOT BE TRANSFERRED EXCEPT IN COMPLIANCE WITH THE TERMS OF THE LOAN AGREEMENT. 

  
 Exhibit C-1 

 
			
	 GENOMEDX BIOSCIENCES INC.

		
	 By
	 	  

		 	 Name:

		 	 Title:

  
 Exhibit C-2 

 Exhibit C-2 

to Term Loan Agreement 
 FORM
OF PIK LOAN NOTE 
  

			
	 U.S. $[            ]
	  	[DATE]            

 FOR VALUE RECEIVED, the undersigned, GENOMEDX BIOSCIENCES INC.
(“Borrower”), hereby promises to pay to [CRG Partners III L.P./ CRG Partners III–Parallel Fund “A” L.P./CRG Partners III (Cayman) L.P.] or its assigns (the “Lender”) at the Lender’s
principal office in [                ], in immediately available funds, the aggregate principal sum set forth above, or, if greater or less, the aggregate unpaid
principal amount of all PIK Loans made by the Lender pursuant to Section 3.02(d) of the Term Loan Agreement, dated as of September 23, 2015 (as amended, restated, supplemented or otherwise modified, renewed, refinanced or replaced,
the “Loan Agreement”), among Borrower, the Lender, the other lenders party thereto and the Subsidiary Guarantors party thereto, on the date or dates specified in the Loan Agreement, together with interest on the principal
amount of such PIK Loans from time to time outstanding thereunder at the rates, and payable in the manner and on the dates, specified in the Loan Agreement. 

This Note is a Note issued pursuant to the terms of Section 3.02(d) of the Loan Agreement, and this Note and the
holder hereof are entitled to all the benefits and security provided for thereby or referred to therein, to which Loan Agreement reference is hereby made for a statement thereof. All defined terms used in this Note, except terms otherwise defined
herein, shall have the same meaning as in the Loan Agreement. 
 The Lender may supplement this Note by attaching to this
Note a schedule (the “Note Schedule”) to evidence additional PIK Loans made by the Lender to Borrower following the date first above written. The Lender may endorse thereon the date such additional PIK Loan is made and the
principal amount of such additional PIK Loan when made. Such Note Schedule shall form part of this Note and all references to this Note shall mean this Note, as supplemented by such Note Schedule. 

THIS NOTE AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE
LAW OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF ANY OTHER JURISDICTION; PROVIDED THAT SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW SHALL APPLY. 

FOR PURPOSES OF SECTIONS 1272, 1273 AND 1275 OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED, AND THE RULES AND REGULATIONS
THEREUNDER, THIS NOTE IS BEING ISSUED WITH ORIGINAL ISSUE DISCOUNT; PLEASE CONTACT [NAME OF CFO OR TAX DIRECTOR OF ISSUER], [TITLE], [ADDRESS], TELEPHONE: [TEL #] TO OBTAIN INFORMATION REGARDING THE ISSUE PRICE, THE AMOUNT OF ORIGINAL ISSUE DISCOUNT
AND THE YIELD TO MATURITY. 

  
 Exhibit C-2-1 

 Borrower hereby waives demand, presentment, protest or notice of any kind
hereunder, other than notices provided for in the Loan Documents. The non-exercise by the holder hereof of any of its rights hereunder in any particular instance shall not constitute a waiver thereof in such particular or any subsequent instance.

 THIS NOTE MAY NOT BE TRANSFERRED EXCEPT IN COMPLIANCE WITH THE TERMS OF THE LOAN AGREEMENT. 

 

			
	 GENOMEDX BIOSCIENCES INC.

		
	 By
	 	  

		 	 Name:

		 	 Title:

  
 Exhibit C-2-2 

 PIK NOTE SCHEDULE 

This Note Schedule supplements that certain Note issued by Borrower to [CRG Partners III
L.P./        ]3 or its assigns on [DATE]. 
  

									
	 Date of additional PIK Loan
	  	Amount of additional PIK
Loan made	 	  	Notation made by4	 
		  				  			
		  				  			
		  				  			
		  				  			
		  				  			
		  				  			
		  				  			
		  				  			
		  				  			
		  				  			
		  				  			
		  				  			
		  				  			
		  				  			
		  				  			
		  				  			
		  				  			
		  				  			
		  				  			
		  				  			

  

	 3 
	 Delete as appropriate for each Note. 

	 4 
	 Insert name of party making notation (e.g. Borrower or Lender). 

  
 Exhibit C-2-3 

 Exhibit D 

to Term Loan Agreement 
 FORM
OF U.S. TAX COMPLIANCE CERTIFICATE 
 Reference is made to the Term Loan Agreement, dated as of September 23, 2015 (as
the same may be amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”), among GENOMEDX BIOSCIENCES INC., a company incorporated in British Columbia, Canada
(“Borrower”), CRG Partners III L.P., as Agent, CRG Partners III L.P., CRG Partners III–Parallel Fund “A” L.P., CRG Partners III (Cayman) L.P. and other parties from time to time party thereto as lenders
(“Lenders”), and the subsidiary guarantors from time to time party thereto.
[                                        ] (the
“Foreign Lender”) is providing this certificate pursuant to Section 5.03(e)(ii)(B) of the Loan Agreement. The Foreign Lender hereby represents and warrants that: 

1. The Foreign Lender is the sole record owner of the Loans as well as any obligations evidenced by any Note(s) in respect of
which it is providing this certificate; 
 2. The Foreign Lender’s direct or indirect partners/members are the sole
beneficial owners of the Loans as well as any obligations evidenced by any Note(s) in respect of which it is providing this certificate; 

3. Neither the Foreign Lender nor its direct or indirect partners/members is a “bank” for purposes of
Section 881(c)(3)(A) of the Internal Revenue Code of 1986, as amended (the “Code”). In this regard, the Foreign Lender further represents and warrants that: 

(a) neither the Foreign Lender nor its direct or indirect partners/members is subject to regulatory or other legal
requirements as a bank in any jurisdiction; and 
 (b) neither the Foreign Lender nor its direct or indirect
partners/members has been treated as a bank for purposes of any tax, securities law or other filing or submission made to any Governmental Authority, any application made to a rating agency or qualification for any exemption from tax, securities law
or other legal requirements; 
 3. Neither the Foreign Lender nor its direct or indirect partners/members is a 10-percent
shareholder of Borrower within the meaning of Section 881(c)(3)(B) of the Code; and 
 4. Neither the Foreign Lender
nor its direct or indirect partners/members is a controlled foreign corporation receiving interest from a related person within the meaning of Section 881(c)(3)(C) of the Code. 

[Signature follows] 

  
 Exhibit D-1 

 IN WITNESS WHEREOF, the undersigned has caused this certificate to be duly
executed and delivered as of the date indicated below. 
  

			
	 [NAME OF NON-U.S. LENDER]

		
	 By
	 	  

		 	 Name:

		 	 Title:

	
	 Date:
                    

  
 Exhibit D-2 

 Exhibit E 

to Term Loan Agreement 
 FORM
OF COMPLIANCE CERTIFICATE 
 [DATE] 

This certificate is delivered pursuant to Section 8.01(c) of, and in connection with the consummation of the
transactions contemplated in, the Term Loan Agreement, dated as of September 23, 2015 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”), among GENOMEDX
BIOSCIENCES INC., a company incorporated in British Columbia, Canada (“Borrower”), CRG Partners III L.P., as Agent, CRG Partners III L.P., CRG Partners III–Parallel Fund “A” L.P., CRG Partners III (Cayman) L.P.
and other parties from time to time party thereto as lenders (“Lenders”), and the subsidiary guarantors from time to time party thereto. Capitalized terms used herein and not otherwise defined herein are used herein as
defined in the Loan Agreement. 
 The undersigned, a duly authorized Responsible Officer of Borrower having the name and
title set forth below under his signature, hereby certifies solely in his capacity as an officer of Borrower and not in any individual capacity, on behalf of Borrower for the benefit of the Secured Parties and pursuant to Section 8.01(c)
of the Loan Agreement that such Responsible Officer of Borrower is familiar with the Loan Agreement and that, in accordance with each of the following sections of the Loan Agreement, each of the following is true on the date hereof, both before and
after giving effect to any Loan to be made on or before the date hereof: 
 In accordance with
Section 8.01[(a)/(b)] of the Loan Agreement, attached hereto as Annex A are the financial statements for the [fiscal quarter/fiscal year] ended
[                    ] required to be delivered pursuant to Section 8.01[(a)/(b)] of the Loan Agreement. Such financial statements
fairly present in all material respects the consolidated financial position, results of operations and cash flow of Borrower and its Subsidiaries as at the dates indicated therein and for the periods indicated therein in accordance with GAAP
[(subject to the absence of footnote disclosure and normal year-end audit adjustments)]5 [without qualification as to the scope of the audit or as to going concern and without any other similar
qualification together with the certificate from Borrower’s independent auditors with respect to such financial statements required to be delivered pursuant to Section 8.01(c) of the Loan Agreement. The examination by such auditors
in connection with such financial statements has been made in accordance with the standards of the United States’ Public Company accounting Oversight Board (or any successor entity).]6 

Attached hereto as Annex B are the calculations used to determine compliance with each financial covenant contained in
Section 10 of the Loan Agreement. 
 No Default or Event of Default is continuing as of the date hereof[, except
as provided for on Annex C attached hereto, with respect to each of which Borrower proposes to take the 
  

 

	 5 
	 Insert language in brackets only for quarterly certifications. 

	 6 
	 Insert language in brackets only for annual certifications.

  
 Exhibit E-1 

 
actions set forth on Annex C]. 
 IN WITNESS WHEREOF, the
undersigned has executed this certificate on the date first written above. 
  

			
	 GENOMEDX BIOSCIENCES INC.

		
	 By
	 	  

		 	 Name:

		 	 Title:

  
 Exhibit E-2 

 Annex A to Compliance Certificate 

FINANCIAL STATEMENTS 
 [see
attached] 

  
 Exhibit E-3 

 Annex B to Compliance Certificate 

CALCULATIONS OF FINANCIAL COVENANT COMPLIANCE 
  

							
	 I.
	  	 Section 10.01: Minimum Liquidity
	  	
			
	 A.
	  	 Amount of unencumbered cash and Permitted Cash Equivalent Investments (which for greater certainty shall not
include any undrawn credit lines), in each case, to the extent held in an account over which the Lenders have a first priority perfected security interest:
	  	 $            

			
	 B.
	  	 The greater of:
	  	 $            

				
		  	 (1)
	  	 $2,000,000 and
	  	
				
		  	 (2)
	  	 to the extent Borrower has incurred Permitted Priority Debt, the minimum cash balance required of Borrower by
Borrower’s Permitted Priority Debt creditors
	  	
			
		  	 Is Line IA equal to or greater than Line IB?:
	  	 Yes: In compliance;
No: Not in compliance

			
	 II.
	  	 Section 10.02(a)-(e): Minimum Revenue—Subsequent Periods
	  	
			
	 A.
	  	 Revenues during the twelve month period beginning on January 1, 2015
	  	 $            

			
		  	 [Is line II.A equal to or greater than $8,000,000?
	  	 Yes: In
compliance;
No: Not in compliance]7

			
	 B.
	  	 Revenues during the twelve month period beginning on January 1, 2016
	  	 $            

			
		  	 [Is line II.B equal to or greater than $20,000,000?
	  	 Yes: In compliance;
No: Not in
compliance]8

			
	 C.
	  	 Revenues during the twelve month period beginning on January 1, 2017
	  	 $            

			
		  	 [Is line II.C equal to or greater than $30,000,000?
	  	 Yes: In compliance;
No: Not in
compliance]9

			
	 D.
	  	 Revenues during the twelve month period beginning on January 1, 2018
	  	
$            

 

	 7 
	 Include bracketed entry only on the Compliance Certificate to be delivered within 180 days of the end of
2015 pursuant to Section 8.01(b) of the Loan Agreement. 

	 8 
	 Include bracketed entry only on the Compliance Certificate to be delivered within 180 days of the end of
2016 pursuant to Section 8.01(b) of the Loan Agreement. 

	 9 
	 Include bracketed entry only on the Compliance Certificate to be delivered within 180 days of the end of
2017 pursuant to Section 8.01(b) of the Loan Agreement. 

  
 Exhibit E-4 

							
		  	 [Is line II.D equal to or greater than $30,000,000?
	  	 Yes: In
compliance;
No: Not in compliance]10

			
	 E.
	  	 Revenues during the twelve month period beginning on January 1, 2019
	  	
			
		  	 [Is line II.E equal to or greater than $30,000,000?
	  	 Yes: In compliance;
No: Not in
compliance]11

			
	 F.
	  	 Revenues during the twelve month period beginning on January 1, 2020
	  	
			
		  	 [Is line II.F equal to or greater than $30,000,000?
	  	 Yes: In compliance;
No: Not in
compliance]12

  

	 10 
	 Include bracketed entry only on the Compliance Certificate to be delivered within 180 days of the end of
2018 pursuant to Section 8.01(b) of the Loan Agreement. 

	 11 
	 Include bracketed entry only on the Compliance Certificate to be delivered within 180 days of the end of
2019 pursuant to Section 8.01(b) of the Loan Agreement. 

	 12 
	 Include bracketed entry only on the Compliance Certificate to be delivered within 180 days of the end of
2020 pursuant to Section 8.01(b) of the Loan Agreement. 

  
 Exhibit E-5 

 Exhibit F 

to Term Loan Agreement 

OPINION REQUEST 

The opinion of legal counsel to Borrower and each other Obligor should address the following matters (capitalized terms used
but not defined herein have the meanings given to them in the Agreement):13 
  

	 1.
	 Power and authority (Section 7.01) 

 

	 2.
	 Due organization/good standing (Section 7.01) 

 

	 3.
	 Non-contravention of the Obligors’ constating documents (Section 7.02) 

 

	 4.
	 Due authorization (Section 7.02) 

 

	 5.
	 Due execution & delivery (Section 7.02) 

 

	 6.
	 Enforceability (Section 7.02) 

 

	 7.
	 No consents/conflicts (Section 7.03) 

 

	 8.
	 Investment company (Section 7.10(a)) 

 

	 9.
	 Board regulations T, U & X (Section 7.10(b)) 

 

	 10.
	 Legal, valid and enforceable security interest (Section 7.18) 

 

	 11.
	 Perfection of security interest (PPSA, UCC and US/Canadian IP filings, Control Agreements, share capital,
share pledge authorization and perfection by control of pledged collateral) (Section 7.18) 

  

	 12.
	 Choice of law (Sections 12.09 and 12.10) 

 

	 13.
	 No stamp duty or registration or similar tax is assessable with respect to the Loan Documents

  

	 14.
	 No license or registration is required for any secured party solely by virtue of its entry into the Loan
Documents or advance of any Loan 

  

	 15.
	 Submission to jurisdiction (Section 12.10) 

 

	 16.
	 Application of foreign law and enforceability of New York judgment on the Loan Documents in Obligors’
jurisdiction(s) of organization 

  

	 13 
	 The section numbers relate to those sections that are relevant to the particular opinion.

  
 Exhibit F-1 

 Exhibit G 

to Term Loan Agreement 
 FORM
OF LANDLORD CONSENT 
 THIS LANDLORD CONSENT (the “Agreement”) is made and entered into as of
[INSERT DATE] by and among CRG PARTNERS III L.P., as agent for the Lenders (defined below) (“CRIII”), GENOMEDX BIOSCIENCES INC., a company incorporated in British Columbia, Canada (“Debtor”), and
[INSERT NAME OF LANDLORD], a [Delaware] [limited liability company] (“Landlord”). 
 WHEREAS, Debtor
has entered into a term loan agreement and a security agreement (collectively, the “Agreements”), each dated as of [        , 2015], with the lenders party thereto, each in its capacity
as a lender and a secured party (the “Lenders”), with CRIII as Agent for such Lenders (in such capacity, “Agent”), pursuant to which the Agent (for its benefit and for the ratable benefit of the
Lenders) has been granted a security interest in all of Debtor’s personal property, including, but not limited to, inventory, equipment and trade fixtures (hereinafter “Personal Property”); and 

WHEREAS, Landlord is the owner of the real property located at
[                    ] (the “Premises”); and 

WHEREAS, Landlord and Debtor have entered into that certain Lease dated
[                    ][, as amended by
[                    ] dated
[                    ]] ([collectively,] the “Lease”); and 

WHEREAS, certain of the Personal Property has or may become affixed to or be located on, wholly or in part, the Premises. 

NOW, THEREFORE, in consideration of any loans or other financial accommodation extended by Lenders to Debtor at any time, and
other good and valuable consideration, the parties agree as follows: 
 1. Landlord subordinates to the Agent all security
interests or other interests or rights Landlord may now or hereafter have in, or to any of the Personal Property, whether for rent or otherwise, while Debtor is indebted to Lenders. 

2. The Personal Property may be installed in or located on the Premises and is not and shall not be deemed a fixture or part
of the real estate and shall at all times be considered personal property. 
 3. Agent or its representatives may enter upon
the Premises during normal business hours, and upon not less than 24 hours’ advance notice, to inspect the Personal Property. 

4. Upon and during the continuance of an Event of Default under the Agreements, Agent or its representatives, at Agent’s
option, upon written notice delivered to Landlord not less than ten (10) business days in advance, may enter the Premises during normal business hours for the purpose of repossessing, removing or otherwise dealing with said Personal Property;

  
 Exhibit G-1 

 
provided that neither Agent nor Lenders shall be permitted to operate the business of Debtor on the Premises or sell, auction or otherwise dispose of any Personal Property at the Premises or
advertise any of the foregoing; and such license shall continue, from the date Agent enters the Premises for as long as Agent reasonably deems necessary but not to exceed a period of ninety (90) days. During the period Agent occupies the
Premises, it shall pay to Landlord the rent provided under the Lease relating to the Premises, prorated on a per diem basis to be determined on a thirty (30) day month, without incurring any other obligations of Debtor. 

5. Agent shall pay to Landlord any costs for damage to the Premises or the building in which the Premises is located in
removing or otherwise dealing with said Personal Property pursuant to paragraph 4 above, and shall indemnify and hold harmless Landlord from and against (i) all claims, disputes and expenses, including reasonable attorneys’ fees, suffered
or incurred by Landlord arising from Agent’s exercise of any of its rights hereunder, and (ii) any injury to third persons, caused by actions of Agent pursuant to this consent. 

6. Landlord agrees to give notice to Agent in writing by certified mail or facsimile of Landlord’s intent to exercise its
remedies in response to any default by Debtor of any of the provisions of the Lease, to: 
 CRG Partners III L.P. 

1000 Main Street, Suite 2500 

Houston, TX 77002 

Attention: General Counsel 

Fax: 

7. Landlord shall have no obligation to preserve or protect the Personal Property or take any action in connection therewith,
and Agent, on behalf of the Lenders, waives all claims they may now or hereafter have against Landlord in connection with the Personal Property. 

8. This consent shall terminate and be of no further force or effect upon the earlier of (i) the date on which all
indebtedness secured by the Personal Property indefeasibly is paid in full in cash and (ii) the date on which the Lease is terminated or expires. 

9. Nothing contained herein shall be construed to amend the Lease, and the Lease remains unchanged and in full force and
effect. 
 This consent shall be construed and interpreted in accordance with and governed by the laws of the State of
[                    ]. 

This consent may not be changed or terminated orally and is binding upon and shall inure to the benefit of Landlord, Agent,
Lenders and Debtor and the heirs, personal representatives, successors and assigns of Landlord, Agent, Lenders and Debtor. 
 [Signature Page
follows] 

  
 Exhibit G-2 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the
date first above written. 
  

			
	 LANDLORD:

	
	
[                    ]

		
	 By
	 	  

		 	 Name:

		 	 Title:

  

									
	 AGENT:

	
	 CRG PARTNERS III L.P.,

		 	 By CRG PARTNERS III GP L.P., its General Partner

		 		 	 By CRG PARTNERS III GP LLC, its General Partner

				
		 		 	 By
	 	  

		 		 		 	 Name:
	 	 Charles Tate

		 		 		 	 Title:
	 	 Sole Member

 

			
	 Address for Notices:

	
	 1000 Main Street, Suite 2500

	 Houston, TX 77002

	 Attn:
	 	 General Counsel

	 Tel.:
	 	
	 Fax:
	 	
	 Email:
	 	

  

			
	 Acknowledged and Agreed:

	 GENOMEDX BIOSCIENCES INC.

		
	 By
	 	  

		 	 Name:

		 	 Title:

  
 Exhibit G-3 

 Exhibit H 

to Term Loan Agreement 
 FORM
OF SUBORDINATION AGREEMENT 
 This Subordination Agreement is made as of
[                    ] (this “Agreement”) among CRG Partners III L.P., a Delaware limited partnership
(“CRIII”),             (“            ” and, collectively with CRIII,
             and their successors and assigns, the “Senior Lenders”), and
[                    ], a [                    ]
[corporation] (“Subordinated Creditor”). 
 RECITALS: 

A. [INSERT NAME OF BORROWER], a [Delaware] [corporation] (“Borrower”), will, as of the date hereof,
issue in favor of Subordinated Creditor the Subordinated Note (as defined below)[, and grant a security interest in the Subordinated Collateral (as defined below) in favor of Subordinated Creditor]. 

B. Senior Lenders and Borrower have entered into the Senior Loan Agreement (as defined below) and the Senior Security
Agreement (as defined below) under which Borrower has granted a security interest in the Collateral (as defined below) in favor of Senior Lenders as security for the payment of Borrower’s obligations under the Senior Loan Agreement. 

C. To induce Senior Lenders to make and maintain the credit extensions to Borrower under the Senior Loan Agreement,
Subordinated Creditor is willing to subordinate the Subordinated Debt (as defined below) to the Senior Debt (as defined below)[, and all liens securing the Subordinated Debt to the Senior Creditors’ liens on and security interests in the
Collateral] on the terms and conditions herein set forth. 
 NOW, THEREFORE, THE PARTIES AGREE AS FOLLOWS: 

1. Definitions. As used herein, the following terms have the following meanings: 

“Bankruptcy Code” means title 11 of the United States Code, 11 U.S.C. §§ 101 et seq.

 “Collateral” has the meaning set forth in the Senior Security Agreement. 

“Enforcement Action” means, with respect to any indebtedness, obligation (contingent or otherwise) or
Collateral at any time held by any lender or noteholder, (i) commencing, by judicial or non-judicial means, the enforcement of, or otherwise attempting to enforce, such indebtedness, obligation or Collateral of any of the default remedies under
any of the applicable agreements or documents of such lender or noteholder, the UCC, PPSA or other applicable law (other than the mere issuance of a notice of default or notice of the right by such lender or noteholder to seek specific performance
with respect to any covenants in favor of such lender or noteholder), (ii) repossessing, selling, leasing or otherwise disposing of all or any part of such Collateral, including without limitation causing any attachment of, levy upon, execution
against, foreclosure upon or the taking of other action against or institution of other proceedings with respect to any Collateral, or exercising account debtor or obligor notification or collection rights with respect to all or any portion thereof,
or attempting or agreeing to do so, (iii) appropriating, 

  
 Exhibit H-1 

 
setting off or applying to such lender or noteholder’s claim any part or all of such Collateral or other property in the possession of, or coming into the possession of, such lender or
noteholder or its agent, trustee or bailee, (iv) asserting any claim or interest in any insurance with respect to such indebtedness, obligation or Collateral, (v) instituting or commencing, or joining with any Person in commencing, any
action or proceeding with respect to any of the foregoing rights or remedies (including any action of foreclosure, enforcement, collection or execution and any Insolvency Event involving any Obligor), (vi) exercising any rights under any
lockbox agreement, account control agreement, landlord waiver or bailee’s letter or similar agreement or arrangement to which the Subordinated Creditor is a party, (vii) [causing or compelling the pledge or delivery of Subordinated
Collateral], or (viii) otherwise enforcing, or attempting to enforce, any other rights or remedies under or with respect to any such indebtedness, obligation or Collateral. 

“Insolvency Event” means that any Obligor or any of
its subsidiaries shall have (i) applied for, consented to or acquiesced in the appointment of a trustee, receiver or other custodian for it or any of its property, or (ii) made a general assignment for the benefit of creditors or similar
arrangement in respect of such Obligor’s or subsidiary’s creditors generally or any substantial portion thereof, or (iii) permitted, consented to, or suffered to exist the appointment of a trustee, receiver or other custodian for it
or for a substantial part of its property, or (iv) commenced any case, action or proceeding before any court or other governmental agency or authority relating to bankruptcy, reorganization, insolvency, debt arrangement or relief or other case,
action or proceeding under any bankruptcy or insolvency law, or any dissolution, winding up or liquidation case, action or proceeding, including without limitation any case under the Bankruptcy Code, in respect of it, or (v) (A) permitted,
consented to, or suffered to exist the commencement of any case, action or proceeding before any court or other governmental agency or authority relating to bankruptcy, reorganization, insolvency, debt arrangement or relief or other case, action or
proceeding under any bankruptcy or insolvency law, or any dissolution, winding up or liquidation case, action or proceeding, including without limitation any case under the Bankruptcy Code, in respect of it, or (B) any such case, action or
proceeding shall have resulted in the entry of an order for relief or shall have remained for sixty (60) days undismissed. 

“Obligor” has the meaning set forth in the Senior Loan Agreement. 

“Person” has the meaning set forth in the Senior Loan Agreement. 

“Senior Debt” means the Obligations (as defined in the Senior Loan Agreement).

 “Senior Discharge Date” means the first date on which all of the Senior
Debt (other than contingent indemnification obligations) has been paid indefeasibly in full in cash and all commitments of Senior Lenders under the Senior Loan Documents have been terminated. 

“Senior Loan Agreement” means that certain Term Loan Agreement, dated as of
[            , 2015], by and among Borrower and Senior Lenders, as amended, restated, supplemented or otherwise modified from time to time. 

“Senior Loan Documents” means, collectively, the Loan Documents (as defined in
the Senior Loan Agreement), in each case as amended, restated, supplemented or otherwise modified  

  
 Exhibit H-2 

 
from time to time. 
 “Senior Security
Agreement” means that certain Security Agreement, dated as of [                    ], among Borrower, the other Obligors party
thereto, and the Secured Parties (as defined therein), as amended, restated, supplemented or otherwise modified from time to time. 

[”Subordinated Collateral” means any property or assets that may at any time be
or become subject to a lien or security interest in favor of the Subordinated Creditor pursuant to the Subordinated Collateral Documents or otherwise, and all products and proceeds of any of the foregoing.] 

[”Subordinated Collateral Documents” means, collectively, each security
agreement, deed of trust, mortgage, pledge agreement and any other agreement pursuant to which any Obligor or any other Person provides a lien on or security interest in its assets in favor of the Subordinated Creditor, and all financing statements,
fixture filings, patent, trademark and copyright filings, assignments, acknowledgments and other filings, documents and agreements made or delivered pursuant thereto.] 

“Subordinated Debt” means and includes all obligations, liabilities and
indebtedness of Borrower owed to Subordinated Creditor, whether direct or indirect, absolute or contingent, due or to become due, or now existing or hereafter incurred, including without limitation, principal, premium (if any), interest, fees,
charges, expenses, costs, professional fees and expenses, and reimbursement obligations. 

“Subordinated Debt Documents” means, collectively, the Subordinated Note and each
other loan document or agreement entered into by Borrower in connection with the Subordinated Note[, including without limitation each Subordinated Collateral Document], as amended, restated, supplemented or otherwise modified from time to time.

 “Subordinated Note” means that certain
$[            ] subordinated promissory note, dated [            ], issued by Borrower to Subordinated Creditor, as amended,
restated, supplemented or otherwise modified from time to time. 
 “UCC”
means the Uniform Commercial Code of any applicable jurisdiction and, if the applicable jurisdiction shall not have any Uniform Commercial Code, the Uniform Commercial Code as in effect in the State of New York. 

2. Liens. (a) Subordinated Creditor represents and warrants that 14[the
Subordinated Debt is unsecured. Subordinated Creditor agrees that it will not request or accept any security interest in any Collateral to secure the Subordinated Debt; provided that, should Subordinated Creditor obtain a lien or security
interest on any asset or Collateral to secure all or any portion of the Subordinated Debt for any reason (which action shall be in violation of this Agreement), notwithstanding the respective dates of attachment and perfection of the security
interests in the Collateral in favor of Senior Lenders or Subordinated Creditor, or any contrary provision of the UCC, or any applicable law or decision to the contrary, or the provisions of the Senior Loan 

 

	 14 
	 Select one, as appropriate. 

  
 Exhibit H-3 

 
Documents or the Subordinated Debt Documents, and irrespective of whether Subordinated Creditor or Senior Lenders hold possession of any or all part of the Collateral, all now existing or
hereafter arising security interests in the Collateral in favor of Subordinated Creditor in respect of the Subordinated Debt Documents shall at all times be subordinate to the security interest in such Collateral in favor of Senior Lenders in
respect of the Senior Loan Documents.] [all liens and security interests, if any, now or hereafter existing that secure the Subordinated Debt, are hereby subordinated and junior in all respects to the liens and security interests now or hereafter
existing securing the Senior Debt, regardless of the time, manner or order of attachment or perfection of any such liens and security interests, the time or order of filing of financing statements, the acquisition of purchase money or other liens or
security interests, the time of giving or failure to give notice of the acquisition or expected acquisition of purchase money or other liens or security interests, or any other circumstances whatsoever.] 

(b) Subordinated Creditor acknowledges that Senior Lenders have been granted liens upon the Collateral [(including the
Subordinated Collateral)], and Subordinated Creditor hereby consents thereto and to the incurrence of the Senior Debt. 

(c) Until the Senior Discharge Date, in the event of any private or public sale or other disposition of all or any portion of
the Collateral, Subordinated Creditor agrees that such Collateral shall be sold or otherwise disposed of free and clear of any liens in favor of Subordinated Creditor. Subordinated Creditor agrees that any such sale or disposition of Collateral
shall not require any consent from Subordinated Creditor, and Subordinated Creditor hereby waives any right it may have to object to such sale or disposition. 

(d) [Subordinated Creditor agrees that it will not request or accept any guaranty of the Subordinated Debt.] 

(e) [Each of Senior Lenders and Subordinated Creditor agrees to hold all collateral in which a lien may be perfected by
possession or control (“Possessory Collateral”) in its possession, custody, or control (or in the possession, custody, or control of agents or bailees for any such party) as agent for the other solely for the purpose of
perfecting the security interest granted to each in such Possessory Collateral subject to the terms and conditions of this Agreement. Neither any Senior Lender nor Subordinated Creditor shall have any obligation whatsoever to the other to assure
that any Possessory Collateral is genuine or owned by any Obligor or any other Person or to preserve its rights or benefits or those of any Person. The duties or responsibilities of Senior Lenders and Subordinated Creditor under this
Section 2(e) are and shall be limited solely to holding or maintaining control of the Possessory Collateral as agent for the others for purposes of perfecting the lien or security interest held by such others. Senior Lenders are not and
shall not be deemed to be a fiduciary of any kind for Subordinated Creditor or any other Person.] 
 3. Payment Subordination.
(a) Notwithstanding the terms of the Subordinated Debt Documents, until the Senior Discharge Date, (i) all payments and distributions of any kind or character, whether in cash, property or securities, in respect of the Subordinated Debt
are subordinated in right and time of payment to all payments in respect of the Senior Debt, and (ii) Subordinated Creditor will not demand, sue for or receive from Borrower (and Borrower will not pay) any part of the Subordinated Debt, whether
by payment, prepayment, distribution, setoff, or  

  
 Exhibit H-4 

 
otherwise, or accelerate the Subordinated Debt. 
 (b) Subordinated
Creditor must deliver to Senior Lenders in the form received (except for endorsement or assignment by Subordinated Creditor) any payment, distribution, security or proceeds it receives on the Subordinated Debt other than according to this Agreement.

 4. Subordination of Remedies. Until the Senior Discharge Date, and whether or not any Insolvency Event has occurred, Subordinated
Creditor will not accelerate the maturity of all or any portion of the Subordinated Debt, enforce, attempt to enforce, or exercise any right or remedy with respect to any Collateral [(including the Subordinated Collateral)] or the Subordinated Debt,
or take any other Enforcement Action with respect to the Subordinated Debt [or the Subordinated Collateral]. 
 5. Payments
Over. All payments and distributions of any kind, whether in cash, property or securities, in respect of the Subordinated Debt to which Subordinated Creditor would be entitled if the Subordinated Debt were not subordinated pursuant to this
Agreement, shall be paid to Senior Lenders in respect of the Senior Debt, regardless of whether such Senior Debt, or any portion thereof, is reduced, expunged, disallowed, subordinated or recharacterized. Notwithstanding the foregoing, if any
payment or distribution of any kind, whether in cash, property or securities, shall be received by Subordinated Creditor on account of the Subordinated Debt [or the Subordinated Collateral] before Senior Discharge Date (whether or not expressly
characterized as such), then such payment or distribution shall be segregated by Subordinated Creditor and held in trust for, and shall be promptly paid over to, Senior Lenders in the same form as received, with any necessary endorsements or as a
court of competent jurisdiction may otherwise direct, in respect of the Senior Debt, regardless of whether such Senior Debt, or any portion thereof, is reduced, expunged, disallowed, subordinated or recharacterized. Subordinated Creditor irrevocably
appoints Senior Lenders as Subordinated Creditor’s attorney-in-fact, and grants to Senior Lenders a power of attorney with full power of substitution (which power of attorney is coupled with an interest), in the name of Subordinated Creditor or
in the name of Senior Lenders, for the use and benefit of Senior Lenders, without notice to Subordinated Creditor, to make any such endorsements. This Section 5 shall be enforceable even if Senior Lenders’ liens on the Collateral
are alleged, determined, or held to constitute fraudulent transfers (whether constructive or actual), preferential transfers, or otherwise avoided or voidable, set aside, recharacterized or equitably subordinated. 

6. Insolvency Proceedings. (a) This Agreement is intended to constitute and shall be deemed to constitute a “subordination
agreement” within the meaning of Section 510(a) of the Bankruptcy Code and is intended to be and shall be interpreted to be enforceable to the maximum extent permitted pursuant to applicable nonbankruptcy law. All references to the
Borrower or any other Obligor shall include the Borrower or such Obligor as debtor and debtor-in-possession and any receiver or trustee for the Borrower or any other Obligor (as the case may be) in connection with any case under the Bankruptcy Code
or in connection with any other Insolvency Event. 
 (b) Without limiting the generality of the other provisions of
this Agreement, until the Senior Discharge Date, without the express written consent of Senior Lenders, Subordinated 

  
 Exhibit H-5 

 
Creditor shall not institute or commence (nor shall it join with or support any third party instituting, commencing, opposing, objecting or contesting, as the case may be, or otherwise suffer to
exist), any Insolvency Event involving the Borrower or any other Obligor. 
 (c) Senior Lenders shall have the right to
enforce rights, exercise remedies (including set-off and the right to credit bid its debt) and make determinations regarding the release, disposition, or restrictions with respect to the Collateral without any consultation with or consent of
Subordinated Creditor. 
 (d) Subordinated Creditor will not, and hereby waives any right to bring, join in, or otherwise
support or take any action to (i) contest the validity, legality, enforceability, perfection, priority or avoidability of any of the Senior Debt, any of the Senior Loan Documents or any security interests and/or liens of Senior Lenders on or in
any property or assets of Borrower or any other Obligor, including without limitation, the Collateral; (ii) interfere with or in any manner oppose or support any other Person in opposing any foreclosure on or other disposition of any Collateral
by the Senior Lender in accordance with applicable law, or otherwise to contest, protest, object to or interfere with the manner in which Senior Lenders may seek to enforce the Liens on any Collateral; (iii) provide a debtor-in-possession
facility (including on a priming basis) to the Borrower or any other Obligor, under Section 362, 363 or 364 of the Bankruptcy Code or any other applicable law, without the consent, in their sole discretion, of Senior Lenders; or
(iv) exercise any rights against Senior Lenders or the Collateral under Section 506(c) of the Bankruptcy Code. [Subordinated Creditor hereby waives any and all rights it may have as a junior lien creditor or otherwise to contest, protest,
object to or interfere with the manner in which Senior Lender seeks to enforce its liens on or security interests in any Collateral.] 

(e) Subordinated Creditor will not, and hereby waives any right to, oppose, contest, object to, join in, or otherwise support
any opposition to or objection with respect to, (i) any request or motion of Senior Lenders seeking, pursuant to Section 362(d) of the Bankruptcy Code or otherwise, the modification, lifting or vacating of the automatic stay of
Section 362(a) of the Bankruptcy Code or from any other stay in connection with any Insolvency Event or seeking adequate protection of Senior Lenders’ interests in the Collateral or with respect to the Senior Debt (whether under Sections
362, 363, and/or 364 of the Bankruptcy Code or other applicable law), and, until Senior Discharge Date, Subordinated Creditor agrees that it shall not seek relief from such automatic stay without the prior written consent of Senior Lenders;
(ii) any debtor-in-possession financing (including on a priming basis) or use of cash collateral (as defined in Section 363(a) of the Bankruptcy Code or other applicable law) arrangement by the Borrower, whether from Senior Lenders or any
other third party under Section 362, 363 or 364 of the Bankruptcy Code or any other applicable law, if Senior Lenders, in their sole discretion, consent to such debtor-in-possession financing or cash collateral arrangement, and Subordinated
Creditor shall not request adequate protection (whether under Sections 362, 363, and/or 364 of the Bankruptcy Code or other applicable law) or any other relief in connection therewith; (iii) any sale or other disposition of the Collateral or
substantially all of the assets of the Borrower or any other Obligor (include any such sale free and clear of liens or other claims) under Section 363 of the Bankruptcy Code or other applicable law if Senior Lenders, in their sole discretion,
consent to such sale or disposition; (vii) Senior Lenders’ exercise or enforcement of its right to make an election under Section 1111(b) of the Bankruptcy Code, and Subordinated Creditor hereby

  
 Exhibit H-6 

 
waives any claim it may hereafter have against Senior Lenders arising out of such election; (viii) Senior Lenders’ exercise or enforcement of its right to credit bid any or all of its
debt claims against the Borrower or any other Obligor, including, without limitation, the Senior Debt; or (ix) any plan of reorganization or liquidation if Senior Lenders, in their sole discretion, consent to, vote in favor of, or otherwise do
not oppose such plan of reorganization or liquidation, and, in furtherance thereof, Subordinated Creditor hereby grants to Senior Lenders the right to vote Subordinated Creditor’s claim or claims (as such term is defined in the Bankruptcy Code)
arising on account of or in connection with the Subordinated Debt, as Subordinated Creditor’s agent, with respect to any plan of reorganization or liquidation to which Subordinated Creditor may be entitled to vote in any bankruptcy or
liquidation proceeding or in connection with any other Insolvency Event of the Borrower or any other Obligor. 
 7. Distributions of
Proceeds of Collateral. All realizations upon any Collateral pursuant to or in connection with an Enforcement Action, an Insolvency Event or otherwise shall be paid or delivered to Senior Lenders in respect of the Senior Debt until the Senior
Discharge Date before any payment may be made to Subordinated Creditor.  
 8. Release of Liens. In the event of any private
or public sale or other disposition, by or with the consent of Senior Lenders, of all or any portion of the Collateral, Subordinated Creditor agrees that such sale or disposition shall be free and clear of any liens Subordinated Creditor may have on
such Collateral[, and, if the sale or other disposition includes any pledged equity interests in any Obligor, if the Subordinated Collateral includes any such any pledged equity interests, the Subordinated Creditor further agrees to release the
entities whose pledged equity interests are sold from all Subordinated Debt]. Subordinated Creditor agrees that, in connection with any such sale or other disposition, (i) Senior Lenders are authorized to file any and all UCC, PPSA and other
applicable lien releases and/or terminations in respect of any liens held by Subordinated Creditor in connection with such a sale or other disposition, and (ii) it shall execute any and all lien releases or other documents reasonably requested
by Senior Lenders in connection therewith. In furtherance of the foregoing, Subordinated Creditor hereby appoints Senior Lenders as its attorney-in-fact, with full authority in the place and stead of Subordinated Creditor and full power of
substitution and in the name of Subordinated Creditor or otherwise, to execute and deliver any document or instrument which Subordinated Creditor is required to deliver pursuant to this Section 8, such appointment being coupled with an
interest and irrevocable. Subordinated Creditor agrees that Senior Lenders may release or refrain from enforcing its security interest in any Collateral, or permit the use or consumption of such Collateral by Borrower free of any Subordinated
Creditor security interest, without incurring any liability to Subordinated Creditor. 
 9. Attorney-In-Fact. Until the Senior
Discharge Date, Subordinated Creditor irrevocably appoints Senior Lenders as its attorney-in-fact, with power of attorney with power of substitution, in Subordinated Creditor’s name or in Senior Lenders’ name, for Senior Lenders’ use
and benefit without notice to Subordinated Creditor, to do the following during an Insolvency Event:  
 (a) file any
claims in respect of the Subordinated Debt on behalf of Subordinated Creditor if Subordinated Creditor does not do so at least 30 days before the time to file claims expires; and 

  
 Exhibit H-7 

 (b) vote Subordinated Creditor’s claim or claims (as such term is
defined in the Bankruptcy Code) arising on account of or in connection with the Subordinated Debt, as Subordinated Creditor’s agent, with respect to any plan of reorganization or liquidation to which Subordinated Creditor may be entitled to
vote in any bankruptcy or liquidation proceeding or in connection with any other Insolvency Event of the Borrower or any other Obligor. 

Such power of attorney is irrevocable and coupled with an interest. 

10. Legend; Amendment of Debt. (a) Subordinated Creditor will immediately put a legend on or otherwise indicate on the
Subordinated Note that the Subordinated Note is subject to this Agreement.  
 (b) Until the Senior Discharge Date,
Subordinated Creditor shall not, without prior written consent of Senior Lenders, agree to any amendment, modification or waiver of any provision of the Subordinated Debt Documents, if the effect of such amendment, modification or waiver is to:
(i) terminate or impair the subordination of the Subordinated Debt in favor of Senior Lenders; (ii) increase the interest rate on the Subordinated Debt or change (to earlier dates) the dates upon which principal, interest and other sums
are due under the Subordinated Note; (iii) alter the redemption, prepayment or subordination provisions of the Subordinated Debt; (iv) impose on Borrower or any other Obligor any new or additional prepayment charges, premiums,
reimbursement obligations, reimbursable costs or expenses, fees or other payment obligations; (v) alter the representations, warranties, covenants, events of default, remedies and other provisions in a manner which would make such provisions
materially more onerous, restrictive or burdensome to Borrower or any other Obligor; (vi) 15[grant a lien or security interest in favor of any holder of the Subordinated Debt on any asset or
Collateral to secure all or any portion of the Subordinated Debt][terminate or impair the subordination of any security interest or lien securing the Subordinated Debt in favor of Senior Lenders]; or (vii) otherwise increase the obligations,
liabilities and indebtedness in respect of the Subordinated Debt or confer additional rights upon Subordinated Creditor, which individually or in the aggregate would be materially adverse to Borrower, any other Obligor or Senior Lenders. Any such
amendment, modification or waiver made in violation of this Section 10(b) shall be void. 
 (c) At any time
without notice to Subordinated Creditor, Senior Lenders may take such action with respect to the Senior Debt as Senior Lenders, in their sole discretion, may deem appropriate, including, without limitation, terminating advances, increasing the
principal, extending the time of payment, increasing interest rates, renewing, compromising or otherwise amending any documents affecting the Senior Debt and any Collateral securing the Senior Debt, and enforcing or failing to enforce any rights
against Borrower or any other person. No action or inaction will impair or otherwise affect Senior Lenders’ rights under this Agreement. 

11. Certain Waivers. (a) Subordinated Creditor hereby (i) waives any and all notice of the incurrence of the Senior Debt or
any part thereof; (ii) waives any and all rights it may have to require Senior Lenders to marshal assets, to exercise rights or remedies in a particular manner, to forbear from exercising such rights and remedies in any particular manner or
order, or to claim the benefit of any appraisal, valuation or other similar right that may otherwise be available  
  

	 15 
	 Select one, as appropriate. 

  
 Exhibit H-8 

 
under applicable law, regardless of whether any action or failure to act by or on behalf of Senior Lenders is adverse to the interest of Subordinated Creditor; (iii) agrees that Senior
Lenders shall have no liability to Subordinated Creditor, and Subordinated Creditor hereby waives any claim against Senior Lenders arising out of any and all actions not in breach of this Agreement which Senior Lenders may take or permit or omit to
take with respect to the Senior Loan Documents (including any failure to perfect or obtain perfected security interests in the Collateral), the collection of the Senior Debt or the foreclosure upon, or sale, liquidation or other disposition of, any
Collateral; and (iv) agrees that Senior Lenders have no duty, express or implied, fiduciary or otherwise, to them in respect of the maintenance or preservation of the Collateral, the Senior Debt or otherwise. Without limiting the foregoing,
Subordinated Creditor agrees that Senior Lenders shall have no duty or obligation to maximize the return to any class of creditors holding indebtedness of any type (whether Senior Debt or Subordinated Debt), notwithstanding that the order and timing
of any realization, sale, disposition or liquidation of the Collateral may affect the amount of proceeds actually received by such class of creditors from such realization, sale, disposition or liquidation. 

(b) Subordinated Creditor confirms that this Agreement shall govern as between the Senior Lenders and the Subordinated
Creditor irrespective of: (i) any lack of validity or enforceability of any Senior Loan Document or any Subordinated Debt Document; (ii) the occurrence of any Insolvency Event in respect of any Obligor; (iii) whether the Senior Debt,
or the liens or security interests securing the Senior Debt, shall be held to be unperfected, deficient, invalid, void, voidable, voided, unenforceable, subordinated, reduced, discharged or are set aside by a court of competent jurisdiction,
including pursuant or in connection with any Insolvency Event; (iv) any change in the time, manner or place of payment of, or in any other terms of, all or any of the Senior Debt or the Subordinated Debt, or any amendment or waiver or other
modification, including any increase in the amount thereof, whether by course of conduct or otherwise, of the terms of any Senior Loan Document or any Subordinated Debt Document or any guarantee thereof; or (v) any other circumstances which
otherwise might constitute a defense available to, or a discharge of, any Obligor in respect of the Senior Debt or the Subordinated Debt. 

12. Representations and Warranties. Subordinated Creditor represents and warrants to Senior Lenders that: 

(a) all action on the part of Subordinated Creditor, its officers, directors, partners, members and shareholders, as
applicable, necessary for the authorization of this Agreement and the performance of all obligations of Subordinated Creditor hereunder has been taken; 

(b) this Agreement constitutes the legal, valid and binding obligation of Subordinated Creditor, enforceable against
Subordinated Creditor in accordance with its terms; 
 (c) the execution, delivery and performance of and compliance with
this Agreement by Subordinated Creditor will not (i) result in any material violation or default of any term of any of Subordinated Creditor’s charter, formation or other organizational documents (such as Articles or Certificate of
Incorporation, bylaws, partnership agreement, operating agreement, etc.) or (ii) violate any material applicable law, rule or regulation; and 

  
 Exhibit H-9 

 (d) Subordinated Creditor has not previously assigned any interest in the
Subordinated Debt[ or any Subordinated Collateral], and no Person other than the Subordinated Creditor owns an interest in the Subordinated Debt[ or Subordinated Collateral]. 

13. Term; Reinstatement. This Agreement shall remain in full force and effect until the Senior Discharge Date, notwithstanding the
occurrence of an Insolvency Event. If, after the Senior Discharge Date, Senior Lenders must disgorge any payments made on the Senior Debt for any reason (including, without limitation, in connection with the bankruptcy of Borrower or in connection
with any other Insolvency Event), this Agreement and the relative rights and priorities provided in it, will be reinstated as to all disgorged payments as though such payments had not been made, and Subordinated Creditor will immediately pay Senior
Lenders all payments received in respect of the Subordinated Debt to the extent such payments or retention thereof would have been prohibited under this Agreement.  

14. Successors and Assigns. This Agreement binds Subordinated Creditor, its successors or assigns, and benefits Senior Lenders’
successors or assigns. This Agreement is for Subordinated Creditor’s and Senior Lenders’ benefit and not for the benefit of Borrower or any other party. Subordinated Creditor shall not sell, assign, pledge, dispose of or otherwise transfer
all or any portion of the Subordinated Debt or any related document or any interest in any Collateral therefor unless prior to the consummation of any such action, the transferee thereof shall execute and deliver to Senior Lenders an agreement of
such transferee to be bound hereby, or an agreement substantially identical to this Agreement providing for the continued subjection of the Subordinated Debt, the interests of the transferee in the Collateral and the remedies of the transferee with
respect thereto as provided herein with respect to Subordinated Creditor and for the continued effectiveness of all of the other rights of Senior Lenders arising under this Agreement, in each case in form satisfactory to Senior Lenders. Any such
sale, assignment, pledge, disposition or transfer not made in compliance with the terms of this Section 14 shall be void. 

15. Further Assurances. Subordinated Creditor hereby agrees to execute such documents and/or take such further action as Senior Lenders
may at any time or times reasonably request in order to carry out the provisions and intent of this Agreement, including, without limitation, ratifications and confirmations of this Agreement from time to time hereafter, as and when requested by
Senior Lenders. 
 16. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed
an original and all of which together shall constitute one instrument. Executed counterparts may be delivered by facsimile. 
 17.
Governing Law; Waiver of Jury Trial. (a) This Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles of
conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that Section 5-1401 of the New York General Obligations Law shall apply.  

(b) EACH PARTY HERETO WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS

  
 Exhibit H-10 

 
AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREIN. 
 18. Entire Agreement;
Waivers and Amendments. This Agreement represents the entire agreement with respect to the subject matter hereof, and supersedes all prior negotiations, agreements and commitments. Senior Lenders and Subordinated Creditor are not relying on any
representations by the other creditor party or Borrower in entering into this Agreement, and each of Senior Lenders and Subordinated Creditor has kept and will continue to keep itself fully apprised of the financial and other condition of Borrower.
No amendment, modification, supplement, termination, consent or waiver of or to any provision of this Agreement, nor any consent to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by Senior
Lenders and Subordinated Creditor. Any waiver of any provision of this Agreement, or any consent to any departure from the terms of any provision of this Agreement, shall be effective only in the specific instance and for the specific purpose for
which given.  
 19. No Waiver. No failure or delay on the part of any Senior Lender or Subordinated Creditor in the exercise
of any power, right, remedy or privilege under this Agreement shall impair such power, right, remedy or privilege or shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude any other
or further exercise of any other power, right or privilege. The rights and remedies under this Agreement are cumulative and not exclusive of any rights, remedies, powers and privileges that may otherwise be available to Senior Lenders. 

20. Legal Fees. In the event of any legal action to enforce the rights of a party under this Agreement, the party prevailing in such
action shall be entitled, in addition to such other relief as may be granted, all reasonable, invoiced and out-of-pocket costs and expenses, including reasonable attorneys’ fees, incurred in such action. 

21. Severability. Any provision of this Agreement which is illegal, invalid, prohibited or unenforceable in any jurisdiction shall, as
to such jurisdiction, be ineffective to the extent such illegality, invalidity, prohibition or unenforceability without invalidating or impairing the remaining provisions hereof or affecting the validity or enforceability of such provision in any
other jurisdiction. 
 22. Notices. All notices, demands, instructions and other communications required or permitted to be
given to or made upon any party hereto shall be in writing and shall be delivered or sent by first-class mail, postage prepaid, or by overnight courier or messenger service or by facsimile or electronic mail, message confirmed, and shall be deemed
to be effective for purposes of this Agreement on the day that delivery is made or refused. Unless otherwise specified in a notice mailed or delivered in accordance with the foregoing sentence, notices, demands, instructions and other communications
in writing shall be given to or made upon the respective parties hereto at their respective addresses and facsimile numbers indicated on the signature pages hereto. 

23. No Third-Party Beneficiaries; Other Benefits. The terms and provisions of this Agreement are intended solely for the benefit of
each party hereto and their respective successors and permitted assigns, and the parties do not intend to confer third party beneficiary rights upon  

  
 Exhibit H-11 

 
any other person. Subordinated Creditor understands that there may be various agreements between Senior Lenders and the Borrower or the other Obligors evidencing and governing the Senior Debt,
and Subordinated Creditor acknowledges and agrees that such agreements are not intended to confer any benefits on Subordinated Creditor and that Senior Lenders shall have no obligation to Subordinated Creditor or any other Person to exercise any
rights, enforce any remedies, or take any actions which may be available to it under such agreements. 
 [Signature pages follow] 

  
 Exhibit H-12 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the
date first above written. 
  

			
	 SUBORDINATED CREDITOR:

	
[                    ]

		
		 	
	 By
	 	  

		 	 Name:

		 	 Title:

 Address for Notices: 

 

			
	 SENIOR LENDERS:

	
	 CRG PARTNERS III L.P.,

	
	 By CRG PARTNERS III GP L.P., its General Partner

	 By CRG PARTNERS III GP LLC, its General Partner

		
	 By
	 	  

	 Name:
	 	 Charles Tate

	 Title:
	 	 Sole Member

	
	 Address for Notices:

	
	 1000 Main Street, Suite 2500

	 Houston, TX 77002

	 Attn:
	 	 General Counsel

	 Tel.:
	 	
	 Fax:
	 	
	 Email:
	 	

  
 Exhibit H-13 

			
	 GENOMEDX BIOSCIENCES INC.

		
	 By
	 	  

		 	 Name:

		 	 Title:

 

			
	 Address for Notices:

	
[                    ]

	
[                    ]

	
[                    ]

	 Attn:
	 	
[                    ]

	 Tel.:
	 	
[                    ]

	 Fax:
	 	
[                    ]

	 Email:
	 	
[                    ]

  
 Exhibit H-14 

 Exhibit I 

to Term Loan Agreement 
 FORM
OF INTERCREDITOR AGREEMENT 
 This Intercreditor Agreement, dated as of
[                    ] (this “Agreement”), is made among CRG Partners III L.P., a Delaware limited partnership
(“CRGIII”), and [                    ], a
[                    ]
(“[                    ]” and collectively with CRGIII,
[                    ] and their successors and assignees, “CRG”), and [INSERT NAME OF A/R LENDER], a
[                    ] (“[A/R Lender]”). 

RECITALS 
  

	 A.
	 [A/R Lender] and GenomeDx Biosciences Inc, a company incorporated in British Columbia, Canada
(“Borrower”), have entered into the A/R Facility Agreement (as defined below), which, along with any other obligations owing to [A/R Lender] by Borrower, is secured by certain property of Borrower [and the other Obligors (as
defined below)]. 

  

	 B.
	 CRG and Borrower have entered into that certain Term Loan Agreement, dated as of
[                    ] (as amended, restated, supplemented or otherwise modified from time to time, the “CRG Term Loan
Agreement”), which is secured by certain property of Borrower and the other Obligors. 

  

	 C.
	 To induce each of [A/R Lender] and CRG (collectively, “Creditors” and each
individually, a “Creditor”) to make and maintain the credit extensions under the A/R Facility Agreement and the CRG Term Loan Agreement, respectively, the other Creditor is willing to enter into this Agreement to, among other
things, subordinate certain of its liens on the terms and conditions herein set forth. 

 NOW, THEREFORE, THE PARTIES AGREE
AS FOLLOWS: 
 1. Definitions. As used herein, the following terms have the following meanings: 

“A/R Facility Agreement” means that certain [Credit Agreement] between [A/R Lender] and
Borrower dated as of [                    ] as the same may be amended, restated, supplemented or otherwise modified from time to time.

 “A/R Facility Documents” means the A/R Facility Agreement and all [Loan
Documents], each as defined in the A/R Facility Agreement.  
 “A/R Facility Senior
Collateral” means (i) [Borrower’s] accounts arising from the sale of inventory or services, excluding IP/Equipment Accounts (collectively, “Inventory/Service Accounts”), (ii) [Borrower’s]
inventory, (iii) to the extent evidencing, governing, or securing [Borrower’s] Inventory/Service Accounts or inventory, [Borrower’s] general intangibles (excluding Intellectual Property), chattel paper, instruments and documents,
(iv) to the extent held in a segregated deposit account that does not contain other cash, cash proceeds of [Borrower’s] Inventory/Survice Accounts and inventory, and (v) proceeds of insurance policies 

  
 Exhibit I-1 

 
covering [Borrower’s] Inventory/Service Accounts and inventory received with respect to such accounts and inventory; provided that, for purposes of
clarification, notwithstanding the foregoing, in no event shall “A/R Facility Senior Collateral” include (A) any right, title or interest of any Obligor in any Intellectual Property or any licenses thereof, (B) any accounts or
proceeds arising from the sale, transfer, licensing or other disposition of any Intellectual Property or licenses, or from the sale, transfer, lease or other disposition of equipment (collectively, “IP/Equipment Accounts”),
(C) equipment, (D) to the extent evidencing, governing, securing or otherwise related to equipment, any general intangibles, chattel paper, instruments or documents, or (E) proceeds of equipment or proceeds of insurance policies with
respect to equipment. 
 “[A/R Lender]” shall have the meaning provided
to such term in the introductory paragraph hereto, and when such term is used herein relating to an Enforcement Action or an Insolvency Proceeding shall include any Receiver appointed by [A/R Lender]. 

“Bankruptcy Code” means the federal bankruptcy law of the United States as from time to
time in effect, currently as Title 11 of the United States Code. Section references to current sections of the Bankruptcy Code shall refer to comparable sections of any revised version thereof if section numbering is changed. 

“Bankruptcy Law” means the Bankruptcy Code, Canadian Insolvency Laws and any similar
federal, state, provincial or foreign law for liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, arrangement (including under any relevant incorporating statute), rearrangement, receivership, insolvency,
reorganization, judicial management, winding up, administration or the relief of debtors. 

“Canadian Insolvency Laws” means any of the Bankruptcy and Insolvency Act (Canada), the
Companies’ Creditors Arrangement Act (Canada), and the Winding-Up and Restructuring Act (Canada) and any proceeding under applicable federal or provincial corporate law seeking an arrangement or compromise of some or all of the debts of a
Person or a stay of proceedings to enforce some or all claims of creditors against a Person. 

“Claim” means, (i) in the case of [A/R Lender], any and all present and future
“claims” (used in its broadest sense, as contemplated by and defined in Section 101(5) of the Bankruptcy Code or as contemplated by any other Bankruptcy Law, but without regard to whether such claim would be disallowed under the
Bankruptcy Code or any other Bankruptcy Law) of [A/R Lender] now or hereafter arising or existing under or relating to the A/R Facility Documents (with the portion of [A/R Lender]’s Claim at any time consisting of the aggregate principal amount
of indebtedness under the A/R Facility Documents not to exceed the lesser of $[            ] and 80% of the face amount at such time of [Borrower’s] non delinquent accounts
receivable), whether joint, several, or joint and several, whether fixed or indeterminate, due or not yet due, contingent or non-contingent, matured or unmatured, liquidated or unliquidated, or disputed or undisputed, whether under a guaranty or a
letter of credit, and whether arising under contract, in tort, by law, or otherwise, any interest or fees thereon (including interest or fees that accrue after the filing of a petition by or against any Obligor under any Bankruptcy Law, irrespective
of whether allowable under such Bankruptcy Law), any costs of Enforcement Actions, including reasonable attorneys’ fees and costs, and any prepayment or termination fees, and (ii) in the case of CRG, any and all present and future
“claims” (used in its  

  
 Exhibit I-2 

 
broadest sense, as contemplated by and defined in Section 101(5) of the Bankruptcy Code or as contemplated by any other Bankruptcy Law, but without regard to whether such claim would be
disallowed under such Bankruptcy Law) of CRG now or hereafter arising or existing under or relating to the CRG Documents, whether joint, several, or joint and several, whether fixed or indeterminate, due or not yet due, contingent or non-contingent,
matured or unmatured, liquidated or unliquidated, or disputed or undisputed, whether under a guaranty or a letter of credit, and whether arising under contract, in tort, by law, or otherwise, any interest or fees thereon (including interest or fees
that accrue after the filing of a petition by or against any Obligor under any Bankruptcy Law, irrespective of whether allowable under such Bankruptcy Law), any costs of Enforcement Actions, including reasonable attorneys’ fees and costs, and
any prepayment or termination fees. 
 “Collateral” means all real or personal property of any
Obligor in which any Creditor now or hereafter has a security interest. 
 “Common Collateral” means
all Collateral in which both [A/R Lender] and CRG have a security interest. 
 “CRG” shall have the
meaning provided to such term in the introductory paragraph hereto, and when such term is used herein relating to an Enforcement Action or an Insolvency Proceeding shall include any Receiver appointed by CRG.“CRG Documents”
means all documentation related to the CRG Term Loan Agreement and all Loan Documents (as defined in the CRG Term Loan Agreement), including security or pledge agreements and all other related agreements. 

“CRG Senior Collateral” means all Collateral in which CRG has a security interest, other than the A/R
Facility Senior Collateral, including, for the avoidance of doubt and without limitation, any additional Collateral in which CRG may have a security interest following the commencement of or in connection with any Insolvency Proceeding, including
without limitation Collateral subject to any CRG security interests, superpriority claims, or other rights arising under Sections 507(b) and 552 of the Bankruptcy Code or any other similar Bankruptcy Law. 

“Credit Documents” means, collectively, the CRG Documents and the A/R Facility Documents. 

“Enforcement Action” means, with respect to any Creditor and with respect to any Claim of such
Creditor or any item of Collateral in which such Creditor has or claims a security interest, lien, or right of offset, (i) any action, whether judicial or nonjudicial, to repossess, collect, offset, recoup, give notification to third parties
with respect to, sell, dispose of, foreclose upon, give notice of sale, disposition, or foreclosure with respect to, or obtain equitable or injunctive relief with respect to, such Claim or Collateral, (ii) any action in connection with any
Insolvency Proceeding to protect, defend, enforce or assert rights with respect to such Claim or Collateral, including without limitation filing and defending any proof of claim, opposing or joining in the opposition of any sale of assets or
confirmation of a plan of reorganization, or opposing or joining in the opposition of any proposed debtor-in-possession loan or use of cash collateral, and (iii) the filing of, or the joining in the filing of, an involuntary bankruptcy or
insolvency proceeding against any Obligor. 

  
 Exhibit I-3 

 “Intellectual Property” means, collectively, all
copyrights, copyright registrations and applications for copyright registrations, including all renewals and extensions thereof, all rights to recover for past, present or future infringements thereof and all other rights whatsoever accruing
thereunder or pertaining thereto (collectively, “Copyrights”), all patents and patent applications, including the inventions and improvements described and claimed therein together with the reissues, divisions, continuations,
renewals, extensions and continuations in part thereof, all damages and payments for past or future infringements thereof and rights to sue therefor, and all rights corresponding thereto throughout the world and all income, royalties, damages and
payments now or hereafter due and/or payable under or with respect thereto (collectively, “Patents”), and all trade names, trademarks and service marks, logos, trademark and service mark registrations, and applications for
trademark and service mark registrations, including all renewals of trademark and service mark registrations, all rights to recover for all past, present and future infringements thereof and all rights to sue therefor, and all rights corresponding
thereto throughout the world (collectively, “Trademarks”), together, in each case, with the product lines and goodwill of the business connected with the use of, and symbolized by, each such trade name, trademark and service
mark, together with (a) all inventions, processes, production methods, proprietary information, know-how and trade secrets; (b) all licenses or user or other agreements granted to any Obligor with respect to any of the foregoing, in each
case whether now or hereafter owned or used; (c) all information, customer lists, identification of suppliers, data, plans, blueprints, specifications, designs, drawings, recorded knowledge, surveys, engineering reports, test reports, manuals,
materials standards, processing standards, performance standards, catalogs, computer and automatic machinery software and programs; (d) all field repair data, sales data and other information relating to sales or service of products now or
hereafter manufactured; (e) all accounting information and all media in which or on which any information or knowledge or data or records may be recorded or stored and all computer programs used for the compilation or printout of such
information, knowledge, records or data; (f) all licenses, consents, permits, variances, certifications and approvals of governmental agencies now or hereafter held by any Obligor; and (g) all causes of action, claims and warranties now or
hereafter owned or acquired by any Obligor in respect of any of the items listed above. 
 “Junior
Collateral” means, (i) in the case of [A/R Lender], all Common Collateral consisting of CRG Senior Collateral and (ii) in the case of CRG, all Common Collateral consisting of A/R Facility Senior Collateral. 

“Obligor” means Borrower, each subsidiary thereof and each other person or entity that provides a
guaranty of, or collateral for, any Claim of any Creditor. 
 “PPSA” means the Personal Property
Security Act (British Columbia) and the regulations thereunder, as from time to time in effect, provided, however, if attachment, perfection or priority of a Creditor’s security interests in any Collateral is governed by the personal property
security laws of any jurisdiction other than British Columbia, “PPSA” shall mean those personal property security laws in such other jurisdiction for the purposes of the provisions hereof relating to such attachment, perfection or priority
and for the definitions related to such provisions. 
 “Proceeds Sweep Period” means the period
beginning on the later to occur of (i) the occurrence of an event of default under any Creditor’s Credit Documents and (ii) receipt by the 

  
 Exhibit I-4 

 
other Creditor of written notice from such Creditor of such event of default, and ending on the date on which such event of default shall have been waived in writing by the Creditor issuing such
notice. 
 “Receiver” means any receiver, interim receiver, receiver-manager, trustee, custodian,
conservator, sequestrator, liquidator, rehabilitator, administrator, assignee for the benefit of creditors, mortgagee in possession (or agent therefor), monitor or any similar Person. 

“Senior Collateral” means, (i) in the case of [A/R Lender], all A/R Facility Senior Collateral
and (ii) in the case of CRG, all CRG Senior Collateral. 
 “UCC” means the Uniform Commercial
Code of any applicable jurisdiction and, if the applicable jurisdiction shall not have any Uniform Commercial Code, the Uniform Commercial Code as in effect in the State of New York. The following terms have the meanings given to them in the
applicable UCC: “account”, “chattel paper”, “commodity account”, “deposit account”, “document”, “equipment”, “general intangible”, “instrument”, “inventory”,
“proceeds” and “securities account”. 
 2. Lien Subordination. (a) Notwithstanding the respective dates of
attachment or perfection of the security interests of CRG and the security interests of [A/R Lender], or any contrary provision of the UCC, PPSA or any applicable law or decision, or the provisions of the Credit Documents, and irrespective of
whether [A/R Lender] or CRG holds possession of all or any part of the Collateral, (i) all now existing and hereafter arising security interests of [A/R Lender] in any A/R Facility Senior Collateral shall at all times be senior to the security
interests of CRG in such A/R Facility Senior Collateral, and (ii) all now existing and hereafter arising security interests of CRG in any CRG Senior Collateral shall at all times be senior to the security interests of [A/R Lender] in such CRG
Senior Collateral. 
 (b) Each Creditor hereby: 

(i) acknowledges and consents to (A) [Borrower][each Obligor] granting to the other Creditor a security interest in the
Common Collateral of such other Creditor, (B) the other Creditor filing any and all financing statements and other documents as reasonably deemed necessary by the other Creditor in order to perfect its security interest in its Common
Collateral, and (C) [Borrower’s][each Obligor’s] entry into the Credit Documents to which the other Creditor is a party. 

(ii) acknowledges, agrees and covenants, notwithstanding Section 2(c) but subject to Section 5, that
it shall not contest, challenge or dispute the validity, attachment, perfection, priority or enforceability of the other Creditor’s security interest in the Common Collateral, or the validity, priority or enforceability of the other
Creditor’s Claim. For the avoidance of doubt and notwithstanding anything in this Agreement to the contrary, [A/R Lender] shall not file or join in any motion or pleading in connection with any Insolvency Proceeding or take any other action
seeking to recharacterize any Intellectual Property, the proceeds thereof, or any other CRG Senior Collateral or proceeds thereof as A/R Facility Senior Collateral. 

(c) Subject to Section 2(b)(ii), the priorities provided for herein with respect to

  
 Exhibit I-5 

 
security interests and liens are applicable only to the extent that such security interests and liens are enforceable, perfected and have not been avoided; if a security interest or lien is
judicially determined to be unenforceable or unperfected or is judicially avoided with respect to one or more Claims or any part thereof, the priorities provided for herein shall not be available to such security interest or lien to the extent that
it is avoided or determined to be unenforceable. Nothing in this Section 2(c) affects the operation of any turnover of payment provisions hereof, or of any other agreements among any of the parties hereto. 

3. Distribution of Proceeds of Common Collateral. (a) During each Proceeds Sweep Period, all proceeds including proceeds of any
sale, exchange, collection, or other disposition of: 
 (i) A/R Facility Senior Collateral shall be distributed first, to
[A/R Lender], in an amount up to the amount of [A/R Lender]’s Claim; then, to CRG, in an amount up to the amount of CRG’s Claim; 

(ii) CRG Senior Collateral shall be distributed first, to CRG, in an amount up to the amount of CRG’s Claim; then, to
[A/R Lender], in an amount up to the amount of [A/R Lender]’s Claim. 
 (b) In the event that, notwithstanding
Section 3(a), either Creditor shall during any Proceeds Sweep Period receive any payment, distribution, security or proceeds constituting its Junior Collateral prior to the indefeasible payment in full of the other Creditor’s Claims
and termination of all commitments of the other Creditor under its Credit Documents, such Creditor shall hold in trust, for such other Creditor, such payment, distribution, security or proceeds, and shall deliver to such other Creditor, in the form
received (with any necessary endorsements or as a court of competent jurisdiction may otherwise direct) such payment, distribution, security or proceeds for application to the other Creditor’s Claims in accordance with Section 3(a).

 (c) At all times other than during a Proceeds Sweep Period, all proceeds including proceeds of any sale, exchange,
collection, or other disposition of Collateral shall be distributed or applied, as applicable, in accordance with the CRG Documents and the A/R Facility Documents. 

(d) Except as expressly set forth herein, nothing in this Section 3 shall obligate either Creditor (i) to
sell, exchange, collect or otherwise dispose of Collateral at any time, or (ii) to take any action in violation of any stay imposed in connection with any Insolvency Proceeding, including without limitation the automatic stay in
Section 362(a) of the Bankruptcy Code or any other similar Bankruptcy Law, nor shall either Creditor have any liability to the other arising from or in connection with such Creditor’s failure to take such action. 

4. Subordination of Remedies. Each Creditor (for purposes of this Section 4, the “Junior Creditor”)
agrees, subject to Section 5, that, (i) unless and until all Claims of the other Creditor (for purposes of this Section 4, the “Senior Creditor”) have been indefeasibly paid in full and all
commitments of the Senior Creditor under its Credit Documents have been terminated, or (ii) until the expiration of a period of 180 days from the date of notice of default under the Senior Creditor’s Credit Documents given by the Senior
Creditor to the Junior Creditor, whichever is earlier, and whether or not any Insolvency Proceeding has been commenced by or against any 

  
 Exhibit I-6 

 
Obligor, the Junior Creditor shall not, without the prior written consent of the Senior Creditor, enforce, or attempt to enforce, any rights or remedies under or with respect to any of such
Junior Creditor’s Junior Collateral, including causing or compelling the pledge or delivery of such Junior Collateral, any attachment of, levy upon, execution against, foreclosure upon or the taking of other action against or institution of
other proceedings with respect to any such Junior Collateral, notifying any account debtors of any Obligor, asserting any claim or interest in any insurance with respect to such Junior Collateral, or exercising any rights under any lockbox
agreement, account control agreement, landlord waiver or bailee’s letter or similar agreement or arrangement with respect to such Junior Collateral, or institute or commence, or join with any person or entity in commencing, any action or
proceeding with respect to such rights or remedies (including any action of foreclosure, enforcement, collection or execution and any Insolvency Proceeding involving any Obligor), except that notwithstanding the foregoing, at all times, including
during a Proceeds Sweep Period, the Junior Creditor shall be able to exercise its rights under a lockbox agreement or an account control agreement with respect to any deposit account, securities account or commodity account constituting Collateral,
including its rights to freeze such account or exercise any rights of offset, provided that any distribution or withdrawal from such account shall be applied in accordance with Section 3(a). 

5. Insolvency Proceedings. (a) Rights Continue. In the event of any Obligor’s insolvency, reorganization or any case,
action or proceeding, commenced by or against such Obligor, under any bankruptcy or insolvency law or laws relating to the relief of debtors, including, without limitation, any voluntary or involuntary bankruptcy (including any case commenced under
Bankruptcy Law), insolvency, receivership, liquidation, foreclosure, power of sale, dissolution, winding-up or other similar statutory or common law proceeding or arrangement involving any Obligor, the readjustment of its liabilities, any assignment
for the benefit of its creditors, any marshalling of its assets or liabilities, or any proceeding seeking the appointment of a Receiver or other insolvency official with similar powers with respect to such Person (each, an “Insolvency
Proceeding”), (i) this Agreement shall remain in full force and effect in accordance with Section 510(a) of the United States Bankruptcy Code or any other applicable Bankruptcy Law, and (ii) the Collateral shall include,
without limitation, all Collateral arising during or after any such Insolvency Proceeding (which Collateral shall be subject to the priorities set forth in this Agreement). 

(b) Proof of Claim, Sales and Plans. At any meeting of creditors or in the event of any Insolvency Proceeding, each
Creditor shall retain the right to vote, file a proof of claim and otherwise act with respect to its Claims (including the right to vote to accept or reject any plan of partial or complete liquidation, reorganization, arrangement, composition, or
extension (a “Plan”)), provided that (i) neither Creditor shall initiate, prosecute or participate in any claim or action in such Insolvency Proceeding directly or indirectly challenging the enforceability, validity,
perfection or priority of the other’s Claims, this Agreement, the Credit Documents, or any liens securing the other Creditor’s Claims; and (ii) neither Creditor shall propose any Plan or file or join in any motion or pleading in
support of any motion or Plan or exercise any other voting rights unless such Plan provides for the treatment of the Creditors’ claims in accordance with the terms of Section 5(g) and otherwise consistent with the terms of this
Agreement, or that would otherwise impair the timely repayment of the other Creditor’s Claims in accordance with its terms or impair or impede any rights of the other Creditor. 

  
 Exhibit I-7 

 Each Creditor acknowledges that the interests of [A/R Lender] are distinct
from those of CRG, having regard to the nature of the obligations owed by the Obligors, the nature and priority of their respective security and the remedies available to them. In the event of the commencement of any Proceedings, each of the
Creditors acknowledges and agrees that (a) [A/R Lender], and (b) CRG, shall be treated as unaffected creditors or, alternatively, shall be placed in separate classes for all purposes related to such proceedings including, without
limitation, for the purposes of voting on or approving any plan of arrangement, proposal, compromise, reorganization plan or other agreement or document with similar effect. 

(c) Finance and Sale Issues. (i) If any Obligor shall be subject to any Insolvency Proceeding and a Creditor shall
desire to permit the use by such Obligor of cash collateral (as defined in Section 363(a) of the Bankruptcy Code or as contemplated by any other Bankruptcy Law, “Cash Collateral”) constituting such Creditor’s Senior
Collateral or to permit any Obligor to obtain financing (including on a priming basis with respect to such Creditor’s Senior Collateral), whether from such Creditor or any other third party under Section 362, 363 or 364 of the Bankruptcy
Code, other similar Bankruptcy Law or any other applicable law (each, a “Post-Petition Financing”), then the other Creditor agrees that it shall not oppose or raise any objection to or contest (or join with or support any
third party opposing, objecting to or contesting), such use of Cash Collateral or Post-Petition Financing and shall not request adequate protection or any other relief in connection therewith (except as specifically permitted under
Section 5(e)); provided, however, that, notwithstanding the foregoing, either Creditor shall be entitled to oppose, raise objection to, or contest (or join with or support any third party opposing, objecting to, or
contesting) any such use of Cash Collateral or Post-Petition Financing if such proposed use of Cash Collateral or Post-Petition Financing would result in any liens on such Creditor’s Senior Collateral to be subordinated to or pari passu
with such Cash Collateral or Post-Petition Financing. 
 (ii) Each Creditor agrees that it shall raise no objection to,
oppose or contest (or join with or support any third party opposing, objecting to or contesting), a sale, revesting or other disposition of any Collateral constituting its Junior Collateral free and clear of its liens or other Claims, whether under
Sections 363 or 1141 of the Bankruptcy Code, other Bankruptcy Law or other applicable law, if the other Creditor has consented to such sale or disposition of such assets; provided, however, that, notwithstanding the foregoing
and for the avoidance of doubt, either Creditor shall be entitled to oppose, raise objection to, or contest (or join with or support any third party opposing, objecting to, or contesting) any sale, revesting or other disposition of any Collateral
constituting its Senior Collateral free and clear of its liens or other Claims. 
 (d) Relief from the Automatic
Stay. Each Creditor agrees that, until the other Creditor’s Claims have been indefeasibly paid in full, such Creditor shall not seek relief, pursuant to Section 362(d) of the Bankruptcy Code, other similar Bankruptcy Law or otherwise,
from the automatic stay of Section 362(a) of the Bankruptcy Code or other similar Bankruptcy Law or from any other stay in any Insolvency Proceeding in respect of its Junior Collateral without the prior written consent of such other Creditor.

 (e) Adequate Protection. [A/R Lender] agrees that it shall not: 

  
 Exhibit I-8 

 (i) oppose, object to or contest (or join with or support any third party
opposing, objecting to or contesting) (A) any request by CRG for adequate protection in any Insolvency Proceeding (or any granting of such request), or (B) any objection by CRG to any motion, relief, action or proceeding based on such
Senior Creditor claiming a lack of adequate protection; or 
 (ii) seek or accept any form of adequate protection under any
of Sections 362, 363 and/or 364 of the Bankruptcy Code or other similar Bankruptcy Law with respect to the Collateral, except to the extent that, in the sole discretion of CRG, the receipt by [A/R Lender] of any such adequate protection would not
reduce (or would not have the effect of reducing) or adversely affect the adequate protection that CRG otherwise would be entitled to receive, it being understood that, in any event, (y) no adequate protection shall be requested or accepted by
[A/R Lender] unless CRG is satisfied in its sole discretion with the adequate protection afforded to CRG, and (z) any such adequate protection is in the form of a replacement lien on the Obligors’ assets, which lien shall be subordinated
to the liens securing CRG’s Claims (including any replacement liens granted in respect of CRG’s Claims) and any Post-Petition Financing (and all obligations relating thereto) on the same basis as the other liens securing [A/R
Lender]’s Claims are so subordinated to the liens securing CRG’s Claims as set forth in this Agreement. 
 (f)
Post-Petition Interest. Each Creditor shall not oppose or seek to challenge any claim by the other Creditor for allowance in any Insolvency Proceeding of Claims consisting of post-petition interest, fees or expenses, provided that the
treatment of such Claims are consistent with the Creditors’ relative priorities set forth in this Agreement. 
 (g)
Separate Class. Without limiting anything to the contrary contained herein or in the Credit Documents, each Creditor acknowledges and agrees that (i) the grants of liens pursuant to the CRG Documents and the A/R Facility Documents
constitute two separate and distinct grants of liens, and (ii) because of, among other things, their differing rights in the Collateral, each Creditor’s Claims are fundamentally different from the other’s Claims and must be separately
classified in any Plan proposed or adopted in an Insolvency Proceeding. To further effectuate the intent of the parties as provided in the immediately preceding sentence, if it is held that the respective Claims of the Creditors in respect of the
Collateral constitute only one secured claim (rather than separate classes of senior and junior secured claims), then each Creditor hereby acknowledges and agrees (x) that all distributions shall be made as if there were separate classes of
senior and junior secured claims against the Obligors in respect of the Collateral, and (y) to turn over to the other Creditor amounts otherwise received or receivable by it in the manner described in Section 3(b) to the extent
necessary to effectuate the intent of this sentence. 
 (h) Waiver. Each Creditor waives any claim it may hereafter
have against the other Creditor arising out of the election by such other Creditor of the application to the claims of such other Creditor of Section 1111(b)(2) of the Bankruptcy Code or other similar Bankruptcy Law, and/or out of any Cash
Collateral or Post-Petition Financing arrangement or out of any grant of a lien in connection with the Collateral in any Insolvency Proceeding. 

6. Notice of Default. Each Creditor shall give to the other prompt written notice of the occurrence of any default or event of default
(which has not been promptly waived or cured) under any of its Credit Documents of which it has knowledge (and any subsequent cure or 

  
 Exhibit I-9 

 
waiver thereof) and shall, simultaneously with giving any notice of default or acceleration to Borrower, provide to the other Creditor a copy of such notice of default. [A/R Lender] acknowledges
and agrees that any event of default under the A/R Facility Documents shall be deemed to be an event of default under the CRG Documents. For the avoidance of doubt, nothing in this Section 6 shall obligate either Creditor to provide any
notice in violation of any stay imposed in connection with any Insolvency Proceeding, including without limitation the automatic stay in Section 362(a) of the Bankruptcy Code or other similar Bankruptcy Law, nor shall either Creditor have any
liability to the other arising from or in connection with such Creditor’s failure to take such action. 
 7. Release of Liens.
In the event of any private or public sale or other disposition, by or with the consent of any Creditor (for purposes of this Section 7, the “Senior Creditor”), of all or any portion of such Creditor’s Senior
Collateral, the other Creditor (for purposes of this Section 7, the “Junior Creditor”) agrees that such sale or disposition shall be free and clear of such Junior Creditor’s liens, provided that such sale or
disposition is made in accordance with the UCC, PPSA or applicable provisions of any Bankruptcy Law, including without limitation Sections 363(f) or 1141(c) of the Bankruptcy Code. The Junior Creditor agrees that, in connection with any such sale or
other disposition, (i) the Senior Creditor is authorized to file any and all UCC, PPSA and other applicable lien releases and/or terminations in respect of the liens held by the Junior Creditor in connection with such a sale or other
disposition, and (ii) it shall execute any and all lien releases or other documents reasonably requested by the Senior Creditor in connection therewith. 

8. Attorney-In-Fact. Until the CRG Claims have been fully paid in cash and CRG’s arrangements to lend any funds to the Obligors
have been terminated, [A/R Lender] irrevocably appoints CRG as [A/R Lender]’s attorney-in-fact, and grants to CRG a power of attorney with full power of substitution (which power of attorney is coupled with an interest), in the name of [A/R
Lender] or in the name of CRG, for the use and benefit of CRG, without notice to [A/R Lender], to perform at CRG’s option the following acts in any bankruptcy, insolvency or similar proceeding involving Borrower: 

(a) To file the appropriate claim or claims in respect of the [A/R Lender] Claims on behalf of [A/R Lender] if [A/R Lender]
does not do so prior to 30 days before the expiration of the time to file claims in such proceeding and if CRG elects, in its sole discretion, to file such claim or claims; and 

(b) To accept or reject any plan of reorganization or arrangement on behalf of [A/R Lender] and to otherwise vote [A/R
Lender]’s claims in respect of any [A/R Lender] Claim in any manner that CRG deems appropriate for the enforcement of its rights hereunder. 

9. Agent for Perfection. (a) [A/R Lender] acknowledges that applicable provisions of the UCC or PPSA may require, in order
to properly perfect CRG’s security interest in the Common Collateral securing the CRG Claims, that CRG possess certain of such Common Collateral, and may require the execution of control agreements in favor of CRG concerning such Common
Collateral. In order to help ensure that CRG’s security interest in such Common Collateral is properly perfected (but subject to and without waiving the other provisions of this Agreement), [A/R Lender] agrees to hold both for itself and,
solely for the purposes of perfection and without 

  
 Exhibit I-10 

 
incurring any duties or obligations to CRG as a result thereof or with respect thereto, for the benefit of CRG, any such Common Collateral, and agrees that CRG’s lien in such Common
Collateral shall be deemed perfected in accordance with applicable law. 
 (b) CRG acknowledges that applicable provisions
of the UCC or PPSA may require, in order to properly perfect [A/R Lender]’s security interest in the Common Collateral securing the [A/R Lender] Claims, that [A/R Lender] possess certain of such Common Collateral, and may require the execution
of control agreements in favor of [A/R Lender] concerning such Common Collateral. In order to help ensure that [A/R Lender]’s security interest in such Common Collateral is properly perfected (but subject to and without waiving the other
provisions of this Agreement), CRG agrees to hold both for itself and, solely for the purposes of perfection and without incurring any additional duties or obligations to [A/R Lender] as a result thereof or with respect thereto, for the benefit of
[A/R Lender], any such Common Collateral, and agrees that [A/R Lender]’s lien in such Common Collateral shall be deemed perfected in accordance with applicable law. 

10. Credit Documents. (a) Each Creditor represents and warrants that it has provided to the other true, correct and complete
copies of all Credit Documents which relate to its credit agreement. 
 (b) At any time and from time to time, without
notice to the other Creditor, each Creditor may take such actions with respect to its Claims as such Creditor, in its sole discretion, may deem appropriate, including, without limitation, terminating advances under its Credit Documents, increasing
the principal amount, extending the time of payment, increasing applicable interest to the default rate, renewing, compromising or otherwise amending the terms of any documents affecting its Claims and any Collateral therefor, and enforcing or
failing to enforce any rights against Borrower or any other person, and no such action or inaction described in this sentence shall impair or otherwise affect such Creditor’s rights hereunder; provided, however, that (i) neither
Creditor shall take any action that is inconsistent with the provisions of this Agreement, and (ii) [A/R Lender] shall not increase the portion of [A/R Lender]’s Claim consisting of principal to an amount in excess of
$[                    ] without the prior written consent of CRG. Each Creditor waives the benefits, if any, of any statutory or common law rule that
may permit a subordinating creditor to assert any defenses of a surety or guarantor, or that may give the subordinating creditor the right to require a senior creditor to marshal assets, and each Creditor agrees that it shall not assert any such
defenses or rights. 
 (c) Each Creditor agrees that any other Creditor may release or refrain from enforcing its security
interest in the Collateral, or permit the use or consumption of such Collateral by any Obligor free of the other Creditor’s security interest, without incurring any liability to any other Creditor. 

11. Waiver of Right to Require Marshaling. Each Creditor hereby expressly waives any right that it otherwise might have to require any
other Creditor to marshal assets or to resort to Collateral in any particular order or manner, whether provided for by common law or statute. No Creditor shall be required to enforce any guaranty or any security interest or lien given by any person
or entity as a condition precedent or concurrent to the taking of any Enforcement Action with respect to the Collateral. 

  
 Exhibit I-11 

 12. Representations and Warranties. Each Creditor represents and warrants to the
other that: 
 (a) all action on the part of such Creditor, its officers, directors, partners, members and shareholders, as
applicable, necessary for the authorization of this Agreement and the performance of all obligations of such Creditor hereunder has been taken; 

(b) this Agreement constitutes the legal, valid and binding obligation of such Creditor, enforceable against such Creditor in
accordance with its terms; 
 (c) the execution, delivery and performance of and compliance with this Agreement by such
Creditor will not (i) result in any material violation or default of any term of any of such Creditor’s charter, formation or other organizational documents (such as Articles or Certificate of Incorporation, bylaws, partnership agreement,
operating agreement, etc.) or (ii) violate any material applicable law, rule or regulation. 
 13. Disgorgement. (a) If, at
any time after payment in full of the [A/R Lender] Claims any payments of the [A/R Lender] Claims must be disgorged by [A/R Lender] for any reason (including, without limitation, any Insolvency Proceeding), this Agreement and the relative rights and
priorities set forth herein shall be reinstated as to all such disgorged payments as though such payments had not been made and CRG shall immediately pay over to [A/R Lender] all money or funds received or retained by CRG with respect to the CRG
Claims to the extent that such receipt or retention would have been prohibited hereunder. 
 (b) If, at any time after
payment in full of the CRG Claims any payments of the CRG Claims must be disgorged by CRG for any reason (including, without limitation, any Insolvency Proceeding), this Agreement and the relative rights and priorities set forth herein shall be
reinstated as to all such disgorged payments as though such payments had not been made and [A/R Lender] shall immediately pay over to CRG all money or funds received or retained by [A/R Lender] with respect to the [A/R Lender] Claims to the extent
that such receipt or retention would have been prohibited hereunder. 
 14. Successors and Assigns. This Agreement shall bind any
successors or assignees of each Creditor. This Agreement shall remain effective until all Claims are indefeasibly paid or otherwise satisfied in full and Creditors have no commitment to extend credit under the Credit Documents. This Agreement is
solely for the benefit of the Creditors and not for the benefit of Borrower or any other party. Each Creditor shall not sell, assign, pledge, dispose of or otherwise transfer all or any portion of its Claims or any of its Credit Documents or any
interest in any Common Collateral unless, prior to the consummation of any such action, the transferee thereof shall execute and deliver to the other Creditor an agreement of such transferee to be bound hereby, or an agreement substantially
identical to this Agreement providing for the continued subjection of such Claims, the interests of the transferee in the Collateral and the remedies of the transferee with respect thereto as provided herein with respect to the transferring Creditor
and for the continued effectiveness of all of the other rights of the other Creditor arising under this Agreement, in each case in form satisfactory to the other Creditor. 

15. Further Assurances. Each Creditor hereby agrees to execute such documents and/or 

  
 Exhibit I-12 

 
take such further action as the other Creditor may at any time or times reasonably request in order to carry out the provisions and intent of this Agreement, including, without limitation,
ratifications and confirmations of this Agreement from time to time hereafter, as and when requested by the other Creditor. 
 16.
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. 

17. Governing Law; Waiver of Jury Trial. (a) This Agreement and the rights and obligations of the parties hereunder shall be
governed by, and construed in accordance with, the law of the State of New York without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction. 

(b) EACH CREDITOR WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS
AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREIN. 
 18. Entire Agreement. This Agreement represents the entire agreement
with respect to the subject matter hereof, and supersedes all prior negotiations, agreements and commitments. Each Creditor is not relying on any representations by the other Creditor, Borrower or any other Obligor in entering into this Agreement,
and each Creditor has kept and will continue to keep itself fully apprised of the financial and other condition of each Obligor. This Agreement may be amended only by written instrument signed by the Creditors. 

19. Relationship among Creditors. The relationship among the Creditors is, and at all times shall remain solely that of Creditors.
Creditors shall not under any circumstances be construed to be partners or joint venturers of one another; nor shall the Creditors under any circumstances be deemed to be in a relationship of confidence or trust or a fiduciary relationship with one
another, or to owe any fiduciary duty to one another. Creditors do not undertake or assume any responsibility or duty to one another to select, review, inspect, supervise, pass judgment upon or otherwise inform each other of any matter in connection
with any Obligor’s property, any Collateral held by any Creditor or the operations of any Obligor. Each Creditor shall rely entirely on its own judgment with respect to such matters, and any review, inspection, supervision, exercise of judgment
or supply of information undertaken or assumed by any Creditor in connection with such matters is solely for the protection of such Creditor. 

20. Severability. Any provision of this Agreement which is illegal, invalid, prohibited or unenforceable in any jurisdiction shall, as
to such jurisdiction, be ineffective to the extent such illegality, invalidity, prohibition or unenforceability without invalidating or impairing the remaining provisions hereof or affecting the validity or enforceability of such provision in any
other jurisdiction. 
 21. Notices. All notices, demands, instructions and other communications required or permitted to be given to
or made upon any party hereto shall be in writing and shall be delivered or sent by first-class mail, postage prepaid, or by overnight courier or messenger service or by facsimile, message confirmed, and shall be deemed to be effective for purposes
of this Agreement on the day that delivery is made or refused. Unless otherwise specified in a notice 

  
 Exhibit I-13 

 
mailed or delivered in accordance with the foregoing sentence, notices, demands, instructions and other communications in writing shall be given to or made upon the respective parties hereto at
their respective addresses and facsimile numbers indicated on the signature pages hereto. 
 [Signature pages follow.] 

  
 Exhibit I-14 

 IN WITNESS WHEREOF, the undersigned have executed this Intercreditor
Agreement as of the date first above written. 
  

			
	 [A/R Lender]:

	
	 [INSERT NAME OF A/R LENDER]

		
	 By
	 	
                  
   

	 Name:
	 	
[                    ]

	 Title:
	 	
[                    ]

	
	 Address for Notices:

	
	
[                    ]

	
[                    ]

	
[                    ]

	 Tel:
	 	
[                    ]

	 Email:
	 	
[                    ]

  
 Exhibit I-15 

									
	 LENDERS:

	
	 CRG PARTNERS III L.P., in its

capacity as a Lender and as Agent

		 	 By CRG PARTNERS III GP L.P., its General Partner

		 		 	 By CRG PARTNERS III GP LLC, its General Partner

				
		 		 	 By
	 	  

		 		 		 	 Name:
	 	 Nathan Hukill

		 		 		 	 Title:
	 	 Authorized Signatory

	
	 CRG PARTNERS III–PARALLEL FUND “A” L.P.,

		 	 By CRG PARTNERS III – PARALLEL FUND “A” GP L.P., its General Partner

		 		 	 By CRG PARTNERS III – PARALLEL FUND “A” GP LLC, its General Partner

				
		 		 	 By
	 	  

		 		 		 	 Name:
	 	 Nathan Hukill

		 		 		 	 Title:
	 	 Authorized Signatory

	
	 CRG PARTNERS III (CAYMAN) L.P.,

		 	 By CRG PARTNERS III (CAYMAN) GP L.P., its General Partner

		 		 	 By CRG PARTNERS III (CAYMAN) GP LLC, its General Partner

				
		 		 	 By
	 	  

		 		 		 	 Name:
	 	 Nathan Hukill

		 		 		 	 Title:
	 	 Authorized Signatory

									
	
	 Address for Notices:

	
	 1000 Main Street, Suite 2500

	 Houston, TX 77002

	 Attn:
	 	 General Counsel

	 Tel.:
	 	
	 Fax:
	 	
	 Email: 

  
 Exhibit I-16 

					
	 Acknowledged and Agreed to:

	
	 BORROWER:

	
	 GENOMEDX BIOSCIENCES INC.

		
	 By
	 	  

		 	 Name:
	 	 Dave Matthews

		 	 Title:
	 	 Chief Financial Officer

					
	
	 Address for Notices:

	
	 10355 Science Center Drive, Suite 240

	 San Diego, California 92121

	 Tel.:
	 	
	 Fax:
	 	
	 Email:
	 	

  
 Exhibit I-17 

 Execution Copy 

WAIVER AND AMENDMENT AGREEMENT 

THIS WAIVER AND AMENDMENT AGREEMENT (this “Agreement”), dated as of December 30, 2015, is made
among GENOMEDX BIOSCIENCES INC., a company incorporated in British Columbia, Canada (“Borrower”), the guarantors listed on the signature pages hereof under the heading “SUBSIDIARY GUARANTORS”, CRG PARTNERS III,
L.P., as Agent, and the financial institutions listed on the signature pages hereof under the heading “LENDERS” (each a “Lender” and, collectively, the “Lenders”). 

RECITALS 

WHEREAS, Borrower, the Agent and the Lenders are parties to a Term Loan Agreement dated as of September 23, 2015 (the
“Term Loan Agreement”). 
 WHEREAS, Borrower has failed to deliver to the Lenders (a) pursuant
to Section 8.16(c) of the Term Loan Agreement, a fully executed control agreement required to perfect the security interest created in the HSBC Accounts (the “HSBC Control Agreement”) not later than
30 days after the Closing Date, and (ii) pursuant to Section 8.16(e) of the Term Loan Agreement, evidence that GenomeDx Corp. is in good standing and qualified to transact business in the State of California (the
“Good Standing Certificate”) not later than 15 days after the Closing Date. 
 WHEREAS, the failure
to so deliver each of the HSBC Control Agreement and the Good Standing Certificate in each case constitutes an Event of Default under Section 11.01(d) of the Term Loan Agreement (collectively, the “Existing
Defaults”). 
 WHEREAS, Borrower has requested that the Lenders (i) provide a waiver of each Event of
Default caused by Borrower’s breach of Sections 8.16(c) and (e) of the Term Loan Agreement due to its failure to deliver to the Lenders each of the HSBC Control Agreement and the Good Standing Certificate as required by such
sections, and (ii) amend the Term Loan Agreement to extend the deadlines by which Borrower shall be required to deliver the HSBC Control Agreement and the Good Standing Certificate. 

WHEREAS, the Lenders have agreed to such requests, subject to the terms and conditions hereof. 

NOW THEREFORE, accordingly, the parties hereto agree as follows: 

SECTION 1. Definitions; Interpretation. 

(a) Terms Defined in Term Loan Agreement. All capitalized terms used in this Agreement (including in the recitals
hereof) and not otherwise defined herein shall have the meanings assigned to them in the Term Loan Agreement. 
 (b)
Interpretation. The rules of interpretation set forth in Section 1.03 of the Term Loan Agreement shall be applicable to this Agreement and are incorporated herein by this reference. 

  
 1. 

 SECTION 2. Waiver. Subject to Section 5 hereafter, and with
respect only to the Existing Defaults, the Lenders hereby agree to waive the Existing Defaults (the “Waived Defaults”) caused by Borrower’s failure to deliver the HSBC Control Agreement and the Good Standing Certificate
by the deadlines as specified in Sections 8.16(c) and (e) of the Term Loan Agreement prior to giving effect to this Agreement. 

SECTION 3. Limitations of Waiver. The waiver set forth in Section 2 above shall be limited precisely as
written and relates solely to the breach by Borrower of Sections 8.16(c) and (e) of the Term Loan Agreement by failing to deliver the HSBC Control Agreement and the Good Standing Certificate by the deadlines as specified in such
Sections 8.16(c) and (e) of the Term Loan Agreement prior to giving effect to this Agreement. Nothing in this Agreement shall be deemed to constitute a waiver of noncompliance or breach of any other term or provision in the Term
Loan Agreement or the other Loan Documents, nor prejudice any right or remedy that the Lenders may now have (except to the extent such right or remedy was based upon Defaults that will not exist after giving effect to this Agreement) or may have in
the future under or in connection with the Term Loan Agreement or the other Loan Documents. Nothing contained herein shall be deemed a waiver or consent in respect of (or otherwise affect the Lenders’ ability to enforce) any Default not
explicitly waived by Section 2 including (a) any Default that may now exist or hereafter arise from or otherwise be related to the Waived Defaults, and (b) any Default arising at any time after the Effective Date
and which is similar in type to the Waived Defaults. 
 SECTION 4. Amendments. Subject to Section 5
hereafter, the Term Loan Agreement is hereby amended as follows: 
 (a) Section 8.16(c) of the Term
Loan Agreement is hereby amended by replacing the phrase “30 days” with the phrase “January 31, 2016”. 

(b) Section 8.16(e) of the Term Loan Agreement is hereby amended as follows: 

(i) The phrase “15 days” is hereby replaced with the phrase “180 days”. 

(ii) The period at the end of the section is hereby deleted and replaced with the following: 

“; provided, however, that if Borrower fails to deliver to the Lenders such evidence prior to the occurrence of a
Material Adverse Change or any Event of Default, then such failure shall be immediately deemed to be an “Event of Default” under Section 11.01”. 

SECTION 5. Conditions of Effectiveness. The effectiveness of Sections 2 and 4 of this Agreement shall be subject to the
satisfaction of each of the following conditions precedent (the date of such satisfaction, the “Effective Date”): 

(a) Fees and Expenses. Borrower shall have paid all fees and all invoiced costs and expenses then due in accordance with
Section 7(c). 
 (b) Documents. The Agent and the Lenders shall have received, in form and
substance satisfactory to it a counterpart of this Agreement executed by Borrower, each Subsidiary Guarantor, the Agent, and the Lenders. 

  
 2. 

 (c) No Default or Event of Default has occurred or is continuing or
will result after giving effect to this Agreement. 
 (d) There has been no Material Adverse Effect since
December 31, 2014. 
 (e) Representations and Warranties. Each of the representations and warranties made by
Borrower contained in Section 6 of this Agreement, other than those expressly made as of a specific date, shall be true and correct in all material respects on and as of the Effective Date (other than those representations and warranties
already qualified as to materiality, which shall be true and correct in all respects). 
 SECTION 6. Representations and Warranties.
Borrower represents and warrants to the Agent and the Lenders as follows: 
 (a) Borrower has disclosed to the
Agent and the Lenders all material information relating to each of its obligations set forth in Sections 8.16(c) and (e), and its efforts to comply with each such obligation. 

(b) None of the information furnished by Borrower to the Agent or any Lender in connection with the negotiation of this
Agreement contains any material misstatement of fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. 

(c) Borrower and each Subsidiary Guarantor has full power, authority and legal right to make and perform this Agreement.
This Agreement is within Borrower’s and each Subsidiary Guarantor’s corporate powers and has been duly authorized by all necessary corporate and, if required, by all necessary shareholder action. This Agreement has been duly executed and
delivered by Borrower and each Subsidiary Guarantor, and constitutes a legal, valid and binding obligation of Borrower and each such Subsidiary Guarantor, enforceable against Borrower in accordance with its terms, except as such enforceability may
be limited by (i) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability affecting the enforcement of creditors’ rights and (ii) the application of general principles of equity (regardless of
whether such enforceability is considered in a proceeding in equity or at law). 
 (d) Borrower and each Subsidiary
Guarantor hereby ratifies, confirms, reaffirms, and acknowledges its obligations under the Loan Documents to which it is a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Agreement, except as expressly
provided herein. By executing this Agreement, Borrower and each Subsidiary Guarantor acknowledges that it has read, consulted with its attorneys regarding, and understands, this Agreement. 

SECTION 7. Miscellaneous. 

(a) Term Loan Agreement Otherwise Not Affected; No Waiver. Except as expressly contemplated hereby, the Term Loan
Agreement shall remain unchanged and in full force and effect and is hereby ratified and confirmed in all respects. The Agent’s and the Lenders’ execution and delivery of, or acceptance of, this Agreement and any other documents and
instruments in connection herewith (collectively, the “Waiver and Amendment Documents”) shall 

  
 3. 

 
not be deemed to create a course of dealing or otherwise create any express or implied duty by any of them to provide any other or further amendments, consents or waivers in the future. 

(b) No Reliance. Borrower and each Subsidiary Guarantor hereby acknowledges and confirms to the Agent and the Lenders
that it is executing this Agreement and the other Waiver and Amendment Documents on the basis of its own investigation and for its own reasons without reliance upon any agreement, representation, understanding or communication by or on behalf of any
other Person. 
 (c) Costs and Expenses. Borrower agrees to pay to the Agent and the Lenders on demand all out-of-pocket expenses incurred by the Agent, the Lenders and their respective Affiliates (including the fees, charges and disbursements of counsel for the Lenders), in
connection with the preparation, negotiation, execution and delivery of this Agreement and any other documents to be delivered in connection herewith. 

(d) Binding Effect. This Agreement shall be binding upon, inure to the benefit of and be enforceable by Borrower, each
Subsidiary Guarantor, the Agent, each Lender and their respective successors and assigns. 
 (e) Governing Law. This
Agreement and the other Waiver and Amendment Documents and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement or any other Waiver and Amendment
Document (except, as to any other Waiver and Amendment Document, as expressly set forth therein) and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the law of the State of New York. 

(f) Complete Agreement; Amendments. This Agreement, together with the other Waiver and Amendment Documents and the other
Loan Documents, contains the entire and exclusive agreement of the parties hereto and thereto with reference to the matters discussed herein and therein. This Agreement supersedes all prior commitments, drafts, communications, discussions and
understandings, oral or written, with respect thereto. This Agreement may not be modified, amended or otherwise altered except in accordance with the terms of Section 12.04 of the Term Loan Agreement. 

(g) Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be
effective and valid under all applicable laws and regulations. If, however, any provision of this Agreement shall be prohibited by or invalid under any such law or regulation in any jurisdiction, it shall, as to such jurisdiction, be deemed modified
to conform to the minimum requirements of such law or regulation, or, if for any reason it is not deemed so modified, it shall be ineffective and invalid only to the extent of such prohibition or invalidity without affecting the remaining provisions
of this Agreement, or the validity or effectiveness of such provision in any other jurisdiction. 
 (h) Counterparts.
This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute but one and the
same agreement. Delivery of an executed counterpart of a signature page of this Agreement by facsimile 

  
 4. 

 
or in electronic (i.e., “pdf” or “tif”) format shall be effective as delivery of a manually executed counterpart of this Agreement. 

(i) Interpretation. This Agreement and the other Waiver and Amendment Documents are the result of negotiations between
and have been reviewed by counsel to the Agent, the Lenders, Borrower, the Subsidiary Guarantors and other parties, and are the product of all parties hereto. Accordingly, this Agreement and the other Waiver and Amendment Documents shall not be
construed against any of the Agent or the Lenders merely because of its involvement in the preparation thereof. 
 (j)
Loan Documents. This Agreement and the other Waiver and Amendment Documents shall constitute Loan Documents. 
 (k)
Controlling Provisions. In the event of any inconsistencies between the provisions of this Agreement and the provisions of any other Loan Document, the provisions of this Agreement shall govern and prevail. Except as expressly modified by this
Agreement, the Loan Documents shall not be modified and shall remain in full force and effect. 
 [Remainder of page intentionally left
blank] 

  
 5. 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as
of the date first above written. 
  

			
	 BORROWER

	
	 GENOMEDX BIOSCIENCES INC.

		
	 By:
	 	 /s/ Bill Kachioff

		 	 Name: Bill Kachioff

		 	 Title: Chief Financial Officer

	
	 SUBSIDIARY GUARANTOR

	
	 GENOMEDX BIOSCIENCES CORP.

		
	 By:
	 	 /s/ Bill Kachioff

		 	 Name: Bill Kachioff

		 	 Title: Chief Financial Officer

 [Signature page 1 to Waiver and Amendment] 

			
	 THE LENDERS

	
	 CRG PARTNERS III L.P., in its

capacity as a Lender and as Agent

	 By CRG PARTNERS III GP L.P., its General Partner

	 By CRG PARTNERS III GP LLC, its General Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

  

					
	 CRG PARTNERS III–PARALLEL FUND “A” L.P.,

	 By CRG PARTNERS III – PARALLEL FUND “A” GP L.P., its General
Partner

	 By CRG PARTNERS III – PARALLEL FUND “A” GP LLC, its General
Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

			
		 	 Witness:
	 	 /s/ Nicole Nesson

		
		 	 Name: Nicole Nesson

 [Signature page 2 to Waiver and Amendment] 

 Execution Copy 

AMENDMENT AGREEMENT NO. 2 

THIS AMENDMENT AGREEMENT NO. 2 (this “Amendment”), dated as of December 30, 2015, is made among
GenomeDx Biosciences Inc., a company incorporated in British Columbia, Canada (the “Borrower”), the Subsidiary Guarantor listed on the signature pages hereof under the heading “SUBSIDIARY GUARANTOR” (the
“Subsidiary Guarantor”, and together with the Borrower, each an “Obligor” and, collectively, the “Obligors”), the Lenders listed on the signature pages hereof under the heading
“LENDERS” (each a “Lender” and, collectively, the “Lenders”) and CRG PARTNERS III L.P., as administrative and collateral agent for the Lenders hereunder (in such capacity, the
“Agent”). 
 The Obligors and the Lenders are parties to that certain Term Loan Agreement, dated as
of September 23, 2015, as amended by that certain Waiver and Amendment Agreement, dated as of the date hereof (as further amended, amended and restated, modified or supplemented from time to time, the “Loan Agreement”).

 The parties hereto desire to amend the Loan Agreement on the terms and subject to the conditions set forth herein. 

Accordingly, the parties hereto agree as follows: 

SECTION 1. Definitions; Interpretation. 

(a) Terms Defined in Loan Agreement. All capitalized terms used in this Amendment (including in the recitals hereof) and
not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement. 
 (b) Interpretation.
The rules of interpretation set forth in Section 1.03 of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference. 

SECTION 2. Amendments. 

Subject to Section 3, the Loan Agreement is hereby amended as follows: 

(a) Section 10.02(a) of the Loan Agreement is hereby amended and restated in its entirety to read as
follows: 
 “(a) during the twelve month period beginning on January 1, 2015, of at least $7,000,000;” 

(b) Annex B of Exhibit E of the Loan Agreement is hereby replaced in its entirety by Annex B to Compliance
Certificate attached hereto. 
 SECTION 3. Conditions of Effectiveness. 

The effectiveness of Section 2 shall be subject to the following conditions precedent: 

  
 1 

 (a) The Obligors, all of the Lenders and the Agent shall have duly
executed and delivered this Amendment pursuant to Section 12.04 of the Loan Agreement. 
 (b)
The Obligors shall have paid or reimbursed Lenders for Lenders’ reasonable out of pocket costs and expenses incurred in connection with this Amendment, including Lenders’ reasonable out of pocket legal fees and costs, pursuant to
Section 12.03(a)(i)(z) of the Loan Agreement. 
 (c) The representations and warranties in
Section 4 shall be true and correct on the date hereof and on the first date on which the conditions set forth in Sections 3(a) and (b) shall have been satisfied. 

SECTION 4. Representations and Warranties; Reaffirmation. 

(a) Each Obligor hereby represents and warrants to each Lender as follows: 

(i) Such Obligor has full power, authority and legal right to make and perform this Amendment. This Amendment is within
such Obligor’s corporate powers and has been duly authorized by all necessary corporate and, if required, by all necessary shareholder action. This Amendment has been duly executed and delivered by such Obligor and constitutes legal, valid and
binding obligations of such Obligor, enforceable against such Obligor in accordance with its terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability
affecting the enforcement of creditors’ rights and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). This Amendment (x) does not require
any consent or approval of, registration or filing with, or any other action by, any Governmental Authority or any third party, except for such as have been obtained or made and are in full force and effect, (y) will not violate any applicable
law or regulation or the charter, bylaws or other organizational documents of such Obligor and its Subsidiaries or any order of any Governmental Authority, other than any such violations that, individually or in the aggregate, could not reasonably
be expected to have a Material Adverse Effect, (z) will not violate or result in an event of default under any material indenture, agreement or other instrument binding upon such Obligor and its Subsidiaries or assets, or give rise to a right
thereunder to require any payment to be made by any such Person. 
 (ii) No Default has occurred or is continuing or
will result after giving effect to this Amendment. 
 (iii) The representations and warranties made by or with respect
to such Obligor in Section 7 of the Loan Agreement are true in all material respects (taking into account any changes made to schedules updated in accordance with Section 7.20 of the Loan
Agreement), except that such representations and warranties that refer to a specific earlier date were true in all material respects on such earlier date. 

(iv) There has been no Material Adverse Effect since the date of the Loan Agreement. 

(b) Each Obligor hereby ratifies, confirms, reaffirms, and acknowledges its obligations under the Loan Documents to
which it is a party and agrees that the Loan Documents remain in 

  
 2. 

 
full force and effect, undiminished by this Amendment, except as expressly provided herein. By executing this Amendment, each Obligor acknowledges that it has read, consulted with its attorneys
regarding, and understands, this Amendment. 
 SECTION 5. Governing Law; Submission To Jurisdiction; Waiver Of Jury Trial. 

(a) Governing Law. This Amendment and the rights and obligations of the parties hereunder shall be governed by, and
construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that
Section 5-1401 of the New York General Obligations Law shall apply. 
 (b)
Submission to Jurisdiction. Each Obligor agrees that any suit, action or proceeding with respect to this Amendment or any other Loan Document to which it is a party or any judgment entered by any court in respect thereof may be brought initially
in the federal or state courts in Houston, Texas or in the courts of its own corporate domicile and irrevocably submits to the non-exclusive jurisdiction of each such court for the purpose of any such suit,
action, proceeding or judgment. This Section 5 is for the benefit of the Lenders only and, as a result, no Lender shall be prevented from taking proceedings in any other courts with jurisdiction. To the extent allowed by
applicable Laws, the Lenders may take concurrent proceedings in any number of jurisdictions. 
 (c) Waiver of Jury
Trial. Each Obligor and each Lender hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any suit, action or proceeding arising out of or relating to this Amendment, the other Loan
Documents or the transactions contemplated hereby or thereby. 
 SECTION 6. Miscellaneous. 

(a) No Waiver. Nothing contained herein shall be deemed to constitute a waiver of compliance with any term or condition
contained in the Loan Agreement or any of the other Loan Documents or constitute a course of conduct or dealing among the parties. Except as expressly stated herein, the Lenders reserve all rights, privileges and remedies under the Loan Documents.
Except as amended hereby, the Loan Agreement and other Loan Documents remain unmodified and in full force and effect. All references in the Loan Documents to the Loan Agreement shall be deemed to be references to the Loan Agreement as amended
hereby. 
 (b) Severability. In case any provision of or obligation under this Amendment shall be invalid, illegal or
unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby. 

(c) Headings. Headings and captions used in this Amendment (including the Exhibits, Schedules and Annexes hereto, if
any) are included for convenience of reference only and shall not be given any substantive effect. 
 (d) Integration.
This Amendment constitutes a Loan Document and, together with the other Loan Documents, incorporates all negotiations of the parties hereto with respect to the 

  
 3. 

 
subject matter hereof and is the final expression and agreement of the parties hereto with respect to the subject matter hereof. 

(e) Counterparts. This Amendment may be executed in any number of counterparts, all of which taken together shall
constitute one and the same instrument and any of the parties hereto may execute this Amendment by signing any such counterpart. 

(f) Controlling Provisions. In the event of any inconsistencies between the provisions of this Amendment and the
provisions of any other Loan Document, the provisions of this Amendment shall govern and prevail. Except as expressly modified by this Amendment, the Loan Documents shall not be modified and shall remain in full force and effect. 

[Remainder of page intentionally left blank] 

  
 4. 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as
of the date first above written. 
  

			
	 BORROWER

	
	 GENOMEDX BIOSCIENCES INC.

		
	 By:
	 	 /s/ Bill Kachioff

		 	 Name: Bill Kachioff

		 	 Title: Chief Financial Officer

	
	 Address for Notices:

	
	 10355 Science Center Drive

	 San Diego, CA 92121

	
	 Tel: 

	 Toll Free: 

	 Email: 

	
	 SUBSIDIARY GUARANTOR

	
	 GENOMEDX BIOSCIENCES CORP.

		
	 By:
	 	 /s/ Bill Kachioff

		 	 Name: Bill Kachioff

		 	 Title: Chief Financial Officer

	
	 Address for Notices:

	
	 10355 Science Center Drive

	 San Diego, CA 92121

	
	 Tel: 

	 Toll Free: 

	 Email: 

  
 S-1 

 LENDERS 

CRG PARTNERS III L.P., in its 

capacity as a Lender and as Agent 

By CRG PARTNERS III GP L.P., its General Partner 

By CRG PARTNERS III GP LLC, its General Partner 
  

			
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

 CRG PARTNERS III–PARALLEL FUND “A” L.P., 

By CRG PARTNERS III – PARALLEL FUND 

  “A” GP L.P., its General Partner 

By CRG PARTNERS III – PARALLEL 

FUND “A” GP LLC, its General Partner 
  

			
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

 CRG PARTNERS III (CAYMAN) L.P., 

By CRG PARTNERS III (CAYMAN) GP L.P., 

its General Partner 

By CRG PARTNERS III (CAYMAN) GP LLC, 

its General Partner 
  

			
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

		
		 	 Witness: /s/ Nicole
Nesson                               

		
		 	 Name: Nicole Nesson

 Address for Notices: 

1000 Main Street, Suite 2500 

Houston, TX 77002 
 Attn: General
Counsel 
 Tel.: 
 Fax: 

Email: 
 [Signature Page
2 to Amendment Agreement] 

 Annex B to Compliance Certificate 

CALCULATIONS OF FINANCIAL COVENANT COMPLIANCE 
  

					
	 I.
	  	 Section 10.01: Minimum Liquidity
	  	
			
	 I.
	  	 Amount of unencumbered cash and Permitted Cash Equivalent Investments (which for greater certainty shall not include any
undrawn credit lines), in each case, to the extent held in an account over which the Lenders have a first priority perfected security interest:
	  	 $___________

			
	     A.
	  	 The greater of:
	  	 $___________

			
		  	 (a)   $2,000,000 and
	  	
			
		  	 (b)   to the extent Borrower has incurred Permitted Priority
Debt, the minimum cash balance required of Borrower by Borrower’s Permitted Priority Debt creditors
	  	
			
		  	 Is Line IA equal to or greater than Line IB?:
	  	 Yes: In compliance; No: Not in compliance

			
	 II.
	  	 Section 10.02(a)-(c): Minimum Revenue¬ Subsequent Periods
	  	
			
	     A.
	  	 Revenues during the twelve month period beginning on January 1, 2015
	  	 $___________

			
		  	 [Is line II.A equal to or greater than $7,000,000?
	  	 Yes: In compliance;

No: Not in compliance]1

			
	     B.
	  	 Revenues during the twelve month period beginning on January 1, 2016
	  	 $___________

			
		  	 [Is line II.B equal to or greater than $20,000,000?
	  	 Yes: In compliance;

No: Not in compliance]2

			
	     C.
	  	 Revenues during the twelve month period beginning on January 1, 2017
	  	 $___________

			
		  	 [Is line II.C equal to or greater than $30,000,000?
	  	 Yes: In compliance;

No: Not in
compliance]3

  

	 1 
	 Include bracketed entry only on the Compliance Certificate to be delivered within 180 days of the end of
2015 pursuant to Section 8.01(b) of the Loan Agreement. 

	 2 
	 Include bracketed entry only on the Compliance Certificate to be delivered within 180 days of the end of
2016 pursuant to Section 8.01(b) of the Loan Agreement. 

	 3 
	 Include bracketed entry only on the Compliance Certificate to be delivered within 180 days of the end of
2017 pursuant to Section 8.01(b) of the Loan Agreement. 

  
 Annex B—Page 1 

					
	     D.
	  	 Revenues during the twelve month period beginning on January 1, 2018
	  	 $___________

			
		  	 [Is line II.D equal to or greater than $30,000,000?
	  	 Yes: In compliance;

No: Not in compliance]4

			
	     E.
	  	 Revenues during the twelve month period beginning on January 1, 2019
	  	 $___________

			
		  	 [IS LINE II.E EQUAL TO OR GREATER THAN $30,000,000?
	  	 Yes: in compliance;

No: not in compliance]5

			
	     F.
	  	 Revenues during the twelve month period beginning on January 1, 2020
	  	 $___________

			
		  	 [Is line II.F equal to or greater than $30,000,000?
	  	 Yes: In compliance;

No: Not in compliance]6

  

	 4 
	 Include bracketed entry only on the Compliance Certificate to be delivered within 180 days of the end of
2018 pursuant to Section 8.01(b) of the Loan Agreement. 

	 5 
	 Include bracketed entry only on the Compliance Certificate to be delivered within 180 days of the end of
2019 pursuant to Section 8.01(b) of the Loan Agreement. 

	 6 
	 Include bracketed entry only on the Compliance Certificate to be delivered within 180 days of the end of
2020 pursuant to Section 8.01(b) of the Loan Agreement. 

  
 Annex B—Page 2 

 Execution Version 

WAIVER AND AMENDMENT AGREEMENT NO. 3 

THIS WAIVER AND AMENDMENT AGREEMENT NO. 3 (this “Agreement”), dated as of April 21, 2016, is made
among GENOMEDX BIOSCIENCES INC., a company incorporated in British Columbia, Canada (“Borrower”), the guarantors listed on the signature pages hereof under the heading “SUBSIDIARY GUARANTORS”, CRG SERVICING LLC, as
Agent, and the financial institutions listed on the signature pages hereof under the heading “LENDERS” (each a “Lender” and, collectively, the “Lenders”). 

RECITALS 

WHEREAS, Borrower, the Agent and the Lenders are parties to a Term Loan Agreement dated as of September 23, 2015 as
amended by that Waiver and Amendment Agreement, dated as of December 30, 2015 and by that Amendment Agreement No. 2, dated as of December 30, 2015 (as further amended, amended and restated, modified or supplemented from time to time,
the “Term Loan Agreement”). 
 WHEREAS, Borrower has failed to deliver to the Lenders pursuant to
Section 8.16(e) of the Term Loan Agreement, evidence that GenomeDx Corp. is in good standing and qualified to transact business in the State of California (the “Good Standing Certificate”) not later than 180 days after
the Closing Date. 
 WHEREAS, the failure to so deliver the Good Standing Certificate constitutes an Event of Default under
Section 11.01(d) of the Term Loan Agreement (the “Existing Default”). 

WHEREAS, Borrower has requested that the Lenders (i) provide a waiver of the Event of Default caused by Borrower’s
breach of Section 8.16(e) of the Term Loan Agreement due to its failure to deliver to the Lenders the Good Standing Certificate as required by such section, and (ii) amend the Term Loan Agreement to extend the deadline
by which Borrower shall be required to deliver the Good Standing Certificate. 
 WHEREAS, the Lenders have agreed to such
requests, subject to the terms and conditions hereof. 
 NOW THEREFORE, accordingly, the parties hereto agree as follows:

 SECTION 1. Definitions; Interpretation. 

(a) Terms Defined in Term Loan Agreement. All capitalized terms used in this Agreement (including in the recitals
hereof) and not otherwise defined herein shall have the meanings assigned to them in the Term Loan Agreement. 
 (b)
Interpretation. The rules of interpretation set forth in Section 1.03 of the Term Loan Agreement shall be applicable to this Agreement and are incorporated herein by this reference. 

  
 1 

 SECTION 2. Waiver. Subject to Section 5 hereafter, and with
respect only to the Existing Default, the Lenders hereby agree to waive the Existing Default (the “Waived Default”) caused by Borrower’s failure to deliver the Good Standing Certificate by the deadline as specified in
Section 8.16(e) of the Term Loan Agreement prior to giving effect to this Agreement. 
 SECTION 3. Limitations
of Waiver. The waiver set forth in Section 2 above shall be limited precisely as written and relates solely to the breach by Borrower of Section 8.16(e) of the Term Loan Agreement by failing to
deliver the Good Standing Certificate by the deadline as specified in such Sections 8.16(e) of the Term Loan Agreement prior to giving effect to this Agreement. Nothing in this Agreement shall be deemed to constitute a waiver of noncompliance
or breach of any other term or provision in the Term Loan Agreement or the other Loan Documents, nor prejudice any right or remedy that the Lenders may now have (except to the extent such right or remedy was based upon Defaults that will not exist
after giving effect to this Agreement) or may have in the future under or in connection with the Term Loan Agreement or the other Loan Documents. Nothing contained herein shall be deemed a waiver or consent in respect of (or otherwise affect the
Lenders’ ability to enforce) any Default not explicitly waived by Section 2 including (a) any Default that may now exist or hereafter arise from or otherwise be related to the Waived Default, and (b) any
Default arising at any time after the Effective Date and which is similar in type to the Waived Default. 
 SECTION 4. Amendments.
Subject to Section 5 hereafter, the Term Loan Agreement is hereby amended as follows: 
 (a)
Section 8.16(e) of the Term Loan Agreement is hereby amended by replacing the phrase “180 days after the date hereof” with the phrase “June 30, 2016”. 

SECTION 5. Conditions of Effectiveness. The effectiveness of Sections 2 and 4 of this Agreement shall be subject to the
satisfaction of each of the following conditions precedent (the date of such satisfaction, the “Effective Date”): 

(a) Fees and Expenses. Borrower shall have paid all fees and all invoiced costs and expenses then due in accordance with
Section 7(c). 
 (b) Documents. The Agent and the Lenders shall have received, in form and
substance satisfactory to it a counterpart of this Agreement executed by Borrower, each Subsidiary Guarantor, the Agent, and the Lenders. 

(c) No Default or Event of Default has occurred or is continuing or will result after giving effect to this Agreement.

 (d) There has been no Material Adverse Effect since December 31, 2014. 

(e) Representations and Warranties. Each of the representations and warranties made by Borrower contained in
Section 6 of this Agreement, other than those expressly made as of a specific date, shall be true and correct in all material respects on and as of the Effective Date (other than those representations and warranties already
qualified as to materiality, which shall be true and correct in all respects). 

  
 2 

 SECTION 6. Representations and Warranties. Borrower represents and warrants to the
Agent and the Lenders as follows: 
 (a) Borrower has disclosed to the Agent and the Lenders all material information
relating to its obligation set forth in Section 8.16(e), and its efforts to comply with such obligation. 

(b) None of the information furnished by Borrower to the Agent or any Lender in connection with the negotiation of this
Agreement contains any material misstatement of fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. 

(c) Borrower and each Subsidiary Guarantor has full power, authority and legal right to make and perform this Agreement.
This Agreement is within Borrower’s and each Subsidiary Guarantor’s corporate powers and has been duly authorized by all necessary corporate and, if required, by all necessary shareholder action. This Agreement has been duly executed and
delivered by Borrower and each Subsidiary Guarantor, and constitutes a legal, valid and binding obligation of Borrower and each such Subsidiary Guarantor, enforceable against Borrower in accordance with its terms, except as such enforceability may
be limited by (i) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability affecting the enforcement of creditors’ rights and (ii) the application of general principles of equity (regardless of
whether such enforceability is considered in a proceeding in equity or at law). 
 (d) Borrower and each Subsidiary
Guarantor hereby ratifies, confirms, reaffirms, and acknowledges its obligations under the Loan Documents to which it is a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Agreement, except as expressly
provided herein. By executing this Agreement, Borrower and each Subsidiary Guarantor acknowledges that it has read, consulted with its attorneys regarding, and understands, this Agreement. 

SECTION 7. Miscellaneous. 

(a) Term Loan Agreement Otherwise Not Affected; No Waiver. Except as expressly contemplated hereby, the Term Loan
Agreement shall remain unchanged and in full force and effect and is hereby ratified and confirmed in all respects. The Agent’s and the Lenders’ execution and delivery of, or acceptance of, this Agreement and any other documents and
instruments in connection herewith (collectively, the “Waiver and Amendment Documents”) shall not be deemed to create a course of dealing or otherwise create any express or implied duty by any of them to provide any other or
further amendments, consents or waivers in the future. 
 (b) No Reliance. Borrower and each Subsidiary Guarantor
hereby acknowledges and confirms to the Agent and the Lenders that it is executing this Agreement and the other Waiver and Amendment Documents on the basis of its own investigation and for its own reasons without reliance upon any agreement,
representation, understanding or communication by or on behalf of any other Person. 
 (c) Costs and Expenses.
Borrower agrees to pay to the Agent and the Lenders on demand all out-of-pocket expenses incurred by the Agent, the Lenders and their respective Affiliates (including
the fees, charges and disbursements of counsel for the Lenders), in connection 

  
 3 

 
with the preparation, negotiation, execution and delivery of this Agreement and any other documents to be delivered in connection herewith. 

(d) Binding Effect. This Agreement shall be binding upon, inure to the benefit of and be enforceable by Borrower, each
Subsidiary Guarantor, the Agent, each Lender and their respective successors and assigns. 
 (e) Governing Law. This
Agreement and the other Waiver and Amendment Documents and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement or any other Waiver and Amendment
Document (except, as to any other Waiver and Amendment Document, as expressly set forth therein) and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the law of the State of New York. 

(f) Complete Agreement; Amendments. This Agreement, together with the other Waiver and Amendment Documents and the other
Loan Documents, contains the entire and exclusive agreement of the parties hereto and thereto with reference to the matters discussed herein and therein. This Agreement supersedes all prior commitments, drafts, communications, discussions and
understandings, oral or written, with respect thereto. This Agreement may not be modified, amended or otherwise altered except in accordance with the terms of Section 12.04 of the Term Loan Agreement. 

(g) Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be
effective and valid under all applicable laws and regulations. If, however, any provision of this Agreement shall be prohibited by or invalid under any such law or regulation in any jurisdiction, it shall, as to such jurisdiction, be deemed modified
to conform to the minimum requirements of such law or regulation, or, if for any reason it is not deemed so modified, it shall be ineffective and invalid only to the extent of such prohibition or invalidity without affecting the remaining provisions
of this Agreement, or the validity or effectiveness of such provision in any other jurisdiction. 
 (h) Counterparts.
This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute but one and the
same agreement. Delivery of an executed counterpart of a signature page of this Agreement by facsimile or in electronic (i.e., “pdf” or “tif”) format shall be effective as delivery of a manually executed counterpart of this
Agreement. 
 (i) Interpretation. This Agreement and the other Waiver and Amendment Documents are the result of
negotiations between and have been reviewed by counsel to the Agent, the Lenders, Borrower, the Subsidiary Guarantors and other parties, and are the product of all parties hereto. Accordingly, this Agreement and the other Waiver and Amendment
Documents shall not be construed against any of the Agent or the Lenders merely because of its involvement in the preparation thereof. 

(j) Loan Documents. This Agreement and the other Waiver and Amendment Documents shall constitute Loan Documents. 

  
 4 

 (k) Controlling Provisions. In the event of any inconsistencies
between the provisions of this Agreement and the provisions of any other Loan Document, the provisions of this Agreement shall govern and prevail. Except as expressly modified by this Agreement, the Loan Documents shall not be modified and shall
remain in full force and effect. 
 [Remainder of page intentionally left blank] 

  
 5 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement, as
of the date first above written. 
  

			
	 BORROWER

	
	 GENOMEDX BIOSCIENCES INC.

		
	 By:
	 	 /s/ Bill Kachioff

		 	 Name: Bill Kachioff

		 	 Title: Chief Financial Officer

	
	 SUBSIDIARY GUARANTOR

	
	 GENOMEDX BIOSCIENCES CORP.

		
	 By:
	 	 /s/ Bill Kachioff

		 	 Name: Bill Kachioff

		 	 Title: Chief Financial Officer

 [Signature page 1 to Waiver and Amendment NO. 3] 

			
	 THE LENDERS

	
	 CRG PARTNERS III L.P.,

	 By CRG PARTNERS III GP L.P., its General Partner

	 By CRG PARTNERS III GP LLC, its General Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

  

			
	 CRG PARTNERS III–PARALLEL FUND “A” L.P.,

	 By CRG PARTNERS III – PARALLEL FUND “A” GP L.P., its General
Partner

	 By CRG PARTNERS III – PARALLEL FUND “A” GP LLC, its General
Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

  

					
	 CRG PARTNERS III (CAYMAN) L.P.,

	 By CRG PARTNERS III (CAYMAN) GP L.P.,

its General Partner

	 By CRG PARTNERS III (CAYMAN) GP LLC,

its General Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

			
		 	 Witness:
	 	 /s/ Nicole Nesson

		
		 	 Name: Nicole Nesson

  
 [Signature page 2 to
Waiver and Amendment NO. 3] 

			
	 AGENT

	
	 CRG SERVICING LLC, as Agent

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

  
 [Signature page 3 to
Waiver and Amendment NO. 3] 

 Execution Version 

AMENDMENT AGREEMENT NO. 4 

THIS AMENDMENT AGREEMENT NO. 4 (this “Amendment”), dated as of October 27, 2016, is made among
GenomeDx Biosciences Inc., a company incorporated in British Columbia, Canada (the “Borrower”), the Subsidiary Guarantor listed on the signature pages hereof under the heading “SUBSIDIARY GUARANTOR” (the
“Subsidiary Guarantor”, and together with the Borrower, each an “Obligor” and, collectively, the “Obligors”), the Lenders listed on the signature pages hereof under the heading
“LENDERS” (each a “Lender” and, collectively, the “Lenders”) and CRG PARTNERS III L.P., as administrative and collateral agent for the Lenders hereunder (in such capacity, the
“Agent”). 
 The Obligors and the Lenders are parties to that certain Term Loan Agreement, dated as
of September 23, 2015, as amended by that Waiver and Amendment Agreement, dated as of December 30, 2015, that Amendment Agreement No. 2, dated as of December 30, 2015 and that Waiver and Amendment Agreement No. 3, dated as
of April 21, 2016 (as further amended, amended and restated, modified or supplemented from time to time, the “Loan Agreement”). 

The parties hereto desire to amend the Loan Agreement on the terms and subject to the conditions set forth herein. 

Accordingly, the parties hereto agree as follows: 

SECTION 1. Definitions; Interpretation. 

(a) Terms Defined in Loan Agreement. All capitalized terms used in this Amendment (including in the recitals hereof) and
not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement. 
 (b) Interpretation.
The rules of interpretation set forth in Section 1.03 of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference. 

SECTION 2. Amendments. 

Subject to Section 3, the Loan Agreement is hereby amended as follows: 

(a) The definition of “Commitment Period” in Section 1.01 of the Loan
Agreement is hereby amended and restated in its entirety as follows: 
 ““Commitment Period”
means the period from and including the first date on which all of the conditions precedent set forth in Section 6.01 have been satisfied (or waived by the Lenders) and through and including March 31, 2017.” 

(b) The definition of “Interest-Only Period” in Section 1.01 of the
Loan Agreement is hereby amended and restated in its entirety as follows: 

  
 1 

 ““Interest-Only Period” means (i) the
period from and including the first Borrowing Date and through and including the sixteenth (16th) Payment Date following the first Borrowing 

““Interest-Only Period” means (i) the period from and including the first Borrowing Date and
through and including the sixteenth (16th) Payment Date following the first Borrowing Date, or (ii) upon the completion of a Qualified IPO that raises more than $40,000,000 of gross proceeds
at a pre-money valuation of more than $150,000,000, the period from and including the first Borrowing Date and through and including the twentieth (20th)
Payment Date following the first Borrowing Date.” 
 (c) The definition of “PIK Period”
in Section 1.01 of the Loan Agreement is hereby amended and restated in its entirety as follows: 

““PIK Period” means the period beginning on the first Borrowing Date through and including the
earlier to occur of (i) (A) the sixteenth (16th) Payment Date after the first Borrowing Date, or (B) upon the completion of a Qualified IPO that raises more than $40,000,000 of gross
proceeds at a pre-money valuation of more than $150,000,000, the twentieth (20th) Payment Date after the first Borrowing Date, and (ii) the date on
which any Default shall have occurred (provided that if such Default shall have been cured or waived, the PIK Period shall resume until the earlier to occur of the next Default and (A) the sixteenth (16th) Payment Date after the first Borrowing Date, or (B) upon the completion of a Qualified IPO that raises more than $40,000,000 of gross proceeds at a
pre-money valuation of more than $150,000,000, the twentieth (20th) Payment Date after the first Borrowing Date).” 

(d) Sections 6.02 and 6.03 of the Loan Agreement are hereby amended and restated in their entirety to read as
follows: 
 6.02 Conditions to Second Borrowing. The obligation of each Lender to make a Loan as part of a second
Borrowing is subject to the following conditions precedent: 
 (a) Borrowing Date. Such Borrowing shall occur on or
prior to March 31, 2017. 
 (b) Amount of Borrowing. The amount of such Borrowing shall be at Borrower’s
option and shall be up to $5,000,000. 
 (c) Borrowing Milestone. Borrower shall have achieved minimum Revenue of at
least $12,000,000 during any consecutive twelve (12) month period, provided that Borrower shall have achieved such Borrowing milestone relating to minimum Revenue no later than March 31, 2017. For the avoidance of doubt, the condition of
this Section 6.02(c) and Section 6.03(c) may be satisfied with the same twelve (12) month period. 

(d) Notice of Milestone Achievement and Audit. Borrower shall have delivered to the Lenders a notice certifying
satisfaction of the conditions set forth in Section 6.02(c) no later than 60 calendar days thereafter, and the Lenders shall have been reasonably satisfied with the evidence of such achievement and with the results of its
audit of Borrower’s Revenue by examining Borrower’s books and records. 

  
 2 

 (e) Notice of Borrowing. A Notice of Borrowing shall have been
received no later than 60 calendar days after satisfaction of the condition set forth in Section 6.02(c). 

“6.03 Conditions to Third Borrowing. The obligation of each Lender to make a Loan as part of a third
Borrowing is subject to the following conditions precedent: 
 (a) Borrowing Date. Such Borrowing shall occur on or
prior to March 31, 2017. 
 (b) Amount of Borrowing. The amount of such Borrowing shall be at Borrower’s
option and shall be up to $5,000,000. 
 (c) Borrowing Milestone. Borrower shall have achieved minimum Revenue of at
least $12,000,000 during any consecutive twelve (12) month period, provided that Borrower shall have achieved such Borrowing milestone relating to minimum Revenue no later than March 31, 2017. For the avoidance of doubt, the conditions of
this Section 6.03(c) and Section 6.02(c) may be satisfied with the same twelve (12) month period. 

(d) Notice of Milestone Achievement and Audit. Borrower shall have delivered to the Lenders a notice certifying
satisfaction of the conditions set forth in Section 6.03(c) no later than 60 calendar days thereafter, and the Lenders shall have been reasonably satisfied with the evidence of such achievement and with the results of its audit of
Borrower’s Revenue by examining Borrower’s books and records. 
 (e) Notice of Borrowing. A Notice of
Borrowing shall have been received no later than 60 calendar days after satisfaction of the condition set forth in Section 6.03(c). 

(f) Second Borrowing. A second Borrowing has occurred pursuant to Section 6.02.” 

(e) Section 10.02(b) of the Loan Agreement is hereby amended and restated in its entirety to read as
follows: 
 “(b) during the twelve month period beginning on January 1, 2016, of at least $12,000,000;” 

(f) Annex B of Exhibit E of the Loan Agreement is hereby replaced in its entirety by Annex B to Compliance
Certificate attached hereto. 
 SECTION 3. Conditions of Effectiveness. 

The effectiveness of Section 2 shall be subject to the following conditions precedent: 

(a) The Obligors, all of the Lenders and the Agent shall have duly executed and delivered this Amendment pursuant to
Section 12.04 of the Loan Agreement. 
 (b) The Obligors shall have paid or reimbursed
Lenders for Lenders’ reasonable out of pocket costs and expenses incurred in connection with this Amendment, including Lenders’ reasonable out of pocket legal fees and costs, pursuant to Section 12.03(a)(i)(z) of
the Loan Agreement. 

  
 3 

 (c) The representations and warranties in
Section 4 shall be true and correct on the date hereof and on the first date on which the conditions set forth in Sections 3(a) and (b) shall have been satisfied. 

SECTION 4. Representations and Warranties; Reaffirmation. 

(a) Each Obligor hereby represents and warrants to each Lender as follows: 

(i) Such Obligor has full power, authority and legal right to make and perform this Amendment. This Amendment is within
such Obligor’s corporate powers and has been duly authorized by all necessary corporate and, if required, by all necessary shareholder action. This Amendment has been duly executed and delivered by such Obligor and constitutes legal, valid and
binding obligations of such Obligor, enforceable against such Obligor in accordance with its terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability
affecting the enforcement of creditors’ rights and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). This Amendment (x) does not require
any consent or approval of, registration or filing with, or any other action by, any Governmental Authority or any third party, except for such as have been obtained or made and are in full force and effect, (y) will not violate any applicable
law or regulation or the charter, bylaws or other organizational documents of such Obligor and its Subsidiaries or any order of any Governmental Authority, other than any such violations that, individually or in the aggregate, could not reasonably
be expected to have a Material Adverse Effect, (z) will not violate or result in an event of default under any material indenture, agreement or other instrument binding upon such Obligor and its Subsidiaries or assets, or give rise to a right
thereunder to require any payment to be made by any such Person. 
 (ii) No Default has occurred or is continuing or
will result after giving effect to this Amendment. 
 (iii) The representations and warranties made by or with respect
to such Obligor in Section 7 of the Loan Agreement are true in all material respects (taking into account any changes made to schedules updated in accordance with Section 7.20 of the Loan
Agreement), except that such representations and warranties that refer to a specific earlier date were true in all material respects on such earlier date. 

(iv) There has been no Material Adverse Effect since the date of the Loan Agreement. 

(b) Each Obligor hereby ratifies, confirms, reaffirms, and acknowledges its obligations under the Loan Documents to
which it is a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Amendment, except as expressly provided herein. By executing this Amendment, each Obligor acknowledges that it has read, consulted with its
attorneys regarding, and understands, this Amendment. 
 SECTION 5. Governing Law; Submission To Jurisdiction; Waiver Of Jury Trial.

 (a) Governing Law. This Amendment and the rights and obligations of the parties hereunder shall be governed by, and
construed in accordance with, the law of the State of New 

  
 4 

 
York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that
Section 5-1401 of the New York General Obligations Law shall apply. 
 (b)
Submission to Jurisdiction. Each Obligor agrees that any suit, action or proceeding with respect to this Amendment or any other Loan Document to which it is a party or any judgment entered by any court in respect thereof may be brought initially
in the federal or state courts in Houston, Texas or in the courts of its own corporate domicile and irrevocably submits to the non-exclusive jurisdiction of each such court for the purpose of any such suit,
action, proceeding or judgment. This Section 5 is for the benefit of the Lenders only and, as a result, no Lender shall be prevented from taking proceedings in any other courts with jurisdiction. To the extent allowed by
applicable Laws, the Lenders may take concurrent proceedings in any number of jurisdictions. 
 (c) Waiver of Jury
Trial. Each Obligor and each Lender hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any suit, action or proceeding arising out of or relating to this Amendment, the other Loan
Documents or the transactions contemplated hereby or thereby. 
 SECTION 6. Miscellaneous. 

(a) No Waiver. Nothing contained herein shall be deemed to constitute a waiver of compliance with any term or condition
contained in the Loan Agreement or any of the other Loan Documents or constitute a course of conduct or dealing among the parties. Except as expressly stated herein, the Lenders reserve all rights, privileges and remedies under the Loan Documents.
Except as amended hereby, the Loan Agreement and other Loan Documents remain unmodified and in full force and effect. All references in the Loan Documents to the Loan Agreement shall be deemed to be references to the Loan Agreement as amended
hereby. 
 (b) Severability. In case any provision of or obligation under this Amendment shall be invalid, illegal or
unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby. 

(c) Headings. Headings and captions used in this Amendment (including the Exhibits, Schedules and Annexes hereto, if
any) are included for convenience of reference only and shall not be given any substantive effect. 
 (d) Integration.
This Amendment constitutes a Loan Document and, together with the other Loan Documents, incorporates all negotiations of the parties hereto with respect to the subject matter hereof and is the final expression and agreement of the parties hereto
with respect to the subject matter hereof. 
 (e) Counterparts. This Amendment may be executed in any number of
counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Amendment by signing any such counterpart. 

  
 5 

 (f) Controlling Provisions. In the event of any inconsistencies
between the provisions of this Amendment and the provisions of any other Loan Document, the provisions of this Amendment shall govern and prevail. Except as expressly modified by this Amendment, the Loan Documents shall not be modified and shall
remain in full force and effect. 
 [Remainder of page intentionally left blank] 

  
 6 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as
of the date first above written. 
  

			
	 BORROWER

	
	 GENOMEDX BIOSCIENCES INC.

		
	 By:
	 	 /s/ Bill Kachioff

		 	 Name: Bill Kachioff

		 	 Title: Chief Financial Officer

	
	 Address for Notices:

	
	 10355 Science Center Drive

	 San Diego, CA 92121

 
			
		
	 Tel:
	 	
	 Toll Free:
	 	
	 Email:
	 	
	
	 SUBSIDIARY GUARANTOR

	
	 GENOMEDX BIOSCIENCES CORP.

			
		
	 By:
	 	 /s/ Bill Kachioff

		 	 Name: Bill Kachioff

		 	 Title: Chief Financial Officer

 
			
	
	 Address for Notices:

	
	 10355 Science Center Drive

	 San Diego, CA 92121

		
	 Tel:
	 	
	 Toll Free:
	 	
	 Email:
	 	

  
 [Signature page 1 to
Amendment Agreement No. 4] 

 THE LENDERS 

CRG PARTNERS III L.P., in its General Partners 

By CRG PARTNERS III GP L.P., its General 

Partner 
  

			
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

 CRG PARTNERS III–PARALLEL FUND “A” L.P., 

By CRG PARTNERS III – PARALLEL FUND 

“A” GP L.P., its General Partner 

  By CRG PARTNERS III – PARALLEL 

  FUND “A” GP LLC, its General Partner 

 

			
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

 CRG PARTNERS III (CAYMAN) L.P., 

By CRG PARTNERS III (CAYMAN) GP L.P., its General Partner 

  By CRG PARTNERS III (CAYMAN) GP LLC, 

  Its General Partners 
  

					
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

			
		 	 Witness:
	 	 /s/ Nicole Nesson

		
		 	 Name: Nicole Nesson

  
 [Signature page 2 to
Amendment Agreement No. 4] 

			
	 AGENT

	
	 CRG SERVICING LLC, as Agent

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

  
 [Signature page 3 to
Amendment Agreement No. 4] 

 Annex B to Compliance Certificate 

CALCULATIONS OF FINANCIAL COVENANT COMPLIANCE 
  

					
	 I.
	  	 Section 10.01: Minimum Liquidity
	  	
			
	 I.
	  	 Amount of unencumbered cash and Permitted Cash Equivalent Investments (which for greater certainty
shall not include any
undrawn credit lines), in each case, to the extent held in an account over which
the Lenders have a first priority perfected security interest:
	  	 $_______________

			
	     A.
	  	 The greater of:
	  	 $_______________

			
		  	 (a)   $2,000,000 and
	  	
			
		  	 (b)   to the extent Borrower has incurred Permitted Priority
Debt, the minimum cash
balance required of Borrower by Borrower’s Permitted Priority Debt creditors
	  	
			
		  	 Is Line IA equal to or greater than Line IB?:
	  	 Yes: In compliance;

No: Not in compliance

			
	 II.
	  	 Section 10.02(a)-(c): Minimum Revenue— Subsequent Periods
	  	
			
	     A.
	  	 Revenues during the twelve month period beginning on January 1, 2015
	  	 $_______________

			
		  	 [Is line II.A equal to or greater than $7,000,000?
	  	 Yes: In compliance;

No: Not in compliance]1

			
	     B.
	  	 Revenues during the twelve month period beginning on January 1, 2016
	  	 $_______________

			
		  	 [Is line II.B equal to or greater than $12,000,000?
	  	 Yes: In compliance;

No: Not in compliance]2

			
	     C.
	  	 Revenues during the twelve month period beginning on January 1, 2017
	  	 $_______________

			
		  	 [Is line II.C equal to or greater than $30,000,000?
	  	 Yes: In compliance;

No: Not in
compliance]3

  

	 1 
	 Include bracketed entry only on the Compliance Certificate to be delivered within 180 days of the end of
2015 pursuant to Section 8.01(b) of the Loan Agreement. 

	 2 
	 Include bracketed entry only on the Compliance Certificate to be delivered within 180 days of the end of
2016 pursuant to Section 8.01(b) of the Loan Agreement. 

	 3 
	 Include bracketed entry only on the Compliance Certificate to be delivered within 180 days of the end of
2017 pursuant to Section 8.01(b) of the Loan Agreement. 

  
 Annex B–Page 1 

					
	     D.
	  	 Revenues during the twelve month period beginning on January 1, 2018
	  	 $_______________

			
		  	 [Is line II.D equal to or greater than $30,000,000?
	  	 Yes: In compliance;

No: Not in
 compliance]4

			
	     E.
	  	 Revenues during the twelve month period beginning on January 1, 2019
	  	 $_______________

			
		  	 [Is line II.E equal to or greater than $30,000,000?
	  	 Yes: In compliance;

No: Not in
 compliance]5

			
	     F.
	  	 Revenues during the twelve month period beginning on January 1, 2020
	  	 $_______________

			
		  	 [Is line II.F equal to or greater than $30,000,000?
	  	 Yes: In compliance;

No: Not in
 compliance]6

  

	 4 
	 Include bracketed entry only on the Compliance Certificate to be delivered within 180 days of the end of
2019 pursuant to Section 8.01(b) of the Loan Agreement. 

	 5 
	 Include bracketed entry only on the Compliance Certificate to be delivered within 180 days of the end of
2019 pursuant to Section 8.01(b) of the Loan Agreement. 

	 6 
	 Include bracketed entry only on the Compliance Certificate to be delivered within 180 days of the end of
2020 pursuant to Section 8.01(b) of the Loan Agreement. 

  
 Annex B–Page 2 

 EXECUTION VERSION 

AMENDMENT AGREEMENT NO. 5 

THIS AMENDMENT AGREEMENT NO. 5 (this “Amendment”), dated as of December 26, 2017, is made among
GenomeDx Biosciences Inc., a company incorporated in British Columbia, Canada (the “Borrower”), the Subsidiary Guarantor listed on the signature pages hereof under the heading “SUBSIDIARY GUARANTOR” (the
“Subsidiary Guarantor”, and together with the Borrower, each an “Obligor” and, collectively, the “Obligors”), the Lenders listed on the signature pages hereof under the heading
“LENDERS” (each a “Lender” and, collectively, the “Lenders”) and CRG PARTNERS III L.P., as administrative and collateral agent for the Lenders hereunder (in such capacity, the
“Agent”). 
 The Obligors and the Lenders are parties to that certain Term Loan Agreement, dated as
of September 23, 2015, as amended by that Waiver and Amendment Agreement, dated as of December 30, 2015, Amendment Agreement No. 2, dated as of December 30, 2015, Waiver and Amendment Agreement No. 3, dated as of
April 21, 2016, and Amendment Agreement No. 4, dated as of October 27, 2016 (as further amended, amended and restated, modified or supplemented from time to time, the “Loan Agreement”). 

The parties hereto desire to amend the Loan Agreement on the terms and subject to the conditions set forth herein. 

Accordingly, the parties hereto agree as follows: 

SECTION 1. Definitions; Interpretation. 

(a) Terms Defined in Loan Agreement. All capitalized terms used in this Amendment (including in the recitals hereof) and
not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement. 
 (b) Interpretation.
The rules of interpretation set forth in Section 1.03 of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference. 

SECTION 2. Amendments. 

Subject to Section 3, the Loan Agreement is hereby amended as follows: 

(a) Section 1.01 is hereby amended by amending and restating the definition of “Fee
Letter” therein to read in its entirety as follows: 
 “ “Fee Letter” means that
fee letter agreement dated as of December 26, 2017, between Borrower and CRG Partners III L.P., as administrative and collateral agent for the Lenders.” 

(b) Section 10.01 is hereby amended by adding the following language immediately prior to the
“.” at the end thereof: “; provided that, for the period between December 26, 2017 and January 22, 2017, such minimum Liquidity shall be at least $1,000,000”. 

  
 1. 

 (c) Section 10.02(c) is hereby amended and
restated in its entirety to read as follows: 
 “(c) during the twelve month period beginning on
January 1, 2017, of at least $13,000,000;” 
 (d) A new Section 10.02(d) is hereby
added and shall read in its entirety as follows: 
 “(d) during the twelve month period beginning on
January 1, 2018, and during each twelve month period thereafter beginning on January 1 of each such period, of at least $30,000,000.” 

SECTION 3. Conditions of Effectiveness. 

The effectiveness of Section 2 shall be subject to the following conditions precedent: 

(a) The Obligors, all of the Lenders and the Agent shall have duly executed and delivered this Amendment pursuant to
Section 12.04 of the Loan Agreement. 
 (b) The Obligors shall have paid or reimbursed
Lenders for Lenders’ reasonable out of pocket costs and expenses incurred in connection with this Amendment, including Lenders’ reasonable out of pocket legal fees and costs, pursuant to Section 12.03(a)(i)(z) of
the Loan Agreement. 
 (c) The representations and warranties in Section 4 shall be true and
correct on the date hereof and on the first date on which the conditions set forth in Sections 3(a) and (b) shall have been satisfied. 

(d) The Borrower shall have executed and delivered the amended and restated Fee Letter in the form attached hereto as
Exhibit A. 
 SECTION 4. Representations and Warranties; Reaffirmation; Post-Closing Covenant. 

(a) Each Obligor hereby represents and warrants to each Lender as follows: 

(i) Such Obligor has full power, authority and legal right to make and perform this Amendment. This Amendment is within
such Obligor’s corporate powers and has been duly authorized by all necessary corporate and, if required, by all necessary shareholder action. This Amendment has been duly executed and delivered by such Obligor and constitutes legal, valid and
binding obligations of such Obligor, enforceable against such Obligor in accordance with its terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability
affecting the enforcement of creditors’ rights and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). This Amendment (x) does not require
any consent or approval of, registration or filing with, or any other action by, any Governmental Authority or any third party, except for such as have been obtained or made and are in full force and effect, (y) will not violate any applicable
law or regulation or the charter, bylaws or other organizational documents of such Obligor and its Subsidiaries or any order of any Governmental Authority, other than any such violations that, individually or in the aggregate, could not reasonably
be expected to have a Material Adverse Effect, (z) will not violate or result in an event of default under any 

  
 2. 

 
material indenture, agreement or other instrument binding upon such Obligor and its Subsidiaries or assets, or give rise to a right thereunder to require any payment to be made by any such
Person. 
 (ii) No Default has occurred or is continuing or will result after giving effect to this Amendment. 

(iii) The representations and warranties made by or with respect to such Obligor in Section 7
of the Loan Agreement are true in all material respects, except that (A) such representations and warranties that refer to a specific earlier date were true in all material respects on such earlier date and (B) such representations and
warranties do not take into account any changes to be made to the schedules pursuant to Section 4(c) below. 

(iv) There has been no Material Adverse Effect since the date of the Loan Agreement, other than any Material Adverse
Effect that has been communicated prior to the date hereof to any Lender in its role as a Board Observer. 
 (b) Each
Obligor hereby ratifies, confirms, reaffirms, and acknowledges its obligations under the Loan Documents to which it is a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Amendment, except as expressly
provided herein. By executing this Amendment, each Obligor acknowledges that it has read, consulted with its attorneys regarding, and understands, this Amendment. 

(c) Within 30 days after the date hereof, each Obligor shall update, in accordance with
Section 7.20 of the Loan Agreement, all schedules that are permitted to be updated pursuant to such provision. Notwithstanding Section 7.20 of the Loan Agreement or any other provision of the Loan
Documents to the contrary, such updates shall be in form and substance satisfactory to the Lenders. Any failure to comply with this post-closing covenant shall constitute an immediate Event of Default. 

SECTION 5. Governing Law; Submission To Jurisdiction; Waiver Of Jury Trial. 

(a) Governing Law. This Amendment and the rights and obligations of the parties hereunder shall be governed by, and
construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that
Section 5-1401 of the New York General Obligations Law shall apply. 
 (b)
Submission to Jurisdiction. Each Obligor agrees that any suit, action or proceeding with respect to this Amendment or any other Loan Document to which it is a party or any judgment entered by any court in respect thereof may be brought initially
in the federal or state courts in Houston, Texas or in the courts of its own corporate domicile and irrevocably submits to the non-exclusive jurisdiction of each such court for the purpose of any such suit,
action, proceeding or judgment. This Section 5 is for the benefit of the Lenders only and, as a result, no Lender shall be prevented from taking proceedings in any other courts with jurisdiction. To the extent allowed by
applicable Laws, the Lenders may take concurrent proceedings in any number of jurisdictions. 

  
 3. 

 (c) Waiver of Jury Trial. Each Obligor and each Lender hereby
irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any suit, action or proceeding arising out of or relating to this Amendment, the other Loan Documents or the transactions contemplated
hereby or thereby. 
 SECTION 6. Miscellaneous. 

(a) No Waiver. Nothing contained herein shall be deemed to constitute a waiver of compliance with any term or condition
contained in the Loan Agreement or any of the other Loan Documents or constitute a course of conduct or dealing among the parties. Except as expressly stated herein, the Lenders reserve all rights, privileges and remedies under the Loan Documents
(including, without limitation, all such rights, privileges and remedies with respect to any Default, Event of Default or Material Adverse Effect, whether communicated or not to the Lenders or Agent). Except as amended hereby, the Loan Agreement and
other Loan Documents remain unmodified and in full force and effect. All references in the Loan Documents to the Loan Agreement shall be deemed to be references to the Loan Agreement as amended hereby. 

(b) Severability. In case any provision of or obligation under this Amendment shall be invalid, illegal or unenforceable
in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby. 

(c) Headings. Headings and captions used in this Amendment (including the Exhibits, Schedules and Annexes hereto, if
any) are included for convenience of reference only and shall not be given any substantive effect. 
 (d) Integration.
This Amendment constitutes a Loan Document and, together with the other Loan Documents, incorporates all negotiations of the parties hereto with respect to the subject matter hereof and is the final expression and agreement of the parties hereto
with respect to the subject matter hereof. 
 (e) Counterparts. This Amendment may be executed in any number of
counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Amendment by signing any such counterpart. 

(f) Controlling Provisions. In the event of any inconsistencies between the provisions of this Amendment and the
provisions of any other Loan Document, the provisions of this Amendment shall govern and prevail. Except as expressly modified by this Amendment, the Loan Documents shall not be modified and shall remain in full force and effect. 

(g) Clarification. Borrower and Lenders hereby acknowledge and agree that, in the event that any portion of the Loans
becomes due and payable prior to the Stated Maturity Date, whether as a result of acceleration or any other required prepayment event, the “Redemption Date” for purposes of calculating the Prepayment Premium (to the extent
due) will be the date of such acceleration or the date of occurrence of the event that triggered such obligation to prepay. 
 [Remainder
of page intentionally left blank] 

  
 4. 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as
of the date first above written. 
  

					
	 BORROWER

	
	 GENOMEDX BIOSCIENCES INC.

		
	 By:
	 	 /s/ Doug Dolginow

		 	 Name:
	 	 Doug Dolginow

		 	 Title:
	 	 CEO

	
	 Address for Notices:

	
	 1038 Homer Street

	 Vancouver, BC

	 Canada V6B 2W9

	
	 Tel:

	 Email:

	
	 SUBSIDIARY GUARANTOR

	
	 GENOMEDX BIOSCIENCES CORP.

		
	 By:
	 	 /s/ Doug Dolginow

		 	 Name:
	 	 Doug Dolginow

		 	 Title:
	 	 CEO

	
	 Address for Notices:

	
	 10355 Science Center Drive, Suite 240

	 San Diego, CA 92121

	
	 Tel:

	 Email:

  

  
 [Signature Page 1 to
Amendment Agreement No. 5] 

			
	 THE LENDERS

	
	 CRG PARTNERS III L.P.,

	         By CRG PARTNERS III GP L.P., its General Partner

	             By CRG PARTNERS III GP LLC, its

            General Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

  

			
	 CRG PARTNERS III–PARALLEL FUND “A” L.P.,

	         By CRG PARTNERS III – PARALLEL FUND

        “A” GP L.P., its General Partner

	             By CRG PARTNERS III – PARALLEL

            FUND “A” GP LLC, its General Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

  

					
	 CRG PARTNERS III (CAYMAN) L.P.,

	         By CRG PARTNERS III (CAYMAN) GP L.P.,

        its General Partner

	             By CRG PARTNERS III (CAYMAN) GP LLC,

            its General Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

			
		 	 Witness:
	 	 /s/ Cameron Hui

		
		 	 Name: Cameron Hui

  

  
 [Signature Page 2 to
Amendment Agreement No. 5] 

			
	 AGENT

	
	 CRG SERVICING LLC, as Agent

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

  

  
 [Signature Page 3 to
Amendment Agreement No. 5] 

 Exhibit A to Amendment No. 5 

FEE LETTER 
 [see attached] 

 

  
 Annex B—Page 1 

 AMENDMENT AGREEMENT NO. 6 

THIS AMENDMENT AGREEMENT NO. 6 (this “Amendment”), dated as of January 15, 2018, is made among
GenomeDx Biosciences Inc., a company incorporated in British Columbia, Canada (the “Borrower”), the Subsidiary Guarantor listed on the signature pages hereof under the heading “SUBSIDIARY GUARANTOR” (the
“Subsidiary Guarantor”, and together with the Borrower, each an “Obligor” and, collectively, the “Obligors”), the Lenders listed on the signature pages hereof under the heading
“LENDERS” (each a “Lender” and, collectively, the “Lenders”) and CRG PARTNERS III L.P., as administrative and collateral agent for the Lenders hereunder (in such capacity, the
“Agent”). 
 The Obligors and the Lenders are parties to that certain Term Loan Agreement, dated as
of September 23, 2015, as amended by that Waiver and Amendment Agreement, dated as of December 30, 2015, Amendment Agreement No. 2, dated as of December 30, 2015, Waiver and Amendment Agreement No. 3, dated as of
April 21, 2016, Amendment Agreement No. 4, dated as of October 27, 2016, and Amendment Agreement No. 5, dated as of December 26, 2017 (as further amended, amended and restated, modified or supplemented from time to time, the
“Loan Agreement”). 
 The parties hereto desire to amend the Loan Agreement on the terms and subject
to the conditions set forth herein. 
 Accordingly, the parties hereto agree as follows: 

SECTION 1. Definitions; Interpretation. 

(a) Terms Defined in Loan Agreement. All capitalized terms used in this Amendment (including in the recitals hereof) and
not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement. 
 (b) Interpretation.
The rules of interpretation set forth in Section 1.03 of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference. 

SECTION 2. Amendments. 

Subject to Section 3, the Loan Agreement is hereby amended as follows: 

(a) Section 10.01 is hereby amended by amending and restating the proviso at the end thereof to read
in its entirety as follows: 
 “; provided that, for the period between December 26, 2017
and January 19, 2018, such minimum Liquidity shall be at least $500,000, and for the period between January 20, 2018 and February 28, 2018, such minimum Liquidity shall be at least $1,000,000”. 

SECTION 3. Conditions of Effectiveness. 

  
 1 

 The effectiveness of Section 2 shall be subject to the following conditions precedent:

 (a) The Obligors, all of the Lenders and the Agent shall have duly executed and delivered this Amendment pursuant
to Section 12.04 of the Loan Agreement. 
 (b) The Obligors shall have paid or reimbursed Lenders for
Lenders’ reasonable out of pocket costs and expenses incurred in connection with this Amendment, including Lenders’ reasonable out of pocket legal fees and costs, pursuant to Section 12.03(a)(i)(z) of the Loan Agreement. 

(c) The representations and warranties in Section 4 shall be true and correct on the date
hereof and on the first date on which the conditions set forth in Sections 3(a) and (b) shall have been satisfied. 

SECTION 4. Representations and Warranties; Reaffirmation; Post-Closing Covenant. 

(a) Each Obligor hereby represents and warrants to each Lender as follows: 

(i) Such Obligor has full power, authority and legal right to make and perform this Amendment. This Amendment is within
such Obligor’s corporate powers and has been duly authorized by all necessary corporate and, if required, by all necessary shareholder action. This Amendment has been duly executed and delivered by such Obligor and constitutes legal, valid and
binding obligations of such Obligor, enforceable against such Obligor in accordance with its terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability
affecting the enforcement of creditors’ rights and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). This Amendment (x) does not require
any consent or approval of, registration or filing with, or any other action by, any Governmental Authority or any third party, except for such as have been obtained or made and are in full force and effect, (y) will not violate any applicable
law or regulation or the charter, bylaws or other organizational documents of such Obligor and its Subsidiaries or any order of any Governmental Authority, other than any such violations that, individually or in the aggregate, could not reasonably
be expected to have a Material Adverse Effect, (z) will not violate or result in an event of default under any material indenture, agreement or other instrument binding upon such Obligor and its Subsidiaries or assets, or give rise to a right
thereunder to require any payment to be made by any such Person. 
 (ii) No Default has occurred or is continuing or
will result after giving effect to this Amendment. 
 (iii) The representations and warranties made by or with respect
to such Obligor in Section 7 of the Loan Agreement are true in all material respects, except that (A) such representations and warranties that refer to a specific earlier date were true in all material respects on such
earlier date and (B) such representations and warranties do not take into account any changes to be made to the schedules pursuant to Section 4(c) below. 

(iv) There has been no Material Adverse Effect since the date of the Loan Agreement, other than any Material Adverse
Effect that has been communicated prior to the date hereof to any Lender in its role as a Board Observer. 

  
 2 

 (b) Each Obligor hereby ratifies, confirms, reaffirms, and
acknowledges its obligations under the Loan Documents to which it is a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Amendment, except as expressly provided herein. By executing this Amendment, each
Obligor acknowledges that it has read, consulted with its attorneys regarding, and understands, this Amendment. 
 (c)
Within 30 days after the date hereof, each Obligor shall update, in accordance with Section 7.20 of the Loan Agreement, all schedules that are permitted to be updated pursuant to such provision. Notwithstanding
Section 7.20 of the Loan Agreement or any other provision of the Loan Documents to the contrary, such updates shall be in form and substance satisfactory to the Lenders. Any failure to comply with this post-closing covenant
shall constitute an immediate Event of Default. 
 SECTION 5. Governing Law; Submission To Jurisdiction; Waiver Of Jury Trial. 

(a) Governing Law. This Amendment and the rights and obligations of the parties hereunder shall be governed by, and
construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that
Section 5-1401 of the New York General Obligations Law shall apply. 
 (b)
Submission to Jurisdiction. Each Obligor agrees that any suit, action or proceeding with respect to this Amendment or any other Loan Document to which it is a party or any judgment entered by any court in respect thereof may be brought initially
in the federal or state courts in Houston, Texas or in the courts of its own corporate domicile and irrevocably submits to the non-exclusive jurisdiction of each such court for the purpose of any such suit,
action, proceeding or judgment. This Section 5 is for the benefit of the Lenders only and, as a result, no Lender shall be prevented from taking proceedings in any other courts with jurisdiction. To the extent allowed by
applicable Laws, the Lenders may take concurrent proceedings in any number of jurisdictions. 
 (c) Waiver of Jury
Trial. Each Obligor and each Lender hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any suit, action or proceeding arising out of or relating to this Amendment, the other Loan
Documents or the transactions contemplated hereby or thereby. 
 SECTION 6. Miscellaneous. 

(a) No Waiver. Nothing contained herein shall be deemed to constitute a waiver of compliance with any term or condition
contained in the Loan Agreement or any of the other Loan Documents or constitute a course of conduct or dealing among the parties. Except as expressly stated herein, the Lenders reserve all rights, privileges and remedies under the Loan Documents
(including, without limitation, all such rights, privileges and remedies with respect to any Default, Event of Default or Material Adverse Effect, whether communicated or not to the Lenders or Agent). Except as amended hereby, the Loan Agreement and
other Loan Documents remain unmodified and in full force and effect. All references in the Loan Documents to the Loan Agreement shall be deemed to be references to the Loan Agreement as amended hereby. 

  
 3 

 (b) Severability. In case any provision of or obligation under this
Amendment shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be
affected or impaired thereby. 
 (c) Headings. Headings and captions used in this Amendment (including the Exhibits,
Schedules and Annexes hereto, if any) are included for convenience of reference only and shall not be given any substantive effect. 

(d) Integration. This Amendment constitutes a Loan Document and, together with the other Loan Documents, incorporates
all negotiations of the parties hereto with respect to the subject matter hereof and is the final expression and agreement of the parties hereto with respect to the subject matter hereof. 

(e) Counterparts. This Amendment may be executed in any number of counterparts, all of which taken together shall
constitute one and the same instrument and any of the parties hereto may execute this Amendment by signing any such counterpart. 

(f) Controlling Provisions. In the event of any inconsistencies between the provisions of this Amendment and the
provisions of any other Loan Document, the provisions of this Amendment shall govern and prevail. Except as expressly modified by this Amendment, the Loan Documents shall not be modified and shall remain in full force and effect. 

[Remainder of page intentionally left blank] 

  
 4 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as
of the date first above written. 
  

			
	 BORROWER

	
	 GENOMEDX BIOSCIENCES INC.

		
	 By:
	 	 /s/ Doug Dolginow

		 	 Name: Doug Dolginow

		 	 Title: CEO

	
	 Address for Notices:

	
	 1038 Homer Street

	 Vancouver, BC

	 Canada V6B 2W9

	
	 Tel:

	 Email:

	
	 SUBSIDIARY GUARANTOR

	
	 GENOMEDX BIOSCIENCES CORP.

		
	 By:
	 	 /s/ Doug Dolginow

		 	 Name: Doug Dolginow

		 	 Title: CEO

	
	 Address for Notices:

	 10355 Science Center Drive, Suite 240

	 San Diego, CA 92121

	
	 Tel:

	 Email:

 [Signature Page 3 to Amendment Agreement No. 6] 

			
	 THE LENDERS

	
	 CRG PARTNERS III L.P.,

	 By CRG PARTNERS III GP L.P., its General Partner

	 By CRG PARTNERS III GP LLC, its General Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

  

			
	 CRG PARTNERS III–PARALLEL FUND “A” L.P.,

	 By CRG PARTNERS III – PARALLEL FUND “A” GP L.P., its General
Partner

	 By CRG PARTNERS III – PARALLEL FUND “A” GP LLC, its General
Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

  

					
	 CRG PARTNERS III (CAYMAN) L.P.,

	 By CRG PARTNERS III (CAYMAN) GP L.P., its General Partner

	 By CRG PARTNERS III (CAYMAN) GP LLC, its General Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

			
		 	 Witness:
	 	 /s/ Nicole Nesson

		
		 	 Name: Nicole Nesson

 [Signature Page 3 to Amendment Agreement No. 6] 

 AGENT 
  

			
	 CRG SERVICING LLC, as Agent

		
	 By
	 	 /s/ Nathan Hukill

		 	 Nathan Hukill

		 	 Authorized Signatory

 [Signature Page 3 to Amendment Agreement No. 6] 

 AMENDMENT AGREEMENT NO. 7 

THIS AMENDMENT AGREEMENT NO. 7 (this “Amendment”), dated as of March 5, 2018 and effective as of
February 28, 2018, is made among GenomeDx Biosciences Inc., a company incorporated in British Columbia, Canada (the “Borrower”), the Subsidiary Guarantor listed on the signature pages hereof under the heading
“SUBSIDIARY GUARANTOR” (the “Subsidiary Guarantor”, and together with the Borrower, each an “Obligor” and, collectively, the “Obligors”), the Lenders listed on the
signature pages hereof under the heading “LENDERS” (each a “Lender” and, collectively, the “Lenders”) and CRG PARTNERS III L.P., as administrative and collateral agent for the Lenders
hereunder (in such capacity, the “Agent”). 
 The Obligors and the Lenders are parties to that
certain Term Loan Agreement, dated as of September 23, 2015, as amended by that Waiver and Amendment Agreement, dated as of December 30, 2015, Amendment Agreement No. 2, dated as of December 30, 2015, Waiver and Amendment
Agreement No. 3, dated as of April 21, 2016, Amendment Agreement No. 4, dated as of October 27, 2016, Amendment Agreement No. 5, dated as of December 26, 2017, and Amendment Agreement No. 6, dated as of
January 15, 2018 (as further amended, amended and restated, modified or supplemented from time to time, the “Loan Agreement”). 

The parties hereto desire to amend the Loan Agreement on the terms and subject to the conditions set forth herein. 

Accordingly, the parties hereto agree as follows: 

SECTION 1. Definitions; Interpretation. 

(a) Terms Defined in Loan Agreement. All capitalized terms used in this Amendment (including in the recitals hereof) and
not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement. 
 (b) Interpretation.
The rules of interpretation set forth in Section 1.03 of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference. 

SECTION 2. Amendments. 

Subject to Section 3, the Loan Agreement is hereby amended as follows: 

(a) Section 10.01 is hereby amended by amending and restating the proviso at the end thereof to read
in its entirety as follows: 
 “; provided that, for the period between January 20, 2018
and March 30, 2018, such minimum Liquidity shall be at least $1,000,000”. 
 SECTION 3. Conditions of Effectiveness. 

The effectiveness of Section 2 shall be subject to the following conditions precedent: 

  
 1 

 (a) The Obligors, all of the Lenders and the Agent shall have duly
executed and delivered this Amendment pursuant to Section 12.04 of the Loan Agreement. 
 (b)
The Obligors shall have paid or reimbursed Lenders for Lenders’ reasonable out of pocket costs and expenses incurred in connection with this Amendment, including Lenders’ reasonable out of pocket legal fees and costs, pursuant to
Section 12.03(a)(i)(z) of the Loan Agreement. 
 (c) The representations and warranties in
Section 4 shall be true and correct on the date hereof and on the first date on which the conditions set forth in Sections 3(a) and (b) shall have been satisfied. 

SECTION 4. Representations and Warranties; Reaffirmation; Post-Closing Covenant. 

(a) Each Obligor hereby represents and warrants to each Lender as follows: 

(i) Such Obligor has full power, authority and legal right to make and perform this Amendment. This Amendment is within
such Obligor’s corporate powers and has been duly authorized by all necessary corporate and, if required, by all necessary shareholder action. This Amendment has been duly executed and delivered by such Obligor and constitutes legal, valid and
binding obligations of such Obligor, enforceable against such Obligor in accordance with its terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability
affecting the enforcement of creditors’ rights and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). This Amendment (x) does not require
any consent or approval of, registration or filing with, or any other action by, any Governmental Authority or any third party, except for such as have been obtained or made and are in full force and effect, (y) will not violate any applicable
law or regulation or the charter, bylaws or other organizational documents of such Obligor and its Subsidiaries or any order of any Governmental Authority, other than any such violations that, individually or in the aggregate, could not reasonably
be expected to have a Material Adverse Effect, (z) will not violate or result in an event of default under any material indenture, agreement or other instrument binding upon such Obligor and its Subsidiaries or assets, or give rise to a right
thereunder to require any payment to be made by any such Person. 
 (ii) No Default has occurred or is continuing or
will result after giving effect to this Amendment. 
 (iii) The representations and warranties made by or with respect
to such Obligor in Section 7 of the Loan Agreement are true in all material respects, except that (A) such representations and warranties that refer to a specific earlier date were true in all material respects on such
earlier date and (B) such representations and warranties do not take into account any changes that may be made to the schedules pursuant to Section 4(c) below. 

(iv) There has been no Material Adverse Effect since the date of the Loan Agreement, other than any Material Adverse
Effect that has been communicated prior to the date hereof to any Lender in its role as a Board Observer. 

  
 2 

 (b) Each Obligor hereby ratifies, confirms, reaffirms, and
acknowledges its obligations under the Loan Documents to which it is a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Amendment, except as expressly provided herein. By executing this Amendment, each
Obligor acknowledges that it has read, consulted with its attorneys regarding, and understands, this Amendment. 
 (c)
On January 25, 2018, the Borrower provided the Lenders updated versions of the schedules of the Loan Agreement that are permitted to be updated pursuant to Section 7.20 of the Loan Agreement. If such revised
schedules are not current to a material extent on the effective date of this Amendment, each Obligor shall update, in accordance with Section 7.20 of the Loan Agreement, such schedules within 30 days after the date hereof.
Notwithstanding Section 7.20 of the Loan Agreement or any other provision of the Loan Documents to the contrary, any such updates shall be in form and substance satisfactory to the Lenders. Any failure to comply with this
post-closing covenant shall constitute an immediate Event of Default. 
 SECTION 5. Governing Law; Submission To Jurisdiction; Waiver Of
Jury Trial. 
 (a) Governing Law. This Amendment and the rights and obligations of the parties hereunder shall be
governed by, and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that Section 5-1401 of the New York General Obligations Law shall apply. 
 (b)
Submission to Jurisdiction. Each Obligor agrees that any suit, action or proceeding with respect to this Amendment or any other Loan Document to which it is a party or any judgment entered by any court in respect thereof may be brought initially
in the federal or state courts in Houston, Texas or in the courts of its own corporate domicile and irrevocably submits to the non-exclusive jurisdiction of each such court for the purpose of any such suit,
action, proceeding or judgment. This Section 5 is for the benefit of the Lenders only and, as a result, no Lender shall be prevented from taking proceedings in any other courts with jurisdiction. To the extent allowed by
applicable Laws, the Lenders may take concurrent proceedings in any number of jurisdictions. 
 (c) Waiver of Jury
Trial. Each Obligor and each Lender hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any suit, action or proceeding arising out of or relating to this Amendment, the other Loan
Documents or the transactions contemplated hereby or thereby. 
 SECTION 6. Miscellaneous. 

(a) No Waiver. Nothing contained herein shall be deemed to constitute a waiver of compliance with any term or condition
contained in the Loan Agreement or any of the other Loan Documents or constitute a course of conduct or dealing among the parties. Except as expressly stated herein, the Lenders reserve all rights, privileges and remedies under the Loan Documents
(including, without limitation, all such rights, privileges and remedies with respect to any Default, Event of Default or Material Adverse Effect, whether communicated or not to the Lenders or Agent). Except as amended hereby, the Loan Agreement and
other Loan Documents remain 

  
 3 

 
unmodified and in full force and effect. All references in the Loan Documents to the Loan Agreement shall be deemed to be references to the Loan Agreement as amended hereby. 

(b) Severability. In case any provision of or obligation under this Amendment shall be invalid, illegal or unenforceable
in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby. 

(c) Headings. Headings and captions used in this Amendment (including the Exhibits, Schedules and Annexes hereto, if
any) are included for convenience of reference only and shall not be given any substantive effect. 
 (d) Integration.
This Amendment constitutes a Loan Document and, together with the other Loan Documents, incorporates all negotiations of the parties hereto with respect to the subject matter hereof and is the final expression and agreement of the parties hereto
with respect to the subject matter hereof. 
 (e) Counterparts. This Amendment may be executed in any number of
counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Amendment by signing any such counterpart. 

(f) Controlling Provisions. In the event of any inconsistencies between the provisions of this Amendment and the
provisions of any other Loan Document, the provisions of this Amendment shall govern and prevail. Except as expressly modified by this Amendment, the Loan Documents shall not be modified and shall remain in full force and effect. 

[Remainder of page intentionally left blank] 

  
 4 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as
of the date first above written. 
  

			
	 BORROWER

	
	 GENOMEDX BIOSCIENCES INC.

		
	 By:
	 	 /s/ Michael Rodriguez

		 	 Name: Michael Rodriguez

		 	 Title: Chief Financial Officer

	
	 Address for Notices:

	 1038 Homer Street

	 Vancouver, BC

	 Canada V6B 2W9

	
	 Tel:

	 Email:

	
	 SUBSIDIARY GUARANTOR

	
	 GENOMEDX BIOSCIENCES CORP.

		
	 By:
	 	 /s/ Elai Davicioni

		 	 Name: Elai Davicioni

		 	 Title: President & CSO

	
	 Address for Notices:

	
	 10355 Science Center Drive, Suite 240

	 San Diego, CA 92121

	
	 Tel:

	 Email:

 [Signature Page to Amendment Agreement No. 7] 

			
	 THE LENDERS

	
	 CRG PARTNERS III L.P.,

	 By CRG PARTNERS III GP L.P., its General Partner

	 By CRG PARTNERS III GP LLC, its General Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

  

			
	 CRG PARTNERS III–PARALLEL FUND “A” L.P.,

	 By CRG PARTNERS III – PARALLEL FUND “A” GP L.P., its General
Partner

	 By CRG PARTNERS III – PARALLEL FUND “A” GP LLC, its General
Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

  

					
	 CRG PARTNERS III (CAYMAN) L.P.,

	 By CRG PARTNERS III (CAYMAN) GP L.P., its General Partner

	 By CRG PARTNERS III (CAYMAN) GP LLC, its General Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

			
		 	 Witness:
	 	 /s/ Nicole Nesson

		
		 	 Name: Nicole Nesson

 [Signature Page to Amendment Agreement No. 7] 

 AGENT 
  

			
	 CRG SERVICING LLC, as Agent

		
	 By
	 	 /s/ Nathan Hukill

		 	 Nathan Hukill

		 	 Authorized Signatory

 [Signature Page to Amendment Agreement No. 7] 

 AMENDMENT AGREEMENT NO. 8 

THIS AMENDMENT AGREEMENT NO. 8 (this “Amendment”), dated as of March 30, 2018, is made among
GenomeDx Biosciences Inc., a company incorporated in British Columbia, Canada (the “Borrower”), the Subsidiary Guarantor listed on the signature pages hereof under the heading “SUBSIDIARY GUARANTOR” (the
“Subsidiary Guarantor”, and together with the Borrower, each an “Obligor” and, collectively, the “Obligors”), the Lenders listed on the signature pages hereof under the heading
“LENDERS” (each a “Lender” and, collectively, the “Lenders”) and CRG PARTNERS III L.P., as administrative and collateral agent for the Lenders hereunder (in such capacity, the
“Agent”). 
 The Obligors and the Lenders are parties to that certain Term Loan Agreement, dated as
of September 23, 2015, as amended by that Waiver and Amendment Agreement, dated as of December 30, 2015, Amendment Agreement No. 2, dated as of December 30, 2015, Waiver and Amendment Agreement No. 3, dated as of
April 21, 2016, Amendment Agreement No. 4, dated as of October 27, 2016, Amendment Agreement No. 5, dated as of December 26, 2017, and Amendment Agreement No. 6, dated as of January 15, 2018, and Amendment
Agreement No. 7, dated as of March 5, 2018 (as further amended, amended and restated, modified or supplemented from time to time, the “Loan Agreement”). 

The parties hereto desire to amend the Loan Agreement on the terms and subject to the conditions set forth herein. 

Accordingly, the parties hereto agree as follows: 

SECTION 1. Definitions; Interpretation. 

(a) Terms Defined in Loan Agreement. All capitalized terms used in this Amendment (including in the recitals hereof) and
not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement. 
 (b) Interpretation.
The rules of interpretation set forth in Section 1.03 of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference. 

SECTION 2. Amendments. 

Subject to Section 3, the Loan Agreement is hereby amended as follows: 

(a) Section 10.01 is hereby amended by amending and restating the proviso at the end thereof to read
in its entirety as follows: 
 “; provided that, for the period between March 30, 2018 and
April 6, 2018, such minimum Liquidity shall be at least $500,000”. 
 SECTION 3. Conditions of Effectiveness. 

The effectiveness of Section 2 shall be subject to the following conditions precedent: 

  
 1 

 (a) The Obligors, all of the Lenders and the Agent shall have duly
executed and delivered this Amendment pursuant to Section 12.04 of the Loan Agreement. 
 (b)
The Obligors shall have paid or reimbursed Lenders for Lenders’ reasonable out of pocket costs and expenses incurred in connection with this Amendment, including Lenders’ reasonable out of pocket legal fees and costs, pursuant to
Section 12.03(a)(i)(z) of the Loan Agreement. 
 (c) The representations and warranties in
Section 4 shall be true and correct on the date hereof and on the first date on which the conditions set forth in Sections 3(a) and (b) shall have been satisfied. 

SECTION 4. Representations and Warranties; Reaffirmation. 

(a) Each Obligor hereby represents and warrants to each Lender as follows: 

(i) Such Obligor has full power, authority and legal right to make and perform this Amendment. This Amendment is within
such Obligor’s corporate powers and has been duly authorized by all necessary corporate and, if required, by all necessary shareholder action. This Amendment has been duly executed and delivered by such Obligor and constitutes legal, valid and
binding obligations of such Obligor, enforceable against such Obligor in accordance with its terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability
affecting the enforcement of creditors’ rights and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). This Amendment (x) does not require
any consent or approval of, registration or filing with, or any other action by, any Governmental Authority or any third party, except for such as have been obtained or made and are in full force and effect, (y) will not violate any applicable
law or regulation or the charter, bylaws or other organizational documents of such Obligor and its Subsidiaries or any order of any Governmental Authority, other than any such violations that, individually or in the aggregate, could not reasonably
be expected to have a Material Adverse Effect, (z) will not violate or result in an event of default under any material indenture, agreement or other instrument binding upon such Obligor and its Subsidiaries or assets, or give rise to a right
thereunder to require any payment to be made by any such Person. 
 (ii) No Default has occurred or is continuing or
will result after giving effect to this Amendment. 
 (iii) The representations and warranties made by or with respect
to such Obligor in Section 7 of the Loan Agreement are true in all material respects, except that such representations and warranties that refer to a specific earlier date were true in all material respects on such earlier
date. 
 (iv) There has been no Material Adverse Effect since the date of the Loan Agreement, other than any Material
Adverse Effect that has been communicated prior to the date hereof to any Lender in its role as a Board Observer. 
 (b)
Each Obligor hereby ratifies, confirms, reaffirms, and acknowledges its obligations under the Loan Documents to which it is a party and agrees that the Loan Documents remain in 

  
 2 

 
full force and effect, undiminished by this Amendment, except as expressly provided herein. By executing this Amendment, each Obligor acknowledges that it has read, consulted with its attorneys
regarding, and understands, this Amendment. 
 SECTION 5. Governing Law; Submission To Jurisdiction; Waiver Of Jury Trial. 

(a) Governing Law. This Amendment and the rights and obligations of the parties hereunder shall be governed by, and
construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that
Section 5-1401 of the New York General Obligations Law shall apply. 
 (b)
Submission to Jurisdiction. Each Obligor agrees that any suit, action or proceeding with respect to this Amendment or any other Loan Document to which it is a party or any judgment entered by any court in respect thereof may be brought initially
in the federal or state courts in Houston, Texas or in the courts of its own corporate domicile and irrevocably submits to the non-exclusive jurisdiction of each such court for the purpose of any such suit,
action, proceeding or judgment. This Section 5 is for the benefit of the Lenders only and, as a result, no Lender shall be prevented from taking proceedings in any other courts with jurisdiction. To the extent allowed by
applicable Laws, the Lenders may take concurrent proceedings in any number of jurisdictions. 
 (c) Waiver of Jury
Trial. Each Obligor and each Lender hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any suit, action or proceeding arising out of or relating to this Amendment, the other Loan
Documents or the transactions contemplated hereby or thereby. 
 SECTION 6. Miscellaneous. 

(a) No Waiver. Nothing contained herein shall be deemed to constitute a waiver of compliance with any term or condition
contained in the Loan Agreement or any of the other Loan Documents or constitute a course of conduct or dealing among the parties. Except as expressly stated herein, the Lenders reserve all rights, privileges and remedies under the Loan Documents
(including, without limitation, all such rights, privileges and remedies with respect to any Default, Event of Default or Material Adverse Effect, whether communicated or not to the Lenders or Agent). Except as amended hereby, the Loan Agreement and
other Loan Documents remain unmodified and in full force and effect. All references in the Loan Documents to the Loan Agreement shall be deemed to be references to the Loan Agreement as amended hereby. 

(b) Severability. In case any provision of or obligation under this Amendment shall be invalid, illegal or unenforceable
in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby. 

(c) Headings. Headings and captions used in this Amendment (including the Exhibits, Schedules and Annexes hereto, if
any) are included for convenience of reference only and shall not be given any substantive effect. 

  
 3 

 (d) Integration. This Amendment constitutes a Loan Document and,
together with the other Loan Documents, incorporates all negotiations of the parties hereto with respect to the subject matter hereof and is the final expression and agreement of the parties hereto with respect to the subject matter hereof. 

(e) Counterparts. This Amendment may be executed in any number of counterparts, all of which taken together shall
constitute one and the same instrument and any of the parties hereto may execute this Amendment by signing any such counterpart. 

(f) Controlling Provisions. In the event of any inconsistencies between the provisions of this Amendment and the
provisions of any other Loan Document, the provisions of this Amendment shall govern and prevail. Except as expressly modified by this Amendment, the Loan Documents shall not be modified and shall remain in full force and effect. 

[Remainder of page intentionally left blank] 

  
 4 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as
of the date first above written. 
  

			
	 BORROWER

	
	 GENOMEDX BIOSCIENCES INC.

			
		
	 By:
	 	 /s/ Michael Rodriguez

			
		 	 Name: Michael Rodriguez

		 	 Title: Chief Financial Officer

	
	 Address for Notices:

	 1038 Homer Street

	 Vancouver, BC

	 Canada V6B 2W9

	
	 Tel:

	 Email:

	
	 SUBSIDIARY GUARANTOR

	
	 GENOMEDX BIOSCIENCES CORP.

			
		
	 By:
	 	 /s/ Edwin Hendrick

			
		 	 Name: Edwin Hendrick

		 	 Title: CCO

	  
 Address for
Notices:
 10355 Science Center Drive, Suite 240

San Diego, CA 92121
  

Tel:
 Email:

 [Signature Page to Amendment Agreement] 

			
	 THE LENDERS

	
	 CRG PARTNERS III L.P.,

	 By CRG PARTNERS III GP L.P., its General Partner

	 By CRG PARTNERS III GP LLC, its General Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

  

			
	 CRG PARTNERS III–PARALLEL FUND “A” L.P.,

	 By CRG PARTNERS III – PARALLEL FUND “A” GP L.P., its General
Partner

	 By CRG PARTNERS III – PARALLEL FUND “A” GP LLC, its General
Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

  

					
	 CRG PARTNERS III (CAYMAN) L.P.,

	 By CRG PARTNERS III (CAYMAN) GP L.P., its General Partner

	 By CRG PARTNERS III (CAYMAN) GP LLC, its General Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

			
		 	 Witness:
	 	 /s/ Cameron Hui

		
		 	 Name: Cameron Hui

 [Signature Page to Amendment Agreement] 

 AGENT 
  

			
	 CRG SERVICING LLC, as Agent

		
	 By
	 	 /s/ Nathan Hukill

		 	 Nathan Hukill

		 	 Authorized Signatory

 [Signature Page to Amendment Agreement] 

 AMENDMENT AGREEMENT NO. 9 

THIS AMENDMENT AGREEMENT NO. 9 (this “Amendment”), dated April 5, 2018 and effective as of
April 4, 2018, is made among GenomeDx Biosciences Inc., a company incorporated in British Columbia, Canada (the “Borrower”), the Subsidiary Guarantor listed on the signature pages hereof under the heading
“SUBSIDIARY GUARANTOR” (the “Subsidiary Guarantor”, and together with the Borrower, each an “Obligor” and, collectively, the “Obligors”), the Lenders listed on the
signature pages hereof under the heading “LENDERS” (each a “Lender” and, collectively, the “Lenders”) and CRG PARTNERS III L.P., as administrative and collateral agent for the Lenders
hereunder (in such capacity, the “Agent”). 
 The Obligors and the Lenders are parties to that
certain Term Loan Agreement, dated as of September 23, 2015, as amended by that Waiver and Amendment Agreement, dated as of December 30, 2015, Amendment Agreement No. 2, dated as of December 30, 2015, Waiver and Amendment
Agreement No. 3, dated as of April 21, 2016, Amendment Agreement No. 4, dated as of October 27, 2016, Amendment Agreement No. 5, dated as of December 26, 2017, and Amendment Agreement No. 6, dated as of
January 15, 2018, Amendment Agreement No. 7, dated as of March 5, 2018, and Amendment Agreement No. 8, dated as of March 30, 2018 (as further amended, amended and restated, modified or supplemented from time to time, the
“Loan Agreement”). 
 The parties hereto desire to amend the Loan Agreement on the terms and subject
to the conditions set forth herein. 
 Accordingly, the parties hereto agree as follows: 

SECTION 1. Definitions; Interpretation. 

(a) Terms Defined in Loan Agreement. All capitalized terms used in this Amendment (including in the recitals hereof) and
not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement. 
 (b) Interpretation.
The rules of interpretation set forth in Section 1.03 of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference. 

SECTION 2. Amendments. 

Subject to Section 3, the Loan Agreement is hereby amended as follows: 

(a) Section 10.01 is hereby amended by amending and restating the proviso at the end thereof to read
in its entirety as follows: 
 “; provided that, for the period from April 4, 2018, to
April 5, 2018, such minimum Liquidity shall be at least $200,000, and for the period from April 6, 2018, to April 16, 2018, such minimum Liquidity shall be at least $500,000”. 

  
 1 

 SECTION 3. Conditions of Effectiveness. 

The effectiveness of Section 2 shall be subject to the following conditions precedent: 

(a) The Obligors, all of the Lenders and the Agent shall have duly executed and delivered this Amendment pursuant to
Section 12.04 of the Loan Agreement. 
 (b) The Obligors shall have paid or reimbursed
Lenders for Lenders’ reasonable out of pocket costs and expenses incurred in connection with this Amendment, including Lenders’ reasonable out of pocket legal fees and costs, pursuant to Section 12.03(a)(i)(z) of
the Loan Agreement. 
 (c) The representations and warranties in Section 4 shall be true and
correct on the date hereof and on the first date on which the conditions set forth in Sections 3(a) and (b) shall have been satisfied. 

SECTION 4. Representations and Warranties; Reaffirmation. 

(a) Each Obligor hereby represents and warrants to each Lender as follows: 

(i) Such Obligor has full power, authority and legal right to make and perform this Amendment. This Amendment is within
such Obligor’s corporate powers and has been duly authorized by all necessary corporate and, if required, by all necessary shareholder action. This Amendment has been duly executed and delivered by such Obligor and constitutes legal, valid and
binding obligations of such Obligor, enforceable against such Obligor in accordance with its terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability
affecting the enforcement of creditors’ rights and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). This Amendment (x) does not require
any consent or approval of, registration or filing with, or any other action by, any Governmental Authority or any third party, except for such as have been obtained or made and are in full force and effect, (y) will not violate any applicable
law or regulation or the charter, bylaws or other organizational documents of such Obligor and its Subsidiaries or any order of any Governmental Authority, other than any such violations that, individually or in the aggregate, could not reasonably
be expected to have a Material Adverse Effect, (z) will not violate or result in an event of default under any material indenture, agreement or other instrument binding upon such Obligor and its Subsidiaries or assets, or give rise to a right
thereunder to require any payment to be made by any such Person. 
 (ii) No Default has occurred or is continuing or
will result after giving effect to this Amendment. 
 (iii) The representations and warranties made by or with respect
to such Obligor in Section 7 of the Loan Agreement are true in all material respects, except that such representations and warranties that refer to a specific earlier date were true in all material respects on such earlier
date. 

  
 2 

 (iv) There has been no Material Adverse Effect since the date of the
Loan Agreement, other than any Material Adverse Effect that has been communicated prior to the date hereof to any Lender in its role as a Board Observer. 

(b) Each Obligor hereby ratifies, confirms, reaffirms, and acknowledges its obligations under the Loan Documents to
which it is a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Amendment, except as expressly provided herein. By executing this Amendment, each Obligor acknowledges that it has read, consulted with its
attorneys regarding, and understands, this Amendment. 
 SECTION 5. Governing Law; Submission To Jurisdiction; Waiver Of Jury Trial.

 (a) Governing Law. This Amendment and the rights and obligations of the parties hereunder shall be governed by, and
construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that
Section 5-1401 of the New York General Obligations Law shall apply. 
 (b)
Submission to Jurisdiction. Each Obligor agrees that any suit, action or proceeding with respect to this Amendment or any other Loan Document to which it is a party or any judgment entered by any court in respect thereof may be brought initially
in the federal or state courts in Houston, Texas or in the courts of its own corporate domicile and irrevocably submits to the non-exclusive jurisdiction of each such court for the purpose of any such suit,
action, proceeding or judgment. This Section 5 is for the benefit of the Lenders only and, as a result, no Lender shall be prevented from taking proceedings in any other courts with jurisdiction. To the extent allowed by
applicable Laws, the Lenders may take concurrent proceedings in any number of jurisdictions. 
 (c) Waiver of Jury
Trial. Each Obligor and each Lender hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any suit, action or proceeding arising out of or relating to this Amendment, the other Loan
Documents or the transactions contemplated hereby or thereby. 
 SECTION 6. Miscellaneous. 

(a) No Waiver. Nothing contained herein shall be deemed to constitute a waiver of compliance with any term or condition
contained in the Loan Agreement or any of the other Loan Documents or constitute a course of conduct or dealing among the parties. Except as expressly stated herein, the Lenders reserve all rights, privileges and remedies under the Loan Documents
(including, without limitation, all such rights, privileges and remedies with respect to any Default, Event of Default or Material Adverse Effect, whether communicated or not to the Lenders or Agent). Except as amended hereby, the Loan Agreement and
other Loan Documents remain unmodified and in full force and effect. All references in the Loan Documents to the Loan Agreement shall be deemed to be references to the Loan Agreement as amended hereby. 

(b) Severability. In case any provision of or obligation under this Amendment shall be invalid, illegal or unenforceable
in any jurisdiction, the validity, legality and enforceability of the 

  
 3 

 
remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby. 

(c) Headings. Headings and captions used in this Amendment (including the Exhibits, Schedules and Annexes hereto, if
any) are included for convenience of reference only and shall not be given any substantive effect. 
 (d) Integration.
This Amendment constitutes a Loan Document and, together with the other Loan Documents, incorporates all negotiations of the parties hereto with respect to the subject matter hereof and is the final expression and agreement of the parties hereto
with respect to the subject matter hereof. 
 (e) Counterparts. This Amendment may be executed in any number of
counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Amendment by signing any such counterpart. 

(f) Controlling Provisions. In the event of any inconsistencies between the provisions of this Amendment and the
provisions of any other Loan Document, the provisions of this Amendment shall govern and prevail. Except as expressly modified by this Amendment, the Loan Documents shall not be modified and shall remain in full force and effect. 

[Remainder of page intentionally left blank] 

  
 4 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as
of the date first above written. 
  

			
	 BORROWER

	
	 GENOMEDX BIOSCIENCES INC.

			
		
	 By:
	 	 /s/ Michael Rodriguez

			
		 	 Name: Michael Rodriguez

		 	 Title: Chief Financial Officer

	  
 Address for
Notices:
  
 1038 Homer Street

Vancouver, BC
 Canada V6B
2W9

	  
 Tel:

Email:

	
	 SUBSIDIARY GUARANTOR

	
	 GENOMEDX BIOSCIENCES CORP.

			
		
	 By:
	 	 /s/ Elai Davicioni

			
		 	 Name: Elai Davicioni

		 	 Title: President & CSO

	  
 Address for
Notices:
  
 10355 Science Center Drive, Suite 240

San Diego, CA 92121
  

Tel:
 Email:

 [Signature Page to Amendment Agreement] 

			
	 THE LENDERS

	
	 CRG PARTNERS III L.P.,

	 By CRG PARTNERS III GP L.P., its General Partner

	 By CRG PARTNERS III GP LLC, its General
Partner

			
		
	 By
	 	 /s/ Nathan Hukill

			
		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

  

			
	 CRG PARTNERS III–PARALLEL FUND “A” L.P.,

	 By CRG PARTNERS III – PARALLEL FUND “A” GP L.P., its General
Partner

	 By CRG PARTNERS III – PARALLEL FUND “A” GP LLC, its General
Partner

			
		
	 By
	 	 /s/ Nathan Hukill

			
		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

  

					
	 CRG PARTNERS III (CAYMAN) L.P.,

	 By CRG PARTNERS III (CAYMAN) GP L.P., its General Partner

	 By CRG PARTNERS III (CAYMAN) GP LLC, its General
Partner

					
		
	 By
	 	 /s/ Nathan
Hukill

					
		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

			
		 	 Witness:
	 	 /s/ Nicole Nesson

		
		 	 Name: Nicole Nesson

 [Signature Page to Amendment Agreement] 

 AGENT 
  

			
	 CRG SERVICING LLC, as Agent

			
		
	 By
	 	 /s/ Nathan Hukill

			
		 	 Nathan Hukill

		 	 Authorized Signatory

 [Signature Page to Amendment Agreement] 

 AMENDMENT AGREEMENT NO. 10 

THIS AMENDMENT AGREEMENT NO. 10 (this “Amendment”), dated June 12, 2018, is made among GenomeDx
Biosciences Inc., a company incorporated in British Columbia, Canada (the “Borrower”), the Subsidiary Guarantor listed on the signature pages hereof under the heading “SUBSIDIARY GUARANTOR” (the
“Subsidiary Guarantor”, and together with the Borrower, each an “Obligor” and, collectively, the “Obligors”), the Lenders listed on the signature pages hereof under the heading
“LENDERS” (each a “Lender” and, collectively, the “Lenders”) and CRG PARTNERS III L.P., as administrative and collateral agent for the Lenders hereunder (in such capacity, the
“Agent”). 
 The Obligors and the Lenders are parties to that certain Term Loan Agreement, dated as
of September 23, 2015, as amended by that Waiver and Amendment Agreement, dated as of December 30, 2015, Amendment Agreement No. 2, dated as of December 30, 2015, Waiver and Amendment Agreement No. 3, dated as of
April 21, 2016, Amendment Agreement No. 4, dated as of October 27, 2016, Amendment Agreement No. 5, dated as of December 26, 2017, and Amendment Agreement No. 6, dated as of January 15, 2018, Amendment Agreement
No. 7, dated as of March 5, 2018, Amendment Agreement No. 8, dated as of March 30, 2018, and Amendment Agreement No. 9, dated as of April 5, 2018 (as further amended, amended and restated, modified or supplemented from
time to time, the “Loan Agreement”). 
 The parties hereto desire to amend the Loan Agreement on the
terms and subject to the conditions set forth herein. 
 Accordingly, the parties hereto agree as follows: 

SECTION 1. Definitions; Interpretation. 

(a) Terms Defined in Loan Agreement. All capitalized terms used in this Amendment (including in the recitals hereof) and
not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement. 
 (b) Interpretation.
The rules of interpretation set forth in Section 1.03 of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference. 

SECTION 2. Amendments. 

Subject to Section 3, the Loan Agreement is hereby amended as follows: 

(a) Section 10.01 is hereby amended by amending and restating the proviso at the end thereof to read
in its entirety as follows: 
 “; provided that, for the period from June 12, 2018, to
September 30, 2018, such minimum Liquidity shall be at least $1,000,000”. 

  
 1 

 SECTION 3. Conditions of Effectiveness. 

The effectiveness of Section 2 shall be subject to the following conditions precedent: 

(a) The Obligors, all of the Lenders and the Agent shall have duly executed and delivered this Amendment pursuant to
Section 12.04 of the Loan Agreement. 
 (b) The Obligors shall have paid or reimbursed
Lenders for Lenders’ reasonable out of pocket costs and expenses incurred in connection with this Amendment, including Lenders’ reasonable out of pocket legal fees and costs, pursuant to Section 12.03(a)(i)(z) of
the Loan Agreement. 
 (c) The representations and warranties in Section 4 shall be true and
correct on the date hereof and on the first date on which the conditions set forth in Sections 3(a) and (b) shall have been satisfied. 

SECTION 4. Representations and Warranties; Reaffirmation. 

(a) Each Obligor hereby represents and warrants to each Lender as follows: 

(i) Such Obligor has full power, authority and legal right to make and perform this Amendment. This Amendment is within
such Obligor’s corporate powers and has been duly authorized by all necessary corporate and, if required, by all necessary shareholder action. This Amendment has been duly executed and delivered by such Obligor and constitutes legal, valid and
binding obligations of such Obligor, enforceable against such Obligor in accordance with its terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability
affecting the enforcement of creditors’ rights and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). This Amendment (x) does not require
any consent or approval of, registration or filing with, or any other action by, any Governmental Authority or any third party, except for such as have been obtained or made and are in full force and effect, (y) will not violate any applicable
law or regulation or the charter, bylaws or other organizational documents of such Obligor and its Subsidiaries or any order of any Governmental Authority, other than any such violations that, individually or in the aggregate, could not reasonably
be expected to have a Material Adverse Effect, (z) will not violate or result in an event of default under any material indenture, agreement or other instrument binding upon such Obligor and its Subsidiaries or assets, or give rise to a right
thereunder to require any payment to be made by any such Person. 
 (ii) No Default has occurred or is continuing or
will result after giving effect to this Amendment. 
 (iii) The representations and warranties made by or with respect
to such Obligor in Section 7 of the Loan Agreement are true in all material respects, except that such representations and warranties that refer to a specific earlier date were true in all material respects on such earlier
date. 

  
 2 

 (iv) There has been no Material Adverse Effect since the date of the
Loan Agreement, other than any Material Adverse Effect that has been communicated prior to the date hereof to any Lender in its role as a Board Observer. 

(b) Each Obligor hereby ratifies, confirms, reaffirms, and acknowledges its obligations under the Loan Documents to
which it is a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Amendment, except as expressly provided herein. By executing this Amendment, each Obligor acknowledges that it has read, consulted with its
attorneys regarding, and understands, this Amendment. 
 SECTION 5. Governing Law; Submission To Jurisdiction; Waiver Of Jury Trial.

 (a) Governing Law. This Amendment and the rights and obligations of the parties hereunder shall be governed by, and
construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that
Section 5-1401 of the New York General Obligations Law shall apply. 
 (b)
Submission to Jurisdiction. Each Obligor agrees that any suit, action or proceeding with respect to this Amendment or any other Loan Document to which it is a party or any judgment entered by any court in respect thereof may be brought initially
in the federal or state courts in Houston, Texas or in the courts of its own corporate domicile and irrevocably submits to the non-exclusive jurisdiction of each such court for the purpose of any such suit,
action, proceeding or judgment. This Section 5 is for the benefit of the Lenders only and, as a result, no Lender shall be prevented from taking proceedings in any other courts with jurisdiction. To the extent allowed by
applicable Laws, the Lenders may take concurrent proceedings in any number of jurisdictions. 
 (c) Waiver of Jury
Trial. Each Obligor and each Lender hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any suit, action or proceeding arising out of or relating to this Amendment, the other Loan
Documents or the transactions contemplated hereby or thereby. 
 SECTION 6. Miscellaneous. 

(a) No Waiver. Nothing contained herein shall be deemed to constitute a waiver of compliance with any term or condition
contained in the Loan Agreement or any of the other Loan Documents or constitute a course of conduct or dealing among the parties. Except as expressly stated herein, the Lenders reserve all rights, privileges and remedies under the Loan Documents
(including, without limitation, all such rights, privileges and remedies with respect to any Default, Event of Default or Material Adverse Effect, whether communicated or not to the Lenders or Agent). Except as amended hereby, the Loan Agreement and
other Loan Documents remain unmodified and in full force and effect. All references in the Loan Documents to the Loan Agreement shall be deemed to be references to the Loan Agreement as amended hereby. 

(b) Severability. In case any provision of or obligation under this Amendment shall be invalid, illegal or unenforceable
in any jurisdiction, the validity, legality and enforceability of the 

  
 3 

 
remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby. 

(c) Headings. Headings and captions used in this Amendment (including the Exhibits, Schedules and Annexes hereto, if
any) are included for convenience of reference only and shall not be given any substantive effect. 
 (d) Integration.
This Amendment constitutes a Loan Document and, together with the other Loan Documents, incorporates all negotiations of the parties hereto with respect to the subject matter hereof and is the final expression and agreement of the parties hereto
with respect to the subject matter hereof. 
 (e) Counterparts. This Amendment may be executed in any number of
counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Amendment by signing any such counterpart. 

(f) Controlling Provisions. In the event of any inconsistencies between the provisions of this Amendment and the
provisions of any other Loan Document, the provisions of this Amendment shall govern and prevail. Except as expressly modified by this Amendment, the Loan Documents shall not be modified and shall remain in full force and effect. 

[Remainder of page intentionally left blank] 

  
 4 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as
of the date first above written. 
  

			
	 BORROWER

	
	 GENOMEDX BIOSCIENCES INC.

		
	 By:
	 	 /s/ Michael Rodriguez

		 	 Name: Michael Rodriguez

		 	 Title: Chief Financial Officer

	
	 Address for Notices:

	
	 1038 Homer Street

	 Vancouver, BC

	 Canada V6B 2W9

	
	 Tel: 

	 Email: 

	
	 SUBSIDIARY GUARANTOR

	
	 GENOMEDX BIOSCIENCES CORP.

		
	 By:
	 	 /s/ Elai Davicioni

		 	 Name: Elai Davicioni

		 	 Title: President & CSO

	
	 Address for Notices:

	
	 10355 Science Center Drive, Suite 240

	 San Diego, CA 92121

	
	 Tel: 

	 Email: 

 [Signature Page to Amendment Agreement] 

					
	 THE LENDERS

	
	 CRG PARTNERS III L.P.,

	     By CRG PARTNERS III GP L.P., its General

    Partner

	 By CRG PARTNERS III GP LLC, its General

Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

	
	 CRG PARTNERS III–PARALLEL FUND “A” L.P.,

	     By CRG PARTNERS III – PARALLEL FUND

    “A” GP L.P., its General Partner

	 By CRG PARTNERS III – PARALLEL

FUND “A” GP LLC, its General Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

	
	 CRG PARTNERS III (CAYMAN) L.P.,

	     By CRG PARTNERS III (CAYMAN) GP L.P., its

    General Partner

	 By CRG PARTNERS III (CAYMAN) GP LLC,

its General Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

			
		 	 Witness:
	 	 /s/ Nicole Nesson

		
		 	 Name: Nicole Nesson

 [Signature Page to Amendment Agreement] 

 AGENT 
  

			
	 CRG SERVICING LLC, as Agent

		
	 By
	 	 /s/ Nathan Hukill

		 	 Nathan Hukill

		 	 Authorized Signatory

 [Signature Page to Amendment Agreement] 

 AMENDMENT AGREEMENT NO. 11 

THIS AMENDMENT AGREEMENT NO. 11 (this “Amendment”), dated September 26, 2018, is made among
GenomeDx Inc., a company incorporated in Delaware and formerly known as GenomeDx Biosciences Inc., a company incorporated in British Columbia, Canada (the “Borrower”), the Subsidiary Guarantor listed on the signature pages
hereof under the heading “SUBSIDIARY GUARANTOR” (the “Subsidiary Guarantor”, and together with the Borrower, each an “Obligor” and, collectively, the “Obligors”), the
Lenders listed on the signature pages hereof under the heading “LENDERS” (each a “Lender” and, collectively, the “Lenders”) and CRG PARTNERS III L.P., as administrative and collateral agent
for the Lenders hereunder (in such capacity, the “Agent”). 
 The Obligors and the Lenders are
parties to that certain Term Loan Agreement, dated as of September 23, 2015, as amended by that Waiver and Amendment Agreement, dated as of December 30, 2015, Amendment Agreement No. 2, dated as of December 30, 2015, Waiver and
Amendment Agreement No. 3, dated as of April 21, 2016, Amendment Agreement No. 4, dated as of October 27, 2016, Amendment Agreement No. 5, dated as of December 26, 2017, and Amendment Agreement No. 6, dated as of
January 15, 2018, Amendment Agreement No. 7, dated as of March 5, 2018, Amendment Agreement No. 8, dated as of March 30, 2018, Amendment Agreement No. 9, dated as of April 5, 2018, and Amendment Agreement
No. 10, dated as of June 12, 2018 (as further amended, amended and restated, modified or supplemented from time to time, the “Loan Agreement”). 

The parties hereto desire to amend the Loan Agreement on the terms and subject to the conditions set forth herein. 

Accordingly, the parties hereto agree as follows: 

SECTION 1. Definitions; Interpretation. 

(a) Terms Defined in Loan Agreement. All capitalized terms used in this Amendment (including in the recitals hereof) and
not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement. 
 (b) Interpretation.
The rules of interpretation set forth in Section 1.03 of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference. 

SECTION 2. Amendments. 

Subject to Section 3, the Loan Agreement is hereby amended as follows: 

(a) Section 10.01 is hereby amended by amending and restating the proviso at the end thereof to read
in its entirety as follows: 
 “; provided that, for the period (i) from June 12,
2018, to September 26, 2018, such minimum Liquidity shall be at least $1,000,000, (ii) from September 27, 2018, to October 10, 2018, such minimum 

  
 1 

 
Liquidity shall be at least $500,000, and (iii) from October 11, 2018, to November 30, 2018, such minimum Liquidity shall be at least $1,000,000”. 

SECTION 3. Conditions of Effectiveness. 

The effectiveness of Section 2 shall be subject to the following conditions precedent: 

(a) The Obligors, all of the Lenders and the Agent shall have duly executed and delivered this Amendment pursuant to
Section 12.04 of the Loan Agreement. 
 (b) The Obligors shall have paid or reimbursed
Lenders for Lenders’ reasonable out of pocket costs and expenses incurred in connection with this Amendment, including Lenders’ reasonable out of pocket legal fees and costs, pursuant to Section 12.03(a)(i)(z) of
the Loan Agreement. 
 (c) The representations and warranties in Section 4 shall be true and
correct on the date hereof and on the first date on which the conditions set forth in Sections 3(a) and (b) shall have been satisfied. 

SECTION 4. Representations and Warranties; Reaffirmation. 

(a) Each Obligor hereby represents and warrants to each Lender as follows: 

(i) Such Obligor has full power, authority and legal right to make and perform this Amendment. This Amendment is within
such Obligor’s corporate powers and has been duly authorized by all necessary corporate and, if required, by all necessary shareholder action. This Amendment has been duly executed and delivered by such Obligor and constitutes legal, valid and
binding obligations of such Obligor, enforceable against such Obligor in accordance with its terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability
affecting the enforcement of creditors’ rights and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). This Amendment (x) does not require
any consent or approval of, registration or filing with, or any other action by, any Governmental Authority or any third party, except for such as have been obtained or made and are in full force and effect, (y) will not violate any applicable
law or regulation or the charter, bylaws or other organizational documents of such Obligor and its Subsidiaries or any order of any Governmental Authority, other than any such violations that, individually or in the aggregate, could not reasonably
be expected to have a Material Adverse Effect, (z) will not violate or result in an event of default under any material indenture, agreement or other instrument binding upon such Obligor and its Subsidiaries or assets, or give rise to a right
thereunder to require any payment to be made by any such Person. 
 (ii) No Default has occurred or is continuing or
will result after giving effect to this Amendment. 
 (iii) The representations and warranties made by or with respect
to such Obligor in Section 7 of the Loan Agreement are true in all material respects, except that (A) such representations and warranties that refer to a specific earlier date were true in all material respects

  
 2 

 
on such earlier date, and (B) such representations and warranties do not take into account any changes that may be made to the schedules pursuant to Section 4(c)
below. 
 (iv) There has been no Material Adverse Effect since the date of the Loan Agreement, other than any Material
Adverse Effect that has been communicated prior to the date hereof to any Lender in its role as a Board Observer or director on the Board of Directors of the Borrower. 

(b) Each Obligor hereby ratifies, confirms, reaffirms, and acknowledges its obligations under the Loan Documents to
which it is a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Amendment, except as expressly provided herein. By executing this Amendment, each Obligor acknowledges that it has read, consulted with its
attorneys regarding, and understands, this Amendment. 
 (c) The Borrower has previously provided the Lenders updated
versions of the schedules of the Loan Agreement that are permitted to be updated pursuant to Section 7.20 of the Loan Agreement. If such revised schedules are not current to a material extent on the effective date of this
Amendment, each Obligor shall update, in accordance with Section 7.20 of the Loan Agreement, such schedules within 30 days after the date hereof. Notwithstanding Section 7.20 of the Loan Agreement
or any other provision of the Loan Documents to the contrary, any such updates shall be in form and substance satisfactory to the Lenders. Any failure to comply with this post-closing covenant shall constitute an immediate Event of Default. 

SECTION 5. Governing Law; Submission To Jurisdiction; Waiver Of Jury Trial. 

(a) Governing Law. This Amendment and the rights and obligations of the parties hereunder shall be governed by, and
construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that
Section 5-1401 of the New York General Obligations Law shall apply. 
 (b)
Submission to Jurisdiction. Each Obligor agrees that any suit, action or proceeding with respect to this Amendment or any other Loan Document to which it is a party or any judgment entered by any court in respect thereof may be brought initially
in the federal or state courts in Houston, Texas or in the courts of its own corporate domicile and irrevocably submits to the non-exclusive jurisdiction of each such court for the purpose of any such suit,
action, proceeding or judgment. This Section 5 is for the benefit of the Lenders only and, as a result, no Lender shall be prevented from taking proceedings in any other courts with jurisdiction. To the extent allowed by
applicable Laws, the Lenders may take concurrent proceedings in any number of jurisdictions. 
 (c) Waiver of Jury
Trial. Each Obligor and each Lender hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any suit, action or proceeding arising out of or relating to this Amendment, the other Loan
Documents or the transactions contemplated hereby or thereby. 

  
 3 

 SECTION 6. Miscellaneous. 

(a) No Waiver. Nothing contained herein shall be deemed to constitute a waiver of compliance with any term or condition
contained in the Loan Agreement or any of the other Loan Documents or constitute a course of conduct or dealing among the parties. Except as expressly stated herein, the Lenders reserve all rights, privileges and remedies under the Loan Documents
(including, without limitation, all such rights, privileges and remedies with respect to any Default, Event of Default or Material Adverse Effect, whether communicated or not to the Lenders or Agent). Except as amended hereby, the Loan Agreement and
other Loan Documents remain unmodified and in full force and effect. All references in the Loan Documents to the Loan Agreement shall be deemed to be references to the Loan Agreement as amended hereby. 

(b) Severability. In case any provision of or obligation under this Amendment shall be invalid, illegal or unenforceable
in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby. 

(c) Headings. Headings and captions used in this Amendment (including the Exhibits, Schedules and Annexes hereto, if
any) are included for convenience of reference only and shall not be given any substantive effect. 
 (d) Integration.
This Amendment constitutes a Loan Document and, together with the other Loan Documents, incorporates all negotiations of the parties hereto with respect to the subject matter hereof and is the final expression and agreement of the parties hereto
with respect to the subject matter hereof. 
 (e) Counterparts. This Amendment may be executed in any number of
counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Amendment by signing any such counterpart. 

(f) Controlling Provisions. In the event of any inconsistencies between the provisions of this Amendment and the
provisions of any other Loan Document, the provisions of this Amendment shall govern and prevail. Except as expressly modified by this Amendment, the Loan Documents shall not be modified and shall remain in full force and effect. 

[Remainder of page intentionally left blank] 

  
 4 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as
of the date first above written. 
  

			
	 BORROWER

	
	 GENOMEDX INC. (formerly known as GenomeDx Biosciences Inc.)

		
	 By:
	 	 /s/ Tina Nova, PhD

		 	 Name: Tina Nova, PhD

		 	 Title: President & CEO

	
	 Address for Notices:

	
	 1152 Mainland St., Suite 430

	 Vancouver, BC

	 Canada V6B 4X2

	
	 Tel: 

	 with a copy by email: 

	
	 SUBSIDIARY GUARANTOR

	
	 GENOMEDX BIOSCIENCES CORP.

		
	 By:
	 	 /s/ Tina Nova, PhD

		 	 Name: Tina Nova, PhD

		 	 Title: President & CEO

	
	 Address for Notices:

	
	 10355 Science Center Drive, Suite 240

	 San Diego, CA 92121

	
	 Tel: 

	 with a copy by email: 

 [Signature Page to Amendment Agreement] 

					
	 THE LENDERS

	
	 CRG PARTNERS III L.P.,

	     By CRG PARTNERS III GP L.P., its

    General Partner

	 By CRG PARTNERS III GP LLC, its

General Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

	
	 CRG PARTNERS III–PARALLEL FUND “A” L.P.,

	     By CRG PARTNERS III – PARALLEL FUND

    “A” GP L.P., its General Partner

	 By CRG PARTNERS III – PARALLEL

FUND “A” GP LLC, its General Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

	
	 CRG PARTNERS III (CAYMAN) L.P.,

	     By CRG PARTNERS III (CAYMAN) GP

    L.P., its General Partner

	 By CRG PARTNERS III (CAYMAN) GP

LLC, its General Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

			
		 	 Witness:
	 	 /s/ Nicole Nesson

		
		 	 Name: Nicole Nesson

 [Signature Page to Amendment Agreement] 

 AGENT 
  

			
	 CRG SERVICING LLC, as Agent

		
	 By
	 	 /s/ Nathan Hukill

		 	 Nathan Hukill

		 	 Authorized Signatory

 [Signature Page to Amendment Agreement] 

 Execution Version 

AMENDMENT AGREEMENT NO. 12 

THIS AMENDMENT AGREEMENT NO. 12 (this “Amendment”), dated December 7, 2018, is made among
GenomeDx Inc., a company incorporated in Delaware and formerly known as GenomeDx Biosciences Inc., a company incorporated in British Columbia, Canada (the “Borrower”), the Subsidiary Guarantor listed on the signature pages
hereof under the heading “SUBSIDIARY GUARANTOR” (the “Subsidiary Guarantor”, and together with the Borrower, each an “Obligor” and, collectively, the “Obligors”), the
Lenders listed on the signature pages here of under the heading “LENDERS” (each a “Lender” and, collectively, the “Lenders”) and CRG PARTNERS III L.P., as administrative and collateral agent
for the Lenders hereunder (in such capacity, the “Agent). 
 The Obligors and the Lenders are parties to that certain
Term Loan Agreement, dated as of September 23, 2015, as amended by that Waiver and Amendment Agreement, dated as of December 30, 2015, Amendment Agreement No. 2, dated as of December 30, 2015, Waiver and Amendment Agreement
No. 3, dated as of April 21, 2016, Amendment Agreement No. 4, dated as of October 27, 2016, Amendment Agreement No. 5, dated as of December 26, 2017, and Amendment Agreement No. 6, dated as of January 15,
2018, Amendment Agreement No. 7, dated as of March 5, 2018, Amendment Agreement No. 8, dated as of March 30, 2018, Amendment Agreement No. 9, dated as of April 5, 2018, Amendment Agreement No. 10, dated as of
June 12, 2018 and Amendment Agreement No. 11, dated as of September 26, 2018 (as further amended, amended and restated, modified or supplemented from time to time, the “Loan Agreement”). 

The parties hereto desire to amend the Loan Agreement on the terms and subject to the conditions set forth herein. 

Accordingly, the parties hereto agree as follows: 

SECTION 1. Definitions; Interpretation. 

(a) Terms Defined in Loan Agreement. All capitalized terms used in this Amendment (including in the recitals hereof) and
not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement. 
 (b) Interpretation.
The rules of interpretation set forth in Section 1.03 of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference. 

SECTION 2. Amendments. 

Subject to Section 3, the Loan Agreement is hereby amended as follows: 

(a) Section 10.01 is hereby amended by replacing the date “November 30, 2018” where it
appears therein with “January 31, 2019”. 

  
 1 

 SECTION 3. Conditions of Effectiveness. 

The effectiveness of Section 2 shall be subject to the following conditions precedent: 

(a) The Obligors, all of the Lenders and the Agent shall have duly executed and delivered this Amendment pursuant to
Section 12.04 of the Loan Agreement. 
 (b) The Obligors shall have paid or reimbursed
Lenders for Lenders’ reasonable out of pocket costs and expenses incurred in connection with this Amendment, including Lenders’ reasonable out of pocket legal fees and costs, pursuant to Section 12.03(a)(i)(z) of
the Loan Agreement. 
 (c) The representations and warranties in Section 4 shall be true and
correct on the date hereof and on the first date on which the conditions set forth in Sections 3(a) and (b) shall have been satisfied. 

SECTION 4. Representations and Warranties; Reaffirmation. 

(a) Each Obligor hereby represents and warrants to each Lender as follows: 

(i) Such Obligor has full power, authority and legal right to make and perform this Amendment. This Amendment is within
such Obligor’s corporate powers and has been duly authorized by all necessary corporate and, if required, by all necessary shareholder action. This Amendment has been duly executed and delivered by such Obligor and constitutes legal, valid and
binding obligations of such Obligor, enforceable against such Obligor in accordance with its terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability
affecting the enforcement of creditors’ rights and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). This Amendment (x) does not require
any consent or approval of, registration or filing with, or any other action by, any Governmental Authority or any third party, except for such as have been obtained or made and are in full force and effect, (y) will not violate any applicable
law or regulation or the charter, bylaws or other organizational documents of such Obligor and its Subsidiaries or any order of any Governmental Authority, other than any such violations that, individually or in the aggregate, could not reasonably
be expected to have a Material Adverse Effect, (z) will not violate or result in an event of default under any material indenture, agreement or other instrument binding upon such Obligor and its Subsidiaries or assets, or give rise to a right
thereunder to require any payment to be made by any such Person. 
 (ii) No Default has occurred or is continuing or
will result after giving effect to this Amendment. 
 (iii) The representations and warranties made by or with respect
to such Obligor in Section 7 of the Loan Agreement are true in all material respects, except that (A) such representations and warranties that refer to a specific earlier date were true in all material respects on such
earlier date, and (B) such representations and warranties do not take into account any changes that may be made to the schedules pursuant to Section 4(c) below. 

  
 2 

 (iv) There has been no Material Adverse Effect since the date of the
Loan Agreement, other than any Material Adverse Effect that has been communicated prior to the date hereof to any Lender in its role as a Board Observer or director on the Board of Directors of the Borrower. 

(b) Each Obligor hereby ratifies, confirms, reaffirms, and acknowledges its obligations under the Loan Documents to
which it is a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Amendment, except as expressly provided herein. By executing this Amendment, each Obligor acknowledges that it has read, consulted with its
attorneys regarding, and understands, this Amendment. 
 (c) The Borrower has previously provided the Lenders updated
versions of the schedules of the Loan Agreement that are permitted to be updated pursuant to Section 7.20 of the Loan Agreement. If such revised schedules are not current to a material extent on the effective date of this
Amendment, each Obligor shall update, in accordance with Section 7.20 of the Loan Agreement, such schedules within 30 days after the date hereof. Notwithstanding Section 7.20 of the Loan Agreement
or any other provision of the Loan Documents to the contrary, any such updates shall be in form and substance satisfactory to the Lenders. Any failure to comply with this post-closing covenant shall constitute an immediate Event of Default. 

SECTION 5. Governing Law; Submission To Jurisdiction; Waiver Of Jury Trial. 

(a) Governing Law. This Amendment and the rights and obligations of the parties hereunder shall be governed by, and
construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that
Section 5-1401 of the New York General Obligations Law shall apply. 
 (b)
Submission to Jurisdiction. Each Obligor agrees that any suit, action or proceeding with respect to this Amendment or any other Loan Document to which it is a party or any judgment entered by any court in respect thereof may be brought initially
in the federal or state courts in Houston, Texas or in the courts of its own corporate domicile and irrevocably submits to the non-exclusive jurisdiction of each such court for the purpose of any such suit,
action, proceeding or judgment. This Section 5 is for the benefit of the Lenders only and, as a result, no Lender shall be prevented from taking proceedings in any other courts with jurisdiction. To the extent allowed by
applicable Laws, the Lenders may take concurrent proceedings in any number of jurisdictions. 
 (c) Waiver of Jury
Trial. Each Obligor and each Lender hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any suit, action or proceeding arising out of or relating to this Amendment, the other Loan
Documents or the transactions contemplated hereby or thereby. 
 SECTION 6. Miscellaneous. 

(a) No Waiver. Nothing contained herein shall be deemed to constitute a waiver of compliance with any term or condition
contained in the Loan Agreement or any of the other Loan Documents or constitute a course of conduct or dealing among the parties. Except as expressly 

  
 3 

 
stated herein, the Lenders reserve all rights, privileges and remedies under the Loan Documents (including, without limitation, all such rights, privileges and remedies with respect to any
Default, Event of Default or Material Adverse Effect, whether communicated or not to the Lenders or Agent). Except as amended hereby, the Loan Agreement and other Loan Documents remain unmodified and in full force and effect. All references in the
Loan Documents to the Loan Agreement shall be deemed to be references to the Loan Agreement as amended hereby. 
 (b)
Severability. In case any provision of or obligation under this Amendment shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision
or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby. 
 (c) Headings.
Headings and captions used in this Amendment (including the Exhibits, Schedules and Annexes hereto, if any) are included for convenience of reference only and shall not be given any substantive effect. 

(d) Integration. This Amendment constitutes a Loan Document and, together with the other Loan Documents, incorporates
all negotiations of the parties hereto with respect to the subject matter hereof and is the final expression and agreement of the parties hereto with respect to the subject matter hereof. 

(e) Counterparts. This Amendment may be executed in any number of counterparts, all of which taken together shall
constitute one and the same instrument and any of the parties hereto may execute this Amendment by signing any such counterpart. 

(f) Controlling Provisions. In the event of any inconsistencies between the provisions of this Amendment and the
provisions of any other Loan Document, the provisions of this Amendment shall govern and prevail. Except as expressly modified by this Amendment, the Loan Documents shall not be modified and shall remain in full force and effect. 

[Remainder of page intentionally left blank] 

  
 4 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as
of the date first above written. 
  

			
	 BORROWER

	
	 GENOMEDX INC. (formerly known as GenomeDx Biosciences Inc.)

		
	 By:
	 	 /s/ Tina Nova, PhD

		 	 Name: Tina Nova, PhD

		 	 Title: President & CEO

	
	 Address for Notices:

	
	 1152 Mainland St., Suite 430

	 Vancouver, BC

	 Canada V6B 4X2

	
	 Tel: 

	 with a copy by email: 

	
	 SUBSIDIARY GUARANTOR

	
	 GENOMEDX BIOSCIENCES CORP.

		
	 By:
	 	 /s/ Tina Nova, PhD

		 	 Name: Tina Nova, PhD

		 	 Title: President & CEO

	
	 Address for Notices:

	
	 10355 Science Center Drive, Suite 240

	 San Diego, CA 92121

	
	 Tel: 

	 with a copy by email: 

 [Signature Page to Amendment Agreement] 

			
	 THE LENDERS

	
	 CRG PARTNERS III L.P.,

	 By CRG PARTNERS III GP L.P., its General Partner

	 By CRG PARTNERS III GP LLC, its General Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

	
	 CRG PARTNERS III–PARALLEL FUND “A” L.P.,

	 By CRG PARTNERS III – PARALLEL FUND “A” GP L.P., its General
Partner

	 By CRG PARTNERS III – PARALLEL FUND “A” GP LLC, its General
Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

  

					
	 CRG PARTNERS III (CAYMAN) L.P.,

	 By CRG PARTNERS III (CAYMAN) GP L.P., its General Partner

	 By CRG PARTNERS III (CAYMAN) GP LLC, its General Partner

		
	 By
	 	 /s/ Nathan Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

			
		 	 Witness:
	 	 /s/ Nicole Nesson

		
		 	 Name: Nicole Nesson

 [Signature Page to Amendment Agreement] 

			
	 AGENT

	
	 CRG SERVICING LLC, as Agent

		
	 By
	 	 /s/ Nathan Hukill

		 	 Nathan Hukill

		 	 Authorized Signatory

 [Signature Page to Amendment Agreement] 

 Execution Version 

AMENDMENT AGREEMENT NO. 13 AND WAIVER 

THIS AMENDMENT AGREEMENT NO. 13 AND WAIVER (this “Amendment”), dated as of April 15, 2019 and
effective as of February 1, 2019 (the “Effective Date”), is made among Decipher Biosciences, Inc., a company incorporated in Delaware and formerly known as GenomeDx Inc., a company incorporated in Delaware and formerly
known as GenomeDx Biosciences Inc., a company incorporated in British Columbia, Canada (the “Borrower”), the Subsidiary Guarantor listed on the signature pages hereof under the heading “SUBSIDIARY GUARANTOR” (the
“Subsidiary Guarantor”, and together with the Borrower, each an “Obligor” and, collectively, the “Obligors”), the Lenders listed on the signature pages hereof under the heading
“LENDERS” (each a “Lender” and, collectively, the “Lenders”) and CRG SERVICING LLC, as administrative and collateral agent for the Lenders hereunder (in such capacity, the
“Agent”). 
 The Obligors and the Lenders are parties to that certain Term Loan Agreement, dated as
of September 23, 2015 (as amended, amended and restated, modified or supplemented from time to time prior to the date hereof, the “Loan Agreement”). 

The parties hereto desire to waive certain provisions of the Loan Agreement, and to amend the Loan Agreement, in each case, on
the terms and subject to the conditions set forth herein. 
 Accordingly, the parties hereto agree as follows: 

SECTION 1. Definitions; Interpretation. 

(a) Terms Defined in Loan Agreement. All capitalized terms used in this Amendment (including in the recitals hereof) and
not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement. 
 (b) Interpretation.
The rules of interpretation set forth in Section 1.03 of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference. 

SECTION 2. Waiver 

(a) Subject to Section 4, the Lenders hereby waive compliance with
Section 10.02(d) of the Loan Agreement solely with respect to the twelve month period beginning on January 1, 2018. 

(b) The waiver set forth in Section 2(a) shall be limited precisely as written. Except as
expressly stated herein, nothing in this Amendment shall be deemed to constitute a waiver of noncompliance or breach of any other term or provision in the Loan Agreement or the other Loan Documents, nor prejudice any right or remedy that the Lenders
may now have or may have in the future under or in connection with the Loan Agreement or the other Loan Documents. 
 Nothing contained
herein shall be deemed a waiver or consent in respect of (or otherwise affect the Lenders’ ability to enforce) any condition not explicitly waived by Section 2(a). 

  
 1 

 SECTION 3. Amendments. Subject to Section 4, the Loan
Agreement is hereby amended as follows: 
 (a) Section 1.01 is hereby amended by adding the following defined
terms in the appropriate alphabetical order: 
 “”acceleration” and
“Acceleration” have the meanings set forth in Section 11.02. 

“Acceleration Premium” has the meaning set forth in Section 11.02(c). 

“Amendment 13” means that certain Amendment Agreement No. 13 and Waiver, dated as of
April 15, 2019 and effective as of February 1, 2019, made by and among the Borrower, the Subsidiary Guarantors, the Lenders, and Agent. 

“Back-End Facility Fee” has the meaning set forth in the Fee
Letter.” 
 (b) The definition of “Fee Letter” in Section 1.01 is hereby amended and
restated in its entirety as follows: 
 ““Fee Letter” means that certain fee letter agreement
dated as of December 26, 2017, between Borrower and CRG Partners III L.P., as administrative agent and collateral agent for the Lenders, as amended, amended and restated, modified or supplemented from time to time.” 

(c) The definition of “Interest-Only Period” in Section 1.01 is hereby amended and restated
in its entirety as follows: 
 ““Interest-Only Period” means the period from and including the
first Borrowing Date and through and including the Payment Date immediately preceding the Maturity Date.” 
 (d)
The definition of “Prepayment Premium” in Section 1.01 is hereby amended and restated in its entirety as follows: 

““Prepayment Premium” means, if the prepayment occurs: 

(A) on or prior to the fourth (4th) Payment Date, the
Prepayment Premium shall be an amount equal to 5.00% of the aggregate outstanding principal amount of the Loans being prepaid on such Redemption Date; 

(B) after the fourth (4th) Payment Date, and on or prior
to the eighth (8th) Payment Date, the Prepayment Premium shall be an amount equal to 4.00% of the aggregate outstanding principal amount of the Loans being prepaid on such Redemption Date; 

(C) after the eighth (8th) Payment Date, and on or prior
to the twelfth (12th) Payment Date, the Prepayment Premium shall be an amount equal to 3.00% of the aggregate outstanding principal amount of the Loans being prepaid on such Redemption Date; 

  
 2 

 (D) after the twelfth (12th) Payment Date, and on or prior to the sixteenth (16th) Payment Date, the Prepayment Premium shall be an amount equal to 2.00% of the aggregate
outstanding principal amount of the Loans being prepaid on such Redemption Date; 
 (E) after the sixteenth
(16th) Payment Date, and on or prior to the twentieth (20th) Payment Date, the Prepayment Premium shall be an amount equal to 1.00% of the
aggregate outstanding principal amount of the Loans being prepaid on such Redemption Date; 
 (F) after the
twentieth (20th) Payment Date, the Prepayment Premium shall be an amount equal to 0.00% of the aggregate outstanding principal amount of the Loans being prepaid on such Redemption Date; 

provided that, to determine the aggregate outstanding principal amount of the Loans, and how many Payment Dates
have occurred, as of any Redemption Date for purposes of this definition: 
 (i) if, as of such Redemption
Date, Borrower shall have made only one Borrowing, the number of Payment Dates shall be deemed to be the number of Payment Dates that shall have occurred following the first Borrowing Date; and 

(ii) if, as of such Redemption Date, Borrower shall have made more than one Borrowing, then the Prepayment
Premium shall equal the sum of multiple Prepayment Premiums calculated with respect to the Loans of each Borrowing, each of which Prepayment Premiums shall be calculated based on solely the aggregate outstanding principal amount of the Loans
borrowed in such Borrowing (and PIK Loans subsequently borrowed in respect of interest payments thereon), as though the applicable number of Payment Dates equals the number of Payment Dates that shall have occurred following the applicable Borrowing
Date. In the case of any partial prepayment, the amount of such prepayment shall be allocated to Loans made in the various Borrowings (and PIK Loans in respect thereof) in the order in which such Borrowings were made; and 

The Prepayment Premium payable upon any prepayment shall be in addition to any payments required pursuant to the Fee
Letter.” 
 (e) The definition of “Redemption Date” in
Section 1.01 is hereby amended and restated in its entirety as follows: 

‘“Redemption Date” means, as the context may require, (i) the Payment Date on
which an optional prepayment is made pursuant to Section 3.03(a), (ii) the date of an Asset Sale or Change of Control in connection with which a prepayment pursuant to Section 3.03(b), (iii) the
date mandated by a Requirement of Law as described in Section 5.02(b), and (iv) in the event that Loans become due and payable prior to the Stated Maturity Date for any reason not related to the foregoing clauses
(i) through (iii) (other than by reason of the Loans becoming due and payable pursuant to an Acceleration), the date on which a prepayment is due.” 

  
 3 

 (f) The definition of “Redemption Price” in
Section 1.01 is hereby amended and restated in its entirety as follows: 
 ““Redemption
Price” means an amount equal to the aggregate principal amount of the Loans being prepaid plus the Prepayment Premium plus any accrued but unpaid interest and any fees then due and owing (including the
Back-End Facility Fee).” 
 (g) Section 3.02(d) is
hereby amended by replacing the text “9.00%” where it appears therein with “8.00%” and replacing the text “4.00%” where it appears therein with “5.00%”. 

(h) A new Section 3.02(f) is hereby added immediately after
Section 3.02(e), to read in its entirety as follows: 
 “(f) Redemption Price. For the
avoidance of doubt, in the event any Loans shall become due and payable for any reason, interest pursuant to Sections 3.02(a) and (b) shall accrue on the Redemption Price for such Loans from and after the date such Redemption
Price is due and payable until paid in full.” 
 (i) Section 3.03(a) is hereby amended and
restated in its entirety as follows: 
 “(a) Optional Prepayments. Upon prior written notice to Agent delivered
pursuant to Section 4.03, Borrower shall have the right to optionally prepay in whole or in part the outstanding principal amount of the Loans on any Payment Date for the Redemption Price. No partial prepayment shall be
made under this Section 3.03(a) in connection with any event described in Section 3.03(b).” 

(j) Section 10.01 is hereby amended by (a) replacing the date “January 31, 2019” where
it appears therein with “February 28, 2019”, and (b) deleting the “and” before the “(iii)” in the proviso and adding the following immediately before the period in such proviso: 

“, and (iv) from March 1, 2019, to March 31, 2019, such minimum Liquidity shall be at least $200,000.”

 (k) Section 10.02(d) is hereby amended and restated in its entirety as follows: 

“(d) during the twelve month period beginning on January 1, 2019, of at least $16,000,000; and” 

(l) A new Section 10.02(e) is hereby added immediately after
Section 10.02(d), to read in its entirety as follows: 
 “(e) during the twelve month period
beginning on January 1, 2020, and during each twelve month period thereafter beginning on January 1 of each such period, of at least $36,000,000.” 

  
 4 

 (m) Section 11.02 is hereby amended and restated
in its entirety as follows: 
 “11.02 Remedies. 

(a) Upon the occurrence of any Event of Default, then, and in every such event (other than an Event of Default described in
Section 11.01(i), (j) or (k)), and at any time thereafter during the continuance of such event, the Majority Lenders may, by notice to Borrower, take either or both of the following actions, at the same or
different times: (i) terminate the Commitments, and thereupon the Commitments shall terminate immediately, and (ii) declare the Loans then outstanding to be due and payable in whole (or in part, in which case any principal not so declared
to be due and payable may thereafter be declared to be due and payable) (an “acceleration”), and thereupon the principal of the Loans so declared to be due and payable, together with accrued interest thereon and all fees and
other Obligations shall become due and payable immediately and the Obligors shall immediately pay all Obligations, including the Back-End Facility Fee and an Acceleration Premium as calculated below, all
without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor. 
 (b) Upon
the occurrence of any Event of Default described in Section 11.01(i), (j) or (k), the Commitments shall automatically terminate and the principal of the Loans then outstanding, together with accrued interest
thereon and all fees and other Obligations, shall automatically become due and payable immediately (an “acceleration” and, together with any acceleration defined in Section 11.02(a), each, an
“Acceleration”) and the Obligors shall immediately pay all Obligations, including the Back-End Facility Fee and an Acceleration Premium as calculated below, all without presentment,
demand, protest or other notice of any kind, all of which are hereby waived by each Obligor. 
 (c) Acceleration Premium
Calculation. The applicable “Acceleration Premium” shall be an amount calculated as follows: 

(i) If the date of Acceleration occurs: 

(A) on or prior to the fourth (4th) Payment Date, the
Acceleration Premium shall be an amount equal to 5.00% of the aggregate outstanding principal amount of the Loans subject to the Acceleration; 

(B) after the fourth (4th) Payment Date, and on or prior to the eighth (8th) Payment Date, the Acceleration
Premium shall be an amount equal to 4.00% of the aggregate outstanding principal amount of the Loans subject to the Acceleration; 

(C) after the eighth (8th) Payment Date, and on or prior to the twelfth (12th) Payment Date, the Acceleration
Premium shall be an amount equal to 3.00% of the aggregate outstanding principal amount of the Loans subject to the Acceleration; 

  
 5 

 (D) after the twelfth (12th) Payment Date, and on or prior
to the sixteenth (16th) Payment Date, the Acceleration Premium shall be an amount equal to 2.00% of the aggregate outstanding principal amount of the Loans subject to the Acceleration; 

(E) after the sixteenth (16th) Payment Date, and on or prior to the twentieth (20th) Payment Date, the
Acceleration Premium shall be an amount equal to 1.00% of the aggregate outstanding principal amount of the Loans subject to the Acceleration; 

(F) after the twentieth (20th) Payment Date, the Acceleration Premium shall be an amount equal to 0.00% of the
aggregate outstanding principal amount of the Loans subject to the Acceleration. 
 (ii) To determine the aggregate
outstanding principal amount of the Loans subject to the Acceleration, and how many Payment Dates have occurred, as of any date of Acceleration, for purposes of this Section 11.02(c): 

(A) if, as of such date of Acceleration, Borrower shall have made only one Borrowing, the number of Payment
Dates shall be deemed to be the number of Payment Dates that shall have occurred following the first Borrowing Date; and 

(B) if, as of such date of Acceleration, Borrower shall have made more than one Borrowing, then the
Acceleration Premium shall equal the sum of multiple Acceleration Premiums calculated with respect to the Loans of each Borrowing, each of which Acceleration Premiums shall be calculated based on solely the aggregate outstanding principal amount of
the Loans borrowed in such Borrowing (and PIK Loans subsequently borrowed in respect of interest payments thereon), as though the applicable number of Payment Dates equals the number of Payment Dates that shall have occurred following the applicable
Borrowing Date. In the case that the Loans subject to Acceleration does not equal the full principal amount of Loans outstanding, the amount of such payment shall be allocated to Loans made in the various Borrowings (and PIK Loans in respect
thereof) in the order in which such Borrowings were made. 
  

	 	 (d)
	 (i) For the avoidance of doubt, the Acceleration Premium and the
Back-End Facility Fee that are payable upon Acceleration of the Loans shall be due and payable at any time the Loans become due and payable prior to the Stated Maturity Date due to Acceleration pursuant to the
terms of this Agreement (in which case it shall be due immediately, upon the giving of notice to Borrower in accordance with Section 11.02(a), or automatically, in accordance with
Section 11.02(b)), whether by operation of law or otherwise (including where bankruptcy filings or the exercise 

  
 6 

	 	  
	 of any bankruptcy right or power, whether in any plan of reorganization or otherwise, results or would
result in a payment, discharge, modification or other treatment of the Loans or Loan Documents that would otherwise evade, avoid, or otherwise disappoint the expectations of Lenders in receiving the full benefit of their bargained-for Acceleration Premium and their bargained-for Back-End Facility Fee as provided herein and in the Fee Letter). The
Obligors and Lenders acknowledge and agree that any Acceleration Premium and the Back-End Facility Fee due and payable in accordance with the Loan Documents shall not constitute unmatured interest, whether
under section 502(b)(2) of the Bankruptcy Code or otherwise, but instead is reasonably calculated to ensure that the Lenders receive the benefit of their bargain under the terms of this Agreement, whether in a bankruptcy case or otherwise.

 (ii) Each Obligor acknowledges and agrees that, prior to executing this Agreement and Amendment 13, it
has had the opportunity to review, evaluate and negotiate the Acceleration Premium calculation and the Back-End Facility Fee with its advisors and acknowledges that the Acceleration Premium is a reasonable
approximation of Lenders’ liquidated damages upon Acceleration and, accordingly, each Obligor will not contest or object to the reasonableness thereof. Each Obligor understands and acknowledges that Lenders have entered into this Agreement in
reliance upon the Acceleration Premium and the Back-End Facility Fee. Each Obligor acknowledges and agrees that the Lenders shall be entitled to recover the full amount of the Obligations, including the
Acceleration Premium and the Back-End Facility Fee in each and every circumstance in which such amount is due pursuant to or in connection with this Agreement and the Fee Letter, including in the case of any
Obligor’s bankruptcy filing, so that the Lenders shall receive the benefit of their bargain hereunder and otherwise receive full recovery of the agreed-upon return under every possible circumstance, and Borrower hereby waives any defense to
payment, whether such defense may be based in public policy, ambiguity, or otherwise. Each Obligor further acknowledges and agrees, and waives any argument to the contrary, that payment of such amounts does not constitute a penalty or an otherwise
unenforceable or invalid obligation. Any damages that the Lenders may suffer or incur resulting from or arising in connection with any breach by Borrower shall constitute secured obligations owing to the Lenders 

(iii) For the avoidance of doubt, in the event of any Acceleration, interest pursuant to Sections 3.02(a) and
(b) shall accrue on all Obligations, including the Back-End Facility Fee and an Acceleration Premium, from and after the date such Obligations are due and payable until paid in full.” 

(n) A new Section 12.22 is hereby added immediately after
Section 12.21, to read in its entirety as follows: 
 “12.22 Redemption Price.
(a) For the avoidance of doubt, the Prepayment Premium (as a component of the Redemption Price) and Back-End Facility Fee shall be due and payable whenever so stated in this Agreement (and the Fee Letter,
as applicable), or by any 

  
 7 

 
applicable operation of law, regardless of the circumstances causing any related payment prior to the Stated Maturity Date (other than an Acceleration, in which case the Acceleration Premium
instead shall be payable). 
 (b) The Obligors and Lenders acknowledge and agree that any Prepayment Premium due and payable
in accordance with the Loan Documents shall not constitute unmatured interest, whether under section 502(b)(2) of the Bankruptcy Code or otherwise, but instead is reasonably calculated to ensure that the Lenders receive the benefit of their bargain
under the terms of this Agreement. 
 (c) Each Obligor acknowledges and agrees that, prior to executing this Agreement, it
has had the opportunity to review, evaluate and negotiate the Prepayment Premium calculation with its advisors and acknowledges that the Prepayment Premium is a reasonable approximation of Lenders’ liquidated damages upon repayment on any
Redemption Date prior to the Stated Maturity Date and, accordingly, each Obligor will not contest or object to the reasonableness thereof. Each Obligor understands and acknowledges that Lenders have entered into this Agreement in reliance upon the
Prepayment Premium. Each Obligor acknowledges and agrees that the Lenders shall be entitled to recover the full amount of the Obligations, including the Prepayment Premium in each and every circumstance in which such amount is due pursuant to or in
connection with this Agreement, so that the Lenders shall receive the benefit of their bargain hereunder and otherwise receive full recovery of the agreed-upon return under every possible circumstance, and Borrower hereby waives any defense to
payment, whether such defense may be based in public policy, ambiguity, or otherwise. Each Obligor further acknowledges and agrees, and waives any argument to the contrary, that payment of such amounts does not constitute a penalty or an otherwise
unenforceable or invalid obligation. Any damages that the Lenders may suffer or incur resulting from or arising in connection with any breach by Borrower shall constitute secured obligations owing to the Lenders.” 

SECTION 4. Conditions of Effectiveness. Sections 2 and 3 are effective, as of the Effective Date, subject to the
satisfaction of the following conditions precedent: 
 (a) The Obligors, all of the Lenders and the Agent shall have
duly executed and delivered this Amendment pursuant to Section 12.04 of the Loan Agreement. 

(b) The Obligors shall have paid or reimbursed Lenders for Lenders’ reasonable out of pocket costs and expenses
incurred in connection with this Amendment, including Lenders’ reasonable out of pocket legal fees and costs, pursuant to Section 12.03(a)(i)(z) of the Loan Agreement. 

(c) The representations and warranties in Section 6 shall be true and correct on the date hereof, the Effective
Date and on the first date on which the conditions set forth in Sections 4(a) and (b) shall have been satisfied. 

SECTION 5. Fee Letter. As of the date hereof, the Fee Letter, dated as of December 26, 2017, among Borrower and Agent is hereby
amended as follows: 

  
 8 

 (a) Section 2(a) is hereby amended by replacing
the text “seven percent (7%)” where it appears therein with “twelve percent (12%)”. 
 (b)
Section 2(b) is hereby amended by replacing the text “seven percent (7%)” where it appears therein with “twelve percent (12%)”. 

SECTION 6. Representations and Warranties; Reaffirmation. 

(a) Each Obligor hereby represents and warrants to each Lender as follows: 

(i) Such Obligor has full power, authority and legal right to make and perform this Amendment. This Amendment is within
such Obligor’s corporate powers and has been duly authorized by all necessary corporate and, if required, by all necessary shareholder action. This Amendment has been duly executed and delivered by such Obligor and constitutes legal, valid and
binding obligations of such Obligor, enforceable against such Obligor in accordance with its terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability
affecting the enforcement of creditors’ rights and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). This Amendment (x) does not require
any consent or approval of, registration or filing with, or any other action by, any Governmental Authority or any third party, except for such as have been obtained or made and are in full force and effect, (y) will not violate any applicable
law or regulation or the charter, bylaws or other organizational documents of such Obligor and its Subsidiaries or any order of any Governmental Authority, other than any such violations that, individually or in the aggregate, could not reasonably
be expected to have a Material Adverse Effect, (z) will not violate or result in an event of default under any material indenture, agreement or other instrument binding upon such Obligor and its Subsidiaries or assets, or give rise to a right
thereunder to require any payment to be made by any such Person. 
 (ii) No Default has occurred or is continuing or
will result after giving effect to this Amendment. 
 (iii) The representations and warranties made by or with respect
to such Obligor in Section 7 of the Loan Agreement are true in all material respects, except that (A) such representations and warranties that refer to a specific earlier date were true in all material respects on such
earlier date, and (B) such representations and warranties do not take into account any changes that may be made to the schedules pursuant to Section 5(c) below. 

(iv) There has been no Material Adverse Effect since the date of the Loan Agreement, other than any Material Adverse
Effect that has been communicated prior to the date hereof to any Lender in its role as a Board Observer or director on the Board of Directors of the Borrower. 

(b) Each Obligor hereby ratifies, confirms, reaffirms, and acknowledges its obligations under the Loan Documents to
which it is a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Amendment, except as expressly provided herein. By executing this Amendment, each Obligor acknowledges that it has read, consulted with its
attorneys regarding, and understands, this Amendment. 

  
 9 

 (c) The Borrower has previously provided the Lenders updated versions
of the schedules of the Loan Agreement that are permitted to be updated pursuant to Section 7.20 of the Loan Agreement. If such revised schedules are not current to a material extent on the effective date of this Amendment, each Obligor shall
update, in accordance with Section 7.20 of the Loan Agreement, such schedules within 30 days after the date hereof. Notwithstanding Section 7.20 of the Loan Agreement or any other provision of the Loan Documents to the contrary, any such
updates shall be in form and substance satisfactory to the Lenders. Any failure to comply with this post-closing covenant shall constitute an immediate Event of Default. 

SECTION 7. Governing Law; Submission To Jurisdiction; Waiver Of Jury Trial. 

(a) Governing Law. This Amendment and the rights and obligations of the parties hereunder shall be governed by, and
construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that
Section 5-1401 of the New York General Obligations Law shall apply. 
 (b)
Submission to Jurisdiction. Each Obligor agrees that any suit, action or proceeding with respect to this Amendment or any other Loan Document to which it is a party or any judgment entered by any court in respect thereof may be brought initially
in the federal or state courts in Houston, Texas or in the courts of its own corporate domicile and irrevocably submits to the non-exclusive jurisdiction of each such court for the purpose of any such suit,
action, proceeding or judgment. This Section 7 is for the benefit of the Lenders only and, as a result, no Lender shall be prevented from taking proceedings in any other courts with jurisdiction. To the extent allowed by
applicable Laws, the Lenders may take concurrent proceedings in any number of jurisdictions. 
 (c) Waiver of Jury
Trial. Each Obligor and each Lender hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any suit, action or proceeding arising out of or relating to this Amendment, the other Loan
Documents or the transactions contemplated hereby or thereby. 
 SECTION 8. Miscellaneous. 

(a) No Waiver. Nothing contained herein shall be deemed to constitute a waiver of compliance with any term or condition
contained in the Loan Agreement or any of the other Loan Documents or constitute a course of conduct or dealing among the parties. Except as expressly stated herein, the Lenders reserve all rights, privileges and remedies under the Loan Documents
(including, without limitation, all such rights, privileges and remedies with respect to any Default, Event of Default or Material Adverse Effect, whether communicated or not to the Lenders or Agent). Except as amended hereby, the Loan Agreement and
other Loan Documents remain unmodified and in full force and effect. All references in the Loan Documents to the Loan Agreement shall be deemed to be references to the Loan Agreement as amended hereby. 

(b) Severability. In case any provision of or obligation under this Amendment shall be invalid, illegal or unenforceable
in any jurisdiction, the validity, legality and enforceability of the 

  
 10 

 
remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby. 

(c) Headings. Headings and captions used in this Amendment (including the Exhibits, Schedules and Annexes hereto, if
any) are included for convenience of reference only and shall not be given any substantive effect. 
 (d) Integration.
This Amendment constitutes a Loan Document and, together with the other Loan Documents, incorporates all negotiations of the parties hereto with respect to the subject matter hereof and is the final expression and agreement of the parties hereto
with respect to the subject matter hereof. 
 (e) Counterparts. This Amendment may be executed in any number of
counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Amendment by signing any such counterpart. 

(f) Controlling Provisions. In the event of any inconsistencies between the provisions of this Amendment and the
provisions of any other Loan Document, the provisions of this Amendment shall govern and prevail. Except as expressly modified by this Amendment, the Loan Documents shall not be modified and shall remain in full force and effect. 

[Remainder of page intentionally left blank] 

  
 11 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as
of the date first above written. 
  

			
	 BORROWER

	
	 DECIPHER BIOSCIENCES, INC.

		
	 By:
	 	 /s/ Tina Nova, PhD

		 	 Name: Tina Nova, PhD

		 	 Title: President & CEO

	
	 Address for Notices:

	 10355 Science Center Drive, Suite 240

	 San Diego, CA 92121

	
	 Tel: 

	 with a copy by email: 

	
	 SUBSIDIARY GUARANTOR

	
	 GENOMEDX BIOSCIENCES CORP.

		
	 By:
	 	 /s/ Tina Nova, PhD

		 	 Name: Tina Nova, PhD

		 	 Title: President & CEO

	
	 Address for Notices:

	 10355 Science Center Drive, Suite 240

	 San Diego, CA 92121

	
	 Tel: 

	 with a copy by email: 

  
 [Signature Page to
Amendment Agreement] 

					
	 THE LENDERS

	
	 CRG PARTNERS III L.P.,

	 By CRG PARTNERS III GP L.P., its General Partner

	 By CRG PARTNERS III GP LLC, its General Partner

		
	 By
	 	 /s/ Nathan
Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

	
	 CRG PARTNERS III–PARALLEL FUND “A”
L.P.,

	 By CRG PARTNERS III – PARALLEL FUND “A” GP L.P., its General
Partner

	 By CRG PARTNERS III – PARALLEL FUND “A” GP LLC, its General
Partner

		
	 By
	 	 /s/ Nathan
Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

	
	 CRG PARTNERS III (CAYMAN) L.P.,

	 By CRG PARTNERS III (CAYMAN) GP L.P., its General Partner

	 By CRG PARTNERS III (CAYMAN) GP LLC, its General Partner

		
	 By
	 	 /s/ Nathan
Hukill

		 	 Name: Nathan Hukill

		 	 Title: Authorized Signatory

			
		 	 Witness:
	 	 /s/ Nicole Nesson

		
		 	 Name: Nicole Nesson

  

  
 [Signature Page to
Amendment Agreement] 

 AGENT 
  

			
	 CRG SERVICING LLC, as Agent

		
	 By
	 	 /s/ Nathan Hukill

		 	 Nathan Hukill

		 	 Authorized Signatory

  
 [Signature Page to
Amendment Agreement] 

 AMENDMENT AGREEMENT NO. 14 

THIS AMENDMENT AGREEMENT NO. 14 (this “Amendment”), dated as of November 13, 2019, is made among
Decipher Biosciences, Inc., a company incorporated in Delaware and formerly known as GenomeDx Inc., a company incorporated in Delaware and formerly known as GenomeDx Biosciences Inc., a company incorporated in British Columbia, Canada (the
“Borrower”), the Subsidiary Guarantor listed on the signature pages hereof under the heading “SUBSIDIARY GUARANTOR” (the “Subsidiary Guarantor”, and together with the Borrower, each an
“Obligor” and, collectively, the “Obligors”), the Lenders listed on the signature pages hereof under the heading “LENDERS” (each a “Lender” and, collectively, the
“Lenders”) and CRG SERVICING LLC, as administrative and collateral agent for the Lenders hereunder (in such capacity, the “Agent”). 

The Obligors and the Lenders are parties to that certain Term Loan Agreement, dated as of September 23, 2015 (as amended,
amended and restated, modified or supplemented from time to time prior to the date hereof, the “Loan Agreement”). 

The parties hereto desire to waive certain provisions of the Loan Agreement, and to amend the Loan Agreement, in each case, on
the terms and subject to the conditions set forth herein. 
 Accordingly, the parties hereto agree as follows: 

SECTION 1 Definitions; Interpretation. 

(a) Terms Defined in Loan Agreement. All capitalized terms used in this Amendment (including in the recitals
hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement. 
 (b)
Interpretation. The rules of interpretation set forth in Section 1.03 of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference. 

SECTION 2 Amendments. Subject to Section 3, the Loan Agreement is hereby amended as follows: 

(a) The definition of “Commitment Period” in Section 1.01 of the Loan
Agreement is hereby amended by replacing the text “March 31, 2017” where is appears therein with “December 31, 2019”. 

(b) Section 2.01 of the Loan Agreement is hereby amended by replacing the text
“three” where it appears therein with “four”. 
 (c) Schedule 1 to the Loan Agreement is
hereby amended and restated in its entirety as set forth on Annex A attached hereto. 

  
 1 

 SECTION 3 Conditions of Effectiveness. Section 2 is effective,
subject to the satisfaction of the following conditions precedent: 
 (a) The Obligors, all of the Lenders and the
Agent shall have duly executed and delivered this Amendment pursuant to Section 12.04 of the Loan Agreement. 

(b) The Obligors shall have paid or reimbursed Lenders for Lenders’ reasonable out of pocket costs and expenses incurred
in connection with this Amendment, including Lenders’ reasonable out of pocket legal fees and costs, pursuant to Section 12.03(a)(i)(z) of the Loan Agreement. 

(c) The representations and warranties in Section 4 shall be true and correct on the date hereof, and
on the first date on which the conditions set forth in Sections 3(a) and (b) shall have been satisfied. 
 SECTION 4
Representations and Warranties; Reaffirmation. 
 (a) Each Obligor hereby represents and warrants to each Lender as
follows: 
 (i) Such Obligor has full power, authority and legal right to make and perform this Amendment. This Amendment is
within such Obligor’s corporate powers and has been duly authorized by all necessary corporate and, if required, by all necessary shareholder action. This Amendment has been duly executed and delivered by such Obligor and constitutes legal,
valid and binding obligations of such Obligor, enforceable against such Obligor in accordance with its terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general
applicability affecting the enforcement of creditors’ rights and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). This Amendment
(x) does not require any consent or approval of, registration or filing with, or any other action by, any Governmental Authority or any third party, except for such as have been obtained or made and are in full force and effect, (y) will
not violate any applicable law or regulation or the charter, bylaws or other organizational documents of such Obligor and its Subsidiaries or any order of any Governmental Authority, other than any such violations that, individually or in the
aggregate, could not reasonably be expected to have a Material Adverse Effect, (z) will not violate or result in an event of default under any material indenture, agreement or other instrument binding upon such Obligor and its Subsidiaries or
assets, or give rise to a right thereunder to require any payment to be made by any such Person. 
 (ii) No Default has
occurred or is continuing or will result after giving effect to this Amendment. 
 (iii) The representations and warranties
made by or with respect to such Obligor in Section 7 of the Loan Agreement are true in all material respects, except that (A) such representations and warranties that refer to a specific earlier date were true in all material respects on
such earlier date, and (B) such representations and warranties do not take into account any changes that may be made to the schedules pursuant to Section 4(c) below. 

  
 2 

 (iv) There has been no Material Adverse Effect since the date of the Loan
Agreement, other than any Material Adverse Effect that has been communicated prior to the date hereof to any Lender in its role as a Board Observer or director on the Board of Directors of the Borrower. 

(b) Each Obligor hereby ratifies, confirms, reaffirms, and acknowledges its obligations under the Loan Documents to which it is
a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Amendment, except as expressly provided herein. By executing this Amendment, each Obligor acknowledges that it has read, consulted with its attorneys
regarding, and understands, this Amendment. 
 (c) The Borrower has previously provided the Lenders updated versions of the
schedules of the Loan Agreement that are permitted to be updated pursuant to Section 7.20 of the Loan Agreement. If such revised schedules are not current to a material extent on the effective date of this Amendment, each Obligor shall update,
in accordance with Section 7.20 of the Loan Agreement, such schedules within 30 days after the date hereof. Notwithstanding Section 7.20 of the Loan Agreement or any other provision of the Loan Documents to the contrary, any such updates
shall be in form and substance satisfactory to the Lenders. Any failure to comply with this post-closing covenant shall constitute an immediate Event of Default. 

SECTION 5 Governing Law; Submission To Jurisdiction; Waiver Of Jury Trial. 

(a) Governing Law. This Amendment and the rights and obligations of the parties hereunder shall be governed by,
and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that
Section 5-1401 of the New York General Obligations Law shall apply. 
 (b)
Submission to Jurisdiction. Each Obligor agrees that any suit, action or proceeding with respect to this Amendment or any other Loan Document to which it is a party or any judgment entered by any court in respect thereof may be brought
initially in the federal or state courts in Houston, Texas or in the courts of its own corporate domicile and irrevocably submits to the non-exclusive jurisdiction of each such court for the purpose of any
such suit, action, proceeding or judgment. This Section 5 is for the benefit of the Lenders only and, as a result, no Lender shall be prevented from taking proceedings in any other courts with jurisdiction. To the extent
allowed by applicable Laws, the Lenders may take concurrent proceedings in any number of jurisdictions. 
 (c) Waiver of
Jury Trial. Each Obligor and each Lender hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any suit, action or proceeding arising out of or relating to this Amendment, the
other Loan Documents or the transactions contemplated hereby or thereby. 
 SECTION 6 Miscellaneous. 

(a) No Waiver. Nothing contained herein shall be deemed to constitute a waiver of compliance with any term or
condition contained in the Loan Agreement or any of the other Loan Documents or constitute a course of conduct or dealing among the parties. Except as 

  
 3 

 expressly stated herein, the Lenders reserve all rights, privileges and remedies under the
Loan Documents (including, without limitation, all such rights, privileges and remedies with respect to any Default, Event of Default or Material Adverse Effect, whether communicated or not to the Lenders or Agent). Except as amended hereby, the
Loan Agreement and other Loan Documents remain unmodified and in full force and effect. All references in the Loan Documents to the Loan Agreement shall be deemed to be references to the Loan Agreement as amended hereby. 

(b) Severability. In case any provision of or obligation under this Amendment shall be invalid, illegal or
unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby. 

(c) Headings. Headings and captions used in this Amendment (including the Exhibits, Schedules and Annexes hereto,
if any) are included for convenience of reference only and shall not be given any substantive effect. 
 (d)
Integration. This Amendment constitutes a Loan Document and, together with the other Loan Documents, incorporates all negotiations of the parties hereto with respect to the subject matter hereof and is the final expression and
agreement of the parties hereto with respect to the subject matter hereof. 
 (e) Counterparts. This Amendment may be
executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Amendment by signing any such counterpart. 

(f) Controlling Provisions. In the event of any inconsistencies between the provisions of this Amendment and the
provisions of any other Loan Document, the provisions of this Amendment shall govern and prevail. Except as expressly modified by this Amendment, the Loan Documents shall not be modified and shall remain in full force and effect. 

[Remainder of page intentionally left blank] 

  
 4 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as
of the date first above written. 
  

					
	BORROWER
	
	DECIPHER BIOSCIENCES, INC.
		
	By	 	 /s/ Brent Vetter

		 	Name:	 	Brent Vetter
		 	Title:	 	Chief Financial Officer
	
	Address for Notices:
	
	10355 Science Center Drive, Suite 240
	San Diego, CA 92121
	
	 Tel: 888.792.1601
 with a copy by
email: notices@genomedx.com

	
	SUBSIDIARY GUARANTOR
	
	GENOMEDX BIOSCIENCES CORP.
		
	By	 	 /s/ Brent Vetter

		 	Name:	 	Brent Vetter
		 	Title:	 	Chief Financial Officer
	
	Address for Notices:
	
	10355 Science Center Drive, Suite 240
	San Diego, CA 92121
	
	 Tel: 888.792.1601
 with a copy by
email: notices@genomedx.com

  

  
 [Signature Page to
Amendment Agreement] 

 THE LENDERS 
  

							
	 CRG PARTNERS III – PARALLEL FUND “A” L.P.

	 By CRG PARTNERS III – PARALLEL FUND “A” GP L.P., its General Partner

	 By CRG PARTNERS III – PARALLEL FUND “A” GP LLC, its General Partner

			
		 	By:	 	 /s/ Nathan Hukill

		 		 	Name: Nathan Hukill
		 		 	Title: Authorized Signatory

  

							
	 CRG PARTNERS III

	 By CRG PARTNERS III GP L.P., its General Partner

	 By CRG PARTNERS III GP LLC, its General Partner

			
		 	By:	 	 /s/ Nathan Hukill

		 		 	Nathan Hukill
		 		 	Authorized Signatory

  

							
	CRG PARTNERS III (CAYMAN) UNLEV AIV I L.P.
	 By CRG PARTNERS III (CAYMAN) GP L.P., its General Partner

	 By CRG PARTNERS III (CAYMAN) GP LLC, its General Partner

			
		 	By:	 	 /s/ Nathan Hukill

		 		 	Nathan Hukill
		 		 	Authorized Signatory

  

			
	Witness:	 	 /s/ Nicole Nesson

	Name:	 	Nicole Nesson

  

							
	CRG PARTNERS III (CAYMAN) LEV AIV I L.P.
	
	 By CRG PARTNERS III (CAYMAN) GP L.P., its General Partner

	 By CRG PARTNERS III (CAYMAN) GP LLC, its General Partner

			
		 	By:	 	 /s/ Nathan Hukill

		 		 	Name: Nathan Hukill
		 		 	Title: Authorized Signatory

  

  
 [Signature Page to
Amendment Agreement] 

			
	Witness:	 	 /s/ Nicole Nesson

	Name:	 	Nicole Nesson

 CRG PARTNERS III – PARALLEL FUND“B” (CAYMAN)
L.P. 

					
	 By: CRG PARTNERS III (CAYMAN) GP L.P.,

its General Partner

	 By: CRG PARTNERS III (CAYMAN) GP LLC,

its General Partner

			
		 	By:	 	 /s/ Nathan Hukill

		 		 	Nathan Hukill
		 		 	Authorized Signatory

  

			
	Witness:	 	 /s/ Nicole Nesson

	Name:	 	Nicole Nesson

  

  
 [Signature Page to
Amendment Agreement] 

					
	 AGENT

	
	 CRG SERVICING LLC, as Agent

			
	      	 	By	 	 /s/ Nathan Hukill

		 		 	Nathan Hukill
		 		 	Authorized Signatory

  
 [Signature Page to
Amendment Agreement] 

 ANNEX A 

Schedule 1 
 to Term Loan
Agreement 
 COMMITMENTS 
  

									
	 Lender
	  	Commitment	 	  	Proportionate Share	 
	 CRG Partners III L.P.
	  	$	4,188,411.86	 	  	 	13.96	% 
	 CRG Partners III (Cayman) Unlev AIV I L.P.
	  	$	819,181.50	 	  	 	2.73	% 
	 CRG Partners III–Parallel Fund“A” L.P.
	  	$	2,560,325.01	 	  	 	8.53	% 
	 CRG Partners III - Parallel Fund “B” L.P.
	  	$	12,597,392.76	 	  	 	41.99	% 
	 CRG Partners III (Cayman) Lev AIV I L.P.
	  	$	9,834,688.87	 	  	 	32.78	% 
	 TOTAL
	  	$	30,000,000.00	 	  	 	100	%EX-10.14

 Exhibit 10.14 

LEASE 
 10355
SCIENCE CENTER DRIVE 
 TORREY PINES SCIENCE CENTER LIMITED PARTNERSHIP, 

a Delaware limited partnership, 

as Landlord, 
 and 

GENOMEDX BIOSCIENCES CORP., 
 a
Delaware corporation, 
 as Tenant. 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  		  	[GenomeDx Biosciences, Corp.]

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	 1.
	 	 PREMISES, BUILDING, PROJECT, AND COMMON AREAS
	  	 	4	 
	 2.
	 	 LEASE TERM; OPTION TERM
	  	 	5	 
	 3.
	 	 BASE RENT
	  	 	8	 
	 4.
	 	 ADDITIONAL RENT
	  	 	8	 
	 5.
	 	 USE OF PREMISES
	  	 	14	 
	 6.
	 	 SERVICES AND UTILITIES
	  	 	18	 
	 7.
	 	 REPAIRS
	  	 	20	 
	 8.
	 	 ADDITIONS AND ALTERATIONS
	  	 	21	 
	 9.
	 	 COVENANT AGAINST LIENS
	  	 	22	 
	 10.
	 	 INSURANCE
	  	 	23	 
	 11.
	 	 DAMAGE AND DESTRUCTION
	  	 	24	 
	 12.
	 	 NONWAIVER
	  	 	26	 
	 13.
	 	 CONDEMNATION
	  	 	26	 
	 14.
	 	 ASSIGNMENT AND SUBLETTING
	  	 	26	 
	 15.
	 	 SURRENDER OF PREMISES; OWNERSHIP AND REMOVAL OF TRADE FIXTURES
	  	 	30	 
	 16.
	 	 HOLDING OVER
	  	 	31	 
	 17.
	 	 ESTOPPEL CERTIFICATES
	  	 	31	 
	 18.
	 	 SUBORDINATION (collectively, the “Superior Holders”)
	  	 	31	 
	 19.
	 	 DEFAULTS; REMEDIES
	  	 	32	 
	 20.
	 	 COVENANT OF QUIET ENJOYMENT
	  	 	34	 
	 21.
	 	 SECURITY DEPOSIT
	  	 	34	 
	 22.
	 	 COMMUNICATIONS AND COMPUTER LINE
	  	 	36	 
	 23.
	 	 SIGNS
	  	 	36	 
	 24.
	 	 COMPLIANCE WITH LAW
	  	 	37	 
	 25.
	 	 LATE CHARGES
	  	 	37	 
	 26.
	 	 LANDLORD’S RIGHT TO CURE DEFAULT; PAYMENTS BY TENANT
	  	 	38	 
	 27.
	 	 ENTRY BY LANDLORD
	  	 	38	 
	 28.
	 	 TENANT PARKING
	  	 	38	 
	 29.
	 	 MISCELLANEOUS PROVISIONS
	  	 	38	 
		
	 EXHIBITS
	  			
	 A
	 	 OUTLINE OF PREMISES
	  			
	 A-1
	 	 PROJECT SITE PLAN
	  			
	 A-2
	 	 INITIAL OCCUPANCY PREMISES AND DELAYED OCCUPANCY PREMISES
	  			

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	(i)	  	[GenomeDx Biosciences, Corp.]

							
	 	 	 	  	Page	 
			
	 B-1
	 	 TENANT WORK LETTER – MOVING AND CABLING ALLOWANCE
	  			
	 B-2
	 	 TENANT WORK LETTER FOR INITIAL OCCUPANCY PREMISES
	  			
	 B-3
	 	 TENANT WORK LETTER FOR DELAYED OCCUPANCY PREMISES
	  			
	 C
	 	 FORM OF NOTICE OF LEASE TERM DATES
	  			
	 D
	 	 FORM OF TENANT’S ESTOPPEL CERTIFICATE
	  			
	 E
	 	 ENVIRONMENTAL QUESTIONNAIRE
	  			
	 F
	 	 FORM OF GUARANTY
	  			

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	(ii)	  	[GenomeDx Biosciences, Corp.]

 INDEX 

 

					
	 	  	Page(s)	 
		
	 Abatement Event
	  	 	34	 
	 Advocate Arbitrators
	  	 	7	 
	 Alterations
	  	 	21	 
	 Base Rent
	  	 	8	 
	 Brokers
	  	 	42	 
	 Building
	  	 	4	 
	 Building Hours
	  	 	18	 
	 Common Areas
	  	 	4	 
	 Comparable Buildings
	  	 	7	 
	 Contemplated Effective Date
	  	 	28	 
	 Contemplated Transfer Space
	  	 	28	 
	 Direct Expenses
	  	 	9	 
	 Eligibility Period
	  	 	34	 
	 Environmental Questionnaire
	  	 	14	 
	 Estimate
	  	 	13	 
	 Estimate Statement
	  	 	13	 
	 Estimated Direct Expenses
	  	 	13	 
	 Existing Hazardous Materials
	  	 	16	 
	 Expense Year
	  	 	9	 
	 Force Majeure
	  	 	41	 
	 Holidays
	  	 	18	 
	 HVAC
	  	 	18	 
	 Intention to Transfer Notice
	  	 	28	 
	 Landlord
	  	 	1	 
	 Landlord Parties
	  	 	23	 
	 Landlord Repair Notice
	  	 	25	 
	 Lease
	  	 	1	 
	 Lease Commencement Date
	  	 	5	 
	 Lease Expiration Date
	  	 	6	 
	 Lease Term
	  	 	5	 
	 Lease Year
	  	 	6	 
	 Lines
	  	 	36	 
	 Mail
	  	 	41	 
	 Moving and Cabling Allowance
	  	 	1	 
	 Moving Costs
	  	 	1	 
	 Net Worth
	  	 	30	 
	 Neutral Arbitrator
	  	 	7	 
	 Nine Month Period
	  	 	29	 
	 Notices
	  	 	41	 
	 Objectionable Name
	  	 	37	 
	 Operating Expenses
	  	 	9	 
	 Option Rent
	  	 	6	 
	 Option Term
	  	 	6	 
	 Original Improvements
	  	 	24	 
	 Original Tenant
	  	 	6	 
	 Outside Agreement Date
	  	 	7	 
	 Permitted Transferee Assignee
	  	 	30	 
	 Premises
	  	 	4	 
	 Project,
	  	 	4	 
	 Security Deposit
	  	 	35	 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	(iii)	  	[GenomeDx Biosciences, Corp.]

					
	 Sign Specifications
	  	 	37	 
	 Statement
	  	 	13	 
	 Subject Space
	  	 	27	 
	 Summary
	  	 	1	 
	 Superior Holders
	  	 	32	 
	 Tax Expenses
	  	 	12	 
	 Telecommunications and HVAC Equipment
	  	 	44	 
	 Tenant
	  	 	1	 
	 Tenant Work Letter
	  	 	4	 
	 Tenant’s Agents
	  	 	14	 
	 Tenant’s Share
	  	 	12	 
	 Transfer Notice
	  	 	27	 
	 Transferee
	  	 	27	 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	(iv)	  	[GenomeDx Biosciences, Corp.]

 10355 SCIENCE CENTER DRIVE 

LEASE 

This Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease
Information (the “Summary”), below, is made by and between TORREY PINES SCIENCE CENTER LIMITED PARTNERSHIP, a Delaware limited partnership (“Landlord”), and GENOMEDX BIOSCIENCES CORP., a Delaware corporation
(“Tenant”). 
 SUMMARY OF BASIC LEASE INFORMATION 

 

					
	 TERMS OF LEASE
	  	 DESCRIPTION

			
	 1.
	  	 Date:
	  	 September 25, 2014

			
	 2.
	  	 Premises

(Article 1).
	  	
			
		  	 2.1   Building:
	  	 That certain two (2)-story building located at 10355 Science Center Drive, San Diego, California 92121, containing a total
of 40,894 rentable square feet.

			
		  	 2.2   Premises:
	  	 Approximately 11,002 rentable square feet of space located on the second (2nd) floor of the Building and commonly known as
Suites 4 and 5, as further set forth in Exhibit A to the Lease. The portion of the Premises consisting of 7,216 rentable square feet, as further set forth on Exhibit A-2, shall also
be known as the “Initial Occupancy Premises,” and the portion of the Premises consisting of 3,786 rentable (2,820 usable) square feet, as further set forth on Exhibit A-2,
shall also be known as the “Delayed Occupancy Premises.”

			
	 3.
	  	 Lease Term

(Article 2).
	  	
			
		  	 3.1   Length of Term:
	  	 Five (5) years and five (5) months from the Lease Commencement Date.

			
		  	 3.2   Lease Commencement

        Date:
	  	 The earlier to occur of (i) the date upon which Tenant first commences to conduct business in the Premises (other than
in connection with Tenant’s occupancy of the Early Access Premises), and (ii) the date upon which the Initial Occupancy Premises are “Ready for Occupancy,” as that term is defined in Section 5.1 of the Tenant
Work Letter attached to the Lease as Exhibit B-2, which Lease Commencement Date is anticipated to be January 31, 2015.

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  		  	[GenomeDx Biosciences, Corp.]

					
		  	 3.3   Lease Expiration Date:
	  	 If the Lease Commencement Date shall be the first day of a calendar month, then the day immediately preceding the five (5)
year five (5) month anniversary of the Lease Commencement Date; or, if the Lease Commencement Date shall be other than the first day of a calendar month, then the last day of the month in which the five (5) year five (5) month anniversary of the
Lease Commencement Date occurs.

			
	 4.
	  	 Base Rent

(Article 3):
	  	

  

													
	 Months During
Lease Term
	  	Annual
Base Rent	 	  	Monthly
Installment
of Base Rent*	 	  	Approximate
Monthly Base
Rent per Rentable
Square Foot	 
	 1 – 12
	  	$	396,072.00	 	  	$	33,006.00	 	  	$	3.00	 
	 13 – 24
	  	$	407,954.16	 	  	$	33,996.18	 	  	$	3.09	 
	 25 – 36
	  	$	420,192.84	 	  	$	35,016.07	 	  	$	3.18	 
	 37 – 48
	  	$	432,798.60	 	  	$	36,066.55	 	  	$	3.28	 
	 49 – 60
	  	$	445,782.48	 	  	$	37,148.54	 	  	$	3.38	 
	 61 - 65
	  	$	459,156.00	 	  	$	38,263.00	 	  	$	3.48	 

  

	*	 The calculation of the Monthly Installment of Base Rent reflects an annual increase of 3%, rounded to the
nearest cent, after the previous Lease Year. 

  

					
	 5.
	  	 Tenant Improvement Allowance:
	  	 Premises (Exhibit B-1): Landlord shall provide a moving/cabling allowance to Tenant in an
amount up to $22,004.00 (i.e., an amount equal to $2.00 per rentable square foot of the Premises). Tenant shall have the ability to apply such moving/cabling allowance towards Tenant Improvements.

			
		  		  	 Initial Occupancy Premises (Exhibit B-2): An amount equal to $14,432.00 (i.e., $2.00 per
rentable square foot of the Initial Occupancy Premises based upon 7,216 rentable square feet in the Initial Occupancy Premises).

			
		  		  	 Delayed Occupancy Premises (Exhibit B-3): An amount equal to $197,400.00 (i.e., $70.00
per usable square foot of the Delayed Occupancy Premises based upon 2,820 usable square feet in the Delayed Occupancy Premises).

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-2-	  	[GenomeDx Biosciences, Corp.]

					
	 6.
	  	 Tenant’s Share

(Article 4):
	  	 Twenty-six and 90/100 percent (26.90%).

			
	 7.
	  	 Permitted Use

(Article 5):
	  	  
 The Premises shall be used only for general office,
research and development, engineering, laboratory, storage and/or warehouse uses, including, but not limited to, administrative offices and other lawful uses reasonably related to or incidental to such specified uses, all (i) consistent with
first class life sciences projects in the Torrey Pines area of San Diego, California (“First Class Life Sciences Projects”), and (ii) in compliance with, and subject to, applicable laws and the terms of this
Lease.

			
	 8.
	  	 Security Deposit

(Article 21):
	  	  
 $200,000.00, subject to reduction pursuant to the
terms of Article 21 of this Lease.

			
	 9.
	  	 Parking

(Article 28):
	  	  
 Three (3) unreserved parking spaces for every
1,000 rentable square feet of the Premises, subject to the terms of Article 28 of the Lease.

			
	 10.
	  	 Address of Tenant

(Section 29.18):
	  	  
 Genomedx Biosciences

Set 400-311 Water Street

Vancouver, British Columbia V6B 1B8

Canada
 Attention: Chief Financial
Officer

			
	 11.
	  	 Address of Landlord

(Section 29.18):
	  	 See Section 29.18 of the Lease.

			
	 12.
	  	 Broker(s)

(Section 29.24):
	  	 Tenant: Jones Lang LaSalle, Inc.

			
		  		  	 Landlord: CBRE, Inc.

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-3-	  	[GenomeDx Biosciences, Corp.]

	1.	 PREMISES, BUILDING, PROJECT, AND COMMON AREAS 

1.1    Premises, Building, Project and Common Areas. 

1.1.1    The Premises. Landlord hereby leases to Tenant and Tenant hereby leases from
Landlord the premises set forth in Section 2.2 of the Summary (the “Premises”). The outline of the Premises is set forth in Exhibit A attached hereto. The outline of the “Building”
and the “Project,” as those terms are defined in Section 1.1.2 below, are further depicted on the Site Plan attached hereto as Exhibit A-1. The parties
hereto agree that the lease of the Premises is upon and subject to the terms, covenants and conditions herein set forth, and Tenant covenants as a material part of the consideration for this Lease to keep and perform each and all of such terms,
covenants and conditions by it to be kept and performed and that this Lease is made upon the condition of such performance. The parties hereto hereby acknowledge that the purpose of Exhibit A is to show the approximate location of the
Premises only, and such Exhibit is not meant to constitute an agreement, representation or warranty as to the construction of the Premises, the precise area thereof or the specific location of the “Common Areas,” as that term is
defined in Section 1.1.3, below, or the elements thereof or of the accessways to the Premises or the “Project,” as that term is defined in Section 1.1.2, below. Except as specifically set
forth in this Lease and in the Tenant Work Letters attached hereto as Exhibits B-1, B-2 or
B-3 (as applicable, the “Tenant Work Letter”), Landlord shall not be obligated to provide or pay for any improvement work or services related to the improvement of the Premises.
Tenant also acknowledges that neither Landlord nor any agent of Landlord has made any representation or warranty regarding the condition of the Premises, the Building or the Project or with respect to the suitability of any of the foregoing for the
conduct of Tenant’s business, except as specifically set forth in this Lease and the Tenant Work Letter. The taking of possession of the Premises by Tenant shall conclusively establish that the Premises and the Building were at such time in
good and sanitary order, condition and repair. For purposes of Section 1938 of the California Civil Code, Landlord hereby discloses to Tenant, and Tenant hereby acknowledges, that the Project, Building and Premises have not undergone inspection
by a Certified Access Specialist (CASp). 
 1.1.2    The Building and The Project. The
Premises constitute a portion of the entire building set forth in Section 2.1 of the Summary (the “Building”). The Building is an office/laboratory project currently known as “10355 Science
Center.” The term “Project,” as used in this Lease, shall mean (i) the Building and the Common Areas, (ii) the land (which is improved with landscaping, parking facilities and other improvements) upon which the
Building and the Common Areas are located, and (iii) at Landlord’s reasonable discretion, any additional real property, areas, land, buildings or other improvements added thereto outside of the foregoing. 

1.1.3    Common Areas. Tenant shall have the
non-exclusive right to use in common with other tenants in the Project, and subject to the rules and regulations referred to in Article 5 of this Lease, those portions of the Project which are provided,
from time to time, for use in common by Landlord, Tenant and any other tenants of the Project (such areas, together with such other portions of the Project designated by Landlord, in its reasonable discretion, are collectively referred to herein as
the “Common Areas”). Subject to Section 7.2 hereof, the manner in which the Common Areas are maintained and operated shall be at the sole discretion of Landlord and the use thereof shall be subject to such
rules, regulations and restrictions as Landlord may make from time to time; provided that such manner, rules, regulations and restrictions are consistent with those in use in comparable First Class Life Sciences Projects. Landlord reserves the
right to close temporarily, make alterations or additions to, or change the location of elements of the Project and the Common Areas, provided that, in connection therewith, Landlord shall perform such closures, alterations, additions or changes in
a commercially reasonable manner and shall use commercially reasonable efforts to minimize any interference with Tenant’s use of and access to the Premises, and shall not reduce the number of parking spaces available to Tenant (except
temporarily), and shall use reasonable efforts to give Tenant notice of any planned power shutdown at least five (5) business days in advance. 

1.2    Rentable Square Feet of Premises. The rentable square footage of the Premises is
hereby deemed to be as set forth in Section 2.2 of the Summary, and shall not be subject to measurement or adjustment during the Lease Term, except in connection with an expansion or reduction in the physical space of the Premises or the
Building in accordance with this Lease. 
 1.3    Intentionally Omitted. 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-4-	  	[GenomeDx Biosciences, Corp.]

 1.4    Beneficial Occupancy. Tenant shall
have the right to have up to six (6) employees of Tenant at any one point in time, and its vendors, occupy the lab portion of the Initial Occupancy Premises (the “Early Access Premises”) for a period commencing on or before
December 1, 2014 and terminating on the Lease Commencement Date, for the purpose of installing and validating equipment (including, without limitation, Installation Qualification, Operational Qualification and Performance Qualification of all
instruments and equipment necessary to perform the Decipher assay and formal validation that the Decipher assay is performing equivalently to current facility), provided that (A) Tenant shall give Landlord at least five (5) days’
prior notice of any such occupancy of the Early Access Premises, (B) a temporary certificate of occupancy shall have been issued by the appropriate governmental authorities for each such portion to be occupied, (C) all of the terms and
conditions of the Lease shall apply, other than Tenant’s obligation to pay “Base Rent,” as that term is defined in Article 3 below, and “Tenant’s Share” of the annual “Building Direct Expenses,” as those terms
are defined in Article 4, below, (provided Tenant shall be obligated to all utility costs incurred by Tenant during such early occupancy), and (D) such occupancy of the Early Access Premises shall not delay or unreasonably interfere with the
completion of the tenant improvements described on each respective Tenant Work Letter (collectively or individually, as the context may require, the “Tenant Improvements”). 

1.5    Late Delivery. If Landlord fails to deliver possession of (i) the Early Access
Premises to Tenant on or before December 15, 2014, or (ii) the Initial Occupancy Premises on or before February 15, 2015 (as applicable, each a “Anticipated Delivery Date”), then, with respect to such portion of the
Premises that Landlord failed to timely deliver, Tenant shall receive an abatement of Base Rent equal to the sum of (A) one-half (1⁄2) day of Base Rent for each full day that occurs after the applicable Anticipated Delivery Date and before the later of (1) the date Landlord delivers such portion of the Premises to Tenant, and (2) the
date that occurs thirty (30) days after the applicable Anticipated Delivery Date, and (B) one (1) day of Base Rent for each full day that occurs after the date that occurs thirty (30) days after the applicable Anticipated Delivery
Date and before the date Landlord delivers such portion of the Premises to Tenant. 
 1.5.1    Each
Anticipated Delivery Date shall be delayed by one day for each day that Landlord’s delivery of the applicable portion of the Premises is delayed due to any of the following: 

1.5.1.1    Any delay caused by Tenant, including Tenant’s failure to provide needed information or
to approve the “Approved Working Drawings,” as that term is defined in Section 1 of the Tenant Work Letter, within one (1) business day. 

1.5.1.2    Any delay due to events of Force Majeure, including any failure of the applicable municipal
authority to issue any necessary permits within six (6) weeks of submittal, or any delay in the inspector approving the temporary occupancy plan. 

1.5.1.3    Tenant’s failure to deliver a complete and accurate Hazardous Materials list on or before
August 29, 2014. 
 1.5.2    If delivery of either the Early Access Premises or the Initial
Occupancy Premises has not occurred by the date that is one hundred twenty (120) days after the corresponding Anticipated Delivery Date, as may be extended pursuant to the express terms of this Lease, then Tenant shall have the right to
terminate this Lease by providing notice thereof to Landlord, following which termination Landlord and Tenant shall be relieved from any and all liability to each other resulting hereunder except that Landlord shall promptly return to Tenant any
sums deposited with Landlord; provided, however, Tenant’s right to terminate this Lease pursuant to this Section 1.5.2 shall expire if not exercised by the date on which Landlord delivers the Early Access Premises or the Initial Occupancy
Premises, as applicable. Tenant’s rights to terminate this Lease, as set forth in this Section 1.5.2, shall be Tenant’s sole and exclusive remedy at law or in equity for Landlord’s failure to deliver the Early Access Premises or
the Initial Occupancy Premises, as the case may be. 
  

	2.	 LEASE TERM; OPTION TERM 

2.1    Lease Term. The terms and provisions of this Lease shall be effective as of the date of this Lease.
The term of this Lease (the “Lease Term”) shall be as set forth in Section 3.1 of the Summary, shall commence on the date set forth in Section 3.2 of the Summary (the “Lease Commencement
Date”), and shall terminate on the date set forth in Section 3.3 of the Summary (the “Lease Expiration Date”) unless this Lease is sooner terminated as

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-5-	  	[GenomeDx Biosciences, Corp.]

 
hereinafter provided. For purposes of this Lease, the term “Lease Year” shall mean each consecutive twelve (12) month period during the Lease Term. At any time during the
Lease Term, Landlord may deliver to Tenant a notice in the form as set forth in Exhibit C, attached hereto, as a confirmation only of the information set forth therein, which Tenant shall execute and return to Landlord within five
(5) days of receipt thereof, provided that Tenant agrees with the factual assertions made in such form. 

2.2    Option Term. 

2.2.1    Option Right. Landlord hereby grants to the originally named Tenant herein
(“Original Tenant”), and its “Permitted Transferee Assignee,” as that term is defined in Section 14.8 of this Lease, below, one (1) option (the “Option”) to extend the Lease Term for a period of
three (3) years (the “Option Term”), with respect to the entire Premises, which option shall be exercisable only by written notice delivered by Tenant to Landlord as provided below, provided that, as of the date of
delivery of such notice, Tenant is not in default under this Lease beyond any applicable notice and cure periods, and has not previously received written notice from Landlord that Tenant was then in default under this Lease, beyond any applicable
cure periods, more than once during the immediately preceding twelve (12) month period. Upon the proper exercise of such option to extend, and provided that, at Landlord’s option, as of the end of the Lease Term, Tenant is not in default
under this Lease beyond any applicable cure periods, the Lease Term, as it applies to the Premises, shall be extended by the Option Term. The rights contained in this Section 2.2 shall be personal to Original Tenant and any
Permitted Transferee Assignee and may be exercised by Original Tenant or a Permitted Transferee Assignee only (and not by any other assignee, sublessee or Transferee of Tenant’s interest in this Lease). 

2.2.2    Exercise of Option. If Tenant wishes to exercise the Option, then Tenant shall
deliver written notice (the “Extension Notice”) to Landlord not more than twelve (12) months nor less than nine (9) months prior to the expiration of the initial Lease Term, stating that Tenant thereby exercises the
Option. In the event that Tenant so exercises the Option, this Lease shall continue in full force and effect for the duration of the Option Term. 

2.2.3    Rental During Option Term. The annual Rent payable by Tenant during the Option Term
(the “Option Rent”) shall be equal to the “Fair Rental Value,” as that term is defined below, for the Premises as of the commencement date of the Option Term; provided that any annual Rent escalations during the Option
Term shall be limited to a maximum of three percent (3%). The “Fair Rental Value,” as used in this Lease, shall be equal to the annual rent per rentable square foot (including additional rent and considering any “base
year” or “expense stop” applicable thereto), including all escalations, at which tenants (pursuant to leases consummated within the twelve (12) month period preceding the first day of the Option Term), are leasing non-sublease, non-encumbered, non-equity space which is not significantly greater or smaller in size than the subject space, for a
comparable lease term, in an arm’s length transaction, which comparable space is located in the “Comparable Buildings,” as that term is defined in this Section 2.2.3, below (transactions satisfying the
foregoing criteria shall be known as the “Comparable Transactions”), taking into consideration the following concessions (the “Concessions”): (a) rental abatement concessions, if any, being granted such tenants in
connection with such comparable space; (b) tenant improvements or allowances provided or to be provided for such comparable space, and taking into account the value, if any, of the existing improvements in the subject space, such value to be
based upon the age, condition, design, quality of finishes and layout of the improvements and the extent to which the same can be utilized by a general office user other than Tenant; and (c) other reasonable monetary concessions being granted
such tenants in connection with such comparable space; provided, however, that in calculating the Fair Rental Value, no consideration shall be given to (i) the fact that Landlord is or is not required to pay a real estate brokerage commission
in connection with Tenant’s exercise of its right to extend the Lease Term, or the fact that landlords are or are not paying real estate brokerage commissions in connection with such comparable space, and (ii) any period of rental
abatement, if any, granted to tenants in comparable transactions in connection with the design, permitting and construction of tenant improvements in such comparable spaces. The Fair Rental Value shall additionally include a determination as to
whether, and if so to what extent, Tenant must provide Landlord with an increased Security Deposit (which may be in the form of a letter of credit), for Tenant’s Rent obligations in connection with Tenant’s lease of the Premises during the
Option Term. Such determination shall be made by reviewing the extent of financial security then generally being imposed in Comparable Transactions from tenants of comparable financial condition and credit history to the then existing financial
condition and credit history of Tenant (with appropriate adjustments to account for differences in the then-existing financial condition of Tenant and such other tenants). The Concessions (A) shall be reflected in the effective rental rate
(which effective rental rate shall take into consideration the total dollar value of such Concessions as amortized on a straight-

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-6-	  	[GenomeDx Biosciences, Corp.]

 
line basis over the applicable term of the Comparable Transaction (in which case such Concessions evidenced in the effective rental rate shall not be granted to Tenant)) payable by Tenant, or
(B) at Landlord’s election, all such Concessions shall be granted to Tenant in kind. The term “Comparable Buildings” shall mean the Building and those other first-class institutionally-owned
mid- and high-rise office buildings located in the Torrey Pines area of San Diego, California. Notwithstanding anything to the contrary contained in Section 2.2.2 above, if there are
not a sufficient number of Comparable Transactions with a comparable lease term to the Option Term to determine the Fair Rental Value for a lease of such duration, then the Fair Rental Value for purposes of this Section 2.2
shall be equal to that of Comparable Transactions with a term of five (5) years, provided that the Concessions shall be appropriately prorated on a fractional basis to account for the shorter term of lease. 

2.2.4    Determination of Option Rent. In the event Tenant timely and appropriately
exercises an option to extend the Lease Term, Landlord shall notify Tenant of Landlord’s determination of the Option Rent on or before the Lease Expiration Date. If Tenant, on or before the date which is thirty (30) days following the date
upon which Tenant receives Landlord’s determination of the Option Rent, objects to Landlord’s determination of the Option Rent, then Landlord and Tenant shall attempt to agree upon the Option Rent in each of Landlord’s and
Tenant’s reasonable discretion. If Landlord and Tenant fail to reach agreement within thirty (30) days following Tenant’s objection to the Option Rent (the “Outside Agreement Date”), then each party shall make a
separate determination of the Option Rent, as the case may be, within five (5) days, and such determinations shall be submitted to arbitration in accordance with Sections 2.2.4.1 through 2.2.4.7, below. If Tenant fails to object
to Landlord’s determination of the Option Rent within the time period set forth herein, then Tenant shall be deemed to have accepted Landlord’s determination of Option Rent. 

2.2.4.1    Landlord and Tenant shall each appoint one arbitrator who shall be, at the option of the
appointing party, a real estate broker, appraiser or attorney who shall have been active over the five (5) year period ending on the date of such appointment in the leasing or appraisal, as the case may be, of commercial office properties in
North San Diego, California. The determination of the arbitrators shall be limited solely to the issue of whether Landlord’s or Tenant’s submitted Option Rent is the closest to the actual Option Rent, taking into account the requirements
of Section 2.2.3 of this Lease, as determined by the arbitrators. Each such arbitrator shall be appointed within fifteen (15) days after the Outside Agreement Date. Landlord and Tenant may consult with their selected
arbitrators prior to appointment and may select an arbitrator who is favorable to their respective positions. The arbitrators so selected by Landlord and Tenant shall be deemed “Advocate Arbitrators.” 

2.2.4.2    The two (2) Advocate Arbitrators so appointed shall be specifically required pursuant to
an engagement letter within ten (10) days of the date of the appointment of the last appointed Advocate Arbitrator to agree upon and appoint a third arbitrator (“Neutral Arbitrator”) who shall be qualified under the same
criteria set forth hereinabove for qualification of the two Advocate Arbitrators, except that neither the Landlord or Tenant or either parties’ Advocate Arbitrator may, directly or indirectly, consult with the Neutral Arbitrator prior or
subsequent to his or her appearance. The Neutral Arbitrator shall be retained via an engagement letter jointly prepared by Landlord’s counsel and Tenant’s counsel. 

2.2.4.3    The three arbitrators shall, within thirty (30) days of the appointment of the Neutral
Arbitrator, reach a decision as to whether the parties shall use Landlord’s or Tenant’s submitted Option Rent, and shall notify Landlord and Tenant thereof. 

2.2.4.4    The decision of the majority of the three arbitrators shall be binding upon Landlord and
Tenant. 
 2.2.4.5    If either Landlord or Tenant fails to appoint an Advocate Arbitrator within
fifteen (15) days after the Outside Agreement Date, then either party may petition the presiding judge of the Superior Court of San Diego County to appoint such Advocate Arbitrator subject to the criteria in Section 2.2.4.1 of this
Lease, or if he or she refuses to act, either party may petition any judge having jurisdiction over the parties to appoint such Advocate Arbitrator. 

2.2.4.6    If the two (2) Advocate Arbitrators fail to agree upon and appoint the Neutral
Arbitrator, then either party may petition the presiding judge of the Superior Court of San Diego County to appoint 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-7-	  	[GenomeDx Biosciences, Corp.]

 
the Neutral Arbitrator, subject to criteria in Section 2.2.4.2 of this Lease, or if he or she refuses to act, either party may petition any judge having jurisdiction
over the parties to appoint such arbitrator. 
 2.2.4.7    The cost of the arbitration shall be paid by
Landlord and Tenant equally. 
 2.2.4.8    In the event that the Option Rent shall not have been
determined pursuant to the terms hereof prior to the commencement of the Option Term, Tenant shall be required to pay the Option Rent initially provided by Landlord to Tenant, and upon the final determination of the Option Rent, the payments made by
Tenant shall be reconciled with the actual amounts of Option Rent due, and the appropriate party shall promptly make any corresponding payment to the other party. 

2.2.5    Termination of Option Right. The Option shall be personal to Original Tenant and
any Permitted Transferee Assignee and may be exercised by Original Tenant or a Permitted Transferee Assignee (and not by any other assignee, sublessee or “Transferee,” as that term is defined in Section 14.1 of this Lease, of
Tenant’s interest in this Lease) if the Lease then remains in full force and effect and if Original Tenant or a Permitted Transferee Assignee occupies the entire Premises at the time the option to extend is exercised and, at Landlord’s
option, as of the commencement of the Option Term. The option right granted herein shall terminate upon the failure by Tenant to exercise the Option in accordance with this Section 2.2. 

 

	3.	 BASE RENT 

3.1    Base Rent. Tenant shall pay, without prior notice or demand, to Landlord or
Landlord’s agent at the management office of the Project, or, at Landlord’s option, at such other place as Landlord may from time to time designate in writing, by a check for currency which, at the time of payment, is legal tender for
private or public debts in the United States of America, base rent (“Base Rent”) as set forth in Section 4 of the Summary, payable in equal monthly installments as set forth in Section 4 of the Summary in advance on or
before the first day of each and every calendar month during the Lease Term, without any setoff or deduction whatsoever. The Base Rent for the first full month of the Lease Term shall be paid at the time of Tenant’s execution of this Lease. If
any Rent payment date (including the Lease Commencement Date) falls on a day of the month other than the first day of such month or if any payment of Rent is for a period which is shorter than one month, the Rent for any fractional month shall
accrue on a daily basis for the period from the date such payment is due to the end of such calendar month or to the end of the Lease Term at a rate per day which is equal to 1/365 of the applicable annual Rent. All other payments or adjustments
required to be made under the terms of this Lease that require proration on a time basis shall be prorated on the same basis. 

3.2    Abated Minimum Rental. Provided that Tenant is not then in default under the Lease,
beyond any applicable notice and cure period set forth in this Lease, then until the first (1st) day of the fifteenth (15th) full calendar month of the Lease Term (the “Rent Abatement
Period”), Tenant shall not be obligated to pay any Base Rent otherwise attributable to the Delayed Occupancy Space during such Rent Abatement Period (the “Rent Abatement”). Landlord and Tenant acknowledge that the aggregate
amount of the Rent Abatement equals One Hundred Fifty-Nine Thousand Six Hundred Ninety-Three and 48/100_ Dollars ($159,693.48). Tenant acknowledges and agrees that the foregoing Rent Abatement has been granted to Tenant as additional consideration
for entering into this Lease, and for agreeing to pay the rent and performing the terms and conditions otherwise required under the Lease, as hereby amended. If (i) Tenant shall be in default under this Lease and shall fail to cure such default
within the notice and cure period, if any, permitted for cure pursuant to this Lease, or (ii) this Lease shall be terminated for any reason other than a default by Landlord, then the dollar amount of the unapplied portion of the Rent Abatement
as of the date of such default shall be converted to a credit to be applied to the Base Rent applicable at the end of the Lease Term and Tenant shall immediately be obligated to begin paying Base Rent for the Premises in full. 

 

	4.	 ADDITIONAL RENT 

4.1    General Terms. 

4.1.1    Direct Expenses; Additional Rent. In addition to paying the Base Rent specified in
Article 3 of this Lease, Tenant shall pay “Tenant’s Share” of the annual “Direct Expenses,” as those terms are 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-8-	  	[GenomeDx Biosciences, Corp.]

 
defined in Sections 4.2.6 and 4.2.2 of this Lease, respectively. Such payments by Tenant, together with any and all other amounts payable by Tenant to Landlord pursuant to the terms of
this Lease, are hereinafter collectively referred to as the “Additional Rent”, and the Base Rent and the Additional Rent are herein collectively referred to as “Rent.” All amounts due under this Article 4 as
Additional Rent shall be payable for the same periods and in the same manner as the Base Rent. Without limitation on other obligations of Tenant which survive the expiration of the Lease Term, the obligations of Tenant to pay the Additional Rent
provided for in this Article 4 shall survive the expiration of the Lease Term. 

4.1.2    Triple Net Lease. Landlord and Tenant acknowledge that, except as otherwise
provided to the contrary in this Lease, it is their intent and agreement that this Lease be a “TRIPLE NET” lease and that as such, the provisions contained in this Lease are intended to pass on to Tenant or reimburse Landlord for
the costs and expenses reasonably associated with this Lease, the Premises, Tenant’s Share of the Project, and Tenant’s operation therefrom. To the extent such costs and expenses payable by Tenant cannot be charged directly to, and paid
by, Tenant, such costs and expenses shall be paid by Landlord but reimbursed by Tenant as Additional Rent. 

4.2    Definitions of Key Terms Relating to Additional Rent. As used in this Article
4, the following terms shall have the meanings hereinafter set forth: 
 4.2.1    Intentionally
Deleted. 
 4.2.2    “Direct Expenses” shall mean “Operating Expenses”
and “Tax Expenses.” 
 4.2.3    “Expense Year” shall mean each
calendar year in which any portion of the Lease Term falls, through and including the calendar year in which the Lease Term expires, provided that Landlord, upon notice to Tenant, may change the Expense Year from time to time to any other twelve
(12) consecutive month period, and, in the event of any such change, Tenant’s Share of Direct Expenses shall be equitably adjusted for any Expense Year involved in any such change. 

4.2.4    “Operating Expenses” shall mean all expenses, costs and amounts of every kind
and nature which Landlord pays or accrues during any Expense Year because of or in connection with the ownership, management, maintenance, security, repair, replacement, restoration or operation of the Project, or any portion thereof, in accordance
with sound real estate management and accounting principles. Without limiting the generality of the foregoing, Operating Expenses shall specifically include any and all of the following: (i) the cost of supplying all utilities, the cost of
operating, repairing, maintaining, and renovating the utility, telephone, mechanical, sanitary, storm drainage, and elevator systems, and the cost of maintenance and service contracts in connection therewith; (ii) the cost of licenses,
certificates, permits and inspections and the cost of contesting any governmental enactments which may affect Operating Expenses, and the costs incurred in connection with a governmentally mandated transportation system management program or similar
program; (iii) the cost of all insurance carried by Landlord in connection with the Project and Premises as reasonably determined by Landlord; (iv) the cost of landscaping, relamping, and all supplies, tools, equipment and materials used
in the operation, repair and maintenance of the Project, or any portion thereof; (v) the cost of parking area operation, repair, restoration, and maintenance; (vi) fees and other costs, including management and/or incentive fees,
consulting fees, legal fees and accounting fees, of all contractors and consultants in connection with the management, operation, maintenance and repair of the Project, provided that any such fees may not exceed the greater of (A) those fees
typically charged by owners of the Comparable Buildings, and (B) four percent (4%) of gross revenues (adjusted and grossed up to reflect a one hundred percent (100%) occupancy of the Project with all tenants paying full rent, as contrasted with
free rent, half-rent and the like); (vii) payments under any equipment rental agreements and the fair rental value of any management office space; (viii) subject to item (f), below, wages, salaries and other compensation and benefits, including
taxes levied thereon, of all persons engaged in the operation, maintenance and security of the Project; (ix) costs under any instrument pertaining to the sharing of costs by the Project; (x) operation, repair, maintenance and replacement
of all systems and equipment and components thereof of the Project; (xi) the cost of janitorial, alarm, security and other services, replacement of wall and floor coverings, ceiling tiles and fixtures in common areas, maintenance and
replacement of curbs and walkways, repair to roofs and re-roofing; (xii) amortization (including interest on the unamortized cost) over such period of time as Landlord shall reasonably determine, of the
cost of acquiring or the rental expense of personal property used in the maintenance, operation and repair of the Project, or any portion thereof; (xiii) the cost of capital improvements or other costs incurred in connection with the Project
(A) which are intended to effect economies in the operation or 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-9-	  	[GenomeDx Biosciences, Corp.]

 
maintenance of the Project, or any portion thereof, or to reduce current or future Operating Expenses or to enhance the safety or security of the Project or its occupants, (B) that are
required to comply with present or anticipated conservation programs, (C) which are replacements or modifications of nonstructural items located in the Common Areas required to keep the Common Areas in good order or condition, or (D) that
are required under any governmental law or regulation; provided, however, that any such capital expenditure shall be amortized (including interest on the amortized cost) over such period of time as Landlord shall reasonably determine; and
(xiv) costs, fees, charges or assessments imposed by, or resulting from any mandate imposed on Landlord by, any federal, state or local government for fire and police protection, trash removal, community services, or other services which do not
constitute “Tax Expenses” as that term is defined in Section 4.2.5, below, (xv) cost of tenant relation programs reasonably established by Landlord, and (xvi) payments under any easement, license,
operating agreement, declaration, restrictive covenant, or instrument pertaining to the sharing of costs by the Building, including, without limitation, any covenants, conditions and restrictions affecting the property, and reciprocal easement
agreements affecting the property, any parking licenses, and any agreements with transit agencies affecting the Property (collectively, “Underlying Documents”). Notwithstanding the foregoing, for purposes of this Lease, Operating
Expenses shall not, however, include: 
 (a)    costs, including legal fees, space planners’ fees,
advertising and promotional expenses (except as otherwise set forth above), and brokerage fees incurred in connection with the original construction or development, or past or future leasing of the Project (including without limitation in connection
with negotiations or disputes with tenants), and costs, including permit, license and inspection costs, incurred with respect to the installation of tenant improvements made for new tenants initially occupying space in the Project after the Lease
Commencement Date or incurred in renovating or otherwise improving, decorating, painting or redecorating vacant space for tenants or other occupants of the Project (excluding, however, such costs relating to any common areas of the Project or
parking facilities); 
 (b)    except as set forth in items (xii), (xiii), and (xiv) above,
depreciation, interest and principal payments on mortgages and other debt costs, if any, penalties and interest; 

(c)    costs for which the Landlord is reimbursed by any tenant or occupant of the Project, by insurance
by its carrier or any tenant’s carrier or by anyone else or by receipt of a condemnation award, including, without limitation, costs of repairs and other work occasioned by fire, windstorm, or other casualty, and electric power costs for which
any tenant directly contracts with the local public service company; 
 (d)    any bad debt loss, rent
loss, or reserves for bad debts or rent loss; 
 (e)    costs associated with the operation of the
business of the partnership or entity which constitutes the Landlord, as the same are distinguished from the costs of operation of the Project (which shall specifically include, but not be limited to, accounting costs associated with the operation
of the Project). Costs associated with the operation of the business of the partnership or entity which constitutes the Landlord include costs of partnership accounting and legal matters, costs of defending any lawsuits with any mortgagee (except as
the actions of the Tenant may be in issue), costs of selling, syndicating, financing, mortgaging or hypothecating any of the Landlord’s interest in the Project, and costs incurred in connection with any disputes between Landlord and its
employees, between Landlord and Project management, or between Landlord and other tenants or occupants; 

(f)    the wages and benefits of any employee who does not devote substantially all of his or her
employed time to the Project unless such wages and benefits are prorated to reflect time spent on operating and managing the Project vis-a-vis time spent on matters
unrelated to operating and managing the Project; provided, that in no event shall Operating Expenses for purposes of this Lease include wages and/or benefits attributable to personnel above the level of Project manager; 

(g)    amount paid as ground rental for the Project by the Landlord; 

(h)    except for a Project management fee to the extent allowed pursuant to item (vi) above,
overhead and profit increment paid to the Landlord or to subsidiaries or affiliates of the Landlord for services in the Project to the extent the same exceeds the costs of such services rendered by qualified, first-class unaffiliated third parties
on a competitive basis; 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-10-	  	[GenomeDx Biosciences, Corp.]

 (i)    any compensation paid to clerks, attendants or
other persons in commercial concessions operated by the Landlord, provided that any compensation paid to any concierge at the Project shall be includable as an Operating Expense; 

(j)    rentals and other related expenses incurred in leasing air conditioning systems, elevators or
other equipment which if purchased the cost of which would be excluded from Operating Expenses as a capital cost, except equipment not affixed to the Project which is used in providing engineering, janitorial or similar services and, further
excepting from this exclusion such equipment rented or leased to remedy or ameliorate an emergency condition in the Project; 

(k)    all items and services for which (A) Tenant pays directly, (B) Tenant or any other
tenant in the Project reimburses Landlord or (C) Landlord provides selectively to one or more tenants (other than Tenant) without reimbursement; 

(l)    any costs expressly excluded from Operating Expenses elsewhere in this Lease; 

(m)    rent for any office space occupied by Project management personnel to the extent the size or
rental rate of such office space exceeds the size or fair market rental value of office space occupied by management personnel of the comparable buildings in the vicinity of the Building, with adjustment where appropriate for the size of the
applicable project; 
 (n)    costs of items considered capital repairs, replacements, improvements and
equipment under sound real estate management and accounting principles consistently applied and consistent with the determination of capital expenses by landlords of the Comparable Buildings, except as expressly included in Operating Expenses
pursuant to the definition above; 
 (o)    expenses in connection with services or other benefits of a
type that are not provided to Tenant but which are provided another tenant or occupant of the Project; 

(p)    any fines or penalties incurred due to violations by Landlord or any tenant at the Project (other
than Tenant) of any governmental rule or authority, this Lease or any other lease in the Project, or due to Landlord’s gross negligence or willful misconduct; 

(q)    costs incurred to comply with laws relating to the removal of hazardous material (as defined under
applicable law) which was in existence in the Building or on the Project prior to the Lease Commencement Date, and was of such a nature that a federal, State or municipal governmental authority, if it had then had knowledge of the presence of such
hazardous material, in the state, and under the conditions that it then existed in the Building or on the Project, would have then required the removal of such hazardous material or other remedial or containment action with respect thereto; and
costs incurred to remove, remedy, contain, or treat hazardous material, which hazardous material is brought into the Building or onto the Project after the date hereof by Landlord or any other tenant of the Project and is of such a nature, at that
time, that a federal, State or municipal governmental authority, if it had then had knowledge of the presence of such hazardous material, in the state, and under the conditions, that it then exists in the Building or on the Project, would have then
required the removal of such hazardous material or other remedial or containment action with respect thereto; and 

(r)    costs for the acquisition of sculpture, paintings, or other objects of art and extraordinary
expenses in connection therewith. 
 If Landlord is not furnishing any particular work or service (the cost of which, if
performed by Landlord, would be included in Operating Expenses) to a tenant who has undertaken to perform such work or service in lieu of the performance thereof by Landlord, Operating Expenses shall be deemed to be increased by an amount equal to
the additional Operating Expenses which would reasonably have been incurred during such period by Landlord if it had at its own expense furnished such work or service to such tenant. If the Project is not at least ninety-five percent (95%) occupied
during all or a portion of any Expense Year, Landlord shall make an appropriate adjustment to the components of Operating Expenses for such year to determine the amount of Operating Expenses that would have

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-11-	  	[GenomeDx Biosciences, Corp.]

 
been incurred had the Project been ninety-five percent (95%) occupied; and the amount so determined shall be deemed to have been the amount of Operating Expenses for such year. 

4.2.5    Taxes. 

4.2.5.1    “Tax Expenses” shall mean all federal, state, county, or local governmental or
municipal taxes, fees, charges or other impositions of every kind and nature, whether general, special, ordinary or extraordinary (including, without limitation, real estate taxes, general and special assessments, transit taxes, leasehold taxes or
taxes based upon the receipt of rent, including gross receipts or sales taxes applicable to the receipt of rent, unless required to be paid by Tenant, personal property taxes imposed upon the fixtures, machinery, equipment, apparatus, systems and
equipment, appurtenances, furniture and other personal property used in connection with the Project, or any portion thereof), which shall be paid or accrued during any Expense Year (without regard to any different fiscal year used by such
governmental or municipal authority) because of or in connection with the ownership, leasing and operation of the Project, or any portion thereof. 

4.2.5.2    Tax Expenses shall include, without limitation: (i) Any tax on the rent, right to rent or
other income from the Project, or any portion thereof, or as against the business of leasing the Project, or any portion thereof; (ii) Any assessment, tax, fee, levy or charge in addition to, or in substitution, partially or totally, of any
assessment, tax, fee, levy or charge previously included within the definition of real property tax; (iii) Any assessment, tax, fee, levy, or charge allocable to or measured by the area of the Premises or the Rent payable hereunder, including,
without limitation, any business or gross income tax or excise tax with respect to the receipt of such rent, or upon or with respect to the possession, leasing, operating, management, maintenance, alteration, repair, use or occupancy by Tenant of
the Premises, or any portion thereof; and (iv) Any assessment, tax, fee, levy or charge, upon this transaction or any document to which Tenant is a party, creating or transferring an interest or an estate in the Premises or the improvements
thereon. For the avoidance of doubt, no item shall be “double-counted” as both an Operating Expense and a Tax Expense. 

4.2.5.3    Any costs and expenses (including, without limitation, reasonable attorneys’ and
consultants’ fees) incurred in attempting to protest, reduce or minimize Tax Expenses shall be included in Tax Expenses in the Expense Year such expenses are incurred. Tax refunds shall be credited against Tax Expenses and refunded to Tenant
regardless of when received, based on the Expense Year to which the refund is applicable, provided that in no event shall the amount to be refunded to Tenant for any such Expense Year exceed the total amount paid by Tenant as Additional Rent under
this Article 4 for such Expense Year. If Tax Expenses for any period during the Lease Term or any extension thereof are increased after payment thereof for any reason, including, without limitation, error or reassessment by applicable governmental
or municipal authorities, Tenant shall pay Landlord upon demand Tenant’s Share of any such increased Tax Expenses. Notwithstanding anything to the contrary contained in this Section 4.2.5, there shall be excluded from
Tax Expenses (i) all excess profits taxes, franchise taxes, gift taxes, capital stock taxes, inheritance and succession taxes, estate taxes, federal and state income taxes, and other taxes to the extent applicable to Landlord’s net income
(as opposed to rents, receipts or income attributable to operations at the Project), (ii) any items included as Operating Expenses, and (iii) any items paid by Tenant under Section 4.5 of this Lease. 

4.2.6    “Tenant’s Share” shall mean the percentage set forth in
Section 6 of the Summary, which percentage has as the numerator the rentable square feet of the Premises and as the denominator, the total rentable square feet of the Building. The percentage constituting Tenant’s
Share is subject to revision in the event that either (i) rentable square footage is added to or removed from the Premises by agreement between Landlord and Tenant or pursuant to the terms of this Lease or (ii) rentable square footage is
added or removed from the Building. 
 4.3    Allocation of Direct Expenses. The parties
acknowledge that the Building is a part of a multi-building project and that the costs and expenses incurred in connection with the Project (i.e., the Direct Expenses) should be shared between the Building and the other buildings in the Project.
Accordingly, as set forth in Section 4.2 above, Direct Expenses (which consist of Operating Expenses and tax Expenses) are determined annually for the Project as a whole, and a portion of the Direct Expenses, which portion shall be determined
by Landlord on an equitable basis, shall be allocated to the Building (as opposed to other buildings in the Project). Such portion of Direct Expenses allocated to the Building shall include all Direct Expenses attributable solely to the Building and
an equitable portion of the Direct Expenses attributable to the Project as a whole, and shall not include Direct Expenses attributable solely to other buildings in the Project. 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-12-	  	[GenomeDx Biosciences, Corp.]

 4.4    Calculation and Payment of Additional
Rent. Tenant shall pay to Landlord, in the manner set forth in Section 4.4.1, below, and as Additional Rent, Tenant’s Share of Direct Expenses for each Expense Year. Notwithstanding anything to the contrary
contained in this Article 4, the aggregate “Controllable Expenses,” as that term is defined below, included in Direct Expenses in any Expense Year after the first (1st) Expense
Year shall not increase by more than five percent (5%) over the amount of Controllable Expenses included in Direct Expenses for the immediately preceding Expense Year. For purposes of this Section 4.4, “Controllable
Expenses” shall mean all Direct Expenses except: (i) Tax Expenses and any and all assessments, including assessment districts and government-mandated charges with respect to the Building or Project, or any part thereof;
(ii) insurance carried by Landlord; (iii) costs of utilities, including, without limitation, electricity, water, HVAC and sewer charges, utility surcharges and assessments, and refuse removal; (iv) the costs of capital alterations,
capital additions, capital improvements, capital repairs and capital replacements to the extent included in Operating Expenses pursuant to the definition in Section 4.2.4, above; (v) costs of repair and maintenance
(excluding preventive maintenance), (vi) cost of services provided under a union contract, (vii) payments under any covenants, conditions and restrictions affecting the Project, and (viii) cost to repair caused by any casualty, vandalism
or for any other cause outside of Landlord’s reasonable control. 
 4.4.1    Statement of
Actual Direct Expenses and Payment by Tenant. Landlord shall deliver to Tenant within one hundred fifty (150) days following the end of each Expense Year, a statement (the “Statement”) which shall state the Direct
Expenses incurred or accrued for such preceding Expense Year, and which shall indicate the amount of Tenant’s Share of Direct Expenses. Upon receipt of the Statement for each Expense Year commencing or ending during the Lease Term, Tenant shall
pay, with its next installment of Base Rent due, the full amount of Tenant’s Share of Direct Expenses for such Expense Year, less the amounts, if any, paid during such Expense Year as Estimated Direct Expenses (as that term is defined in
Section 4.4.2, below) and if Tenant paid more as Estimated Direct Expenses than the actual Tenant’s Share of Direct Expenses, Tenant shall receive a credit in the amount of Tenant’s overpayment against Rent next
due under this Lease. The failure of Landlord to timely furnish the Statement for any Expense Year shall not prejudice Landlord or Tenant from enforcing its rights under this Article 4. Even though the Lease Term has expired and Tenant has
vacated the Premises, when the final determination is made of Tenant’s Share of Direct Expenses for the Expense Year in which this Lease terminates, Tenant shall immediately pay to Landlord such amount, and if Tenant paid more as Estimated
Direct Expenses than the actual Tenant’s Share of Direct Expenses, Landlord shall, within thirty (30) days, deliver a check payable to Tenant in the amount of the overpayment. The provisions of this Section 4.4.1
shall survive the expiration or earlier termination of the Lease Term. 
 4.4.2    Statement of
Estimated Direct Expenses. In addition, Landlord shall endeavor to give Tenant a yearly expense estimate statement (the “Estimate Statement”) which shall set forth Landlord’s reasonable estimate (the
“Estimate”) of what the total amount of Direct Expenses for the then-current Expense Year shall be and the estimated Tenant’s Share of Direct Expenses (the “Estimated Direct Expenses”). The failure of Landlord
to timely furnish the Estimate Statement for any Expense Year shall not preclude Landlord from enforcing its rights to collect any Estimated Direct Expenses under this Article 4, nor shall Landlord be prohibited from revising any Estimate
Statement or Estimated Direct Expenses theretofore delivered to the extent necessary. Thereafter, Tenant shall pay, with its next installment of Base Rent due, a fraction of the Estimated Direct Expenses for the then-current Expense Year (reduced by
any amounts paid pursuant to the last sentence of this Section 4.4.2). Such fraction shall have as its numerator the number of months which have elapsed in such current Expense Year, including the month of such payment, and
twelve (12) as its denominator. In the event that during an Expense Year, Landlord wishes to revise the Estimate Statement previously delivered for such Expense Year, Landlord may deliver a revised Estimate Statement to Tenant, which shall
thereafter be used to determine the Estimate for the remainder of such Expense Year. Until a new Estimate Statement is furnished (which Landlord shall have the right to deliver to Tenant at any time), Tenant shall pay monthly, with the monthly Base
Rent installments, an amount equal to one-twelfth (1/12) of the total Estimated Direct Expenses set forth in the previous Estimate Statement delivered by Landlord to Tenant. 

4.5    Taxes and Other Charges for Which Tenant Is Directly Responsible. Tenant shall be
liable for and shall pay prior to delinquency, taxes levied against Tenant’s equipment, furniture, fixtures and any other personal property located in or about the Premises. If any such taxes on Tenant’s equipment, furniture, fixtures and
any other personal property are levied against Landlord or Landlord’s property or if the assessed value of Landlord’s property is increased by the inclusion therein of a value placed upon such equipment, furniture, fixtures or any other
personal property and if Landlord pays the taxes based upon such increased assessment, which Landlord shall have the right to do regardless of the validity thereof but only under proper protest if requested by Tenant, Tenant shall upon demand

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-13-	  	[GenomeDx Biosciences, Corp.]

 
repay to Landlord the taxes so levied against Landlord or the proportion of such taxes resulting from such increase in the assessment, as the case may be. 

 

	5.	 USE OF PREMISES 

5.1    Permitted Use. Tenant shall use the Premises solely for the Permitted Use set forth in
Section 7 of the Summary and Tenant shall not use or permit the Premises or the Project to be used for any other purpose or purposes whatsoever without the prior written consent of Landlord, which may be withheld in
Landlord’s sole discretion. 
 5.2    Prohibited Uses. Tenant further covenants and
agrees that Tenant shall not use, or suffer or permit any person or persons to use, the Premises or any part thereof for any use or purpose in violation of the laws of the United States of America, the State of California, or the ordinances,
regulations or requirements of the local municipal or county governing body or other lawful authorities having jurisdiction over the Project) including, without limitation, any such laws, ordinances, regulations or requirements relating to hazardous
materials or substances, as those terms are defined by applicable laws now or hereafter in effect, or any Underlying Documents. Landlord shall have the right to impose reasonable and customary rule and regulations regarding the use of the Project,
as reasonably deemed necessary by Landlord with respect to the orderly operation of the Project, and Tenant shall comply with such reasonable rules and regulations. Tenant shall not do or permit anything to be done in or about the Premises which
will in any way damage the reputation of the Project or obstruct or interfere with the rights of other tenants or occupants of the Building, or injure or annoy them or use or allow the Premises to be used for any improper, unlawful or objectionable
purpose, nor shall Tenant cause, maintain or permit any nuisance in, on or about the Premises. Tenant shall comply with, and Tenant’s rights and obligations under the Lease and Tenant’s use of the Premises shall be subject and subordinate
to, all recorded easements, covenants, conditions, and restrictions now or hereafter affecting the Project. 

5.3    Hazardous Materials. 

5.3.1    Tenant’s Obligations. 

5.3.1.1    Prohibitions. As a material inducement to Landlord to enter into this Lease with
Tenant, Tenant has fully and accurately completed Landlord’s Pre-Leasing Environmental Exposure Questionnaire (the “Environmental Questionnaire”), which is attached as Exhibit
E. Tenant agrees that except for those chemicals or materials, and their respective quantities, specifically listed on the Environmental Questionnaire, and except for small quantities customarily used in business offices, neither Tenant nor
Tenant’s employees, contractors and subcontractors of any tier, entities with a contractual relationship with Tenant (other than Landlord), or any entity acting as an agent or sub-agent of Tenant
(collectively, “Tenant’s Agents”) will produce, use, store or generate any “Hazardous Materials,” as that term is defined below, on, under or about the Premises, nor cause or permit any Hazardous Material to be
brought upon, placed, stored, manufactured, generated, blended, handled, recycled, used or “Released,” as that term is defined below, on, in, under or about the Premises. If any information provided to Landlord by Tenant on the
Environmental Questionnaire, or otherwise relating to information concerning Hazardous Materials is false, incomplete, or misleading in any material respect, the same shall be deemed a default by Tenant under this Lease. Upon Landlord’s
request, or in the event of any material change in Tenant’s use of Hazardous Materials at the Premises, Tenant shall deliver to Landlord an updated Environmental Questionnaire at least once a year. Landlord’s prior written consent shall be
required to any Hazardous Materials use for the Premises not described on the initial Environmental Questionnaire, such consent to be withheld in Landlord’s sole discretion; provided, however, with respect to Hazardous Materials that are
similar to the Hazardous Materials listed on the Environmental Questionnaire in terms of their hazardous character, handling profile, usage and quantity, Landlord shall not unreasonably withhold, condition or delay its consent. Tenant shall not
install or permit any underground storage tank on the Premises. For purposes of this Lease, “Hazardous Materials” means all flammable explosives, petroleum and petroleum products, waste oil, radon, radioactive materials, toxic
pollutants, asbestos, polychlorinated biphenyls (“PCBs”), medical waste, chemicals known to cause cancer or reproductive toxicity, pollutants, contaminants, hazardous wastes, toxic substances or related materials, including without
limitation any chemical, element, compound, mixture, solution, substance, object, waste or any combination thereof, which is or may be hazardous to human health, safety or to the environment due to its radioactivity, ignitability, corrosiveness,
reactivity, explosiveness, toxicity, carcinogenicity, infectiousness or other harmful or potentially harmful properties or effects, or defined as, regulated as or included in, 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-14-	  	[GenomeDx Biosciences, Corp.]

 
the definition of “hazardous substances,” “hazardous wastes,” “hazardous materials,” or “toxic substances” under any Environmental Laws. The term
“Hazardous Materials” for purposes of this Lease shall also include any mold, fungus or spores, whether or not the same is defined, listed, or otherwise classified as a “hazardous material” under any Environmental Laws, if such
mold, fungus or spores may pose a risk to human health or the environment or negatively impact the value of the Premises. For purposes of this Lease, “Release” or “Released” or “Releases” shall mean
any release, deposit, discharge, emission, leaking, spilling, seeping, migrating, injecting, pumping, pouring, emptying, escaping, dumping, disposing, or other movement of Hazardous Materials into the environment. 

5.3.1.2    Notices to Landlord. Tenant shall notify Landlord in writing as soon as possible
but in no event later than five (5) days after (i) the occurrence of any actual, alleged or threatened Release of any Hazardous Material in, on, under, from, about or in the vicinity of the Premises (whether past or present), regardless of
the source or quantity of any such Release, or (ii) Tenant becomes aware of any regulatory actions, inquiries, inspections, investigations, directives, or any cleanup, compliance, enforcement or abatement proceedings (including any threatened
or contemplated investigations or proceedings) relating to or potentially affecting the Premises, or (iii) Tenant becomes aware of any claims by any person or entity relating to any Hazardous Materials in, on, under, from, about or in the
vicinity of the Premises, whether relating to damage, contribution, cost recovery, compensation, loss or injury. Collectively, the matters set forth in clauses (i), (ii) and (iii) above are hereinafter referred to as “Hazardous
Materials Claims”. Tenant shall promptly forward to Landlord copies of all orders, notices, permits, applications and other communications and reports in connection with any Hazardous Materials Claims. Additionally, each party shall
promptly advise the other in writing of the advising party’s discovery of any occurrence or condition on, in, under or about the Premises or Project that could subject Tenant or Landlord to any liability, or restrictions on ownership,
occupancy, transferability or use of the Premises or Project under any “Environmental Laws,” as that term is defined below. Tenant shall not enter into any legal proceeding or other action, settlement, consent decree or other compromise
with respect to any Hazardous Materials Claims without first notifying Landlord of Tenant’s intention to do so and affording Landlord the opportunity to join and participate, as a party if Landlord so elects, in such proceedings and in no event
shall Tenant enter into any agreements which are binding on Landlord or the Premises without Landlord’s prior written consent. Landlord shall have the right to appear at and participate in, any and all legal or other administrative proceedings
concerning any Hazardous Materials Claim. For purposes of this Lease, “Environmental Laws” means all applicable present and future laws relating to the protection of human health, safety, wildlife or the environment, including,
without limitation, (i) all requirements pertaining to reporting, licensing, permitting, investigation and/or remediation of emissions, discharges, Releases, or threatened Releases of Hazardous Materials, whether solid, liquid, or gaseous in
nature, into the air, surface water, groundwater, or land, or relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport, or handling of Hazardous Materials; and (ii) all requirements pertaining to the
health and safety of employees or the public. Environmental Laws include, but are not limited to, the Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42 USC § 9601, et seq., the Hazardous Materials Transportation
Authorization Act of 1994, 49 USC § 5101, et seq., the Solid Waste Disposal Act, as amended by the Resource Conservation and Recovery Act of 1976, and Hazardous and Solid Waste Amendments of 1984, 42 USC § 6901, et seq., the Federal
Water Pollution Control Act, as amended by the Clean Water Act of 1977, 33 USC § 1251, et seq., the Clean Air Act of 1966, 42 USC § 7401, et seq., the Toxic Substances Control Act of 1976, 15 USC § 2601, et seq., the Safe
Drinking Water Act of 1974, 42 USC §§ 300f through 300j, the Occupational Safety and Health Act of 1970, as amended, 29 USC § 651 et seq., the Oil Pollution Act of 1990, 33 USC § 2701 et seq., the Emergency Planning and Community
Right-To-Know Act of 1986, 42 USC § 11001 et seq., the National Environmental Policy Act of 1969, 42 USC § 4321 et seq., the Federal Insecticide, Fungicide and
Rodenticide Act of 1947, 7 USC § 136 et seq., California Carpenter-Presley-Tanner Hazardous Substance Account Act, California Health & Safety Code §§ 25300 et seq., Hazardous Materials Release Response Plans and Inventory
Act, California Health & Safety Code, §§ 25500 et seq., Underground Storage of Hazardous Substances provisions, California Health & Safety Code, §§ 25280 et seq., California Hazardous Waste Control Law,
California Health & Safety Code, §§ 25100 et seq., and any other state or local law counterparts, as amended, as such applicable laws, are in effect as of the Lease Commencement Date, or thereafter adopted, published, or
promulgated. 
 5.3.1.3    Releases of Hazardous Materials. If, due to the acts or
omissions of Tenant or any Tenant’s Agent, any Release of any Hazardous Material in, on, under, from or about the Premises shall occur at any time during the Lease, in addition to notifying Landlord as specified above, Tenant, at its own sole
cost and expense, shall (i) immediately comply with any and all reporting requirements imposed pursuant to any and all Environmental Laws, (ii) provide a written certification to Landlord indicating that Tenant has complied with all

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-15-	  	[GenomeDx Biosciences, Corp.]

 
applicable reporting requirements, (iii) take any and all necessary investigation, corrective and remedial action in accordance with any and all applicable Environmental Laws, utilizing an
environmental consultant reasonably approved by Landlord, all in accordance with the provisions and requirements of this Section 5.3, including, without limitation,
Section 5.3.4, and (iv) take any such additional investigative, remedial and corrective actions as Landlord shall in its reasonable discretion deem necessary such that the Premises are remediated
to the condition existing prior to such Release. 
 5.3.1.4    Indemnification. 

5.3.1.4.1    In General. Without limiting in any way Tenant’s obligations under any
other provision of this Lease, Tenant shall be solely responsible for and shall protect, defend, indemnify and hold the Landlord Parties harmless from and against any and all claims, judgments, losses, damages, costs, expenses, penalties,
enforcement actions, taxes, fines, remedial actions, liabilities (including, without limitation, actual attorneys’ fees, litigation, arbitration and administrative proceeding costs, expert and consultant fees and laboratory costs) including,
without limitation, consequential damages and sums paid in settlement of claims, which arise during or after the Lease Term, whether foreseeable or unforeseeable, directly or indirectly arising out of or attributable to the presence, use,
generation, manufacture, treatment, handling, refining, production, processing, storage, Release or presence of Hazardous Materials in, on, under or about the Premises by Tenant or Tenant’s Agents, except to the extent such liabilities result
from the gross negligence or willful misconduct of Landlord following the Lease Commencement Date, and except to the extent (x) caused by the presence of Hazardous Materials in, on or under the Premises on the date of this Lease and was not
exacerbated by Tenant or Tenant’s Agents after the Lease Commencement Date, and/or (y) not caused by Tenant or any Tenant’s Agent. Landlord shall protect, defend, indemnify and hold Tenant harmless from any Hazardous Materials Claims
to the extent caused by or arising from any Hazardous Materials Released after the date of this Lease by Landlord or any Landlord Parties. 

5.3.1.4.2    Limitations. Notwithstanding anything in
Section 5.3.1.4, above, to the contrary, Tenant’s indemnity of Landlord as set forth in Section 5.3.1.4, above, shall not be applicable to claims
based upon Hazardous Materials which may exist in, on or about the Premises as of the date of this Lease (“Existing Hazardous Materials”), except to the extent that Tenant’s construction activities (not including the initial
construction of the Tenant Improvements by Landlord pursuant to the Tenant Work Letter) and/or Tenant’s other acts or omissions (including Tenant’s failure to remove, remediate or otherwise treat or
“Clean-up,” as that term is defined in Section 5.3.4, below, the subject Existing Hazardous Materials during the tenancy of the Premises) caused or
exacerbated the subject claim. 
 5.3.1.5    Compliance with Environmental Laws. Without
limiting the generality of Tenant’s obligation to comply with applicable laws as otherwise provided in this Lease, Tenant shall, at its sole cost and expense, comply with all Environmental Laws applicable to Tenant’s Hazardous Materials.
Tenant shall obtain and maintain any and all necessary permits, licenses, certifications and approvals appropriate or required for the use, handling, storage, and disposal of any Hazardous Materials used, stored, generated, transported, handled,
blended, or recycled by Tenant on the Premises. Landlord shall have a continuing right, without obligation, to require Tenant to obtain, and to review and inspect any and all such permits, licenses, certifications and approvals, together with copies
of any and all Hazardous Materials management plans and programs, any and all Hazardous Materials risk management and pollution prevention programs, and any and all Hazardous Materials emergency response and employee training programs respecting
Tenant’s use of Hazardous Materials. Upon request of Landlord, Tenant shall deliver to Landlord a narrative description explaining the nature and scope of Tenant’s activities involving Hazardous Materials and showing to Landlord’s
satisfaction compliance with all Environmental Laws and the terms of this Lease. 

5.3.2    Assurance of Performance. 

5.3.2.1    Environmental Assessments In General. Landlord may, but shall not be required to,
engage from time to time such contractors as Landlord determines to be appropriate to perform environmental assessments of a scope reasonably determined by Landlord (an “Environmental Assessment”) to ensure Tenant’s compliance
with the requirements of this Lease with respect to Hazardous Materials. 
 5.3.2.2    Costs of
Environmental Assessments. All costs and expenses incurred by Landlord in connection with any such Environmental Assessment initially shall be paid by Landlord; provided that if 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-16-	  	[GenomeDx Biosciences, Corp.]

 
any such Environmental Assessment shows that Tenant has failed to comply with the provisions of this Section 5.3, then all of the costs and expenses
of such Environmental Assessment shall be reimbursed by Tenant as Additional Rent within thirty (30) days after receipt of written demand therefor. 

5.3.3    Tenant’s Obligations upon Surrender. At the expiration or earlier termination
of the Lease Term, Tenant, at Tenant’s sole cost and expense, shall: (i) cause an Environmental Assessment of the Premises to be conducted in accordance with Section 15.3; (ii) cause all
Hazardous Materials introduced by Tenant or Tenant’s Agents to be removed from the Premises and disposed of in accordance with all Environmental Laws and as necessary to allow the Premises to be used for the same uses of the Premises as are
allowed as of the Lease Commencement Date; and (iii) cause to be removed all containers installed or used by Tenant or Tenant’s Agents to store any Hazardous Materials on the Premises, and cause to be repaired any damage to the Premises
caused by such removal. 
 5.3.4    Clean-up. 

5.3.4.1    Environmental Reports; Clean-Up. If any
written report, including any report containing results of any Environmental Assessment (an “Environmental Report”) shall indicate (i) the presence of any Hazardous Materials as to which Tenant has a removal or remediation
obligation under this Section 5.3, and (ii) that as a result of same, the investigation, characterization, monitoring, assessment, repair, closure, remediation, removal, or other clean-up (the “Clean-up”) of any Hazardous Materials is required, Tenant shall immediately prepare and submit to Landlord within thirty (30) days after
receipt of the Environmental Report a comprehensive plan, subject to Landlord’s written approval (not to be unreasonably withheld, conditioned or delayed), specifying the actions to be taken by Tenant to perform the Clean-up so that the Premises are restored to the conditions required by this Lease. Upon Landlord’s approval of the Clean-up plan, Tenant shall, at Tenant’s sole
cost and expense, without limitation on any rights and remedies of Landlord under this Lease, immediately implement such plan with a consultant reasonably acceptable to Landlord and proceed to Clean-Up
Hazardous Materials in accordance with all applicable laws and as required by such plan and this Lease. If, within thirty (30) days after receiving a copy of such Environmental Report, Tenant fails either (a) to complete such Clean-up, or (b) with respect to any Clean-up that cannot be completed within such thirty-day period, fails to proceed with
diligence to prepare the Clean-up plan and complete the Clean-up as promptly as practicable, then Landlord shall have the right, but not the obligation, and without
waiving any other rights under this Lease, to carry out any Clean-up recommended by the Environmental Report or required by any governmental authority having jurisdiction over the Premises, and recover all of
the costs and expenses thereof from Tenant as Additional Rent, payable within thirty (30) days after receipt of written demand therefor. 

5.3.4.2    No Rent Abatement. In the event that Tenant’s failure to complete the Clean-up prevents or delays a third-party from occupying the Premises, Tenant shall continue to pay all Rent due or accruing under this Lease during any Clean-up, and shall
not be entitled to any reduction, offset or deferral of any Base Rent or Additional Rent due or accruing under this Lease during any such Clean-up. 

5.3.4.3    Surrender of Premises. Tenant shall complete any
Clean-up prior to surrender of the Premises upon the expiration or earlier termination of this Lease. Tenant shall obtain and deliver to Landlord a letter or other written determination from the overseeing
governmental authority confirming that the Clean-up has been completed in accordance with all requirements of such governmental authority and that no further response action of any kind is required for the
unrestricted use of the Premises (“Closure Letter”). Upon the expiration or earlier termination of this Lease, Tenant shall also be obligated to close all permits obtained in connection with Hazardous Materials in accordance with
applicable laws. 
 5.3.4.4    Failure to Timely
Clean-Up. Should any Clean-up for which Tenant is responsible not be completed, or should Tenant not receive the Closure Letter and any governmental approvals
required under Environmental Laws in conjunction with such Clean-up prior to the expiration or earlier termination of this Lease, then Tenant shall be liable to Landlord as a holdover tenant (as more
particularly provided in Article 16) until Tenant has fully complied with its obligations under this Section 5.3. 

5.3.5    Confidentiality. Unless compelled to do so by applicable law, Tenant agrees that
Tenant shall not disclose, discuss, disseminate or copy any information, data, findings, communications, conclusions and reports regarding the environmental condition of the Premises to any Person (other than Tenant’s consultants,

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-17-	  	[GenomeDx Biosciences, Corp.]

 
attorneys, property managers and employees that have a need to know such information), including any governmental authority, without the prior written consent of Landlord. In the event Tenant
reasonably believes that disclosure is compelled by applicable law, it shall provide Landlord ten (10) days’ advance notice of disclosure of confidential information so that Landlord may attempt to obtain a protective order. Tenant may
additionally release such information to bona fide prospective investors, purchasers or lenders, subject to any such parties’ written agreement to be bound by the terms of this Section 5.3. 

5.3.6    Copies of Environmental Reports. Within thirty (30) days of receipt thereof,
Tenant shall provide Landlord with a copy of any and all environmental assessments, audits, studies and reports in Tenant’s possession regarding Tenant’s activities with respect to the Premises, or ground water beneath the Land, or the
environmental condition or Clean-up thereof. Tenant shall be obligated to provide Landlord with a copy of such materials without regard to whether such materials are generated by Tenant or prepared for Tenant,
or how Tenant comes into possession of such materials. 
 5.3.7    Landlord Obligation.
Landlord agrees to remediate or encapsulate any Hazardous Materials existing in the Project as of the Lease Commencement Date, and any Hazardous Materials that are released in, on or about the Project after the Lease Commencement Date by anyone
other than Tenant or Tenant’s Agents, to the extent that Landlord’s failure to so remediate would be in violation of applicable law and would prohibit Tenant from obtaining or maintaining a certificate of occupancy for the Premises, or
would unreasonably and materially affect the safety of Tenant’s employees or create a significant health hazard for Tenant’s employees, or would otherwise materially and adversely affect Tenant’s use of or access to the Premises. 

5.3.8    Signs, Response Plans, Etc. Tenant shall be responsible for posting on the Premises
any signs required under applicable Environmental Laws applicable to Tenant’s Hazardous Materials. Tenant shall also complete and file any business response plans or inventories required by any applicable laws. Tenant shall concurrently file a
copy of any such business response plan or inventory with Landlord. 
 5.3.9    Survival.
Each covenant, agreement, representation, warranty and indemnification made by Tenant set forth in this Section 5.3 shall survive the expiration or earlier termination of this Lease and shall remain
effective until all of Tenant’s obligations under this Section 5.3 have been completely performed and satisfied. 
  

	6.	 SERVICES AND UTILITIES 

6.1    Standard Tenant Services. Landlord shall provide the following services on all days
(unless otherwise stated below) during the Lease Term. 
 6.1.1    Subject to limitations imposed by all
governmental rules, regulations and guidelines applicable thereto, Landlord shall provide heating, ventilation and air conditioning (“HVAC”) when necessary for normal comfort for normal office use in the Premises from 7:00 A.M. to
6:00 P.M. Monday through Friday, and on Saturdays from 8:00 A.M. to 1:00 P.M. (collectively, the “Building Hours”), except for the date of observation of New Year’s Day, President’s Day, Memorial Day, Independence Day,
Labor Day, Thanksgiving Day, Christmas Day and, at Landlord’s discretion, other locally or nationally recognized holidays (collectively, the “Holidays”). Tenant shall cooperate fully with Landlord at all times and abide by all
regulations and requirements that Landlord may reasonably prescribe for the proper functioning and protection of the HVAC, electrical, mechanical and plumbing systems. 

6.1.2    Landlord shall provide reasonably sufficient electricity to the Premises (including adequate
electrical wiring and facilities for connection to Tenant’s lighting fixtures and incidental use equipment), provided that (i) the connected electrical load of the incidental use equipment does not exceed an average of two and one-half (2.5) watts per usable square foot of the Premises during the Building Hours, calculated on a monthly basis, and the electricity so furnished for incidental use equipment will be at a nominal one hundred
twenty (120) volts and no electrical circuit for the supply of such incidental use equipment will require a current capacity exceeding twenty (20) amperes, and (ii) the connected electrical load of Tenant’s lighting fixtures does
not exceed an average of one and one-half (1.5) watts per usable square foot of the Premises during the Building Hours, calculated on a monthly basis, and the electricity so furnished for Tenant’s
lighting will be at a nominal one hundred twenty (120) volts. Tenant will design Tenant’s electrical system serving any equipment producing nonlinear electrical loads to accommodate such 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-18-	  	[GenomeDx Biosciences, Corp.]

 
nonlinear electrical loads, including, but not limited to, oversizing neutral conductors, derating transformers and/or providing power-line filters. Engineering plans shall include a calculation
of Tenant’s fully connected electrical design load with and without demand factors and shall indicate the number of watts of unmetered and submetered loads. Tenant shall bear the cost of replacement of lamps, starters and ballasts for non-Building standard lighting fixtures within the Premises. Tenant shall pay for all utilities (including without limitation, electricity, gas, sewer and water) attributable to its use of the entire Premises, and
shall also provide its own janitorial and security services for the Building. Such utility use shall include electricity, water, and gas use for lighting, incidental use and “HVAC,” as that term is defined above. 

6.1.3    Landlord shall not provide janitorial services for the Premises. Tenant shall be solely
responsible for performing all janitorial services and other cleaning of the Premises, all in compliance with applicable laws. The janitorial and cleaning of the Premises shall be adequate to maintain the Premises in a manner consistent with First
Class Life Sciences Projects. 
 6.1.4    Subject to applicable laws and the other provisions of
this Lease, and except in the event of an emergency, Tenant shall have access to the Building, the Premises and the common areas of the Building, other than common areas requiring access with a Building engineer, twenty-four (24) hours per day,
seven (7) days per week, every day of the year. 
 6.2    Overstandard Tenant Use. If
Tenant desires to use heat, ventilation or air conditioning during hours other than those for which Landlord is obligated to supply such utilities pursuant to the terms of Section 6.1 of this Lease, Tenant shall give
Landlord such prior notice, if any, as Landlord shall from time to time establish as appropriate (but in no event more than forty-eight (48) hours), of Tenant’s desired use in order to supply such utilities, and Landlord shall supply such
utilities to Tenant at such hourly cost to Tenant (which shall be treated as Additional Rent) as Landlord shall from time to time establish. Landlord shall have the exclusive right, but not the obligation, to provide any additional services which
may be required by Tenant, including, without limitation, locksmithing, lamp replacement, additional janitorial service, and additional repairs and maintenance. If Tenant requests any such additional services, then Tenant shall pay to Landlord the
cost of such additional services, including a reasonable standard fee of Landlord for its involvement with such additional services, promptly upon being billed for same. 

6.3    Interruption of Use. Tenant agrees that Landlord shall not be liable for damages, by
abatement of Rent or otherwise, for failure to furnish or delay in furnishing any service (including telephone and telecommunication services), or for any diminution in the quality or quantity thereof, when such failure or delay or diminution is
occasioned, in whole or in part, by breakage, repairs, replacements, or improvements, by any strike, lockout or other labor trouble, by inability to secure electricity, gas, water, or other fuel at the Building or Project after reasonable effort to
do so, by any riot or other dangerous condition, emergency, accident or casualty whatsoever, by act or default of Tenant or other parties, or by any other cause; and such failures or delays or diminution shall never be deemed to constitute an
eviction or disturbance of Tenant’s use and possession of the Premises or relieve Tenant from paying Rent or performing any of its obligations under this Lease (except to the extent set forth in Section 19.5.2).
Furthermore, Landlord shall not be liable under any circumstances for a loss of, or injury to, property or for injury to, or interference with, Tenant’s business, including, without limitation, loss of profits, however occurring, through or in
connection with or incidental to a failure to furnish any of the services or utilities as set forth in this Article 6. 

6.4    Energy Performance Disclosure Information. Tenant hereby acknowledges that Landlord
may be required to disclose certain information concerning the energy performance of the Building pursuant to California Public Resources Code Section 25402.10 and the regulations adopted pursuant thereto (collectively the “Energy
Disclosure Requirements”). Tenant hereby acknowledges prior receipt of the Data Verification Checklist, as defined in the Energy Disclosure Requirements (the “Energy Disclosure Information”), and agrees that, to
Tenant’s knowledge, Landlord has timely complied in full with Landlord’s obligations under the Energy Disclosure Requirements. Tenant acknowledges and agrees that (i) Landlord makes no representation or warranty regarding the energy
performance of the Building or the accuracy or completeness of the Energy Disclosure Information, (ii) the Energy Disclosure Information is for the current occupancy and use of the Building and that the energy performance of the Building may
vary depending on future occupancy and/or use of the Building, and (iii) Landlord shall have no liability to Tenant for any errors or omissions in the Energy Disclosure Information. If and to the extent not prohibited by applicable laws, Tenant
hereby waives any right Tenant may have to receive the Energy Disclosure Information, including, without limitation, any right Tenant may have to terminate this Lease as a result of Landlord’s failure to

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-19-	  	[GenomeDx Biosciences, Corp.]

 
disclose such information. Further, Tenant hereby releases Landlord from any and all losses, costs, damages, expenses and/or liabilities relating to, arising out of and/or resulting from the
Energy Disclosure Requirements, including, without limitation, any liabilities arising as a result of Landlord’s failure to disclose the Energy Disclosure Information to Tenant prior to the execution of this Lease. Tenant’s acknowledgment
of the AS-IS condition of the Premises pursuant to the terms of this Lease shall be deemed to include the energy performance of the Building. Tenant further acknowledges that pursuant to the Energy Disclosure
Requirements, Landlord may be required in the future to disclose information concerning Tenant’s energy usage to certain third parties, including, without limitation, prospective purchasers, lenders and tenants of the Building (the
“Tenant Energy Use Disclosure”). Tenant hereby (A) consents to all such Tenant Energy Use Disclosures, and (B) acknowledges that Landlord shall not be required to notify Tenant of any Tenant Energy Use Disclosure. Further,
Tenant hereby releases Landlord from any and all losses, costs, damages, expenses and liabilities relating to, arising out of and/or resulting from any Tenant Energy Use Disclosure. The terms of this Section 6.3 shall
survive the expiration or earlier termination of this Lease. 
 6.5    Tenant Security
System. Tenant may, at its own expense, install its own security system (“Tenant’s Security System”) in the Premises; provided, however, that Tenant shall coordinate the installation and operation of Tenant’s
Security System with Landlord to assure Landlord that Tenant’s Security System is compatible with Landlord’s security system, if any, and the Building systems and equipment, and to the extent that Tenant’s Security System is not
compatible with Landlord’s security system, if any, or Building systems and equipment, Tenant shall remain entitled to install or operate the Tenant’s Security System but only to the extent that the Tenant’s Security System does not
interfere with the operation of Landlord’s security system, if any, and the Building systems and equipment. Tenant shall be solely responsible, at Tenant’s sole cost and expense, for the installation, monitoring, operation and removal of
Tenant’s Security System. Tenant’s Security System shall be installed by Tenant in accordance with the terms of Article 8 of this Lease. 
  

	7.	 REPAIRS 

7.1    Tenant’s Repair Obligations. Tenant shall, at Tenant’s own expense, keep the
Premises, including all improvements, fixtures, furnishings, and systems and equipment therein (including, without limitation, plumbing fixtures and equipment such as dishwashers, garbage disposals, and
insta-hot dispensers), and the floor or floors of the Building on which the Premises are located, in good order, repair and condition at all times during the Lease Term. In addition, Tenant shall, at
Tenant’s own expense, but under the supervision and subject to the prior reasonable approval of Landlord, and within any reasonable period of time specified by Landlord, promptly and adequately repair all damage to the Premises and replace or
repair all damaged, broken, or worn fixtures and appurtenances, except for damage caused by ordinary wear and tear or beyond the reasonable control of Tenant; provided however, that, at Landlord’s option, or if Tenant fails to make such
repairs, Landlord may, but need not, make such repairs and replacements, and Tenant shall pay Landlord the cost thereof, including a percentage of the cost thereof (to be uniformly established for the Building and/or the Project) sufficient to
reimburse Landlord for all overhead, general conditions, fees and other costs or expenses arising from Landlord’s involvement with such repairs and replacements forthwith upon being billed for same. To the extent that any of the foregoing
maintenance or repair obligations of Tenant pursuant to this Section 7.1 involve electrical, low voltage, cabling or similar work, such work shall be performed in accordance with the terms of
Section 8.6 of this Lease. 
 7.2    Landlord’s Repair
Obligations. Notwithstanding the foregoing, Landlord shall be responsible for repairs to the exterior walls (including exterior windows), foundation and roof (including roof membrane) of the Building, the structural portions of the floors of
the Building, and the base Building systems and equipment of the Building and Common Areas and maintaining same in good order and repair consistent with a First Class Life Sciences Project, except to the extent that such repairs are required
due to the negligence or willful misconduct of Tenant; provided, however, that if such repairs are due to the negligence or willful misconduct of Tenant, Landlord shall nevertheless make such repairs at Tenant’s expense, or, if covered by
Landlord’s insurance, Tenant shall only be obligated to pay any deductible in connection therewith. Subject to the terms of Article 27, below, Landlord may, but shall not be required to, enter the Premises at all reasonable times and
upon reasonable prior notice to make such repairs, alterations, improvements or additions to the Premises or to the Project or to any equipment located in the Project as Landlord shall desire or deem necessary or as Landlord may be required to do by
governmental or quasi-governmental authority or court order or decree; provided that Landlord shall use commercially reasonable efforts to minimize any disturbance of Tenant’s use and occupancy of the Premises for the Permitted Use. Tenant
hereby waives 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-20-	  	[GenomeDx Biosciences, Corp.]

 
any and all rights under and benefits of subsection 1 of Section 1932 and Sections 1941 and 1942 of the California Civil Code or under any similar law, statute, or ordinance now or hereafter
in effect. 
  

	8.	 ADDITIONS AND ALTERATIONS 

8.1    Landlord’s Consent to Alterations. Tenant may not make any improvements,
alterations, additions or changes to the Premises or any mechanical, plumbing or HVAC facilities or systems pertaining to the Premises (collectively, the “Alterations”) without first procuring the prior written consent of Landlord
to such Alterations, which consent shall be requested by Tenant not less than fifteen (15) business days prior to the commencement thereof, and which consent shall not be unreasonably withheld, conditioned or delayed by Landlord, provided it
shall be deemed reasonable for Landlord to withhold its consent to any Alteration which adversely affects the structural portions or the systems or equipment of the Building or is visible from the exterior of the Building. Notwithstanding the
foregoing, Tenant shall be permitted to make Alterations following fifteen (15) business days’ notice to Landlord, but without Landlord’s prior consent, to the extent that such Alterations (i) do not affect the Building systems
or equipment, (ii) are not visible from the exterior of the Building, and (iii) cost less than $50,000.00 for a particular job of work. The construction of the Tenant Improvements to the Premises shall be governed by the terms of the
Tenant Work Letter and not the terms of this Article 8. 
 8.2    Manner of
Construction. Landlord may impose, as a condition of its consent to any and all Alterations or repairs of the Premises or about the Premises, such reasonable requirements as Landlord in its reasonable discretion may deem desirable,
including, but not limited to, the requirement that upon Landlord’s request (subject to Section 8.5 below), Tenant shall, at Tenant’s expense, remove such Alterations upon the expiration or any early termination
of the Lease Term. Tenant shall construct such Alterations and perform such repairs in a good and workmanlike manner, in conformance with any and all applicable federal, state, county or municipal laws, rules and regulations and pursuant to a valid
building permit, issued by the city in which the Building is located (or other applicable governmental authority). Upon completion of any Alterations (or repairs), Tenant shall deliver to Landlord final lien waivers from all contractors,
subcontractors and materialmen who performed such work. In addition to Tenant’s obligations under Article 9 of this Lease, upon completion of any Alterations, Tenant agrees to cause a Notice of Completion to be recorded in the office of
the Recorder of the County of San Diego in accordance with Section 3093 of the Civil Code of the State of California or any successor statute, and Tenant shall deliver to the Project construction manager a reproducible copy of the “as
built” drawings of the Alterations as well as all permits, approvals and other documents issued by any governmental agency in connection with the Alterations. 

8.3    Payment for Improvements. If Tenant orders any work directly from Landlord, Tenant
shall pay to Landlord an amount equal to three percent (3%) of the cost of such work to compensate Landlord for all overhead, general conditions, fees and other costs and expenses arising from Landlord’s involvement with such work. If Tenant
does not order any work directly from Landlord, Tenant shall reimburse Landlord for Landlord’s reasonable, actual, out-of-pocket costs and expenses actually
incurred in connection with Landlord’s review of such work. 
 8.4    Construction
Insurance. In addition to the requirements of Article 10 of this Lease, in the event that Tenant makes any Alterations, prior to the commencement of such Alterations, Tenant shall provide Landlord with evidence that Tenant carries
“Builder’s All Risk” insurance in an amount reasonably approved by Landlord covering the construction of such Alterations, and such other insurance as Landlord may reasonably require, it being understood and agreed that all of
such Alterations shall be insured by Tenant pursuant to Article 10 of this Lease immediately upon completion thereof. In addition, Tenant’s contractors and subcontractors shall be required to carry (i) Commercial General Liability
Insurance in an amount reasonably approved by Landlord, with Landlord, and, at Landlord’s option, Landlord’s property manager and project manager, as additional insureds in an amount reasonably approved by Landlord, and otherwise in
accordance with the requirements of Article 10 of this Lease, and (ii) workers compensation insurance with a waiver of subrogation in favor of Landlord . Landlord may, in its reasonable discretion, require Tenant to obtain a lien and completion
bond or some alternate form of security satisfactory to Landlord in an amount sufficient to ensure the lien-free completion of such Alterations and naming Landlord as a co-obligee. 

8.5    Landlord’s Property. All Alterations, improvements, fixtures, equipment and/or
appurtenances which may be installed or placed in or about the Premises, from time to time, shall be at the sole cost of Tenant and shall be and become the property of Landlord and remain in place at the Premises following the expiration or earlier
termination of this Lease. Notwithstanding the foregoing, Landlord may, by written notice to Tenant prior to the end 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-21-	  	[GenomeDx Biosciences, Corp.]

 
of the Lease Term, or given following any earlier termination of this Lease, require Tenant, at Tenant’s expense, to remove any Alterations and/or improvements and/or systems and equipment
within the Premises (excluding, however, the Tenant Improvements initially constructed in the Initial Occupancy Premises pursuant to Exhibit B, and, to the extent materially consistent with the Tenant Improvements initially constructed
in the lab portion of the Initial Occupancy Premises, the Tenant Improvements initially constructed in the Delayed Occupancy Premises) and to repair any damage to the Premises and Building caused by such removal and return the affected portion of
the Premises to a condition comparable to that which existed upon Landlord’s delivery of the Premises to Tenant; provided; however, that notwithstanding the foregoing, upon request by Tenant at the time of Tenant’s request for
Landlord’s consent to any Alteration or improvement, Landlord shall promptly notify Tenant whether the applicable Alteration or improvement will be required to be removed pursuant to the terms of this Section 8.5. If
Tenant fails to complete any required removal and/or to repair any damage caused by the removal of any Alterations and/or improvements and/or systems and equipment in the Premises and return the affected portion of the Premises to a condition
comparable to that which existed upon Landlord’s delivery of the Premises to Tenant (excepting normal wear and tear and damage by casualty), Landlord may do so and may charge the actual and reasonable cost thereof to Tenant. Tenant hereby
protects, defends, indemnifies and holds Landlord harmless from any liability, cost, obligation, expense or claim of lien in any manner relating to the installation, placement, removal or financing of any such Alterations, improvements, fixtures
and/or equipment in, on or about the Premises, which obligations of Tenant shall survive the expiration or earlier termination of this Lease. 

8.6    Union Contractors. Notwithstanding anything to the contrary in this Article 8
or elsewhere in this Lease, prior to starting work on any Alterations (other than the Tenant Improvements described in Exhibits B-1, B-2 and
B-3, which shall be contracted for by Landlord in accordance with the terms thereof), Tenant shall engage contractors and subcontractors specified by Landlord who (i) are bound by and
signatory to a collective bargaining agreement with a labor organization (a) whose jurisdiction covers the type of work to be performed on the Project and (b) which is an Approved Building Trades Department Contractor or Subcontractor, and
(ii) observe area standards for wages and other terms and conditions of employment, including fringe benefits (“Union Contractors”). Tenant may reasonably approve such contractors and subcontractors so long as they are Union
Contractors in all instances. For purposes hereof, an “Approved Building Trades Department Contractor or Subcontractor” is a contractor or subcontractor who is currently affiliated with the Building and Construction Trades Department of
the AFL-CIO (the “BCTD”) or, if no such BCTD-affiliated contractor or subcontractor is available for a particular trade (e.g., carpentry work), a contractor or subcontractor which is
affiliated with a national trade union which was formerly affiliated with the BCTD and which recognizes (and will recognize and respect, for its work on the Premises), the jurisdictional limitations established by the local BCTD. All Alterations,
including the Tenant Improvements, to be performed within the Building and Premises by or on behalf of Tenant or anyone claiming by or under Tenant shall be performed by Union Contractors. More specifically, Tenant warrants that all contractors,
subcontractors and craftspersons performing Alterations, including without limitation the Tenant Improvements, shall be current members of trade unions governing their respective trades. In the event that Tenant engages any Union Contractors in
accordance with the provisions of this Section 8.6, Landlord shall reimburse Tenant for the amount by which the cost of the work performed by such Union Contractor exceeds the anticipated cost of such work if the same were
performed by a non-Union Contractor, as determined based on at least one bid obtained by Tenant from one or more non-Union Contractors reasonably approved by Landlord,
or, if Tenant is unable to secure any such bids, then as reasonably determined by Landlord (the “Union Premium”); provided, however, in no event shall Tenant be required to obtain bids from any Union Contractors in connection with
the calculation of the Union Premium. Landlord shall reimburse Tenant for the Union Premium within thirty (30) days after Landlord’s receipt of Tenant’s written demand for the same, which demand shall include invoices and lien
releases from the Union Contractor that performed the work for which reimbursement is sought. Notwithstanding anything to the contrary contained this Section 8.6 above, in the event that either (i) Landlord fails to
specify a Union Contractor reasonably acceptable to Tenant within thirty (30) days following a written request therefor by Tenant to Landlord, or (ii) a Union Contractor is not reasonably available to perform certain work in connection
with any Alterations or Tenant Improvements (i.e., within forty-five (45) days of Tenant’s proposed time frames, as evidenced by complete plans and specifications for such work), then Tenant may proceed to engage a non-Union Contractor to perform such work. 
 9.    COVENANT AGAINST
LIENS    Tenant shall keep the Project and Premises free from any liens or encumbrances arising out of the work performed, materials furnished or obligations incurred by or on behalf of Tenant, and shall protect, defend,
indemnify and hold Landlord harmless from and against any claims, liabilities, judgments or costs (including, without limitation, reasonable attorneys’ fees and costs) arising out of same or in connection

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-22-	  	[GenomeDx Biosciences, Corp.]

 
therewith. Tenant shall give Landlord notice at least fifteen (15) days prior to the commencement of any such work on the Premises (or such additional time as may be necessary under
applicable laws) to afford Landlord the opportunity of posting and recording appropriate notices of non-responsibility (to the extent applicable pursuant to then applicable laws). Tenant shall remove any such
lien or encumbrance by bond or otherwise within ten (10) business days after notice by Landlord, and if Tenant shall fail to do so, Landlord may pay the amount necessary to remove such lien or encumbrance, without being responsible for
investigating the validity thereof. 
  

	10.	 INSURANCE 

10.1    Indemnification and Waiver. Except to the extent arising from the gross negligence or
willful misconduct of Landlord or Landlord Parties, or Landlord’s breach of the terms of this Lease, Tenant hereby assumes all risk of damage to property or injury to persons in, upon or about the Premises from any cause whatsoever and agrees
that Landlord, its partners, subpartners and their respective officers, agents, servants, employees, lenders, any property manager and independent contractors (collectively, “Landlord Parties”) shall not be liable for, and are
hereby released from any responsibility for, any damage either to person or property or resulting from the loss of use thereof, which damage is sustained by Tenant or by other persons claiming through Tenant. Tenant shall indemnify, defend, protect,
and hold harmless the Landlord Parties from any and all claims, loss, cost, damage, injury, expense and liability (including without limitation court costs and reasonable attorneys’ fees) during the Lease Term (and any period of holding over by
Tenant) incurred in connection with or arising from any cause in, on or about the Premises, any acts, omissions or negligence of Tenant or of any person claiming by, through or under Tenant, or of the contractors, agents, servants, employees,
invitees, guests or licensees of Tenant or any such person, in, on or about the Project or any breach of the terms of this Lease, either prior to, during, or after the expiration of the Lease Term. Should Landlord be named as a defendant in any suit
brought against Tenant in connection with or arising out of Tenant’s occupancy of the Premises, Tenant shall pay to Landlord its reasonable costs and expenses incurred in such suit, including without limitation, its actual professional fees
such as reasonable appraisers’, accountants’ and attorneys’ fees. The provisions of this Section 10.1 shall survive the expiration or sooner termination of this Lease with respect to any claims or liability
arising in connection with any event occurring prior to such expiration or termination. 

10.2    Tenant’s Compliance With Landlord’s Property Insurance. Landlord shall
insure the Building during the Lease Term against loss or damage under an “all risk” property insurance policy. Such coverage shall be in such amounts, from such companies, and on such other terms and conditions, as Landlord may from time
to time reasonably determine. Additionally, at the option of Landlord, such insurance coverage may include the risks of earthquakes and/or flood damage and additional hazards, a rental loss endorsement and one or more loss payee endorsements in
favor of the holders of any mortgages or deeds of trust encumbering the interest of Landlord in the Building or the ground or underlying lessors of the Building, or any portion thereof. Tenant shall, at Tenant’s expense, comply with all
insurance company requirements pertaining to the use of the Premises. If Tenant’s conduct or use of the Premises causes any increase in the premium for such insurance policies then Tenant shall reimburse Landlord for any such increase. Tenant,
at Tenant’s expense, shall comply with all rules, orders, regulations or requirements of the American Insurance Association (formerly the National Board of Fire Underwriters) and with any similar body. Tenant shall also provide Landlord and
Landlord’s insurer(s) with such information regarding the use of the Premises and any damage to the Premises as they may require in connection with the placement of insurance for the Premises or the adjusting of any losses to the Premises. 

10.3    Tenant’s Insurance. Tenant shall maintain the following coverages in the
following amounts. 
 10.3.1    Commercial General Liability Insurance on an occurrence form covering
the insured against claims of bodily injury, personal injury and property damage (including loss of use thereof) arising out of Tenant’s operations, and contractual liabilities including a contractual coverage, and including products and
completed operations coverage, for limits of liability on a per location basis of not less than: 
  

			
	 Bodily Injury and
	  	 $2,000,000 each occurrence

	 Property Damage Liability
	  	 $2,000,000 annual aggregate

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-23-	  	[GenomeDx Biosciences, Corp.]

			
	 Personal Injury Liability
	  	 $3,000,000 each occurrence

		  	 $3,000,000 annual aggregate

 10.3.2    Property Insurance covering (i) all office furniture,
business and trade fixtures, office equipment, free-standing cabinet work, movable partitions, merchandise and all other items of Tenant’s property on the Premises installed by, for, or at the expense of Tenant, (ii) the Tenant
Improvements, and any other improvements which exist in the Premises as of the Lease Commencement Date (excluding the Base Building) (the “Original Improvements”), and (iii) all other improvements, alterations and additions to
the Premises made during the Lease Term. Such insurance shall be written on an “all risks” of physical loss or damage basis, for the full replacement cost value (subject to reasonable deductible amounts) new without deduction for
depreciation of the covered items and in amounts that meet any co-insurance clauses of the policies of insurance and shall include coverage for damage or other loss caused by fire or other peril including, but
not limited to, vandalism and malicious mischief, theft, water damage of any type, including sprinkler leakage, bursting or stoppage of pipes, and explosion. 

10.3.3    Business Income Interruption for one (1) year plus Extra Expense insurance in such amounts
as will reimburse Tenant for actual direct or indirect loss of earnings attributable to the risks outlined in Section 10.3.2 above. 

10.3.4    Worker’s Compensation and Employer’s Liability or other similar insurance pursuant to
all applicable state and local statutes and regulations. The policy shall include a waiver of subrogation in favor of Landlord, its employees, Lenders and any property manager or partners. 

10.4    Form of Policies. The minimum limits of policies of insurance required of Tenant
under this Lease shall in no event limit the liability of Tenant under this Lease. Such insurance shall (i) name Landlord, its subsidiaries and affiliates, its property manager (if any) and any other party the Landlord so specifies, as an
additional insured or loss payee, as applicable, including Landlord’s managing agent, if any; (ii) be issued by an insurance company having a rating of not less than A:IX in Best’s Insurance Guide or which is otherwise acceptable to
Landlord and licensed to do business in the State of California; (iv) be primary insurance as to all claims thereunder and provide that any insurance carried by Landlord is excess and is non-contributing
with any insurance required of Tenant; (v) be in form and content reasonably acceptable to Landlord; and (vi) provide that said insurance shall not be canceled or coverage changed unless thirty (30) days’ prior written notice
shall have been given to Landlord and any mortgagee of Landlord (unless such cancellation is the result of non-payment of premiums). Tenant shall deliver said policy or policies or certificates thereof to
Landlord on or before the Lease Commencement Date and at least ten (10) days before the expiration dates thereof. In the event Tenant shall fail to procure such insurance, or to deliver such policies or certificate, Landlord may, at its option,
procure such policies for the account of Tenant, and the cost thereof shall be paid to Landlord within five (5) days after delivery to Tenant of bills therefor. 

10.5    Subrogation. Landlord and Tenant hereby agree to look solely to, and seek recovery
only from, their respective insurance carriers in the event of a property or business interruption loss to the extent that such coverage is agreed to be provided hereunder. The parties each hereby waive all rights and claims against each other for
such losses, and waive all rights of subrogation of their respective insurers, provided such waiver of subrogation shall not affect the right to the insured to recover thereunder. The parties agree that their respective insurance policies do now, or
shall, contain the express waiver of subrogation. 
 10.6    Additional Insurance
Obligations. Tenant shall carry and maintain during the entire Lease Term, at Tenant’s sole cost and expense, increased amounts of the insurance required to be carried by Tenant pursuant to this Article 10 and such other
reasonable types of insurance coverage and in such reasonable amounts covering the Premises and Tenant’s operations therein, as may be reasonably requested by Landlord or Landlord’s lender, but in no event in excess of the amounts and
types of insurance then being required by landlords of buildings comparable to and in the vicinity of the Building. 
  

	11.	 DAMAGE AND DESTRUCTION 

11.1    Repair of Damage to Premises by Landlord. Tenant shall promptly notify Landlord of
any damage to the Premises resulting from fire or any other casualty. If the Premises or any Common Areas serving or providing access to the Premises shall be damaged by fire or other casualty, Landlord shall promptly and diligently,

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-24-	  	[GenomeDx Biosciences, Corp.]

 
subject to reasonable delays for insurance adjustment or other matters beyond Landlord’s reasonable control, and subject to all other terms of this Article 11, restore the Base
Building and such Common Areas. Such restoration shall be to substantially the same condition of the Base Building and the Common Areas prior to the casualty, except for modifications required by zoning and building codes and other laws or by the
holder of a mortgage on the Building or Project or any other modifications to the Common Areas deemed desirable by Landlord, which are consistent with the character of the Project, provided that access to the Premises shall not be materially
impaired. Upon the occurrence of any damage to the Premises, upon notice (the “Landlord Repair Notice”) to Tenant from Landlord, Tenant shall assign to Landlord (or to any party designated by Landlord) all insurance proceeds payable
to Tenant under Tenant’s insurance required under Section 10.3.2(ii) and (iii) of this Lease to the extent such insurance proceeds relate to damage of which Landlord is undertaking restoration, and Landlord shall
repair any injury or damage to the Tenant Improvements and the Original Improvements installed in the Premises and shall return such Tenant Improvements and Original Improvements to their original condition; provided that if the cost of such repair
by Landlord exceeds the amount of insurance proceeds received by Landlord from Tenant’s insurance carrier (including by taking into account any deductible or self-insured retention), as assigned by Tenant, the excess cost of such repairs shall
be paid by Tenant to Landlord prior to Landlord’s commencement of repair of the damage. Prior to the commencement of construction, Tenant shall submit to Landlord, for Landlord’s review and approval, all plans, specifications and working
drawings relating thereto, and Landlord shall, in its reasonable discretion, select the contractor to perform such improvement work; provided that Landlord shall require the selected contractor to bid each of the major subcontractors (as reasonably
determined by Landlord) with at least three (3) qualified subcontractors and Tenant shall have the right to select the subcontractors from among the bidding subcontractors that (a) submitted qualified bids which were consistent with the
bid assumptions and directions, and (b) committed to Landlord’s time schedule for construction of the improvements. Landlord shall not be liable for any reasonable inconvenience or annoyance to Tenant or its visitors, or injury to
Tenant’s business resulting in any way from such damage or the repair thereof; provided however, that if such fire or other casualty shall have damaged the Premises or Common Areas necessary to Tenant’s occupancy, and the Premises are not
occupied by Tenant as a result thereof, then during the time and to the extent the Premises are unfit for occupancy, the Rent shall be abated in proportion to the ratio that the amount of rentable square feet of the Premises which is unfit for
occupancy for the purposes permitted under this Lease bears to the total rentable square feet of the Premises. 

11.2    Landlord’s Option to Repair. Notwithstanding the terms of
Section 11.1 of this Lease, Landlord may elect not to rebuild and/or restore the Premises, Building and/or Project, and instead terminate this Lease, by notifying Tenant in writing of such termination within sixty
(60) days after the date of discovery of the damage, such notice to include a termination date giving Tenant sixty (60) days to vacate the Premises, but Landlord may so elect only if the Building or Project shall be damaged by fire or
other casualty or cause, whether or not the Premises are affected, and one or more of the following conditions is present: (i) in Landlord’s reasonable judgment, repairs cannot reasonably be completed within one hundred eighty
(180) days after the date of discovery of the damage (when such repairs are made without the payment of overtime or other premiums); (ii) the holder of any mortgage on the Building or Project or ground lessor with respect to the Building or
Project shall require that the insurance proceeds or any portion thereof be used to retire the mortgage debt, or shall terminate the ground lease, as the case may be; (iii) at least $100,000 of the damage is not fully covered by Landlord’s
insurance policies; (iv) Landlord decides to rebuild the Building or Common Areas so that they will be substantially different structurally or architecturally; (v) the damage occurs during the last twelve (12) months of the Lease
Term; or (vi) any owner of any other portion of the Project, other than Landlord, does not intend to repair the damage to such portion of the Project; provided, however, that if Landlord does not elect to terminate this Lease pursuant to
Landlord’s termination right as provided above, and the repairs cannot, in the reasonable opinion of Landlord, be completed within one hundred eighty (180) days after being commenced, Tenant may elect, no earlier than sixty (60) days
after the date of the damage and not later than ninety (90) days after the date of such damage, to terminate this Lease by written notice to Landlord effective as of the date specified in the notice, which date shall not be less than thirty
(30) days nor more than sixty (60) days after the date such notice is given by Tenant. Notwithstanding the provisions of this Section 11.2, Tenant shall have the right to terminate this Lease under this Section 11.2 only if each
of the following conditions is satisfied: (a) the damage to the Project by fire or other casualty was not caused by the gross negligence or intentional act of Tenant or its partners or subpartners and their respective officers, agents,
servants, employees, and independent contractors; (b) as a result of the damage, Tenant cannot reasonably conduct business from the Premises; and, (c) as a result of the damage to the Project, Tenant does not occupy or use the Premises at
all. In addition, Tenant may terminate this Lease if the damage to the Premises occurs during the last twelve (12) months of the Lease Term, and, as a result of such damage, Tenant cannot reasonably conduct business from the Premises for a
period of sixty (60) days or more. 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-25-	  	[GenomeDx Biosciences, Corp.]

 11.3    Waiver of Statutory Provisions.
The provisions of this Lease, including this Article 11, constitute an express agreement between Landlord and Tenant with respect to any and all damage to, or destruction of, all or any part of the Premises, the Building or the Project, and
any statute or regulation of the State of California, including, without limitation, Sections 1932(2) and 1933(4) of the California Civil Code, with respect to any rights or obligations concerning damage or destruction in the absence of an express
agreement between the parties, and any other statute or regulation, now or hereafter in effect, shall have no application to this Lease or any damage or destruction to all or any part of the Premises, the Building or the Project. 

12.    NONWAIVER    No provision of this Lease shall be deemed waived by either party
hereto unlessexpressly waived in a writing signed thereby. The waiver by either party hereto of any breach of any term, covenant or condition herein contained shall not be deemed to be a waiver of any subsequent breach of same or any other term,
covenant or condition herein contained. The subsequent acceptance of Rent hereunder by Landlord shall not be deemed to be a waiver of any preceding breach by Tenant of any term, covenant or condition of this Lease, other than the failure of Tenant
to pay the particular Rent so accepted, regardless of Landlord’s knowledge of such preceding breach at the time of acceptance of such Rent. No acceptance of a lesser amount than the Rent herein stipulated shall be deemed a waiver of
Landlord’s right to receive the full amount due, nor shall any endorsement or statement on any check or payment or any letter accompanying such check or payment be deemed an accord and satisfaction, and Landlord may accept such check or payment
without prejudice to Landlord’s right to recover the full amount due. No receipt of monies by Landlord from Tenant after the termination of this Lease shall in any way alter the length of the Lease Term or of Tenant’s right of possession
hereunder, or after the giving of any notice shall reinstate, continue or extend the Lease Term or affect any notice given Tenant prior to the receipt of such monies, it being agreed that after the service of notice or the commencement of a suit, or
after final judgment for possession of the Premises, Landlord may receive and collect any Rent due, and the payment of said Rent shall not waive or affect said notice, suit or judgment. 

13.    CONDEMNATION    If the whole or any part of the Premises, Building or Project
shall be taken by power of eminent domain or condemned by any competent authority for any public or quasi-public use or purpose, or if any adjacent property or street shall be so taken or condemned, or reconfigured or vacated by such authority in
such manner as to require the use, reconstruction or remodeling of any part of the Premises, Building or Project, or if Landlord shall grant a deed or other instrument in lieu of such taking by eminent domain or condemnation, Landlord shall have the
option to terminate this Lease effective as of the date possession is required to be surrendered to the authority. Tenant shall not because of such taking assert any claim against Landlord or the authority for any compensation because of such taking
and Landlord shall be entitled to the entire award or payment in connection therewith, except that Tenant shall have the right to file any separate claim available to Tenant for any taking of Tenant’s personal property and fixtures belonging to
Tenant and removable by Tenant upon expiration of the Lease Term pursuant to the terms of this Lease, and for moving expenses, so long as such claims do not diminish the award available to Landlord, its ground lessor with respect to the Building or
Project or its mortgagee, and such claim is payable separately to Tenant. All Rent shall be apportioned as of the date of such termination. If any part of the Premises shall be taken, and this Lease shall not be so terminated, the Rent shall be
proportionately abated. Tenant hereby waives any and all rights it might otherwise have pursuant to Section 1265.130 of The California Code of Civil Procedure. Notwithstanding anything to the contrary contained in this Article 13, in the event
of a temporary taking of all or any portion of the Premises for a period of one hundred and eighty (180) days or less, then this Lease shall not terminate but the Base Rent and the Additional Rent shall be abated for the period of such taking
in proportion to the ratio that the amount of rentable square feet of the Premises taken bears to the total rentable square feet of the Premises. Landlord shall be entitled to receive the entire award made in connection with any such temporary
taking, provided, however, that Tenant shall be entitled to a share of the award for any loss of fixtures and improvements and for moving and other reasonable expenses. 
  

	14.	 ASSIGNMENT AND SUBLETTING 

14.1    Transfers. Except as permitted in Section 14.8 below,
Tenant shall not, without the prior written consent of Landlord, assign, mortgage, pledge, hypothecate, encumber, or permit any lien to attach to, or otherwise transfer, this Lease or any interest hereunder, permit any assignment, or other transfer
of this Lease or any interest hereunder by operation of law, sublet the Premises or any part thereof, or enter into any license or concession agreements or otherwise permit the occupancy or use of the Premises or any part thereof by any persons
other than Tenant and its employees and contractors (all of the foregoing are hereinafter sometimes referred to collectively as 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-26-	  	[GenomeDx Biosciences, Corp.]

 
“Transfers” and any person to whom any Transfer is made or sought to be made is hereinafter sometimes referred to as a “Transferee”). If Tenant desires
Landlord’s consent to any Transfer, Tenant shall notify Landlord in writing, which notice (the “Transfer Notice”) shall include (i) the proposed effective date of the Transfer, which shall not be less than fifteen
(15) business days nor more than one hundred eighty (180) days after the date of delivery of the Transfer Notice, (ii) a description of the portion of the Premises to be transferred (the “Subject Space”), (iii) all of
the terms of the proposed Transfer and the consideration therefor, including calculation of the “Transfer Premium”, as that term is defined in Section 14.3 below, in connection with such Transfer, the name
and address of the proposed Transferee, and a copy of all existing executed and/or proposed documentation pertaining to the proposed Transfer, and (iv) current financial statements of the proposed Transferee certified by an officer, partner or
owner thereof, business credit and personal references and history of the proposed Transferee and any other information reasonably required by Landlord which will enable Landlord to determine the financial responsibility, character, and reputation
of the proposed Transferee, nature of such Transferee’s business and proposed use of the Subject Space. Any Transfer made without Landlord’s prior written consent shall, at Landlord’s option, be null, void and of no effect, and shall,
at Landlord’s option, constitute a default by Tenant under this Lease. Whether or not Landlord consents to any proposed Transfer, Tenant shall pay Landlord’s reasonable review and processing fees, as well as any reasonable professional
fees (including, without limitation, attorneys’, accountants’, architects’, engineers’ and consultants’ fees) incurred by Landlord (not to exceed $2,500), within thirty (30) days after written request by Landlord. 

14.2    Landlord’s Consent. Landlord shall not unreasonably withhold, condition or
delay its consent to any proposed Transfer of the Subject Space to the Transferee on the terms specified in the Transfer Notice. Without limitation as to other reasonable grounds for withholding consent, the parties hereby agree that it shall be
reasonable under this Lease and under any applicable law for Landlord to withhold consent to any proposed Transfer where one or more of the following apply: 

14.2.1    The Transferee is of a character, reputation, or engaged in a business or proposes to use the
Premises or sublet Premises, as the case may be, which is not consistent with the quality of the Building or the Project; 

14.2.2    The Transferee is either a governmental agency or instrumentality thereof; 

14.2.3    The Transferee is not a party of reasonable financial worth and/or financial stability in light
of the responsibilities to be undertaken in connection with the Transfer on the date consent is requested; 

14.2.4    The Transferee is a person or entity with whom Landlord is then negotiating to lease space in
the Building (including any existing tenant of the Building with whom Landlord is then negotiating to lease additional or expansion space in the Building); 

14.2.5    Tenant is then in default hereunder beyond any applicable cure period herein provided; 

14.2.6    In the event of a sublease, (i) Tenant is negotiating a lower rental rate than the average
rental rate then being paid by tenants in the Building, (ii) the Transferee is not expressly subject to all of the obligations of Tenant under this Lease nor restricted from further Transferring the sublease without Landlord’s prior
written consent in each instance, and (iii) the sublease expires beyond the Lease Expiration Date or the termination date of any applicable additional term; or 

14.2.7    The proposed Transfer would cause a violation of another lease for space in the Project, or
would give an occupant of the Project a right to cancel its lease. 
 If Landlord consents to any Transfer pursuant to the
terms of this Section 14.2 (and does not exercise any recapture rights Landlord may have under Section 14.4 of this Lease), Tenant may within six (6) months after Landlord’s consent, but
not later than the expiration of said six-month period, enter into such Transfer of the Premises or portion thereof, upon substantially the same terms and conditions as are set forth in the Transfer Notice
furnished by Tenant to Landlord pursuant to Section 14.1 of this Lease, provided that if there are any changes in the terms and conditions from those specified in the Transfer Notice such that Landlord would initially have
been entitled to refuse its consent to such Transfer under this Section 14.2, Tenant shall again submit the Transfer to Landlord for its approval and other action under this Article 14 (including Landlord’s
right of recapture, if any, under Section 14.4 of this 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-27-	  	[GenomeDx Biosciences, Corp.]

 
Lease). Notwithstanding anything to the contrary in this Lease, if Tenant or any proposed Transferee claims that Landlord has unreasonably withheld or delayed its consent under
Section 14.2 or otherwise has breached or acted unreasonably under this Article 14, their sole remedies shall be a suit for contract damages (other than damages for injury to, or interference with, Tenant’s
business including, without limitation, loss of profits, however occurring) or declaratory judgment and an injunction for the relief sought, and Tenant hereby waives all other remedies, including, without limitation, any right at law or equity to
terminate this Lease, on its own behalf and, to the extent permitted under all applicable laws, on behalf of the proposed Transferee. 

14.3    Transfer Premium. If Landlord consents to a Transfer, as a condition thereto which
the parties hereby agree is reasonable, Tenant shall pay to Landlord fifty percent (50%) of any “Transfer Premium,” as that term is defined in this Section 14.3, received by Tenant from such Transferee.
“Transfer Premium” shall mean all rent, additional rent or other consideration payable by such Transferee in connection with the Transfer in excess of the Rent and Additional Rent payable by Tenant under this Lease during the term
of the Transfer on a per rentable square foot basis if less than all of the Premises is transferred, and after deduction of (i) any costs of improvements made to the Subject Space in connection with such Transfer, (ii) brokerage
commissions paid in connection with such Transfer, (iii) fees paid to Landlord in connection with Tenant’s request for consent, and (iv) reasonable legal fees incurred in connection with such Transfer. “Transfer
Premium” shall also include, but not be limited to, key money, bonus money or other cash consideration paid by Transferee to Tenant in connection with such Transfer, and any payment in excess of fair market value for services rendered by
Tenant to Transferee or for assets, fixtures, inventory, equipment, or furniture transferred by Tenant to Transferee in connection with such Transfer (but shall not include, in the case of an assignment, any payment by Transferee to Tenant in an
amount equal to the security deposit then held by Landlord, and, in the case of a sublease, the amount of any security deposit paid by Transferee to Tenant). The determination of the amount of Landlord’s applicable share of the Transfer Premium
shall be made on a monthly basis as rent or other consideration is received by Tenant under the Transfer. 

14.4    Landlord’s Option as to Subject Space. Notwithstanding anything to the contrary
contained in this Article 14 (except for Section 14.8), in the event Tenant contemplates a Transfer which, together with all prior Transfers then remaining in effect, would cause fifty percent (50%) or more of the
Premises to be Transferred for more than fifty percent (50%) of the then remaining Lease Term (taking into account any extension of the Lease Term which has irrevocably exercised by Tenant), Tenant shall give Landlord notice (the “Intention
to Transfer Notice”) of such contemplated Transfer (whether or not the contemplated Transferee or the terms of such contemplated Transfer have been determined). The Intention to Transfer Notice shall specify the portion of and amount of
rentable square feet of the Premises which Tenant intends to Transfer (the “Contemplated Transfer Space”), the contemplated date of commencement of the Contemplated Transfer (the “Contemplated Effective Date”), and
the contemplated length of the term of such contemplated Transfer, and shall specify that such Intention to Transfer Notice is delivered to Landlord pursuant to this Section 14.4 in order to allow Landlord to elect to
recapture the Contemplated Transfer Space. Thereafter, Landlord shall have the option, by giving written notice (a “Recapture Notice”) to Tenant within fifteen (15) business days after receipt of any Intention to Transfer
Notice, to recapture the Contemplated Transfer Space. Such recapture shall cancel and terminate this Lease with respect to such Contemplated Transfer Space as of the Contemplated Effective Date. In the event of a recapture by Landlord, if this Lease
shall be canceled with respect to less than the entire Premises, the Rent reserved herein shall be prorated on the basis of the number of rentable square feet retained by Tenant in proportion to the number of rentable square feet contained in the
Premises, and this Lease as so amended shall continue thereafter in full force and effect, and upon request of either party, the parties shall execute written confirmation of the same. If Landlord delivers a Recapture Notice to Tenant with respect
to a Transfer of less than the entire Premises, Tenant may within ten (10) days after Tenant’s receipt of such Recapture Notice, deliver written notice to Landlord indicating that Tenant is rescinding its request for consent to the
proposed Transfer, in which case such Transfer shall not be consummated and this Lease shall remain in full force and effect as to the portion of the Premises that was the subject of the proposed Transfer. If Landlord declines, or fails to elect in
a timely manner, to recapture such Contemplated Transfer Space under this Section 14.4, then, subject to the other terms of this Article 14, for a period of nine (9) months (the “Nine Month
Period”) commencing on the last day of such fifteen (15) business day period, Landlord shall not have any right to recapture the Contemplated Transfer Space with respect to any Transfer made during the Nine Month Period, provided that
any such Transfer is substantially on the terms set forth in the Intention to Transfer Notice, and provided further that any such Transfer shall be subject to the remaining terms of this Article 14. If such a Transfer is not so consummated
within the Nine Month Period (or if a Transfer is so consummated, then upon the expiration of the term of any Transfer of such Contemplated Transfer Space 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-28-	  	[GenomeDx Biosciences, Corp.]

 
consummated within such Nine Month Period), Tenant shall again be required to submit a new Intention to Transfer Notice to Landlord with respect any contemplated Transfer, as provided above in
this Section 14.4. 
 14.5    Effect of Transfer. If Landlord
consents to a Transfer, (i) the terms and conditions of this Lease shall in no way be deemed to have been waived or modified, (ii) such consent shall not be deemed consent to any further Transfer by either Tenant or a Transferee,
(iii) Tenant shall deliver to Landlord, promptly after execution, an original executed copy of all documentation pertaining to the Transfer in form reasonably acceptable to Landlord, (iv) Tenant shall furnish upon Landlord’s request a
complete statement, certified by an independent certified public accountant, or Tenant’s chief financial officer, setting forth in detail the computation of any Transfer Premium Tenant has derived and shall derive from such Transfer, and
(v) no Transfer relating to this Lease or agreement entered into with respect thereto, whether with or without Landlord’s consent, shall relieve Tenant or any guarantor of the Lease from any liability under this Lease, including, without
limitation, in connection with the Subject Space. Landlord or its authorized representatives shall have the right at all reasonable times to audit the books, records and papers of Tenant relating to any Transfer, and shall have the right to make
copies thereof. If the Transfer Premium respecting any Transfer shall be found understated, Tenant shall, within thirty (30) days after demand, pay the deficiency, and if understated by more than five percent (5%), Tenant shall pay
Landlord’s costs of such audit. 
 14.6    Additional Transfers. For purposes of this
Lease, the term “Transfer” shall also include (i) if Tenant is a partnership, the withdrawal or change, voluntary, involuntary or by operation of law, of fifty percent (50%) or more of the partnership interests in Tenant
(except with respect to transfers to other then-existing holders of a partnership interest in Tenant), within a twelve (12)-month period, or the dissolution of the partnership without immediate reconstitution thereof, and (ii) if Tenant is a
closely held corporation (i.e., whose stock is not publicly held and not traded through an exchange or over the counter), (A) the dissolution, merger, consolidation or other reorganization of Tenant or (B) the sale or other transfer of
an aggregate of fifty percent (50%) or more of the voting shares of Tenant (other than to immediate family members by reason of gift or death or to other then-existing shareholders of Tenant), within a twelve (12)-month period, or (C) the sale,
mortgage, hypothecation or pledge of an aggregate of fifty percent (50%) or more of the value of the unencumbered assets of Tenant within a twelve (12)-month period. 

14.7    Occurrence of Default. Any Transfer hereunder shall be subordinate and subject to
the provisions of this Lease, and if this Lease shall be terminated during the term of any Transfer, Landlord shall have the right to: (i) treat such Transfer as cancelled and repossess the Subject Space by any lawful means, or
(ii) require that such Transferee attorn to and recognize Landlord as its landlord under any such Transfer. If Tenant shall be in default under this Lease, Landlord is hereby irrevocably authorized, as Tenant’s agent and attorney-in-fact, to direct any Transferee to make all payments under or in connection with the Transfer directly to Landlord (which Landlord shall apply towards Tenant’s
obligations under this Lease) until such default is cured. Such Transferee shall rely on any representation by Landlord that Tenant is in default hereunder, without any need for confirmation thereof by Tenant. Upon any assignment, the assignee shall
assume in writing all obligations and covenants of Tenant thereafter to be performed or observed under this Lease. No collection or acceptance of rent by Landlord from any Transferee shall be deemed a waiver of any provision of this Article
14 or the approval of any Transferee or a release of Tenant from any obligation under this Lease, whether theretofore or thereafter accruing. In no event shall Landlord’s enforcement of any provision of this Lease against any Transferee be
deemed a waiver of Landlord’s right to enforce any term of this Lease against Tenant or any other person. If Tenant’s obligations hereunder have been guaranteed, Landlord’s consent to any Transfer shall not be effective unless the
guarantor also consents to such Transfer. 

14.8    Non-Transfers. Notwithstanding anything to
the contrary contained in this Article 14, (A) an assignment or subletting of all or a portion of the Premises to an affiliate of Tenant (an entity which is controlled by, controls, or is under common control with, Tenant), (B) ) a sale of
interests (partnership, stock, membership or other) in Tenant in connection with either a bonafide financing for the benefit of the Tenant or an initial public offering of Tenant’s stock on a nationally-recognized stock exchange, (C) an
assignment of the Lease to an entity which acquires all or substantially all of the stock or assets of Tenant, or (D) an assignment of the Lease to an entity which is the resulting entity of a merger or consolidation of Tenant during the Lease
Term, shall not be deemed a Transfer requiring Landlord’s consent under this Article 14 (any such assignee or sublessee described in items (A) through (D) of this Section 14.8 hereinafter referred to as a
“Permitted Transferee”), provided that (i) Tenant notifies Landlord prior to the effective date of any such assignment or sublease (or promptly following the same if prior notice is not appropriate under applicable securities
or other law) and promptly supplies Landlord with any documents or information 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-29-	  	[GenomeDx Biosciences, Corp.]

 
reasonably requested by Landlord regarding such transfer or transferee as set forth above, (ii) Tenant is not then in default, beyond any applicable notice and cure period, and such
assignment or sublease is not a subterfuge by Tenant to avoid its obligations under this Lease, (iii) such Permitted Transferee shall be of a character and reputation consistent with the quality of the Building, (iv) in the event of an
assignment, such Permitted Transferee shall have a tangible net worth (not including goodwill as an asset) computed in accordance with generally accepted accounting principles (“Net Worth”) at least equal to the Net Worth of Tenant
on the day immediately preceding the effective date of such assignment or sublease, and (v) no assignment relating to this Lease, whether with or without Landlord’s consent, shall relieve Tenant from any liability under this Lease, and, in
the event of an assignment of Tenant’s entire interest in this Lease, the liability of Tenant and such transferee shall be joint and several. An assignee of Tenant’s entire interest in this Lease who qualifies as a Permitted Transferee may
also be referred to herein as a “Permitted Transferee Assignee.” “Control,” as used in this Section 14.8, shall mean the ownership, directly or indirectly, of at least fifty-one percent (51%) of the voting securities of, or possession of the right to vote, in the ordinary direction of its affairs, of at least fifty-one percent (51 %) of the
voting interest in, any person or entity. No such permitted assignment or subletting shall serve to release Tenant from any of its obligations under this Lease. 

15.    SURRENDER OF PREMISES; OWNERSHIP AND REMOVAL OF TRADE FIXTURES 

15.1    Surrender of Premises. No act or thing done by Landlord or any agent or employee of
Landlord during the Lease Term shall be deemed to constitute an acceptance by Landlord of a surrender of the Premises unless such intent is specifically acknowledged in writing by Landlord. The delivery of keys to the Premises to Landlord or any
agent or employee of Landlord shall not constitute a surrender of the Premises or effect a termination of this Lease, whether or not the keys are thereafter retained by Landlord, and notwithstanding such delivery Tenant shall be entitled to the
return of such keys at any reasonable time upon request until this Lease shall have been properly terminated. The voluntary or other surrender of this Lease by Tenant, whether accepted by Landlord or not, or a mutual termination hereof, shall not
work a merger, and at the option of Landlord shall operate as an assignment to Landlord of all subleases or subtenancies affecting the Premises or terminate any or all such sublessees or subtenancies. 

15.2    Removal of Tenant Property by Tenant. Upon the expiration of the Lease Term, or upon
any earlier termination of this Lease, Tenant shall, subject to the provisions of this Article 15, quit and surrender possession of the Premises to Landlord in as good order and condition as when Tenant took possession and as thereafter
improved by Landlord and/or Tenant, reasonable wear and tear, casualty and repairs which are specifically made the responsibility of Landlord hereunder excepted. Upon such expiration or termination, Tenant shall, without expense to Landlord, remove
or cause to be removed from the Premises all debris and rubbish, and such items of furniture, equipment, free-standing cabinet work, movable partitions and other articles of personal property owned by Tenant or installed or placed by Tenant at its
expense in the Premises, and such similar articles of any other persons claiming under Tenant, as Landlord may, in its reasonable discretion, require to be removed, and Tenant shall repair at its own expense all damage to the Premises and Building
resulting from such removal. 
 15.3    Environmental Assessment. In connection with its
surrender of the Premises, Tenant shall submit to Landlord, at least ninety (90) days prior to the expiration date of this Lease (or in the event of an earlier termination of this Lease, as soon as reasonably possible following such
termination), an environmental Assessment of the Premises by a competent and experienced environmental engineer or engineering firm reasonably satisfactory to Landlord (pursuant to a contract reasonably approved by Landlord and providing that
Landlord can rely on the Environmental Assessment), which (i) evidences that the Premises are in a clean and safe condition and free and clear of any Hazardous Materials for which Tenant is responsible under the terms of this Lease; and
(ii) includes a review of the Premises by an environmental consultant for asbestos, mold, fungus, spores, and other moisture conditions, on-site chemical use, and lead-based paint. If such Environmental
Assessment reveals that remediation or Clean-up is required under any Environmental Laws for which Tenant is responsible under the terms of this Lease, Tenant shall submit a remediation plan prepared by a
recognized environmental consultant and shall be responsible for all costs of remediation and Clean-up, as more particularly provided in Section 5.3, above. 

15.4    Condition of the Building and Premises Upon Surrender. In addition to the above
requirements of this Article 15, upon the expiration of the Lease Term, or upon any earlier termination of this Lease, Tenant shall surrender the Premises and Building such that the same are in compliance with all Applicable Laws (subject to
Section 15.3 above) and with Tenant having complied with all of Tenant’s obligations under this Lease, including those 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-30-	  	[GenomeDx Biosciences, Corp.]

 
relating to improvement, repair, maintenance, compliance with law, testing and other related obligations of Tenant set forth in Article 7 of this Lease. In the event that the Building and
Premises shall be surrendered in a condition which does not comply with the terms of this Section 15.4, because Tenant failed to comply with its obligations set forth in Lease, then following thirty (30) days’
notice to Tenant, during which thirty (30) day period Tenant shall have the right to cure such noncompliance, Landlord shall be entitled to expend all reasonable costs in order to cause the same to comply with the required condition upon
surrender and Tenant shall promptly reimburse Landlord for all such costs upon notice and Tenant shall be deemed during the period that Tenant or Landlord, as the case may be, perform the cure of such noncompliance to be in holdover under Article
16 of this Lease. 
 16.    HOLDING OVER If Tenant holds over after the expiration of the Lease Term
or earlier termination thereof, with the express or implied consent of Landlord, such tenancy shall be from month-to-month only, and shall not constitute a renewal
hereof or an extension for any further term. If Tenant holds over after the expiration of the Lease Term of earlier termination thereof, without the express or implied consent of Landlord, such tenancy shall be deemed to be a tenancy by sufferance
only, and shall not constitute a renewal hereof or an extension for any further term. In either case, Rent shall be payable at a monthly rate equal to (i) one hundred twenty-five percent (125%) of the Rent applicable during the last rental
period of the Lease Term under this Lease for the first (1st) month of such holdover, and (ii) one hundred fifty percent (150%) thereafter. Such month-to-month tenancy or tenancy by sufferance, as the case may be, shall be subject to every other applicable term, covenant and agreement contained herein. Nothing contained in this Article 16 shall
be construed as consent by Landlord to any holding over by Tenant, and Landlord expressly reserves the right to require Tenant to surrender possession of the Premises to Landlord as provided in this Lease upon the expiration or other termination of
this Lease. The provisions of this Article 16 shall not be deemed to limit or constitute a waiver of any other rights or remedies of Landlord provided herein or at law. If Tenant fails to surrender the Premises upon the termination or expiration of
this Lease, in addition to any other liabilities to Landlord accruing therefrom, Tenant shall protect, defend, indemnify and hold Landlord harmless from all loss, costs (including reasonable attorneys’ fees) and liability resulting from such
failure, including, without limiting the generality of the foregoing, any claims made by any succeeding tenant founded upon such failure to surrender and any lost profits to Landlord resulting therefrom. 

17.    ESTOPPEL CERTIFICATES Within ten (10) business days following a request in writing by Landlord,
Tenant shall execute, acknowledge and deliver to Landlord an estoppel certificate, which, as submitted by Landlord, shall be substantially in the form of Exhibit D, attached hereto (or such other form as may be required by any
prospective mortgagee or purchaser of the Project, or any portion thereof), indicating therein any exceptions thereto that may exist at that time, and shall also contain any other information reasonably requested by Landlord or Landlord’s
mortgagee or prospective mortgagee. Any such certificate may be relied upon by any prospective mortgagee or purchaser of all or any portion of the Project. Tenant shall execute and deliver whatever other instruments may be reasonably required for
such purposes. At any time during the Lease Term, Landlord may require Tenant to provide Landlord with a current financial statement and financial statements of the two (2) years prior to the current financial statement year. Such statements
shall be prepared in accordance with generally accepted accounting principles and, if such is the normal practice of Tenant, shall be audited by an independent certified public accountant. Failure of Tenant to timely execute, acknowledge and deliver
such estoppel certificate or other instruments shall constitute an acceptance of the Premises and an acknowledgment by Tenant that statements included in the estoppel certificate are true and correct, without exception. 

18.    SUBORDINATION This Lease shall be subject and subordinate to all present and future ground or
underlying leases of the Building or Project and to the lien of any mortgage, trust deed or other encumbrances now or hereafter in force against the Building or Project or any part thereof, if any, and to all renewals, extensions, modifications,
consolidations and replacements thereof, and to all advances made or hereafter to be made upon the security of such mortgages or trust deeds, unless the holders of such mortgages, trust deeds or other encumbrances, or the lessors under such ground
lease or underlying leases, require in writing that this Lease be superior thereto (collectively, the “Superior Holders”). Tenant covenants and agrees in the event any proceedings are brought for the foreclosure of any such mortgage
or deed in lieu thereof (or if any ground lease is terminated), to attorn, without any deductions or set-offs whatsoever, to the lienholder or purchaser or any successors thereto upon any such foreclosure sale
or deed in lieu thereof (or to the ground lessor), if so requested to do so by such purchaser or lienholder or ground lessor, and to recognize such purchaser or lienholder or ground lessor as the lessor under this Lease, provided such lienholder or
purchaser or ground lessor shall agree to accept this Lease and not disturb Tenant’s occupancy, so long as Tenant timely pays the rent and observes and performs the terms, covenants and conditions of this Lease to be

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-31-	  	[GenomeDx Biosciences, Corp.]

 
observed and performed by Tenant. Landlord’s interest herein may be assigned as security at any time to any lienholder. Tenant shall, within ten (10) days of request by Landlord,
execute such further instruments or assurances as Landlord may reasonably deem necessary to evidence or confirm the subordination or superiority of this Lease to any such mortgages, trust deeds, ground leases or underlying leases. Tenant waives the
provisions of any current or future statute, rule or law which may give or purport to give Tenant any right or election to terminate or otherwise adversely affect this Lease and the obligations of the Tenant hereunder in the event of any foreclosure
proceeding or sale. Landlord shall use commercially reasonable efforts to deliver to Tenant, (x) with respect to each existing Superior Holder, within sixty (60) days following the full execution and delivery of this Lease and
(y) with respect to each future Superior Holder, prior to the creation of an interest in any portion of the Project in such new Superior Holder, a commercially reasonable subordination non-disturbance and
attornment agreement , which requires such Superior Holder to accept this Lease, and not to disturb Tenant’s possession, so long as an event of default beyond any applicable notice and cure periods by Tenant is not then continuing (a
“SNDAA”) executed by Landlord and any existing Superior Holder. 
 19.    DEFAULTS; REMEDIES 

19.1    Events of Default. The occurrence of any of the following shall constitute a default
of this Lease by Tenant: 
 19.1.1    Any failure by Tenant to pay any Rent or any other charge required
to be paid under this Lease, or any part thereof, when due unless such failure is cured within five (5) business days after notice; or 

19.1.2    Except where a specific time period is otherwise set forth for Tenant’s performance in this
Lease, in which event the failure to perform by Tenant within such time period shall be a default by Tenant under this Section 19.1.2, any failure by Tenant to observe or perform any other provision, covenant or condition
of this Lease to be observed or performed by Tenant where such failure continues for thirty (30) days after written notice thereof from Landlord to Tenant; provided that if the nature of such default is such that the same cannot reasonably be
cured within a thirty (30) day period, Tenant shall not be deemed to be in default if it diligently commences such cure within such period and thereafter diligently proceeds to rectify and cure such default; or 

19.1.3    Abandonment of the entire Premises by Tenant; or 

19.1.4    The failure by Tenant to observe or perform according to the provisions of Articles 5,
14, 17 or 18 of this Lease where such failure continues for more than two (2) business days after notice from Landlord; or 

19.1.5    Tenant’s failure to take possession of the Premises within ten (10) business days
after the Lease Commencement Date. 
 The notice periods provided herein are in lieu of, and not in addition to, any notice
periods provided by law. 
 19.2    Remedies Upon Default. Upon the occurrence of any
event of default by Tenant (as described in Section 19.1 above), Landlord shall have, in addition to any other remedies available to Landlord at law or in equity (all of which remedies shall be distinct, separate and
cumulative), the option to pursue any one or more of the following remedies, each and all of which shall be cumulative and nonexclusive, without any notice or demand whatsoever. 

19.2.1    Terminate this Lease, in which event Tenant shall immediately surrender the Premises to
Landlord, and if Tenant fails to do so, Landlord may, without prejudice to any other remedy which it may have for possession or arrearages in rent, enter upon and take possession of the Premises and expel or remove Tenant and any other person who
may be occupying the Premises or any part thereof, without being liable for prosecution or any claim or damages therefor; and Landlord may recover from Tenant the following: 

(i)    The worth at the time of award of the unpaid rent which has been earned at the time of such
termination; plus 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-32-	  	[GenomeDx Biosciences, Corp.]

 (ii)    The worth at the time of award of the amount by
which the unpaid rent which would have been earned after termination until the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus 

(iii)    The worth at the time of award of the amount by which the unpaid rent for the balance of the
Lease Term after the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus 

(iv)    Any other amount necessary to compensate Landlord for all the detriment proximately caused by
Tenant’s failure to perform its obligations under this Lease or which in the ordinary course of things would be likely to result therefrom, specifically including but not limited to, brokerage commissions and advertising expenses incurred,
expenses of remodeling the Premises or any portion thereof for a new tenant, whether for the same or a different use, and any special concessions made to obtain a new tenant; and 

(v)    At Landlord’s election, such other amounts in addition to or in lieu of the foregoing as may
be permitted from time to time by applicable law. 
 The term “rent” as used in this
Section 19.2 shall be deemed to be and to mean all sums of every nature required to be paid by Tenant pursuant to the terms of this Lease, whether to Landlord or to others. As used in Sections 19.2.1(i) and
(ii), above, the “worth at the time of award” shall be computed by allowing interest at the rate set forth in Article 25 of this Lease, but in no case greater than the maximum amount of such interest permitted by law. As used
in Section 19.2.1(iii) above, the “worth at the time of award” shall be computed by discounting such amount at the discount rate of the Federal Reserve Bank of San Francisco at the time of award plus one
percent (1%). 
 19.2.2    Landlord shall have the remedy described in California Civil Code
Section 1951.4 (lessor may continue lease in effect after lessee’s breach and abandonment and recover rent as it becomes due, if lessee has the right to sublet or assign, subject only to reasonable limitations). Accordingly, if Landlord
does not elect to terminate this Lease on account of any default by Tenant, Landlord may, from time to time, without terminating this Lease, enforce all of its rights and remedies under this Lease, including the right to recover all rent as it
becomes due. 
 19.2.3    Landlord shall at all times have the rights and remedies (which shall be
cumulative with each other and cumulative and in addition to those rights and remedies available under Sections 19.2.1 and 19.2.2, above, or any law or other provision of this Lease), without prior demand or notice except as required
by applicable law, to seek any declaratory, injunctive or other equitable relief, and specifically enforce this Lease, or restrain or enjoin a violation or breach of any provision hereof. 

19.3    Subleases of Tenant. Whether or not Landlord elects to terminate this Lease on
account of any default by Tenant, as set forth in this Article 19, Landlord shall have the right to terminate any and all subleases, licenses, concessions or other consensual arrangements for possession entered into by Tenant and affecting
the Premises or may, in Landlord’s sole discretion, succeed to Tenant’s interest in such subleases, licenses, concessions or arrangements. In the event of Landlord’s election to succeed to Tenant’s interest in any such subleases,
licenses, concessions or arrangements, Tenant shall, as of the date of notice by Landlord of such election, have no further right to or interest in the rent or other consideration receivable thereunder. 

19.4    Efforts to Relet. No re-entry or
repossession, repairs, maintenance, changes, alterations and additions, reletting, appointment of a receiver to protect Landlord’s interests hereunder, or any other action or omission by Landlord shall be construed as an election by Landlord to
terminate this Lease or Tenant’s right to possession, or to accept a surrender of the Premises, nor shall same operate to release Tenant in whole or in part from any of Tenant’s obligations hereunder, unless express written notice of such
intention is sent by Landlord to Tenant. Tenant hereby irrevocably waives any right otherwise available under any law to redeem or reinstate this Lease. 

19.5    Landlord Default. 

19.5.1    General. Notwithstanding anything to the contrary set forth in this Lease, Landlord
shall not be in default in the performance of any obligation required to be performed by Landlord pursuant to this Lease 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-33-	  	[GenomeDx Biosciences, Corp.]

 
unless Landlord fails to perform such obligation within thirty (30) days after the receipt of notice from Tenant specifying in detail Landlord’s failure to perform; provided, however,
if the nature of Landlord’s obligation is such that more than thirty (30) days are required for its performance, then Landlord shall not be in default under this Lease if it shall commence such performance within such thirty (30) day
period and thereafter diligently pursue the same to completion. Upon any such default by Landlord under this Lease, Tenant may, except as otherwise specifically provided in this Lease to the contrary, exercise any of its rights provided at law or in
equity. 
 19.5.2    Abatement of Rent. In the event that Tenant is prevented from using,
and does not use, the Premises or any portion thereof, as a result of (i) any repair, maintenance or alteration performed by Landlord, or which Landlord failed to perform, after the Lease Commencement Date and required by this Lease, which
substantially interferes with Tenant’s use of the Premises, or (ii) any failure to provide services, utilities or access to the Premises as required by this Lease (either such set of circumstances as set forth in items (i) or (ii),
above, to be known as an “Abatement Event”), then Tenant shall give Landlord notice of such Abatement Event, and if such Abatement Event continues for five (5) consecutive business days after Landlord’s receipt of any such
notice (the “Eligibility Period”) and either (A) Landlord does not diligently commence and pursue to completion the remedy of such Abatement Event during the Eligibility Period, or (B) Landlord receives proceeds from its
rental interruption insurance which covers such Abatement Event, then the Base Rent, Tenant’s Share of Direct Expenses shall be abated or reduced, as the case may be, after expiration of the Eligibility Period for such time that Tenant
continues to be so prevented from using, and does not use for the normal conduct of Tenant’s business, the Premises or a portion thereof, in the proportion that the rentable area of the portion of the Premises that Tenant is prevented from
using, and does not use, bears to the total rentable area of the Premises; provided, however, in the event that Tenant is prevented from using, and does not use, a portion of the Premises for a period of time in excess of the Eligibility Period and
the remaining portion of the Premises is not sufficient to allow Tenant to effectively conduct its business therein, and if Tenant does not conduct its business from such remaining portion, then for such time after expiration of the Eligibility
Period during which Tenant is so prevented from effectively conducting its business therein, the Base Rent and Tenant’s Share of Direct Expenses for the entire Premises shall be abated for such time as Tenant continues to be so prevented from
using, and does not use, the Premises. If, however, Tenant reoccupies any portion of the Premises during such period, the Rent allocable to such reoccupied portion, based on the proportion that the rentable area of such reoccupied portion of the
Premises bears to the total rentable area of the Premises, shall be payable by Tenant from the date Tenant reoccupies such portion of the Premises. To the extent an Abatement Event is caused by an event covered by Articles 11 or 13 of this Lease,
then Tenant’s right to abate rent shall be governed by the terms of such Article 11 or 13, as applicable, and the Eligibility Period shall not be applicable thereto. Such right to abate Base Rent and Tenant’s Share of Direct Expenses shall
be Tenant’s sole and exclusive remedy for rent abatement at law or in equity for an Abatement Event. Except as provided in this Section 19.5.2, nothing contained herein shall be interpreted to mean that Tenant is
excused from paying Rent due hereunder. 
 20.    COVENANT OF QUIET ENJOYMENT Landlord covenants that
Tenant, on paying the Rent, charges for services and other payments herein reserved and on keeping, observing and performing all the other terms, covenants, conditions, provisions and agreements herein contained on the part of Tenant to be kept,
observed and performed, shall, during the Lease Term, peaceably and quietly have, hold and enjoy the Premises subject to the terms, covenants, conditions, provisions and agreements hereof without interference by any persons lawfully claiming by or
through Landlord. The foregoing covenant is in lieu of any other covenant express or implied. 
 21.    SECURITY DEPOSIT 

21.1    In General. Concurrently with Tenant’s execution of this Lease, Tenant shall
deposit with Landlord a security deposit (the “Security Deposit”) in the amount set forth in Section 8 of the Summary, as security for the faithful performance by Tenant of all of its obligations under this Lease. If Tenant
defaults with respect to any provisions of this Lease (and such default is not cured within the applicable cure period under this Lease), including, but not limited to, the provisions relating to the payment of Rent, the removal of property and the
repair of resultant damage, Landlord may, without notice to Tenant, but shall not be required to apply all or any part of the Security Deposit for the payment of any Rent or any other sum in default and Tenant shall, upon demand therefor, restore
the Security Deposit to its original amount. Any unapplied portion of the Security Deposit shall be returned to Tenant, or, at Landlord’s option, to the last assignee of Tenant’s interest hereunder, within sixty (60) days following
the expiration of the Lease Term. Tenant shall not be entitled to any interest on the Security Deposit. Tenant hereby irrevocably waives and relinquishes any and all rights, benefits, or protections, if any, Tenant now has, or in the future

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-34-	  	[GenomeDx Biosciences, Corp.]

 
may have, under Section 1950.7 (excluding subsection 1950.7(b)) of the California Civil Code, any successor statute, and all other provisions of law, now or hereafter in effect, including,
but not limited to, any provision of law which (i) establishes the time frame by which a landlord must refund a security deposit under a lease, and/or (ii) provides that a landlord may claim from a security deposit only those sums
reasonably necessary to remedy defaults in the payment of rent, to repair damage caused by a tenant or to clean the subject premises. Tenant acknowledges and agrees that (a) any statutory time frames for the return of a security deposit are
superseded by the express period identified in this Article 21, above, and (b) rather than be so limited, Landlord may claim from the Security Deposit (1) any and all sums expressly identified in this Article 21, above, and
(2) any additional sums reasonably necessary to compensate Landlord for any and all losses or damages caused by Tenant’s default of this Lease, including, but not limited to, all damages or rent due upon termination of Lease pursuant to
Section 1951.2 of the California Civil Code. 
 21.2    Reduction in Security
Deposit. 
 21.2.1    Subject to the terms hereof, provided that (A) Tenant satisfied the
“Financial Condition” (as defined in Section 21.3, below), and (B) Tenant has not previously been in default under this Lease beyond any applicable notice and cure periods and is then not in default under
this Lease, the Security Deposit shall be reduced to $47,599.00. In connection therewith, provided that the Financial Condition has been satisfied, then Tenant shall have the right to deliver a notice to Landlord (the “Security Deposit
Financial Condition Reduction Notice”), which notice shall include reasonable evidence as described in Section 21.3 below demonstrating that Tenant has satisfied the Financial Condition, requesting that Landlord
return the excess Security Deposit held by Landlord pursuant to the terms hereof, in which event Landlord shall within thirty (30) days thereafter, issue a check payable to Tenant in the amount of the excess Security Deposit. Until such time as
Tenant shall deliver the Security Deposit Financial Condition Reduction Notice in accordance with the terms hereof, all amounts originally held by Landlord as a security deposit shall remain a part of the Security Deposit pursuant to the terms
hereof. 
 21.2.2    Notwithstanding anything to the contrary in this
Section 21.2, in the event that as of the end of each of the first three (3) Lease Years both (i) Tenant has not delivered a Security Deposit Financial Condition Reduction Notice to Landlord, and (ii) Tenant
is not then in default under this Lease, then the Security Deposit shall be reduced by $50,800.33 as of the end of each such Lease Year. Tenant shall have the right to deliver a notice to Landlord (the “Security Deposit Anniversary Reduction
Notice”) on or after each such reduction date, requesting that Landlord return the excess Security Deposit held by Landlord pursuant to the terms hereof, in which event Landlord shall within thirty (30) days thereafter, issue a check
payable to Tenant in the amount of the excess Security Deposit. For the avoidance of doubt, (A) following all three such reductions in the amount of the Security Deposit pursuant to this Section 21.2.2, the Security
Deposit shall equal $47,599.00, and (B) if the Security Deposit is reduced pursuant to the terms of Section 21.2.1, above, then Tenant shall thereafter not have the right to reduce the Security Deposit pursuant to this
Section 21.2.2. Until such time as Tenant shall deliver the Security Deposit Anniversary Reduction Notice in accordance with the terms hereof, all amounts originally held by Landlord as a security deposit shall remain a
part of the Security Deposit pursuant to the terms hereof. 
 21.3    Financial Condition.
The “Financial Condition” as used in this Lease shall refer to the condition that Tenant shall have the amount of “Available Cash,” as set forth in the following table, as of the corresponding “Test Point” set
forth in the following table. The term “Available Cash” shall mean the total cash deposits held by Tenant in Tenant’s account as working capital, as evidenced by bank and/or investment account statements, as applicable;
provided that Available Cash shall not include any cash deposits held by Tenant which are a subterfuge by Tenant in order to satisfy the Financial Condition. Notwithstanding the foregoing, Tenant shall have the right (in Tenant’s sole
discretion) to have Available Cash include the total cash deposits held by an entity which controls Tenant, or is under common control with Tenant (an “Affiliate Entity”), in such Affiliate Entity’s account as working capital;
provided that, in the event that Tenant elects to include such cash deposits of its Affiliate Entity in determining the amount of Available Cash, such Affiliate Entity shall execute, and deliver to Landlord, a guaranty of this Lease materially in
the form attached hereto as Exhibit F prior to any reduction in the Security Deposit pursuant to the terms and conditions of Section 21.2.1 above. 

 

					
	 Test Point
	  	
Available Cash
	 
	 Lease Commencement Date
	  	$	20,000,000	 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-35-	  	[GenomeDx Biosciences, Corp.]

					
	 The three (3) month anniversary of the Lease Commencement
Date
	  	$	17,500,000	 
	 The six (6) month anniversary of the Lease Commencement
Date
	  	$	15,000,000	 
	 The nine (9) month anniversary of the Lease Commencement
Date
	  	$	12,500,000	 
	 The twelve (12) month anniversary of the Lease Commencement
Date
	  	$	10,000,000	 

 22.    COMMUNICATIONS AND COMPUTER LINE Tenant may install, maintain,
replace, remove or use any communications or computer wires and cables serving the Premises (collectively, the “Lines”), provided that Tenant shall obtain Landlord’s prior written consent (not to be unreasonably withheld,
conditioned or delayed), use an experienced and qualified contractor reasonably approved in writing by Landlord, and comply with all of the other provisions of Articles 7 and 8 of this Lease. Tenant shall pay all costs in connection therewith.
Landlord reserves the right, upon notice to Tenant prior to the expiration or earlier termination of this Lease, to require that Tenant, at Tenant’s sole cost and expense, remove any Lines installed by Tenant located in or serving the Premises
prior to the expiration or earlier termination of this Lease. 
 23.    SIGNS 

23.1    Exterior Signage. Subject to Landlord’s prior written approval, which shall not
be unreasonably withheld, conditioned or delayed, and provided all signs are in keeping with the quality, design and style of the Building and Project, Tenant, at its sole cost and expense, may install identification signage on the existing Building
monument sign (collectively, “Tenant Signage”); provided, however, in no event shall Tenant’s Signage include an “Objectionable Name,” as that term is defined in Section 23.3, of this Lease.
All such signage shall be subject to Tenant’s obtaining all required governmental approvals. All permitted signs shall be maintained by Tenant at its expense in a first-class and safe condition and appearance. Upon the expiration or earlier
termination of this Lease, Tenant shall remove all of its signs at Tenant’s sole cost and expense. The graphics, materials, color, design, lettering, lighting, size, illumination, specifications and exact location of Tenant’s Signage
(collectively, the “Sign Specifications”) shall be subject to the prior written approval of Landlord, which approval shall not be unreasonably withheld, conditioned or delayed, and shall be consistent and compatible with the quality
and nature of the Project. Tenant hereby acknowledges that, notwithstanding Landlord’s approval of Tenant’s Signage, Landlord has made no representation or warranty to Tenant with respect to the probability of obtaining all necessary
governmental approvals and permits for Tenant’s Signage. In the event Tenant does not receive the necessary governmental approvals and permits for Tenant’s Signage, Tenant’s and Landlord’s rights and obligations under the
remaining terms of this Lease shall be unaffected. 
 23.2    Objectionable Name.
Tenant’s Signage shall not include a name or logo which relates to an entity which is of a character or reputation, or is associated with a political faction or orientation, which is inconsistent with the quality of the Project, or which would
otherwise reasonably offend a landlord of the Comparable Buildings (an “Objectionable Name”). The parties hereby agree that the following name, or any reasonable derivation thereof, shall be deemed not to constitute an Objectionable
Name: “GenomeDx Bioscience Corp..” 
 23.3    Prohibited Signage and Other
Items. Any signs, notices, logos, pictures, names or advertisements which are installed and that have not been separately approved by Landlord may be removed without notice by Landlord at the sole expense of Tenant. Any signs, window
coverings, or blinds (even if the same are located behind the Landlord-approved window coverings for the Building), or other items visible from the exterior of the Premises or Building, shall be subject to the prior approval of Landlord, in its sole
discretion. 
 23.4    Termination of Right to Tenant’s Signage. The rights contained
in this Article 23 shall be personal to Original Tenant and any Permitted Transferee, and may only be exercised and maintained by such parties (and not any other assignee, sublessee or other transferee of the Original Tenant’s interest
in this Lease) to the extent (x) they are not in default under this Lease (beyond any applicable notice and cure period) and (y) if they occupy the entire Premises. 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-36-	  	[GenomeDx Biosciences, Corp.]

 23.5    Identification Signage. Tenant
may, at Tenant’s sole cost and expense, install identifying signage outside the entrance to the Premises, and such signage shall be comparable to that used by Landlord for other similar floors in the Building and shall comply with
Landlord’s Building standard signage program. 
 23.6    Building Directory. If a
building directory is located in the lobby of the Building, then Tenant shall have the right, at Tenant’s expense, to use up to one (1) line on such directory for Tenant’s name to be displayed in building standard font and size. Any
changes to the initial strips on the Building directory shall be at Tenant’s sole cost and expense. 

24.    COMPLIANCE WITH LAW Tenant shall not do anything or suffer anything to be done in or about the
Premises or the Project which will in any way conflict with any law, statute, ordinance or other governmental rule, regulation or requirement now in force or which may hereafter be enacted or promulgated (“Applicable Laws”).
Following the Lease Commencement Date, at its sole cost and expense, Tenant shall promptly comply with all such Applicable Laws which relate to (i) Tenant’s use of the Premises, (ii) any Alterations made by Tenant to the Premises, or
(iii) the Building, but as to the Building, only to the extent such obligations are triggered by Alterations made by Tenant to the Premises to the extent such Alterations are not normal and customary business office improvements. Should any
Applicable Law now or hereafter be imposed on Tenant by a state, federal or local governmental body charged with the establishment, regulation and enforcement of occupational, health or safety standards for employers, employees, landlords or
tenants, then Tenant agrees, at its sole cost and expense, to comply promptly with such Applicable Law. Tenant shall be responsible, at its sole cost and expense, to make all alterations to the Premises as are required to comply with the Applicable
Laws to the extent required in this Article 24. Notwithstanding the foregoing terms of this Article 24 to the contrary, Tenant may defer such compliance with Applicable Laws while Tenant contests, in a court of proper jurisdiction, in good
faith, the applicability of such Applicable Laws to the Premises or Tenant’s specific use or occupancy of the Premises; provided, however, Tenant may only defer such compliance if such deferral shall not (a) prohibit Tenant from obtaining
or maintaining a certificate of occupancy for the Premises, (b) prohibit Landlord from obtaining or maintaining a certificate of occupancy for the Building or any portion thereof, (c) unreasonably and materially affect the safety of the
employees and/or invitees of Landlord or Tenant, (d) create a significant health hazard for the employees and/or invitees of Landlord or Tenant, (e) otherwise materially and adversely affect Tenant’s use of or access to the Buildings
or the Premises, or (f) impose material obligations, liability, fines, or penalties upon Landlord, or would materially and adversely affect the use of or access to the Building by Landlord. The judgment of any court of competent jurisdiction or
the admission of Tenant in any judicial action, regardless of whether Landlord is a party thereto, that Tenant has violated any of said governmental measures, shall be conclusive of that fact as between Landlord and Tenant. Landlord shall comply
with all Applicable Laws relating to the Building, provided that compliance with such Applicable Laws is not the responsibility of Tenant under this Lease, and provided further that Landlord’s failure to comply therewith would prohibit Tenant
from obtaining or maintaining a certificate of occupancy for the Premises, or would unreasonably and materially affect the safety of Tenant’s employees or create a significant health hazard for Tenant’s employees, or would otherwise
materially and adversely affect Tenant’s use of or access to the Premises. 
 25.    LATE CHARGES If
any installment of Rent or any other sum due from Tenant shall not be received by Landlord or Landlord’s designee within five (5) business days after Tenant’s receipt of written notice from Landlord that said amount is due, then
Tenant shall pay to Landlord a late charge equal to five percent (5%) of the overdue amount plus any reasonable attorneys’ fees incurred by Landlord by reason of Tenant’s failure to pay Rent and/or other charges when due hereunder.
Notwithstanding the foregoing, Landlord shall not charge Tenant a late charge for the first late payment in any twelve (12) month period (but in no event with respect to any subsequent late payment in any twelve (12) month period) during
the Lease Term that Tenant fails to timely pay Rent or another sum due under this Lease, provided that such late payment is made within three (3) business days following the expiration of the five (5) business day period following written
notice. The late charge shall be deemed Additional Rent and the right to require it shall be in addition to all of Landlord’s other rights and remedies hereunder or at law and shall not be construed as liquidated damages or as limiting
Landlord’s remedies in any manner. In addition to the late charge described above, any Rent or other amounts owing hereunder which are not paid within ten (10) business days after the date they are due shall bear interest from the date
when due until paid at a rate per annum equal to the lesser of (i) the annual “Bank Prime Loan” rate cited in the Federal Reserve Statistical Release Publication G.13(415), published on the first Tuesday of each calendar month (or
such other comparable index as Landlord and Tenant shall reasonably agree upon if such rate ceases to be published) plus four (4) percentage points, and (ii) the highest rate permitted by applicable law. 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-37-	  	[GenomeDx Biosciences, Corp.]

 26.    LANDLORD’S RIGHT TO CURE DEFAULT; PAYMENTS BY TENANT 

26.1    Landlord’s Cure. All covenants and agreements to be kept or performed by Tenant
under this Lease shall be performed by Tenant at Tenant’s sole cost and expense and without any reduction of Rent, except to the extent, if any, otherwise expressly provided herein. If Tenant shall fail to perform any obligation under this
Lease, and such failure shall continue in excess of the time allowed under Section 19.1.2, above, unless a specific time period is otherwise stated in this Lease, Landlord may, but shall not be obligated to, make any such
payment or perform any such act on Tenant’s part without waiving its rights based upon any default of Tenant and without releasing Tenant from any obligations hereunder. 

26.2    Tenant’s Reimbursement. Except as may be specifically provided to the contrary
in this Lease, Tenant shall pay to Landlord, upon delivery by Landlord to Tenant of statements therefor: (i) sums equal to expenditures reasonably made and obligations incurred by Landlord in connection with the remedying by Landlord of
Tenant’s defaults pursuant to the provisions of Section 26.1; (ii) sums equal to all losses, costs, liabilities, damages and expenses referred to in Article 10 of this Lease; and (iii) sums equal to all
expenditures made and obligations incurred by Landlord in collecting or attempting to collect the Rent or in enforcing or attempting to enforce any rights of Landlord under this Lease or pursuant to law, including, without limitation, all reasonable
legal fees and other amounts so expended. Tenant’s obligations under this Section 26.2 shall survive the expiration or sooner termination of the Lease Term. 

27.    ENTRY BY LANDLORD Landlord reserves the right at all reasonable times and upon at least twenty-four
(24) hours prior notice to Tenant (except in the case of an emergency) to enter the Premises to (i) inspect them; (ii) show the Premises to prospective purchasers, or to current or prospective mortgagees, ground or underlying lessors
or insurers or, during the last nine (9) months of the Lease Term, to prospective tenants; (iii) post notices of nonresponsibility (to the extent applicable pursuant to then applicable law); or (iv) alter, improve or repair the
Premises or the Building, or for structural alterations, repairs or improvements to the Building or the Building’s systems and equipment. Landlord may make any such entries without the abatement of Rent, except as otherwise provided in this
Lease, and may take such reasonable steps as required to accomplish the stated purposes. In an emergency, Landlord shall have the right to use any means that Landlord may deem proper to open the doors in and to the Premises. Any entry into the
Premises by Landlord in the manner hereinbefore described shall not be deemed to be a forcible or unlawful entry into, or a detainer of, the Premises, or an actual or constructive eviction of Tenant from any portion of the Premises. Except in the
event of an emergency, Tenant shall have the right to have an employee of Tenant accompany Landlord in connection with any such entry, provided that Landlord shall not be required to delay or reschedule any such entry due to the unavailability of
Tenant’s employee. 
 28.    TENANT PARKING Tenant shall have the right to use the amount of parking
set forth in Section 9 of the Summary, in the on-site parking facility (or facilities) which serve the Project. Tenant shall abide by all reasonable rules and regulations which are prescribed from time to
time for the orderly operation and use of the parking facility where the parking passes are located (including any sticker or other identification system established by Landlord and the prohibition of vehicle repair and maintenance activities in the
parking facilities), and shall cooperate in seeing that Tenant’s employees and visitors also comply with such rules and regulations. Tenant’s use of the Project parking facility shall be at Tenant’s sole risk and Tenant acknowledges
and agrees that Landlord shall have no liability whatsoever for damage to the vehicles of Tenant, its employees and/or visitors, or for other personal injury or property damage or theft relating to or connected with the parking rights granted herein
or any of Tenant’s, its employees’ and/or visitors’ use of the parking facilities. 
 29.    MISCELLANEOUS PROVISIONS

 29.1    Terms; Captions. The words “Landlord” and
“Tenant” as used herein shall include the plural as well as the singular. The necessary grammatical changes required to make the provisions hereof apply either to corporations or partnerships or individuals, men or women, as the
case may require, shall in all cases be assumed as though in each case fully expressed. The captions of Articles and Sections are for convenience only and shall not be deemed to limit, construe, affect or alter the meaning of such Articles and
Sections. 
 29.2    Binding Effect. Subject to all other provisions of this Lease, each
of the covenants, conditions and provisions of this Lease shall extend to and shall, as the case may require, bind or inure to the benefit not only of 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-38-	  	[GenomeDx Biosciences, Corp.]

 
Landlord and of Tenant, but also of their respective heirs, personal representatives, successors or assigns, provided this clause shall not permit any assignment by Tenant contrary to the
provisions of Article 14 of this Lease. 
 29.3    No Air Rights. No rights to any
view or to light or air over any property, whether belonging to Landlord or any other person, are granted to Tenant by this Lease. If at any time any windows of the Premises are temporarily darkened or the light or view therefrom is obstructed by
reason of any repairs, improvements, maintenance or cleaning in or about the Project, the same shall be without liability to Landlord and without any reduction or diminution of Tenant’s obligations under this Lease. 

29.4    Modification of Lease. Should any current or prospective mortgagee or ground lessor
for the Building or Project require a modification of this Lease, which modification will not cause an increased cost or expense to Tenant or in any other way materially and adversely change the rights and obligations of Tenant hereunder, then and
in such event, Tenant agrees that this Lease may be so modified and agrees to execute whatever documents are reasonably required therefor and to deliver the same to Landlord within ten (10) business days following a request therefor. At the
request of Landlord or any mortgagee or ground lessor, Tenant agrees to execute a short form of Lease and deliver the same to Landlord within ten (10) business days following the request therefor. 

29.5    Transfer of Landlord’s Interest. Tenant acknowledges that Landlord has the
right to transfer all or any portion of its interest in the Project or Building and in this Lease, and Tenant agrees that in the event of any such transfer, Landlord shall automatically be released from all liability under this Lease and Tenant
agrees to look solely to such transferee for the performance of Landlord’s obligations hereunder after the date of transfer and such transferee shall be deemed to have fully assumed and be liable for all obligations of this Lease to be
performed by Landlord, including the return of any Security Deposit, and Tenant shall attorn to such transferee. 

29.6    Prohibition Against Recording. Except as provided in
Section 29.4 of this Lease, neither this Lease, nor any memorandum, affidavit or other writing with respect thereto, shall be recorded by Tenant or by anyone acting through, under or on behalf of Tenant. 

29.7    Landlord’s Title. Landlord’s title is and always shall be paramount to the
title of Tenant. Nothing herein contained shall empower Tenant to do any act which can, shall or may encumber the title of Landlord. 

29.8    Relationship of Parties. Nothing contained in this Lease shall be deemed or
construed by the parties hereto or by any third party to create the relationship of principal and agent, partnership, joint venturer or any association between Landlord and Tenant. 

29.9    Application of Payments. Landlord shall have the right to apply payments received
from Tenant pursuant to this Lease, regardless of Tenant’s designation of such payments, to satisfy any obligations of Tenant hereunder, in such order and amounts as Landlord, in its sole discretion, may elect. 

29.10    Time of Essence. Time is of the essence with respect to the performance of every
provision of this Lease in which time of performance is a factor. 
 29.11    Partial
Invalidity. If any term, provision or condition contained in this Lease shall, to any extent, be invalid or unenforceable, the remainder of this Lease, or the application of such term, provision or condition to persons or circumstances other
than those with respect to which it is invalid or unenforceable, shall not be affected thereby, and each and every other term, provision and condition of this Lease shall be valid and enforceable to the fullest extent possible permitted by law. 

29.12    No Warranty. In executing and delivering this Lease, Tenant has not relied on any
representations, including, but not limited to, any representation as to the amount of any item comprising Additional Rent or the amount of the Additional Rent in the aggregate or that Landlord is furnishing the same services to other tenants, at
all, on the same level or on the same basis, or any warranty or any statement of Landlord which is not set forth herein or in one or more of the exhibits attached hereto. 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-39-	  	[GenomeDx Biosciences, Corp.]

 29.13    Landlord Exculpation. The
liability of Landlord or the Landlord Parties to Tenant for any default by Landlord under this Lease or arising in connection herewith or with Landlord’s operation, management, leasing, repair, renovation, alteration or any other matter
relating to the Project or the Premises shall be limited solely and exclusively to an amount which is equal to the interest of Landlord in the Building. Neither Landlord, nor any of the Landlord Parties shall have any personal liability therefor,
and Tenant hereby expressly waives and releases such personal liability on behalf of itself and all persons claiming by, through or under Tenant. The limitations of liability contained in this Section 29.13 shall inure to
the benefit of Landlord’s and the Landlord Parties’ present and future partners, beneficiaries, officers, directors, trustees, shareholders, agents and employees, and their respective partners, heirs, successors and assigns. Under no
circumstances shall any present or future partner of Landlord (if Landlord is a partnership), or trustee or beneficiary (if Landlord or any partner of Landlord is a trust), have any liability for the performance of Landlord’s obligations under
this Lease. Notwithstanding any contrary provision herein, neither Landlord nor the Landlord Parties shall be liable under any circumstances for injury or damage to, or interference with, Tenant’s business, including but not limited to, loss of
profits, loss of rents or other revenues, loss of business opportunity, loss of goodwill or loss of use, in each case, however occurring, or loss to inventory, scientific research, scientific experiments, laboratory animals, products, specimens,
samples, and/or scientific, business, accounting and other records of every kind and description kept at the premises and any and all income derived or derivable therefrom. 

29.14    Entire Agreement. It is understood and acknowledged that there are no oral
agreements between the parties hereto affecting this Lease and this Lease constitutes the parties’ entire agreement with respect to the leasing of the Premises and supersedes and cancels any and all previous negotiations, arrangements,
brochures, agreements and understandings, if any, between the parties hereto or displayed by Landlord to Tenant with respect to the subject matter thereof, and none thereof shall be used to interpret or construe this Lease. None of the terms,
covenants, conditions or provisions of this Lease can be modified, deleted or added to except in writing signed by the parties hereto. 

29.15    Right to Lease. Landlord reserves the absolute right to effect such other tenancies
in the Project as Landlord in the exercise of its sole business judgment shall determine to best promote the interests of the Building or Project. Tenant does not rely on the fact, nor does Landlord represent, that any specific tenant or type or
number of tenants shall, during the Lease Term, occupy any space in the Building or Project. 

29.16    Force Majeure. Any prevention, delay or stoppage due to strikes, lockouts, labor
disputes, acts of God, acts of war, terrorist acts, inability to obtain services, labor, or materials or reasonable substitutes therefor, governmental actions, civil commotions, fire or other casualty, and other causes beyond the reasonable control
of the party obligated to perform, except with respect to the obligations imposed with regard to Rent and other charges to be paid by Tenant pursuant to this Lease (collectively, a “Force Majeure”), notwithstanding anything to the
contrary contained in this Lease, shall excuse the performance of such party for a period equal to any such prevention, delay or stoppage and, therefore, if this Lease specifies a time period for performance of an obligation of either party, that
time period shall be extended by the period of any delay in such party’s performance caused by a Force Majeure. 

29.17    Waiver of Redemption by Tenant. Tenant hereby waives, for Tenant and for all those
claiming under Tenant, any and all rights now or hereafter existing to redeem by order or judgment of any court or by any legal process or writ, Tenant’s right of occupancy of the Premises after any termination of this Lease. 

29.18    Notices. All notices, demands, statements, designations, approvals or other
communications (collectively, “Notices”) given or required to be given by either party to the other hereunder or by law shall be in writing, shall be (A) sent by United States certified or registered mail, postage prepaid,
return receipt requested (“Mail”), (B) transmitted by telecopy, if such telecopy is promptly followed by a Notice sent by Mail, (C) delivered by a nationally recognized overnight courier, or (D) delivered personally. Any
Notice shall be sent, transmitted, or delivered, as the case may be, to Tenant at the appropriate address set forth in Section 10 of the Summary, or to such other place as Tenant may from time to time designate in a Notice
to Landlord, or to Landlord at the addresses set forth below, or to such other places as Landlord may from time to time designate in a Notice to Tenant. Any Notice will be deemed given (i) three (3) days after the date it is posted if sent by
Mail, (ii) the date the telecopy is transmitted, (iii) the date the overnight courier delivery is made, or (iv) the date personal delivery is made. As of the date of this Lease, any Notices to Landlord must be sent, transmitted, or
delivered, as the case may be, to the following addresses: 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-40-	  	[GenomeDx Biosciences, Corp.]

 Torrey Pines Science Center Limited Partnership 

c/o HCP, Inc. 

462 Stevens Avenue, Suite 107 

Solana Beach, California 92075 

Attention: Mike Dorris 

with a copy to: 

Torrey Pines Science Center Limited Partnership 

c/o HCP, Inc. 

3760 Kilroy Airport Way, Suite 300 

Long Beach, CA 90806-2473 

Attn: Legal Department 

and 

Allen Matkins Leck Gamble Mallory & Natsis LLP 

1901 Avenue of the Stars, Suite 1800 

Los Angeles, California 90067 

Attention: Anton N. Natsis, Esq. 

29.19    Joint and Several. If there is more than one tenant, the obligations imposed upon
Tenant under this Lease shall be joint and several. 
 29.20    Authority. If Tenant is a
corporation, trust or partnership, each individual executing this Lease on behalf of Tenant hereby represents and warrants that Tenant is a duly formed and existing entity qualified to do business in the State of California and that Tenant has full
right and authority to execute and deliver this Lease and that each person signing on behalf of Tenant is authorized to do so. In such event, Tenant shall, within ten (10) days after execution of this Lease, deliver to Landlord satisfactory
evidence of such authority and, if a corporation, upon demand by Landlord, also deliver to Landlord satisfactory evidence of (i) good standing in Tenant’s state of incorporation and (ii) qualification to do business in the State of
California. 
 29.21    Attorneys’ Fees. In the event that either Landlord or Tenant
should bring suit for the possession of the Premises, for the recovery of any sum due under this Lease, or because of the breach of any provision of this Lease or for any other relief against the other, then all costs and expenses, including
reasonable attorneys’ fees, incurred by the prevailing party therein shall be paid by the other party, which obligation on the part of the other party shall be deemed to have accrued on the date of the commencement of such action and shall be
enforceable whether or not the action is prosecuted to judgment. 
 29.22    Governing Law; WAIVER
OF TRIAL BY JURY. This Lease shall be construed and enforced in accordance with the laws of the State of California. IN ANY ACTION OR PROCEEDING ARISING HEREFROM, LANDLORD AND TENANT HEREBY CONSENT TO (I) THE JURISDICTION OF ANY
COMPETENT COURT WITHIN THE STATE OF CALIFORNIA, (II) SERVICE OF PROCESS BY ANY MEANS AUTHORIZED BY CALIFORNIA LAW, AND (III) IN THE INTEREST OF SAVING TIME AND EXPENSE, TRIAL WITHOUT A JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT
BY EITHER OF THE PARTIES HERETO AGAINST THE OTHER OR THEIR SUCCESSORS IN RESPECT OF ANY MATTER ARISING OUT OF OR IN CONNECTION WITH THIS LEASE, THE RELATIONSHIP OF LANDLORD AND TENANT, TENANT’S USE OR OCCUPANCY OF THE PREMISES, AND/OR ANY CLAIM
FOR INJURY OR DAMAGE, OR ANY EMERGENCY OR STATUTORY REMEDY. IN THE EVENT LANDLORD COMMENCES ANY SUMMARY PROCEEDINGS OR ACTION FOR NONPAYMENT OF BASE RENT OR ADDITIONAL RENT, TENANT SHALL NOT INTERPOSE ANY COUNTERCLAIM OF ANY NATURE OR DESCRIPTION
(UNLESS SUCH COUNTERCLAIM SHALL BE MANDATORY) IN ANY SUCH PROCEEDING OR ACTION, BUT SHALL BE RELEGATED TO AN INDEPENDENT ACTION AT LAW. 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-41-	  	[GenomeDx Biosciences, Corp.]

 29.23    Submission of Lease. Submission
of this instrument for examination or signature by Tenant does not constitute a reservation of, option for or option to lease, and it is not effective as a lease or otherwise until execution and delivery by both Landlord and Tenant. 

29.24    Brokers. Landlord and Tenant hereby warrant to each other that they have had no
dealings with any real estate broker or agent in connection with the negotiation of this Lease, excepting only the real estate brokers or agents specified in Section 12 of the Summary (the “Brokers”), and
that they know of no other real estate broker or agent who is entitled to a commission in connection with this Lease. Each party agrees to indemnify and defend the other party against and hold the other party harmless from any and all claims,
demands, losses, liabilities, lawsuits, judgments, costs and expenses (including without limitation reasonable attorneys’ fees) with respect to any leasing commission or equivalent compensation alleged to be owing on account of any dealings
with any real estate broker or agent, other than the Brokers, occurring by, through, or under the indemnifying party. Landlord shall pay Brokers a commission pursuant to a separate written agreement. The terms of this
Section 29.24 shall survive the expiration or earlier termination of the Lease Term. 

29.25    Independent Covenants. This Lease shall be construed as though the covenants herein
between Landlord and Tenant are independent and not dependent and Tenant hereby expressly waives the benefit of any statute to the contrary and agrees that if Landlord fails to perform its obligations set forth herein, Tenant shall not be entitled
to make any repairs or perform any acts hereunder at Landlord’s expense or to any setoff of the Rent or other amounts owing hereunder against Landlord. 

29.26    Project or Building Name, Address and Signage. Landlord shall have the right at any
time to change the name and/or address of the Project or Building and to install, affix and maintain any and all signs on the exterior and on the interior of the Project or Building as Landlord may, in Landlord’s sole discretion, desire. Tenant
shall not use the name of the Project or Building or use pictures or illustrations of the Project or Building in advertising or other publicity or for any purpose other than as the address of the business to be conducted by Tenant in the Premises,
without the prior written consent of Landlord (not to be unreasonably withheld, conditioned or delayed). 

29.27    Counterparts. This Lease may be executed in counterparts with the same effect as if
both parties hereto had executed the same document. Both counterparts shall be construed together and shall constitute a single lease. 

29.28    Confidentiality. Tenant acknowledges that the content of this Lease and any related
documents are confidential information. Except as otherwise required by Applicable Law (including applicable securities regulations), Tenant shall keep such confidential information strictly confidential and shall not disclose such confidential
information to any person or entity other than Tenant’s financial, legal, and space planning consultants, and current or prospective assignees, subtenants, investors, lender and purchasers. 

29.29    Development of the Project. 

29.29.1    Subdivision. Landlord reserves the right to subdivide all or a portion of the
buildings and Common Areas. Tenant agrees to execute and deliver, upon demand by Landlord and in the form requested by Landlord, any additional documents needed to conform this Lease to the circumstances resulting from a subdivision and any all maps
in connection therewith. Notwithstanding anything to the contrary set forth in this Lease, the separate ownership of any buildings and/or Common Areas by an entity other than Landlord shall not affect the calculation of Direct Expenses or
Tenant’s payment of Tenant’s Share of Direct Expenses. 
 29.29.2    Construction of
Property and Other Improvements. Tenant acknowledges that portions of the Project may be under construction following Tenant’s occupancy of the Premises, and that such construction may result in levels of noise, dust, obstruction of
access, etc. which are in excess of that present in a fully constructed project. Tenant hereby waives any and all rent offsets or claims of constructive eviction which may arise in connection with such construction. 

29.30    No Violation. Tenant hereby warrants and represents that neither its execution of
nor performance under this Lease shall cause Tenant to be in violation of any agreement, instrument, contract, law, rule or regulation 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-42-	  	[GenomeDx Biosciences, Corp.]

 
by which Tenant is bound, and Tenant shall protect, defend, indemnify and hold Landlord harmless against any claims, demands, losses, damages, liabilities, costs and expenses, including, without
limitation, reasonable attorneys’ fees and costs, arising from Tenant’s breach of this warranty and representation. 

29.31    Transportation Management. Tenant shall fully comply with all present or future
programs intended to manage parking, transportation or traffic in and around the Project and/or the Building, and in connection therewith, Tenant shall take responsible action for the transportation planning and management of all employees located
at the Premises by working directly with Landlord, any governmental transportation management organization or any other transportation-related committees or entities. Such programs may include, without limitation: (i) restrictions on the number
of peak-hour vehicle trips generated by Tenant; (ii) increased vehicle occupancy; (iii) implementation of an in-house ridesharing program and an employee transportation coordinator; (iv) working
with employees and any Project, Building or area-wide ridesharing program manager; (v) instituting employer-sponsored incentives (financial or in-kind) to encourage employees to rideshare; and
(vi) utilizing flexible work shifts for employees. 
 29.32    Rooftop Rights. In
accordance with, and subject to, the terms and conditions set forth in Article 8 (except for any consent rights of Landlord in Section 8.1 above, which shall be superseded for the purposes of this
Section 29.32 by Section 29.32.2 below), Tenant may install and maintain, at Tenant’s sole cost and expense, the following equipment: (i) one (1) satellite dish/antennae on the roof of
the Building for receiving of signals or broadcasts (as opposed to the generation or transmission of any such signals or broadcasts) and related communications equipment servicing the business conducted by Tenant from within the Premises, and
(ii) supplemental HVAC equipment (all such equipment is defined collectively as the “Telecommunications and HVAC Equipment”). 

29.32.1    Landlord makes no representations or warranties whatsoever with respect to the condition of the
roof of the Building, or the fitness or suitability of the roof of the Building for the installation, maintenance and operation of the Telecommunications and HVAC Equipment, including, without limitation, with respect to the quality and clarity of
any receptions and transmissions to or from the Telecommunications and HVAC Equipment and the presence of any interference with such signals whether emanating from the Building or otherwise. 

29.32.2    In the event Tenant elects to exercise its right to install any Telecommunications and HVAC
Equipment, then Tenant shall give Landlord prior notice thereof. Such Telecommunications and HVAC Equipment shall be installed (i) pursuant to plans and specifications approved by Landlord (specifically including, without limitation, all
mounting and waterproofing details), which approval will not be unreasonably withheld, conditioned, or delayed, and (ii) in a manner which will not invalidate any warranty held by Landlord with respect to the roof or the roof membrane. In
addition, the physical appearance, size and weight of the Telecommunications and HVAC Equipment shall be subject to Landlord’s reasonable approval. The location of any such installation of the Telecommunications and HVAC Equipment shall be
designated by Tenant subject to Landlord’s reasonable approval, and Landlord may require Tenant to install screening around such Telecommunications and HVAC Equipment, at Tenant’s sole cost and expense, as reasonably designated by
Landlord. Tenant shall reimburse to Landlord the actual costs reasonably incurred by Landlord in reviewing such Telecommunications and HVAC Equipment. Notwithstanding any such review or approval by Landlord, Tenant shall remain solely liable for any
damage to any portion of the roof or roof membrane, specifically including any penetrations, in connection with Tenant’s installation, use, maintenance and/or repair of such Telecommunications and HVAC Equipment, and Landlord shall have no
liability therewith; provided that if any such damage is covered by Landlord’s insurance, Tenant shall only be obligated to pay any deductible in connection therewith. Such Telecommunications and HVAC Equipment shall, in all instances, comply
with applicable governmental laws, codes, rules and regulations. In no event shall any such Telecommunications and HVAC Equipment unreasonably interfere with any rooftop equipment of any other tenant or occupant of the Building or Project, or
interfere with any rooftop equipment of any other third-party with whom Landlord has any third-party agreement. 

29.32.3    Tenant shall maintain such Telecommunications and HVAC Equipment, at Tenant’s sole cost
and expense. Tenant shall remove such Telecommunications and HVAC Equipment upon the expiration or earlier termination of the Lease. In connection with any such removal, Tenant shall return the affected portion of the rooftop and the Premises to the
condition the rooftop and the Premises would have been in had no such Telecommunications and HVAC Equipment been installed (reasonable wear and tear excepted). 

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-43-	  	[GenomeDx Biosciences, Corp.]

 29.32.4    Landlord reserves the right, upon not less
than thirty (30) days prior written notice to Tenant, to substitute the area in which the Telecommunications and HVAC Equipment is located for a comparable area on the roof of the Building reasonably approved by Tenant, provided that Tenant
shall promptly relocate the Telecommunications and HVAC Equipment and Landlord shall pay all expenses reasonably incurred in moving Tenant’s Telecommunications and HVAC Equipment to such new location, within thirty (30) days after
Landlord’s receipt from Tenant of invoices marked as paid, unconditional mechanic’s lien releases and other supporting documentation as Landlord may reasonably request. In the event Landlord elects to exercise its right to relocate such
Telecommunications and HVAC Equipment, Landlord shall use commercially reasonable efforts not to materially interfere with Tenant’s reception or transmission or materially interfere with Tenant’s normal day-to-day business at the Premises. 
 29.32.5    For the
purposes of determining Tenant’s obligations under this Lease with respect to its use of the Telecommunications and HVAC Equipment and areas of the Building in which the Telecommunications and HVAC Equipment is located, the areas in which the
Telecommunications and HVAC Equipment is located (to the extent outside the Premises) shall be deemed to be a portion of the Premises (but Tenant shall have no obligation to pay Rent with respect to such portion); consequently, all of the provisions
of this Lease with respect to Tenant’s obligations as to the Premises shall apply to the installation, use and maintenance of the Telecommunications and HVAC Equipment, including, without limitation, the provisions relating to insurance,
indemnity, repairs and maintenance, and compliance with laws. 
 IN WITNESS WHEREOF, Landlord and Tenant have caused this
Lease to be executed the day and date first above written. 
  

									
	 LANDLORD:
  

TORREY PINES SCIENCE CENTER LIMITED PARTNERSHIP,

a Delaware limited partnership
	 		 	 TENANT:
  

GENOMEDX BIOSCIENCES CORP.,
 a
Delaware corporation

					
		 		 		 	 By:
	 	 /s/ David Matthews

				
	 By:
	 	 /s/ Jonathan M. Bergschneider
	 		 	 David Matthews

		 		 		 	Print Name
	 Jonathan M. Bergschneider
	 		 		 	
	Print Name	 		 	 Its:
	 	 CFO

					
	 Its:
	 	 Executive Vice President
	 		 		 	
		 		 		 	 By:
	 	  

				
		 		 		 	     

		 		 		 	Print Name
					
		 		 		 	 Its:
	 	  

  

					
		  		  	HCP, INC.
		  		  	[10355 Science Center Drive]
		  	-44-	  	[GenomeDx Biosciences, Corp.]

 EXHIBIT A 

10355 SCIENCE CENTER DRIVE 

OUTLINE OF PREMISES 
  

 

  

					
		  		  	HCP, INC.
		  	EXHIBIT A	  	[10355 Science Center Drive]
		  	-1-	  	[GenomeDx Biosciences, Corp.]

 EXHIBIT A-1 

10355 SCIENCE CENTER DRIVE 

PROJECT SITE PLAN 
  

 

  

					
		  		  	HCP, INC.
		  	EXHIBIT A-1	  	[10355 Science Center Drive]
		  	-1-	  	[GenomeDx Biosciences, Corp.]

 EXHIBIT A-2 

INITIAL OCCUPANCY PREMISES AND DELAYED OCCUPANCY PREMISES 

 
 

 

  

					
		  		  	HCP, INC.
		  	EXHIBIT A-2	  	[10355 Science Center Drive]
		  	-1-	  	[GenomeDx Biosciences, Corp.]

 EXHIBIT B-1 

10355 SCIENCE CENTER DRIVE 

TENANT WORK LETTER 

SECTION 1 

MOVING AND CABLING ALLOWANCE 

Tenant shall be entitled to an allowance (the “Moving and Cabling Allowance”) in an amount equal to Twenty-Two Thousand Four and No/100 Dollars ($22,004.00) (i.e., an amount equal to $2.00 per rentable square foot of the Premises) to be utilized by Tenant for “Moving Costs,” as that term is defined,
below, and the cost of installing cabling in the Premises. Subject to Section 2 below, in no event shall Landlord be obligated to disburse any portion of the Moving and Cabling Allowance for any purpose other than reimbursement for reasonable out-of-pocket costs and expenses actually incurred by Tenant in relocating to the Premises and/or for cabling to be used in the Premises (collectively, “Moving
Costs”). Provided that the Lease Commencement Date has occurred and that the relocation of Tenant’s business to the Premises is completed or underway, Landlord shall disburse the Moving and Cabling Allowance for Moving Costs within
thirty (30) days following receipt by Landlord of invoices marked as having been paid or other evidence in form and content reasonably satisfactory to Landlord in support of such costs and expenses. Landlord shall only be obligated to disburse
any component of the Moving and Cabling Allowance to the extent the same is incurred by Tenant. In no event shall the Moving and Cabling Allowance provided for herein be available to Tenant as a credit against rent or other amounts owing to Landlord
pursuant to this Lease or in any manner other than as expressly provided in this Lease. Further, in no event shall Landlord’s disbursements hereunder exceed the Moving and Cabling Allowance. 

SECTION 2 

APPLICATION OF MOVING AND CABLING ALLOWANCE TO TENANT IMPROVEMENTS 

Tenant may in its sole discretion elect, by providing Landlord with written notice thereof, to apply some or all of the Moving
and Cabling Allowance to (i) the cost of Tenant Improvements with respect to either or both of the Initial Occupancy Premises or the Delayed Occupancy Premises, in each case subject to the terms and conditions in the corresponding Tenant Work
Letter, and/or (ii) any fees or other expenses payable to Tenant’s construction manager in connection with any of the Tenant Improvements; provided that in no event shall such election increase the total amount of the Moving and Cabling
Allowance. 
 SECTION 3 

DEADLINE FOR USE OF MOVING AND CABLING ALLOWANCE 

In the event that Tenant shall fail to utilize the Moving and Cabling Allowance (or to submit documentation for payment as
provided for herein) within one hundred eighty (180) days following the Lease Commencement Date (the “Allowance Termination Date”), then such unused amounts shall revert to Landlord and Tenant shall have no further rights with
respect thereto; provided that the Moving and Cabling Allowance shall remain available to Tenant to the extent that Tenant has elected on or prior to the Allowance Termination Date to apply the Moving and Cabling Allowance to Tenant Improvements
pursuant to Section 2 above. 

  

					
		  		  	HCP, INC.
		  	EXHIBIT B-1	  	[10355 Science Center Drive]
		  	-1-	  	[GenomeDx Biosciences, Corp.]

 EXHIBIT B-2 

10355 SCIENCE CENTER DRIVE 

TENANT WORK LETTER FOR INITIAL OCCUPANCY PREMISES 

This Tenant Work Letter shall set forth the terms and conditions relating to the construction of the tenant improvements in
the Initial Occupancy Premises. The terms of this Tenant Work Letter shall not be applicable to the Delayed Occupancy Premises. This Tenant Work Letter is essentially organized chronologically and addresses the issues of the construction of the
Premises, in sequence, as such issues will arise during the actual construction of the Premises. All references in this Tenant Work Letter to Articles or Sections of “this Lease” shall mean the relevant portion of Articles 1 through 29 of
the Lease to which this Tenant Work Letter is attached as Exhibit B-2 and of which this Tenant Work Letter forms a part, and all references in this Tenant Work Letter to Sections of “this
Tenant Work Letter” shall mean the relevant portion of Sections 1 through 6 of this Tenant Work Letter. 
 SECTION 1 

TENANT IMPROVEMENTS 

1.1    Landlord Work. 

1.1.1    Notwithstanding anything set forth in this Lease to the contrary, upon the Lease Commencement
Date, the Building Systems, as that term is defined below, shall be in good working condition and repair, and Landlord hereby covenants that the Building Systems shall remain in good working condition for a period of one (1) year following the
Lease Commencement Date. Notwithstanding anything in this Lease to the contrary, Landlord shall, at Landlord’s sole cost and expense (which shall not be deemed an Operating Expense), repair or replace any failed or inoperable portion of the
Building Systems during such one (1) year period (“Landlord’s Warranty”), provided that the need to repair or replace was not caused by the misuse, misconduct, damage, destruction, omissions, and/or negligence
(collectively, “Tenant Damage”) of Tenant, its subtenants and/or assignees, if any, or any company which is acquired, sold or merged with Tenant, or by any modifications, Alterations, or improvements constructed by or on behalf of
Tenant. To the extent repairs which Landlord is required to make pursuant to this Section 1.1.1 are necessitated in part by Tenant Damage, then Tenant shall reimburse Landlord for an equitable proportion of the reasonable
cost of such repair. If it is determined that any portion of the Building Systems were not in good working condition and repair at any time prior to the expiration of the Landlord’s Warranty, then Landlord shall not be liable to Tenant for any
damages, but as Tenant’s sole remedy, Landlord, at no cost to Tenant, shall promptly commence such work or take such other action as may be necessary to place the same in good working condition and repair, and shall thereafter diligently pursue
the same to completion. In addition, Landlord covenants that to its actual knowledge the Building structure (including, without limitation, the exterior and structural components of the Building) is without material defect that would material impact
Tenant’s ability to use the Premises for the Permitted Use, as of the date of this Lease. As used in this Tenant Work Letter, the “Building Systems” shall mean the base Building mechanical, electrical, life safety, plumbing, sprinkler
and HVAC systems installed or furnished by Landlord. 
 1.1.2    Landlord shall, at Landlord’s sole
cost and expense, perform such work as in necessary to multi-tenant the Building, including, without limitation, code-compliant separation to the Building, the main lobby, Common Area restrooms, common conference rooms and common lunch rooms. 

1.1.3    To the extent required in order to allow Tenant to obtain a certificate of occupancy, or its
legal equivalent, for the Premises for the Permitted Use, Landlord shall cause the Building, including the Initial Occupancy Premises, to comply with applicable building codes and other governmental laws, ordinances and regulations, including but
not limited to those related to handicap access (collectively, “Building Codes”), which were enacted and enforced as of the date of this Lease; provided, however, Landlord shall not be obligated to cause the Building to comply with
applicable Building Codes to the extent such requirement is triggered by the unique nature 

  

					
		  		  	HCP, INC.
		  	EXHIBIT B-2	  	[10355 Science Center Drive]
		  	-1-	  	[GenomeDx Biosciences, Corp.]

 
of Tenant’s specific use of the Premises for other than general office use and general laboratory use typical of tenants in the Building. 

1.2    Tenant Improvements. Landlord and Tenant have approved that certain “GDX
Construction Change” plans prepared by Ferguson Pape Baldwin Architects dated September 2, 2014 and submitted to the City of San Diego on September 2, 2014 (the “Approved Working Drawings”). Landlord shall construct
the improvements in the Premises (the “Turn-Key Tenant Improvements”) in good workmanlike condition pursuant to the Approved Working Drawings, and Tenant shall make no changes or
modifications to the Approved Working Drawings, without the prior written consent of Landlord, which consent may be withheld in Landlord’s sole discretion if such change or modification is reasonably likely to directly or indirectly materially
delay the “Substantial Completion,” as that term is defined in Section 5.1 of this Tenant Work Letter, of the Premises or increase the cost of designing or constructing the
Turn-Key Tenant Improvements. Notwithstanding the foregoing, the Turn-Key Tenant Improvements shall specifically exclude (i) any improvements set forth in the
Approved Working Drawings which are located outside of the Premises, and (ii) the Excluded Improvements (as that term is defined below). The Turn-Key Tenant Improvements shall be constructed in accordance
with Landlord’s Building standards, using Building standard methods, materials and finishes. Tenant shall not be responsible for any unforeseen costs in the construction of the Turn-Key Tenant
Improvements, whether arising out of a deficiency of the Building or otherwise, unless such increase cost is due to the act or omission of Tenant. Notwithstanding the foregoing, except as specifically set forth in
Section 2, below, the Turn-Key Tenant Improvements shall not include built-in furniture, equipment, cubicle systems (including the cabling and
phone wiring), personal property and/or any above-standard electrical, mechanical or plumbing systems. For purposes of this Exhibit B-2, the term “Excluded Improvements” shall
mean, collectively, the following items or improvements which are set forth in the Approved Working Drawings: (A) Pass Through Door from Pre-PCR area to Post-PCR
area, (B) Sink at Post-Gowning, (C) Coat Hook Panels, (D) Half Lites at Lab Doors, (E) Add Leafs to 3 doors, (F) Storefront Doors at 4 Conference Rooms, (G) Floor Boxes – 6 at open office, (H) Card Reader at
Lab Door. 
 SECTION 2 

TENANT IMPROVEMENTS ALLOWANCE 

2.1    Tenant Improvement Allowance. Tenant shall be entitled to a one-time tenant improvement allowance (the “Tenant Improvement Allowance”) in the amount of $2.00 per rentable square foot of the Initial Occupancy Premises to pay for both (i) the Excluded
Improvements and (ii) Tenant requested changes to the Approved Working Drawings (collectively, the “Elective Tenant Improvements” and, together with the Turn-Key Tenant Improvements, the
“Tenant Improvements”); provided that Tenant may in its sole discretion elect to apply some or all of the Tenant Improvement Allowance to any fees or other expenses payable to Tenant’s construction manager in connection with
any of the Tenant Improvements. In no event shall Landlord be obligated to make disbursements pursuant to this Tenant Work Letter in a total amount which exceeds the Tenant Improvement Allowance. In the event that the Tenant Improvement Allowance is
not fully utilized by Tenant on or before the second (2nd) anniversary of the Lease Commencement Date, then such unused amounts shall revert to Landlord, and Tenant shall have no further rights with respect thereto. Any Elective Tenant Improvements
that require the use of Building risers, raceways, shafts and/or conduits, shall be subject to Landlord’s reasonable rules, regulations, and restrictions, including the requirement that any cabling vendor must be selected from a list provided
by Landlord, and that the amount and location of any such cabling must be reasonably approved by Landlord. All Elective Tenant Improvements for which the Tenant Improvement Allowance has been made available shall be deemed Landlord’s property
under the terms of the Lease. 
 SECTION 3 

CONTRACTOR’S WARRANTIES AND GUARANTIES 

Landlord hereby assigns to Tenant all warranties and guaranties by the contractor who constructs the Tenant Improvements (the
“Contractor”) relating to the Tenant Improvements, and Tenant hereby waives all claims against 

  

					
		  		  	HCP, INC.
		  	EXHIBIT B-2	  	[10355 Science Center Drive]
		  	-2-	  	[GenomeDx Biosciences, Corp.]

 
Landlord relating to, or arising out of the construction of, the Tenant Improvements (except to the extent such claims arise out of Landlord’s gross negligence). 

SECTION 4 

INTENTIONALLY OMITTED 

SECTION 5 

COMPLETION OF THE TENANT IMPROVEMENTS; 

LEASE COMMENCEMENT DATE 

5.1    Ready for Occupancy. The Premises shall be deemed “Ready for
Occupancy” upon the Substantial Completion of the Premises. For purposes of this Lease, “Substantial Completion” of the Premises shall occur upon the completion of construction of the Tenant Improvements in the Premises to
the architect’s reasonable satisfaction, with the exception of any punch list items and any tenant fixtures, work-stations, built-in furniture, or equipment to be installed by Tenant or under the
supervision of Contractor. 
 5.2    Delay of the Substantial Completion of the Premises.
Except as provided in this Section 5.2, the Lease Commencement Date shall occur as set forth in this Lease and Section 5.1, above. If there shall be a delay or there are delays in the Substantial
Completion of the Premises or in the occurrence of any of the other conditions precedent to the Lease Commencement Date, as set forth in of this Lease, as a direct, indirect, partial, or total result of: 

5.2.1    Tenant’s failure to timely approve any matter requiring Tenant’s approval; 

5.2.2    A breach by Tenant of the terms of this Tenant Work Letter or this Lease; 

5.2.3    Tenant’s request for changes to the Tenant Improvements; 

5.2.4    Tenant failure to timely pay to Landlord the Over-Allowance Amount; 

5.2.5    Tenant’s requirement for materials, components, finishes or improvements which are not
available in a commercially reasonable time given the anticipated date of Substantial Completion of the Premises, as set forth in this Lease, or which are different from, or not included in, Landlord’s standard improvement package items for the
Building; or 
 5.2.6    Any other acts or omissions of Tenant, or its agents, or employees; 

then, notwithstanding anything to the contrary set forth in this Lease or this Tenant Work Letter and regardless of the actual date of the
Substantial Completion of the Premises, the date of Substantial Completion of the Premises shall be deemed to be the date the Substantial Completion of the Premises would have occurred if no Tenant delay or delays, as set forth above, had occurred.

 SECTION 6 

MISCELLANEOUS 

6.1    Tenant’s Entry Into the Premises Prior to Substantial Completion. Subject to
Section 1.4 of this Lease, provided that Tenant and its agents do not interfere with Contractor’s work in the Building and the Premises, Contractor shall allow Tenant access to the Initial Occupancy Premises at least thirty (30) days
prior to the Substantial Completion of the Initial Occupancy Premises for the purpose of Tenant installing Tenant’s furniture, equipment and/or fixtures (including Tenant’s data and telephone equipment) in the Initial Occupancy Premises.
Prior to Tenant’s entry into the Initial Occupancy Premises as permitted by the terms of this Section 6.1, Tenant shall submit a schedule to Landlord and Contractor, for their reasonable approval, which schedule shall
detail the timing and purpose of 

  

					
		  		  	HCP, INC.
		  	EXHIBIT B-2	  	[10355 Science Center Drive]
		  	-3-	  	[GenomeDx Biosciences, Corp.]

 
Tenant’s entry. Tenant shall hold Landlord harmless from and indemnify, protect and defend Landlord against any loss or damage to the Building or Premises and against injury to any persons
caused by Tenant’s actions pursuant to this Section 6.1. 
 6.2    Freight Elevators.
Landlord shall, consistent with its obligations to other tenants of the Building, make the freight elevator reasonably available to Tenant in connection with initial decorating, furnishing and moving into the Premises. 

6.3    Tenant’s Representative. Tenant has designated Dave Matthews, Chief Financial Officer
as its sole representative with respect to the matters set forth in this Tenant Work Letter, who, until further notice to Landlord, shall have full authority and responsibility to act on behalf of the Tenant as required in this Tenant Work Letter.

 6.4    Landlord’s Representative. Landlord has designated Ken Richter of PMA, Inc. as its
sole representative with respect to the matters set forth in this Tenant Work Letter, who, until further notice to Tenant, shall have full authority and responsibility to act on behalf of the Landlord as required in this Tenant Work Letter. 

6.5    Tenant’s Agents. All contractors, subcontractors, laborers, materialmen, and suppliers
retained by Tenant in connection with the Tenant Improvements shall be union labor in compliance with the then existing master labor agreements. 

6.6    Time of the Essence in This Tenant Work Letter. Unless otherwise indicated, all references
herein to a “number of days” shall mean and refer to calendar days. In all instances where Tenant is required to approve or deliver an item, if no written notice of approval is given or the item is not delivered within the stated time
period, at Landlord’s sole option, at the end of such period the item shall automatically be deemed approved or delivered by Tenant and the next succeeding time period shall commence. 

6.7    Tenant’s Lease Default. Notwithstanding any provision to the contrary contained in this
Lease, if an event of default as described in this Lease beyond any applicable cure period has occurred at any time on or before the Substantial Completion of the Premises, then (i) in addition to all other rights and remedies granted to
Landlord pursuant to this Lease, Landlord shall have the right to cause Contractor to cease the construction of the Premises (in which case, Tenant shall be responsible for any delay in the Substantial Completion of the Premises caused by such work
stoppage as set forth in Section 4 of this Tenant Work Letter), and (ii) all other obligations of Landlord under the terms of this Tenant Work Letter shall be forgiven until such time as such default is cured pursuant to the terms of this
Lease. 
 6.8    Cooperation by Tenant. Tenant acknowledges that the timing of the completion of
the Approved Work Drawings and the Tenant Improvements is of the utmost importance to Landlord. Accordingly, Tenant hereby agrees to fully and diligently cooperate with all reasonable requests by Landlord in connection with or related to the design
and construction of the Tenant Improvements, and in connection therewith, shall respond to Landlord’s requests for information and/or approvals, except as specifically set forth herein to the contrary, within three (3) business days
following request by Landlord. 

  

					
		  		  	HCP, INC.
		  	EXHIBIT B-2	  	[10355 Science Center Drive]
		  	-4-	  	[GenomeDx Biosciences, Corp.]

 EXHIBIT B-3 

TENANT WORK LETTER FOR DELAYED OCCUPANCY PREMISES 

This Tenant Work Letter shall set forth the terms and conditions relating to the construction of the tenant improvements in
the Delayed Occupancy Premises. The terms of this Tenant Work Letter shall not be applicable to the Initial Occupancy Premises. This Tenant Work Letter is essentially organized chronologically and addresses the issues of the construction of the
Delayed Occupancy Premises, in sequence, as such issues will arise during the actual construction of the Delayed Occupancy Premises. All references in this Tenant Work Letter to Articles or Sections of “this Lease” shall mean the relevant
portion of Articles 1 through 29 of the Lease to which this Tenant Work Letter is attached as Exhibit B and of which this Tenant Work Letter forms a part, and all references in this Tenant Work Letter to Sections of “this Tenant Work
Letter” shall mean the relevant portion of Sections 1 through 6 of this Tenant Work Letter. 
 SECTION 1 

LANDLORD’S INITIAL CONSTRUCTION IN THE DELAYED OCCUPANCY PREMISES 

Landlord has constructed, at its sole cost and expense, the base, shell, and core (i) of the Delayed Occupancy Premises
and (ii) of the floor of the Building on which the Delayed Occupancy Premises is located (collectively, the “Base, Shell, and Core”). The Base, Shell and Core shall consist of those portions of the Delayed Occupancy Premises
which were in existence prior to the construction of the tenant improvements in the Delayed Occupancy Premises for the prior tenant of the Delayed Occupancy Premises. Notwithstanding anything set forth in this Tenant Work Letter to the contrary,
Tenant shall accept the Base, Shell and Core from Landlord in their presently existing, “as-is” condition. 

SECTION 2 
 TENANT
IMPROVEMENTS 
 2.1    Tenant Improvement Allowance. Provided that Tenant has
satisfied the Financial Condition set forth in Section 21.2 of the Lease, then Tenant shall be entitled to a one-time tenant improvement allowance (the “Tenant Improvement Allowance”) in
the amount of $70.00 per usable square foot of the Delayed Occupancy Premises for the costs relating to the initial design and construction of Tenant’s improvements which are permanently affixed (including furniture, equipment and equipment
attached to the walls, ceiling or slab) to the Delayed Occupancy Premises (the “Tenant Improvements”); provided that Tenant may in its sole discretion elect to apply up to $10,000.00 of the Tenant Improvement Allowance to any fees
or other expenses payable to Tenant’s construction manager in connection with any of the Tenant Improvements. Subject to Section 2.3 below, in no event shall Landlord be obligated to make disbursements pursuant to this Tenant Work Letter
if Tenant fails to satisfy the Financial Condition set forth in Section 21.2 of the Lease, and, if Tenant does satisfy the Financial Condition set forth in Section 21.2 of the Lease, then in no event shall Landlord be obligated to make
disbursements pursuant to this Tenant Work Letter in a total amount which exceeds the Tenant Improvement Allowance. Subject to Section 2.3 below, in the event that the Tenant Improvement Allowance is not fully utilized by Tenant on or before
the second (2nd) anniversary of the Lease Commencement Date, then such unused amounts shall revert to Landlord, and Tenant shall have no further rights with respect thereto. Any Tenant Improvements that require the use of Building risers, raceways,
shafts and/or conduits, shall be subject to Landlord’s reasonable rules, regulations, and restrictions, including the requirement that any cabling vendor must be selected from a list provided by Landlord, and that the amount and location of any
such cabling must be reasonably approved by Landlord. All Tenant Improvements for which the Tenant Improvement Allowance has been made available shall be deemed Landlord’s property under the terms of the Lease; provided, however, Landlord may,
by written notice to Tenant at the time Landlord approves the Final Working Drawings, require Tenant, at Tenant’s expense, to remove any Tenant Improvements and to repair any damage to the Delayed Occupancy Premises and Building caused by such
removal and return the affected portion of the Delayed Occupancy Premises to their condition existing prior to the installment of such Tenant Improvements; provided further, however, 

  

					
		  		  	HCP, INC.
		  	EXHIBIT B-3	  	[10355 Science Center Drive]
		  	-1-	  	[GenomeDx Biosciences, Corp.]

 
Landlord shall not require Tenant to remove any Tenant Improvement to the extent the same are materially consistent with the Tenant Improvements initially construction in the lab portion of the
Initial Occupancy Premises. 
 2.2    Disbursement of the Tenant Improvement Allowance.
Except as otherwise set forth in this Tenant Work Letter, the Tenant Improvement Allowance shall be disbursed by Landlord (each of which disbursements shall be made pursuant to Landlord’s disbursement process) only for the following items and
costs (collectively, the “Tenant Improvement Allowance Items”): 
 2.2.1    Payment of
the fees of the “Architect” and the “Engineers,” as those terms are defined in Section 3.1 of this Tenant Work Letter, which fees shall, notwithstanding anything to the contrary contained in this Tenant
Work Letter, not exceed an aggregate amount equal to $6.00 per rentable square foot of the Delayed Occupancy Premises, and payment of the fees incurred by, and the cost of documents and materials supplied by, Landlord and Landlord’s consultants
in connection with the preparation and review of the “Construction Drawings,” as that term is defined in Section 3.1 of this Tenant Work Letter; 

2.2.2    The payment of plan check, permit and license fees relating to construction of the Tenant
Improvements; 
 2.2.3    The cost of construction of the Tenant Improvements, including, without
limitation, testing and inspection costs, freight elevator usage, hoisting and trash removal costs, and contractors’ fees and general conditions; 

2.2.4    The cost of any changes in the Base, Shell and Core when such changes are required by the
Construction Drawings (including if such changes are due to the fact that such work is prepared on an unoccupied basis), such cost to include all direct architectural and/or engineering fees and expenses incurred in connection therewith; 

2.2.5    The cost of any changes to the Construction Drawings or Tenant Improvements required by all
applicable building codes (the “Code”); 
 2.2.6    The cost of connection of the
Delayed Occupancy Premises to the Building’s energy management systems; 
 2.2.7    The cost of the
“Landlord Supervision Fee,” as that term is defined in Section 4.3.2 of this Tenant Work Letter; 

2.2.8    Sales and use taxes and Title 24 fees; and 

2.2.9    All other costs to be expended by Landlord in connection with the construction of the Tenant
Improvements. 
 2.3    Disbursement at End of Term. Notwithstanding anything to the
contrary in this Section 2, in the event that (i) Landlord did not pay to Tenant the Tenant Improvement Allowance during the Lease Term by virtue of Tenant’s failure to satisfy the Financial Condition, (ii) Tenant nevertheless
constructed some or all of the Tenant Improvements contemplated by this Tenant Work Letter, and (iii) this Lease is not terminated early due to a default by Tenant, then promptly following the Lease Expiration Date, Landlord shall pay to Tenant
an amount equal to the amount spent by Tenant for Tenant Improvement Allowance Items (in accordance with the other terms of this Tenant Work Letter), up to the amount of the Tenant Improvement Allowance. 

2.4    Standard Tenant Improvement Package. Landlord has established specifications (the
“Specifications”) for the Building standard components to be used in the construction of the Tenant Improvements in the Delayed Occupancy Premises (collectively, the “Standard Improvement Package”), which
Specifications shall be supplied to Tenant by Landlord. The quality of Tenant Improvements shall be equal to or of greater quality than the quality of the Specifications, provided that Landlord may, at Landlord’s option, require the Tenant
Improvements to comply with certain reasonable Specifications. Landlord may make reasonable changes to the Specifications for 

  

					
		  		  	HCP, INC.
		  	EXHIBIT B-3	  	[10355 Science Center Drive]
		  	-2-	  	[GenomeDx Biosciences, Corp.]

 
the Standard Improvement Package from time to time; provided that the Specifications shall be consistent with the Space Plan attached as Schedule 1 to Exhibit
B-2 of this Lease. 
 SECTION 3 

CONSTRUCTION DRAWINGS 

3.1    Selection of Architect/Construction Drawings. Tenant shall retain an architect/space
planner mutually and reasonably acceptable to Landlord and Tenant (the “Architect”) to prepare the “Construction Drawings,” as that term is defined in this Section 3.1. Tenant shall retain the engineering consultants
designated by Landlord (the “Engineers”) to prepare all plans and engineering working drawings relating to the structural, mechanical, electrical, plumbing, HVAC, life safety, and sprinkler work of the Tenant Improvements. The plans
and drawings to be prepared by Architect and the Engineers hereunder shall be known collectively as the “Construction Drawings.” All Construction Drawings shall comply with the drawing format and specifications as determined by Landlord,
and shall be subject to Landlord’s reasonable approval. Tenant and Architect shall verify, in the field, the dimensions and conditions as shown on the relevant portions of the base Building plans, and Tenant and Architect shall be solely
responsible for the same, and Landlord shall have no responsibility in connection therewith. Landlord’s review of the Construction Drawings as set forth in this Section 3, shall be for its sole purpose and shall not imply Landlord’s
review of the same, or obligate Landlord to review the same, for quality, design, Code compliance or other like matters. Accordingly, notwithstanding that any Construction Drawings are reviewed by Landlord or its space planner, architect, engineers
and consultants, and notwithstanding any advice or assistance which may be rendered to Tenant by Landlord or Landlord’s space planner, architect, engineers, and consultants, Landlord shall have no liability whatsoever in connection therewith
and shall not be responsible for any omissions or errors contained in the Construction Drawings, and Tenant’s waiver and indemnity set forth in this Lease shall specifically apply to the Construction Drawings. 

3.2    Final Space Plan. Tenant and the Architect shall prepare the final space plan for
Tenant Improvements in the Delayed Occupancy Premises (collectively, the “Final Space Plan”), which Final Space Plan shall include a layout and designation of all offices, rooms and other partitioning, their intended use, and
equipment to be contained therein, and shall deliver four (4) copies signed by Tenant of the Final Space Plan to Landlord for Landlord’s reasonable approval. 

3.3    Final Working Drawings. Tenant, the Architect and the Engineers shall complete the
architectural and engineering drawings for the Delayed Occupancy Premises, and the final architectural working drawings in a form which is complete to allow subcontractors to bid on the work and to obtain all applicable permits (collectively, the
“Final Working Drawings”) and shall submit two (2) copies signed by Tenant of the same to Landlord for Landlord’s reasonable approval. 

3.4    Permits. The Final Working Drawings shall be approved by Landlord (the
“Approved Working Drawings”) prior to the commencement of the construction of the Tenant Improvements. Tenant shall submit the Approved Working Drawings to the appropriate municipal authorities for all applicable building permits
necessary to allow “Contractor,” as that term is defined in Section 4. 1, below, to commence and fully complete the construction of the Tenant Improvements (the “Permits”), and, in connection therewith, Tenant shall
coordinate with Landlord in order to allow Landlord, at its option, to take part in all phases of the permitting process and shall supply Landlord, as soon as possible, with all plan check numbers and dates of submittal and obtain the Permits on or
before the date set forth in Schedule 1. Notwithstanding anything to the contrary set forth in this Section 3.4, Tenant hereby agrees that neither Landlord nor Landlord’s consultants shall be responsible for obtaining any building permit
or certificate of occupancy for the Delayed Occupancy Premises and that the obtaining of the same shall be Tenant’s responsibility; provided however that Landlord shall, in any event, cooperate with Tenant in executing permit applications and
performing other ministerial acts reasonably necessary to enable Tenant to obtain any such permit or certificate of occupancy. No changes, modifications or alterations in the Approved Working Drawings may be made without the prior written consent of
Landlord, provided that Landlord may withhold its consent, in its sole discretion, to any change in the Approved Working Drawings if such change is reasonably likely to directly or indirectly delay the “Substantial Completion” (as defined
in Exhibit B-2 above) of the Delayed Occupancy Premises as that term is defined in Section 5.1 of this Tenant Work Letter. 

  

					
		  		  	HCP, INC.
		  	EXHIBIT B-3	  	[10355 Science Center Drive]
		  	-3-	  	[GenomeDx Biosciences, Corp.]

 3.5    Time Deadlines. Tenant shall use
its best, good faith, efforts and all due diligence to cooperate with the Architect, the Engineers, and Landlord to complete all phases of the Construction Drawings and the permitting process and to receive the permits, and with Contractor for
approval of the “Cost Proposal,” as that term is defined in Section 4.2 of this Tenant Work Letter, as soon as possible after the execution of this Lease, and, in that regard, shall meet with Landlord on a scheduled basis to be
reasonably determined by Landlord, to discuss Tenant’s progress in connection with the same. 
 SECTION 4 

CONSTRUCTION OF THE TENANT IMPROVEMENTS 

4.1    Contractor. A contractor mutually and reasonably acceptable to Landlord and Tenant
(“Contractor”) shall construct the Tenant Improvements. 
 4.2    Cost
Proposal. After the Approved Working Drawings are signed by Landlord and Tenant, Landlord shall provide Tenant with a cost proposal in accordance with the Approved Working Drawings, which cost proposal shall include, as nearly as possible,
the cost of all Tenant Improvement Allowance Items to be incurred by Tenant in connection with the design and construction of the Tenant Improvements (the “Cost Proposal”). Tenant shall approve and deliver the Cost Proposal to
Landlord within five (5) business days of the receipt of the same, and upon receipt of the same by Landlord, Landlord shall be released by Tenant to purchase the items set forth in the Cost Proposal and to commence the construction relating to
such items. The date by which Tenant must approve and deliver the Cost Proposal to Landlord shall be known hereafter as the “Cost Proposal Delivery Date”. 

4.3    Construction of Tenant Improvements by Contractor under the Supervision of Landlord.

 4.3.1    Over-Allowance Amount. On the Cost Proposal Delivery Date, Tenant shall deliver
to Landlord cash in an amount (the “Over-Allowance Amount”) equal to the difference between (i) the amount of the Cost Proposal and (ii) the amount of the Tenant Improvement Allowance. The Over-Allowance Amount shall be
disbursed by Landlord prior to the disbursement of any then remaining portion of the Tenant Improvement Allowance, and such disbursement shall be pursuant to the same procedure as the Tenant Improvement Allowance. In the event that, after the Cost
Proposal Delivery Date, any revisions, changes, or substitutions shall be made to the Construction Drawings or the Tenant Improvements, any additional costs which arise in connection with such revisions, changes or substitutions or any other
additional costs shall be paid by Tenant to Landlord promptly upon Landlord’s request as an addition to the Over-Allowance Amount. 

4.3.2    Landlord’s Retention of Contractor. Landlord shall independently retain
Contractor to construct the Tenant Improvements in accordance with the Approved Working Drawings (subject to the following sentence) and the Cost Proposal and Landlord shall supervise the construction by Contractor, and Tenant shall pay a
construction supervision and management fee (the “Landlord Supervision Fee”) to Landlord in an amount equal to the sum of (i) an amount equal to six percent (6%) of the first $100,000.00 of the Tenant Improvement Allowance plus
the Over-Allowance Amount (as such Over-Allowance Amount may increase pursuant to the terms of this Tenant Work Letter), and (ii) an amount equal to three percent (3%) of any amount of the Tenant Improvement Allowance plus the Over-Allowance
Amount (as such Over-Allowance Amount may increase pursuant to the terms of this Tenant Work Letter) that exceeds $100,000.00. In the event of a conflict between the Approved Working Drawings and Landlord’s construction rules and regulations,
Landlord shall determine which shall prevail, making a reasonable effort to preserve the result of the Approved Working Drawings. Notwithstanding anything set forth in this Tenant Work Letter to the contrary, construction of the Tenant Improvements
shall not commence until (a) Landlord has a fully executed and delivered contract with Contractor for the construction of the Tenant Improvements, (b) Tenant has procured and delivered to Landlord a copy of all Permits, and (c) Tenant
has delivered to Landlord the Over-Allowance Amount. 
 4.3.3    Contractor’s Warranties and
Guaranties. Landlord hereby assigns to Tenant all warranties and guaranties by Contractor relating to the Tenant Improvements, and Tenant hereby waives all claims against Landlord relating to, or arising out of the construction of, the
Tenant Improvements. 

  

					
		  		  	HCP, INC.
		  	EXHIBIT B-3	  	[10355 Science Center Drive]
		  	-4-	  	[GenomeDx Biosciences, Corp.]

 4.3.4    Tenant’s Covenants. Tenant
hereby indemnifies Landlord for any loss, claims, damages or delays arising from the actions of Architect on the Delayed Occupancy Premises or in the Building. Within ten (10) days after completion of construction of the Tenant Improvements,
Tenant shall cause Contractor and Architect to cause a Notice of Completion to be recorded in the office of the County Recorder of the county in which the Building is located in accordance with Section 3093 of the Civil Code of the State of
California or any successor statute and furnish a copy thereof to Landlord upon recordation, failing which, Landlord may itself execute and file the same on behalf of Tenant as Tenant’s agent for such purpose. In addition, within thirty
(30) days following the Substantial Completion of the Delayed Occupancy Premises, Tenant shall have prepared and delivered to the Building two (2) copies signed by Tenant of the “as built” plans and specifications (including all
working drawings) for the Tenant Improvements. 
 SECTION 5 

INTENTIONALLY OMITTED 

SECTION 6 

MISCELLANEOUS 

6.1    Tenant’s Entry Into the Delayed Occupancy Premises Prior to Substantial
Completion. Provided that Tenant and its agents do not interfere with Contractor’s work in the Building and the Delayed Occupancy Premises, Contractor shall allow Tenant access to the Delayed Occupancy Premises prior to the Substantial
Completion of the Delayed Occupancy Premises for the purpose of Tenant installing overstandard equipment or fixtures (including Tenant’s data and telephone equipment) in the Delayed Occupancy Premises. Prior to Tenant’s entry into the
Delayed Occupancy Premises as permitted by the terms of this Section 6.1, Tenant shall submit a schedule to Landlord and Contractor, for their reasonable approval, which schedule shall detail the timing and purpose of Tenant’s entry.
Tenant shall hold Landlord harmless from and indemnify, protect and defend Landlord against any loss or damage to the Building or Delayed Occupancy Premises and against injury to any persons caused by Tenant’s actions pursuant to this
Section 6.1. 
 6.2    Freight Elevators. Landlord shall, consistent with its
obligations to other tenants of the Building, make the freight elevator reasonably available to Tenant in connection with initial decorating, furnishing and moving into the Delayed Occupancy Premises. 

6.3    Tenant’s Representative. Tenant has designated Dave Matthews, Chief Financial
Officer as its sole representative with respect to the matters set forth in this Tenant Work Letter, who, until further notice to Landlord, shall have full authority and responsibility to act on behalf of the Tenant as required in this Tenant Work
Letter. 
 6.4    Landlord’s Representative. Landlord has designated Landlord has
designated Ken Richter of PMA, Inc. as its sole representative with respect to the matters set forth in this Tenant Work Letter, who, until further notice to Tenant, shall have full authority and responsibility to act on behalf of the Landlord as
required in this Tenant Work Letter. 
 6.5    Tenant’s Agents. All contractors,
subcontractors, laborers, materialmen, and suppliers retained directly by Tenant shall be from a list of supplied by Landlord and shall all be union labor in compliance with the then existing master labor agreements. 

6.6    Time of the Essence in This Tenant Work Letter. Unless otherwise indicated, all
references herein to a “number of days” shall mean and refer to calendar days. In all instances where Tenant is required to approve or deliver an item, if no written notice of approval is given or the item is not delivered within the
stated time period, at Landlord’s sole option, at the end of such period the item shall automatically be deemed approved or delivered by Tenant and the next succeeding time period shall commence. 

  

					
		  		  	HCP, INC.
		  	EXHIBIT B-3	  	[10355 Science Center Drive]
		  	-5-	  	[GenomeDx Biosciences, Corp.]

 6.7    Tenant’s Lease Default.
Notwithstanding any provision to the contrary contained in this Lease, if an event of default as described in this Lease, or a default by Tenant under this Tenant Work Letter, beyond any applicable cure periods has occurred at any time on or before
the Substantial Completion of the Delayed Occupancy Premises, then (i) in addition to all other rights and remedies granted to Landlord pursuant to this Lease, Landlord shall have the right to withhold payment of all or any portion of the
Tenant Improvement Allowance and/or Landlord may cause Contractor to cease the construction of the Delayed Occupancy Premises (in which case, Tenant shall be responsible for any delay in the Substantial Completion of the Delayed Occupancy Premises
caused by such work stoppage as set forth in Section 5 of this Tenant Work Letter), and (ii) all other obligations of Landlord under the terms of this Tenant Work Letter shall be forgiven until such time as such default is cured pursuant
to the terms of this Lease. 

  

					
		  		  	HCP, INC.
		  	EXHIBIT B-3	  	[10355 Science Center Drive]
		  	-6-	  	[GenomeDx Biosciences, Corp.]

 EXHIBIT C 

10355 SCIENCE CENTER DRIVE 

NOTICE OF LEASE TERM DATES 

To:                     
                  

                       
                      

                       
                      

                       
                      
  

	 	Re:	 Lease dated             ,
20     between                     , a
                     (“Landlord”), and
                    , a
                     (“Tenant”) concerning Suite
             on floor(s)              of the building located at
                    , California. 

Gentlemen: 
 In
accordance with the Lease (the “Lease”), we wish to advise you and/or confirm as follows: 
  

	 	1.	 The Lease Term shall commence on or has commenced on
                     for a term of
                     ending on
                    . 

  

	 	2.	 Rent commenced to accrue on
                    , in the amount of
                    . 

  

	 	3.	 If the Lease Commencement Date is other than the first day of the month, the first billing will contain a
pro rata adjustment. Each billing thereafter, with the exception of the final billing, shall be for the full amount of the monthly installment as provided for in the Lease. 

 

	 	4.	 Your rent checks should be made payable to
                     at
                    . 

  

	 	5.	 The exact number of rentable/usable square feet within the Premises is
                 square feet. 

  

	 	6.	 Tenant’s Share as adjusted based upon the exact number of usable square feet within the Premises is
                %. 

  

	
	 “Landlord”:

	
	
                       
                                         
                      ,

	
a                       
                                         
                    

	
	
By:                      
                                         
                 

	
Its:                   
                                         
               

  

					
		  		  	HCP, INC.
		  	EXHIBIT C	  	[10355 Science Center Drive]
		  	-1-	  	[GenomeDx Biosciences, Corp.]

	
	 Agreed to and Accepted as 
of            ,
20    .

	
	 “Tenant”:

	
	
                      
                                         
                       

	
a                       
                                         
                    

	
	
By:                      
                                         
                 

	
Its:                   
                                         
               

  

					
		  		  	HCP, INC.
		  	EXHIBIT C	  	[10355 Science Center Drive]
		  	-2-	  	[GenomeDx Biosciences, Corp.]

 EXHIBIT D 

10355 SCIENCE CENTER DRIVE 

FORM OF TENANT’S ESTOPPEL CERTIFICATE 

The undersigned, as Tenant under that certain Lease (the “Lease”) made and entered into as of
            , 20     by and between
                     as Landlord, and the undersigned as Tenant, for Premises consisting of the entire office building located at
                            , California, certifies as follows: 

1.        Attached hereto as Exhibit A is a true and correct copy of the
Lease and all amendments and modifications thereto. The documents contained in Exhibit A represent the entire agreement between the parties as to the Premises. 

2.        The undersigned currently occupies the Premises described in the Lease, the
Lease Commencement Date commenced on                     , and the Lease Expiration Date will occur on
             

3.        The undersigned has no option to terminate or cancel the Lease or to
purchase all or any part of the Premises, the Building and/or the Project, except as follows:                     . 

4.        Base Rent became payable on
                    . 

5.        The Lease is in full force and effect and has not been modified,
supplemented or amended in any way except as provided in Exhibit A. 

6.        Tenant has not transferred, assigned, or sublet any portion of the Premises
nor entered into any license or concession agreements with respect thereto, except as follows:                      

7.        All monthly installments of Base Rent, all Additional Rent and all monthly
installments of estimated Additional Rent have been paid when due through                     . The current monthly installment of Base Rent
is $            . 

8.        To Tenant’s knowledge, all conditions of the Lease to be performed by
Landlord necessary to the enforceability of the Lease have been satisfied and Landlord is not in default thereunder and the undersigned has not delivered any notice to Landlord regarding a default by Landlord thereunder, except as follows:
                    . 

9.        The Lease does not require Landlord to provide any rental concessions or to
pay any leasing brokerage commissions, except as follows:                     . 

10.        No rental has been paid more than thirty (30) days in advance and no
security has been deposited with Landlord except as provided in the Lease, except as follows:                     . 

11.        As of the date hereof, there are no existing defenses or offsets, or, to
Tenant’s knowledge, claims or any basis for a claim, that the undersigned has against Landlord, except as follows:                     .

 12.        If Tenant is a corporation or partnership, Tenant hereby represents
and warrants that Tenant is a duly formed and existing entity qualified to do business in California and that Tenant has full right and authority to execute and deliver this Estoppel Certificate and that each person signing on behalf of Tenant is
authorized to do so. 
 13.        There are no actions pending against the
undersigned under the bankruptcy or similar laws of the United States or any state. 

  

					
		  		  	HCP, INC.
		  	EXHIBIT D	  	[10355 Science Center Drive]
		  	-1-	  	[GenomeDx Biosciences, Corp.]

 14.        To the undersigned’s
knowledge, all tenant improvement work to be performed by Landlord under the Lease has been completed in accordance with the Lease and has been accepted by the undersigned and all reimbursements and allowances due to the undersigned under the Lease
in connection with any tenant improvement work have been paid in full, except as follows:                     . 

15.        All work (if any) in the common areas required by the Lease to be completed
by Landlord has been completed and all parking spaces required by the Lease have been furnished and/or all parking ratios required by the Lease have been met, except as follows:
                    . 

The undersigned acknowledges that this Estoppel Certificate may be delivered to Landlord or to a prospective mortgagee or
prospective purchaser, and acknowledges that said prospective mortgagee or prospective purchaser will be relying upon the statements contained herein in making the loan or acquiring the property of which the Premises are a part and that receipt by
it of this certificate is a condition of making such loan or acquiring such property. 
 Executed at
                     on the          day of
            , 200    . 
  

	
	 “Tenant”:

	
	
                       
                                         
                ,

	
a                       
                                         
              

	
	
By:                      
                                         
           

	
Its:                   
                                         
       

	
	
By:                      
                                         
           

	
Its:                   
                                         
      

  

					
		  		  	HCP, INC.
		  	EXHIBIT D	  	[10355 Science Center Drive]
		  	-2-	  	[GenomeDx Biosciences, Corp.]

 EXHIBIT E 

10355 SCIENCE CENTER DRIVE 

ENVIRONMENTAL QUESTIONNAIRE 

ENVIRONMENTAL QUESTIONNAIRE 

FOR COMMERCIAL AND INDUSTRIAL PROPERTIES 
  

			
	 Property Name:
	  	 
	 Property Address:
	  	 

 Instructions: The following questionnaire is to be completed by the Lessee
representative with knowledge of the planned operations for the specified building/location. Please print clearly and attach additional sheets as necessary. 

1.0    PROCESS INFORMATION 

Describe planned use, and include brief description of manufacturing processes employed. 

 

	
	  

	 
	 

 2.0     HAZARDOUS MATERIALS  

Are hazardous materials used or stored? If so, continue with the next question. If not, go to Section 3.0. 

 

	2.1	 Are any of the following materials handled on the
Property?                                        
                                         
                                Yes ☐ No ☐ 

(A material is handled if it is used, generated, processed, produced, packaged, treated, stored, emitted, discharged, or disposed.) If so,
complete this section. If this question is not applicable, skip this section and go on to Section 5.0. 
  

							
		 	 ☐ Explosives
	  	 ☐ Fuels
	  	 ☐ Oils

		 	 ☐ Solvents
	  	 ☐ Oxidizers
	  	 ☐ Organics/Inorganics

		 	 ☐ Acids
	  	 ☐ Bases
	  	 ☐ Pesticides

		 	 ☐ Gases
	  	 ☐ PCBs
	  	 ☐ Radioactive Materials

		 	 ☐ Other (please specify)
	  		  	

  

	2-2.	 If any of the groups of materials checked in Section 2.1, please list the specific material(s), use(s),
and quantity of each chemical used or stored on the site in the Table below. If convenient, you may substitute a chemical inventory and list the uses of each of the chemicals in each category separately. 

 

																			
	Material    	  	        Physical State (Solid, Liquid, or Gas)	  	Usage	 	  	Container Size	 	  	Number of Containers	 	  	Total Quantity	 
	 	  	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	 	  	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	 	  	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	 	  	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	 	  	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 

  

					
		  		  	HCP, INC.
		  	EXHIBIT E	  	[10355 Science Center Drive]
		  	-1-	  	[GenomeDx Biosciences, Corp.]

	2-3.	 Describe the planned storage area location(s) for these materials. Please include site maps and drawings as
appropriate. 

  

	
	  

	 
	 

 3.0     HAZARDOUS WASTES 
  

			
	 Are hazardous wastes generated?
	  	Yes ☐ No ☐

 If yes, continue with the next question. If not, skip this section and go to section 4.0. 

 

	3.1	 Are any of the following wastes generated, handled, or disposed of (where applicable) on the Property?

  

							
		 	 ☐ Hazardous wastes
	  	 ☐ Industrial Wastewater
	  	
		 	 ☐ Waste oils
	  	 ☐ PCBs
	  	
		 	 ☐ Air emissions
	  	 ☐ Sludges
	  	
		 	 ☐ Regulated Wastes
	  	 ☐ Other (please specify)
	  	

  

	3-2.	 List and quantify the materials identified in Question 3-1 of this
section. 

  

											
	
WASTE
 GENERATED
	  	 RCRA listed

Waste?
	  	SOURCE	  	
APPROXIMATE          

MONTHLY QUANTITY          
	  	 WASTE

CHARACTERIZATION
	  	DISPOSITION
	
    
	  	 	  	 	  	 	  	 	  	 
	
    
	  	 	  	 	  	 	  	 	  	 
	
    
	  	 	  	 	  	 	  	 	  	 
	
    
	  	 	  	 	  	 	  	 	  	 

  

	3-3.	 Please include name, location, and permit number (e.g. EPA ID No.) for transporter and disposal facility, if
applicable). Attach separate pages as necessary. 

  

							
	Transporter/Disposal Facility Name	  	Facility Location	  	Transporter (T) or Disposal (D) Facility	  	Permit Number
	     
	  	 	  	 	  	 
	     
	  	 	  	 	  	 
	     
	  	 	  	 	  	 
	     
	  	 	  	 	  	 

  

	3-4.	 Are pollution controls or monitoring employed in the process to prevent or minimize the release of wastes
into the environment?    Yes ☐ No ☐ 

  

	3-5.	 If so, please describe. 

 

	
	  

	 
	 

 4.0    USTS/ASTS 

  

					
		  		  	HCP, INC.
		  	EXHIBIT E	  	[10355 Science Center Drive]
		  	-2-	  	[GenomeDx Biosciences, Corp.]

	4.1	 Are underground storage tanks (USTs), aboveground storage tanks (ASTs), or associated pipelines used for the
storage of petroleum products, chemicals, or liquid wastes present on site (lease renewals) or required for planned operations (new tenants)? Yes     No     

If not, continue with section 5.0. If yes, please describe capacity, contents, age, type of the USTs or ASTs, as well any
associated leak detection/spill prevention measures. Please attach additional pages if necessary. 
  

									
	 Capacity

 
	 	 Contents

 
	 	 Year

Installed
  
	  	 Type
(Steel,
Fiberglass, etc)
  
	  	
Associated Leak Detection / Spill

Prevention Measures*
  

	        	 	        	 	        	  	        	  	        
	        	 	        	 	        	  	        	  	        
	        	 	        	 	        	  	        	  	        

  

	*Note:	 The following are examples of leak detection / spill prevention measures: 

	 	Integrity	 testing
                Inventory reconciliation        Leak detection system 

	 	Overfill	 spill protection    Secondary
containment          Cathodic protection 

  

	4-2.	 Please provide copies of written tank integrity test results and/or monitoring documentation, if available.

  

			
	 4-3.  Is the UST/AST
registered and permitted with the appropriate regulatory agencies?
	  	Yes ☐ No ☐

 If so, please attach a copy of the required permits. 

 

	4-4.	 If this Questionnaire is being completed for a lease renewal, and if any of the USTs/ASTs have leaked,
please state the substance released, the media(s) impacted (e.g., soil, water, asphalt, etc.), the actions taken, and all remedial responses to the incident. 

  

	
	 
	 
	 

  

			
	 4-5.  If this Questionnaire is
being completed for a lease renewal, have USTs/ASTs been removed from the Property?
	  	Yes ☐ No ☐

 If yes, please provide any official closure letters or reports and supporting documentation
(e.g., analytical test results, remediation report results, etc.). 
  

	4-6.	 For Lease renewals, are there any above or below ground pipelines on site used to transfer chemicals or
wastes? 

 Yes ☐ No ☐ 

For new tenants, are installations of this type required for the planned operations? 

Yes ☐ No ☐ 
 If yes to
either question, please describe. 
  

	
	 
	 
	 

 5.0     ASBESTOS CONTAINING BUILDING MATERIALS 

Please be advised that an asbestos survey may have been performed at the Property. If provided, please review the information that identifies
the locations of known asbestos containing material or presumed asbestos containing 

  

					
		  		  	HCP, INC.
		  	EXHIBIT E	  	[10355 Science Center Drive]
		  	-3-	  	[GenomeDx Biosciences, Corp.]

 
material. All personnel and appropriate subcontractors should be notified of the presence of these materials, and informed not to disturb these materials. Any activity that involves the
disturbance or removal of these materials must be done by an appropriately trained individual/contractor. 
 6.0     REGULATORY

  

			
	 6-1.  Does the operation have
or require a National Pollutant Discharge Elimination System (NPDES) or equivalent permit?
	  	Yes ☐ No ☐

 If so, please attach a copy of this permit. 

 

			
	 6-2.  Has a Hazardous
Materials Business Plan been developed for the site?
	  	Yes ☐ No ☐

 If so, please attach a copy. 

CERTIFICATION 
 I am familiar with the
real property described in this questionnaire. By signing below, I represent and warrant that the answers to the above questions are complete and accurate to the best of my knowledge. I also understand that Lessor will rely on the completeness and
accuracy of my answers in assessing any environmental liability risks associated with the property. 
  

			
	 Signature:
	 	  

	 Name:
	 	  

	 Title:
	 	  

	 Date:
	 	  

	 Telephone:
	 	  

  

					
		  		  	HCP, INC.
		  	EXHIBIT E	  	[10355 Science Center Drive]
		  	-4-	  	[GenomeDx Biosciences, Corp.]

 EXHIBIT F 

10355 SCIENCE CENTER DRIVE 

FORM OF GUARANTY OF LEASE 

THIS GUARANTY OF LEASE (this “Guaranty”) is made as of
            , 20    , by                     , a
                     (the “Guarantor”), whose address is as set forth in Section 10 hereof, in favor of TORREY PINES
SCIENCE CENTER LIMITED PARTNERSHIP, Delaware limited partnership (“Landlord”). 
 WHEREAS, Landlord and
GENOMEDX BIOSCIENCES CORP., a Delaware corporation (“Tenant”) have entered into that certain Lease dated September 25, 2014 (the “Lease”) concerning that certain premises commonly known as Suites 4 and 5 and
located on the second (2nd) floor of that certain building located at 10355 Science Center Drive, San Diego, California 92121; and 

WHEREAS, Guarantor has a financial interest in the Tenant; and 

WHEREAS, Tenant would not be entitled to include the cash deposits of Guarantor in determining the Available Cash (as that
term is defined in Section 21.3 of the Lease) pursuant to Sections 21.2 and 21.3 of the Lease if Guarantor did not execute and deliver to Landlord this Guaranty. 

NOW, THEREFORE, for and in consideration, and as a material inducement, of the inclusion of the cash deposits of Guarantor in
determining the Available Cash pursuant to Sections 21.2 and 21.3 of the Lease, Guarantor hereby absolutely, presently, continually, unconditionally and irrevocably guarantees the prompt payment by Tenant of all rentals and other sums
payable by Tenant under the Lease and the faithful and prompt performance by Tenant of each and every one of the terms, conditions and covenants of said Lease to be kept and performed by Tenant, and further agrees as follows: 

1.    It is specifically agreed and understood that the terms, covenants and conditions of the Lease may
be altered, affected, modified, amended, compromised, released or otherwise changed by agreement between Landlord and Tenant, or by course of conduct and Guarantor does guaranty and promise to perform all of the obligations of Tenant under the Lease
as so altered, affected, modified, amended, compromised, released or changed and the Lease may be assigned by or with the consent of Landlord or any assignee of Landlord without consent or notice to Guarantor and that this Guaranty shall thereupon
and thereafter guaranty the performance of said Lease as so changed, modified, amended, compromised, released, altered or assigned. 

2.    This Guaranty shall not be released, modified or affected by failure or delay on the part of
Landlord to enforce any of the rights or remedies of Landlord under the Lease. 
 3.    Guarantor’s
liability under this Guaranty shall continue until all rents due under the Lease have been paid in full in cash and until all other obligations of Tenant to Landlord under the Lease have been satisfied. If all or any portion of Tenant’s
obligations under the Lease is paid or performed by Tenant, the obligations of Guarantor hereunder shall continue and remain in full force and effect in the event that all or any part of such payment(s) or performance(s) is avoided or recovered
directly or indirectly (but only to the extent of such avoidance or recovery) from Landlord as a preference, fraudulent transfer or otherwise. 

4.    Guarantor warrants and represents to Landlord that Guarantor now has and will continue to have full
and complete access to any and all information concerning the Lease, the value of the assets owned or to be acquired by Tenant, Tenant’s financial status and its ability to pay and perform the obligations owed to Landlord under the Lease.
Guarantor further warrants and represents that Guarantor has reviewed and approved copies of the Lease and is fully informed of the remedies Landlord may pursue, with or without notice to Tenant, in the event of default under the Lease. So long as
any of the Guarantor’s obligations hereunder remains unsatisfied or owing to Landlord, 

  

					
		  		  	HCP, INC.
		  	EXHIBIT F	  	[10355 Science Center Drive]
		  	-1-	  	[GenomeDx Biosciences, Corp.]

 
Guarantor shall keep itself sufficiently informed as to all aspects of Tenant’s financial condition relevant to Tenant’s performance of said obligations. 

5.    Guarantor hereby covenants and agrees with Landlord that if a default shall at any time occur in the
payment of any sums due under the Lease by Tenant or in the performance of any other obligation of Tenant under the Lease, Guarantor shall and will forthwith upon demand pay such sums and any arrears thereof, to Landlord in legal currency of the
United States of America for payment of public and private debts, and take all other actions necessary to cure such default and perform such obligations of Tenant. 

6.    The liability of Guarantor under this Guaranty is a guaranty of payment and performance and not of
collectibility, and is not conditioned or contingent upon the genuineness, validity, regularity or enforceability of the Lease or the pursuit by Landlord of any remedies which it now has or may hereafter have with respect thereto, at law, in equity
or otherwise. 
 7.    Guarantor hereby waives and agrees not to assert or take advantage of to the
extent permitted by law: (i) all notices to Guarantor, to Tenant, or to any other person, including, but not limited to, notices of the acceptance of this Guaranty or the creation, renewal, extension, assignment, modification or accrual of any
of the obligations owed to Landlord under the Lease and, except to the extent set forth in Section 9 hereof, enforcement of any right or remedy with respect thereto, and notice of any other matters relating thereto;
(ii) notice of acceptance of this Guaranty; (iii) demand of payment, presentation and protest; (iv) any right to require Landlord to apply to any default any security deposit or other security it may hold under the Lease; (v) any
right or defense that may arise by reason of the incapability, lack of authority, death or disability of Tenant or any other person; (vi) all principles or provisions of law which conflict with the terms of this Guaranty, and (vii) any
other rights and defenses that are or may become available to Guarantor by reason of Sections 2787 through 2855, inclusive, of the California Civil Code. Guarantor further agrees that Landlord may enforce this Guaranty upon the occurrence of a
default under the Lease, notwithstanding any dispute between Landlord and Tenant with respect to the existence of said default or performance of the obligations under the Lease or any counterclaim, set-off or
other claim which Tenant may allege against Landlord with respect thereto. Moreover, Guarantor agrees that Guarantor’s obligations shall not be affected by any circumstances which constitute a legal or equitable discharge of a guarantor or
surety. 
 8.    Guarantor agrees that Landlord may enforce this Guaranty without the necessity of
proceeding against Tenant or any other guarantor. Guarantor hereby waives the right to require Landlord to proceed against Tenant, to proceed against any other guarantor, to exercise any right or remedy under the Lease or to pursue any other remedy
or to enforce any other right. 
 9.    (a)     Guarantor agrees that nothing
contained herein shall prevent Landlord from suing on the Lease or from exercising any rights available to it thereunder and that the exercise of any of the aforesaid rights shall not constitute a legal or equitable discharge of Guarantor. Without
limiting the generality of the foregoing, Guarantor hereby expressly waives any and all benefits under California Civil Code § § 2809, 2810, 2815, 2819, 2821, 2822, 2824, 2839, 2845, 2847, 2848, 2849, 2850, 2855, 2899 and 3433. 

(b)    Guarantor agrees that Guarantor shall have no right of subrogation against Tenant or any right of
contribution against any other guarantor unless and until all amounts due under the Lease have been paid in full and all other obligations under the Lease have been satisfied. Guarantor further agrees that, to the extent the waiver of
Guarantor’s rights of subrogation and contribution as set forth herein is found by a court of competent jurisdiction to be void or voidable for any reason, any rights of subrogation Guarantor may have against Tenant shall be junior and
subordinate to any rights Landlord may have against Tenant. 
 (c)    The obligations of Guarantor under
this Guaranty shall not be altered, limited or affected by any case, voluntary or involuntary, involving the bankruptcy, insolvency, receivership, reorganization, liquidation or arrangement of Tenant or any defense which Tenant may have by reason of
order, decree or decision of any court or administrative body resulting from any such case. Guarantor acknowledges and agrees that any payment which accrues with respect to Tenant’s obligations under the Lease (including, without limitation,
the payment of rent) after the commencement of any such proceeding (or, if any such payment ceases to accrue by operation of law by reason of the commencement of such proceeding, such payment as would have accrued if said proceedings had not been
commenced) shall be included in Guarantor’s obligations hereunder because it is the intention of the parties that said 

  

					
		  		  	HCP, INC.
		  	EXHIBIT F	  	[10355 Science Center Drive]
		  	-2-	  	[GenomeDx Biosciences, Corp.]

 
obligations should be determined without regard to any rule or law or order which may relieve Tenant of any of its obligations under the Lease. Guarantor hereby permits any trustee in bankruptcy,
receiver, debtor-in-possession, assignee for the benefit of creditors or similar person to pay Landlord, or allow the claim of Landlord in respect of, any such payment
accruing after the date on which such proceeding is commenced. Guarantor hereby assigns to Landlord Guarantor’s right to receive any payments (in an amount which is no greater than Tenant’s then-outstanding obligations under the Lease)
from any trustee in bankruptcy, receiver, debtor-in-possession, assignee for the benefit of creditors or similar person by way of dividend, adequate protection payment
or otherwise. 
 10.    Any notice, statement, demand, consent, approval or other communication required
or permitted to be given, rendered or made by either party to the other, pursuant to this Guaranty or pursuant to any applicable law or requirement of public authority, shall be in writing (whether or not so stated elsewhere in this Guaranty) and
shall be deemed to have been properly given, rendered or made only if hand-delivered or sent by first-class mail, postage pre-paid, addressed to the other party at its respective address set forth below, and
shall be deemed to have been given, rendered or made on the day it is hand-delivered or one day after it is mailed, unless it is mailed outside of San Diego County, California, in which case it shall be deemed to have been given, rendered or made on
the third business day after the day it is mailed. By giving notice as provided above, either party may designate a different address for notices, statements, demands, consents, approvals or other communications intended for it. 

 

							
		 	 To Guarantor:
	  	  
	  	
		 		  	  
	  	
		 		  	  
	  	
		 		  	  
	  	
				
		 		  	 (Prior to “Lease Commencement Date,” as that term is defined in Section 3.2 of the Summary of Basic Lease
Information included in the Lease)
	  	
				
		 		  	  
	  	
		 		  	  
	  	
		 		  	  
	  	
		 		  	  
	  	
				
		 		  	 (After the “Lease Commencement Date,” as that term is defined in Section 3.2 of the Summary of Basic
Lease Information included in the Lease)
	  	
				
		 	 To Landlord:
	  	  
	  	
		 		  	  
	  	
		 		  	  
	  	
		 		  	  
	  	

 11.    Guarantor represents and warrants to Landlord as follows: 

(a)    No consent of any other person, including, without limitation, any creditors of Guarantor, and no
license, permit, approval or authorization of, exemption by, notice or report to, or registration, filing or declaration with, any governmental authority is required by Guarantor in connection with this Guaranty or the execution, delivery,
performance, validity or enforceability of this Guaranty and all obligations required hereunder. This Guaranty has been duly executed and delivered by Guarantor, and constitutes the legally valid and binding obligation of Guarantor enforceable
against such Guarantor in accordance with its terms. 
 (b)    The execution, delivery and performance
of this Guaranty will not violate any provision of any existing law or regulation binding on Guarantor, or any order, judgment, award or decree of any court, arbitrator or governmental authority binding on Guarantor, or of any mortgage, indenture,
lease, contract or other agreement, instrument or undertaking to which Guarantor is a party or by which Guarantor or any of Guarantor’s assets may be bound, and will not result in, or require, the creation or imposition of any lien on any of
Guarantor’s property, assets 

  

					
		  		  	HCP, INC.
		  	EXHIBIT F	  	[10355 Science Center Drive]
		  	-3-	  	[GenomeDx Biosciences, Corp.]

 
or revenues pursuant to the provisions of any such mortgage, indenture, lease, contract, or other agreement, instrument or undertaking. 

12.    The obligations of Tenant under the Lease to execute and deliver estoppel statements, as therein
provided, shall be deemed to also require the Guarantor hereunder to do and provide the same relative to Guarantor. 

13.    This Guaranty shall be binding upon Guarantor, Guarantor’s heirs, representatives,
administrators, executors, successors and assigns and shall inure to the benefit of and shall be enforceable by Landlord, its successors, endorsees and assigns. Any married person executing this Guaranty agrees that recourse may be had against
community assets and against his separate property for the satisfaction of all obligations herein guaranteed. As used herein, the singular shall include the plural, and the masculine shall include the feminine and neuter and vice versa, if the
context so requires. 
 14.    The term “Landlord” whenever used herein refers to and
means the Landlord specifically named in the Lease and also any assignee of said Landlord, whether by outright assignment or by assignment for security, and also any successor to the interest of said Landlord or of any assignee in the Lease or any
part thereof, whether by assignment or otherwise. So long as the Landlord’s interest in or to the Premises (as that term is used in the Lease) or the rents, issues and profits therefrom, or in, to or under the Lease, are subject to any mortgage
or deed of trust or assignment for security, no acquisition by the mortgagee, beneficiary, trustee or assignee (as applicable) thereunder of the Landlord’s interest in the Premises or under the Lease shall affect the continuing obligations of
Guarantor under this Guaranty, which obligations shall continue in full force and effect for the benefit of the mortgagee, beneficiary, trustee or assignee under such mortgage, deed of trust or assignment, or any purchaser at sale by judicial
foreclosure or under private power of sale, and of the successors and assigns of any such mortgagee, beneficiary, trustee, assignee or purchaser. 

15.    The term “Tenant” whenever used herein refers to and means the Tenant in the Lease
specifically named and also any assignee or sublessee of said Lease and also any successor to the interests of said Tenant, assignee or sublessee of such Lease or any part thereof, whether by assignment, sublease or otherwise, to the extent that
either (x) the original Tenant named in the Lease remains liable for the obligations of such assignee or sublessee, or (y) such assignee or sublessee is a Permitted Transferee (as that term is defined in
Section 14.8 of the Lease). 
 16.    In the event of any litigation regarding
the enforcement or validity of this Guaranty, the non-prevailing party shall be obligated to pay all reasonable out-of-pocket
charges, costs and expenses (including, without limitation, reasonable attorneys’ fees) incurred by the prevailing party, whether or not any action or proceeding is commenced regarding such dispute and whether or not such litigation is
prosecuted to judgment. 
 17.    This Guaranty shall be governed by and construed in accordance with
the laws of the State of California, and in a case involving diversity of citizenship, shall be litigated in and subject to the jurisdiction of the courts of California. 

18.    Every provision of this Guaranty is intended to be severable. In the event any term or provision
hereof is declared to be illegal or invalid for any reason whatsoever by a court of competent jurisdiction, such illegality or invalidity shall not affect the balance of the terms and provisions hereof, which terms and provisions shall remain
binding and enforceable. 
 19.    This Guaranty may be executed in any number of counterparts each of
which shall be deemed an original and all of which shall constitute one and the same Guaranty with the same effect as if all parties had signed the same signature page. Any signature page of this Guaranty may be detached from any counterpart of this
Guaranty and re-attached to any other counterpart of this Guaranty identical in form hereto but having attached to it one or more additional signature pages. 

20.    No failure or delay on the part of Landlord to exercise any power, right or privilege under this
Guaranty shall impair any such power, right or privilege, or be construed to be a waiver of any default or any acquiescence therein, nor shall any single or partial exercise of such power, right or privilege preclude other or further exercise
thereof or of any other right, power or privilege. 

  

					
		  		  	HCP, INC.
		  	EXHIBIT F	  	[10355 Science Center Drive]
		  	-4-	  	[GenomeDx Biosciences, Corp.]

 21.    This Guaranty shall constitute the entire
agreement between Guarantor and the Landlord with respect to the subject matter hereof. No provision of this Guaranty or right of Landlord hereunder may be waived nor may Guarantor be released from any obligation hereunder except by a writing duly
executed by an authorized officer, director or trustee of Landlord. 
 22.    The liability of Guarantor
and all rights, powers and remedies of Landlord hereunder and under any other agreement now or at any time hereafter in force between Landlord and Guarantor relating to the Lease shall be cumulative and not alternative and such rights, powers and
remedies shall be in addition to all rights, powers and remedies given to Landlord by law. 
 IN WITNESS WHEREOF, Guarantor
has executed this Guaranty as of the day and year first above written 
  

			
		 	 GUARANTOR

		
		 	
                       
                                         
            ,

		 	
a                       
                                         
          

		
		 	
By:                      
                                         
       

		 	
Name:                      
                                         
  

		 	
Its:                      
                                         
        

  

					
		  		  	HCP, INC.
		  	EXHIBIT F	  	[10355 Science Center Drive]
		  	-5-	  	[GenomeDx Biosciences, Corp.]

 FIRST AMENDMENT TO LEASE 

This FIRST AMENDMENT TO LEASE (“First Amendment”) is made and entered into as of the 27th day of October, 2015, by and between TORREY PINES SCIENCE CENTER LIMITED PARTNERSHIP, a Delaware limited partnership (“Landlord”), and GENOMEDX BIOSCIENCES CORP., a Delaware
corporation (“Tenant”). 
 R E C I T A L S: 

A.    Landlord and Tenant entered into that certain Lease dated September 25, 2014 (the
“Lease”), whereby Landlord leases to Tenant and Tenant leases from Landlord that certain 11,002 rentable square feet of space commonly known as Suite 200 (“Existing Premises”) and located on the second (2nd) floor of that certain building located at 10355 Science Center Drive, San Diego, California 92121 (“Building”). 

B.    Tenant desires to expand the Existing Premises to include that certain 5,193 rentable square feet of
space commonly known as Suite 120 (the “Expansion Premises”) and located on the first (1st) floor of the Building, as delineated on Exhibit A attached hereto and made a
part hereof, and to make other modifications to the Lease, and in connection therewith, Landlord and Tenant desire to amend the Lease as hereinafter provided. 

A G R E E M E N T: 

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants contained herein, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 

1.    Capitalized Terms. All capitalized terms when used herein shall have the same meaning
as is given such terms in the Lease unless expressly superseded by the terms of this First Amendment. 

2.    Remeasurement of Building. The Building has been remeasured and, in accordance
therewith, Landlord and Tenant hereby stipulate and agree that, notwithstanding any contrary provision contained in the Lease, and effective as of the date of this First Amendment, the Building shall be deemed to contain 46,249 rentable square feet
of space. Accordingly, effective as of the date of this First Amendment, all references in the Lease to “40,894 rentable square feet” shall be deemed to reference “46,249 rentable square feet.” For purposes of the Lease, as
amended hereby, the “rentable square feet” of the Building shall be deemed as set forth in this Section 2. 

3.    Modification of Premises. 

3.1.    In General. Effective as of the date (the “Expansion Commencement
Date”) which is the earlier to occur of (i) the date upon which Tenant first commences to conduct business in the Expansion Premises (specifically excluding Tenant’s access to the Expansion Premises pursuant to the terms and
provisions of Section 6.1 of the Tenant Work Letter attached hereto as Exhibit B (the “Tenant Work Letter”) for the purpose set forth in Section 6.1 of the Tenant
Work Letter and not to conduct business from the Expansion Premises), and (ii) the later to occur of (A) the date upon which the Expansion Premises are “Ready for Occupancy,” as that term is defined in
Section 5.1 of the Tenant Work Letter, and (B) March 1, 2016, Tenant shall lease from Landlord and Landlord shall lease to Tenant the Expansion Premises. Consequently, effective upon the Expansion Commencement
Date, the Existing Premises shall be increased to include the Expansion Premises. Landlord and Tenant hereby acknowledge that such addition of the Expansion Premises to the Existing Premises shall, effective as of the Expansion Commencement Date,
increase the size of the Premises to 16,195 rentable square feet. The Existing Premises and the Expansion Premises may hereinafter collectively be referred to as the “Premises,” and shall be collectively known as Suites 120 and 200.

 3.2.    Outside Date. Except as specifically provided below, the terms and provisions
of this First Amendment shall not be void or voidable as a result of any failure of the Expansion Commencement Date to occur by any particular date, provided that the commencement date for the Expansion Premises shall not occur until the Expansion
Commencement Date. If the Expansion Commencement Date does not occur on or before June 30, 2016 (the “Outside Date”), as the same may be delayed pursuant to this Section 3.2, below, then Tenant shall
have the one-time right (the “Termination Right”) to terminate this First Amendment as it relates to the Expansion Premises only upon written notice to Landlord (the “Termination
Notice”), which Termination Notice shall be delivered on any date (the “Termination Date”) which occurs during the first (1st) five (5) days of any calendar month
following the Outside Date (as the same may be delayed pursuant to Section 3.2, below) and prior to the Expansion Commencement Date; provided that the Outside Date shall be delayed on a day-for-day basis to the extent that the “Substantial Completion” of the “Tenant Improvements,” as those terms are defined in Sections 1.2 and 5.1 of the Tenant Work Letter,
is delayed by an event of Force Majeure (as that term is defined in Section 29.16 of the Lease) or a Tenant Delay (as that term is defined in Section 5.2 of the Tenant Work Letter). In addition, in
no event may Tenant exercise the Termination Right if, at the time Tenant delivers the Termination Notice to Landlord, Tenant is in default under the Lease (beyond all applicable notice and cure periods). In the event that Tenant’s lease of the
Expansion Premises is terminated pursuant to the terms of this Section 3, then, effective as of the Termination Date, (A) Sections 3.1, 4, 5.2, 5.3, 6.2, 7, 9 and
10 this First Amendment and Exhibits A and B attached hereto shall be null and void and without further force or effect, (B) except as specifically set forth in Sections 2 and 6.1 of this First
Amendment, the Lease shall remain unmodified by this First Amendment and in full force and effect, and (C) Landlord and Tenant shall be relieved of their respective obligations under the Lease, as amended hereby, in connection with the
Expansion Premises, with the same force and effect as if the Lease, as amended hereby, in connection with the Expansion Premises, were scheduled to expire in accordance with 

  

					
		  		  	[10355 Science Center Drive]
		  		  	[First Amendment]
		  		  	[GenomeDx Biosciences Corp.]

 
its terms as of such Termination Date, subject to the provisions of the Lease, as amended hereby, in connection with the Expansion Premises, which expressly survive the expiration or earlier
termination of the Lease, as amended hereby, in connection with the Expansion Premises, and Landlord shall, within thirty (30) days following the Termination Date, return to Tenant any amounts previously paid by Tenant to Landlord in accordance
with Sections 5.2 and 10 below. Specifically excluding the Termination Right, Landlord shall have no liability whatsoever to Tenant to the extent relating to or arising from Landlord’s inability or failure to deliver, or
Landlord’s delay in delivering, the Expansion Premises to Tenant. 
 4.    Expansion
Term. The term of Tenant’s lease of the Expansion Premises (the “Expansion Term”) shall commence on the Expansion Commencement Date and shall expire coterminously with Tenant’s lease of the Existing Premises on the
Lease Expiration Date (i.e., June 30, 2020), unless sooner terminated as provided in the Lease, as amended, and subject to Tenant’s right to extend the Lease Term for the entire Premises pursuant to Section 2.2 of
the Lease. 
 5.    Base Rent. 

5.1.    Existing Premises. Tenant shall continue paying monthly installments of Base Rent
for the Existing Premises in accordance with the terms set forth in the Lease. 

5.2.    Expansion Premises. Commencing on the Expansion Commencement Date, and continuing
throughout the Expansion Term, Tenant shall pay to Landlord monthly installments of Base Rent for the Expansion Premises as follows: 
  

													
	 Period During Expansion Term
	  	Annual
Base Rent	 	  	Monthly
Installment
of Base Rent**	 	  	Approximate
Monthly
Rental Rate
per Rentable
Square Foot	 
	 Expansion Commencement Date - the last day of the twelfth (12th) full calendar month to occur
during the Expansion Term*
	  	$	202,527.00	 	  	$	16,877.25	 	  	$	3.25	 
	 The first (1st) day of the thirteenth (13th) full calendar month to occur during the Expansion Term — the last day of the twenty-fourth (24th) full calendar month to occur during the
Expansion Term
	  	$	208,602.84	 	  	$	17,383.57	 	  	 	#3.35	 
	 The first (1st) day of the twenty-fifth (25th) full calendar month to occur during the Expansion Term — the last day of the thirty sixth (36th) full calendar month to occur during the
Expansion Term
	  	$	214,860,96	 	  	$	17,905.80	 	  	$	3,45	 
	 The first (1st) day of the thirty-seventh (37th) full calendar month to occur during the Expansion Term — the last day of the forty eight (48th) full calendar month to occur during the
Expansion Term
	  	$	221,306.76	 	  	$	18,442.23	 	  	$	3.55	 
	 The first (1st) day of the forty-ninth (49th) full calendar month to occur during the Expansion Term — June 30, 2020
	  	$	227,946.00	 	  	$	18,9956.50	 	  	$	3.66	 

  

					
		  		  	[10355 Science Center Drive]
		  		  	[First Amendment]
		  	-2-	  	[GenomeDx Biosciences Corp.]

	 	*	 Subject to the terms set forth in Section 5.3 below, fifty percent (50%) of the Base Rent attributable
to the Expansion Premises during the four (4) month period commencing on the first (1st) day of the second (2nd) full calendar month to
occur during the Expansion Term and continuing until the last day of the fifth (5th) full calendar month to occur during the Expansion Term, shall be abated. 

	 	**	 The calculation of the Monthly Installment of Base Rent reflects an annual increase of 3%, rounded to the
nearest cent, after the previous twelve (12) month period. 

 On or before the Expansion Commencement
Date, Tenant shall pay to Landlord the Base Rent payable in connection with the Expansion Premises for the first full calendar month of the Expansion Term. 

5.3.    Partial Abated Base Rent. Provided that Tenant is not then in default under the
Lease, as amended, beyond any applicable notice and cure period set forth in the Lease, then during the four (4) month period commencing on the first (1st) day of the second (2nd) full calendar month to occur during the Expansion Term and continuing until the last day fifth (5th) full calendar month to occur during the
Expansion Term (the “Partial Base Rent Abatement Period”), Tenant shall not be obligated to pay fifty percent (50%) of any Base Rent otherwise attributable to the Expansion Premises during such Partial Base Rent Abatement Period
(the “Partial Base Rent Abatement”). Landlord and Tenant acknowledge that the aggregate amount of the Partial Base Rent Abatement equals Thirty-Three Thousand Seven Hundred Fifty-Four and 52/100 Dollars ($33,754.52, i.e., $8,438.63
per month). Tenant acknowledges and agrees that the foregoing Partial Base Rent Abatement has been granted to Tenant as additional consideration for entering into this First Amendment, and for agreeing to pay the rent and performing the terms and
conditions otherwise required under the Lease, as hereby amended. If (i) Tenant shall be in default under the Lease, as amended, and shall fail to cure such default within the notice and cure period, if any, permitted for cure pursuant to the
Lease, or (ii) the Lease, as amended, shall be terminated for any reason other than a default by Landlord, then the dollar amount of the unapplied portion of the Partial Base Rent Abatement as of the date of such default shall be converted to a
credit to be applied to the Base Rent applicable at the end of the Expansion Term, and Tenant shall immediately be obligated to begin paying Base Rent for the Expansion Premises in full. 

6.    Tenant’s Share of Direct Expenses. 

6.1.    Existing Premises. Tenant shall continue paying Tenant’s Share of the annual
Direct Expenses in connection with the Existing Premises in accordance with the terms set forth in the Lease; provided that with respect to the calculation of Tenant’s Share of the annual Direct Expenses in connection with the Existing
Premises, Tenant’s Share in connection with the Existing Premises shall equal twenty-three and 79/100 percent (23.79%). 

6.2.    Expansion Premises. During the Expansion Term, Tenant shall pay Tenant’s Share
of the annual Direct Expenses in connection with the Expansion Premises which arise or accrue on or after the Expansion Commencement Date in accordance with the terms of the Lease, provided that with respect to the calculation of Tenant’s Share
of the annual Direct Expenses in connection with the Expansion Premises which arise or accrue during such period, Tenant’s Share in connection with the Expansion Premises shall equal eleven and 23/100 percent (11.23%). 

7.    Condition of Premises. 

7.1.    Existing Premises. Landlord makes no representation, warranty or promise as to the
condition of the Existing Premises or the Project or their suitability for the purpose intended by Tenant, except as specifically set forth in the Lease, and Landlord and Tenant acknowledge that Tenant has been occupying the Existing Premises
pursuant to the Lease, has had full opportunity to review the condition of the Existing Premises and Project and has done so, and therefore, except as specifically set forth in the Lease, Tenant shall continue to accept the Existing Premises and
Project in their then presently existing, “as is” condition. Landlord shall not be obligated to provide or pay for any improvement work or services related to the improvement of the Existing Premises, except as specifically set forth in
the Lease. 
 7.2.    Expansion Premises. Landlord makes no representation, warranty or
promise as to the condition of the Expansion Premises, or the suitability for the purpose intended by Tenant, except as specifically set forth in the Tenant Work Letter and the Lease, as amended hereby. Except as specifically set forth in the Tenant
Work Letter and the Lease, as amended hereby, Tenant shall accept the Expansion Premises in its presently existing, “as is” condition and Landlord shall not be obligated to provide or pay for any improvement work or services related to the
improvement of the Expansion Premises. 
 8.    Brokers. Landlord and Tenant hereby
warrant to each other that they have had no dealings with any real estate broker or agent in connection with the negotiation of this First Amendment other than CBRE, Inc.. and Jones Lang LaSalle Brokerage, Inc. (collectively, the
“Brokers”), and that they know of no other real estate broker or agent 

  

					
		  		  	[10355 Science Center Drive]
		  		  	[First Amendment]
		  	-3-	  	[GenomeDx Biosciences Corp.]

 
who is entitled to a commission in connection with this First Amendment. Each party agrees to indemnify and defend the other party against and hold the other party harmless from any and all
claims, demands, losses, liabilities, lawsuits, judgments, and costs and expenses (including, without limitation, reasonable attorneys’ fees) with respect to any leasing commission or equivalent compensation alleged to be owing on account of
the indemnifying party’s dealings with any real estate broker or agent, other than the Brokers. Landlord shall pay the Brokers pursuant to the terms of separate commission agreements. The terms of this Section 8 shall
survive the expiration or earlier termination of this First Amendment. 
 9.    Parking.
In addition to Tenant’s parking rights in connection with the Existing Premises pursuant to Article 28 of the Lease, effective as of the Expansion Commencement Date and continuing throughout the Expansion Term, Tenant shall have the
right to use up to fourteen (14) unreserved parking spaces in connection with Tenant’s lease of the Expansion Premises, which parking spaces shall pertain to the on-site parking facility (or
facilities) which serve the Project. Except as set forth in this Section 9, Tenant shall use such unreserved parking spaces in accordance with the provisions of Article 28 of the Lease. 

10.    Security Deposit. Notwithstanding anything in the Lease to the contrary, the Security
Deposit held by Landlord pursuant to the Lease, as amended hereby, shall equal Seventy-One Thousand Six Hundred Thirty-One and 50/100 Dollars ($71,631.50). Landlord and
Tenant acknowledge that, in accordance with Article 21 of the Lease, Tenant has previously delivered the sum of Forty-Seven Thousand Five Hundred Ninety-Nine and 00/100 Dollars ($47,599.00) to Landlord as security for the faithful performance
by Tenant of the terms, covenants and conditions of the Lease. Concurrently with Tenant’s execution of this First Amendment, Tenant shall deposit with Landlord an amount equal to Twenty-Four Thousand
Thirty-Two and 50/100 Dollars ($24,032.50) to be held by Landlord as a part of the Security Deposit. Notwithstanding any provision to the contrary contained in the Lease, given that the Financial Condition has
been satisfied, effective as of the date of this First Amendment, Section 21.3 of the Lease shall be deleted in its entirety and of no further force or effect. 

11.    No Further Modification. Except as set forth in this First Amendment, all of the
terms and provisions of the Lease shall apply with respect to the Premises and shall remain unmodified and in full force and effect. 
 [The
remainder of the page is intentionally left blank. Signatures on next page.] 

  

					
		  		  	[10355 Science Center Drive]
		  		  	[First Amendment]
		  	-4-	  	[GenomeDx Biosciences Corp.]

 IN WITNESS WHEREOF, this First Amendment has been executed as of the day and
year first above written. 
  

									
	 LANDLORD:
	 		 	 TENANT:

			
	 TORREY PINES SCIENCE CENTER LIMITED PARTNERSHIP,

a Delaware limited partnership
	 		 	 GENOMEDX BIOSCIENCES CORP.,

a Delaware corporation

					
		 		 		 	 By:
	 	 /s/ Dave Matthews

				
	 By:
	 	 /s/ Jonathan M. Bergschneider
	 		 	 Dave Matthews

	  
 Jonathan
M. Bergschneider
	 		 	
                       
     Print Name

	
                       
     Print Name
	 		 	 Its:
	 	 CFO

					
	 Its:
	 	 EVP
	 		 	 By:
	 	  

					
		 		 		 		 	
		 		 	  

                        
    Print Name

				
		 		 	 Its:
	 	  

  

					
		  		  	[10355 Science Center Drive]
		  		  	[First Amendment]
		  	-5-	  	[GenomeDx Biosciences Corp.]

 EXHIBIT A 

10355 SCIENCE CENTER DRIVE 

OUTLINE OF EXPANSION PREMISES 
  

 
 

 
  

  

					
		  		  	[10355 Science Center Drive]
		  	EXHIBIT A	  	[First Amendment]
		  	-1-	  	[GenomeDx Biosciences Corp.]

 EXHIBIT B 

10355 SCIENCE CENTER DRIVE 

TENANT WORK LETTER 

This Tenant Work Letter shall set forth the terms and conditions relating to the construction of the improvements in the
Expansion Premises. This Tenant Work Letter is essentially organized chronologically and addresses the issues of the construction of the Expansion Premises, in sequence, as such issues will arise during the actual construction of the Expansion
Premises. All references in this Tenant Work Letter to Articles or Sections of “this First Amendment” shall mean the relevant portion of Sections 1 through 11 of the First Amendment to which this Tenant Work Letter is
attached as Exhibit B and of which this Tenant Work Letter forms a part, and all references in this Tenant Work Letter to Sections of “this Tenant Work Letter” shall mean the relevant portion of Sections 1 through
6 of this Tenant Work Letter. 
 SECTION 1 

EXPANSION TENANT IMPROVEMENTS 

1.1    Landlord Work. 

1.1.1    Notwithstanding anything set forth in the Lease, as amended hereby, to the contrary, upon the
Expansion Commencement Date, the “Building Systems,” as that term is defined below, shall be in good working condition and repair, and Landlord hereby covenants that the Building Systems shall remain in good working condition for a period
of one (1) year following the Expansion Commencement Date. Notwithstanding anything in the Lease, as amended hereby, to the contrary, Landlord shall, at Landlord’s sole cost and expense (which shall not be deemed an Operating Expense),
repair or replace any failed or inoperable portion of the Building Systems during such one (1) year period (“Landlord’s Warranty”), provided that the need to repair or replace was not caused by the misuse, misconduct,
damage, destruction, omissions, and/or negligence (collectively, “Tenant Damage”) of Tenant, its subtenants and/or assignees, if any, or any company which is acquired, sold or merged with Tenant, or by any modifications,
Alterations, or improvements constructed by or on behalf of Tenant. To the extent repairs which Landlord is required to make pursuant to this Section 1.1.1 are necessitated in part by Tenant Damage, then Tenant shall
reimburse Landlord for an equitable proportion of the reasonable cost of such repair. If it is determined that any portion of the Building Systems were not in good working condition and repair at any time prior to the expiration of the
Landlord’s Warranty, then Landlord shall not be liable to Tenant for any damages, but as Tenant’s sole remedy, Landlord, at no cost to Tenant, shall promptly commence such work or take such other action as may be necessary to place the
same in good working condition and repair, and shall thereafter diligently pursue the same to completion. In addition, Landlord covenants that to its actual knowledge the Building structure (including, without limitation, the exterior and structural
components of the Building) is without material defect that would materially impact Tenant’s ability to use the Expansion Premises for the Permitted Use, as of the date of this First Amendment. As used in this Tenant Work Letter, the
“Building Systems” shall mean the base Building mechanical, electrical, life safety, plumbing, sprinkler and HVAC systems installed or furnished by Landlord. 

1.1.2    To the extent required in order to allow Tenant to obtain a certificate of occupancy, or its
legal equivalent, for the Expansion Premises for the Permitted Use, Landlord shall cause the Building, including the Expansion Premises, to comply with applicable building codes and other governmental laws, ordinances and regulations, including but
not limited to those related to handicap access (collectively, “Building Codes”), which were enacted and enforced as of the date of this First Amendment; provided, however, Landlord shall not be obligated to cause the Building to
comply with applicable Building Codes to the extent such requirement is triggered by the unique nature of Tenant’s specific use of the Premises for other than general office use and general laboratory use typical of tenants in the Building.

 1.2    Expansion Tenant Improvements. Landlord and Tenant have approved those certain
construction drawings set forth in that certain design development submittal prepared by Ferguson Pape Baldwin Architects dated October 21, 2015, which contains those certain sheets set forth on Schedule 1 attached hereto, but
only to the extent that such constructions drawings provide for work which is to be done within the Expansion Premises (collectively, and only to the extent that such constructions drawings provide for work which is to be done within the Expansion
Premises, the “Construction Drawings”). Within five (5) business days of the date Tenant executes this First Amendment, Tenant shall cooperate in good faith with Landlord’s architects and engineers to supply such
information necessary to allow the Landlord’s architects and engineers to complete the architectural and engineering drawings for the Expansion Premises, and the final architectural working drawings in a form which is complete to allow
subcontractors to bid on the work and to obtain all applicable permits and in a manner consistent with, and which are a natural and logical extension of, the Construction Drawings (collectively, the “Approved Working Drawings”).
Landlord shall construct, at its sole cost and expense (except as specifically set forth in this Section 1.2 below and Section 2 below), the improvements in the Expansion Premises (the
“Expansion Tenant Improvements”) in good workmanlike condition pursuant to the Approved Working Drawings, and Tenant shall make no changes or modifications to the Construction Drawings or, once completed, the Approved Working
Drawings, without the prior written consent of Landlord, which consent may be withheld in Landlord’s sole discretion if such change or modification is reasonably likely to directly or indirectly materially delay the “Substantial
Completion,” as that term is defined in Section 5.1 of this Tenant Work Letter, of the Expansion Premises or increase the cost of designing or constructing the Expansion Tenant Improvements. The Expansion Tenant
Improvements shall be constructed in accordance with Landlord’s Building standards, using Building standard methods, materials and finishes. Except as specifically set forth in Section 2 below, Tenant shall not be
responsible for any costs (whether foreseen or unforeseen) in the construction of the Expansion Tenant Improvements, whether arising out of a deficiency of the Building or otherwise, unless such increase cost is due to the act or omission 

 

  

					
		  		  	[10355 Science Center Drive]
		  	EXHIBIT B	  	[First Amendment]
		  	-1-	  	[GenomeDx Biosciences Corp.]

 
of Tenant. Notwithstanding the foregoing, the Expansion Tenant Improvements shall not include built-in furniture, equipment, cubicle systems (including the
cabling and phone wiring), personal property and/or any above-standard electrical, mechanical or plumbing systems. 
 SECTION 2

 TENANT’S CONTRIBUTION AMOUNT 

Notwithstanding anything to the contrary contained herein, Tenant shall be responsible for a portion of the cost to construct
the Expansion Tenant Improvements in an amount (the “Tenant Contribution Amount”) equal to (i) Thirty-Seven Thousand and 00/100 Dollars ($37,000.00), minus (ii) the amount (the “Value Engineered Reduction
Amount”) of any cost savings which results from Landlord and Tenant’s mutual agreement (in each of such party’s sole discretion) to value engineer and revise the scope of those certain Expansion Tenant Improvements which are both
(A) set forth in the Construction Drawings and (B) located within the IT Room of the Expansion Premises. Tenant shall pay the Tenant Contribution Amount to Landlord prior to the commencement of the construction of the Expansion Tenant
Improvements and within ten (10) business days following Landlord’s delivery to Tenant of written request therefor and reasonable supporting documentation in connection with Landlord’s calculation of the Value Engineered Reduction
Amount, if any. 
 SECTION 3 

CONTRACTOR’S WARRANTIES AND GUARANTIES 

Landlord hereby assigns to Tenant all warranties and guaranties by the contractor who constructs the Expansion Tenant
Improvements (the “Contractor”) relating to the Expansion Tenant Improvements, and Tenant hereby waives all claims against Landlord relating to, or arising out of the construction of, the Expansion Tenant Improvements (except to the
extent such claims arise out of Landlord’s gross negligence). 
 SECTION 4 

INTENTIONALLY OMITTED 

SECTION 5 

COMPLETION OF THE EXPANSION TENANT IMPROVEMENTS; 

EXPANSION COMMENCEMENT DATE 

5.1    Ready for Occupancy. The Expansion Premises shall be deemed “Ready for
Occupancy” upon the Substantial Completion of the Expansion Premises. For purposes of this First Amendment, “Substantial Completion” of the Expansion Premises shall occur upon the completion of construction of the Expansion
Tenant Improvements in the Expansion Premises to the architect’s reasonable satisfaction, with the exception of any punch list items and any tenant fixtures, work-stations, built-in furniture, or
equipment to be installed by Tenant or under the supervision of Contractor. 
 5.2    Delay of the
Substantial Completion of the Expansion Premises. Except as provided in this Section 5.2, the Expansion Commencement Date shall occur as set forth in this First Amendment and Section 5.1,
above. If there shall be a delay or there are delays in the Substantial Completion of the Expansion Premises or in the occurrence of any of the other conditions precedent to the Expansion Commencement Date, as set forth in of this First Amendment,
as a direct, indirect, partial, or total result of (each, a “Tenant Delay”): 

5.2.1    Tenant’s failure to timely approve any matter requiring Tenant’s approval; 

5.2.2    A breach by Tenant of the terms of this Tenant Work Letter or the Lease, as amended; 

5.2.3    Tenant’s request for changes to the Expansion Tenant Improvements and/or the Construction
Drawings; 
 5.2.4    Tenant’s access to the Expansion Premises pursuant to
Section 6.1 below; 
 5.2.5    Tenant’s requirement for materials,
components, finishes or improvements which are not available in a commercially reasonable time given the anticipated date of Substantial Completion of the Expansion Premises, as set forth in this First Amendment, or which are different from, or not
included in, Landlord’s standard improvement package items for the Building; 
 5.2.6    Any other
acts or omissions of Tenant, or its agents, or employees; or 
 5.2.7    Any failure by Tenant to timely
pay the Tenant Contribution Amount to Landlord. 
 then, notwithstanding anything to the contrary set forth in the Lease, as amended hereby, or this Tenant
Work Letter and regardless of the actual date of the Substantial Completion of the Expansion Premises, the date of Substantial Completion of the Expansion Premises shall be deemed to be the date the Substantial Completion of the Expansion Premises
would have occurred if no Tenant delay or delays, as set forth above, had occurred. 
  

  

					
		  		  	[10355 Science Center Drive]
		  	EXHIBIT B	  	[First Amendment]
		  	-2-	  	[GenomeDx Biosciences Corp.]

 SECTION 6 

MISCELLANEOUS 

6.1    Tenant’s Entry Into the Expansion Premises Prior to Substantial Completion. Provided
that Tenant and its agents do not unreasonably interfere with Contractor’s work in the Building and the Expansion Premises, Contractor shall allow Tenant access to the Expansion Premises at least thirty (30) days prior to the Substantial
Completion of the Expansion Premises for the purpose of Tenant installing Tenant’s furniture, security system, equipment and/or fixtures (including Tenant’s data and telephone cabling and equipment) in the Expansion Premises. Prior to
Tenant’s entry into the Expansion Premises as permitted by the terms of this Section 6.1, Tenant shall coordinate with Landlord and Contractor so as to not unreasonably interfere with Landlord’s and/or
Contractor’s work in the Building and the Expansion Premises. Tenant shall hold Landlord harmless from and indemnify, protect and defend Landlord against any loss or damage to the Building or Expansion Premises and against injury to any persons
caused by Tenant’s actions pursuant to this Section 6.1. Notwithstanding Tenant’s access to the Expansion Premises pursuant to this Section 6.1, Tenant shall not be responsible for any
Rent with respect to the Expansion Premises prior to the Expansion Commencement Date, except in connection with Tenant’s indemnity obligations specifically set forth in this Section 6.1 above. 

6.2    Freight Elevators. Landlord shall, consistent with its obligations to other tenants of the
Building, make the freight elevator reasonably available to Tenant in connection with initial decorating, furnishing and moving into the Expansion Premises. 

6.3    Tenant’s Representative. Tenant has designated Annalisa Marquez as its sole
representative with respect to the matters set forth in this Tenant Work Letter, who, until further notice to Landlord, shall have full authority and responsibility to act on behalf of the Tenant as required in this Tenant Work Letter. 

6.4    Landlord’s Representative. Landlord has designated Ken Richter of PMA, Inc. as its sole
representative with respect to the matters set forth in this Tenant Work Letter, who, until further notice to Tenant, shall have full authority and responsibility to act on behalf of the Landlord as required in this Tenant Work Letter. 

6.5    Tenant’s Agents. All contractors, subcontractors, laborers, materialmen, and suppliers
retained by Tenant in connection with the Expansion Tenant Improvements shall be union labor in compliance with the then existing master labor agreements. 

6.6    Time of the Essence in This Tenant Work Letter. Unless otherwise indicated, all references
herein to a “number of days” shall mean and refer to calendar days. In all instances where Tenant is required to approve or deliver an item, if no written notice of approval is given or the item is not delivered within the stated time
period, at Landlord’s sole option, at the end of such period the item shall automatically be deemed approved or delivered by Tenant and the next succeeding time period shall commence. 

6.7    Tenant’s Lease Default. Notwithstanding any provision to the contrary contained in the
Lease, as amended hereby, if an event of default as described in this Tenant Work Letter and/or this Lease, as amended, beyond any applicable cure period has occurred at any time on or before the Substantial Completion of the Expansion Premises,
then (i) in addition to all other rights and remedies granted to Landlord pursuant to the Lease, as amended, Landlord shall have the right to cause Contractor to cease the construction of the Expansion Premises (in which case, Tenant shall be
responsible for any delay in the Substantial Completion of the Expansion Premises caused by such work stoppage), and (ii) all other obligations of Landlord under the terms of this Tenant Work Letter shall be forgiven until such time as such
default is cured pursuant to the terms of the Lease, as amended. 
 6.8    Cooperation by Tenant.
Tenant acknowledges that the timing of the completion of the Approved Work Drawings and the Expansion Tenant Improvements is of the utmost importance to Landlord. Accordingly, Tenant hereby agrees to fully and diligently cooperate with all
reasonable requests by Landlord in connection with or related to the design and construction of the Expansion Tenant Improvements, and in connection therewith, shall respond to Landlord’s requests for information and/or approvals, except as
specifically set forth herein to the contrary, within three (3) business days following request by Landlord. 

  

					
		  		  	[10355 Science Center Drive]
		  	EXHIBIT B	  	[First Amendment]
		  	-3-	  	[GenomeDx Biosciences Corp.]

 SCHEDULE 1 TO EXHIBIT B 

10355 SCIENCE CENTER DRIVE 

SHEET INDEX FOR CONSTRUCTION DRAWINGS 

00-GENERAL 

T1.1 TITLE SHEET 
 T1.2 PROJECT
GENERAL NOTES 
 T1.3 ACCESSIBILITY REQUIREMENTS 

T1.4 EXISTING CONTROL AREA PLAN 
 02-ARCHITECTURAL 
 A0.1 FIRST FLOOR DEMOLITION PLAN 

A0.2 FIRST FLOOR DEMOLITION REFLECTED CEILING PLAN 

A1.1 ARCHITECTURAL SITE PLAN 

A2.0 BASEMENT PLAN 
 A2.1 OVERALL
FIRST FLOOR PLAN 
 A2.1A ENLARGED FIRST FLOOR PLAN - NORTHWEST 

A2.1B ENLARGED FIRST FLOOR PLAN - NORTHEAST & BASEMENT 

A2.1 C ENLARGED FIRST FLOOR PLAN - SOUTH 

A2.2 FIRST FLOOR FINISH PLAN 

A2.3 FINISH SCHEDULE 
 A2.4 DOOR
SCHEDULE 
 A2.5 WINDOW SCHEDULE 

A3.1 OVERALL FIRST FLOOR REFLECTED CEILING PLAN 

A3.1A ENLARGED FIRST FLOOR RCP - NORTHWEST 

A3.1B ENLARGED FIRST FLOOR RCP - NORTHEAST & BASEMENT 

A3.1C ENLARGED FIRST FLOOR RCP - SOUTH 

A6.1 INTERIOR ELEVATIONS 
 A8.1
EXTERIOR DETAILS 
 A9.1 INTERIOR WALL DETAILS 

A9.2 INTERIOR CEILING DETAILS 

A9.3 INTERIOR DOOR AND WINDOW DETAILS A9.4 INTERIOR DETAILS 

LF1.0 LAB FURNISHING MENU 
 LF2.1A
ENLARGED LAB PLANS - NORTHWEST 
 LF2.1C ENLARGED LAB PLANS - SOUTH 

LF9.1 LAB FURNISHING DETAILS 
 03-MECHANICAL 
 M0.1 LEAD SHEET 

M0.3 MECHANICAL SCHEDULES 
 M1.1.1
MECHANICAL FIRST FLOOR DEMO PLAN - AREA 1 
 M1.1.2 MECHANICAL FIRST FLOOR DEMO PLAN - AREA 2 

M1.1.3 MECHANICAL FIRST FLOOR DEMO PLAN - AREA 3 

M1.1.4 MECHANICAL FIRST FLOOR DEMO PLAN - AREA 4 

M2.0.2 MECHANICAL BASEMENT FLOOR PLAN - AREA 2 

M2.0.3 MECHANICAL BASEMENT FLOOR PLAN - AREA 3 

M2.1.1 MECHANICAL FIRST FLOOR PLAN - AREA 1 

M2.1.2 MECHANICAL FIRST FLOOR PLAN - AREA 2 

M2.1.3 MECHANICAL FIRST FLOOR PLAN - AREA 3 

M2.1.4 MECHANICAL FIRST FLOOR PLAN - AREA 4 M5.1 DETAILS 

04-PLUMBING 

P0.1 LEAD SHEET 
 P0.2 PLUMBING
SCHEDULE 
 P0.3 PLUMBING SITE PLAN 

P1.1.1 PLUMBING FIRST FLOOR DEMO PLAN - AREA 1 

P1.1.2 PLUMBING FIRST FLOOR DEMO PLAN - AREA 2 

P1.1.3 PLUMBING FIRST FLOOR DEMO PLAN - AREA 3 

P1.1.4 PLUMBING FIRST FLOOR DEMO PLAN - AREA 4 

P2.1.1 PLUMBING FIRST FLOOR PLAN - AREA 1 

P2.1.2 PLUMBING FIRST FLOOR PLAN - AREA 2 

P2.1.3 PLUMBING FIRST FLOOR PLAN - AREA 3 

P2.1.4 PLUMBING FIRST FLOOR PLAN - AREA 4 

05-ELECTRICAL 

E0.1 LEAD SHEET 
 E0.2 LIGHT
FIXTURE SCHEDULE 
 EL1.0.2 LIGHTING BASEMENT FLOOR DEMO PLAN - AREA 2 

EL1.1.1 LIGHTING FIRST FLOOR DEMO PLAN - AREA 1 

EL1.1.2 LIGHTING FIRST FLOOR DEMO PLAN - AREA 2 

EL1.1.3 LIGHTING FIRST FLOOR DEMO PLAN - AREA 3 

EL1.1.4 LIGHTING FIRST FLOOR DEMO PLAN - AREA 4 

EP1.1.1 POWER FIRST FLOOR DEMO PLAN - AREA 1 

EP1.1.2 POWER FIRST FLOOR DEMO PLAN - AREA 2 

EP1.1.3 POWER FIRST FLOOR DEMO PLAN - AREA 3 

  

					
		  	SCHEDULE 1 TO	  	[10355 Science Center Drive]
		  	EXHIBIT B	  	[First Amendment]
		  	-1-	  	[GenomeDx Biosciences Corp.]

 EP1.1.4 POWER FIRST FLOOR DEMO PLAN - AREA 4 

EL2.0.2 LIGHTING BASEMENT FLOOR PLAN - AREA 2 

EL2.1.1 LIGHTING FIRST FLOOR PLAN - AREA 1 

EL2.1.2 LIGHTING FIRST FLOOR PLAN - AREA 2 

EL2.1.3 LIGHTING FIRST FLOOR PLAN - AREA 3 

EL2.1.4 LIGHTING FIRST FLOOR PLAN - AREA 4 

EP2.1.1 POWER FIRST FLOOR PLAN - AREA 1 

EP2.1.2 POWER FIRST FLOOR PLAN - AREA 2 

EP2.1.3 POWER FIRST FLOOR PLAN - AREA 3 

EP2.1.4 POWER FIRST FLOOR PLAN - AREA 4 

E5.1 DETAILS 
 E5.2 DETAILS 

E6.1 SINGLE LINE DIAGRAM 
 E7.1
PANEL SCHEDULES 

  

					
		  	SCHEDULE 1 TO	  	[10355 Science Center Drive]
		  	EXHIBIT B	  	[First Amendment]
		  	-2-	  	[GenomeDx Biosciences Corp.]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]